01423000000000469000450099100020000070000020000270600020000470100020000609100090
00081300053000174210020000701510024000902300053001140350010001674800047001770300
02000224031000300244032000200247036000600249930000600255042000200261117000600263
08500030026920000020027206500090027412200030028304800140028604800140030004800240
03140490038003380490023003760490051003990490029004500490027004790490043005060490
02900549049004200578049013600620043006500756043006500821043006700886#1#0#i#1#200
70529#Brazilian Journal of Medical and Biological Research#Braz J Med Biol Res#B
raz. j. med. biol. res#Revista brasileira de pesquisas médicas e biológicas#0100
-879X#Associação Brasileira de Divulgação Científica#Braz J Med Biol Res#40#5#20
075#BJMBR#1#other#nd#1#20070500#19#^les^hSumario#^lpt^hSumário#^len^hTable of Co
ntents#^len^cBJMBR030^tConcepts and Comments#^len^cBJMBR090^tReview#^len^cBJMBR0
10^tBiochemistry and Molecular Biology#^len^cBJMBR380^tCell Biology#^len^cBJMBR0
50^tImmunology#^len^cBJMBR060^tNeurosciences and Behavior#^len^cBJMBR070^tPharma
cology#^len^cBJMBR080^tPhysiology and Biophysics#^len^cBJMBR700^tInternational S
ymposium of Neuroendocrinology "Neuroendocrine control of body fluid homeostasis
: past, present, future"#^les^tBraz J Med Biol Res^vv.40^nn.5^cRibeirão Preto^mm
ayo^a2007#^lpt^tBraz J Med Biol Res^vv.40^nn.5^cRibeirão Preto^mmaio^a2007#^len^
tBraz J Med Biol Res^vvol.40^nno.5^cRibeirão Preto^mMay^a2007##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#o#1#1#article#1#20
080212#125656#6385.htm#64##
03131000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120048001790100029002270100027002560700124002830700121004070831646005280850
00802174085006302182085002102245085004202266085002602308085003502334117000602369
07200030237505800070237806000110238506000110239605800070240705800050241411200090
2419111001802428114000902446113001702455881002402472002000902496#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#h#2#1#article#1#sc#en#bjmbr#1#3.1#ILUS#TAB
#03#BJMBR010#FAPESP#Braz J Med Biol Res#40#5#20070500#^f615^l619#0100-879X#20070
413#Pipeline for macro- and microarray analyses^len#^rND^1A01 A02^nR.^sVicentini
#^rND^1A01 A02^nM.^sMenossi#Universidade Estadual de Campinas^iA01^1Centro de Bi
ologia Molecular e Engenharia Genética^2Laboratório de Genoma Funcional#Universi
dade Estadual de Campinas^iA02^1Instituto de Biologia^2Departamento de Genética 
e Evolução^cCampinas^sSP^pBrasil#^len^aThe pipeline for macro- and microarray an
alyses (PMmA) is a set of scripts with a web interface developed to analyze DNA 
array data generated by array image quantification software. PMmA is designed fo
r use with single- or double-color array data and to work as a pipeline in five 
classes (data format, normalization, data analysis, clustering, and array maps).
 It can also be used as a plugin in the BioArray Software Environment, an open-s
ource database for array analysis, or used in a local version of the web service
. All scripts in PMmA were developed in the PERL programming language and statis
tical analysis functions were implemented in the R statistical language. Consequ
ently, our package is a platform-independent software. Our algorithms can correc
tly select almost 90% of the differentially expressed genes, showing a superior 
performance compared to other methods of analysis. The pipeline software has bee
n applied to 1536 expressed sequence tags macroarray public data of sugarcane ex
posed to cold for 3 to 48 h. PMmA identified thirty cold-responsive genes previo
usly unidentified in this public dataset. Fourteen genes were up-regulated, two 
had a variable expression and the other fourteen were down-regulated in the trea
tments. These new findings certainly were a consequence of using a superior stat
istical analysis approach, since the original study did not take into account th
e dependence of data variability on the average signal intensity of each gene. T
he web interface, supplementary information, and the package source code are ava
ilable, free, to non-commercial users at http://ipe.cbmeg.unicamp.br/pub/PMmA.#^
dnd^i1#^tm^len^kIntensity-dependent selection of expression ratios^i1#^tm^len^kP
ipeline^i1#^tm^len^kBioArray Software Environment^i1#^tm^len^kNormalization^i1#^
tm^len^kMacroarray, Microarray^i1#other#14#FAPESP#02/01167-1#03/07244-0#UNIEMP#C
NPq#20060221#February 21, 2006#20070202#February 2, 2007#S0100-879X2006005000089
#6385.htm##
03162000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120048001790100029002270100027002560700124002830700121004070831713005280850
00802241085006302249085002102312085004202333085002602375085003502401117000602436
07200030244205800070244506000110245206000110246305800070247405800050248111200090
2486111001802495114000902513113001702522002000902539#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6385.htm#S#f#3#1#article#1#sc#en#bjmbr#1#3.1#ILUS#TAB#03#BJMBR010
#FAPESP#Braz J Med Biol Res#40#5#20070500#^f615^l619#0100-879X#20070413#Pipeline
 for macro- and microarray analyses^len#^rND^1A01 A02^nR.^sVicentini#^rND^1A01 A
02^nM.^sMenossi#Universidade Estadual de Campinas^iA01^1Centro de Biologia Molec
ular e Engenharia Genética^2Laboratório de Genoma Funcional#Universidade Estadua
l de Campinas^iA02^1Instituto de Biologia^2Departamento de Genética e Evolução^c
Campinas^sSP^pBrasil#^len^aThe pipeline for macro- and microarray analyses (PMmA
) is a set of scripts with a web interface developed to analyze DNA array data g
enerated by array image quantification software. PMmA is designed for use with s
ingle- or double-color array data and to work as a pipeline in five classes (dat
a format, normalization, data analysis, clustering, and array maps). It can also
 be used as a plugin in the BioArray Software Environment, an open-source databa
se for array analysis, or used in a local version of the web service. All script
s in PMmA were developed in the PERL programming language and statistical analys
is functions were implemented in the R statistical language. Consequently, our p
ackage is a platform-independent software. Our algorithms can correctly select a
lmost 90% of the differentially expressed genes, showing a superior performance 
compared to other methods of analysis. The pipeline software has been applied to
 1536 expressed sequence tags macroarray public data of sugarcane exposed to col
d for 3 to 48 h. PMmA identified thirty cold-responsive genes previously unident
ified in this public dataset. Fourteen genes were up-regulated, two had a variab
le expression and the other fourteen were down-regulated in the treatments. Thes
e new findings certainly were a consequence of using a superior statistical anal
ysis approach, since the original study did not take into account the dependence
 of data variability on the average signal intensity of each gene. The web inter
face, supplementary information, and the package source code are available, free
, to non-commercial users at <a href="http://ipe.cbmeg.unicamp.br/pub/PMmA" targ
et="_blank">http://ipe.cbmeg.unicamp.br/pub/PMmA</a>.#^dnd^i1#^tm^len^kIntensity
-dependent selection of expression ratios^i1#^tm^len^kPipeline^i1#^tm^len^kBioAr
ray Software Environment^i1#^tm^len^kNormalization^i1#^tm^len^kMacroarray, Micro
array^i1#other#14#FAPESP#02/01167-1#03/07244-0#UNIEMP#CNPq#20060221#February 21,
 2006#20070202#February 2, 2007#6385.htm##
03255000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762230009001860120048001950100028002430100026002710700148002970700123004450831
65300568085000802221085006302229085002102292085004202313085002602355085003502381
11700060241607200030242205800070242506000110243206000110244305800070245405800050
2461112000902466111001802475114000902493113001702502002000902519008008902528#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#l#4#1#article#1#^mMay^a2007#sc
#en#bjmbr#1#3.1#ilus#tab#03#BJMBR010#FAPESP#Braz. j. med. biol. res#40#5#2007050
0#^f615^l619#0100-879X#20070413#Pipeline for macro- and microarray analyses^len#
^rND^1A01 A02^nR^sVicentini#^rND^1A01 A02^nM^sMenossi#^iA01^1Universidade Estadu
al de Campinas^2Centro de Biologia Molecular e Engenharia Genética^3Laboratório 
de Genoma Funcional^cCampinas^sSP^pBrasil#^iA02^1Universidade Estadual de Campin
as^2Instituto de Biologia^3Departamento de Genética e Evolução^cCampinas^sSP^pBr
asil#^len^aThe pipeline for macro- and microarray analyses (PMmA) is a set of sc
ripts with a web interface developed to analyze DNA array data generated by arra
y image quantification software. PMmA is designed for use with single- or double
-color array data and to work as a pipeline in five classes (data format, normal
ization, data analysis, clustering, and array maps). It can also be used as a pl
ugin in the BioArray Software Environment, an open-source database for array ana
lysis, or used in a local version of the web service. All scripts in PMmA were d
eveloped in the PERL programming language and statistical analysis functions wer
e implemented in the R statistical language. Consequently, our package is a plat
form-independent software. Our algorithms can correctly select almost 90 percent
 of the differentially expressed genes, showing a superior performance compared 
to other methods of analysis. The pipeline software has been applied to 1536 exp
ressed sequence tags macroarray public data of sugarcane exposed to cold for 3 t
o 48 h. PMmA identified thirty cold-responsive genes previously unidentified in 
this public dataset. Fourteen genes were up-regulated, two had a variable expres
sion and the other fourteen were down-regulated in the treatments. These new fin
dings certainly were a consequence of using a superior statistical analysis appr
oach, since the original study did not take into account the dependence of data 
variability on the average signal intensity of each gene. The web interface, sup
plementary information, and the package source code are available, free, to non-
commercial users at http://ipe.cbmeg.unicamp.br/pub/PMmA.#^dnd^i1#^tm^len^kInten
sity-dependent selection of expression ratios^i1#^tm^len^kPipeline^i1#^tm^len^kB
ioArray Software Environment^i1#^tm^len^kNormalization^i1#^tm^len^kMacroarray, M
icroarray^i1#other#14#FAPESP#02/01167-1#03/07244-0#UNIEMP#CNPq#20060221#February
 21, 2006#20070202#February 2, 2007#6385.htm#Internet^ihttp://www.scielo.br/scie
lo.php?script=sci_arttext&pid=S0100-879X2007000500003##
00414000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018900070002000900259#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#5#1#article#46#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 615-619</B> </font> (Short Communication)</B></P>      
^cY#6385.htm##
00362000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704013700070002000900207#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#6#2#article#46#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">Pipeline for macro- and microarray analyse
s</font></B> </font>        ^cY#6385.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704039200070002000900462#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#7#3#article#46#<P><font face="Arial, Hel
vetica, sans-serif">R. Vicentini<SUP>1,2</SUP> and <span class="style4"><a href=
"#Correspondence"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>
    <a href="mailto:menossi@unicamp.br"><img src="/img/revistas/bjmbr/v40n5/emai
l-ca.gif" border="0"></a></span></font>    <font face="Arial, Helvetica, sans-se
rif">M. Menossi<SUP>1,2</SUP> </font>      ^cY#6385.htm##
00548000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704032300070002000900393#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#8#4#article#46#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Laborat&oacute;rio de Genoma Funcional, Centro d
e Biologia Molecular e Engenharia Gen&eacute;tica, <SUP>2</SUP>Departamento de G
en&eacute;tica e Evolu&ccedil;&atilde;o, Instituto de Biologia, Universidade Est
adual de Campinas, Campinas, SP, Brasil</font>        ^cY#6385.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#9#5#article#46#<P class="style4"> <A HRE
F="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6385.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#10#6#article#46#<BR>   <A HREF="#Text"><
img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6385.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#11#7#article#46#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6385.htm##
00483000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704025700071002000900328#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#12#8#article#46#<br>  </strong></A><font
 face="Arial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><img src="/img/r
evistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HR
EF="#Acknowledgments"><strong>Acknowledgments</strong></A></font>    ^cY#6385.ht
m##
00490000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704026400071002000900335#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#13#9#article#46#<BR>   <A HREF="#Corresp
ondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font face="Arial, Helv
etica, sans-serif">Correspondence    and Footnotes</font></strong></a>      ^cY#
6385.htm##
00291000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704006400072002000900136#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#14#10#article#46#<P class="style4">  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6385.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038600072002000900458#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#15#11#article#46#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4">Abstract</font><FONT COLOR=#00007F>    </FONT></span>
<A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" AL
IGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face
="Arial, Helvetica, sans-serif">       ^cY#6385.htm##
02006000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704177900072002000901851#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#16#12#article#46#<P>The pipeline for mac
ro- and microarray analyses (PMmA) is a set of scripts    with a web interface d
eveloped to analyze DNA array data generated by array    image quantification so
ftware. PMmA is designed for use with single- or double-color    array data and 
to work as a pipeline in five classes (data format, normalization,    data analy
sis, clustering, and array maps). It can also be used as a plugin    in the BioA
rray Software Environment, an open-source database for array analysis,    or use
d in a local version of the web service. All scripts in PMmA were developed    i
n the PERL programming language and statistical analysis functions were implemen
ted    in the R statistical language. Consequently, our package is a platform-in
dependent    software. Our algorithms can correctly select almost 90% of the dif
ferentially    expressed genes, showing a superior performance compared to other
 methods of    analysis. The pipeline software has been applied to 1536 expresse
d sequence    tags macroarray public data of sugarcane exposed to cold for 3 to 
48 h. PMmA    identified thirty cold-responsive genes previously unidentified in
 this public    dataset. Fourteen genes were up-regulated, two had a variable ex
pression and    the other fourteen were down-regulated in the treatments. These 
new findings    certainly were a consequence of using a superior statistical ana
lysis approach,    since the original study did not take into account the depend
ence of data variability    on the average signal intensity of each gene. The we
b interface, supplementary    information, and the package source code are avail
able, free, to non-commercial    users at <a href="http://ipe.cbmeg.unicamp.br/p
ub/PMmA" target="_blank">http://ipe.cbmeg.unicamp.br/pub/PMmA</a>.      ^cY#6385
.htm##
00433000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704020600072002000900278#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#17#13#article#46#<P><B>Key words: </B> I
ntensity-dependent selection of expression ratios, Pipeline, BioArray Software E
nvironment, Normalization, Macroarray, Microarray </font>  <HR ALIGN=LEFT WIDTH=
100% SIZE=2>       ^cY#6385.htm##
00586000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035900072002000900431#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#18#14#article#46#<P class="style4"><A NA
ME="Text"></A><FONT SIZE=4><B><font color="#00007F" face="Arial, Helvetica, sans
-serif">Text</font></B></FONT><A HREF="#Home"><img src="/img/revistas/bjmbr/v40n
5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></A>    <font face=
"Arial, Helvetica, sans-serif"></font></P>  <font face="Arial, Helvetica, sans-s
erif">      ^cY#6385.htm##
01475000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704124800072002000901320#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#19#15#article#46#<P>Expressed sequence t
ags (ESTs) have provided insights into transcribed genes in a variety of organis
ms and are widely used for gene discovery and expression analysis. DNA arrays ha
ve been used to study gene expression patterns on a genomic scale because they a
llow the simultaneous analysis of thousands of genes. DNA arrays consist of sets
 of probes, such as oligonucleotides or ESTs, that are arranged in an orderly ma
nner on a surface and are hybridized with cDNA obtained from different individua
ls, tissues or physiological states. The signal obtained from each sample is a <
I>bona fide</I> indicator of the amount of RNA in the cells, thus allowing the i
dentification of genes with significant changes in their expression. Arrays can 
be constructed using either a hand-held or a robotically controlled arraying pin
 tool. Each spot in the array has a specific address and represents an oligonucl
eotide or EST. Often the arrays may be constructed with technical replicates, wh
ere the same sequence is fixed in different spots. Surfaces such as glass (micro
arrays) (1) or nylon (macroarrays) (2) are ideal for arrays since nucleic acid c
an be immobilized, hybridized, and detected using the standard techniques of mol
ecular biology.      ^cY#6385.htm##
00823000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704059600072002000900668#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#20#16#article#46#<P>However, because of 
the characteristic noise of array data and the usually limited number of experim
ental replicates, the selection of differentially expressed genes is not easily 
determined (3). This is especially the case in macroarray experiments (4), where
 the requirement for larger amounts of RNA can be a limiting factor in the numbe
r of replicates, and each labeled cDNA sample is hybridized to a different nylon
 membrane, thereby increasing the data variability (in contrast to microarrays, 
in which two samples labeled with different dyes are hybridized on the same slid
e).      ^cY#6385.htm##
00930000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070300072002000900775#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#21#17#article#46#<P>The large amount of 
data obtained in these experiments makes the visualization and analysis of the r
esults challenging. We have developed a suite of interactive scripts (pipeline f
or macro- and microarray analyses, PMmA) that can be used as a pipeline to manag
e and to analyze data from macro- and microarrays. PMmA works with data generate
d by several types of image analysis software, has a web interface, and can be u
sed with a plug-in in the BioArray Software Environment (BASE), an open-source d
atabase (5). All modules in normalization, clustering and data analysis classes 
have plug-ins for installation in BASE. This make it easy for BASE users to run 
all analyses provided by PMmA.      ^cY#6385.htm##
00536000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030900072002000900381#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#22#18#article#46#<P>An important aspect 
of PMmA is its flexibility in handling data from spotted single-color arrays, su
ch as filter arrays (macroarrays). There are only a few free tools available for
 this technique (6), which is cheaper than microarrays and is easier to implemen
t in molecular biology laboratories.      ^cY#6385.htm##
01168000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094100072002000901013#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#23#19#article#46#<P>All scripts in PMmA 
were developed in the PERL programming language (7) and statistical analysis fun
ctions were implemented as scripts in the R statistical language (8). PERL and R
 are freely available under the GNU General Public License and can be used on a 
wide variety of platforms. Consequently, our package is a platform-independent s
oftware because it will run in Linux, Windows and MacOS, and has low hardware re
quirements (the minimum computer free space required is 2 MB). The user can also
 build a local version of the web service, although he will need a web server wi
th CGI allowed, and PERL and R language locally installed. For an optional inter
face with BASE, a local installation of this database is necessary. The basic st
eps for PMmA installation - the edition of a configuration file and the configur
ation of the web server to use the package - can be followed by any user with ba
sic concepts in informatics.      ^cY#6385.htm##
02465000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704223800072002000902310#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#24#20#article#46#<P>The PMmA package con
sists of ten modules that work in a web interface to provide easier access to th
e main computational environment. The input data converter is flexible and can u
se data from any image quantification software that generates tab-delimited data
 and information on the volume (pixel intensity in the spot area) and background
. The data normalization feature adjusts several effects of DNA array techniques
 and allows direct comparison of the data, thus compensating for variations betw
een cDNA labeling, hybridization, and so on. The value used to normalize the dat
a can be the median or average spot intensity, or a value selected by the user, 
such as the array global background. Flags with different meanings are generated
 by the module Arrayflags that can also combine the result with a map of spots i
n the array, thereby providing the user with a more complete output. These flags
 are calculated when spot and background intensities are closer or when there is
 wide variation between intensity of replicate spots. The plot tool easily gener
ates MA-plots, MS-plots and scatterplots using the normalized data. For experime
nts with three or more replicates, the Student <I>t</I>-test can be used to iden
tify genes that are up- or down-regulated by a given treatment, whereas when lit
tle or no replication of array hybridizations is available, intensity-dependent 
selection of expression ratios (ISER) can be used. In fact, ISER is designed to 
deal with data from single-replicated experiments, but can also be used when mor
e samples are compared or replicates are present (9). In this case, the algorith
m is applied separately to the comparison of each pair of samples and to each re
plicate, thus selecting genes that, for any pair of samples, are identified as d
ifferentially expressed in all replicates or in a large (pre-defined) proportion
 of them. The results of ISER or the Student <I>t</I>-test can also be grouped i
nto a more legible form that shows the percentage of genes that are up- or down-
regulated in each experiment. Finally, the output data may be clustered using hi
erarchical clustering or self-organizing map algorithms. The pipeline kernel des
ign is shown in <a href="#Fig1">Figure 1</a>.      ^cY#6385.htm##
00907000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704068000072002000900752#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#25#21#article#46#<P>To show this scripts
 in action we used the PMmA to analyze 1536 ESTs of sugarcane exposed to cold fo
r 3 to 48 h with control in 0 h (10). These data are taken from the Gene Express
ion Omnibus public database (11) under accession numbers GPL210 (platform), GSE8
3 and GSE84 (series), and GSM2431 to GSM2442 (samples). These data consist of a 
set of two high-density filters, each filter containing 768 ESTs in replicate, h
ybridized with a probe of cold treatment (0, 3, 6, 12, 24, and 48 h at 4&#186;C)
. <a href="#Fig2">Figure 2</a> shows the pipeline's graphic output for the compa
rison of 3-h (Data 1) versus 12-h (Data 2) cold treatment in the second filter. 
</font>      ^cY#6385.htm##
01665000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704143800072002000901510#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#26#22#article#46#<P><font face="Arial, H
elvetica, sans-serif">We noted that PMmA identified 61 clones with low-quality s
pots, which were excluded from analysis. Thirty cold-responsive genes that were 
not previously identified by the authors were found in our analysis. Fourteen we
re up-regulated, two had a variable expression and the other fourteen were down-
regulated in the treatments. These genes complemented the original results of No
gueira et al. (10), providing further characterization of the response of sugarc
ane to low temperatures, and their identification was certainly a consequence of
 using different statistical analysis approaches. In the original study, data an
alysis consisted of calculating the expression ratios (treatment/control) and th
eir logarithms for each time point and each replicate. Then, since these log rat
ios were assumed to be normally distributed, their mean and standard deviation w
ere calculated and the genes that showed a log ratio more than 1.65 standard dev
iations distant from the mean and a ratio <font face="Symbol">&#179;</font>2 (re
spectively <font face="Symbol">&#163;</font>0.5 for repressed genes) in both rep
licates were considered to be differentially expressed. This approach does not c
onsider the dependence of data variability on the average signal intensity of ea
ch gene and therefore it may select more false-positive genes than ISER. </font>
   <font face="Arial, Helvetica, sans-serif">      ^cY#6385.htm##
02022000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704179500072002000901867#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#27#23#article#46#<P>PMmA is available fr
ee and is a fully integrated tool that will facilitate the analysis of data from
 DNA arrays. Besides being integrated with BASE, an open-source database for DNA
 array analysis, PMmA normalizes the data, generates information about variation
s in expression, identifies up- or down-regulated genes using the Student <I>t</
I>-test and a new intensity-dependent algorithm developed by our group (ISER) (9
), and generates scatter plots, MA-plots, MS-plots, hierarchical clustering (12)
, and self-organizing maps (13). The use of the ISER algorithm can correctly sel
ect almost 90% of the differentially expressed genes. It is more sensitive to in
tensity-dependent bias in the data, thus showing a superior performance compared
 to the other methods of analysis, and was unaffected by the normalization adopt
ed. Additional new methods of analysis will be included in future versions of PM
mA, mainly the SAM method (14). This method is clearly better than the <I>t</I>-
test. The fundamental problem with the <I>t</I>-test for array experiments is th
at the repetition numbers are often small. In this case the problem is to obtain
 accurate estimates of the standard deviation of individual gene measurements ba
sed on only a few measurements. PMmA is particularly useful for the community th
at uses cDNA arrays. This package will help small labs with no access to a bioin
formatic center to perform modern computational analyses of genetic data.    </f
ont>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v4
0n5/html/6385i01.htm"><img src="/img/revistas/bjmbr/v40n5/6385i01peq.jpg" border
="2"></a></td>      <td width="88%"><font face="Arial, Helvetica, sans-serif">  
        ^cY#6385.htm##
00782000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704055500072002000900627#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#28#24#article#46#<P><a name="Fig1"></a>F
igure 1. The diagram of the pipeline for macro- and microarray analyses. A pipel
ine kernel diagram of pipeline for macro- and microarray analyses shows the ten 
modules in five classes (dotted boxes). Solid arrows indicate the flow of inform
ation and the dashed arrow indicates an optional flow. Note that the output of t
he analysis may be edited prior to appropriate clustering. ISER = intensity-depe
ndent selection of expression ratios.</font> </td>    </tr>  </table>  <font fac
e="Arial, Helvetica, sans-serif">  </font>      ^cY#6385.htm##
01435000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704120800072002000901280#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#29#25#article#46#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (75 K JPG file)]</font>
      <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <font face="Arial, Helvetica, sans-seri
f">  </font>  <table width="100%"  border="0">    <tr align="left" valign="top">
      <td width="12%"><a href="/img/revistas/bjmbr/v40n5/html/6385i02.htm"><img 
src="/img/revistas/bjmbr/v40n5/6385i02peq.jpg" border="2"></a></td>      <td wid
th="88%"><font face="Arial, Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. 
Data analysis with the pipeline for macro- and microarray analyses. Hybridizatio
n with RNA from sugarcane plants exposed to cold stress for 3 and 12 h. <I>A</I>
, Intensity-dependent selection of expression ratios graphic output displaying t
he selection of differentially expressed genes, between 3 (Data 1) and 12 h (Dat
a 2), based on the data variability dependence of intensities. <I>B</I>, Scatter
plot displaying the log<SUB>2</SUB> normalized data. <I>C</I> and <I>D</I>, MA- 
and MS-plots with lowess correction. m2e1 and m2e2 codes indicate the membrane (
m) and experiment (e) numbers defined by the user. </font></td>    </tr>  </tabl
e>  <font face="Arial, Helvetica, sans-serif">  </font>      ^cY#6385.htm##
00382000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015500072002000900227#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#30#26#article#46#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (138 K JPG file)]</font
>       <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6385.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#31#27#article#46#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6385.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017900074002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#32#28#article#46#1#<P>1. Sch
ena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression 
patterns with a complementary DNA microarray. <I>Science</I> 1995; 270: 467-470.
      ^cY#6385.htm##
00412000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017100074002000900245#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#33#29#article#46#2#<P>2. Des
prez T, Amselem J, Caboche M, Hofte H. Differential gene expression in <I>Arabid
opsis</I> monitored using cDNA arrays. <I>Plant J</I> 1998; 14: 643-652.      ^c
Y#6385.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024100074002000900315#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#34#30#article#46#3#<P>3. Lee
 ML, Kuo FC, Whitmore GA, Sklar J. Importance of replication in microarray gene 
expression studies: statistical methods and evidence from repetitive cDNA hybrid
izations. <I>Proc Natl Acad Sci U S A</I> 2000; 97: 9834-9839.      ^cY#6385.htm
##
00405000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016400074002000900238#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#35#31#article#46#4#<P>4. Fre
eman WM, Robertson DJ, Vrana KE. Fundamentals of DNA hybridization arrays for ge
ne expression analysis. <I>Biotechniques</I> 2000; 29: 1042-1055.      ^cY#6385.
htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024400074002000900318#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#36#32#article#46#5#<P>5. Saa
l LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArra
y Software Environment (BASE): a platform for comprehensive management and analy
sis of microarray data. <I>Genome Biol</I> 2002; 3: SOFTWARE0003.      ^cY#6385.
htm##
00395000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015400074002000900228#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#37#33#article#46#6#<P>6. Dud
oit S, Gentleman RC, Quackenbush J. Open source software for the analysis of mic
roarray data. <I>Biotechniques</I> 2003; Suppl: 45-51.       ^cY#6385.htm##
00375000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704013400074002000900208#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#38#34#article#46#7#<P>7. The
 Source for Perl. <a href="http://www.perl.com" target="_blank">http://www.perl.
com</a>.    Accessed July 11, 2006.      ^cY#6385.htm##
00405000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016400074002000900238#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#39#35#article#46#8#<P>8. The
 R Project for Statistical Computing. <a href="http://www.r-project.org" target=
"_blank">http://www.r-project.org</a>.    Accessed July 11, 2006.      ^cY#6385.
htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022800074002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#40#36#article#46#9#<P>9. Dru
mmond RD, Pinheiro A, Rocha CS, Menossi M. ISER: selection of differentially exp
ressed genes from DNA array data by non-linear data transformations and local fi
tting. <I>Bioinformatics</I> 2005; 21: 4427-4429.      ^cY#6385.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020000075002000900275#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#41#37#article#46#10#<P>10. N
ogueira FT, de Rosa VE Jr, Menossi M, Ulian EC, Arruda P. RNA expression profile
s and data mining of sugarcane response to low temperature. <I>Plant Physiol</I>
 2003; 132: 1811-1824.      ^cY#6385.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017800075002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#42#38#article#46#11#<P>11. E
dgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and 
hybridization array data repository. <I>Nucleic Acids Res</I> 2002; 30: 207-210.
      ^cY#6385.htm##
00423000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018100075002000900256#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#43#39#article#46#12#<P>12. E
isen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of geno
me-wide expression patterns. <I>Proc Natl Acad Sci U S A</I> 1998; 95: 14863-148
68.      ^cY#6385.htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026800075002000900343#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#44#40#article#46#13#<P>13. T
amayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, et al. Interpre
ting patterns of gene expression with self-organizing maps: methods and applicat
ion to hematopoietic differentiation. <I>Proc Natl Acad Sci U S A</I> 1999; 96: 
2907-2912.      ^cY#6385.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022600075002000900301#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#p#45#41#article#46#14#<P>14. T
usher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to t
he ionizing radiation response. <I>Proc Natl Acad Sci U S A </I>2001; 98: 5116-5
121.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6385.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040100072002000900473#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#46#42#article#46#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=#00
007F><B>Acknowledgments</B></FONT></FONT></font> <font face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></font>
</P>  <font face="Arial, Helvetica, sans-serif">      ^cY#6385.htm##
00509000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028200072002000900354#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#47#43#article#46#<P>The authors thank Cr
istiane de Souza Rocha (Laborat&oacute;rio de Genoma Funcional, Centro de Biolog
ia Molecular e Engenharia Gen&eacute;tica, Universidade Estadual de Campinas, Ca
mpinas, SP, Brazil) for technical assistance.  </font>  <HR ALIGN=LEFT WIDTH=100
% SIZE=2>      ^cY#6385.htm##
00514000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028700072002000900359#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#48#44#article#46#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B>Correspondence and F
ootnotes</B></FONT></FONT> <A HREF="#Home"><FONT SIZE=4><B><img src="/img/revist
as/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></
FONT></A></P>       ^cY#6385.htm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047000072002000900542#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#49#45#article#46#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence: </B><font face="Arial, Helvetica, sans-serif"> M.   
 Menossi, Laborat&oacute;rio de Genoma Funcional, Centro de Biologia Molecular  
  e Engenharia Gen&eacute;tica, UNICAMP, Caixa Postal 6010, 13083-875 Campinas, 
   SP, Brasil. Fax: +55-19-3521-1089. E-mail: <a href="mailto:menossi@unicamp.br
">menossi@unicamp.br</a></font>  </P>      ^cY#6385.htm##
00601000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037400072002000900446#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6385.htm#S#p#50#46#article#46#<P><font face="Arial, H
elvetica, sans-serif">Research partially supported by FAPESP (Nos. 02/01167-1 an
d 03/07244-0). R. Vicentini was supported by a fellowship from Instituto UNIEMP 
and M. Menossi was the recipient of a research fellowship from CNPq. Received Fe
bruary 21, 2006. Accepted February 2, 2007.</font><font face="Arial, Helvetica, 
sans-serif"> </font>       ^cY#6385.htm##
00601000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100016000890100
01600105010001600121012009200137030000800229065000900237064000500246031000400251
014000800255865000900263002000900272035001000281801000800291#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6385.htm#S#c#51#1#article#14#1#^rND^sSchena^nM#^rND^sShal
on^nD#^rND^sDavis^nRW#^rND^sBrown^nPO#Quantitative monitoring of gene expression
 patterns with a complementary DNA microarray^len#Science#19950000#1995#270#467-
470#20070500#6385.htm#0036-8075#Science##
00586000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100017000900100
01700107010001500124012007600139030000800215065000900223064000500232031000300237
014000800240865000900248002000900257035001000266801000800276#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6385.htm#S#c#52#2#article#14#2#^rND^sDesprez^nT#^rND^sAms
elem^nJ#^rND^sCaboche^nM#^rND^sHofte^nH#Differential gene expression in Arabidop
sis monitored using cDNA arrays^len#Plant J#19980000#1998#14#643-652#20070500#63
85.htm#0960-7412#Plant J##
00680000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100014000870100
01900101010001500120012013800135030002500273065000900298064000500307031000300312
014001000315865000900325002000900334035001000343801002500353#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6385.htm#S#c#53#3#article#14#3#^rND^sLee^nML#^rND^sKuo^nF
C#^rND^sWhitmore^nGA#^rND^sSklar^nJ#Importance of replication in microarray gene
 expression studies: statistical methods and evidence from repetitive cDNA hybri
dizations^len#Proc Natl Acad Sci U S A#20000000#2000#97#9834-9839#20070500#6385.
htm#0027-8424#Proc Natl Acad Sci U S A##
00574000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100020000910100
01600111012007400127030001400201065000900215064000500224031000300229014001000232
865000900242002000900251035001000260801001400270#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6385.htm#S#c#54#4#article#14#4#^rND^sFreeman^nWM#^rND^sRobertson^nDJ#
^rND^sVrana^nKE#Fundamentals of DNA hybridization arrays for gene expression ana
lysis^len#Biotechniques#20000000#2000#29#1042-1055#20070500#6385.htm#0736-6205#B
iotechniques##
00674000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100016000880100
02900104010002000133010001400153010001800167012011400185030001200299710000200311
065000900313064000500322031000200327061001300329865000900342002000900351#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#c#55#5#article#14#5#^rND^sSaal^nLH
#^rND^sTroein^nC#^rND^sVallon-Christersson^nJ#^rND^sGruvberger^nS#^rND^sBorg^nA#
^rND^sPeterson^nC#BioArray Software Environment (BASE): a platform for comprehen
sive management and analysis of microarray data^len#Genome Biol#2#20020000#2002#
3#SOFTWARE0003#20070500#6385.htm##
00563000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100020000890100
02100109012006100130030001400191065000900205064000500214031000600219014000600225
865000900231002000900240035001000249801001400259#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6385.htm#S#c#56#6#article#14#6#^rND^sDudoit^nS#^rND^sGentleman^nRC#^r
ND^sQuackenbush^nJ#Open source software for the analysis of microarray data^len#
Biotechniques#20030000#2003#Suppl#45-51#20070500#6385.htm#0736-6205#Biotechnique
s##
00348000000000193000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710170020000730620020000930610
02300113865000900136002000900145#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.
htm#S#c#57#7#article#14#7#The Source for Perl#http://www.perl.com#Accessed July 
11, 2006#20070500#6385.htm##
00373000000000193000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710170040000730620025001130610
02300138865000900161002000900170#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.
htm#S#c#58#8#article#14#8#The R Project for Statistical Computing#http://www.r-p
roject.org#Accessed July 11, 2006#20070500#6385.htm##
00657000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100018000920100
01600110010001700126012012700143030001500270065000900285064000500294031000300299
014001000302865000900312002000900321035001000330801001500340#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6385.htm#S#c#59#9#article#14#9#^rND^sDrummond^nRD#^rND^sP
inheiro^nA#^rND^sRocha^nCS#^rND^sMenossi^nM#ISER: selection of differentially ex
pressed genes from DNA array data by non-linear data transformations and local f
itting^len#Bioinformatics#20050000#2005#21#4427-4429#20070500#6385.htm#0927-4588
#BIOINFORMATICS##
00647000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100021000940100
01700115010001600132010001600148012008500164030001400249065000900263064000500272
031000400277014001000281865000900291002000900300035001000309801001400319#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#c#60#10#article#14#10#^rND^sNoguei
ra^nFT#^rND^sde^nRosa VE Jr#^rND^sMenossi^nM#^rND^sUlian^nEC#^rND^sArruda^nP#RNA
 expression profiles and data mining of sugarcane response to low temperature^le
n#Plant Physiol#20030000#2003#132#1811-1824#20070500#6385.htm#0032-0889#Plant Ph
ysiol##
00593000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100019000900100
01500109012009000124030001800214065000900232064000500241031000300246014000800249
865000900257002000900266035001000275801001800285#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6385.htm#S#c#61#11#article#14#11#^rND^sEdgar^nR#^rND^sDomrachev^nM#^r
ND^sLash^nAE#Gene Expression Omnibus: NCBI gene expression and hybridization arr
ay data repository^len#Nucleic Acids Res#20020000#2002#30#207-210#20070500#6385.
htm#0305-1048#Nucleic Acids Res##
00621000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100019000910100
01600110010001800126012006800144030002500212065000900237064000500246031000300251
014001200254865000900266002000900275035001000284801002500294#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6385.htm#S#c#62#12#article#14#12#^rND^sEisen^nMB#^rND^sSp
ellman^nPT#^rND^sBrown^nPO#^rND^sBotstein^nD#Cluster analysis and display of gen
ome-wide expression patterns^len#Proc Natl Acad Sci U S A#19980000#1998#95#14863
-14868#20070500#6385.htm#0027-8424#Proc Natl Acad Sci U S A##
00755000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100016000910100
01700107010001300124010002000137010002000157810000600177012012900183030002500312
06500090033706400050034603100030035101400100035486500090036400200090037303500100
0382801002500392#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6385.htm#S#c#63#13#ar
ticle#14#13#^rND^sTamayo^nP#^rND^sSlonim^nD#^rND^sMesirov^nJ#^rND^sZhu^nQ#^rND^s
Kitareewan^nS#^rND^sDmitrovsky^nE#et al#Interpreting patterns of gene expression
 with self-organizing maps: methods and application to hematopoietic differentia
tion^len#Proc Natl Acad Sci U S A#19990000#1999#96#2907-2912#20070500#6385.htm#0
027-8424#Proc Natl Acad Sci U S A##
00604000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100020000920100
01300112012008400125030002500209065000900234064000500243031000300248014001000251
865000900261002000900270035001000279801002500289#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6385.htm#S#c#64#14#article#14#14#^rND^sTusher^nVG#^rND^sTibshirani^nR
#^rND^sChu^nG#Significance analysis of microarrays applied to the ionizing radia
tion response^len#Proc Natl Acad Sci U S A#20010000#2001#98#5116-5121#20070500#6
385.htm#0027-8424#Proc Natl Acad Sci U S A##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#o#1#1#article#1#20
080212#125658#6426.htm#121##
03681000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400110014503500100015622300090
01660120077001750100025002520100025002770100026003020700081003280700163004090832
19000572085000802762085002002770085001902790085003902809085002002848085002402868
11700060289207200030289805800070290105800050290805800320291306000090294505800060
2954112000902960111001502969114000902984113001702993881002403010002000903034#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#h#2#1#article#1#oa#en#bjmbr#1#
3.1#ILUS#TAB#11#BJMBR080#nd#Braz J Med Biol Res#40#5#20070500#^f679^l686#0100-87
9X#20070322#Biphasic modulation of insulin receptor substrate-1 during goitrogen
esis^len#^rND^1A01^nR.^sGrozovsky#^rND^1A02^nM.M.^sMorales#^rND^1A01^nD.P.^sCarv
alho#Universidade Federal do Rio de Janeiro^iA01^1Laboratório de Fisiologia Endó
crina#Universidade Federal do Rio de Janeiro^iA02^1Instituto de Biofísica Carlos
 Chagas Filho^2Laboratório de Fisiologia Celular e Molecular^cRio de Janeiro^sRJ
^pBrasil#^len^aInsulin receptor substrate-1 (IRS-1) is the main intracellular su
bstrate for both insulin and insulin-like growth factor I (IGF-I) receptors and 
is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell pro
liferation through the cyclic AMP intracellular cascade; however, the presence o
f either insulin or IGF-I is required for the mitogenic effect of thyroid-stimul
ating hormone (TSH) to occur. The aim of the present study was to determine whet
her thyroid IRS-1 content is modulated by TSH in vivo. Strikingly, hypothyroid g
oitrous rats, which have chronically high serum TSH levels (control, C = 2.31 ± 
0.28; methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated wit
h 0.03% MMI in drinking water for 21 days, showed significantly reduced thyroid 
IRS-1 mRNA content. Since goiter was already established in these animals by MMI
 for 21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals t
reated with MMI for different periods of time showed a progressive increase in t
hyroid weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MM
I 10d = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.
9 ± 3.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; M
MI 5d = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25
.65 ± 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals
 per group). Thyroid IRS-1 mRNA expression increased progressively during goitro
genesis, being significantly higher by the 14th day of MMI treatment, and then s
tarted to decline, reaching the lowest values by the 21st day, when a significan
t reduction was detected. In the liver of these animals, however, a significant 
decrease of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism 
probably involved in the insulin resistance that occurs in hypothyroidism. The i
ncrease in IRS-1 expression during goitrogenesis may represent an important even
t associated with the increased rate of cell mitosis promoted by TSH and indicat
es that insulin and IGF-I are important co-mitogenic factors in vivo, possibly a
cting through the activation of IRS-1.#^dnd^i1#^tm^len^kThyroid^i1#^tm^len^kGoit
er^i1#^tm^len^kInsulin receptor substrate^i1#^tm^len^kInsulin^i1#^tm^len^kThyrot
ropin^i1#other#27#FAPERJ#CNPq#Howard Hughes Medical Institute#55003669#CAPES#200
60321#March 21, 2006#20070119#January 19, 2007#S0100-879X2006005000090#6426.htm#
#
03659000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400110014503500100015622300090
01660120077001750100025002520100025002770100026003020700081003280700163004090832
20400572085000802776085002002784085001902804085003902823085002002862085002402882
11700060290607200030291205800070291505800050292205800320292706000090295905800060
2968112000902974111001502983114000902998113001703007002000903024#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB
#11#BJMBR080#nd#Braz J Med Biol Res#40#5#20070500#^f679^l686#0100-879X#20070322#
Biphasic modulation of insulin receptor substrate-1 during goitrogenesis^len#^rN
D^1A01^nR.^sGrozovsky#^rND^1A02^nM.M.^sMorales#^rND^1A01^nD.P.^sCarvalho#Univers
idade Federal do Rio de Janeiro^iA01^1Laboratório de Fisiologia Endócrina#Univer
sidade Federal do Rio de Janeiro^iA02^1Instituto de Biofísica Carlos Chagas Filh
o^2Laboratório de Fisiologia Celular e Molecular^cRio de Janeiro^sRJ^pBrasil#^le
n^aInsulin receptor substrate-1 (IRS-1) is the main intracellular substrate for 
both insulin and insulin-like growth factor I (IGF-I) receptors and is critical 
for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation t
hrough the cyclic AMP intracellular cascade; however, the presence of either ins
ulin or IGF-I is required for the mitogenic effect of thyroid-stimulating hormon
e (TSH) to occur. The aim of the present study was to determine whether thyroid 
IRS-1 content is modulated by TSH<i> in vivo</i>. Strikingly, hypothyroid goitro
us rats, which have chronically high serum TSH levels (control, C = 2.31 ± 0.28;
 methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.0
3% MMI in drinking water for 21 days, showed significantly reduced thyroid IRS-1
 mRNA content. Since goiter was already established in these animals by MMI for 
21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals treate
d with MMI for different periods of time showed a progressive increase in thyroi
d weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d
 = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3
.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d
 = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ±
 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per 
group). Thyroid IRS-1 mRNA expression increased progressively during goitrogenes
is, being significantly higher by the 14th day of MMI treatment, and then starte
d to decline, reaching the lowest values by the 21st day, when a significant red
uction was detected. In the liver of these animals, however, a significant decre
ase of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism proba
bly involved in the insulin resistance that occurs in hypothyroidism. The increa
se in IRS-1 expression during goitrogenesis may represent an important event ass
ociated with the increased rate of cell mitosis promoted by TSH and indicates th
at insulin and IGF-I are important co-mitogenic factors <i>in vivo</i>, possibly
 acting through the activation of IRS-1.#^dnd^i1#^tm^len^kThyroid^i1#^tm^len^kGo
iter^i1#^tm^len^kInsulin receptor substrate^i1#^tm^len^kInsulin^i1#^tm^len^kThyr
otropin^i1#other#27#FAPERJ#CNPq#Howard Hughes Medical Institute#55003669#CAPES#2
0060321#March 21, 2006#20070119#January 19, 2007#6426.htm##
03812000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800030012003000240012303100030014703200020015006500090015201400110016103500100
01722230009001820120077001910100024002680100025002920100026003170700111003430700
16500454083219700619085000802816085002002824085001902844085003902863085002002902
08500240292211700060294607200030295205800070295505800050296205800320296706000090
29990580006030081120009030141110015030231140009030381130017030470020009030640080
08903073#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#l#4#1#article#1#^m
May^a2007#oa#en#bjmbr#1#3.1#ilus#tab#11#BJMBR080#nd#Braz. j. med. biol. res#40#5
#20070500#^f679^l686#0100-879X#20070322#Biphasic modulation of insulin receptor 
substrate-1 during goitrogenesis^len#^rND^1A01^nR^sGrozovsky#^rND^1A02^nM. M^sMo
rales#^rND^1A01^nD. P^sCarvalho#^iA01^1Universidade Federal do Rio de Janeiro^2L
aboratório de Fisiologia Endócrina^cRio de Janeiro^sRJ^pBrasil#^iA02^1Universida
de Federal do Rio de Janeiro^2Instituto de Biofísica Carlos Chagas Filho^3Labora
tório de Fisiologia Celular e Molecular^cRio de Janeiro^sRJ^pBrasil#^len^aInsuli
n receptor substrate-1 (IRS-1) is the main intracellular substrate for both insu
lin and insulin-like growth factor I (IGF-I) receptors and is critical for cell 
mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through th
e cyclic AMP intracellular cascade; however, the presence of either insulin or I
GF-I is required for the mitogenic effect of thyroid-stimulating hormone (TSH) t
o occur. The aim of the present study was to determine whether thyroid IRS-1 con
tent is modulated by TSH in vivo. Strikingly, hypothyroid goitrous rats, which h
ave chronically high serum TSH levels (control, C = 2.31 ± 0.28; methimazole (MM
I) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.03 percent MMI in
 drinking water for 21 days, showed significantly reduced thyroid IRS-1 mRNA con
tent. Since goiter was already established in these animals by MMI for 21 days, 
we also evaluated IRS-1 expression during goitrogenesis. Animals treated with MM
I for different periods of time showed a progressive increase in thyroid weight 
(C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d = 33.8 ±
 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3.92 mg, N
 = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d = 9.95 ±
 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ± 1.23; MM
I 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per group). T
hyroid IRS-1 mRNA expression increased progressively during goitrogenesis, being
 significantly higher by the 14th day of MMI treatment, and then started to decl
ine, reaching the lowest values by the 21st day, when a significant reduction wa
s detected. In the liver of these animals, however, a significant decrease of IR
S-1 mRNA was detected after 14 days of MMI treatment, a mechanism probably invol
ved in the insulin resistance that occurs in hypothyroidism. The increase in IRS
-1 expression during goitrogenesis may represent an important event associated w
ith the increased rate of cell mitosis promoted by TSH and indicates that insuli
n and IGF-I are important co-mitogenic factors in vivo, possibly acting through 
the activation of IRS-1.#^dnd^i1#^tm^len^kThyroid^i1#^tm^len^kGoiter^i1#^tm^len^
kInsulin receptor substrate^i1#^tm^len^kInsulin^i1#^tm^len^kThyrotropin^i1#other
#27#FAPERJ#CNPq#Howard Hughes Medical Institute#55003669#CAPES#20060321#March 21
, 2006#20070119#January 19, 2007#6426.htm#Internet^ihttp://www.scielo.br/scielo.
php?script=sci_arttext&pid=S0100-879X2007000500011##
00370000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014500070002000900215#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#5#1#article#90#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, May 2007, Volume
 40(5) 679-686</B> </font></P>      ^cY#6426.htm##
00391000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704016600070002000900236#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#6#2#article#90#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">Biphasic modulation of insulin receptor su
bstrate-1 during goitrogenesis</font></B> </font>        ^cY#6426.htm##
00577000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704035200070002000900422#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#7#3#article#90#<P><font face="Arial, Hel
vetica, sans-serif">R. Grozovsky<SUP>1</SUP>, M.M. Morales<SUP>2</SUP>    and <b
><a href="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border
="0"></a></b>    <a href="mailto:dencarv@biof.ufrj.br"><img src="/img/revistas/b
jmbr/v40n5/email-ca.gif" border="0"></a>    D.P. Carvalho<SUP>1</SUP> </font>   
   ^cY#6426.htm##
00534000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704030900070002000900379#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#8#4#article#90#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Laborat&oacute;rio de Fisiologia End&oacute;crin
a, <SUP>2</SUP>Laborat&oacute;rio de Fisiologia Celular e Molecular, Instituto d
e Biof&iacute;sica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 
Rio de Janeiro, RJ, Brasil</font>       ^cY#6426.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019000070002000900260#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#9#5#article#90#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#6426.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#10#6#article#90#<BR>   <A HREF="#Introdu
ction"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6426.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#11#7#article#90#<BR>   <A HREF="#Materia
l"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#6426.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704017200071002000900243#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#12#8#article#90#<BR>   <A HREF="#Results
"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6426.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018100071002000900252#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#13#9#article#90#<BR>   <A HREF="#Discuss
ion"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#642
6.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#14#10#article#90#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6426.htm##
00436000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704020900072002000900281#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#15#11#article#90#<br>   </strong></A><A 
HREF="#Acknowledgments"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#6426.htm##
00445000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021800072002000900290#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#16#12#article#90#<BR>   <A HREF="#Corres
pondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#6426.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#17#13#article#90#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6426.htm##
00494000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704026700072002000900339#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#18#14#article#90#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font> </P>      
^cY#6426.htm##
02567000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704234000072002000902412#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#19#15#article#90#<P><font face="Arial, H
elvetica, sans-serif">Insulin receptor substrate-1 (IRS-1) is the main intracell
ular substrate for both insulin and insulin-like growth factor I (IGF-I) recepto
rs and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid c
ell proliferation through the cyclic AMP intracellular cascade; however, the pre
sence of either insulin or IGF-I is required for the mitogenic effect of thyroid
-stimulating hormone (TSH) to occur. The aim of the present study was to determi
ne whether thyroid IRS-1 content is modulated by TSH<I> in vivo</I>. Strikingly,
 hypothyroid goitrous rats, which have chronically high serum TSH levels (contro
l, C = 2.31 &#177; 0.28; methimazole (MMI) 21d = 51.02 &#177; 6.02 ng/mL, N = 12
 rats), when treated with 0.03% MMI in drinking water for 21 days, showed signif
icantly reduced thyroid IRS-1 mRNA content. Since goiter was already established
 in these animals by MMI for 21 days, we also evaluated IRS-1 expression during 
goitrogenesis. Animals treated with MMI for different periods of time showed a p
rogressive increase in thyroid weight (C = 22.18 &#177; 1.21; MMI 5d = 32.83 &#1
77; 1.48; MMI 7d = 31.1 &#177; 3.25; MMI 10d = 33.8 &#177; 1.25; MMI 14d = 45.5 
&#177; 2.56; MMI 18d = 53.0 &#177; 3.01; MMI 21d = 61.9 &#177; 3.92 mg, N = 9-15
 animals per group) and serum TSH levels (C = 1.57 &#177; 0.2; MMI 5d = 9.95 &#1
77; 0.74; MMI 7d = 10.38 &#177; 0.84; MMI 10d = 17.72 &#177; 1.47; MMI 14d = 25.
65 &#177; 1.23; MMI 18d = 35.38 &#177; 3.69; MMI 21d = 31.3 &#177; 2.7 ng/mL, N 
= 9-15 animals per group). Thyroid IRS-1 mRNA expression increased progressively
 during goitrogenesis, being significantly higher by the 14th day of MMI treatme
nt, and then started to decline, reaching the lowest values by the 21st day, whe
n a significant reduction was detected. In the liver of these animals, however, 
a significant decrease of IRS-1 mRNA was detected after 14 days of MMI treatment
, a mechanism probably involved in the insulin resistance that occurs in hypothy
roidism. The increase in IRS-1 expression during goitrogenesis may represent an 
important event associated with the increased rate of cell mitosis promoted by T
SH and indicates that insulin and IGF-I are important co-mitogenic factors <I>in
 vivo</I>, possibly acting through the activation of IRS-1. </font>      ^cY#642
6.htm##
00409000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018200072002000900254#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#20#16#article#90#<P><font face="Arial, H
elvetica, sans-serif"><B>Key words: </B> Thyroid, Goiter, Insulin receptor subst
rate, Insulin, Thyrotropin</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6
426.htm##
00664000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043700072002000900509#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#21#17#article#90#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Introduction</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-se
rif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gi
f" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font fac
e="Arial, Helvetica, sans-serif"></font>  <font face="Arial, Helvetica, sans-ser
if">      ^cY#6426.htm##
01182000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704095500072002000901027#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#22#18#article#90#<P>Thyroid gland prolif
eration is under the control of several hormones and growth factors (1-3). Thyro
id-stimulating hormone (TSH) is the main regulator of thyroid cell function and 
proliferation, although several studies using cell culture systems have establis
hed that TSH alone is not a mitogenic factor. In fact, progression of the thyroi
d cell cycle depends on the concerted action of TSH and insulin and/or insulin-l
ike growth factor I (IGF-I), which function as co-mitogenic factors (1-6). Previ
ous studies have demonstrated the presence of IGF-I (IGF-IR) and insulin (IR) re
ceptors in thyrocytes in culture and in human thyroid tissues (4,7). IGF-I can a
lso act as a co-mitogenic factor <I>in vivo</I>, since high goiter prevalence is
 found in acromegaly, a disease characterized by elevated serum IGF-I levels (8)
. Furthermore, transgenic mice overexpressing IGF-I and IGF-IR in the thyroid ha
ve lower TSH requirements and goiter (9).       ^cY#6426.htm##
01072000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084500072002000900917#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#23#19#article#90#<P>The main physiologic
al action of insulin involves glucose, protein and lipid metabolism, whereas IGF
-I acts mainly as a mitogenic hormone (10). Insulin and IGF-I bind to different 
receptors that have a high degree of homology and share a common intracellular p
athway. Activation of either IGF-IR or IR triggers a tyrosine kinase intracellul
ar pathway leading to the phosphorylation of insulin receptor substrate-1 (IRS-1
), the main IR and IGF-IR substrate (11,12). The phosphorylated tyrosine residue
s of IRS-1 are recognized by molecules containing an Src homology 2 domain, whic
h include the growth factor receptor-bound protein and the 85-kDa regulatory sub
unit of phosphatidyl-inositol 3 kinase. The phosphatidyl-inositol 3 kinase signa
ling pathway mediates many cellular events, including increased cellular prolife
ration (13).      ^cY#6426.htm##
00793000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056600072002000900638#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#24#20#article#90#<P>IRS-1 activation is 
critical for cell mitogenesis and its overexpression is associated with neoplast
ic transformation (14). Thus, IRS-1 plays an important role in both cell prolife
ration and differentiation. In cell cultures, TSH positively modulates IR expres
sion through cAMP, in addition to increasing IR and IGF-IR autophosphorylation (
4,15). Taken together, these findings seem to be important for cell cycle progre
ssion and mitosis, although under certain experimental conditions IGF-IR number 
and kinase activity were not increased by cAMP (16).       ^cY#6426.htm##
01061000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704083400072002000900906#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#25#21#article#90#<P>In FRTL-5 cells, TSH
 modulates IR substrates via the cAMP cascade (17). Thus, the aim of the present
 study was to evaluate the regulation of thyroid IRS-1 expression during a mitog
enic stimulus<I> in vivo</I>. We show that in hypothyroid goitrous animals, with
 chronically increased serum TSH levels, thyroid IRS-1 mRNA and protein expressi
on are down-regulated, while during goitrogenesis a biphasic modulation is obser
ved, with an increased IRS-1 content coinciding with the time of greater thyroid
 weight increase. Thus, depending on the rate of thyroid cell proliferation, the
 intracellular pathways may be differently regulated. The present data can proba
bly explain, at least in part, the controversial findings regarding thyroid cell
 proliferation in cell culture models.  </font> <HR ALIGN=LEFT WIDTH=100% SIZE=2
>      ^cY#6426.htm##
00573000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034600072002000900418#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#26#22#article#90#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Material and Methods</B></FONT></FONT></font> <font face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^
cY#6426.htm##
00306000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007900072002000900151#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#27#23#article#90#<P> <font face="Arial, 
Helvetica, sans-serif"><b>Material</b> </font>      ^cY#6426.htm##
00824000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704059700072002000900669#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#28#24#article#90#<P><font face="Arial, H
elvetica, sans-serif">L-thyroxine, methimazole (MMI), bovine serum albumin, and 
chemicals for protein extraction were from Sigma (St. Louis, MO, USA); anti-IRS-
1 primary antibody (goat IgG) and secondary anti-goat IgG antibody were purchase
d from Santa Cruz (Santa Cruz, CA, USA). Chemicals for RNA extraction and RT-PCR
 were purchased from Invitrogen Corporation (Carlsbad, CA, USA), 4',6'-diamidino
-2-phenylindole (DAPI) was purchased from Calbiochem (San Diego, CA, USA) and EC
L reagent for chemiluminescence was from Amersham (Buckinghamshire, England).</f
ont>      ^cY#6426.htm##
00303000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007600072002000900148#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#29#25#article#90#<P><font face="Arial, H
elvetica, sans-serif"><B>Animals</B></font>      ^cY#6426.htm##
00823000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704059600072002000900668#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#30#26#article#90#<P><font face="Arial, H
elvetica, sans-serif">Adult male Wistar rats weighing 200 to 250 g were housed u
nder controlled conditions of temperature (24 &#177; 1&#186;C) and light (12-h l
ight starting at 7:00 am). All experiments were conducted in accordance with sta
ndards of animal care and were approved by the Institutional Committee for Evalu
ation of Animal Use in Research (CAUAP/IBCCF). Rats were divided into two experi
mental groups: hypothyroidism was induced by the addition of 0.03% MMI to the dr
inking water for 21 days and control rats received water <I>ad libitum</I>. </fo
nt>      ^cY#6426.htm##
00754000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704052700072002000900599#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#31#27#article#90#<P><font face="Arial, H
elvetica, sans-serif">In order to evaluate IRS-1 modulation during goitrogenesis
, rats were divided into seven experimental groups. A control group received wat
er <I>ad libitum</I>, and goiter was induced in the seven experimental groups by
 0.03% MMI treatment in drinking water for different periods of time (5, 7, 10, 
14, 18, 21, and 26 days). Experiments were designed in such a way that all anima
ls were sacrificed on the same day. In each experimental group, 9-15 animals wer
e used.</font>      ^cY#6426.htm##
00321000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009400072002000900166#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#32#28#article#90#<P><font face="Arial, H
elvetica, sans-serif"><B>RNA extraction and RT-PCR</B></font>      ^cY#6426.htm#
#
00773000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704054600072002000900618#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#33#29#article#90#<P><font face="Arial, H
elvetica, sans-serif">Total RNA was extracted from a pool of two rat thyroid gla
nds or 50 mg of liver using Trizol<SUP>&#174;</SUP> reagent according to the man
ufacturer's protocol. RNA samples were treated with deoxyribonuclease I (Boehrin
ger, Mannheim, Germany) in order to destroy possible DNA contamination. RNA was 
quantitated by absorbance at 260 nm using a Hitachi spectrophotometer (U-3000, T
okyo, Japan), and RNA integrity was tested by separating the samples by 0.8% aga
rose gel electrophoresis. </font>      ^cY#6426.htm##
01040000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704081300072002000900885#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#34#30#article#90#<P><font face="Arial, H
elvetica, sans-serif">First-strand complementary DNA (cDNA) was synthesized usin
g different amounts of purified RNA, 50 &#181;M Oligo dT, 1 U reverse transcript
ase (Superscript RNase H-reverse transcriptase), 5X first strand buffer, 10 U RN
Asin, and 10 &#181;M dNTP. cDNA was submitted to the polymerase chain reaction (
PCR) using specific primers for rat IRS-1 (50 pmol): forward: 5'-CACCCAGTTTTT CG
ACAC-3', and reverse: 5'-GAGTTGAGC TTCACAAAG-3'. The rat &szlig;-actin primers (
20 pmol) predicted to amplify the 226-bp PCR product (sense: 5'-TATGCCAACACA GTG
CTGTCTGG-3'; antisense: 5'- AAGAA AGCAAGACAGTGATTGTG-3') were used as an interna
l control. Thirty-five cycles PCR were used in the following conditions: 94&#186
;C for 30 s, 50&#186;C for 45 s, 72&#186;C for 45 s. </font>      ^cY#6426.htm##
01027000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704080000072002000900872#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#35#31#article#90#<P><font face="Arial, H
elvetica, sans-serif">The semi-quantitative RT-PCR methods used were validated i
n preliminary experiments. First, the optimal PCR conditions that yielded a sing
le band by agarose gel electrophoresis were determined for each gene in the same
 reaction tube. Second, to determine whether the method was semi-quantitative, s
erial quantities of total RNA from thyroids (62.5, 125, 250, 500, 1000, 2000 ng)
 were used for semi-quantitative RT-PCR amplification of both IRS-1 and &szlig;-
actin, as described before (18). Then, 250 ng RNA was used for the synthesis of 
cDNA for semi-quantitative RT-PCR. All reactions included a negative control (cD
NA made from 250 ng of total RNA isolated from thyroid glands in the absence of 
reverse transcriptase) (data not shown).</font>      ^cY#6426.htm##
00341000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011400072002000900186#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#36#32#article#90#<P><font face="Arial, H
elvetica, sans-serif"><B>Immunoprecipitation and Western blot analysis</B></font
>      ^cY#6426.htm##
00599000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037200072002000900444#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#37#33#article#90#<P><font face="Arial, H
elvetica, sans-serif">Pools of three rat thyroid glands from each group were hom
ogenized with an ultra-turrax blender (IKA Werke, Staufen, Germany) in 0.5 mL 50
 mM HEPES, pH 7.4, and 10 mM EDTA buffer containing 1% Triton X-100, 10% glycero
l, 100 mM sodium fluoride, 100 mM sodium pyrophosphate, 2 mM PMSF, and 0.1 mg/mL
 aprotinin. </font>      ^cY#6426.htm##
01434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704120700072002000901279#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#38#34#article#90#<P><font face="Arial, H
elvetica, sans-serif">The homogenates were centrifuged at 200,000 <I>g</I> at 4&
#186;C in a Beckman 70.1 Ti rotor (Fullerton, CA, USA) for 1 h. Protein concentr
ation in the supernatant was measured by the method of Bradford (19) and 1 mg/mL
 protein was incubated with 0.8 &#181;g anti-IRS-1 antibody (goat IgG) for 18 h 
at 4&#186;C. Immunocomplexes were collected on protein A - Sepharose beads (Phar
macia Biotech, Piscataway, NJ, USA) and washed three times. The pellets containi
ng immunoprecipitated IRS-1 were resuspended in Laemmli sample buffer (20) and r
esolved by polyacrylamide gel electrophoresis (6.5% SDS-PAGE). Proteins were tra
nsferred to a PVDF membrane (Millipore, Billerica, MA, USA), which was then bloc
ked with 0.5% BSA and 2% low-fat dry milk in phosphate buffer containing 0.1% Tw
een (PBS-Tween). The membrane was washed three times with PBS-Tween and incubate
d with an anti-IRS-1 antibody (1:500 dilution) for 2 h. Immunoblotting was perfo
rmed using horseradish peroxidase-conjugated anti-goat IgG (1:2000 dilution). Th
e bands corresponding to IRS-1 were visualized by ECL and quantified by densitom
etry using the ScionImage software (NIH image).</font>      ^cY#6426.htm##
00338000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011100072002000900183#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#39#35#article#90#<P><font face="Arial, H
elvetica, sans-serif"><B>Serum T<SUB>4</SUB> and TSH determinations</B></font>  
    ^cY#6426.htm##
00687000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704046000072002000900532#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#40#36#article#90#<P><font face="Arial, H
elvetica, sans-serif">Serum total T<SUB>4</SUB> was assayed using commercial kit
s (DPC - Diagnostic Products Corporation, Los Angeles, CA, USA), and T<SUB>4</SU
B> standard curves were constructed with hormone-free rat serum. Serum TSH was d
etermined by a specific radioimmunoassay using primary antibodies for rat TSH an
d the standard curve provided by the National Hormone and Peptide Program/NIDDK 
(Bethesda, MD, USA).</font>      ^cY#6426.htm##
00309000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008200072002000900154#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#41#37#article#90#<P><font face="Arial, H
elvetica, sans-serif"><B>DAPI-staining</B></font>      ^cY#6426.htm##
00593000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036600072002000900438#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#42#38#article#90#<P><font face="Arial, H
elvetica, sans-serif">Paraffin-embedded thyroid tissue samples were fixed with 7
0, 75, and 90% ethanol for 10 min. After washing in PBS, thyroid tissue slices w
ere stained by applying a 1:500 diluted DAPI solution for 5 min, rinsed with PBS
, mounted with glycerol, and evaluated by fluorescent microscopy for nucleus cou
nting.</font>      ^cY#6426.htm##
00316000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008900072002000900161#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#43#39#article#90#<P><font face="Arial, H
elvetica, sans-serif"><B>Statistical analysis</B></font>      ^cY#6426.htm##
00516000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028900072002000900361#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#44#40#article#90#<P><font face="Arial, H
elvetica, sans-serif">Data were analyzed statistically by one-way analysis of va
riance (ANOVA) followed by the Newman-Keuls multiple comparison test. Serum TSH 
levels were analyzed after logarithmic transformation.</font>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6426.htm##
00559000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033200072002000900404#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#45#41#article#90#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT SIZE=4><FONT COLOR=#00007F><B>
Results</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"><A HR
EF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6426.htm##
00543000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031600072002000900388#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#46#42#article#90#<P><font face="Arial, H
elvetica, sans-serif">Hypothyroid animals had significantly lower serum T<SUB>4<
/SUB> levels (control = 3.47 &#177; 0.29 &#181;g/dL; hypothyroid = non-detectabl
e) and increased TSH levels (control = 2.31 &#177; 0.28; hypothyroid = 51.02 &#1
77; 6.02 ng/mL, P &lt; 0.001). </font> </P>      ^cY#6426.htm##
00676000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044900072002000900521#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#47#43#article#90#<P><font face="Arial, H
elvetica, sans-serif">In long-term hypothyroid animals, thyroid IRS-1 mRNA was s
ignificantly down-regulated when compared to control animals (data not shown). H
owever, thyroid IRS-1 protein content did not decrease significantly in hypothyr
oid animals (data not shown). Interestingly, decreased mRNA expression was not a
ccompanied by decreased protein content, as determined by immunoprecipitation an
alysis. </font>       ^cY#6426.htm##
02606000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704237900072002000902451#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#48#44#article#90#<P><font face="Arial, H
elvetica, sans-serif">Since TSH induces goiter, and insulin    and IGF-I are imp
ortant co-mitogenic factors <I>in vitro</I>, the finding of    down-regulated IR
S-1 with increased serum TSH levels was unexpected since IRS-1    is the main IR
 and IGF-IR intracellular substrate. Either other IRSs are involved    or the de
crease in IRS-1 when goiter is already established may represent a    physiologi
cal control of thyroid mitogenesis. Another possibility is that decreased    thy
roid IRS-1 might be secondary to the insulin resistance that is established    d
uring hypothyroidism. Thus, we tested IRS-1 expression during goitrogenesis    i
n thyroid and liver. Animals treated with MMI for different periods of time    s
howed a progressive decrease in serum T<SUB>4</SUB> with a corresponding increas
e    in serum TSH (<a href="#Tab1">Table 1</a>) and in cell numbers (<a href="#F
ig1">Figure    1</a>) and the consequent development of goiter. Thyroid weight a
nd serum TSH    levels increased progressively until the 18th day of MMI treatme
nt (<a href="#Tab1">Table    1</a>). Thyroid IRS-1 mRNA (<a href="#Fig2">Figure 
2A</a>) and protein expressions    (<a href="#Fig2">Figure 2B</a>) increased pro
gressively during goitrogenesis    until the 14th day of MMI treatment and start
ed to decline thereafter, reaching    the lowest values by the 21st day of treat
ment, when a significant reduction    was detected compared to all other groups,
 including control animals. Protein    expression analysis showed that the decre
ased IRS-1 protein expression seemed    to be sustained until at least the 26th 
day of MMI treatment (<a href="#Fig2">Figure    2B</a>), when no more increase i
n thyroid weight was detected, indicating that    the down-regulation of IRS-1 m
ight be important for the maintenance of thyroid    gland weight without a furth
er increase between 21 and 26 days. On the other    hand, liver IRS-1 mRNA (<a h
ref="#Fig3">Figure 3</a>) was significantly decreased    on the 14th day of MMI 
treatment and continued to be low until the 21st day    of treatment.</font>  <H
R ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="
left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v40n5/html
/6426i01.htm"><img src="/img/revistas/bjmbr/v40n5/6426i01peq.jpg" border="2"></a
></td>      <td width="88%">    ^cY#6426.htm##
00882000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704065500072002000900727#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#49#45#article#90#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Increase in thyroid cell numb
er during goitrogenesis. Thyroid tissue from rats treated with 0.03% methimazole
 in drinking water during different periods of time (7, 14, and 21 days) and fro
m control (C) rats was embedded in paraffin and tissue sections were stained wit
h 4',6'-diamidino-2-phenylindole for nucleus count. Data are reported as the mea
n &#177; SEM of three experiments with at least 3 rats in each group. *P &lt; 0.
05 compared to control (ANOVA followed by the Newman-Keuls multiple comparison t
est). 40X magnification. </font>      </td>    </tr>  </table>      ^cY#6426.htm
##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038600072002000900458#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#50#46#article#90#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr 
align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v40
n5/html/6426i02.htm"><img src="/img/revistas/bjmbr/v40n5/6426i02peq.jpg" border=
"2"></a></td>      <td width="88%">    ^cY#6426.htm##
01156000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704092900072002000901001#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#51#47#article#90#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2. Thyroid insulin receptor subs
trate-1 (IRS-1) mRNA (A) and protein (B) expression during goitrogenesis in rats
. Thyroid IRS-1 mRNA expression (A) was analyzed by semi-quantitative RT-PCR and
 IRS-1 protein expression (B) was analyzed by immunoprecitation followed by immu
noblotting with anti-IRS-1 antibody. Goiter was induced by treatment with 0.03% 
methimazole (MMI) in drinking water for different periods of time (5, 7, 10, 14,
 18, 21, and 26 days). Data are reported as the mean &#177; SEM of 2-3 rats per 
group in three experiments in <I>A</I> and the mean and the maximal value of two
 different experiments in <I>B</I>. *P &lt; 0.01 compared to control (C, 14 days
) and to the other periods of MMI treatment (21 days; ANOVA followed by the Newm
an-Keuls multiple comparison test). MW = molecular weight. </font>      </td>   
 </tr>  </table>      ^cY#6426.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038600072002000900458#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#52#48#article#90#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr 
align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v40
n5/html/6426i03.htm"><img src="/img/revistas/bjmbr/v40n5/6426i03peq.jpg" border=
"2"></a></td>      <td width="88%">    ^cY#6426.htm##
00946000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704071900072002000900791#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#53#49#article#90#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig3"></a>Figure 3. Liver insulin receptor substr
ate-1 (IRS-1) mRNA expression during hypothyroidism in rats. Liver IRS-1 mRNA ex
pression was analyzed by semi-quantitative RT-PCR. Hypothyroidism was induced by
 treatment with 0.03% methimazole (MMI) in drinking water for different periods 
of time (7, 14, and 21 days). Data are reported as the mean &#177; SEM for 2 rat
s per group in three experiments. *P &lt; 0.01 compared to control (C) and to th
e other periods of MMI treatment (ANOVA followed by the Newman-Keuls multiple co
mparison test). MW = molecular weight; GAPDH = glyceraldehyde 3-phosphate dehydr
ogenase. </font>      </td>    </tr>  </table>      ^cY#6426.htm##
00793000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056600072002000900638#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#54#50#article#90#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr 
align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v40
n5/html/6426t01.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"><
/a></td>      <td width="88%"><font face="Arial, Helvetica, sans-serif"><a name=
"Tab1"></a>Table 1. Serum thyroxine and thyroid-stimulating hormone (TSH) levels
 of hypothyroid rats. </font></td>    </tr>  </table>      ^cY#6426.htm##
00343000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011600072002000900188#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#55#51#article#90#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>      ^cY#6426.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#56#52#article#90#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6426.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027000072002000900342#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#57#53#article#90#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#6426.htm##
00843000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704061600072002000900688#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#58#54#article#90#<P><font face="Arial, H
elvetica, sans-serif">The objective of the present study was to evaluate the mod
ulation of the main insulin receptor substrate, IRS-1, by TSH <I>in vivo</I>. IR
S-1 is the immediate substrate of IR, IGF-IR, RET, and other tyrosine kinase int
racellular pathways, being phosphorylated in multiple tyrosine residues that ser
ve as docking sites for a variety of signaling molecules, the activation of whic
h is critical for cell mitogenesis (21). Since insulin and IGF-I are fundamental
 for TSH-induced thyroid mitogenesis, TSH might regulate their common intracellu
lar substrates. </font>      ^cY#6426.htm##
02724000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704249700072002000902569#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#59#55#article#90#<P><font face="Arial, H
elvetica, sans-serif">In FRTL-5 cell cultures, TSH treatment did not induce any 
changes in either IRS-1 phosphorylation or IRS-1 amount (17). In the present stu
dy, IRS-1 expression was significantly decreased in hypothyroid animals with chr
onically increased serum TSH levels, when goiter had already been established. H
owever, during goitrogenesis IRS-1 expression was significantly increased during
 a period of time coinciding with the greater rate of thyroid weight gain. Thus,
 TSH positively modulated IRS-1 expression, probably depending on the activation
 or inhibition of other intracellular regulatory mechanisms. Therefore, when the
 mitogenic stimulus was predominant, IRS-1 is up-regulated, whereas when the rat
e of mitosis decreases, impairing further thyroid gland weight gain, this pathwa
y is down-regulated. The up-regulation of IRS-1 could stimulate and facilitate m
itogenesis, since this protein plays an important role in intracellular mitogeni
c pathways (21,22). After the establishment of hypothyroidism for a long period 
(21 days), IRS-1 is down-regulated in the thyroid, which could be due to the lac
k of a direct effect of thyroid hormones on the thyroid follicular cell. The pos
sible effects of thyroid hormones on the regulation of thyroid cell proliferatio
n has recently been demonstrated in an animal model of transgenic mice with a mu
tant thyroid hormone receptor &szlig; that exerts a dominant negative effect. Th
ese mice have developed thyroid cancer; however, the thyroid carcinogenesis mech
anism remains to be elucidated (23). In addition, we found that IRS-1 mRNA was n
egatively modulated in the liver of MMI-treated animals. In fact, in contrast to
 the thyroid gland, after 14 days of hypothyroidism, liver IRS-1 mRNA was alread
y significantly decreased. Thus, our results show that increased IRS-1 was thyro
id-specific during goitrogenesis and that the decreased liver IRS-1 expression d
etected in hypothyroid animals might explain, at least in part, the insulin resi
stance described in this model (24). Interestingly, the insulin resistance that 
develops during hypothyroidism seems to occur also in the thyroid gland and to o
vercome the positive control by TSH of IRS-1 mRNA expression. This biphasic modu
lation of IRS-1 might be of physiological importance since the maintenance of th
yroid weight despite high and maintained serum TSH levels should depend on the d
own-regulation of some intracellular mitogenic pathways. </font>      ^cY#6426.h
tm##
00923000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069600072002000900768#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#60#56#article#90#<P><font face="Arial, H
elvetica, sans-serif">Some studies have shown that overexpression of IR, IGF-IR 
and IR/IGF-IR hybrid receptors might occur in thyroid tumors, suggesting that th
is could be an important event in thyroid tumorigenesis (25-27). The present fin
dings of decreased IRS-1 expression in the presence of sustained high serum TSH 
levels might indicate that increased IR activation alone should not lead to thyr
oid tumors, unless the intracellular receptor substrates are deregulated. Anothe
r possibility is that a chronic activation of IR may not promote IRS-1 down-regu
lation, differently from the insulin resistance that occurs in our model during 
hypothyroidism. </font>      ^cY#6426.htm##
01226000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704099900072002000901071#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#61#57#article#90#<P><font face="Arial, H
elvetica, sans-serif">In the present study, we show for the first time that an i
mportant intracellular pathway involved in the mitogenesis of several cell types
 undergoes a biphasic modulation in the thyroid during physiological goitrogenes
is during hypothyroidism. These findings are relevant for a better understanding
 of some apparently controversial findings regarding thyroid cell proliferation,
 since the majority of studies have been done in cell culture models under diffe
rent assay conditions. Moreover, the effects of thyroid hormones on thyrocytes h
ave not been fully understood. However, further studies are needed in order to b
etter understand the factors that regulate IRS-1 expression in the thyroid gland
 <I>in vivo</I>. Also, the expression of IRS-2 should be investigated in this mo
del, as well as the possible intracellular pathways that are activated during go
itrogenesis and after goiter establishment. </font>  <HR ALIGN=LEFT WIDTH=100% S
IZE=2>      ^cY#6426.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#62#58#article#90#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>References</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"
><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6426.
htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026900074002000900343#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#63#59#article#90#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Dumont JE, Lamy F, Roger P, Maenhaut C. P
hysiological and pathological regulation of thyroid cell proliferation and diffe
rentiation by thyrotropin and other factors. <I>Physiol Rev</I> 1992; 72: 667-69
7. </font>      ^cY#6426.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021600074002000900290#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#64#60#article#90#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Medina DL, Santisteban P. Thyrotropin-dep
endent proliferation of <I>in vitro</I> rat thyroid cell systems. <I>Eur J Endoc
rinol</I> 2000; 143: 161-178. </font>      ^cY#6426.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028700074002000900361#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#65#61#article#90#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Kimura T, Van Keymeulen A, Golstein J, Fu
sco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and 
other factors: a critical evaluation of <I>in vitro</I> models. <I>Endocr Rev</I
> 2001; 22: 631-656. </font>      ^cY#6426.htm##
00620000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704037900074002000900453#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#66#62#article#90#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Burikhanov R, Coulonval K, Pirson I, Lamy
 F, Dumont JE, Roger PP. Thyrotropin via cyclic AMP induces insulin receptor exp
ression and insulin co-stimulation of growth and amplifies insulin and insulin-l
ike growth factor signaling pathways in dog thyroid epithelial cells. <I>J Biol 
Chem</I> 1996; 271: 29400-29406. </font>      ^cY#6426.htm##
00593000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704035200074002000900426#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#67#63#article#90#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Deleu S, Pirson I, Coulonval K, Drouin A,
 Taton M, Clermont F, et al. IGF-1 or insulin, and the TSH cyclic AMP cascade se
parately control dog and human thyroid cell growth and DNA synthesis, and comple
ment each other in inducing mitogenesis. <I>Mol Cell Endocrinol</I> 1999; 149: 4
1-51. </font>      ^cY#6426.htm##
00542000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704030100074002000900375#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#68#64#article#90#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Kimura T, Dumont JE, Fusco A, Golstein J.
 Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly vi
a a pathway different from DNA synthesis: comparison with FRTL-5 cells. <I>Eur J
 Endocrinol</I> 1999; 140: 94-103. </font>      ^cY#6426.htm##
00504000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026300074002000900337#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#69#65#article#90#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Van Keymeulen A, Dumont JE, Roger PP. TSH
 induces insulin receptors that mediate insulin costimulation of growth in norma
l human thyroid cells. <I>Biochem Biophys Res Commun</I> 2000; 279: 202-207. </f
ont>      ^cY#6426.htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028500074002000900359#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#70#66#article#90#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Gasperi M, Martino E, Manetti L, Arosio M
, Porretti S, Faglia G, et al. Prevalence of thyroid diseases in patients with a
cromegaly: results of an Italian multi-center study. <I>J Endocrinol Invest</I> 
2002; 25: 240-245. </font>      ^cY#6426.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027800074002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#71#67#article#90#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Clement S, Refetoff S, Robaye B, Dumont J
E, Schurmans S. Low TSH requirement and goiter in transgenic mice overexpressing
 IGF-I and IGF-Ir receptor in the thyroid gland. <I>Endocrinology</I> 2001; 142:
 5131-5139. </font>      ^cY#6426.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023500075002000900310#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#72#68#article#90#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Van Obberghen E, Baron V, Delahaye L, E
manuelli B, Filippa N, Giorgetti-Peraldi S, et al. Surfing the insulin signaling
 web. <I>Eur J Clin Invest</I> 2001; 31: 966-977. </font>      ^cY#6426.htm##
00588000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704034600075002000900421#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#73#69#article#90#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Myers MG Jr, Grammer TC, Wang LM, Sun X
J, Pierce JH, Blenis J, et al. Insulin receptor substrate-1 mediates phosphatidy
linositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth fac
tor-1, and interleukin-4 stimulation. <I>J Biol Chem</I> 1994; 269: 28783-28789.
 </font>      ^cY#6426.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023500075002000900310#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#74#70#article#90#12#<P><font
 face="Arial, Helvetica, sans-serif">12. LeRoith D, Werner H, Beitner-Johnson D,
 Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor
 I receptor. <I>Endocr Rev</I> 1995; 16: 143-163. </font>      ^cY#6426.htm##
00604000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704036200075002000900437#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#75#71#article#90#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Coulonval K, Vandeput F, Stein RC, Kozm
a SC, Lamy F, Dumont JE. Phosphatidylinositol 3-kinase, protein kinase B and rib
osomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by
 cAMP and growth factors in the presence of insulin. <I>Biochem J</I> 2000; 348 
(Pt 2): 351-358. </font>      ^cY#6426.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027700075002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#76#72#article#90#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Tanaka S, Wands JR. A carboxy-terminal 
truncated insulin receptor substrate-1 dominant negative protein reverses the hu
man hepatocellular carcinoma malignant phenotype. <I>J Clin Invest</I> 1996; 98:
 2100-2108. </font>      ^cY#6426.htm##
00544000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030200075002000900377#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#77#73#article#90#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Condorelli G, Formisano P, Miele C, Beg
uinot F. Thyrotropin regulates autophosphorylation and kinase activity in both t
he insulin and the insulin-like growth factor-I receptors in FRTL5 cells. <I>End
ocrinology</I> 1992; 130: 1615-1625. </font>      ^cY#6426.htm##
00591000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704034900075002000900424#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#78#74#article#90#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Takahashi S, Conti M, Prokop C, Van Wyk
 JJ, Earp HS III. Thyrotropin and insulin-like growth factor I regulation of tyr
osine phosphorylation in FRTL-5 cells. Interaction between cAMP-dependent and gr
owth factor-dependent signal transduction. <I>J Biol Chem</I> 1991; 266: 7834-78
41. </font>      ^cY#6426.htm##
00515000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027300075002000900348#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#79#75#article#90#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Ariga M, Nedachi T, Akahori M, Sakamoto
 H, Ito Y, Hakuno F, et al. Signalling pathways of insulin-like growth factor-I 
that are augmented by cAMP in FRTL-5 cells. <I>Biochem J</I> 2000; 348 (Pt 2): 4
09-416. </font>      ^cY#6426.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026700075002000900342#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#80#76#article#90#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Ornellas DS, Nascimento DS, Christoph D
H, Guggino WB, Morales MM. Aldosterone and high-NaCl diet modulate ClC-2 chlorid
e channel gene expression in rat kidney. <I>Pflugers Arch</I> 2002; 444: 193-201
. </font>      ^cY#6426.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025100075002000900326#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#81#77#article#90#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Bradford MM. A rapid and sensitive meth
od for the quantitation of microgram quantities of protein utilizing the princip
le of protein-dye binding. <I>Anal Biochem</I> 1976; 72: 248-254. </font>      ^
cY#6426.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019700075002000900272#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#82#78#article#90#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Laemmli UK. Cleavage of structural prot
eins during the assembly of the head of bacteriophage T4. <I>Nature</I> 1970; 22
7: 680-685. </font>      ^cY#6426.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027000075002000900345#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#83#79#article#90#21#<P><font
 face="Arial, Helvetica, sans-serif">21. Chang Q, Li Y, White MF, Fletcher JA, X
iao S. Constitutive activation of insulin receptor substrate 1 is a frequent eve
nt in human tumors: therapeutic implications. <I>Cancer Res</I> 2002; 62: 6035-6
038. </font>      ^cY#6426.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024900075002000900324#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#84#80#article#90#22#<P><font
 face="Arial, Helvetica, sans-serif">22. Sesti G, Federici M, Hribal ML, Lauro D
, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in
 human metabolic disorders. <I>FASEB J</I> 2001; 15: 2099-2111. </font>      ^cY
#6426.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028000075002000900355#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#85#81#article#90#23#<P><font
 face="Arial, Helvetica, sans-serif">23. Suzuki H, Willingham MC, Cheng SY. Mice
 with a mutation in the thyroid hormone receptor beta gene spontaneously develop
 thyroid carcinoma: a mouse model of thyroid carcinogenesis. <I>Thyroid</I> 2002
; 12: 963-969. </font>      ^cY#6426.htm##
00555000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031300075002000900388#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#86#82#article#90#24#<P><font
 face="Arial, Helvetica, sans-serif">24. Cettour-Rose P, Theander-Carrillo C, As
ensio C, Klein M, Visser TJ, Burger AG, et al. Hypothyroidism in rats decreases 
peripheral glucose utilisation, a defect partially corrected by central leptin i
nfusion. <I>Diabetologia</I> 2005; 48: 624-633. </font>      ^cY#6426.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#87#83#article#90#25#<P><font
 face="Arial, Helvetica, sans-serif">25. Belfiore A, Pandini G, Vella V, Squatri
to S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signa
ling in thyroid cancer. <I>Biochimie</I> 1999; 81: 403-407. </font>      ^cY#642
6.htm##
00534000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029200075002000900367#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#88#84#article#90#26#<P><font
 face="Arial, Helvetica, sans-serif">26. Frittitta L, Sciacca L, Catalfamo R, Ip
polito A, Gangemi P, Pezzino V, et al. Functional insulin receptors are overexpr
essed in thyroid tumors: is this an early event in thyroid tumorigenesis? <I>Can
cer</I> 1999; 85: 492-498. </font>      ^cY#6426.htm##
00499000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025700075002000900332#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#p#89#85#article#90#27#<P><font
 face="Arial, Helvetica, sans-serif">27. Vella V, Sciacca L, Pandini G, Mineo R,
 Squatrito S, Vigneri R, et al. The IGF system in thyroid cancer: new concepts. 
<I>Mol Pathol</I> 2001; 54: 121-124. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> 
     ^cY#6426.htm##
00584000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035700072002000900429#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#90#86#article#90#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=#00
007F><B>Acknowledgments</B></FONT></FONT></font> <font face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></font>
</P>      ^cY#6426.htm##
00450000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022300072002000900295#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#91#87#article#90#<P><font face="Arial, H
elvetica, sans-serif">We are grateful to Norma Lima de Ara&uacute;jo Faria, Adva
ldo Nunes Bezerra and Wagner Nunes Bezerra for technical assistance.</font>  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6426.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034800072002000900420#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#92#88#article#90#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      
 ^cY#6426.htm##
00762000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053500072002000900607#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#93#89#article#90#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/rec
or.gif" border="0"></a>    Address for correspondence:</b> </font><font face="Ar
ial, Helvetica, sans-serif">D.P.    Carvalho, Laborat&oacute;rio de Fisiologia E
nd&oacute;crina, Instituto de Biof&iacute;sica,    Carlos Chagas Filho, UFRJ, CC
S, Bloco G, Ilha do Fund&atilde;o, 21949-900 Rio    de Janeiro, RJ, Brasil. Fax:
 +55-21-2280-8193. E-mail: <a href="mailto:dencarv@biof.ufrj.br">dencarv@biof.uf
rj.br</a></font>  </p>      ^cY#6426.htm##
00487000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704026000072002000900332#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6426.htm#S#p#94#90#article#90#<P><font face="Arial, H
elvetica, sans-serif">Research supported by FAPERJ, CNPq and Howard Hughes Medic
al Institute (No. 55003669). R. Grozovsky was the recipient of a fellowship from
 CAPES. Received March 21, 2006. Accepted January 19, 2007. </font>      ^cY#642
6.htm##
00645000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100014000900100
01500104010001800119012012900137030001200266065000900278064000500287031000300292
014000800295865000900303002000900312035001000321801001200331#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6426.htm#S#c#95#1#article#27#1#^rND^sDumont^nJE#^rND^sLam
y^nF#^rND^sRoger^nP#^rND^sMaenhaut^nC#Physiological and pathological regulation 
of thyroid cell proliferation and differentiation by thyrotropin and other facto
rs^len#Physiol Rev#19920000#1992#72#667-697#20070500#6426.htm#0031-9333#Physiol 
Rev##
00554000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100021000900120
07700111030001700188065000900205064000500214031000400219014000800223865000900231
002000900240035001000249801001700259#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
426.htm#S#c#96#2#article#27#2#^rND^sMedina^nDL#^rND^sSantisteban^nP#Thyrotropin-
dependent proliferation of in vitro rat thyroid cell systems^len#Eur J Endocrino
l#20000000#2000#143#161-178#20070500#6426.htm#0804-4643#Eur J Endocrinol##
00691000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100023000890100
01800112010001500130010001700145010001600162012011200178030001100290065000900301
06400050031003100030031501400080031886500090032600200090033503500100034480100110
0354#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#97#3#article#27#3#^r
ND^sKimura^nT#^rND^sVan^nKeymeulen A#^rND^sGolstein^nJ#^rND^sFusco^nA#^rND^sDumo
nt^nJE#^rND^sRoger^nPP#Regulation of thyroid cell proliferation by TSH and other
 factors: a critical evaluation of in vitro models^len#Endocr Rev#20010000#2001#
22#631-656#20070500#6426.htm#0163-769X#Endocr Rev##
00791000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100019000930100
01600112010001400128010001700142010001600159012020800175030001200383065000900395
06400050040403100040040901400120041386500090042500200090043403500100044380100120
0453#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#98#4#article#27#4#^r
ND^sBurikhanov^nR#^rND^sCoulonval^nK#^rND^sPirson^nI#^rND^sLamy^nF#^rND^sDumont^
nJE#^rND^sRoger^nPP#Thyrotropin via cyclic AMP induces insulin receptor expressi
on and insulin co-stimulation of growth and amplifies insulin and insulin-like g
rowth factor signaling pathways in dog thyroid epithelial cells^len#J Biol Chem#
19960000#1996#271#29400-29406#20070500#6426.htm#0021-9258#J Biol Chem##
00783000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100016000880100
01900104010001600123010001500139010001800154810000600172012017500178030002000353
06500090037306400050038203100040038701400060039186500090039700200090040603500100
0415801002000425#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#99#5#art
icle#27#5#^rND^sDeleu^nS#^rND^sPirson^nI#^rND^sCoulonval^nK#^rND^sDrouin^nA#^rND
^sTaton^nM#^rND^sClermont^nF#et al#IGF-1 or insulin, and the TSH cyclic AMP casc
ade separately control dog and human thyroid cell growth and DNA synthesis, and 
complement each other in inducing mitogenesis^len#Mol Cell Endocrinol#19990000#1
999#149#41-51#20070500#6426.htm#0303-7207#Mol Cell Endocrinol##
00683000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100017000900100
01500107010001800122012015400140030001700294065000900311064000500320031000400325
014000700329865000900336002000900345035001000354801001700364#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6426.htm#S#c#100#6#article#27#6#^rND^sKimura^nT#^rND^sDum
ont^nJE#^rND^sFusco^nA#^rND^sGolstein^nJ#Insulin and TSH promote growth in size 
of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis
: comparison with FRTL-5 cells^len#Eur J Endocrinol#19990000#1999#140#94-103#200
70500#6426.htm#0804-4643#Eur J Endocrinol##
00637000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100023000740100017000970100
01600114012010900130030002700239065000900266064000500275031000400280014000800284
865000900292002000900301035001000310801002700320#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6426.htm#S#c#101#7#article#27#7#^rND^sVan^nKeymeulen A#^rND^sDumont^n
JE#^rND^sRoger^nPP#TSH induces insulin receptors that mediate insulin costimulat
ion of growth in normal human thyroid cells^len#Biochem Biophys Res Commun#20000
000#2000#279#202-207#20070500#6426.htm#0006-291X#Biochem Biophys Res Commun##
00717000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100017000910100
01700108010001600125010001800141010001600159810000600175012010500181030002000286
06500090030606400050031503100030032001400080032386500090033100200090034003500100
0349801002000359#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#102#8#ar
ticle#27#8#^rND^sGasperi^nM#^rND^sMartino^nE#^rND^sManetti^nL#^rND^sArosio^nM#^r
ND^sPorretti^nS#^rND^sFaglia^nG#et al#Prevalence of thyroid diseases in patients
 with acromegaly: results of an Italian multi-center study^len#J Endocrinol Inve
st#20020000#2002#25#240-245#20070500#6426.htm#0391-4097#J Endocrinol Invest##
00675000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910100
01600109010001700125010001900142012011600161030001400277065000900291064000500300
031000400305014001000309865000900319002000900328035001000337801001400347#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#103#9#article#27#9#^rND^sClement
^nS#^rND^sRefetoff^nS#^rND^sRobaye^nB#^rND^sDumont^nJE#^rND^sSchurmans^nS#Low TS
H requirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir rece
ptor in the thyroid gland^len#Endocrinology#20010000#2001#142#5131-5139#20070500
#6426.htm#0013-7227#Endocrinology##
00666000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100015000990100
01800114010001900132010001700151010002700168810000600195012003800201030001800239
06500090025706400050026603100030027101400080027486500090028200200090029103500100
0300801001800310#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#104#10#a
rticle#27#10#^rND^sVan^nObberghen E#^rND^sBaron^nV#^rND^sDelahaye^nL#^rND^sEmanu
elli^nB#^rND^sFilippa^nN#^rND^sGiorgetti-Peraldi^nS#et al#Surfing the insulin si
gnaling web^len#Eur J Clin Invest#20010000#2001#31#966-977#20070500#6426.htm#001
4-2972#Eur J Clin Invest##
00771000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01500113010001400128010001700142010001600159810000600175012017000181030001200351
06500090036306400050037203100040037701400120038186500090039300200090040203500100
0411801001200421#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#105#11#a
rticle#27#11#^rND^sMyers^nMG Jr#^rND^sGrammer^nTC#^rND^sWang^nLM#^rND^sSun^nXJ#^
rND^sPierce^nJH#^rND^sBlenis^nJ#et al#Insulin receptor substrate-1 mediates phos
phatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like gro
wth factor-1, and interleukin-4 stimulation^len#J Biol Chem#19940000#1994#269#28
783-28789#20070500#6426.htm#0021-9258#J Biol Chem##
00612000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
02500109010002100134012008000155030001100235065000900246064000500255031000300260
014000800263865000900271002000900280035001000289801001100299#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6426.htm#S#c#106#12#article#27#12#^rND^sLeRoith^nD#^rND^s
Werner^nH#^rND^sBeitner-Johnson^nD#^rND^sRoberts^nCT Jr#Molecular and cellular a
spects of the insulin-like growth factor I receptor^len#Endocr Rev#19950000#1995
#16#143-163#20070500#6426.htm#0163-769X#Endocr Rev##
00786000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01600113010001600129010001400145010001700159012019100176030001000367065000900377
06400050038603100040039106100070039501400080040286500090041000200090041903500100
0428801001000438#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#107#13#a
rticle#27#13#^rND^sCoulonval^nK#^rND^sVandeput^nF#^rND^sStein^nRC#^rND^sKozma^nS
C#^rND^sLamy^nF#^rND^sDumont^nJE#Phosphatidylinositol 3-kinase, protein kinase B
 and ribosomal S6 kinases in the stimulation of thyroid epithelial cell prolifer
ation by cAMP and growth factors in the presence of insulin^len#Biochem J#200000
00#2000#348#(Pt 2)#351-358#20070500#6426.htm#0264-6021#Biochem J##
00621000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920120
15200108030001400260065000900274064000500283031000300288014001000291865000900301
002000900310035001000319801001400329#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
426.htm#S#c#108#14#article#27#14#^rND^sTanaka^nS#^rND^sWands^nJR#A carboxy-termi
nal truncated insulin receptor substrate-1 dominant negative protein reverses th
e human hepatocellular carcinoma malignant phenotype^len#J Clin Invest#19960000#
1996#98#2100-2108#20070500#6426.htm#0021-9738#J Clin Invest##
00682000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960100
01500115010001800130012014800148030001400296065000900310064000500319031000400324
014001000328865000900338002000900347035001000356801001400366#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6426.htm#S#c#109#15#article#27#15#^rND^sCondorelli^nG#^rN
D^sFormisano^nP#^rND^sMiele^nC#^rND^sBeguinot^nF#Thyrotropin regulates autophosp
horylation and kinase activity in both the insulin and the insulin-like growth f
actor-I receptors in FRTL5 cells^len#Endocrinology#19920000#1992#130#1615-1625#2
0070500#6426.htm#0013-7227#Endocrinology##
00745000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
01600110010001800126010001900144012018800163030001200351065000900363064000500372
031000400377014001000381865000900391002000900400035001000409801001200419#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#110#16#article#27#16#^rND^sTakah
ashi^nS#^rND^sConti^nM#^rND^sProkop^nC#^rND^sVan^nWyk JJ#^rND^sEarp^nHS III#Thyr
otropin and insulin-like growth factor I regulation of tyrosine phosphorylation 
in FRTL-5 cells: Interaction between cAMP-dependent and growth factor-dependent 
signal transduction^len#J Biol Chem#19910000#1991#266#7834-7841#20070500#6426.ht
m#0021-9258#J Biol Chem##
00708000000000349000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01700108010001800125010001300143010001600156810000600172012009900178030001000277
06500090028706400050029603100040030106100070030501400080031286500090032000200090
0329035001000338801001000348#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#
S#c#111#17#article#27#17#^rND^sAriga^nM#^rND^sNedachi^nT#^rND^sAkahori^nM#^rND^s
Sakamoto^nH#^rND^sIto^nY#^rND^sHakuno^nF#et al#Signalling pathways of insulin-li
ke growth factor-I that are augmented by cAMP in FRTL-5 cells^len#Biochem J#2000
0000#2000#348#(Pt 2)#409-416#20070500#6426.htm#0264-6021#Biochem J##
00665000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100021000950100
02000116010001800136010001800154012009700172030001400269065000900283064000500292
031000400297014000800301865000900309002000900318035001000327801001400337#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#112#18#article#27#18#^rND^sOrnel
las^nDS#^rND^sNascimento^nDS#^rND^sChristoph^nDH#^rND^sGuggino^nWB#^rND^sMorales
^nMM#Aldosterone and high-NaCl diet modulate ClC-2 chloride channel gene express
ion in rat kidney^len#Pflugers Arch#20020000#2002#444#193-201#20070500#6426.htm#
0031-6768#Pflugers Arch##
00576000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120136000950300
01300231065000900244064000500253031000300258014000800261865000900269002000900278
035001000287801001300297#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#
113#19#article#27#19#^rND^sBradford^nMM#A rapid and sensitive method for the qua
ntitation of microgram quantities of protein utilizing the principle of protein-
dye binding^len#Anal Biochem#19760000#1976#72#248-254#20070500#6426.htm#0003-269
7#Anal Biochem##
00516000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120088000940300
00700182065000900189064000500198031000400203014000800207865000900215002000900224
035001000233801000700243#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#
114#20#article#27#20#^rND^sLaemmli^nUK#Cleavage of structural proteins during th
e assembly of the head of bacteriophage T4^len#Nature#19700000#1970#227#680-685#
20070500#6426.htm#0028-0836#Nature##
00665000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100012000910100
01600103010001900119010001400138012012200152030001100274065000900285064000500294
031000300299014001000302865000900312002000900321035001000330801001100340#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#115#21#article#27#21#^rND^sChang
^nQ#^rND^sLi^nY#^rND^sWhite^nMF#^rND^sFletcher^nJA#^rND^sXiao^nS#Constitutive ac
tivation of insulin receptor substrate 1 is a frequent event in human tumors: th
erapeutic implications^len#Cancer Res#20020000#2002#62#6035-6038#20070500#6426.h
tm#0008-5472#Cancer res##
00659000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01700109010001500126010001800141010001500159012008800174030000800262065000900270
06400050027903100030028401400100028786500090029700200090030603500100031580100080
0325#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#116#22#article#27#22
#^rND^sSesti^nG#^rND^sFederici^nM#^rND^sHribal^nML#^rND^sLauro^nD#^rND^sSbraccia
^nP#^rND^sLauro^nR#Defects of the insulin receptor substrate (IRS) system in hum
an metabolic disorders^len#FASEB J#20010000#2001#15#2099-2111#20070500#6426.htm#
0892-6638#FASEB j##
00636000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100021000920100
01600113012014800129030000800277065000900285064000500294031000300299014000800302
865000900310002000900319035001000328801000800338#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6426.htm#S#c#117#23#article#27#23#^rND^sSuzuki^nH#^rND^sWillingham^nM
C#^rND^sCheng^nSY#Mice with a mutation in the thyroid hormone receptor beta gene
 spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesi
s^len#Thyroid#20020000#2002#12#963-969#20070500#6426.htm#1050-7256#Thyroid##
00746000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100027000980100
01700125010001500142010001700157010001700174010001300191012012500204030001300329
06500090034206400050035103100030035601400080035986500090036700200090037603500100
0385801001300395#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#118#24#a
rticle#27#24#^rND^sCettour-Rose^nP#^rND^sTheander-Carrillo^nC#^rND^sAsensio^nC#^
rND^sKlein^nM#^rND^sVisser^nTJ#^rND^sBurger^nAG#^rND^set^nal#Hypothyroidism in r
ats decreases peripheral glucose utilisation, a defect partially corrected by ce
ntral leptin infusion^len#Diabetologia#20050000#2005#48#624-633#20070500#6426.ht
m#0012-186X#Diabetologia##
00639000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01500111010001900126010001700145012009000162030001000252065000900262064000500271
031000300276014000800279865000900287002000900296035001000305801001000315#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#119#25#article#27#25#^rND^sBelfi
ore^nA#^rND^sPandini^nG#^rND^sVella^nV#^rND^sSquatrito^nS#^rND^sVigneri^nR#Insul
in/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer
^len#Biochimie#19990000#1999#81#403-407#20070500#6426.htm#0300-9084#Biochimie##
00713000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
01900112010001800131010001700149010001700166810000600183012011900189030000700308
06500090031506400050032403100030032901400080033286500090034000200090034903500100
0358801000700368#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#120#26#a
rticle#27#26#^rND^sFrittitta^nL#^rND^sSciacca^nL#^rND^sCatalfamo^nR#^rND^sIppoli
to^nA#^rND^sGangemi^nP#^rND^sPezzino^nV#et al#Functional insulin receptors are o
verexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis?
^len#Cancer#19990000#1999#85#492-498#20070500#6426.htm#0008-543X#Cancer##
00646000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01700108010001500125010001900140010001700159810000600176012005100182030001100233
06500090024406400050025303100030025801400080026186500090026900200090027803500100
0287801001100297#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6426.htm#S#c#121#27#a
rticle#27#27#^rND^sVella^nV#^rND^sSciacca^nL#^rND^sPandini^nG#^rND^sMineo^nR#^rN
D^sSquatrito^nS#^rND^sVigneri^nR#et al#The IGF system in thyroid cancer: new con
cepts^len#Mol Pathol#20010000#2001#54#121-124#20070500#6426.htm#1366-8714#Mol Pa
thol##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#o#1#1#article#1#20
080212#125703#6468.htm#175##
03204000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015222300090016201201390
01710100022003100100020003320100020003520100020003720100023003920100019004150100
02300434010002500457070013400482070007000616083156200686085000802248085005302256
08500370230908500260234608500180237208500160239011700060240607200030241205800410
24150600015024561120009024711110015024801140009024951130017025048810024025210020
00902545#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#h#2#1#article#1#oa
#en#bjmbr#1#3.1#ILUS#04#BJMBR380#nd#Braz J Med Biol Res#40#5#20070500#^f621^l631
#0100-879X#20070314#TIMP-1 mediates the inhibitory effect of interleukin-6 on th
e proliferation of a hepatocarcinoma cell line in a STAT3-dependent manner^len#^
rND^1A01^nS.-Y.^sGuo#^rND^1A01^nX.^sShen#^rND^1A01^nJ.^sYang#^rND^1A01^nJ.^sYuan
#^rND^1A01^nR.-L.^sYang#^rND^1A01^nK.^sMao#^rND^1A01^nD.-H.^sZhao#^rND^1A01 A02^
nC.-J.^sLi#Nanjing Normal University^iA01^1Life Sciences College^2Jiangsu Key La
boratory for Molecular and Medical Biotechnology^cNanjing^pChina#Nanjing Univers
ity^iA02^1Animal Model Research Center^cNanjing^pChina#^len^aThe tissue inhibito
r of metalloproteinases (TIMP)-1 is a multifunctional protein which is not only 
an inhibitor of matrix metalloproteinases (MMPs) but also to have a possible "cy
tokine-like" action. Here, we first compared mRNA expression of TIMP-1 and MMP-9
 in BEL-7402 (a hepatocellular carcinoma cell line), L-02 (a normal liver cell l
ine) and QSG-7701 (a cell line derived from peripheral tissue of liver carcinoma
) using real-time quantitative RT-PCR. By evaluating the variation of the MMP-9/
TIMP-1 ratio as an index of reciprocal changes of the expression of the two gene
s, we observed that the MMP-9/TIMP-1 ratio was about 13- and 5-fold higher in BE
L-7402 than in L-02 and QSG-7701, respectively. Significantly, overexpression of
 TIMP-1 decreased the MMP-9/TIMP-1 ratio in BEL-7402 and then inhibited the cell
 growth to 60% and reduced the migration to about 30%. Meanwhile, our data showe
d that interleukin-6 (IL-6) (100 ng/mL) could also inhibited the cell growth of 
BEL-7402. Further studies indicated that TIMP-1 mediated the inhibitory effect o
f IL-6 on BEL-7402 cell proliferation in a STAT3-dependent manner, which could f
urther accelerate the expression of the cyclin-dependent kinase inhibitor p21. A
 dominant negative STAT3 mutant totally abolished IL-6-induced TIMP-1 expression
 and its biological functions. The present results demonstrate that TIMP-1 may b
e one of the mediators that regulate the inhibitory effect of IL-6 on BEL-7402 p
roliferation in which STAT3 signal transduction and p21 up-regulation also play 
important roles.#^dnd^i1#^tm^len^kTissue inhibitor of metalloproteinases-1^i1#^t
m^len^kHepatocellular carcinoma^i1#^tm^len^kInterleukin-6^i1#^tm^len^kSTAT3^i1#^
tm^len^kp21^i1#other#40#Natural Science Fund of Jiangsu Province#2000SWX000B501#
20060424#April 24, 2006#20070119#January 19, 2007#S0100-879X2006005000084#6468.h
tm##
03168000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015222300090016201201390
01710100022003100100020003320100020003520100020003720100023003920100019004150100
02300434010002500457070013400482070007000616083156200686085000802248085005302256
08500370230908500260234608500180237208500160239011700060240607200030241205800410
2415060001502456112000902471111001502480114000902495113001702504002000902521#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#f#3#1#article#1#oa#en#bjmbr#1#
3.1#ILUS#04#BJMBR380#nd#Braz J Med Biol Res#40#5#20070500#^f621^l631#0100-879X#2
0070314#TIMP-1 mediates the inhibitory effect of interleukin-6 on the proliferat
ion of a hepatocarcinoma cell line in a STAT3-dependent manner^len#^rND^1A01^nS.
-Y.^sGuo#^rND^1A01^nX.^sShen#^rND^1A01^nJ.^sYang#^rND^1A01^nJ.^sYuan#^rND^1A01^n
R.-L.^sYang#^rND^1A01^nK.^sMao#^rND^1A01^nD.-H.^sZhao#^rND^1A01 A02^nC.-J.^sLi#N
anjing Normal University^iA01^1Life Sciences College^2Jiangsu Key Laboratory for
 Molecular and Medical Biotechnology^cNanjing^pChina#Nanjing University^iA02^1An
imal Model Research Center^cNanjing^pChina#^len^aThe tissue inhibitor of metallo
proteinases (TIMP)-1 is a multifunctional protein which is not only an inhibitor
 of matrix metalloproteinases (MMPs) but also to have a possible "cytokine-like"
 action. Here, we first compared mRNA expression of TIMP-1 and MMP-9 in BEL-7402
 (a hepatocellular carcinoma cell line), L-02 (a normal liver cell line) and QSG
-7701 (a cell line derived from peripheral tissue of liver carcinoma) using real
-time quantitative RT-PCR. By evaluating the variation of the MMP-9/TIMP-1 ratio
 as an index of reciprocal changes of the expression of the two genes, we observ
ed that the MMP-9/TIMP-1 ratio was about 13- and 5-fold higher in BEL-7402 than 
in L-02 and QSG-7701, respectively. Significantly, overexpression of TIMP-1 decr
eased the MMP-9/TIMP-1 ratio in BEL-7402 and then inhibited the cell growth to 6
0% and reduced the migration to about 30%. Meanwhile, our data showed that inter
leukin-6 (IL-6) (100 ng/mL) could also inhibited the cell growth of BEL-7402. Fu
rther studies indicated that TIMP-1 mediated the inhibitory effect of IL-6 on BE
L-7402 cell proliferation in a STAT3-dependent manner, which could further accel
erate the expression of the cyclin-dependent kinase inhibitor p21. A dominant ne
gative STAT3 mutant totally abolished IL-6-induced TIMP-1 expression and its bio
logical functions. The present results demonstrate that TIMP-1 may be one of the
 mediators that regulate the inhibitory effect of IL-6 on BEL-7402 proliferation
 in which STAT3 signal transduction and p21 up-regulation also play important ro
les.#^dnd^i1#^tm^len^kTissue inhibitor of metalloproteinases-1^i1#^tm^len^kHepat
ocellular carcinoma^i1#^tm^len^kInterleukin-6^i1#^tm^len^kSTAT3^i1#^tm^len^kp21^
i1#other#40#Natural Science Fund of Jiangsu Province#2000SWX000B501#20060424#Apr
il 24, 2006#20070119#January 19, 2007#6468.htm##
03311000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000300116
03000240011903100030014303200020014606500090014801400110015703500100016822300090
01780120139001870100022003260100019003480100019003670100019003860100023004050100
01800428010002300446010002500469070013600494070007200630083157600702085000802278
08500530228608500370233908500260237608500180240208500160242011700060243607200030
24420580041024450600015024861120009025011110015025101140009025251130017025340020
00902551008008902560#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#l#4#1#
article#1#^mMay^a2007#oa#en#bjmbr#1#3.1#ilus#04#BJMBR380#nd#Braz. j. med. biol. 
res#40#5#20070500#^f621^l631#0100-879X#20070314#TIMP-1 mediates the inhibitory e
ffect of interleukin-6 on the proliferation of a hepatocarcinoma cell line in a 
STAT3-dependent manner^len#^rND^1A01^nS. -Y^sGuo#^rND^1A01^nX^sShen#^rND^1A01^nJ
^sYang#^rND^1A01^nJ^sYuan#^rND^1A01^nR. -L^sYang#^rND^1A01^nK^sMao#^rND^1A01^nD.
 -H^sZhao#^rND^1A01 A02^nC. -J^sLi#^iA01^1Nanjing Normal University^2Life Scienc
es College^3Jiangsu Key Laboratory for Molecular and Medical Biotechnology^cNanj
ing^pChina#^iA02^1Nanjing University^2Animal Model Research Center^cNanjing^pChi
na#^len^aThe tissue inhibitor of metalloproteinases (TIMP)-1 is a multifunctiona
l protein which is not only an inhibitor of matrix metalloproteinases (MMPs) but
 also to have a possible "cytokine-like" action. Here, we first compared mRNA ex
pression of TIMP-1 and MMP-9 in BEL-7402 (a hepatocellular carcinoma cell line),
 L-02 (a normal liver cell line) and QSG-7701 (a cell line derived from peripher
al tissue of liver carcinoma) using real-time quantitative RT-PCR. By evaluating
 the variation of the MMP-9/TIMP-1 ratio as an index of reciprocal changes of th
e expression of the two genes, we observed that the MMP-9/TIMP-1 ratio was about
 13- and 5-fold higher in BEL-7402 than in L-02 and QSG-7701, respectively. Sign
ificantly, overexpression of TIMP-1 decreased the MMP-9/TIMP-1 ratio in BEL-7402
 and then inhibited the cell growth to 60 percent and reduced the migration to a
bout 30 percent. Meanwhile, our data showed that interleukin-6 (IL-6) (100 ng/mL
) could also inhibited the cell growth of BEL-7402. Further studies indicated th
at TIMP-1 mediated the inhibitory effect of IL-6 on BEL-7402 cell proliferation 
in a STAT3-dependent manner, which could further accelerate the expression of th
e cyclin-dependent kinase inhibitor p21. A dominant negative STAT3 mutant totall
y abolished IL-6-induced TIMP-1 expression and its biological functions. The pre
sent results demonstrate that TIMP-1 may be one of the mediators that regulate t
he inhibitory effect of IL-6 on BEL-7402 proliferation in which STAT3 signal tra
nsduction and p21 up-regulation also play important roles.#^dnd^i1#^tm^len^kTiss
ue inhibitor of metalloproteinases-1^i1#^tm^len^kHepatocellular carcinoma^i1#^tm
^len^kInterleukin-6^i1#^tm^len^kSTAT3^i1#^tm^len^kp21^i1#other#40#Natural Scienc
e Fund of Jiangsu Province#2000SWX000B501#20060424#April 24, 2006#20070119#Janua
ry 19, 2007#6468.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttex
t&pid=S0100-879X2007000500004##
00371000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014500071002000900216#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#5#1#article#131#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, May 2007, Volum
e 40(5) 621-631</B> </font></P>      ^cY#6468.htm##
00439000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704021300071002000900284#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#6#2#article#131#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">TIMP-1 mediates the inhibitory effect of interl
eukin-6 on the proliferation of a hepatocarcinoma cell line in a STAT3-dependent
 manner</font></B>       ^cY#6468.htm##
00676000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704045000071002000900521#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#7#3#article#131#<P><font face="Arial, He
lvetica, sans-serif">S.-Y. Guo<SUP>1</SUP>, X. Shen<SUP>1</SUP>,    J. Yang<SUP>
1</SUP>, J. Yuan<SUP>1</SUP>, R.-L. Yang<SUP>1</SUP>, K. Mao<SUP>1</SUP>,    D.-
H. Zhao<SUP>1</SUP> and <b><a href="#Correspondence"><img src="/img/revistas/bjm
br/v40n5/recor.gif" border="0"></a></b>    <a href="mailto:licj@njnu.edu.cn"><im
g src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a>    C.-J. Li<sup>1
,2</sup> </font>      ^cY#6468.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704019400071002000900265#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#8#4#article#131#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Jiangsu Key Laboratory for Molecular and Medica
l Biotechnology, Life Sciences College, Nanjing Normal University, Nanjing, Chin
a     ^cY#6468.htm##
00332000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704010600071002000900177#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#9#5#article#131#<br>        <SUP>2</SUP>
Animal Model Research Center, Nanjing University, Nanjing, China</font>       ^c
Y#6468.htm##
00417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019000072002000900262#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#10#6#article#131#<P> <font face="Arial, 
Helvetica, sans-serif"><A HREF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/d
own.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A> 
   ^cY#6468.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#11#7#article#131#<BR>   <A HREF="#Introd
uction"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#6468.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#12#8#article#131#<BR>   <A HREF="#Materi
al"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    
^cY#6468.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704017200072002000900244#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#13#9#article#131#<BR>   <A HREF="#Result
s"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6468.htm##
00409000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704018100073002000900254#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#14#10#article#131#<BR>   <A HREF="#Discu
ssion"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#6
468.htm##
00396000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016800073002000900241#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#15#11#article#131#<BR>   <A HREF="#Refer
ences"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6468.htm##
00437000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704020900073002000900282#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#16#12#article#131#<br>   </strong></A><A
 HREF="#Acknowledgments"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowled
gments</strong></A>    ^cY#6468.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704021800073002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#17#13#article#131#<BR>   <A HREF="#Corre
spondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footn
otes</strong></A>  </font>      ^cY#6468.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#18#14#article#131#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6468.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#19#15#article#131#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <fon
t face="Arial, Helvetica, sans-serif">      ^cY#6468.htm##
01796000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704156800073002000901641#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#20#16#article#131#<P>The tissue inhibito
r of metalloproteinases (TIMP)-1 is a multifunctional protein which is not only 
an inhibitor of matrix metalloproteinases (MMPs) but also to have a possible "cy
tokine-like" action. Here, we first compared mRNA expression of TIMP-1 and MMP-9
 in BEL-7402 (a hepatocellular carcinoma cell line), L-02 (a normal liver cell l
ine) and QSG-7701 (a cell line derived from peripheral tissue of liver carcinoma
) using real-time quantitative RT-PCR. By evaluating the variation of the MMP-9/
TIMP-1 ratio as an index of reciprocal changes of the expression of the two gene
s, we observed that the MMP-9/TIMP-1 ratio was about 13- and 5-fold higher in BE
L-7402 than in L-02 and QSG-7701, respectively. Significantly, overexpression of
 TIMP-1 decreased the MMP-9/TIMP-1 ratio in BEL-7402 and then inhibited the cell
 growth to 60% and reduced the migration to about 30%. Meanwhile, our data showe
d that interleukin-6 (IL-6) (100 ng/mL) could also inhibited the cell growth of 
BEL-7402. Further studies indicated that TIMP-1 mediated the inhibitory effect o
f IL-6 on BEL-7402 cell proliferation in a STAT3-dependent manner, which could f
urther accelerate the expression of the cyclin-dependent kinase inhibitor p21. A
 dominant negative STAT3 mutant totally abolished IL-6-induced TIMP-1 expression
 and its biological functions. The present results demonstrate that TIMP-1 may b
e one of the mediators that regulate the inhibitory effect of IL-6 on BEL-7402 p
roliferation in which STAT3 signal transduction and p21 up-regulation also play 
important roles.      ^cY#6468.htm##
00397000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016900073002000900242#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#21#17#article#131#<P><B>Key words: </B> 
Tissue inhibitor of metalloproteinases-1, Hepatocellular carcinoma, Interleukin-
6, STAT3, p21  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6468.htm##
00665000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043700073002000900510#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#22#18#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT SIZE=4><FONT COLOR=#0000
7F><B>Introduction</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-s
erif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font fa
ce="Arial, Helvetica, sans-serif"></font>  <font face="Arial, Helvetica, sans-se
rif">      ^cY#6468.htm##
01216000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704098800073002000901061#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#23#19#article#131#<P>Four tissue inhibit
ors of metalloproteinases (TIMP) have been identified; TIMP-1 has been shown to 
be particularly interesting. In addition to its classical role as a broad specif
ic inhibitor of matrix metalloproteinases (MMP) (1), TIMP- 1 has also been repor
ted to possess growth factor-like (2) and anti-apoptotic properties (3-5). TIMP-
1 expression can be stimulated by a wide variety of agents including serum, grow
th factors, phorbol esters, cytokines, and viruses (6-8). It has been reported t
hat the activation of hepatic stellate cells (HSCs), a key event in the pathophy
siology of liver fibrosis (9), is also accompanied by induction of TIMP-1 activi
ty and the expression of its mRNA (10, 11). It was shown that transgenic TIMP-1 
inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairing hep
atocellular proliferation and tumor angiogenesis (12). All of these studies sugg
ested that TIMP-1 might be involved in the process of liver pathogenesis.       
  ^cY#6468.htm##
01072000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704084400073002000900917#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#24#20#article#131#<P>The pleiotropic cyt
okine interleukin-6 (IL-6) elicits a wide variety of biological activities in di
fferent cell types, including hematopoietic and neuronal cells, keratinocytes, o
steoclasts, and vascular endothelial cells. IL-6 also modulates the hepatic expr
ession of acute-phase response genes during inflammation (13). When HSCs are act
ivated, they secrete and respond to a wide range of cytokines and growth factors
 including IL-6. Furthermore, activated HSCs also secrete and deposit most of th
e excess extracellular matrix (ECM) in the fibrotic liver through increased secr
etion of ECM proteins, including TIMP-1 and TIMP-2 (14). IL-6 has also been iden
tified as a key protective factor from stress. During hyperoxic lung injury, IL-
6 can protect lung cells from apoptosis by inducing the expression of Bcl-2 and 
TIMP-1 (15).      ^cY#6468.htm##
00612000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038400073002000900457#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#25#21#article#131#<P>In the present stud
y, we examined the functional involvement of IL-6 and TIMP-1 during liver carcin
ogenesis. Using a liver carcinoma cell line, we found that IL-6 was able to incr
ease TIMP-1, that IL-6 and TIMP-1 were able to inhibit cell proliferation, and t
hat IL-6 induction of TIMP-1 and p21 expression was STAT3 dependent.  </font>  <
HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6468.htm##
00618000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039000073002000900463#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#26#22#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Material and Methods</B></FONT></FONT></font> <font face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <fon
t face="Arial, Helvetica, sans-serif">      ^cY#6468.htm##
00282000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704005400073002000900127#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#27#23#article#131#<P><b>Antibodies and c
ytokine</b>    </font>      ^cY#6468.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033800073002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#28#24#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The recombinant human IL-6 was obtained from Merck Inc. (
Whitehouse Station, NJ, USA). Rabbit polyclonal antibodies for TIMP-1 and &szlig
;-tubulin were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). All ot
her chemicals were from Amersco Inc. (Kaysville, UT, USA). </font>      ^cY#6468
.htm##
00321000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009300073002000900166#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#29#25#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Plasmids and adenovirus</B> </font>      ^cY#6468.htm#
#
01440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704121200073002000901285#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#30#26#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Dr. David Young (Department of Cell Biology, Harvard Medi
cal School, Boston, MA, USA) kindly provided the reporter plasmid pGL3-TIMP-1, i
n which the promoter region of human TIMP-1, spanning a fragment from -1714 to +
17 bp was inserted before a luciferase reporter gene. The plasmids pcDNA3-TIMP-1
 and pEGFP-TIMP-1 were constructed in our laboratory. The plasmid p21(Waf1) luci
ferase and the control reporter plasmid pSV-&szlig;-galactosidase were gifts of 
Dr. Zhi-Ming Yin (Life Sciences College, Nanjing Normal University, Nanjing, Chi
na). The cDNA encoding STAT3 and dominant negative STAT3 were gifts from Dr. Xin
-Yuan Fu (Department of Pathology, Yale University School of Medicine, New Haven
, CT, USA) and were subcloned into expression vector pcDNA3.0 (pcDNA-STAT3wt and
 pcDNA-STAT3cyf). STAT3cyf is a mutation of Stat3 tyrosine 705 to phenylalanine 
(Y705F) which causes a reduction of the tyrosine phosphorylation of wild-type ST
AT3 and inhibits the action of endogenous STAT3 in transfected cells (16). Dr. X
in-Yuan Fu also provided the M67 reporter plasmid in which STAT3 DNA- binding si
tes were inserted before a luciferase reporter gene. </font>      ^cY#6468.htm##
00956000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072800073002000900801#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#31#27#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Adenoviral vectors expressing human TIMP-1 were generated
 in our laboratory using the method described by He et al. (17). Briefly, the cD
NA encoding full-length human TIMP-1 was cloned into the shuttle vector, pAdTrac
k-CMV, which contains a GFP expression cassette driven by a separate cytomegalov
irus (CMV) promoter. pAdTrack CMV-TIMP-1 was recombined with backbone pAdEasy-1 
in BJ5183 bacteria. Linearized recombinant plasmid DNA was then transfected into
 293 cells, an adenoviral packaging cell line, to generate the recombinant adeno
virus expressing TIMP-1 and GFP (Ad1-TIMP-1). We used a GFP-expressing recombina
nt adenovirus (Ad1) as a parallel empty control. </font>      ^cY#6468.htm##
00656000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704042800073002000900501#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#32#28#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The adenoviral backbone vector and shuttle vector were ki
ndly provided by Dr. Tong-Chuan He (The Howard Hughes Medical Institute, Baltimo
re, MD, USA) (17). The simplified system described by He et al. (17) was used fo
r adenovirus generation and amplification and titer determination. Viral particl
es were purified by cesium chloride density gradient centrifugation. </font>    
  ^cY#6468.htm##
00331000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010300073002000900176#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#33#29#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Recombinant adenovirus infection </B> </font>      ^cY
#6468.htm##
00510000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028200073002000900355#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#34#30#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Adenoviruses were incubated with cells in a small volume 
of serum-free medium at 37ºC. After adsorption for 2 h, fresh complete growth me
dium was added and the cells were further incubated for the following experiment
s. </font>      ^cY#6468.htm##
00328000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010000073002000900173#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#35#31#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Cell culture and transfection </B> </font>      ^cY#64
68.htm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704046900073002000900542#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#36#32#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The BEL-7402, QSG-7701 and L-02 cell lines were purchased
 from the Shanghai Institute of Cell Biology, China, and were grown in Dulbecco'
s modified Eagle's medium (Gibco, Grand Island, NY, USA) supplemented with 10% N
CS (HyClone, Hampton, NH, USA), 2 mM L-glutamine, 20 U/mL penicillin, and 20 mg/
mL streptomycin. The cultures were kept in a 5% CO<SUB>2</SUB> and 95% air humid
ified incubator at 37&#186;C. </font>      ^cY#6468.htm##
00487000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704025900073002000900332#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#37#33#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Transfections were performed using the calcium phosphate 
method. All promoter-luciferase fusions were co-transfected with the pSV-&szlig;
-galactosidase plasmid to estimate transfection efficiency. </font>      ^cY#646
8.htm##
00315000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008700073002000900160#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#38#34#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Cell growth assay</B> </font>      ^cY#6468.htm##
00624000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039600073002000900469#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#39#35#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Subconfluent monolayer cells were trypsinized and plated 
onto a 6-well plate at a density of 10<SUP>4</SUP> cells per well. After overnig
ht post-plating, the cells were either treated with IL-6 (100 ng/mL), or infecte
d with Ad1-TIMP-1. The cell numbers were counted with a hemocytometer after tryp
sinization at different time points. </font>      ^cY#6468.htm##
00327000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009900073002000900172#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#40#36#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Real-time quantitative RT-PCR</B> </font>      ^cY#646
8.htm##
01106000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704087800073002000900951#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#41#37#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Total RNA was isolated from cells using Trizol reagent (I
nvitrogen, Carsbad, CA, USA) according to the protocol of the manufacturer. Tota
l RNA (2 &#181;g) was used for a reverse transcriptional reaction (Amersham Bios
ciences, Piscataway, NJ, USA). The primers were synthesized to amplify specific 
segments of the cDNA sequences of human TIMP-1, MMP-9, and &szlig;-actin; the &s
zlig;-actin was used as an internal control. The primer sequences for each gene 
were as follows: TIMP-1 forward primer: 5' TTC CGA CCT CGT CAT CAG GG 3'; TIMP-1
 reward primer: 5' ATT CAG GCT ATC TGG GAC CGC 3', MMP-9 forward primer: 5' CCT 
GGA GAC CTG AGA ACC AAT C 3'; MMP-9 reward primer: 5' GAT TTC GAC TCT CCA CGC AT
C 3', actin forward primer: 5' TCC TGT GGC ATC CAC GAA ACT 3'; actin reward prim
er: 5' GAA GCA TTT GCG GTG GAC GAT 3'. </font>      ^cY#6468.htm##
00536000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704030800073002000900381#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#42#38#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The qPCR assays were performed with the MyiQ SyBr Green S
upermix system (Bio-Rad, Hercules, CA, USA) and 300 nM sense and antisense prime
rs. The cycling conditions were as follows: initial denaturation at 95ºC for 2 m
in, followed by 40 cycles at 95ºC for     ^cY#6468.htm##
00633000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040500073002000900478#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#43#39#article#131#<BR>   30 s, 60ºC for 
30 s, and 72ºC for 30 s. The expression level of each mRNA was determined relati
ve to the standard curve using the LightCycler computer software (Roche Diagnost
ics, Castle Hill, NSW, Australia). The specificity of the SyBr Green assays was 
confirmed by melting point analysis and gel electrophoresis. The gene expression
 of &szlig;-actin was used for normalization. </font>      ^cY#6468.htm##
00323000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009500073002000900168#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#44#40#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Western blotting analysis</B> </font>      ^cY#6468.ht
m##
01037000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704080900073002000900882#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#45#41#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Cells were washed and lysed in lysis buffer (20 mM Tris-H
Cl, pH 8.0, 75 mM NaCl, 1.5 mM MgCl<SUB>2</SUB>, 1 mM EGTA, 1.0% NP-40, 1 mM PMS
F, 10 &#181;g/mL leupeptin, and 10 mg/mL aprotinin). Protein concentrations were
 determined by Bradford assays. Samples of the extract containing equal amounts 
of total protein were submitted to 10% (w/v) SDS-PAGE and transferred to the PVD
F membrane, which was blocked with 3% BSA-blocking buffer and then incubated wit
h polyclonal anti-TIMP-1 antibody diluted 1:500. The membrane was then incubated
 with the peroxidase-conjugated secondary antibody for 40 min. The blotting patt
erns were developed using the ECL system (Roche, Mannhein, Germany). &szlig;-tub
ulin was blotted as a control of protein loading. </font>      ^cY#6468.htm##
00303000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007500073002000900148#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#46#42#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>ELISA</B> </font>      ^cY#6468.htm##
01389000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704116100073002000901234#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#47#43#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The secreted TIMP-1 protein in culture medium was examine
d by indirect ELISA. Briefly, the wells of polystyrene microtiter plates (Greine
r Bio-One, Maybachstrasse, Frickenhausen, Deutschland) were coated with 150-&#18
1;L culture medium after 72 h of infection with adenovirus. After overnight incu
bation at 4ºC, the wells were washed three times with 0.1 M PBS containing 0.05%
 Tween 20, pH 7.4. The coated wells were blocked with 200 &#181;L 2% BSA for 1 h
 at 37&#186;C and then incubated with 150 &#181;L polyclonal antibody anti-TIMP-
1 diluted 1:1000. After incubation for 2 h at 37&#186;C, the wells were washed a
s before and then incubated with 150 &#181;L of horseradish peroxidase-conjugate
d goat anti-rabbit IgG (1:5000 dilution, Sigma, St. Louis, MO, USA) for 1 h at 3
7&#186;C. After washing, <I>o</I>-phenylenediamine (Shanghai Chemicals, Shanghai
, China) was used as the substrate. The reaction was stopped after 30 min with 5
0 &#181;L 2 M H<SUB>2</SUB>SO<SUB>4</SUB> and absorbance was measured at 490 nm 
using an ELx800 Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VE, USA)
. </font>      ^cY#6468.htm##
00315000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008700073002000900160#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#48#44#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Luciferase assay </B> </font>      ^cY#6468.htm##
01009000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078100073002000900854#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#49#45#article#131#<P><font face="Arial, 
Helvetica, sans-serif">BEL-7402 cells were transfected with the luciferase repor
ter construct (0.2 &#181;g/each well) when cells reached about 60% density on 6-
well plates. At 24 h after transfection, cells were further stimulated with exog
enous IL-6 (100 ng/mL) or infected with Ad1-TIMP-1. Luciferase activities in cel
l lysates were determined with a luminometer (Lumat LB 9507, Berthold, Germany) 
48 h after transfection, using a luciferase assay kit (Promega, WI, USA). Lucife
rase activity was normalized to &szlig;-galactosidase activity to correct transf
ection efficiency. Each experiment was performed in triplicate and was repeated 
at least three times. P values <font face="Symbol">&#163;</font>5% were consider
ed to be significant. </font>      ^cY#6468.htm##
00326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009800073002000900171#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#50#46#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Single-cell migration assay </B> </font>      ^cY#6468
.htm##
00860000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063200073002000900705#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#51#47#article#131#<P><font face="Arial, 
Helvetica, sans-serif">After pEGFP-TIMP-1 transfection, cells were plated onto a
 grid glass coverslip at low-cell density. In order to trace the movement of the
 cells, randomly selected fields were photographed every hour with a Leica digit
al camera. pEGFP-TIMP-1-expressing cells were distinguished under a fluorescence
 microscope and photographed with a Spot Cool CCD (Diagnostic Instruments, Sterl
ing Heights, MI, USA). All pictures were merged together using the Photoshop sof
tware. The migration distance was compared between the "Green" cells (TIMP-1-exp
ressing cells) and normal cells. </font>      ^cY#6468.htm##
00312000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008400073002000900157#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#52#48#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Motility assay</B> </font>      ^cY#6468.htm##
00895000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704066700073002000900740#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#53#49#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The wounding assay was carried out according to the metho
d described by Sato and Rifkin (18). Briefly, BEL-7402 cells were grown to confl
uence on 24-well plates in the presence of Ad1-TIMP-1 adenovirus, Ad1 control ad
enovirus, or mock control. Wounds were made in the monolayer by scraping it with
 a disposable pipette tip to remove a channel of cells. The cells were washed im
mediately with PBS and then cultured for 24 h. The distance from the wound margi
n to the leading edge of the migrating BEL-7402 cells was determined. For each t
reatment, eight measurements were made at identical marked regions. </font>     
 ^cY#6468.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#54#50#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6468.htm##
00636000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040800073002000900481#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#55#51#article#131#<P><font face="Arial, 
Helvetica, sans-serif">All experiments were repeated at least three times. Data 
are reported as means &#177; standard deviation. Statistical differences between
 the two groups were evaluated using the paired Student <I>t</I>-test (Statistic
a, Statsoft Inc., Tulsa, OK, USA). P values less than 0.05 were considered to be
 significant. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6468.htm##
00560000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033200073002000900405#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#56#52#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Results</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"><A H
REF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=
BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6468.htm##
00368000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014000073002000900213#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#57#53#article#131#<P><b><font face="Aria
l, Helvetica, sans-serif">Overexpression of TIMP-1-inhibited cell proliferation 
of BEL-7402</font></b> </P>       ^cY#6468.htm##
01220000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704099200073002000901065#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#58#54#article#131#<P><font face="Arial, 
Helvetica, sans-serif">BEL-7402 is an hepatocellular carcinoma    (HCC) cell lin
e extensively used in the field of hepatoma research in China,    while L-02 is 
a normal liver cell line used as a control and QSG-7701 is a cell    line derive
d from peripheral tissue of liver carcinoma. Their genetic background,    in par
ticular regarding TIMP-1 expression, remains largely unknown. The result    of r
eal-time quantitative PCR showed that the expression of TIMP-1 tended to    be d
ecreased in BEL-7402 cells compared to normal cell lines, whereas the amount    
of mRNA of MMP-9 presented an inverse trend. In addition, we evaluated the varia
tion    of the MMP-9/TIMP-1 ratio as an index of reciprocal changes of the expre
ssion    of the two genes and observed that the MMP-9/TIMP-1 ratio was significa
ntly    higher (about 13- and 5-fold, respectively, P &lt; 0.001) in BEL-7402 th
an in    L-02 and QSG-7701, respectively (<a href="#Fig1">Figue 1A</a>). </font>
      ^cY#6468.htm##
01045000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704081700073002000900890#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#59#55#article#131#<P><font face="Arial, 
Helvetica, sans-serif">When cells overexpressed TIMP-1 by    infection of recomb
inant adenovirus carrying the TIMP-1 gene, the MMP-9/ TIMP-1    ratio was signif
icantly decreased to almost the same level in BEL-7402, QSG-7701    and L-02 (<a
 href="#Fig1">Figure 1A</a>). Cell growth was inhibited in BEL-7402    and QSG-7
701 cell lines (<a href="#Fig1">Figure 1C</a>). The number of BEL-7402    cells 
declined to only about 60% of the number of untreated cells (P &lt; 0.01)    aft
er 6-day culture by induction of TIMP-1, but L-02 was not observably affected   
 by TIMP-1 overexpression. Interestingly, an obvious growth-inhibitory effect   
 on QSG-7701 (P &lt; 0.01) was also observed. The methyl thiazolyl tetrazolium  
  (MTT) assay displayed similar results (data not shown). </font>      ^cY#6468.
htm##
00403000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704017500073002000900248#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#60#56#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>IL-6 inhibited the proliferation of the hepatocarcinom
a cell line BEL-7402 and induced TIMP-1 expression</B> </font>       ^cY#6468.ht
m##
00969000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074100073002000900814#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#61#57#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Increasing evidence has demonstrated    that IL-6 plays a
n important role in regulating cell proliferation. To investigate    the role of
 IL-6 in the HCC cell line, we cultured BEL-7402 cells in a medium    containing
 IL-6 (100 ng/mL) and found that cell proliferation was inhibited.    After 6 da
ys of culture, cell numbers decreased to only about 75% of untreated    cells (P
 &lt; 0.05; <a href="#Fig2">Figure 2A</a>). This was also confirmed    by the MT
T assay (data not shown). The results also showed that IL-6 only began    to hav
e visible effects after 4 days of treatment, which suggests that other    factor
s induced by IL-6 inhibited the proliferation of these cells. </font>      ^cY#6
468.htm##
00663000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043500073002000900508#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#62#58#article#131#<P><font face="Arial, 
Helvetica, sans-serif">To address whether the inhibitory    effect of IL-6 on BE
L-7402 was accompanied by induction of TIMP-1, we checked    the activity of luc
iferase that was under the control of the TIMP-1 promoter.    The data suggested
 that IL-6 was able to induce TIMP-1 expression. The luciferase    activity incr
eased about 9-fold after IL-6 treatment (<a href="#Fig2">Figure    2B</a>). </fo
nt>      ^cY#6468.htm##
00342000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011400073002000900187#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#63#59#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>IL-6 induction of TIMP-1 was STAT3 dependent</B> </fon
t>      ^cY#6468.htm##
01086000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085800073002000900931#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#64#60#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Two functional binding sites for activator protein-1 and 
STAT which responded to IL-6/oncostatin have been identified in the TIMP-1 promo
ter M (19). Here we examined whether STAT3 signaling was involved in TIMP-1 prod
uction induced by IL-6 in BEL-7402. As shown in <a href="#Fig3">Figure 3</a>, th
e TIMP-1 reporter luciferase activity of BEL-7402 cells transfected with wild-ty
pe STAT3 expression vector was up-regulated about 4.4-fold compared to control c
ells, and IL-6 treatment elevated TIMP-1 expression up to 18-fold (P &lt; 0.01) 
in these cells. The dominant negative form of STAT3 totally inhibited the expres
sion of TIMP-1 both in IL-6-treated and -untreated cells. Thus, we found that th
e activation of TIMP-1 gene expression by IL-6 in BEL-7402 cells was dependent o
n STAT3 signaling. </font>      ^cY#6468.htm##
00338000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011000073002000900183#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#65#61#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>p21 was up-regulated by TIMP-1 and IL-6</B> </font>   
    ^cY#6468.htm##
00895000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704066700073002000900740#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#66#62#article#131#<P><font face="Arial, 
Helvetica, sans-serif">To elucidate the mechanism of IL-6-induced    inhibition 
of cell proliferation in BEL-7402, we checked the p21(Waf1) expression    level 
using a luciferase reporter assay. IL-6 enhanced p21 expression about    3.3-fol
d compared to control cells, in which the transient overexpression of    STAT3 a
ugmented the luciferase reporter activity. When the cells were transfected    wi
th STAT3wt and treated with IL-6, they displayed up to 6.7 times more p21    exp
ression than control cells. Moreover, dominant negative STAT3 blocked the    sti
mulation of IL-6 to control levels (<a href="#Fig4">Figure 4A</a>). </font>     
 ^cY#6468.htm##
00526000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029800073002000900371#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#67#63#article#131#<P><font face="Arial, 
Helvetica, sans-serif">TIMP-1 itself was also able to accelerate    p21 expressi
on. The transfection of TIMP-1 resulted in a 5-fold higher expression    of p21 
than the vehicle vector transfection control and blank control (<a href="#Fig4">
Figure    4B</a>). </font>      ^cY#6468.htm##
00341000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011300073002000900186#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#68#64#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>TIMP-1 inhibited the migration of BEL-7402</B> </font>
       ^cY#6468.htm##
00883000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704065500073002000900728#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#69#65#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Both the single-cell migration detection    assay and wou
nding assay showed that cells overexpressing TIMP-1 migrated much    slower than
 control cells did. In <a href="#Fig5">Figure 5A</a>, a, b, c, d    indicate the
 cell center at successive time points. The migration route of each    cell can 
be considered to be a<font face="Symbol">&#174;</font>b<font face="Symbol">&#174
;</font>c<font face="Symbol">&#174;</font>d    approximately, the average motion
 distance of the transfected cells (green cells)    was only about 33% compared 
to the normal cells (<a href="#Fig5">Figure 5B</a>).    </font>      ^cY#6468.ht
m##
01094000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704086600073002000900939#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#70#66#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The mobility of cell groups was detected    by the woundi
ng assay. Confluent monolayers of three groups of BEL-7402 cells    were wounded
 and then cultured for 24 h. The cells were photographed and the    migration di
stance was determined (<a href="#Fig5">Figure 5C</a>,<a href="#Fig5">D</a>).    
The data showed that the migration rates of the Ad1-TIMP-1 group and the Ad1    
group were 28 and 98%, respectively, of the migration of the mock group. Both   
 experiments indicated that TIMP-1 inhibited the migration of BEL-7402 cells.</f
ont>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
0n5/html/6468i01.htm"><img src="/img/revistas/bjmbr/v40n5/6468i01peq.jpg" border
="2"></a></td>      <td width="87%">    ^cY#6468.htm##
01258000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704103000073002000901103#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#71#67#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Overexpression of tissue inh
ibitor of metalloproteinases (TIMP-1) could inhibit the proliferation of the hep
atocellular carcinoma BEL-7402 cell line. <I>A</I>, Comparison of the MMP-9/TIMP
-1 ratio in three different cell lines with recombinant adenovirus carrying TIMP
-1 (Ad1-TIMP-1) and without (mock) TIMP-1 overexpression. <I>B</I>, Detection of
 TIMP-1 overexpression in BEL-7402. Western blotting (WB) analysis was processed
 with &szlig;-tubulin as internal control. The active protein of TIMP-1 secreted
 in the culture medium was detected by ELISA. The mock here indicated the cells 
without any treatment which was an internal control. <I>C</I>, Inhibition of BEL
-7402, L-02 and QSG-7701 proliferation by TIMP-1. The cells were infected with A
d1-TIMP-1, Ad1 control and mock control. The number of cells was counted daily w
ith a hemocytometer after trypsinization and the growth curves were calculated. 
</font>       </td>    </tr>  </table>      ^cY#6468.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038800073002000900461#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#72#68#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (135 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/
v40n5/html/6468i02.htm"><img src="/img/revistas/bjmbr/v40n5/6468i02peq.jpg" bord
er="2"></a></td>      <td width="87%">    ^cY#6468.htm##
01026000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704079800073002000900871#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#73#69#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. Inhibition by interleukin-6 
(IL-6) of the proliferation of the hepatocarcinoma cell line BEL-7402 was accomp
anied by induced tissue inhibitor of metalloproteinases (TIMP-1) expression. <I>
A</I>, BEL-7402 cells were collected by trypsinization and resuspended in cultur
e medium after being treated or not with IL-6. The number of cells was counted w
ith a hemocytometer. <I>B</I>, Cells were transfected with the TIMP-1 reporter p
lasmid and treated or not with IL-6. TIMP-1 expression induced by IL-6 was analy
zed according to the luciferase activity of the TIMP-1 reporter construct. The &
szlig;-gal reporter plasmid was co-transfected to normalize the transfection eff
iciency. </font>      </td>    </tr>  </table>      ^cY#6468.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#74#70#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (68 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
40n5/html/6468i03.htm"><img src="/img/revistas/bjmbr/v40n5/6468i03peq.jpg" borde
r="2"></a></td>      <td width="87%">    ^cY#6468.htm##
01093000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704086500073002000900938#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#75#71#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure 3. <I>A,</I> The induction of t
issue inhibitor of metalloproteinases (TIMP-1) by interleukin-6 (IL-6) was STAT3
 dependent, as demonstrated by a TIMP-1 luciferase reporter activity assay. Cell
s were transfected with TIMP-1 reporter plasmids, co-transfected together with t
he STAT3wt or STAT3cyf constructs. The cells were then treated or not with IL-6.
 <I>B,</I> Functional identification of STAT3wt/cyf protein using a STAT3 report
er (M67) activity assay. Cells were transfected with M67 reporter plasmids, co-t
ransfected together with the pcDNA, pcDNA-STAT3wt or pcDNA-STAT3cyf constructs. 
The cells were then treated or not with IL-6. Each group was co-transfected with
 the &szlig;-gal reporter plasmid to normalize the transfection efficiency. </fo
nt>      </td>    </tr>  </table>      ^cY#6468.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#76#72#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (98 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
40n5/html/6468i04.htm"><img src="/img/revistas/bjmbr/v40n5/6468i04peq.jpg" borde
r="2"></a></td>      <td width="87%">    ^cY#6468.htm##
01015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078700073002000900860#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#77#73#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig4"></a>Figure 4. Up-regulation of p21 induced
 by tissue inhibitor of metalloproteinases (TIMP-1) and interleukin-6 (IL-6) in 
BEL-7402 cells analyzed by the luciferase assay. <I>A</I>, Cells were transfecte
d with p21(Waf1) reporter, co-transfected together with pcDNA3-STAT3wt or pcDNA3
-STAT3cyf constructs. The cells were then treated or not with IL-6. <I>B</I>, Ce
lls were transfected with p21(Waf1) reporter, co-transfected together with pcDNA
3-TIMP-1 or pcDNA3 as an empty parental vector control. Mock was  a blank contro
l representing the cells transfected by nothing. Each group was co-transfected w
ith the &szlig;-gal reporter plasmid to normalize the transfection efficiency.</
font>      </td>    </tr>  </table>      ^cY#6468.htm##
01391000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704116300073002000901236#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#78#74#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (62 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
40n5/html/6468i05.htm"><img src="/img/revistas/bjmbr/v40n5/6468i05peq.jpg" borde
r="2"></a></td>      <td width="87%"><font face="Arial, Helvetica, sans-serif"><
a name="Fig5"></a>Figure 5. Inhibitory effect of tissue inhibitor of metalloprot
einases (TIMP-1) on the migration of BEL-7402 cells. <I>A</I>, The centers of ce
lls monitored every hour are shown by a, b, c, d. The cell on the right overexpr
essed TIMP-1. <I>B</I>, The relative average velocity of single cell migration w
as calculated for TIMP-1-transfected and control cells. <I>C</I>, Ability to mig
rate affected by TIMP-1 using a wounding assay. Confluent monolayers of three gr
oups of BEL-7402 cells were scraped using a tip and then cultured for 24 h. The 
cells were photographed and the migration distance was determined. The beeline i
ndicated the same location. <I>D</I>, The migration distance of three groups was
 determined.     ^cY#6468.htm##
00365000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013700073002000900210#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#79#75#article#131#<BR> *P &lt; 0.01 for 
7402/Ad1-TIMP-1 compared with the 7402/Ad1 group (Student <I>t</I>-test). </font
></td>    </tr>  </table>      ^cY#6468.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011800073002000900191#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#80#76#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (131 K JPG file)]</fon
t></P>      ^cY#6468.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#81#77#article#131#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6468.htm##
00498000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027000073002000900343#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#82#78#article#131#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n
5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  
    ^cY#6468.htm##
00825000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704059700073002000900670#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#83#79#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The ECM forms a microenvironment that can modulate cellul
ar behavior by affecting the contact of the cell with the outside world (20,21).
 Degradation or activation of ECM proteins by proteolysis can change the cellula
r microenvironment rapidly and irreversibly. The turnover of ECM is delicately r
egulated by a pair of contrary functional molecules: MMP and its tissue inhibito
r (TIMP). MMP produces subtle changes of matrix structure by cleaving and also r
eleasing matrix-bound growth factors and thereby controlling differentiation. </
font>      ^cY#6468.htm##
01055000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704082700073002000900900#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#84#80#article#131#<P><font face="Arial, 
Helvetica, sans-serif">MMP-9 has been reported to play an important role in the 
invasion and metastasis of cancers (22). A previous report showed that the MMP-9
/TIMP-1 mRNA ratio differed between the stage II-III group and the stage IV grou
p of lung cancer (23). Imbalance of the ratio between MMP-9 and TIMP-1 may cause
 breakdown of the basement membrane and ECM and is an essential step in tumor in
vasion and metastasis (24). In the present study, BEL-7402 originated from a Chi
nese patient with HCC which exhibited a high metastasis rate. Real-time PCR data
 showed that the MMP-9/TIMP-1 ratio was noticeably higher in BEL-7402 than in th
e normal liver cell line L-02 and QSG-7701, which may be one explanation for the
 high invasive ability of BEL-7402 compared to the other two lines. </font>     
 ^cY#6468.htm##
01010000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078200073002000900855#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#85#81#article#131#<P><font face="Arial, 
Helvetica, sans-serif">TIMP-1 is a multifunctional protein with MMP-dependent an
d -independent actions for the regulation of cell death, cell proliferation, and
 angiogenesis (25). After TIMP-1 was initially characterized as a homologue of e
rythroid potentiating activity factor, it was found to display growth- and survi
val-promoting activity for a wide range of normal or transformed cells (26,27). 
Increasing evidence demonstrates a much more complex role for TIMP-1 during tumo
r progression and angiogenesis, in addition to its regulation of MMP-mediated EC
M degradation. It has been well established that TIMP-1 has anti-apoptotic activ
ity on many different cell types through both MMP-dependent (28,29) and -indepen
dent pathways (30,31). </font>      ^cY#6468.htm##
00866000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063800073002000900711#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#86#82#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Regarding the role of TIMP-1 in cell proliferation, confl
icting data have been reported suggesting that TIMP-1 is mitogenic in certain ca
ncer cells and lymphoid cells (2,32) while it inhibits the growth of normal mamm
ary epithelial cells (33). In the present study, TIMP-1 reduced the growth rate 
of the HCC cell line BEL-7402 by up-regulating the cyclin-dependent kinase inhib
itor p21(Waf1) and reducing the MMP-9/TIMP-1 ratio, suggesting that both MMP-9-T
IMP-1 balance and TIMP-1 expression as a "cytokine-like" protein are required fo
r the regulation of tumor progression. </font>      ^cY#6468.htm##
01157000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704092900073002000901002#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#87#83#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Previous studies have shown that IL-6 has a pivotal role 
in stimulating hepatocytes to produce acute phase proteins cytotoxic to the live
r; moreover, IL-6 has been shown to be a cell cycle progression factor for liver
 cells (34). After 70% partial hepatectomy, liver regeneration is dramatically i
mpaired in IL-6<SUP><font face="Symbol">-/-</font></SUP> livers. Treatment with 
IL-6 clearly accelerated the proliferative response in both IL-6<SUP><font face=
"Symbol">+/+</font></SUP> and IL-6<SUP><font face="Symbol">-/-</font></SUP> live
rs (35). Intense research over the past decade has shown that IL-6 could inhibit
 the proliferation of some cancer cells (36-38). Zeng and Fan (39) suggested tha
t IL-6 could inhibit the growth of the hepatocarcinoma cell line BEL-7402 by inc
reasing the influx of Ca<SUP>2+</SUP> and decreasing the expression of Bcl-2 in 
the cell. </font>      ^cY#6468.htm##
01269000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104100073002000901114#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#88#84#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Acting via gp130, IL-6 activates multiple signaling pathw
ays, including the JAK-STAT, the Src family of protein tyrosine kinases, and pho
sphatidylinositol 3-kinase. It is also known that IL-6 can induce TIMP-1 express
ion (40). As indicated in a previous paper, IL-6 inhibits the proliferation of B
EL-7402 by promoting apoptosis (39). We found that IL-6 treatment did not inhibi
t BEL-7402 proliferation until the fourth day of treatment, suggesting that ther
e might be another mediator induced by IL-6 which actually exerts the inhibitory
 effect. Our data showed that TIMP-1 may be the mediator of the inhibitory effec
ts of IL-6, inducing the remodeling of the ECM. Actually cell growth and prolife
ration result from a balance between the number of dividing cells and the number
 of dying cells. And since TIMP-1 has been shown to inhibit apoptosis, our resul
ts suggested the presence of a potential downstream pathway regulated by TIMP-1 
distinct from the anti-apoptosis pathway. </font>      ^cY#6468.htm##
00624000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039600073002000900469#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#89#85#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The present results showed that IL-6 induced cell growth 
inhibition through TIMP-1 production, which was STAT3 dependent. The downstream 
inhibitory molecule of IL-6 and TIMP-1 was p21. IL-6 could accelerate p21 expres
sion through the STAT3 signaling pathway which may act by decreasing MMP activit
y.</font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6468.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033800073002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#90#86#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>References</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif
"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6468
.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704028000075002000900355#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#91#87#article#131#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Denhardt DT, Feng B, Edwards DR, Cocuzzi
 ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): struc
ture, control of expression and biological functions. <I>Pharmacol Ther</I> 1993
; 59: 329-341. </font>      ^cY#6468.htm##
00544000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704030200075002000900377#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#92#88#article#131#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Hayakawa T, Yamashita K, Tanzawa K, Uchi
jima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloprotein
ases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum
. <I>FEBS Lett</I> 1992; 298: 29-32. </font>      ^cY#6468.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027700075002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#93#89#article#131#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Alexander CM, Howard EW, Bissell MJ, Wer
b Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a t
issue inhibitor of metalloproteinases-1 transgene. <I>J Cell Biol</I> 1996; 135:
 1669-1677. </font>      ^cY#6468.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023000075002000900305#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#94#90#article#131#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Boudreau N, Sympson CJ, Werb Z, Bissell 
MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellula
r matrix. <I>Science</I> 1995; 267: 891-893. </font>      ^cY#6468.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027500075002000900350#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#95#91#article#131#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Guedez L, Courtemanch L, Stetler-Stevens
on M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and
 an antiapoptotic phenotype in germinal center B cells. <I>Blood</I> 1998; 92: 1
342-1349. </font>      ^cY#6468.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027600075002000900351#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#96#92#article#131#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Campbell CE, Flenniken AM, Skup D, Willi
ams BR. Identification of a serum- and phorbol ester-responsive element in the m
urine tissue inhibitor of metalloproteinase gene. <I>J Biol Chem</I> 1991; 266: 
7199-7206. </font>      ^cY#6468.htm##
00568000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704032600075002000900401#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#97#93#article#131#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Uchijima M, Sato H, Fujii M, Seiki M. Ta
x proteins of human T-cell leukemia virus type 1 and 2 induce expression of the 
gene encoding erythroid-potentiating activity (tissue inhibitor of metalloprotei
nases-1, TIMP-1). <I>J Biol Chem</I> 1994; 269: 14946-14950. </font>      ^cY#64
68.htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704026800075002000900343#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#98#94#article#131#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Gewert DR, Coulombe B, Castelino M, Skup
 D, Williams BR. Characterization and expression of a murine gene homologous to 
human EPA/TIMP: a virus-induced gene in the mouse. <I>EMBO J</I> 1987; 6: 651-65
7. </font>      ^cY#6468.htm##
00497000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025500075002000900330#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#99#95#article#131#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Friedman SL. Seminars in medicine of the
 Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanism
s and treatment strategies. <I>N Engl J Med</I> 1993; 328: 1828-1835. </font>   
   ^cY#6468.htm##
00660000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704041600077002000900493#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#100#96#article#131#10#<P><fo
nt face="Arial, Helvetica, sans-serif">10. Nieto N, Dominguez-Rosales JA, Fontan
a L, Salazar A, Armendariz-Borunda J, Greenwel P, et al. Rat hepatic stellate ce
lls contribute to the acute-phase response with increased expression of alpha1(I
) and alpha1(IV) collagens, tissue inhibitor of metalloproteinase-1, and matrix-
metalloproteinase-2 messenger RNAs. <I>Hepatology</I> 2001; 33: 597-607. </font>
      ^cY#6468.htm##
00588000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704034400077002000900421#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#101#97#article#131#11#<P><fo
nt face="Arial, Helvetica, sans-serif">11. Bahr MJ, Vincent KJ, Arthur MJ, Fowle
r AV, Smart DE, Wright MC, et al. Control of the tissue inhibitor of metalloprot
einases-1 promoter in culture-activated rat hepatic stellate cells: regulation b
y activator protein-1 DNA binding proteins. <I>Hepatology</I> 1999; 29: 839-848.
 </font>      ^cY#6468.htm##
00570000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704032600077002000900403#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#102#98#article#131#12#<P><fo
nt face="Arial, Helvetica, sans-serif">12. Martin DC, Sanchez-Sweatman OH, Ho AT
, Inderdeo DS, Tsao MS, Khokha R. Transgenic TIMP-1 inhibits simian virus 40 T a
ntigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferatio
n and tumor angiogenesis. <I>Lab Invest</I> 1999; 79: 225-234. </font>      ^cY#
6468.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704017000077002000900247#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#103#99#article#131#13#<P><fo
nt face="Arial, Helvetica, sans-serif">13. Akira S, Taga T, Kishimoto T. Interle
ukin-6 in biology and medicine. <I>Adv Immunol</I> 1993; 54: 1-78. </font>      
^cY#6468.htm##
00569000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032400078002000900402#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#104#100#article#131#14#<P><f
ont face="Arial, Helvetica, sans-serif">14. Smart DE, Vincent KJ, Arthur MJ, Eic
kelberg O, Castellazzi M, Mann J, et al. JunD regulates transcription of the tis
sue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepat
ic stellate cells. <I>J Biol Chem</I> 2001; 276: 24414-24421. </font>      ^cY#6
468.htm##
00496000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025100078002000900329#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#105#101#article#131#15#<P><f
ont face="Arial, Helvetica, sans-serif">15. Ward NS, Waxman AB, Homer RJ, Mantel
l LL, Einarsson O, Du Y, et al. Interleukin-6-induced protection in hyperoxic ac
ute lung injury. <I>Am J Respir Cell Mol Biol</I> 2000; 22: 535-542. </font>    
  ^cY#6468.htm##
00478000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023300078002000900311#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#106#102#article#131#16#<P><f
ont face="Arial, Helvetica, sans-serif">16. Kaptein A, Paillard V, Saunders M. D
ominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal tra
nsduction. <I>J Biol Chem</I> 1996; 271: 5961-5964.</font>      ^cY#6468.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024000078002000900318#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#107#103#article#131#17#<P><f
ont face="Arial, Helvetica, sans-serif">17. He TC, Zhou S, da Costa LT, Yu J, Ki
nzler KW, Vogelstein B. A simplified system for generating recombinant adenoviru
ses. <I>Proc Natl Acad Sci U S A</I> 1998; 95: 2509-2514. </font>      ^cY#6468.
htm##
00548000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030300078002000900381#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#108#104#article#131#18#<P><f
ont face="Arial, Helvetica, sans-serif">18. Sato Y, Rifkin DB. Inhibition of end
othelial cell movement by pericytes and smooth muscle cells: activation of a lat
ent transforming growth factor-beta 1-like molecule by plasmin during co-culture
. <I>J Cell Biol</I> 1989; 109: 309-315. </font>      ^cY#6468.htm##
00561000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031600078002000900394#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#109#105#article#131#19#<P><f
ont face="Arial, Helvetica, sans-serif">19. Bugno M, Graeve L, Gatsios P, Koj A,
 Heinrich PC, Travis J, et al. Identification of the interleukin-6/oncostatin M 
response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) pr
omoter. <I>Nucleic Acids Res</I> 1995; 23: 5041-5047. </font>      ^cY#6468.htm#
#
00520000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027500078002000900353#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#110#106#article#131#20#<P><f
ont face="Arial, Helvetica, sans-serif">20. Khatiwala CB, Peyton SR, Putnam AJ. 
Intrinsic mechanical properties of the extracellular matrix affect the behavior 
of pre-osteoblastic MC3T3-E1 cells. <I>Am J Physiol Cell Physiol</I> 2006; 290: 
C1640-C1650. </font>      ^cY#6468.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023000078002000900308#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#111#107#article#131#21#<P><f
ont face="Arial, Helvetica, sans-serif">21. Ingber DE. Mechanical signaling and 
the cellular response to extracellular matrix in angiogenesis and cardiovascular
 physiology. <I>Circ Res</I> 2002; 91: 877-887. </font>      ^cY#6468.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028800078002000900366#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#112#108#article#131#22#<P><f
ont face="Arial, Helvetica, sans-serif">22. Iizasa T, Fujisawa T, Suzuki M, Moto
hashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma ma
trix metalloproteinase 9 in non-small cell lung cancer patients. <I>Clin Cancer 
Res</I> 1999; 5: 149-153. </font>      ^cY#6468.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025000078002000900328#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#113#109#article#131#23#<P><f
ont face="Arial, Helvetica, sans-serif">23. Ming SH, Sun TY, Xiao W, Xu XM. Matr
ix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinase-1 in lung 
cancer invasion and metastasis. <I>Chin Med J </I>2005; 118: 69-72. </font>     
 ^cY#6468.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024600078002000900324#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#114#110#article#131#24#<P><f
ont face="Arial, Helvetica, sans-serif">24. Gomez DE, Alonso DF, Yoshiji H, Thor
geirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and 
biological functions. <I>Eur J Cell Biol</I> 1997; 74: 111-122. </font>      ^cY
#6468.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019200078002000900270#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#115#111#article#131#25#<P><f
ont face="Arial, Helvetica, sans-serif">25. Chirco R, Liu XW, Jung KK, Kim HR. N
ovel functions of TIMPs in cell signaling. <I>Cancer Metastasis Rev</I> 2006; 25
: 99-113. </font>      ^cY#6468.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027300078002000900351#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#116#112#article#131#26#<P><f
ont face="Arial, Helvetica, sans-serif">26. Luparello C, Avanzato G, Carella C, 
Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative 
behaviour of clonal breast cancer cells. <I>Breast Cancer Res Treat</I> 1999; 54
: 235-244. </font>      ^cY#6468.htm##
00595000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704035000078002000900428#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#117#113#article#131#27#<P><f
ont face="Arial, Helvetica, sans-serif">27. Oelmann E, Herbst H, Zuhlsdorf M, Al
brecht O, Nolte A, Schmitmann C, et al. Tissue inhibitor of metalloproteinases 1
 is an autocrine and paracrine survival factor, with additional immune-regulator
y functions, expressed by Hodgkin/Reed-Sternberg cells. <I>Blood</I> 2002; 99: 2
58-267. </font>      ^cY#6468.htm##
00640000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704039500078002000900473#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#118#114#article#131#28#<P><f
ont face="Arial, Helvetica, sans-serif">28. Murphy FR, Issa R, Zhou X, Ratnaraja
h S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic st
ellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects 
on matrix metalloproteinase inhibition: implications for reversibility of liver 
fibrosis. <I>J Biol Chem</I> 2002; 277: 11069-11076. </font>      ^cY#6468.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022800078002000900306#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#119#115#article#131#29#<P><f
ont face="Arial, Helvetica, sans-serif">29. Vorotnikova E, Tries M, Braunhut S. 
Retinoids and TIMP1 prevent radiation-induced apoptosis of capillary endothelial
 cells. <I>Radiat Res</I> 2004; 161: 174-184. </font>      ^cY#6468.htm##
00588000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704034300078002000900421#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#120#116#article#131#30#<P><f
ont face="Arial, Helvetica, sans-serif">30. Liu XW, Taube ME, Jung KK, Dong Z, L
ee YJ, Roshy S, et al. Tissue inhibitor of metalloproteinase-1 protects human br
east epithelial cells from extrinsic cell death: a potential oncogenic activity 
of tissue inhibitor of metalloproteinase-1. <I>Cancer Res</I> 2005; 65: 898-906.
 </font>      ^cY#6468.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027200078002000900350#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#121#117#article#131#31#<P><f
ont face="Arial, Helvetica, sans-serif">31. Lambert E, Boudot C, Kadri Z, Soula-
Rothhut M, Sowa ML, Mayeux P, et al. Tissue inhibitor of metalloproteinases-1 si
gnalling pathway leading to erythroid cell survival. <I>Biochem J</I> 2003; 372:
 767-774. </font>      ^cY#6468.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024200078002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#122#118#article#131#32#<P><f
ont face="Arial, Helvetica, sans-serif">32. Bertaux B, Hornebeck W, Eisen AZ, Du
bertret L. Growth stimulation of human keratinocytes by tissue inhibitor of meta
lloproteinases. <I>J Invest Dermatol</I> 1991; 97: 679-685. </font>      ^cY#646
8.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026600078002000900344#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#123#119#article#131#33#<P><f
ont face="Arial, Helvetica, sans-serif">33. Fata JE, Leco KJ, Moorehead RA, Mart
in DC, Khokha R. Timp-1 is important for epithelial proliferation and branching 
morphogenesis during mouse mammary development. <I>Dev Biol</I> 1999; 211: 238-2
54. </font>      ^cY#6468.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024500078002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#124#120#article#131#34#<P><f
ont face="Arial, Helvetica, sans-serif">34. Streetz KL, Wustefeld T, Klein C, Ma
nns MP, Trautwein C. Mediators of inflammation and acute phase response in the l
iver. <I>Cell Mol Biol (Noisy-le-grand)</I> 2001; 47: 661-673. </font>      ^cY#
6468.htm##
00396000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704015100078002000900229#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#125#121#article#131#35#<P><f
ont face="Arial, Helvetica, sans-serif">35. Michalopoulos GK, DeFrances MC. Live
r regeneration. <I>Science</I> 1997; 276: 60-66. </font>      ^cY#6468.htm##
00566000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032100078002000900399#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#126#122#article#131#36#<P><f
ont face="Arial, Helvetica, sans-serif">36. Takizawa H, Ohtoshi T, Ohta K, Yamas
hita N, Hirohata S, Hirai K, et al. Growth inhibition of human lung cancer cell 
lines by interleukin 6 <I>in vitro</I>: a possible role in tumor growth via an a
utocrine mechanism. <I>Cancer Res</I> 1993; 53: 4175-4181. </font>      ^cY#6468
.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025000078002000900328#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#127#123#article#131#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Danforth DN Jr, Sgagias MK. Interleu
kin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast c
ancer cells <I>in vitro</I>. <I>Cancer Res</I> 1993; 53: 1538-1545. </font>     
 ^cY#6468.htm##
00532000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028700078002000900365#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#128#124#article#131#38#<P><f
ont face="Arial, Helvetica, sans-serif">38. Badache A, Hynes NE. Interleukin 6 i
nhibits proliferation and, in cooperation with an epidermal growth factor recept
or autocrine loop, increases migration of T47D breast cancer cells. <I>Cancer Re
s</I> 2001; 61: 383-391. </font>      ^cY#6468.htm##
00476000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023100078002000900309#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#129#125#article#131#39#<P><f
ont face="Arial, Helvetica, sans-serif">39. Zeng XH, Fan XJ. Apoptosis of liver 
cancer cells BEL-7402 induced by IL-6 and its calcium signal transduction pathwa
y. <I>Acta Laser Bio Sinica</I> 2001; 10: 55-61. </font>      ^cY#6468.htm##
00607000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704036200078002000900440#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#p#130#126#article#131#40#<P><f
ont face="Arial, Helvetica, sans-serif">40. Silacci P, Dayer JM, Desgeorges A, P
eter R, Manueddu C, Guerne PA. Interleukin (IL)-6 and its soluble receptor induc
e TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced col
lagenolytic activity. <I>J Biol Chem</I> 1998; 273: 13625-13629. </font>  <HR AL
IGN=LEFT WIDTH=100% SIZE=2>      ^cY#6468.htm##
00587000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704035700075002000900432#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#131#127#article#131#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=
#00007F><B>Acknowledgments</B></FONT></FONT></font> <font face="Arial, Helvetica
, sans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n
5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></fo
nt></P>      ^cY#6468.htm##
01046000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704081600075002000900891#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#132#128#article#131#<P><font face="Arial
, Helvetica, sans-serif">We are grateful to Dr. David Young (Department of Cell 
Biology, Harvard Medical School, Boston, MA, USA) and Dr. Tong-Chuan He (The How
ard Hughes Medical Institute, Baltimore, MD, USA) for their generous gift of the
 construct of the pGL3-TIMP-1 reporter plasmid or adenoviral backbone and shuttl
e vectors. We would like to thank Dr. Xin-Yuan Fu (Department of Pathology, Yale
 University School of Medicine, New Haven, CT, USA) for providing STAT3 wild-typ
e, dominant negative form constructs and M67 reporter plasmid, and thank Dr. Zhi
-Ming Yin (Life Sciences College, Nanjing Normal University, Nanjing, China) for
 providing the p21(Waf1) luciferase plasmid and the control reporter plasmid pSV
-&szlig;-galactosidase. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6468
.htm##
00578000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704034800075002000900423#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#133#129#article#131#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence and Footnotes</B></FONT></FONT> <font face="Arial, Helvetica,
 sans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>   
    ^cY#6468.htm##
00703000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704047300075002000900548#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#134#130#article#131#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/
recor.gif" border="0"></a>    Address for correspondence:</b> </font><font face=
"Arial, Helvetica, sans-serif">C.J.    Li, Jiangsu Key Laboratory for Molecular 
and Medical Biotechnology, Life Sciences    College, Nanjing Normal University, 
Nanjing 210097, China. Fax: +86-25-8359-8812.    E-mail: <a href="mailto:licj@nj
nu.edu.cn">licj@njnu.edu.cn</a></font> </p>      ^cY#6468.htm##
00433000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704020300075002000900278#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6468.htm#S#p#135#131#article#131#<P><font face="Arial
, Helvetica, sans-serif">Research supported by the Natural Science Fund of Jiang
su Province (No. 2000SWX000B501). Received April 24, 2006. Accepted January 19, 
2007. </font>      ^cY#6468.htm##
00678000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100014000930100
01800107010001800125010002000143012011800163030001500281065000900296064000500305
031000300310014000800313865000900321002000900330035001000339801001500349#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#136#1#article#40#1#^rND^sDenhard
t^nDT#^rND^sFeng^nB#^rND^sEdwards^nDR#^rND^sCocuzzi^nET#^rND^sMalyankar^nUM#Tiss
ue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expres
sion and biological functions^len#Pharmacol Ther#19930000#1993#59#329-341#200705
00#6468.htm#0163-7258#Pharmacol Ther##
00695000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100019000920100
01700111010001800128010001500146012014800161030001000309065000900319064000500328
031000400333014000600337865000900343002000900352035001000361801001000371#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#137#2#article#40#2#^rND^sHayakaw
a^nT#^rND^sYamashita^nK#^rND^sTanzawa^nK#^rND^sUchijima^nE#^rND^sIwata^nK#Growth
-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a w
ide range of cells: A possible new growth factor in serum^len#FEBS Lett#19920000
#1992#298#29-32#20070500#6468.htm#0014-5793#FEBS lett##
00654000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100017000940100
01800111010001400129012012900143030001200272065000900284064000500293031000400298
014001000302865000900312002000900321035001000330801001200340#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#138#3#article#40#3#^rND^sAlexander^nCM#^rND^
sHoward^nEW#^rND^sBissell^nMJ#^rND^sWerb^nZ#Rescue of mammary epithelial cell ap
optosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 t
ransgene^len#J Cell Biol#19960000#1996#135#1669-1677#20070500#6468.htm#0021-9525
#J Cell Biol##
00603000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100018000920100
01400110010001800124012008900142030000800231065000900239064000500248031000400253
014000800257865000900265002000900274035001000283801000800293#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#139#4#article#40#4#^rND^sBoudreau^nN#^rND^sS
ympson^nCJ#^rND^sWerb^nZ#^rND^sBissell^nMJ#Suppression of ICE and apoptosis in m
ammary epithelial cells by extracellular matrix^len#Science#19950000#1995#267#89
1-893#20070500#6468.htm#0036-8075#Science##
00628000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100021000900100
02700111012013300138030000600271065000900277064000500286031000300291014001000294
865000900304002000900313035001000322801000600332#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6468.htm#S#c#140#5#article#40#5#^rND^sGuedez^nL#^rND^sCourtemanch^nL#
^rND^sStetler-Stevenson^nM#Tissue inhibitor of metalloproteinase (TIMP)-1 induce
s differentiation and an antiapoptotic phenotype in germinal center B cells^len#
Blood#19980000#1998#92#1342-1349#20070500#6468.htm#0006-4971#Blood##
00653000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100020000930100
01400113010001900127012012500146030001200271065000900283064000500292031000400297
014001000301865000900311002000900320035001000329801001200339#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#141#6#article#40#6#^rND^sCampbell^nCE#^rND^s
Flenniken^nAM#^rND^sSkup^nD#^rND^sWilliams^nBR#Identification of a serum- and ph
orbol ester-responsive element in the murine tissue inhibitor of metalloproteina
se gene^len#J Biol Chem#19910000#1991#266#7199-7206#20070500#6468.htm#0021-9258#
J Biol Chem##
00703000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100014000920100
01500106010001500121012018300136030001200319065000900331064000500340031000400345
014001200349865000900361002000900370035001000379801001200389#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#142#7#article#40#7#^rND^sUchijima^nM#^rND^sS
ato^nH#^rND^sFujii^nM#^rND^sSeiki^nM#Tax proteins of human T-cell leukemia virus
 type 1 and 2 induce expression of the gene encoding erythroid-potentiating acti
vity (tissue inhibitor of metalloproteinases-1, TIMP-1)^len#J Biol Chem#19940000
#1994#269#14946-14950#20070500#6468.htm#0021-9258#J Biol Chem##
00658000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910100
01900109010001400128010001900142012011700161030000700278065000900285064000500294
031000200299014000800301865000900309002000900318035001000327801000700337#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#143#8#article#40#8#^rND^sGewert^
nDR#^rND^sCoulombe^nB#^rND^sCastelino^nM#^rND^sSkup^nD#^rND^sWilliams^nBR#Charac
terization and expression of a murine gene homologous to human EPA/TIMP: a virus
-induced gene in the mouse^len#EMBO J#19870000#1987#6#651-657#20070500#6468.htm#
0261-4189#Embo J##
00546000000000253000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740120101000930300
05000194710000200244065000900246064000500255031000400260014001000264865000900274
002000900283#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#144#9#articl
e#40#9#^rND^sFriedman^nSL#Seminars in medicine of the Beth Israel Hospital, Bost
on: The cellular basis of hepatic fibrosis^len#Mechanisms and treatment strategi
es. N Engl J Med#2#19930000#1993#328#1828-1835#20070500#6468.htm##
00840000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100028000910100
01700119010001700136010002800153010001800181810000600199012022200205030001100427
06500090043806400050044703100030045201400080045586500090046300200090047203500100
0481801001100491#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#145#10#a
rticle#40#10#^rND^sNieto^nN#^rND^sDominguez-Rosales^nJA#^rND^sFontana^nL#^rND^sS
alazar^nA#^rND^sArmendariz-Borunda^nJ#^rND^sGreenwel^nP#et al#Rat hepatic stella
te cells contribute to the acute-phase response with increased expression of alp
ha1(I) and alpha1(IV) collagens, tissue inhibitor of metalloproteinase-1, and ma
trix-metalloproteinase-2 messenger RNAs^len#Hepatology#20010000#2001#33#597-607#
20070500#6468.htm#0161-0538#HEPATOLOGY##
00768000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01700109010001700126010001600143010001700159810000600176012017300182030001100355
06500090036606400050037503100030038001400080038386500090039100200090040003500100
0409801001100419#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#146#11#a
rticle#40#11#^rND^sBahr^nMJ#^rND^sVincent^nKJ#^rND^sArthur^nMJ#^rND^sFowler^nAV#
^rND^sSmart^nDE#^rND^sWright^nMC#et al#Control of the tissue inhibitor of metall
oproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulat
ion by activator protein-1 DNA binding proteins^len#Hepatology#19990000#1999#29#
839-848#20070500#6468.htm#0161-0538#HEPATOLOGY##
00739000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100027000930100
01300120010001900133010001500152010001600167012015500183030001100338065000900349
06400050035803100030036301400080036686500090037400200090038303500100039280100110
0402#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#147#12#article#40#12
#^rND^sMartin^nDC#^rND^sSanchez-Sweatman^nOH#^rND^sHo^nAT#^rND^sInderdeo^nDS#^rN
D^sTsao^nMS#^rND^sKhokha^nR#Transgenic TIMP-1 inhibits simian virus 40 T antigen
-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and 
tumor angiogenesis^len#Lab Invest#19990000#1999#79#225-234#20070500#6468.htm#002
3-6837#Lab Invest##
00530000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100014000910100
01900105012004200124030001200166065000900178064000500187031000300192014000500195
865000900200002000900209035001000218801001200228#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6468.htm#S#c#148#13#article#40#13#^rND^sAkira^nS#^rND^sTaga^nT#^rND^s
Kishimoto^nT#Interleukin-6 in biology and medicine^len#Adv Immunol#19930000#1993
#54#1-78#20070500#6468.htm#0065-2776#Adv Immunol##
00749000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01700110010002000127010002100147010001400168810000600182012014100188030001200329
06500090034106400050035003100040035501400120035986500090037100200090038003500100
0389801001200399#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#149#14#a
rticle#40#14#^rND^sSmart^nDE#^rND^sVincent^nKJ#^rND^sArthur^nMJ#^rND^sEickelberg
^nO#^rND^sCastellazzi^nM#^rND^sMann^nJ#et al#JunD regulates transcription of the
 tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated h
epatic stellate cells^len#J Biol Chem#20010000#2001#276#24414-24421#20070500#646
8.htm#0021-9258#J Biol Chem##
00690000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01600108010001800124010001900142010001200161810000600173012006800179030002600247
06500090027306400050028203100030028701400080029086500090029800200090030703500100
0316801002600326#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#150#15#a
rticle#40#15#^rND^sWard^nNS#^rND^sWaxman^nAB#^rND^sHomer^nRJ#^rND^sMantell^nLL#^
rND^sEinarsson^nO#^rND^sDu^nY#et al#Interleukin-6-induced protection in hyperoxi
c acute lung injury^len#Am J Respir Cell Mol Biol#20000000#2000#22#535-542#20070
500#6468.htm#1044-1549#Am J Respir Cell Mol Biol##
00594000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01800111012009500129030001200224065000900236064000500245031000400250014001000254
865000900264002000900273035001000282801001200292#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6468.htm#S#c#151#16#article#40#16#^rND^sKaptein^nA#^rND^sPaillard^nV#
^rND^sSaunders^nM#Dominant negative stat3 mutant inhibits interleukin-6-induced 
Jak-STAT signal transduction^len#J Biol Chem#19960000#1996#271#5961-5964#2007050
0#6468.htm#0021-9258#J Biol Chem##
00667000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100014000890100
01900103010001200122010001800134010002000152012006400172030002500236065000900261
06400050027003100030027501400100027886500090028800200090029703500100030680100250
0316#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#152#17#article#40#17
#^rND^sHe^nTC#^rND^sZhou^nS#^rND^sda Costa^nLT#^rND^sYu^nJ#^rND^sKinzler^nKW#^rN
D^sVogelstein^nB#A simplified system for generating recombinant adenoviruses^len
#Proc Natl Acad Sci U S A#19980000#1998#95#2509-2514#20070500#6468.htm#0027-8424
#Proc Natl Acad Sci U S A##
00645000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900120
18200107030001200289065000900301064000500310031000400315014000800319865000900327
002000900336035001000345801001200355#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
468.htm#S#c#153#18#article#40#18#^rND^sSato^nY#^rND^sRifkin^nDB#Inhibition of en
dothelial cell movement by pericytes and smooth muscle cells: activation of a la
tent transforming growth factor-beta 1-like molecule by plasmin during co-cultur
e^len#J Cell Biol#19890000#1989#109#309-315#20070500#6468.htm#0021-9525#J Cell B
iol##
00747000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01700107010001300124010001900137010001600156810000600172012014000178030001800318
06500090033606400050034503100030035001400100035386500090036300200090037203500100
0381801001800391#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#154#19#a
rticle#40#19#^rND^sBugno^nM#^rND^sGraeve^nL#^rND^sGatsios^nP#^rND^sKoj^nA#^rND^s
Heinrich^nPC#^rND^sTravis^nJ#et al#Identification of the interleukin-6/oncostati
n M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1
) promoter^len#Nucleic Acids Res#19950000#1995#23#5041-5047#20070500#6468.htm#03
05-1048#Nucleic Acids Res##
00603000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01700113012011900130030002600249710000200275065000900277064000500286031000400291
014001200295865000900307002000900316#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
468.htm#S#c#155#20#article#40#20#^rND^sKhatiwala^nCB#^rND^sPeyton^nSR#^rND^sPutn
am^nAJ#Intrinsic mechanical properties of the extracellular matrix affect the be
havior of pre-osteoblastic MC3T3-E1 cells^len#Am J Physiol Cell Physiol#2#200600
00#2006#290#C1640-C1650#20070500#6468.htm##
00551000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120121000930300
00900214065000900223064000500232031000300237014000800240865000900248002000900257
035001000266801000900276#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#
156#21#article#40#21#^rND^sIngber^nDE#Mechanical signaling and the cellular resp
onse to extracellular matrix in angiogenesis and cardiovascular physiology^len#C
irc Res#20020000#2002#91#877-887#20070500#6468.htm#0009-7330#Circ Res##
00717000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01600110010001900126010001800145010001800163810000600181012010800187030001600295
06500090031106400050032003100020032501400080032786500090033500200090034403500100
0353801001600363#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#157#22#a
rticle#40#22#^rND^sIizasa^nT#^rND^sFujisawa^nT#^rND^sSuzuki^nM#^rND^sMotohashi^n
S#^rND^sYasufuku^nK#^rND^sYasukawa^nT#et al#Elevated levels of circulating plasm
a matrix metalloproteinase 9 in non-small cell lung cancer patients^len#Clin Can
cer Res#19990000#1999#5#149-153#20070500#6468.htm#1078-0432#Clin Cancer Res##
00627000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100014000910100
01400105010001300119012011900132030001100251065000900262064000500271031000400276
014000600280865000900286002000900295035001000304801001100314#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#158#23#article#40#23#^rND^sMing^nSH#^rND^sSu
n^nTY#^rND^sXiao^nW#^rND^sXu^nXM#Matrix metalloproteinases-2, -9 and tissue inhi
bitor of metalloproteinase-1 in lung cancer invasion and metastasis^len#Chin Med
 J#20050000#2005#118#69-72#20070500#6468.htm#0366-6999#Chin Med J##
00628000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01700109010002300126012009200149030001600241065000900257064000500266031000300271
014000800274865000900282002000900291035001000300801001600310#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#159#24#article#40#24#^rND^sGomez^nDE#^rND^sA
lonso^nDF#^rND^sYoshiji^nH#^rND^sThorgeirsson^nUP#Tissue inhibitors of metallopr
oteinases: structure, regulation and biological functions^len#Eur J Cell Biol#19
970000#1997#74#111-122#20070500#6468.htm#0171-9335#Eur J Cell Biol##
00580000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100014000920100
01500106010001400121012004700135030002200182065000900204064000500213031000300218
014000700221865000900228002000900237035001000246801002200256#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#160#25#article#40#25#^rND^sChirco^nR#^rND^sL
iu^nXW#^rND^sJung^nKK#^rND^sKim^nHR#Novel functions of TIMPs in cell signaling^l
en#Cancer Metastasis Rev#20060000#2006#25#99-113#20070500#6468.htm#0167-7659#Can
cer Metastasis Rev##
00663000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01700113010002300130012010700153030002400260065000900284064000500293031000300298
014000800301865000900309002000900318035001000327801002400337#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#161#26#article#40#26#^rND^sLuparello^nC#^rND
^sAvanzato^nG#^rND^sCarella^nC#^rND^sPucci-Minafra^nI#Tissue inhibitor of metall
oprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells^len
#Breast Cancer Res Treat#19990000#1999#54#235-244#20070500#6468.htm#0167-6806#Br
east Cancer Res Treat##
00769000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01900109010001800128010001500146010002000161810000600181012017900187030000600366
06500090037206400050038103100030038601400080038986500090039700200090040603500100
0415801000600425#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#162#27#a
rticle#40#27#^rND^sOelmann^nE#^rND^sHerbst^nH#^rED^sZuhlsdorf^nM#^rND^sAlbrecht^
nO#^rND^sNolte^nA#^rND^sSchmitmann^nC#et al#Tissue inhibitor of metalloproteinas
es 1 is an autocrine and paracrine survival factor, with additional immune-regul
atory functions, expressed by Hodgkin/Reed-Sternberg cells^len#Blood#20020000#20
02#99#258-267#20070500#6468.htm#0006-4971#Blood##
00820000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930100
01400107010002000121010001600141010001700157810000600174012022000180030001200400
06500090041206400050042103100040042601400120043086500090044200200090045103500100
0460801001200470#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#163#28#a
rticle#40#28#^rND^sMurphy^nFR#^rND^sIssa^nR#^rND^sZhou^nX#^rND^sRatnarajah^nS#^r
ND^sNagase^nH#^rND^sArthur^nMJ#et al#Inhibition of apoptosis of activated hepati
c stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effe
cts on matrix metalloproteinase inhibition: implications for reversibility of li
ver fibrosis^len#J Biol Chem#20020000#2002#277#11069-11076#20070500#6468.htm#002
1-9258#J Biol Chem##
00587000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100015000970100
01800112012009100130030001100221065000900232064000500241031000400246014000800250
865000900258002000900267035001000276801001100286#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6468.htm#S#c#164#29#article#40#29#^rND^sVorotnikova^nE#^rND^sTries^nM
#^rND^sBraunhut^nS#Retinoids and TIMP1 prevent radiation-induced apoptosis of ca
pillary endothelial cells^len#Radiat Res#20040000#2004#161#174-184#20070500#6468
.htm#0033-7587#Radiat Res##
00767000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01500106010001400121010001400135010001500149810000600164012018400170030001100354
06500090036506400050037403100030037901400080038286500090039000200090039903500100
0408801001100418#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#165#30#a
rticle#40#30#^rND^sLiu^nXW#^rND^sTaube^nME#^rND^sJung^nKK#^rND^sDong^nZ#^rND^sLe
e^nYJ#^rND^sRoshy^nS#et al#Tissue inhibitor of metalloproteinase-1 protects huma
n breast epithelial cells from extrinsic cell death: a potential oncogenic activ
ity of tissue inhibitor of metalloproteinase-1^len#Cancer Res#20050000#2005#65#8
98-906#20070500#6468.htm#0008-5472#Cancer res##
00695000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01500109010002300124010001500147010001600162810000600178012009900184030001000283
06500090029306400050030203100040030701400080031186500090031900200090032803500100
0337801001000347#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#166#31#a
rticle#40#31#^rND^sLambert^nE#^rND^sBoudot^nC#^rND^sKadri^nZ#^rND^sSoula-Rothhut
^nM#^rND^sSowa^nML#^rND^sMayeux^nP#et al#Tissue inhibitor of metalloproteinases-
1 signalling pathway leading to erythroid cell survival^len#Biochem J#20030000#2
003#372#767-774#20070500#6468.htm#0264-6021#Biochem J##
00626000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01600112010001900128012008800147030001800235065000900253064000500262031000300267
014000800270865000900278002000900287035001000296801001800306#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#167#32#article#40#32#^rND^sBertaux^nB#^rND^s
Hornebeck^nW#^rND^sEisen^nAZ#^rND^sDubertret^nL#Growth stimulation of human kera
tinocytes by tissue inhibitor of metalloproteinases^len#J Invest Dermatol#199100
00#1991#97#679-685#20070500#6468.htm#0022-202X#J Invest Dermatol##
00659000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
02000106010001700126010001600143012011400159030000900273065000900282064000500291
031000400296014000800300865000900308002000900317035001000326801000900336#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#168#33#article#40#33#^rND^sFata^
nJE#^rND^sLeco^nKJ#^rND^sMoorehead^nRA#^rND^sMartin^nDC#^rND^sKhokha^nR#Timp-1 i
s important for epithelial proliferation and branching morphogenesis during mous
e mammary development^len#Dev Biol#19990000#1999#211#238-254#20070500#6468.htm#0
012-1606#Dev Biol##
00609000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01500113010001600128010001900144012006800163030003100231710000200262065000900264
064000500273031000300278014000800281865000900289002000900298#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6468.htm#S#c#169#34#article#40#34#^rND^sStreetz^nKL#^rND^
sWustefeld^nT#^rND^sKlein^nC#^rND^sManns^nMP#^rND^sTrautwein^nC#Mediators of inf
lammation and acute phase response in the liver^len#Cell Mol Biol (Noisy-le-gran
d)#2#20010000#2001#47#661-673#20070500#6468.htm##
00489000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760100020001000120
02300120030000800143065000900151064000500160031000400165014000600169865000900175
002000900184035001000193801000800203#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
468.htm#S#c#170#35#article#40#35#^rND^sMichalopoulos^nGK#^rND^sDeFrances^nMC#Liv
er regeneration^len#Science#19970000#1997#276#60-66#20070500#6468.htm#0036-8075#
Science##
00738000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01400111010001900125010001800144010001500162810000600177012014000183030001100323
06500090033406400050034303100030034801400100035186500090036100200090037003500100
0379801001100389#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#171#36#a
rticle#40#36#^rND^sTakizawa^nH#^rND^sOhtoshi^nT#^rND^sOhta^nK#^rND^sYamashita^nN
#^rND^sHirohata^nS#^rND^sHirai^nK#et al#Growth inhibition of human lung cancer c
ell lines by interleukin 6 in vitro: a possible role in tumor growth via an auto
crine mechanism^len#Cancer Res#19930000#1993#53#4175-4181#20070500#6468.htm#0008
-5472#Cancer res##
00584000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100018000980120
11300116030001100229065000900240064000500249031000300254014001000257865000900267
002000900276035001000285801001100295#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
468.htm#S#c#172#37#article#40#37#^rND^sDanforth^nDN Jr#^rND^sSgagias^nMK#Interle
ukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast 
cancer cells in vitro^len#Cancer Res#19930000#1993#53#1538-1545#20070500#6468.ht
m#0008-5472#Cancer res##
00628000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930120
16600109030001100275065000900286064000500295031000300300014000800303865000900311
002000900320035001000329801001100339#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
468.htm#S#c#173#38#article#40#38#^rND^sBadache^nA#^rND^sHynes^nNE#Interleukin 6 
inhibits proliferation and, in cooperation with an epidermal growth factor recep
tor autocrine loop, increases migration of T47D breast cancer cells^len#Cancer R
es#20010000#2001#61#383-391#20070500#6468.htm#0008-5472#Cancer res##
00541000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100014000910120
10500105030002200210710000200232065000900234064000500243031000300248014000600251
865000900257002000900266#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#
174#39#article#40#39#^rND^sZeng^nXH#^rND^sFan^nXJ#Apoptosis of liver cancer cell
s BEL-7402 induced by IL-6 and its calcium signal transduction pathway^len#Acta 
Laser Bio Sinica#2#20010000#2001#10#55-61#20070500#6468.htm##
00741000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
02000109010001500129010001800144010001700162012015400179030001200333065000900345
06400050035403100040035901400120036386500090037500200090038403500100039380100120
0403#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6468.htm#S#c#175#40#article#40#40
#^rND^sSilacci^nP#^rND^sDayer^nJM#^rND^sDesgeorges^nA#^rND^sPeter^nR#^rND^sManue
ddu^nC#^rND^sGuerne^nPA#Interleukin (IL)-6 and its soluble receptor induce TIMP-
1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenol
ytic activity^len#J Biol Chem#19980000#1998#273#13625-13629#20070500#6468.htm#00
21-9258#J Biol Chem##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#o#1#1#article#1#20
080212#125707#6541.htm#194##
02720000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120128001790100029003070100036003360700128003720700143005000700077006430830
99500720085000801715085002301723085003601746085004601782085002501828085002601853
08500270187911700060190607200030191205800070191506000110192206000110193305800050
19440600012019490600014019611120009019751110014019841140009019981130018020078810
02402025002000902049#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#h#2#1#
article#1#ra#en#bjmbr#1#3.1#ILUS#TAB#02#BJMBR090#FAPESP#Braz J Med Biol Res#40#5
#20070500#^f601^l613#0100-879X#20070314#Combating oncogene activation associated
 with retrovirus-mediated gene therapy of X-linked severe combined immunodeficie
ncy^len#^rND^1A01 A03^nB.E.^sStrauss#^rND^1A02 A03^nE.^sCostanzi-Strauss#Univers
idade de São Paulo^iA01^1Faculdade de Medicina^2Laboratório de Genética e Cardio
logia Molecular^3Setor de Vetores Virais#Universidade de São Paulo^iA02^1Institu
to de Ciências Biomédicas^2Departamento de Biologia Celular e do Desenvolvimento
^cSão Paulo^sSP^pBrasil#MCT^iA03^1Instituto do Milênio: Rede de Terapia Gênica^c
Brasília^sDF^pBrasil#^len^aA successful gene therapy clinical trial that also en
countered serious adverse effects has sparked extensive study and debate about t
he future directions for retrovirus-mediated interventions. Treatment of X-linke
d severe combined immunodeficiency with an oncoretrovirus harboring a normal cop
y of the gc gene was applied in two clinical trials, essentially curing 13 of 16
 infants, restoring a normal immune system without the need for additional immun
e-related therapies. Approximately 3 years after their gene therapy, tragically,
 3 of these children, all from the same trial, developed leukemia as a result of
 this experimental treatment. The current understanding of the mechanism behind 
this leukemogenesis involves three critical and cooperating factors, i.e., viral
 integration, oncogene activation, and the function of the therapeutic gene. In 
this review, we will explore the causes of this unwanted event and some of the p
ossibilities for reducing the risk of its reoccurrence.#^dnd^i1#^tm^len^kRetrovi
rus^i1#^tm^len^kInsertional mutagenesis^i1#^tm^len^kSevere combined immune defic
iency^i1#^tm^len^kGene therapy^i1#^tm^len^kAdverse event^i1#^tm^len^kClinical tr
ial^i1#other#58#FAPESP#00/12156-5#98/15120-0#CNPq#473587/04-1#420036/2005-9#2006
0628#June 28, 2006#20061213#December 13, 2006#S0100-879X2006005000085#6541.htm##
02684000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120128001790100029003070100036003360700128003720700143005000700077006430830
99500720085000801715085002301723085003601746085004601782085002501828085002601853
08500270187911700060190607200030191205800070191506000110192206000110193305800050
19440600012019490600014019611120009019751110014019841140009019981130018020070020
00902025#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#f#3#1#article#1#ra
#en#bjmbr#1#3.1#ILUS#TAB#02#BJMBR090#FAPESP#Braz J Med Biol Res#40#5#20070500#^f
601^l613#0100-879X#20070314#Combating oncogene activation associated with retrov
irus-mediated gene therapy of X-linked severe combined immunodeficiency^len#^rND
^1A01 A03^nB.E.^sStrauss#^rND^1A02 A03^nE.^sCostanzi-Strauss#Universidade de São
 Paulo^iA01^1Faculdade de Medicina^2Laboratório de Genética e Cardiologia Molecu
lar^3Setor de Vetores Virais#Universidade de São Paulo^iA02^1Instituto de Ciênci
as Biomédicas^2Departamento de Biologia Celular e do Desenvolvimento^cSão Paulo^
sSP^pBrasil#MCT^iA03^1Instituto do Milênio: Rede de Terapia Gênica^cBrasília^sDF
^pBrasil#^len^aA successful gene therapy clinical trial that also encountered se
rious adverse effects has sparked extensive study and debate about the future di
rections for retrovirus-mediated interventions. Treatment of X-linked severe com
bined immunodeficiency with an oncoretrovirus harboring a normal copy of the gc 
gene was applied in two clinical trials, essentially curing 13 of 16 infants, re
storing a normal immune system without the need for additional immune-related th
erapies. Approximately 3 years after their gene therapy, tragically, 3 of these 
children, all from the same trial, developed leukemia as a result of this experi
mental treatment. The current understanding of the mechanism behind this leukemo
genesis involves three critical and cooperating factors, i.e., viral integration
, oncogene activation, and the function of the therapeutic gene. In this review,
 we will explore the causes of this unwanted event and some of the possibilities
 for reducing the risk of its reoccurrence.#^dnd^i1#^tm^len^kRetrovirus^i1#^tm^l
en^kInsertional mutagenesis^i1#^tm^len^kSevere combined immune deficiency^i1#^tm
^len^kGene therapy^i1#^tm^len^kAdverse event^i1#^tm^len^kClinical trial^i1#other
#58#FAPESP#00/12156-5#98/15120-0#CNPq#473587/04-1#420036/2005-9#20060628#June 28
, 2006#20061213#December 13, 2006#6541.htm##
02841000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762230009001860120128001950100029003230100035003520700153003870700145005400700
07900685083099500764085000801759085002301767085003601790085004601826085002501872
08500260189708500270192311700060195007200030195605800070195906000110196606000110
19770580005019880600012019930600014020051120009020191110014020281140009020421130
01802051002000902069008008902078#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.
htm#S#l#4#1#article#1#^mMay^a2007#ra#en#bjmbr#1#3.1#ilus#tab#02#BJMBR090#FAPESP#
Braz. j. med. biol. res#40#5#20070500#^f601^l613#0100-879X#20070314#Combating on
cogene activation associated with retrovirus-mediated gene therapy of X-linked s
evere combined immunodeficiency^len#^rND^1A01 A03^nB. E^sStrauss#^rND^1A02 A03^n
E^sCostanzi-Strauss#^iA01^1Universidade de São Paulo^2Faculdade de Medicina^3Lab
oratório de Genética e Cardiologia Molecular. Setor de Vetores Virais^cSão Paulo
^sSP^pBrasil#^iA02^1Universidade de São Paulo^2Instituto de Ciências Biomédicas^
3Departamento de Biologia Celular e do Desenvolvimento^cSão Paulo^sSP^pBrasil#^i
A03^1MCT^2Instituto do Milênio: Rede de Terapia Gênica^cBrasília^sDF^pBrasil#^le
n^aA successful gene therapy clinical trial that also encountered serious advers
e effects has sparked extensive study and debate about the future directions for
 retrovirus-mediated interventions. Treatment of X-linked severe combined immuno
deficiency with an oncoretrovirus harboring a normal copy of the gc gene was app
lied in two clinical trials, essentially curing 13 of 16 infants, restoring a no
rmal immune system without the need for additional immune-related therapies. App
roximately 3 years after their gene therapy, tragically, 3 of these children, al
l from the same trial, developed leukemia as a result of this experimental treat
ment. The current understanding of the mechanism behind this leukemogenesis invo
lves three critical and cooperating factors, i.e., viral integration, oncogene a
ctivation, and the function of the therapeutic gene. In this review, we will exp
lore the causes of this unwanted event and some of the possibilities for reducin
g the risk of its reoccurrence.#^dnd^i1#^tm^len^kRetrovirus^i1#^tm^len^kInsertio
nal mutagenesis^i1#^tm^len^kSevere combined immune deficiency^i1#^tm^len^kGene t
herapy^i1#^tm^len^kAdverse event^i1#^tm^len^kClinical trial^i1#other#58#FAPESP#0
0/12156-5#98/15120-0#CNPq#473587/04-1#420036/2005-9#20060628#June 28, 2006#20061
213#December 13, 2006#6541.htm#Internet^ihttp://www.scielo.br/scielo.php?script=
sci_arttext&pid=S0100-879X2007000500002##
00402000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017600071002000900247#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#5#1#article#132#<P class="style4"> <A NA
ME="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">
<B>May 2007, Volume 40(5) 601-613</B> </font> (Review)</B></P>      ^cY#6541.htm
##
00449000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704022300071002000900294#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#6#2#article#132#<P class="style2"><B><fo
nt size="5" face="Arial, Helvetica, sans-serif">Combating oncogene activation as
sociated with retrovirus-mediated gene therapy of X-linked severe combined immun
odeficiency</font> </B> </P>       ^cY#6541.htm##
00627000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704040100071002000900472#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#7#3#article#132#<P><font face="Arial, He
lvetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/i
mg/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a href="mailto:bstrauss@u
sp.br"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a></span><
/font>    <font face="Arial, Helvetica, sans-serif">B.E. Strauss<SUP>1,3</SUP> a
nd E.    Costanzi-Strauss<sup>2,3</sup> </font>      ^cY#6541.htm##
00401000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017500071002000900246#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#8#4#article#132#<P><font face="Arial, He
lvetica, sans-serif"><sup>1</sup>Setor de Vetores Virais, Laborat&oacute;rio de 
Gen&eacute;tica e Cardiologia Molecular, Faculdade de Medicina     ^cY#6541.htm#
#
00423000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704019700071002000900268#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#9#5#article#132#<br>        <SUP>2</SUP>
Departamento de Biologia Celular e do Desenvolvimento, Instituto de Ci&ecirc;nci
as Biom&eacute;dicas, Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Br
asil     ^cY#6541.htm##
00354000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704012700072002000900199#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#10#6#article#132#<br>  <SUP>3</SUP>Insti
tuto do Mil&ecirc;nio: Rede de Terapia G&ecirc;nica, MCT, Bras&iacute;lia, DF, B
rasil</font>        ^cY#6541.htm##
00466000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704023900072002000900311#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#11#7#article#132#<P class="style4"> <A H
REF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Hel
vetica, sans-serif">Abstract</font></strong></A>    ^cY#6541.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021500072002000900287#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#12#8#article#132#<BR>   <A HREF="#Text">
<img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">
Text</font></strong></A>    ^cY#6541.htm##
00447000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704022000072002000900292#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#13#9#article#132#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, 
sans-serif">References</font>    ^cY#6541.htm##
00506000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027800073002000900351#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#14#10#article#132#<br>   </strong></A> <
A HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font f
ace="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></stron
g></a>      ^cY#6541.htm##
00292000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704006400073002000900137#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#15#11#article#132#<P class="style4">  <H
R ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6541.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040000073002000900473#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#16#12#article#132#<P class="style4"> <A 
NAME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helv
etica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT
></span><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <f
ont face="Arial, Helvetica, sans-serif"> </font>      ^cY#6541.htm##
01359000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704113100073002000901204#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#17#13#article#132#<P><font face="Arial, 
Helvetica, sans-serif">A successful gene therapy clinical trial that also encoun
tered serious adverse effects has sparked extensive study and debate about the f
uture directions for retrovirus-mediated interventions. Treatment of X-linked se
vere combined immunodeficiency with an oncoretrovirus harboring a normal copy of
 the <font face="Symbol">g</font><I>c </I>gene was applied in two clinical trial
s, essentially curing 13 of 16 infants, restoring a normal immune system without
 the need for additional immune-related therapies. Approximately 3 years after t
heir gene therapy, tragically, 3 of these children, all from the same trial, dev
eloped leukemia as a result of this experimental treatment. The current understa
nding of the mechanism behind this leukemogenesis involves three critical and co
operating factors, i.e., viral integration, oncogene activation, and the functio
n of the therapeutic gene. In this review, we will explore the causes of this un
wanted event and some of the possibilities for reducing the risk of its reoccurr
ence.  </font>   <font face="Arial, Helvetica, sans-serif">      ^cY#6541.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019400073002000900267#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#18#14#article#132#<P><B>Key words: </B> 
Retrovirus, Insertional mutagenesis, Severe combined immune deficiency, Gene the
rapy, Adverse event, Clinical trial    </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2
>       ^cY#6541.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033700073002000900410#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#19#15#article#132#<P class="style4"><A N
AME="Text"></A> <font size="4" face="Arial, Helvetica, sans-serif"><b><font colo
r="#00007F">Text</font></b></font><A HREF="#Home"><FONT SIZE=4><B><img src="/img
/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"
></B></FONT></A>  </P> <font face="Arial, Helvetica, sans-serif">      ^cY#6541.
htm##
00701000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047300073002000900546#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#20#16#article#132#<P>The clinical histor
y of gene therapy is quite short, dating back only to 1990. The first gene thera
py trial was the retrovirus-mediated gene transfer of a normal copy of the adeno
sine deaminase (ADA) gene for the treatment of immune deficiency caused by the l
oss of cellular ADA. This trial and others for ADA-X-linked severe combined immu
nodeficiency (ADA-X-SCID) have provided clinical benefit without side effects as
sociated with the retroviral vector (1).       ^cY#6541.htm##
01425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704119700073002000901270#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#21#17#article#132#<P>A critical point in
 developing any gene therapy strategy is matching the vector to its application.
 Viral vectors are widely used since they rely on naturally occurring mechanisms
 in order to deliver genetic material to a target cell (<a href="#Tab1">Table 1<
/a>). Adenovirus, for example, is well suited for applications that do not requi
re long-term expression. Adeno-associated virus may safely provide sustained exp
ression, but the applicability of this vector to the hematopoietic system is con
troversial (2). Currently, much study is focused on the safety of lentiviral vec
tors since their integration in the host genome seems to be less likely to cause
 an adverse effect, though clinical experience with these vectors is limited. In
 contrast, retroviral vectors have a long history in the laboratory and in the c
linic, their popularity being due to their ease of use and stability in the tran
sduced cell. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  bo
rder="0">    <tr align="left" valign="top">      <td width="15%"><a href="/img/r
evistas/bjmbr/v40n5/html/6541t01.htm"><img src="/img/revistas/bjmbr/v40n5/table.
jpg" border="2"></a></td>      <td width="85%">    ^cY#6541.htm##
00385000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015700073002000900230#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#22#18#article#132#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab1"></a>Table 1. Principal features of viral v
ectors. </font>      </td>    </tr>  </table>      ^cY#6541.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019200073002000900265#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#23#19#article#132#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (51 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <font face="Arial, Helvetica, sans-serif">
      ^cY#6541.htm##
01504000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704127600073002000901349#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#24#20#article#132#<P>Although much has b
een learned about the choices of gene transfer vectors, disease targets and ther
apeutic genes, the relatively limited success and highly publicized risks indica
te a clear need for further improvement before gene therapy will become widely a
ccepted. The risk and benefits of gene therapy are typified by the clinical tria
l for X-SCID conducted by Drs. Alain Fischer and Marina Cavazzana-Calvo and coll
eagues (H&ocirc;pital Necker Enfants Malade, Paris, France). In that trial, a no
rmal copy of a defective gene was introduced via retroviral transduction into he
matopoietic stem cells of 1- to 11-month-old infants. The trial was extremely su
ccessful, restoring normal immune function in 9 of the 10 children. However, 3 o
f the patients developed T-cell leukemia due, in part, to the cooperation betwee
n the viral insertion, activation of a cellular oncogene, and the growth-promoti
ng characteristics of the therapeutic gene. Interestingly, a similar trial condu
cted in England, led by Dr. Adrian Thrasher (3), was also successful in treating
 4 of 6 X-SCID patients with this strategy, and no adverse events have been obse
rved. This suggests that an unknown factor may have been present in the French t
rial that exacerbated the onset of leukemia.      ^cY#6541.htm##
01063000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704083500073002000900908#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#25#21#article#132#<P>In the present arti
cle, we will summarize the key components of the French trial, analyze the facto
rs that contributed to the unwanted leukemic transformation and explore some of 
the options for reducing this risk. As stated by the key administrators of these
 X-SCID clinical trials, "research must go on, particularly on vector design" (4
). Among the molecular tools currently available, we propose that specialized co
ntrol of viral expression could help reduce the risk of unwanted oncogene activi
ty. Our work has involved retrovirus-mediated gene transfer for more than 12 yea
rs and we are currently developing retroviral vectors with novel transcriptional
 regulation. We describe here how exploration of vector design as well as transd
uction and transplantation procedures may improve retrovirus-mediated gene thera
py.      ^cY#6541.htm##
00280000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704005200073002000900125#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#26#22#article#132#<P><B>Molecular basis 
of X-linked SCID</B>      ^cY#6541.htm##
01024000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704079600073002000900869#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#27#23#article#132#<P>X-SCID is caused by
 a mutation in the <font face="Symbol">g</font>  subunit of the common cytokine 
receptor (<font face="Symbol">g</font><I>c </I>or<I> IL2RG</I>), preventing T-ce
lls and natural killer cells from developing. Without functional T-cells, activa
tion of B-cells is also limited, leaving the patient with a severely impaired im
mune system. The role of the wild-type <font face="Symbol">g</font><I>c </I>chai
n (encoded on chromosome Xq13) is to participate in the cytokine receptor comple
x that mediates cellular activation by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 
(5,6). Since cytokine activation is often associated with proliferation, the cyt
okine receptor complex, including the <font face="Symbol">g</font><I>c </I>chain
, may represent a growth-promoting assembly.      ^cY#6541.htm##
00633000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040500073002000900478#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#28#24#article#132#<P>Without treatment, 
infants born with X-SCID would die within less than a year due to infection (7,8
). Treatment requires a bone marrow transplant from a suitable donor, yet not al
l patients are able to find a match. Perfect matches may be found from siblings,
 with a 90% successful transplant rate, or up to about 70% when the donor is a h
aploidentical parent or unrelated individual (9,10).       ^cY#6541.htm##
00840000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061200073002000900685#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#29#25#article#132#<P>Following transplan
t, these children are at risk for lymphoma if the donor had a history of infecti
ous mononucleosis. In addition, some transplant recipients do not recover comple
te T-cell function and most patients have deficient B-cell function, requiring l
ife-long immune-globulin-replacement therapy (9). Efforts to improve B-cell func
tion include chemoablation prior to transplant so that hematopoiesis is restored
 entirely from transplanted cells, although this approach involves higher mortal
ity (10). Clearly, X-SCID is a devastating disease and standard treatment modali
ties are inadequate.      ^cY#6541.htm##
00330000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010200073002000900175#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#30#26#article#132#<P><B>Successful gene 
therapy for X-SCID is associated with three serious adverse events</B>      ^cY#
6541.htm##
01791000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704156300073002000901636#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#31#27#article#132#<P>A group of French r
esearchers has conducted the most successful gene therapy trial to date, with co
nsiderable clinical benefit (though only time will tell if a true cure has been 
achieved) to 9 of 10 children with X-SCID (11-13). A second clinical trial for t
his gene therapy approach has been carried out in England and has also been succ
essful in the treatment of 4 of 6 X-SICD patients (3). Until recently, these tri
als have served as the prime example of how to use molecular tools to treat and 
essentially cure a disease by the simple insertion of a functional gene into cel
ls that, due to an inherited mutation, would otherwise be lacking that gene's fu
nction. The strategy used by Drs. Alain Fischer, Marina Cavazzana-Calvo, Adrian 
Thrasher, and colleagues was <I>ex vivo</I> transduction of CD34+ stem cells, de
rived from the patient's own bone marrow, with a replication-defective Moloney m
urine leukemia virus (MLV) vector encoding a normal copy of the <font face="Symb
ol">g</font><I>c </I>gene. The transduced cells were then infused into the patie
nts without preparative conditioning. Note that no perfectly matching donor was 
available for any of the patients in this trial. The age at treatment ranged fro
m 1-11 months (11,14). Of the 16 children treated in these two trials, 15 are st
ill alive and 13 recovered normal T- and B-cell function, requiring no further t
reatment, such as immunoglobulin replacement. One infant from the French trial w
ho did not recover immune cell function underwent allogeneic bone marrow transpl
ant (14).        ^cY#6541.htm##
00712000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704048400073002000900557#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#32#28#article#132#<P>The successfully tr
eated children are able to live in a normal environment and to receive vaccines 
for common childhood diseases resulting in reactive T- and B-cells. Some of the 
patients were treated more than 6 years ago and are considered to be essentially
 cured, though long-term follow-up will be necessary to firmly establish this co
nclusion (11-13). In any case, these positive results are the most striking amon
g those obtained in all gene therapy trials. </font>      ^cY#6541.htm##
01554000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704132600073002000901399#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#33#29#article#132#<P><font face="Arial, 
Helvetica, sans-serif">Tragically, 3 of the children that benefited from the Fre
nch gene therapy trial have developed a lymphoproliferative disease resembling l
eukemia due, in part, to the integration of the retroviral gene transfer vehicle
 near an oncogene (13,15-17). Their white cells were shown to contain a clonal p
opulation of <font face="Symbol">g</font><font face="Symbol">d</font>T-cells and
 this leukemia-like condition was treated with chemotherapy and 1 of these patie
nts later died. For 2 of the patients, molecular analyses of these cells showed 
that the gene transfer vector was present as a single copy, properly expressing 
the therapeutic gene and that the virally encoded cDNA had not suffered any muta
tion (13,15). However, the site of viral integration was shown to be near a know
n oncogene, <I>LMO2</I> (15), as will be addressed in more detail below. The thi
rd child was shown to carry 4 viral insertions in the leukemic cells, including 
at the <I>LMO2</I> locus (16,17). Much study and debate followed the announcemen
t of these adverse events and a clearer picture is beginning to emerge that depi
cts their cause, including retroviral integration, oncogene activation and growt
h-promoting properties of the transgene.  </font>   <font face="Arial, Helvetica
, sans-serif">      ^cY#6541.htm##
00295000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704006700073002000900140#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#34#30#article#132#<P><B>The vector and r
isk of insertional mutagenesis</B>       ^cY#6541.htm##
01015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078700073002000900860#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#35#31#article#132#<P>Retroviral vectors 
based on the Moloney MLV have long been used as the workhorse    of gene transfe
r studies. These vectors are easily manipulated in the laboratory    and have se
veral inherent safety features. To date, retroviral vectors have    been applied
 in 293 (representing 23% of all) clinical trials, making this one    of the mos
t popular gene transfer vehicles historically used in the clinical    setting wh
ich has been applied for the treatment of a variety of diseases, including    ca
ncer and hematopoietic deficiencies (<a href="http://www.wiley.co.uk/genmed/clin
ical/" target="_blank">http://www.wiley.co.uk/genmed/clinical/</a>).    Except f
or the French X-SCID trial, no serious adverse events were reported    to be ass
ociated with the retroviral vector.      ^cY#6541.htm##
01082000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085400073002000900927#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#36#32#article#132#<P>Since the virus int
egrates in the host genome, daughter cells will inherit    a copy of the virus. 
This strategy is beneficial when long-term expression is    desired, as in the c
ase of X-SCID (18). Without integration, the viral sequence    would eventually 
be lost after cell division since the virus cannot replicate    as an episome. U
ntil recently, the only integrating virus approved for clinical    trials was th
e retrovirus, though eight clinical trials utilizing lentivirus    have now been
 listed for the treatment of HIV (<a href="http://www.wiley.co.uk/genmed/clinica
l/" target="_blank">http://www.wiley.co.uk/genmed/clinical/</a>    and Ref. 19).
 Therefore, the retrovirus is the most popular vector currently    available for
 treatments that require prolonged virus expression, such as the    correction o
f immune deficiencies.      ^cY#6541.htm##
01271000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104300073002000901116#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#37#33#article#132#<P>The insertion of a 
recombinant retroviral vector has long been theorized to cause alteration in hos
t-gene expression that could lead to cellular changes, a process known as insert
ional mutagenesis, but was thought to be too rare an event to be of clinical sig
nificance. Mutagenesis, for example, may occur if the virus disrupts an essentia
l gene, thus killing the cell. This is not a threat to the organism or to the ge
ne therapy strategy since this would be a very rare event in a large population 
of independently transduced cells. Thus, the vast majority of cells would surviv
e the insertion of the viral genome. Moreover, insertion occurs in only one chro
mosome, leaving the second allele intact, rendering the problem of disabling an 
essential gene or tumor suppressor less critical (20). In another example, the v
irus may insert itself near a proto-oncogene and activate its expression. In thi
s case, the presence of the virus would give a proliferative advantage to the ce
ll, a critical first step towards transformation.        ^cY#6541.htm##
01005000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704077700073002000900850#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#38#34#article#132#<P>In fact, retroviral
 insertion has been used in order to induce experimental    tumors and identify 
oncogenes involved in the process of transformation, leading    to the creation 
of the Retroviral Tagged Cancer Gene Database (<a href="http://RTCGD.ncifcrf.gov
" target="_blank">http://RTCGD.ncifcrf.gov</a>).    The fact that retroviruses c
an and do promote tumorigenesis is not new, but    was thought to be unrelated t
o the clinical situation. Experimentally induced    tumors are generally created
 using replication-competent viruses (21,22), whereas    the clinical applicatio
n utilizes viruses that are not able to replicate. Until    recently, tumors ind
uced by non-replicating retroviruses had not been observed    in pre-clinical ge
ne therapy animal models.      ^cY#6541.htm##
01178000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704095000073002000901023#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#39#35#article#132#<P>Regulatory elements
 encoded by the virus may influence local gene expression (<a href="#Fig1">Figur
e 1</a>). In the transduced cell, retroviral expression is driven by either the 
viral promoter, called the long-terminal repeat (LTR) or an internal promoter (s
uch as CMV, SV40, ubiquitin, etc.) or by both, permitting a single virus to carr
y two independent expression cassettes. These promoters encode binding sites for
 the transcriptional machinery and may act as enhancers which, by definition, ma
y exert an influence over a large distance. In addition, the 3' LTR is a functio
nal promoter that could drive expression of downstream coding regions (20).     
 </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">   
 <tr align="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmb
r/v40n5/html/6541i01.htm"><img src="/img/revistas/bjmbr/v40n5/6541i01peq.jpg" bo
rder="2"></a></td>      <td width="85%">    ^cY#6541.htm##
01458000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704123000073002000901303#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#40#36#article#132#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Overview of the influence of
 the virus on cellular and therapeutic gene expression. Integration of retroviru
s in the host genome has been shown to favor regions proximal to the promoter of
 cellular genes. Viral expression is controlled by the long-terminal repeat (LTR
) (viral promoter) which may also influence expression of neighboring cellular g
enes. <I>A</I>, In the cases of leukemia noted in the French X-SCID gene therapy
 trial, viral integration occurred near the <I>LMO2 </I>oncogene. In addition, <
font face="Symbol">g</font><I>c</I> gene activity may have cooperated with <I>LM
O2</I>, contributing to proliferation and transformation. <I>B</I>, pCLPG retrov
irus expression of the therapeutic gene is controlled by p53 (as shown in <a hre
f="#Fig2">Figure 2</a>). We propose that interactions of the transgene, cellular
 oncogene and p53 may result in p53-mediated cell death, eliminating cells with 
transformation potential. In addition, replacement of the murine leukemia virus 
enhancer/promoter with the p53-responsive PG element may reduce spurious transge
ne expression during T-cell development. </font>      </td>    </tr>  </table>  
    ^cY#6541.htm##
00418000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019000073002000900263#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#41#37#article#132#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (51 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <font face="Arial, Helvetica, sans-serif">
    ^cY#6541.htm##
01044000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704081600073002000900889#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#42#38#article#132#<P>When driven by the 
LTR, retroviral expression is quite strong and promiscuous, especially in cultur
ed cells. However, retroviral expression is often lost in transduced hematopoiet
ic stem cells upon transplantation since differentiation of these cells may lead
 to chromatin remodeling and methylation of the viral promoter, mechanisms that 
silence the LTR (23). Expression may be sustained under two conditions: 1) modif
ications are made in the LTR in order to protect it from methylation (24), and 2
) positive selection of transduced cells occurs. In the latter case, the presenc
e of the virus and transgene is beneficial to cell survival, selecting cells tha
t harbor an expressed provirus. The Moloney MLV LTR can drive transgene expressi
on to achieve clinical benefit, though not in all circumstances.      ^cY#6541.h
tm##
01811000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704158300073002000901656#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#43#39#article#132#<P>The theoretical ris
k of activating an oncogene upon recombinant virus insertion <I>in vivo</I> was 
experimentally proven only recently. Li et al. (25) transduced mouse bone marrow
 cells with a retroviral vector expressing the <I>dLNGFR</I> marker gene (26) an
d then transplanted these cells in isogenic recipients. These animals showed no 
sign of hematologic disturbances when the bone marrow of these primary recipient
s was pooled and used to transplant secondary recipients. All 10 of the secondar
y recipients, but only the secondary recipients, developed hematologic disorders
, including acute myeloid leukemia in 6 mice (probably due to a clonal populatio
n in the pooled cells used for the second transplantation). The virus was shown 
to insert near the <I>Evi1</I> oncogene, activating its expression, and presumab
ly contributing to proliferation. Interestingly, other marker genes did not lead
 to leukemic transformation in control animals and the authors commented that th
e transgene, meant to serve as a marker, may have protected the cells against ap
optosis, suggesting that the over-abundance of the oncogene combined with the re
sistance to programmed cell death brought these cells two steps closer to transf
ormation. This study was the first to conclusively prove that insertional mutage
nesis by a non-replicating, recombinant retroviral vector could contribute to ne
oplastic transformation in an animal model (25). Moreover, this study followed t
he model that viral insertion, oncogene action and transgene function may cooper
ate and lead to transformation.      ^cY#6541.htm##
01270000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104200073002000901115#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#44#40#article#132#<P>Retroviruses were t
hought to integrate randomly within the host genome. However, this has been prov
en to be an overly simplistic view. Genomic-style strategies to identify inserti
on sites and their proximity to candidate genes and regulatory elements (27,28) 
have shown that MLV retroviruses, such as that used in the X-SCID trial, tend to
 insert near the promoter region of genes (28). Wu et al. (28) have shown that i
ntegration occurs at the locus of a confirmed gene (listed in the RefSeq databas
e) in 34% of MLV insertion events, whereas HIV or recombinant lentivirus inserti
ons land in RefSeq genes at a frequency of 62 or 50%, respectively. Even more st
riking was the observation that MLV vectors show a preference for insertion near
 (&#177; 1 kb) CpG islands associated with transcriptional start sites, yet HIV 
integrates along the length of the gene locus downstream of the promoter. This m
ay imply that the influence of viral elements on host-gene expression may be str
onger for MLV than HIV or lentiviral vectors (28).      ^cY#6541.htm##
00460000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023200073002000900305#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#45#41#article#132#<P>These recent observ
ations have helped define the risk associated with retroviral insertion. Especia
lly for MLV, the integration of the virus near gene promoters may represent an i
ncreased risk of subsequent mutagenesis.      ^cY#6541.htm##
00337000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010900073002000900182#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#46#42#article#132#<P><B>Cooperation betw
een retroviral insertion, oncogene activity and therapeutic gene function</B>   
   ^cY#6541.htm##
01405000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704117700073002000901250#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#47#43#article#132#<P>A recent study sugg
ests that at least three distinct paths merged and directed the leukemogenic tra
nsformation observed in these patients of the French X-SCID gene therapy trial. 
As described above, insertion near the promoter of a cellular oncogene may bring
 about activation of its expression. By analyzing a database of insertion sites 
from cases of mouse hematopoietic tumors caused by wild-type leukemia viruses, D
av&eacute; et al. (29) have found examples of viral insertion at either the <I>L
MO2</I> gene or the <font face="Symbol">g</font><I>c </I>chain gene, or both. Fi
rst, this suggests, as expected, that oncogene activation will contribute to tra
nsformation. Second, and unexpectedly, activation of <font face="Symbol">g</font
><I>c </I>could also promote leukemogenesis. Finally, a specific cooperation may
 exist between <I>LMO2</I> and <font face="Symbol">g</font><I>c </I>chain functi
ons, in this instance upon increased expression after viral insertion, that cont
ributes to proliferation and transformation. This study points out that viral in
tegration alone was not responsible for leukemic events, but required other coop
erating factors.  </font>      ^cY#6541.htm##
01380000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704115200073002000901225#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#48#44#article#132#<P><font face="Arial, 
Helvetica, sans-serif">Understanding <I>LMO2</I> may shed some light on its role
 in the adverse events associated with gene therapy of X-SCID. The <I>LMO2</I> o
ncogene encodes a nuclear LIM-only protein that acts as a transcription factor n
ecessary for erythroid development (16,30). <I>LMO2</I><SUP>-/-</SUP> mice die a
t embryonic day 10.5 due, in part, to a lack of hematopoiesis (31); yet transgen
ic mice overexpressing <I>LMO2</I> in the thymus developed T-cell leukemia (32,3
3). Normal <I>LMO2</I> expression occurs in a variety of tissue types, such as k
idney, liver, lung, spleen, and the central nervous system (34), in addition to 
myeloid and erythroid cells (31). <I>LMO2</I> has also been implicated in promot
ing angiogenesis and capillary remodeling, processes clearly impeded in <I>LMO2<
/I><SUP>-/-</SUP> mice (35). Therefore, <I>LMO2</I> is necessary, but uncontroll
ed expression can contribute to leukemia. In the X-SCID patients who developed l
eukemia, <I>LMO2</I> activity is thought to have played a major part in promotin
g cellular transformation.  </font>   <font face="Arial, Helvetica, sans-serif">
      ^cY#6541.htm##
01566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704133800073002000901411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#49#45#article#132#<P>Was the <I>LMO2</I>
 site targeted by the virus? Based on the current understanding of retrovirus in
tegration, the number of human genes and the number of transduced cells that eac
h patient received, it has been estimated that each patient would have been inje
cted with 10-100 cells harboring insertion at a given expressed gene locus, incl
uding the <I>LMO2</I> site (30). Since this integration site was identified in r
elatively few patients, it may not represent a favored site, but rather an avail
able one. Subsequently, cooperation between <I>LMO2</I> and <font face="Symbol">
g</font><I>c </I>may have provided an advantage for proliferation, selectively e
xpanding this population of cells (<a href="#Fig1">Figures 1</a> and <a href="#F
ig2">2</a>). Therefore, the insertion event, activation of <I>LMO2</I> and its p
otential cooperation with <font face="Symbol">g</font><I>c </I>chain functions a
ll contributed to the leukemogenesis. This understanding may then serve as a sta
rting point for improving future gene therapy applications (36).     </font>  <H
R ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="
left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n5/html
/6541i02.htm"><img src="/img/revistas/bjmbr/v40n5/6541i02peq.jpg" border="2"></a
></td>      <td width="85%">    ^cY#6541.htm##
01705000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704147700073002000901550#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#50#46#article#132#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. Representation of the events
 related to oncogene activation during retrovirus-mediated gene therapy. <I>A</I
>, We propose that the use of p53 as a transcription factor for our modified ret
roviral vector, pCLPG, may also serve as an oncogenic sensor since feedback betw
een oncogene, transgene and p53 activities may result in cell death coordinated 
by p53. Standard murine leukemia virus (MLV) retroviral vectors have been shown 
to cause uncontrolled proliferation in gene therapy applications. <I>B</I>, The 
retroviral long-terminal repeat was modified by the removal of the promoter/enha
ncer region and insertion of the p53-responsive PG element, as described previou
sly (56,57). Endogenous p53 can drive expression of the therapeutic transgene wh
en encoded by the pCLPG retrovirus. We propose that this arrangement may be bene
ficial for gene therapy of hematopoietic diseases. <I>C</I>, Another use for the
 pCLPG strategy is the creation of an auto-regulatory cycle, where p53 is encode
d by the virus and acts as the activator of viral expression. When p53 transcrip
tion is driven by the p53-responsive promoter, a positive feedback loop is estab
lished, resulting in high-level expression and superior anti-tumor activity (57)
. A transgene combination of <font face="Symbol">g</font><I>c </I>plus p53 may p
rove beneficial. HSC = hematopoietic stem cell. </font>      </td>    </tr>  </t
able>      ^cY#6541.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019200073002000900265#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#51#47#article#132#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (83 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <font face="Arial, Helvetica, sans-serif">
      ^cY#6541.htm##
01132000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704090400073002000900977#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#52#48#article#132#<P>A clear and proport
ional relationship between the transduction efficiency, number of proviral integ
ration sites, and tendency to clonal expansion (including leukemogenesis) has be
en observed when oncoretroviral particles are introduced into hematopoietic prog
enitor cells. Transduction, the process of introducing a recombinant virus into 
a target cell, can be characterized by the number of virus particles applied to 
the cells. This relationship, called multiplicity of infection (MOI), reveals th
e number of virus particles/target cell present during transduction. For example
, 4000 virus particles applied to 2000 cells would have an MOI of 2. In this exa
mple we may be tempted to expect that all of the cells would be transduced, but 
the actual transduction efficiency is much lower, since some particles may never
 enter a cell and some cells may receive more than one particle. </font>      ^c
Y#6541.htm##
00901000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067300073002000900746#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#53#49#article#132#<P><font face="Arial, 
Helvetica, sans-serif">At low virus concentrations (MOI <font face="Symbol">&#16
3;</font>1), transduction of a target cell with a retroviral vector typically re
sults in a single particle entering the cell. However, at higher MOI several vir
us particles may enter a single target cell, as was recently shown by quantitati
ve methods (37). Therefore, seeking higher transduction efficiencies by increasi
ng the MOI may lead to increased risk of insertional mutagenesis, though single 
insertion sites were observed in two of the three leukemias that resulted from t
he French X-SCID trial (13). </font>   <font face="Arial, Helvetica, sans-serif"
>      ^cY#6541.htm##
01322000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704109400073002000901167#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#54#50#article#132#<P>A recent paper has 
shown that at low virus concentration, transduction of hematopoietic stem cells 
(HSC) can avoid the leukemogenesis that was observed at higher virus concentrati
ons (38). An oncoretroviral vector encoding the human multidrug resistance gene-
1 <I>(MDR1</I>), a membrane-bound drug efflux pump, was used to transduce HSC at
 low or high doses and these cells were then transplanted in myeloablated, isoge
nic recipient mice. These investigators found that at the low dose no leukemias 
developed even though virus insertion did occur at or near oncogene loci. In con
trast, 50% of the animals transplanted with HSC transduced with high doses of th
e virus developed leukemia. The activity of the <I>MDR1</I> gene, which may prot
ect against apoptosis, may also have been a contributing factor since animals re
ceiving HSC transduced with a virus encoding a fluorescent protein did not devel
op leukemia due to viral insertion. This recent work shows, for the first time, 
the relationship between oncoretroviral transduction efficiency and malignant ri
sk in an animal model.      ^cY#6541.htm##
01379000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704115100073002000901224#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#55#51#article#132#<P>Clonal expansion, t
he accelerated proliferation of a small number of progenitor cells, yields reduc
ed variation in the resulting hematopoietic populations and is a hallmark of non
malignant and malignant hematopoiesis. Retroviruses have long been used as marke
rs of clonal expansion since their insertion sites can be used to identify cell 
populations. However, it has been shown that the viral insertion itself may cont
ribute to nonmalignant clonal expansion. Kustikova et al. (39) have shown that, 
upon transduction of HSC followed by serial transplantation in irradiated recipi
ent mice, clonal expansion was associated with viral insertion at oncogene loci.
 They postulated that these cells had enhanced "fitness" due to unregulated onco
gene expression, though they did not turn malignant. Interestingly, this situati
on has been mirrored in the clinical setting. A recent gene therapy trial for X-
linked chronic granulomatous disease showed that retroviral delivery of the <I>g
p91<SUP>phox</SUP></I> gene yielded an improvement in immune function, though vi
ral activation of cellular oncogenes may have contributed to this success (40). 
     ^cY#6541.htm##
01703000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704147500073002000901548#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#56#52#article#132#<P>New developments su
ggest that the growth-promoting action of <font face="Symbol">g</font><I>c </I>m
ay be as important as viral insertion, or even more, in promoting oncogenesis. W
oods et al. (41) showed that a lentiviral vector with inactivated LTRs and conta
ining the CAG promoter to drive <font face="Symbol">g</font><I>c </I>induced lym
phoma in a mouse model of X-SCID gene therapy, but did not when green fluorescen
t protein was expressed. This suggests that the viral insertion itself was not r
esponsible for the transformation, but <font face="Symbol">g</font><I>c </I>acti
vity was. Similarly, these investigators showed that viral expression of <I>LMO2
</I> could also induce transformation in this model of X-SCID treatment. They ob
served the animals over an extended period of time and noted the onset of lympho
mas at 6 months post-transplantation, a key difference compared to other preclin
ical studies of X-SCID gene therapy which did not provide follow-up beyond 6 mon
ths. Details of the lentiviral insertion sites have not been revealed, but these
 investigators note that several insertion sites were present in transduced cell
s and that this profile was different for each animal. This study did not direct
ly address vector design, therefore it is difficult to infer if lentiviral vecto
rs may provide an advantage over the use of MLV. This study suggests that <font 
face="Symbol">g</font><I>c </I>function can contribute to transformation.   </fo
nt>      ^cY#6541.htm##
00963000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704073500073002000900808#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#57#53#article#132#<P><font face="Arial, 
Helvetica, sans-serif">The target cell phenotype may also have been a contributi
ng factor in the development of leukemia. In a new study, an increased tendency 
towards transformation was observed in a mouse model of X-SCID gene therapy wher
e the <font face="Symbol">g</font><I>c </I>gene was introduced in bone marrow ce
lls with a retroviral vector, but transformation was less likely when the treatm
ent was performed with cells derived from a non-X-SCID animal. This suggests tha
t the X-SCID phenotype may have played a role in permitting transformation to oc
cur in the presence of the retrovirus and <font face="Symbol">g</font><I>c </I>g
ene (42).  </font>   <font face="Arial, Helvetica, sans-serif">      ^cY#6541.ht
m##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#58#54#article#132#<P>Viral integration a
lone was not sufficient to promote transformation in the patients of the French 
X-SCID trial, but insertion into the <I>LMO2</I> locus was likely to be a factor
 contributing to the inappropriate expression of this oncogene. The activities o
f both <I>LMO2</I> and the therapeutic gene, <font face="Symbol">    ^cY#6541.ht
m##
00556000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032800073002000900401#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#59#55#article#132#<br>   g</font><I>c</I
>, influenced the formation of leukemia. The specific role of viral insertion, o
ncogene activation and transgene activity continues to be studied, as described 
below, with the hope of developing strategies that preserve therapeutic benefit 
without elevating the risk of adverse events.    </font>      ^cY#6541.htm##
00367000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013900073002000900212#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#60#56#article#132#<P> <font face="Arial,
 Helvetica, sans-serif"><B>The response from regulatory agencies and the gene th
erapy community</B> </font>      ^cY#6541.htm##
01270000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104200073002000901115#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#61#57#article#132#<P><font face="Arial, 
Helvetica, sans-serif">When the first case of leukemia resulting from the French
 gene therapy trial was announced, US, French and British agencies halted trials
 temporarily, but then allowed them to continue, believing that the case was iso
lated (43). However, the announcement of the second case and the identification 
of the frequency of viral insertion at the <I>LMO2</I> locus in these children p
rompted US agencies to stop 27 trials using retroviral gene transfer to hematopo
ietic stem cells (44). Continuation of these trials has been permitted on a case
-by-case basis. The French trial was reinitiated (45), but was again put on hold
 when the third case of leukemia was discovered. Analysis of the risk <I>vs</I> 
benefit for the treatment of X-SCID by gene therapy has led many to believe that
 the cure of the underlying disease by far outweighs the risk of a serious side 
effect. Trials using a retrovirus for the treatment of SCID due to ADA-deficienc
y have been allowed to continue in the US. </font>      ^cY#6541.htm##
01238000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704101000073002000901083#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#62#58#article#132#<P><font face="Arial, 
Helvetica, sans-serif">The gene therapy community has responded to the unfortuna
te developments in the French trial by carefully analyzing experimental data tha
t were available both before and after these occurrences (4,18,46-48). As shown 
in <a href="#Tab2">Table 2</a>, the French and British X-SCID gene therapy trial
s were quite similar in their design and execution, yet the adverse events have 
been seen only in the French trial. In order to foresee such events, more extens
ive pre-clinical animal studies have been recommended, as described in <a href="
#Tab3">Table 3</a>. One point that is repeatedly raised is the need for improved
 vector design, including improved transcriptional control (49). </font>   <HR A
LIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="lef
t" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n5/html/65
41t02.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"></a></td>  
    <td width="85%">    ^cY#6541.htm##
00543000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031500073002000900388#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#63#59#article#132#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab2"></a>Table 2. Potential factors contributin
g to the development of leukemia in the French X-linked severe combined immunode
ficiency (X-SCID) trial and differences, when present, compared to the British t
rial. </font>      </td>    </tr>  </table>      ^cY#6541.htm##
00834000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704060600073002000900679#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#64#60#article#132#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (113 K JPG file)]</fon
t>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr a
lign="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n
5/html/6541t03.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"></
a></td>      <td width="85%"><font face="Arial, Helvetica, sans-serif"><a name="
Tab3"></a>Table 3. Recommendations by the American Society of Gene Therapy for h
ematopoietic stem cell gene transfer studies in animal models.</font> </td>    <
/tr>  </table>      ^cY#6541.htm##
00376000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014800073002000900221#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#65#61#article#132#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (49 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6541.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002300073002000900096#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#66#62#article#132#<p>&nbsp;</p>      ^cY
#6541.htm##
00362000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013400073002000900207#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#67#63#article#132#<P><font face="Arial, 
Helvetica, sans-serif"><B>Strategies for combating oncogene activation in transd
uced cells</B> </font>      ^cY#6541.htm##
00936000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070800073002000900781#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#68#64#article#132#<P><font face="Arial, 
Helvetica, sans-serif">New technologies that do not rely on random viral integra
tion may one day be developed for the treatment of X-SCID. For example, site-spe
cific integration may permit introduction of the wild-type <font face="Symbol">g
</font><I>c </I>gene at genomic locations known to be void of genes or regulator
y elements (50,51). Alternatively, the endogenous <font face="Symbol">g</font><I
>c </I>gene may be corrected <I>ex vivo</I> by means of homologous recombination
 promoted by engineered zinc-finger proteins, avoiding the need for viral integr
ation (52). Both of these technologies, though promising, are far from being rea
dy for clinical application. </font>      ^cY#6541.htm##
01229000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704100100073002000901074#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#69#65#article#132#<P><font face="Arial, 
Helvetica, sans-serif">Other viral vectors may also be explored to deliver the <
font face="Symbol">g</font><I>c </I>gene. Adenovirus would not be an appropriate
 choice since this vector does not provide long-term stability or sustained tran
sgene expression. Adeno-associated virus is being considered for hematopoietic t
argets, though viral insertion events have been noted in hemophilia patients in 
a gene therapy trial (53). Lentiviruses, the family to which HIV belongs, have b
een developed as recombinant gene transfer vectors and have also been shown, und
er certain conditions, to initiate oncogenesis due to insertional mutagenesis (5
4) or transgene activity (41). However, a recent study has suggested that lentiv
iral vectors may be safer than MLV when applied to hematopoietic stem cells (55)
. Retroviral vectors developed from non-MLV sources are also being evaluated wit
h respect to their reduced propensity to integrate near promoter regions (48,56)
. </font>      ^cY#6541.htm##
01075000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704084700073002000900920#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#70#66#article#132#<P><font face="Arial, 
Helvetica, sans-serif">Assuming that no alternative to the use of the <font face
="Symbol">g</font><I>c </I>gene or integrating vectors is available for X-SCID g
ene therapy, we are left with few options other than to find a balance between t
he efficiency that viral vectors provide and the growth-promoting properties of 
<font face="Symbol">g</font><I>c</I>. Improved safety for retroviral vector desi
gn has been proposed and is within the reach of current technology (18,48). Thes
e strategies include inactivation of the LTR, use of an internal promoter to dri
ve transgene expression, and the inclusion of a suicide gene to permit the selec
tive elimination of transduced cells. However, the work of Woods et al. (41) sug
gests that LTR inactivation and the use of an internal promoter were not satisfa
ctory. </font>       ^cY#6541.htm##
01583000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704135500073002000901428#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#71#67#article#132#<P><font face="Arial, 
Helvetica, sans-serif">Another strategy in development includes    an anti-oncog
enic sensor that would eliminate cells destined for transformation.    Our curre
nt research is related to the development of retroviral vectors with    modified
 transcriptional control. Expression from one of these vectors, called    pCLPG 
(<a href="#Fig2">Figure 2</a>), is controlled by the tumor suppressor    and tra
nscription factor, p53 (57,58). We have initiated experimental work,    which wi
ll take several years to complete, to determine if the employment of    cellular
 p53 to drive viral expression might also be useful for combating oncogene    ac
tivation. Our expectation is that a feedback mechanism would be established    b
etween the oncogene and p53, resulting in the elimination of that cell by apopto
sis    coordinated by p53 (<a href="#Fig1">Figures 1</a> and <a href="#Fig2">2</
a>).    This feedback mechanism may include the activity of the transgene, such 
as <font face="Symbol">g</font><I>c    </I>or <I>dLNGFR</I>, whose growth-promot
ing or anti-apoptotic activity may    induce the protective functions of p53. Th
e novel transcriptional control strategy    present in the pCLPG system may prov
e to be interesting in other gene therapy    models where proliferation stimulat
ed by the transgene is problematic. </font>      ^cY#6541.htm##
00906000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067800073002000900751#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#72#68#article#132#<P><font face="Arial, 
Helvetica, sans-serif">We suspect that modifications of the LTR will have an add
ed benefit beyond the use of the p53 tumor suppressor to drive expression and se
nse oncogene activity. The native Moloney MLV LTR is especially active in develo
ping thymocytes which may promote transgene and oncogene expression at a particu
larly sensitive moment in T-cell maturation. In the pCLPG system, the Moloney ML
V enhancer/promoter elements have been eliminated and thus unwanted LTR activity
 may be avoided during T-cell lymphopoiesis. These ideas remain to be tested exp
erimentally, a process that depends on extensive animal and molecular studies. <
/font>      ^cY#6541.htm##
00322000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009400073002000900167#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#73#69#article#132#<P><font face="Arial, 
Helvetica, sans-serif"><B>Impact on future studies</B> </font>      ^cY#6541.htm
##
01225000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704099700073002000901070#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#74#70#article#132#<P><font face="Arial, 
Helvetica, sans-serif">The next generation of vectors and gene therapy trials wi
ll involve higher standards. Gene therapy has been proven effective by the X-SCI
D trials, yet a potential risk has also been demonstrated. Unquestionably, 10 ch
ildren were successfully treated by the French and British gene therapy trials a
nd did not show any adverse effects, a point that must be underscored when consi
dering the risk of retrovirus-mediated treatment. Clearly, the combination of vi
ral integration, oncogene activation and transgene activity were contributing fa
ctors to the leukemic events. However, a critical difference has not yet come to
 light between the French and British trials that could indicate how to avoid le
ukemogenesis and yet maintain the clinical benefit seen in both protocols. Futur
e trials will benefit from continued study of vectors, target cells, transductio
n strategies, and relevant animal models.</font>   <HR ALIGN=LEFT WIDTH=100% SIZ
E=2>       ^cY#6541.htm##
00545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031700073002000900390#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#75#71#article#132#<P class="style4"> <A 
NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Hel
vetica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT
 SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>      ^cY#6541.htm##
00433000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019100075002000900266#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#76#72#article#132#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Gaspar HB, Thrasher AJ. Gene therapy for
 severe combined immunodeficiencies. <I>Expert Opin Biol Ther</I> 2005; 5: 1175-
1182. </font>      ^cY#6541.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022700075002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#77#73#article#132#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Srivastava A. Hematopoietic stem cell tr
ansduction by recombinant adeno-associated virus vectors: problems and solutions
. <I>Hum Gene Ther</I> 2005; 16: 792-798. </font>      ^cY#6541.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027700075002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#78#74#article#132#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Gaspar HB, Parsley KL, Howe S, King D, G
ilmour KC, Sinclair J, et al. Gene therapy of X-linked severe combined immunodef
iciency by use of a pseudotyped gammaretroviral vector. <I>Lancet</I> 2004; 364:
 2181-2187. </font>      ^cY#6541.htm##
00411000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704016900075002000900244#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#79#75#article#132#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Cavazzana-Calvo M, Thrasher A, Mavilio F
. The future of gene therapy. <I>Nature</I> 2004; 427: 779-781. </font>      ^cY
#6541.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020600075002000900281#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#80#76#article#132#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Schmalstieg FC, Goldman AS. Immune conse
quences of mutations in the human common gamma-chain gene. <I>Mol Genet Metab</I
> 2002; 76: 163-171. </font>      ^cY#6541.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019700075002000900272#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#81#77#article#132#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Malek TR, Porter BO, He YW. Multiple gam
ma c-dependent cytokines regulate T-cell development. <I>Immunol Today</I> 1999;
 20: 71-76. </font>      ^cY#6541.htm##
00413000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704017100075002000900246#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#82#78#article#132#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Rosen FS, Cooper MD, Wedgwood RJ. The pr
imary immunodeficiencies. <I>N Engl J Med</I> 1995; 333: 431-440. </font>      ^
cY#6541.htm##
00426000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018400075002000900259#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#83#79#article#132#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Buckley RH. Primary immunodeficiency dis
eases due to defects in lymphocytes. <I>N Engl J Med</I> 2000; 343: 1313-1324. <
/font>      ^cY#6541.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027700075002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#84#80#article#132#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Buckley RH, Schiff SE, Schiff RI, Marker
t L, Williams LW, Roberts JL, et al. Hematopoietic stem-cell transplantation for
 the treatment of severe combined immunodeficiency. <I>N Engl J Med</I> 1999; 34
0: 508-516. </font>      ^cY#6541.htm##
00623000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704038000076002000900456#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#85#81#article#132#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Haddad E, Landais P, Friedrich W, Gerr
itsen B, Cavazzana-Calvo M, Morgan G, et al. Long-term immune reconstitution and
 outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for 
severe combined immunodeficiency: a European retrospective study of 116 patients
. <I>Blood</I> 1998; 91: 3646-3653. </font>      ^cY#6541.htm##
00535000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029200076002000900368#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#86#82#article#132#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Hacein-Bey-Abina S, le Deist F, Carlie
r F, Bouneaud C, Hue C, de Villartay JP, et al. Sustained correction of X-linked
 severe combined immunodeficiency by <I>ex vivo</I> gene therapy. <I>N Engl J Me
d</I> 2002; 346: 1185-1193. </font>      ^cY#6541.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026200076002000900338#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#87#83#article#132#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Cavazzana-Calvo M, Hacein-Bey S, de Sa
int Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe co
mbined immunodeficiency (SCID)-X1 disease. <I>Science</I> 2000; 288: 669-672. </
font>      ^cY#6541.htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028300076002000900359#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#88#84#article#132#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Hacein-Bey-Abina S, Von Kalle C, Schmi
dt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cel
l proliferation in two patients after gene therapy for SCID-X1. <I>Science</I> 2
003; 302: 415-419. </font>      ^cY#6541.htm##
00423000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018000076002000900256#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#89#85#article#132#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Buckley RH. Gene therapy for SCID - a 
complication after remarkable progress. <I>Lancet</I> 2002; 360: 1185-1186. </fo
nt>      ^cY#6541.htm##
00538000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029500076002000900371#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#90#86#article#132#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Hacein-Bey-Abina S, Von Kalle C, Schmi
dt M, le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after 
successful gene therapy for X-linked severe combined immunodeficiency. <I>N Engl
 J Med</I> 2003; 348: 255-256. </font>      ^cY#6541.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023200076002000900308#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#91#87#article#132#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Nam CH, Rabbitts TH. The role of LMO2 
in development and in T cell leukemia after chromosomal translocation or retrovi
ral insertion. <I>Mol Ther</I> 2006; 13: 15-25. </font>      ^cY#6541.htm##
00427000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018400076002000900260#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#92#88#article#132#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Frederickson RM. Report from the 2nd s
tem cell clonality and genotoxicity retreat. <I>Mol Ther</I> 2005; 12: 379-383. 
</font>      ^cY#6541.htm##
00480000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023700076002000900313#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#93#89#article#132#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Baum C, Dullmann J, Li Z, Fehse B, Mey
er J, Williams DA, et al. Side effects of retroviral gene transfer into hematopo
ietic stem cells. <I>Blood</I> 2003; 101: 2099-2114. </font>      ^cY#6541.htm##
00615000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704037200076002000900448#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#94#90#article#132#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. Aberg JA, Williams PL, Liu T, Lederman
 HM, Hafner R, Torriani FJ, et al. A study of discontinuing maintenance therapy 
in human immunodeficiency virus-infected subjects with disseminated <I>Mycobacte
rium avium</I> complex: AIDS Clinical Trial Group 393 Study Team. <I>J Infect Di
s</I> 2003; 187: 1046-1052. </font>      ^cY#6541.htm##
00389000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704014600076002000900222#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#95#91#article#132#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. Trono D. Virology. Picking the right s
pot. <I>Science</I> 2003; 300: 1670-1671. </font>      ^cY#6541.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027600076002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#96#92#article#132#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. Lund AH, Turner G, Trubetskoy A, Verho
even E, Wientjens E, Hulsman D, et al. Genome-wide retroviral insertional taggin
g of genes involved in cancer in Cdkn2a-deficient mice. <I>Nat Genet</I> 2002; 3
2: 160-165. </font>      ^cY#6541.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018600076002000900262#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#97#93#article#132#22#<P><fon
t face="Arial, Helvetica, sans-serif">22. Mikkers H, Berns A. Retroviral inserti
onal mutagenesis: tagging cancer pathways. <I>Adv Cancer Res</I> 2003; 88: 53-99
. </font>      ^cY#6541.htm##
00529000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028600076002000900362#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#98#94#article#132#23#<P><fon
t face="Arial, Helvetica, sans-serif">23. Challita PM, Kohn DB. Lack of expressi
on from a retroviral vector after transduction of murine hematopoietic stem cell
s is associated with methylation <I>in vivo</I>. <I>Proc Natl Acad Sci U S A</I>
 1994; 91: 2567-2571. </font>      ^cY#6541.htm##
00588000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704034500076002000900421#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#99#95#article#132#24#<P><fon
t face="Arial, Helvetica, sans-serif">24. Challita PM, Skelton D, el-Khoueiry A,
 Yu XJ, Weinberg K, Kohn DB. Multiple modifications in cis elements of the long 
terminal repeat of retroviral vectors lead to increased expression and decreased
 DNA methylation in embryonic carcinoma cells. <I>J Virol</I> 1995; 69: 748-755.
 </font>      ^cY#6541.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704022300077002000900300#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#100#96#article#132#25#<P><fo
nt face="Arial, Helvetica, sans-serif">25. Li Z, Dullmann J, Schiedlmeier B, Sch
midt M, Von Kalle C, Meyer J, et al. Murine leukemia induced by retroviral gene 
marking. <I>Science</I> 2002; 296: 497. </font>      ^cY#6541.htm##
00516000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704027200077002000900349#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#101#97#article#132#26#<P><fo
nt face="Arial, Helvetica, sans-serif">26. Bonini C, Ferrari G, Verzeletti S, Se
rvida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocyt
es for control of allogeneic graft-versus leukemia. <I>Science</I> 1997; 276: 17
19-1724. </font>      ^cY#6541.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704024300077002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#102#98#article#132#27#<P><fo
nt face="Arial, Helvetica, sans-serif">27. Schmidt M, Zickler P, Hoffmann G, Haa
s S, Wissler M, Muessig A, et al. Polyclonal long-term repopulating stem cell cl
ones in a primate model. <I>Blood</I> 2002; 100: 2737-2743. </font>      ^cY#654
1.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704022500077002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#103#99#article#132#28#<P><fo
nt face="Arial, Helvetica, sans-serif">28. Wu X, Li Y, Crise B, Burgess SM. Tran
scription start regions in the human genome are favored targets for MLV integrat
ion. <I>Science</I> 2003; 300: 1749-1751. </font>      ^cY#6541.htm##
00423000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017800078002000900256#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#104#100#article#132#29#<P><f
ont face="Arial, Helvetica, sans-serif">29. Dave UP, Jenkins NA, Copeland NG. Ge
ne therapy insertional mutagenesis insights. <I>Science</I> 2004; 303: 333. </fo
nt>      ^cY#6541.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023800078002000900316#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#105#101#article#132#30#<P><f
ont face="Arial, Helvetica, sans-serif">30. McCormack MP, Rabbitts TH. Activatio
n of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined im
munodeficiency. <I>N Engl J Med</I> 2004; 350: 913-922. </font>      ^cY#6541.ht
m##
00502000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025700078002000900335#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#106#102#article#132#31#<P><f
ont face="Arial, Helvetica, sans-serif">31. Warren AJ, Colledge WH, Carlton MB, 
Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein 
rbtn2 is essential for erythroid development. <I>Cell</I> 1994; 78: 45-57. </fon
t>      ^cY#6541.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027200078002000900350#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#107#103#article#132#32#<P><f
ont face="Arial, Helvetica, sans-serif">32. Larson RC, Osada H, Larson TA, Laven
ir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 causes thymic developmental a
berrations that precede malignancy in transgenic mice. <I>Oncogene</I> 1995; 11:
 853-862. </font>      ^cY#6541.htm##
00552000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030700078002000900385#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#108#104#article#132#33#<P><f
ont face="Arial, Helvetica, sans-serif">33. Larson RC, Lavenir I, Larson TA, Bae
r R, Warren AJ, Wadman I, et al. Protein dimerization between Lmo2 (Rbtn2) and T
al1 alters thymocyte development and potentiates T cell tumorigenesis in transge
nic mice. <I>EMBO J</I> 1996; 15: 1021-1027. </font>      ^cY#6541.htm##
00553000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030800078002000900386#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#109#105#article#132#34#<P><f
ont face="Arial, Helvetica, sans-serif">34. Foroni L, Boehm T, White L, Forster 
A, Sherrington P, Liao XB, et al. The rhombotin gene family encode related LIM-d
omain proteins whose differing expression suggests multiple roles in mouse devel
opment. <I>J Mol Biol</I> 1992; 226: 747-761. </font>      ^cY#6541.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026600078002000900344#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#110#106#article#132#35#<P><f
ont face="Arial, Helvetica, sans-serif">35. Yamada Y, Warren AJ, Dobson C, Forst
er A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary 
for adult mouse hematopoiesis. <I>Proc Natl Acad Sci U S A</I> 1998; 95: 3890-38
95. </font>      ^cY#6541.htm##
00390000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704014500078002000900223#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#111#107#article#132#36#<P><f
ont face="Arial, Helvetica, sans-serif">36. Berns A. Good news for gene therapy.
 <I>N Engl J Med</I> 2004; 350: 1679-1680. </font>      ^cY#6541.htm##
00569000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032400078002000900402#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#112#108#article#132#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Kustikova OS, Wahlers A, Kuhlcke K, 
Stahle B, Zander AR, Baum C, et al. Dose finding with retroviral vectors: correl
ation of retroviral vector copy numbers in single cells with gene transfer effic
iency in a cell population. <I>Blood</I> 2003; 102: 3934-3937.</font>      ^cY#6
541.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029600078002000900374#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#113#109#article#132#38#<P><f
ont face="Arial, Helvetica, sans-serif">38. Modlich U, Kustikova OS, Schmidt M, 
Rudolph C, Meyer J, Li Z, et al. Leukemias following retroviral transfer of mult
idrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. <
I>Blood</I> 2005; 105: 4235-4246. </font>      ^cY#6541.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025600078002000900334#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#114#110#article#132#39#<P><f
ont face="Arial, Helvetica, sans-serif">39. Kustikova O, Fehse B, Modlich U, Yan
g M, Dullmann J, Kamino K, et al. Clonal dominance of hematopoietic stem cells t
riggered by retroviral gene marking. <I>Science</I> 2005; 308: 1171-1174. </font
>      ^cY#6541.htm##
00554000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030900078002000900387#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#115#111#article#132#40#<P><f
ont face="Arial, Helvetica, sans-serif">40. Ott MG, Schmidt M, Schwarzwaelder K,
 Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous 
disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM1
6 or SETBP1. <I>Nat Med</I> 2006; 12: 401-409. </font>      ^cY#6541.htm##
00446000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020100078002000900279#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#116#112#article#132#41#<P><f
ont face="Arial, Helvetica, sans-serif">41. Woods NB, Bottero V, Schmidt M, Von 
Kalle C, Verma IM. Gene therapy: therapeutic gene causing lymphoma. <I>Nature</I
> 2006; 440: 1123. </font>      ^cY#6541.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024500078002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#117#113#article#132#42#<P><f
ont face="Arial, Helvetica, sans-serif">42. Shou Y, Ma Z, Lu T, Sorrentino BP. U
nique risk factors for insertional mutagenesis in a mouse model of XSCID gene th
erapy. <I>Proc Natl Acad Sci U S A</I> 2006; 103: 11730-11735. </font>      ^cY#
6541.htm##
00408000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016300078002000900241#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#118#114#article#132#43#<P><f
ont face="Arial, Helvetica, sans-serif">43. Kaiser J. Gene therapy. RAC's advice
: proceed with caution. <I>Science</I> 2002; 298: 2113-2115. </font>      ^cY#65
41.htm##
00396000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704015100078002000900229#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#119#115#article#132#44#<P><f
ont face="Arial, Helvetica, sans-serif">44. Check E. Second cancer case halts ge
ne-therapy trials. <I>Nature</I> 2003; 421: 305. </font>      ^cY#6541.htm##
00415000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017000078002000900248#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#120#116#article#132#45#<P><f
ont face="Arial, Helvetica, sans-serif">45. Check E. Gene therapists hopeful as 
trials resume with childhood disease. <I>Nature</I> 2004; 429: 587. </font>     
 ^cY#6541.htm##
00433000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018800078002000900266#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#121#117#article#132#46#<P><f
ont face="Arial, Helvetica, sans-serif">46. Friedmann T. Gene therapy's new era:
 a balance of unequivocal benefit and unequivocal harm. <I>Mol Ther</I> 2003; 8:
 5-7. </font>      ^cY#6541.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020600078002000900284#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#122#118#article#132#47#<P><f
ont face="Arial, Helvetica, sans-serif">47. Thomas CE, Ehrhardt A, Kay MA. Progr
ess and problems with the use of viral vectors for gene therapy. <I>Nat Rev Gene
t</I> 2003; 4: 346-358. </font>      ^cY#6541.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020500078002000900283#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#123#119#article#132#48#<P><f
ont face="Arial, Helvetica, sans-serif">48. Nienhuis AW, Dunbar CE, Sorrentino B
P. Genotoxicity of retroviral integration in hematopoietic cells. <I>Mol Ther</I
> 2006; 13: 1031-1049. </font>      ^cY#6541.htm##
00561000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031600078002000900394#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#124#120#article#132#49#<P><f
ont face="Arial, Helvetica, sans-serif">49. Schambach A, Bohne J, Chandra S, Wil
l E, Margison GP, Williams DA, et al. Equal potency of gammaretroviral and lenti
viral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in he
matopoietic cells. <I>Mol Ther</I> 2006; 13: 391-400. </font>      ^cY#6541.htm#
#
00413000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016800078002000900246#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#125#121#article#132#50#<P><f
ont face="Arial, Helvetica, sans-serif">50. Groth AC, Calos MP. Phage integrases
: biology and applications. <I>J Mol Biol</I> 2004; 335: 667-678. </font>      ^
cY#6541.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029600078002000900374#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#126#122#article#132#51#<P><f
ont face="Arial, Helvetica, sans-serif">51. Ishikawa Y, Tanaka N, Murakami K, Uc
hiyama T, Kumaki S, Tsuchiya S, et al. Phage phiC31 integrase-mediated genomic i
ntegration of the common cytokine receptor gamma chain in human T-cell lines. <I
>J Gene Med</I> 2006; 8: 646-653. </font>      ^cY#6541.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026000078002000900338#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#127#123#article#132#52#<P><f
ont face="Arial, Helvetica, sans-serif">52. Urnov FD, Miller JC, Lee YL, Beausej
our CM, Rock JM, Augustus S, et al. Highly efficient endogenous human gene corre
ction using designed zinc-finger nucleases. <I>Nature</I> 2005; 435: 646-651. </
font>      ^cY#6541.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017600078002000900254#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#128#124#article#132#53#<P><f
ont face="Arial, Helvetica, sans-serif">53. Check E. Harmful potential of viral 
vectors fuels doubts over gene therapy. <I>Nature</I> 2003; 423: 573-574. </font
>      ^cY#6541.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028300078002000900361#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#129#125#article#132#54#<P><f
ont face="Arial, Helvetica, sans-serif">54. Themis M, Waddington SN, Schmidt M, 
Von Kalle C, Wang Y, Al-Allaf F, et al. Oncogenesis following delivery of a nonp
rimate lentiviral gene therapy vector to fetal and neonatal mice. <I>Mol Ther</I
> 2005; 12: 763-771. </font>      ^cY#6541.htm##
00555000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031000078002000900388#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#130#126#article#132#55#<P><f
ont face="Arial, Helvetica, sans-serif">55. Montini E, Cesana D, Schmidt M, Sanv
ito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in
 a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integr
ation. <I>Nat Biotechnol</I> 2006; 24: 687-696. </font>      ^cY#6541.htm##
00431000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018600078002000900264#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#131#127#article#132#56#<P><f
ont face="Arial, Helvetica, sans-serif">56. Baum C, Schambach A, Bohne J, Galla 
M. Retrovirus vectors: toward the plentivirus? <I>Mol Ther</I> 2006; 13: 1050-10
63. </font>      ^cY#6541.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017300078002000900251#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#132#128#article#132#57#<P><f
ont face="Arial, Helvetica, sans-serif">57. Strauss BE, Costanzi-Strauss E. pCLP
G: a p53-driven retroviral system. <I>Virology</I> 2004; 321: 165-172. </font>  
    ^cY#6541.htm##
00551000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030600078002000900384#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#p#133#129#article#132#58#<P><f
ont face="Arial, Helvetica, sans-serif">58. Strauss BE, Bajgelman MC, Costanzi-S
trauss E. A novel gene transfer strategy that combines promoter and transgene ac
tivities for improved tumor cell inhibition. <I>Cancer Gene Ther</I> 2005; 12: 9
35-946. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6541.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033900075002000900414#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#134#130#article#132#<P class="style4"><A
 NAME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial
, Helvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT
> <A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6
541.htm##
00682000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704045200075002000900527#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#135#131#article#132#<P class="style4"><B
><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a> 
   Address for correspondence: </B><font face="Arial, Helvetica, sans-serif">B.E
.    Strauss, Instituto do Cora&ccedil;&atilde;o, FM, USP, Av. Dr. En&eacute;as 
C.    Aguiar, 44, Bloco 2, 10&#186; andar, 05403-000 S&atilde;o Paulo, SP, Brasi
l.    Fax: +55-11-3069-5022. E-mail: <a href="mailto:bstrauss@usp.br">bstrauss@u
sp.br</a></font>  </P>      ^cY#6541.htm##
00503000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704027300075002000900348#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6541.htm#S#p#136#132#article#132#<P><font face="Arial
, Helvetica, sans-serif">Research supported by FAPESP (Nos. 00/12156-5 and 98/15
120-0) and CNPq (Nos. 473587/04-1 and 420036/2005-9). Received June 28, 2006. Ac
cepted December 13, 2006.</font><font face="Arial, Helvetica, sans-serif"> </fon
t>       ^cY#6541.htm##
00500000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100019000910120
05600110030002200166710000200188065000900190064000500199031000200204014001000206
865000900216002000900225#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
137#1#article#58#1#^rND^sGaspar^nHB#^rND^sThrasher^nAJ#Gene therapy for severe c
ombined immunodeficiencies^len#Expert Opin Biol Ther#2#20050000#2005#5#1175-1182
#20070500#6541.htm##
00552000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740120111000940300
01400205065000900219064000500228031000300233014000800236865000900244002000900253
035001000262801001400272#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
138#2#article#58#2#^rND^sSrivastava^nA#Hematopoietic stem cell transduction by r
ecombinant adeno-associated virus vectors: problems and solutions^len#Hum Gene T
her#20050000#2005#16#792-798#20070500#6541.htm#1043-0342#Hum Gene Ther##
00696000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910100
01400109010001400123010001800137010001800155810000600173012010900179030000700288
06500090029506400050030403100040030901400100031386500090032300200090033203500100
0341801000700351#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#139#3#ar
ticle#58#3#^rND^sGaspar^nHB#^rND^sParsley^nKL#^rND^sHowe^nS#^rND^sKing^nD#^rND^s
Gilmour^nKC#^rND^sSinclair^nJ#et al#Gene therapy of X-linked severe combined imm
unodeficiency by use of a pseudotyped gammaretroviral vector^len#Lancet#20040000
#2004#364#2181-2187#20070500#6541.htm#0099-5355#Lancet##
00523000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100025000740100018000990100
01700117012003100134030000700165065000900172064000500181031000400186014000800190
865000900198002000900207035001000216801000700226#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6541.htm#S#c#140#4#article#58#4#^rND^sCavazzana-Calvo^nM#^rND^sThrash
er^nA#^rND^sMavilio^nF#The future of gene therapy^len#Nature#20040000#2004#427#7
79-781#20070500#6541.htm#0028-0836#Nature##
00551000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100022000740100018000960120
07400114030001600188065000900204064000500213031000300218014000800221865000900229
002000900238035001000247801001600257#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#141#5#article#58#5#^rND^sSchmalstieg^nFC#^rND^sGoldman^nAS#Immune co
nsequences of mutations in the human common gamma-chain gene^len#Mol Genet Metab
#20020000#2002#76#163-171#20070500#6541.htm#1096-7192#Mol Genet Metab##
00558000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100017000900100
01300107012006900120030001400189065000900203064000500212031000300217014000600220
865000900226002000900235035001000244801001400254#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6541.htm#S#c#142#6#article#58#6#^rND^sMalek^nTR#^rND^sPorter^nBO#^rND
^sHe^nYW#Multiple gamma c-dependent cytokines regulate T-cell development^len#Im
munol Today#20020000#1999#20#71-76#20070500#6541.htm#0167-5699#Immunol Today##
00531000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100017000900100
01900107012003500126030001300161065000900174064000500183031000400188014000800192
865000900200002000900209035001000218801001300228#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6541.htm#S#c#143#7#article#58#7#^rND^sRosen^nFS#^rND^sCooper^nMD#^rND
^sWedgwood^nRJ#The primary immunodeficiencies^len#N Engl J Med#19950000#1995#333
#431-440#20070500#6541.htm#0028-4793#N Engl J Med##
00508000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740120068000920300
01300160065000900173064000500182031000400187014001000191865000900201002000900210
035001000219801001300229#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
144#8#article#58#8#^rND^sBuckley^nRH#Primary immunodeficiency diseases due to de
fects in lymphocytes^len#N Engl J Med#20000000#2000#343#1313-1324#20070500#6541.
htm#0028-4793#N Engl J Med##
00702000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100017000920100
01700109010001700126010001900143010001800162810000600180012009800186030001300284
06500090029706400050030603100040031101400080031586500090032300200090033203500100
0341801001300351#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#145#9#ar
ticle#58#9#^rND^sBuckley^nRH#^rND^sSchiff^nSE#^rND^sSchiff^nRI#^rND^sMarkert^nL#
^rND^sWilliams^nLW#^rND^sRoberts^nJL#et al#Hematopoietic stem-cell transplantati
on for the treatment of severe combined immunodeficiency^len#N Engl J Med#199900
00#1999#340#508-516#20070500#6541.htm#0028-4793#N Engl J Med##
00799000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01900109010001900128010002500147010001600172810000600188012020000194030000600394
06500090040006400050040903100030041401400100041786500090042700200090043603500100
0445801000600455#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#146#10#a
rticle#58#10#^rND^sHaddad^nE#^rND^sLandais^nP#^rND^sFriedrich^nW#^rND^sGerritsen
^nB#^rND^sCavazzana-Calvo^nM#^rND^sMorgan^nG#et al#Long-term immune reconstituti
on and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantatio
n for severe combined immunodeficiency: a European retrospective study of 116 pa
tients^len#Blood#19980000#1998#91#3646-3653#20070500#6541.htm#0006-4971#Blood##
00711000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100026000760100018001020100
01700120010001800137010001300155010002300168810000600191012009400197030001300291
06500090030406400050031303100040031801400100032286500090033200200090034103500100
0350801001300360#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#147#11#a
rticle#58#11#^rND^sHacein-Bey-Abina^nS#^rND^sle Deist^nF#^rND^sCarlier^nF#^rND^s
Bouneaud^nC#^rND^sHue^nC#^rND^sde Villartay^nJP#et al#Sustained correction of X-
linked severe combined immunodeficiency by ex vivo gene therapy^len#N Engl J Med
#20020000#2002#346#1185-1193#20070500#6541.htm#0028-4793#N Engl J Med##
00683000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100025000760100020001010100
02500121010001500146010001400161010001700175810000600192012007700198030000800275
06500090028306400050029203100040029701400080030186500090030900200090031803500100
0327801000800337#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#148#12#a
rticle#58#12#^rND^sCavazzana-Calvo^nM#^rND^sHacein-Bey^nS#^rND^sde Saint Basile^
nG#^rND^sGross^nF#^rND^sYvon^nE#^rND^sNusbaum^nP#et al#Gene therapy of human sev
ere combined immunodeficiency (SCID)-X1 disease^len#Science#20000000#2000#288#66
9-672#20070500#6541.htm#0036-8075#Science##
00704000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100026000760100019001020100
01700121010002000138010001900158010001800177810000600195012009500201030000800296
06500090030406400050031303100040031801400080032286500090033000200090033903500100
0348801000800358#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#149#13#a
rticle#58#13#^rND^sHacein-Bey-Abina^nS#^rND^sVon Kalle^nC#^rND^sSchmidt^nM#^rND^
sMcCormack^nMP#^rND^sWulffraat^nN#^rND^sLeboulch^nP#et al#LMO2-associated clonal
 T cell proliferation in two patients after gene therapy for SCID-X1^len#Science
#20030000#2003#302#415-419#20070500#6541.htm#0036-8075#Science##
00499000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120069000940300
00700163065000900170064000500179031000400184014001000188865000900198002000900207
035001000216801000700226#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
150#14#article#58#14#^rND^sBuckley^nRH#Gene therapy for SCID - a complication af
ter remarkable progress^len#Lancet#20020000#2002#360#1185-1186#20070500#6541.htm
#0099-5355#Lancet##
00721000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100026000760100019001020100
01700121010001800138010001900156010001800175810000600193012010400199030001300303
06500090031606400050032503100040033001400080033486500090034200200090035103500100
0360801001300370#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#151#15#a
rticle#58#15#^rND^sHacein-Bey-Abina^nS#^rND^sVon-Kalle^nC#^rND^sSchmidt^nM#^rND^
sle-Deist^nF#^rND^sWulffraat^nN#^rND^sMcIntyre^nE#et al#A serious adverse event 
after successful gene therapy for X-linked severe combined immunodeficiency^len#
N Engl J Med#20020000#2003#348#255-256#20070500#6541.htm#0028-4793#N Engl J Med#
#
00542000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900120
11500109030000900224710000200233065000900235064000500244031000300249014000600252
865000900258002000900267#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
152#16#article#58#16#^rND^sNam^nCH#^rND^sRabbitts^nTH#The role of LMO2 in develo
pment and in T cell leukemia after chromosomal translocation or retroviral inser
tion^len#Mol Ther#2#20060000#2006#13#15-25#20070500#6541.htm##
00476000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760120069000990300
00900168710000200177065000900179064000500188031000300193014000800196865000900204
002000900213#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#153#17#artic
le#58#17#^rND^sFrederickson^nRM#Report from the 2nd stem cell clonality and geno
toxicity retreat^len#Mol Ther#2#20050000#2005#12#379-383#20070500#6541.htm##
00656000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100018000900100
01200108010001500120010001500135010001900150810000600169012007500175030000600250
06500090025606400050026503100040027001400100027486500090028400200090029303500100
0302801000600312#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#154#18#a
rticle#58#18#^rND^sBaum^nC#^rND^sDullmann^nJ#^rND^sLi^nZ#^rND^sFehse^nB#^rND^sMe
yer^nJ#^rND^sWilliams^nDA#et al#Side effects of retroviral gene transfer into he
matopoietic stem cells^len#Blood#20030000#2003#101#2099-2114#20070500#6541.htm#0
006-4971#Blood##
00791000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
01300111010001900124010001600143010001900159810000600178012018700184030001300371
06500090038406400050039303100040039801400100040286500090041200200090042103500100
0430801001300440#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#155#19#a
rticle#58#19#^rND^sAberg^nJA#^rND^sWilliams^nPL#^rND^sLiu^nT#^rND^sLederman^nHM#
^rND^sHafner^nR#^rND^sTorriani^nFJ#et al#A study of discontinuing maintenance th
erapy in human immunodeficiency virus-infected subjects with disseminated Mycoba
cterium avium complex: AIDS Clinical Trial Group 393 Study Team^len#J Infect Dis
#20030000#2003#187#1046-1052#20070500#6541.htm#0022-1899#J Infect Dis##
00466000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120037000910300
00800128065000900136064000500145031000400150014001000154865000900164002000900173
035001000182801000800192#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
156#20#article#58#20#^rND^sTrono^nD#Virology: Picking the right spot^len#Science
#20030000#2003#300#1670-1671#20070500#6541.htm#0036-8075#Science##
00699000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
02000107010001900127010001900146010001700165810000600182012010000188030001000288
06500090029806400050030703100030031201400080031586500090032300200090033203500100
0341801001000351#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#157#21#a
rticle#58#21#^rND^sLund^nAH#^rND^sTurner^nG#^rND^sTrubetskoy^nA#^rND^sVerhoeven^
nE#^rND^sWientjens^nE#^rND^sHulsman^nD#et al#Genome-wide retroviral insertional 
tagging of genes involved in cancer in Cdkn2a-deficient mice^len#Nat Genet#20020
000#2002#32#160-165#20070500#6541.htm#1061-4036#Nat Genet##
00531000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930120
06400108030001500172065000900187064000500196031000300201014000600204865000900210
002000900219035001000228801001500238#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#158#22#article#58#22#^rND^sMikkers^nH#^rND^sBerns^nA#Retroviral inse
rtional mutagenesis: tagging cancer pathways^len#Adv Cancer Res#20030000#2003#88
#53-99#20070500#6541.htm#0065-230X#Adv Cancer Res##
00634000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950120
14100110030002500251065000900276064000500285031000300290014001000293865000900303
002000900312035001000321801002500331#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#159#23#article#58#23#^rND^sChallita^nPM#^rND^sKohn^nDB#Lack of expre
ssion from a retroviral vector after transduction of murine hematopoietic stem c
ells is associated with methylation in vivo^len#Proc Natl Acad Sci U S A#1994000
0#1994#91#2567-2571#20070500#6541.htm#0027-8424#Proc Natl Acad Sci U S A##
00755000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
02100112010001300133010001800146010001500164012018100179030000800360065000900368
06400050037703100030038201400080038586500090039300200090040203500100041180100080
0421#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#160#24#article#58#24
#^rND^sChallita^nPM#^rND^sSkelton^nD#^rND^sel-Khoueiry^nA#^rND^sYu^nXJ#^rND^sWei
nberg^nK#^rND^sKohn^nDB#Multiple modifications in cis elements of the long termi
nal repeat of retroviral vectors lead to increased expression and decreased DNA 
methylation in embryonic carcinoma cells^len#J Virol#19950000#1995#69#748-755#20
070500#6541.htm#0022-538X#J Virol##
00651000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100018000880100
02200106010001700128010001900145010001500164010001300179012005500192030000800247
06500090025506400050026403100040026901400040027386500090027700200090028603500100
0295801000800305#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#161#25#a
rticle#58#25#^rND^sLi^nZ#^rND^sDullmann^nJ#^rND^sSchiedlmeier^nB#^rND^sSchmidt^n
M#^rND^sVon Kalle^nC#^rND^sMeyer^nJ#^rND^set^nal#Murine leukemia induced by retr
oviral gene marking^len#Science#20020000#2002#296#497#20070500#6541.htm#0036-807
5#Science##
00693000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
02000109010001700129010001700146010001800163810000600181012009600187030000800283
06500090029106400050030003100040030501400100030986500090031900200090032803500100
0337801000800347#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#162#26#a
rticle#58#26#^rND^sBonini^nC#^rND^sFerrari^nG#^rND^sVerzeletti^nS#^rND^sServida^
nP#^rND^sZappone^nE#^rND^sRuggieri^nL#et al#HSV-TK gene transfer into donor lymp
hocytes for control of allogeneic graft-versus leukemia^len#Science#20020000#199
7#276#1719-1724#20070500#6541.htm#0036-8075#Science##
00662000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01800110010001400128010001700142010001700159810000600176012007400182030000600256
06500090026206400050027103100040027601400100028086500090029000200090029903500100
0308801000600318#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#163#27#a
rticle#58#27#^rND^sSchmidt^nM#^rND^sZickler^nP#^rND^sHoffmann^nG#^rND^sHaas^nS#^
rND^sWissler^nM#^rND^sMuessig^nA#et al#Polyclonal long-term repopulating stem ce
ll clones in a primate model^len#Blood#20020000#2002#100#2737-2743#20070500#6541
.htm#0006-4971#Blood##
00599000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100012000880100
01500100010001800115012009200133030000800225065000900233064000500242031000400247
014001000251865000900261002000900270035001000279801000800289#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6541.htm#S#c#164#28#article#58#28#^rND^sWu^nX#^rND^sLi^nY
#^rND^sCrise^nB#^rND^sBurgess^nSM#Transcription start regions in the human genom
e are favored targets for MLV integration^len#Science#20030000#2003#300#1749-175
1#20070500#6541.htm#0036-8075#Science##
00534000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01900109012005000128030000800178065000900186064000500195031000400200014000400204
865000900208002000900217035001000226801000800236#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6541.htm#S#c#165#29#article#58#29#^rND^sDave^nUP#^rND^sJenkins^nNA#^r
ND^sCopeland^nNG#Gene therapy insertional mutagenesis insights^len#Science#20040
000#2004#303#333#20070500#6541.htm#0036-8075#Science##
00581000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960120
10800115030001300223065000900236064000500245031000400250014000800254865000900262
002000900271035001000280801001300290#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#166#30#article#58#30#^rND^sMcCormack^nMP#^rND^sRabbitts^nTH#Activati
on of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined i
mmunodeficiency^len#N Engl J Med#20040000#2004#350#913-922#20070500#6541.htm#002
8-4793#N Engl J Med##
00664000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01800112010001600130010001600146010001900162012009600181030000500277065000900282
06400050029103100030029601400060029986500090030500200090031403500100032380100050
0333#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#167#31#article#58#31
#^rND^sWarren^nAJ#^rND^sColledge^nWH#^rND^sCarlton^nMB#^rND^sEvans^nMJ#^rND^sSmi
th^nAJ#^rND^sRabbitts^nTH#The oncogenic cysteine-rich LIM domain protein rbtn2 i
s essential for erythroid development^len#Cell#19940000#1994#78#45-57#20070500#6
541.htm#0092-8674#Cell##
00665000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01700108010001700125010001900142012011900161030000900280065000900289064000500298
031000300303014000800306865000900314002000900323035001000332801000900342#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#168#32#article#58#32#^rND^sLarso
n^nRC#^rND^sOsada^nH#^rND^sLarson^nTA#^rND^sLavenir^nI#^rND^sRabbitts^nTH#The on
cogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede m
alignancy in transgenic mice^len#Oncogene#19950000#1995#11#853-862#20070500#6541
.htm#0950-9232#Oncogene##
00727000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01700110010001400127010001700141010001600158810000600174012014000180030000700320
06500090032706400050033603100030034101400100034486500090035400200090036303500100
0372801000700382#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#169#33#a
rticle#58#33#^rND^sLarson^nRC#^rND^sLavenir^nI#^rND^sLarson^nTA#^rND^sBaer^nR#^r
ND^sWarren^nAJ#^rND^sWadman^nI#et al#Protein dimerization between Lmo2 (Rbtn2) a
nd Tal1 alters thymocyte development and potentiates T cell tumorigenesis in tra
nsgenic mice^len#EMBO J#19960000#1996#15#1021-1027#20070500#6541.htm#0261-4189#E
mbo J##
00732000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01500107010001700122010002100139010001500160810000600175012013700181030001100318
06500090032906400050033803100040034301400080034786500090035500200090036403500100
0373801001100383#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#170#34#a
rticle#58#34#^rND^sForoni^nL#^rND^sBoehm^nT#^rND^sWhite^nL#^rND^sForster^nA#^rND
^sSherrington^nP#^rND^sLiao^nXB#et al#The rhombotin gene family encode related L
IM-domain proteins whose differing expression suggests multiple roles in mouse d
evelopment^len#J Mol Biol#19920000#1992#226#747-761#20070500#6541.htm#0022-2836#
J Mol Biol##
00693000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01600109010001700125010001700142010001900159012008400178030002500262065000900287
06400050029603100030030101400100030486500090031400200090032303500100033280100250
0342#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#171#35#article#58#35
#^rND^sYamada^nY#^rND^sWarren^nAJ#^rND^sDobson^nC#^rND^sForster^nA#^rND^sPannell
^nR#^rND^sRabbitts^nTH#The T cell leukemia LIM protein Lmo2 is necessary for adu
lt mouse hematopoiesis^len#Proc Natl Acad Sci U S A#19980000#1998#95#3890-3895#2
0070500#6541.htm#0027-8424#Proc Natl Acad Sci U S A##
00470000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120031000910300
01300122065000900135064000500144031000400149014001000153865000900163002000900172
035001000181801001300191#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
172#36#article#58#36#^rND^sBerns^nA#Good news for gene therapy^len#N Engl J Med#
20040000#2004#350#1679-1680#20070500#6541.htm#0028-4793#N Engl J Med##
00744000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01700113010001600130010001700146010001400163810000600177012015500183030000600338
06500090034406400050035303100040035801400100036286500090037200200090038103500100
0390801000600400#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#173#37#a
rticle#58#37#^rND^sKustikova^nOS#^rND^sWahlers^nA#^rND^sKuhlcke^nK#^rND^sStahle^
nB#^rND^sZander^nAR#^rND^sBaum^nC#et al#Dose finding with retroviral vectors: co
rrelation of retroviral vector copy numbers in single cells with gene transfer e
fficiency in a cell population^len#Blood#20030000#2003#102#3934-3937#20070500#65
41.htm#0006-4971#Blood##
00715000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01700113010001700130010001500147010001200162810000600174012012900180030000600309
06500090031506400050032403100040032901400100033386500090034300200090035203500100
0361801000600371#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#174#38#a
rticle#58#38#^rND^sModlich^nU#^rND^sKustikova^nOS#^rND^sSchmidt^nM#^rND^sRudolph
^nC#^rND^sMeyer^nJ#^rND^sLi^nZ#et al#Leukemias following retroviral transfer of 
multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesi
s^len#Blood#20050000#2005#105#4235-4246#20070500#6541.htm#0006-4971#Blood##
00677000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
01700110010001400127010001800141010001600159810000600175012008600181030000800267
06500090027506400050028403100040028901400100029386500090030300200090031203500100
0321801000800331#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#175#39#a
rticle#58#39#^rND^sKustikova^nO#^rND^sFehse^nB#^rND^sModlich^nU#^rND^sYang^nM#^r
ND^sDullmann^nJ#^rND^sKamino^nK#et al#Clonal dominance of hematopoietic stem cel
ls triggered by retroviral gene marking^len#Science#20050000#2005#308#1171-1174#
20070500#6541.htm#0036-8075#Science##
00730000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900100
02400107010001500131010001500146010001500161810000600176012014100182030000800323
06500090033106400050034003100030034501400080034886500090035600200090036503500100
0374801000800384#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#176#40#a
rticle#58#40#^rND^sOtt^nMG#^rND^sSchmidt^nM#^rND^sSchwarzwaelder^nK#^rND^sStein^
nS#^rND^sSiler^nU#^rND^sKoehl^nU#et al#Correction of X-linked chronic granulomat
ous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, P
RDM16 or SETBP1^len#Nat Med#20060000#2006#12#401-409#20070500#6541.htm#1078-8956
#Nat Med##
00592000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01700109010001900126010001600145012005200161030000700213065000900220064000500229
031000400234014000500238865000900243002000900252035001000261801000700271#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#177#41#article#58#41#^rND^sWoods
^nNB#^rND^sBottero^nV#^rND^sSchmidt^nM#^rND^sVon Kalle^nC#^rND^sVerma^nIM#Gene t
herapy: therapeutic gene causing lymphoma^len#Nature#20060000#2006#440#1123#2007
0500#6541.htm#0028-0836#Nature##
00636000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100012000900100
01200102010002100114012009100135030002500226065000900251064000500260031000400265
014001200269865000900281002000900290035001000299801002500309#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6541.htm#S#c#178#42#article#58#42#^rND^sShou^nY#^rND^sMa^
nZ#^rND^sLu^nT#^rND^sSorrentino^nBP#Unique risk factors for insertional mutagene
sis in a mouse model of XSCID gene therapy^len#Proc Natl Acad Sci U S A#20060000
#2006#103#11730-11735#20070500#6541.htm#0027-8424#Proc Natl Acad Sci U S A##
00483000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120053000920300
00800145065000900153064000500162031000400167014001000171865000900181002000900190
035001000199801000800209#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
179#43#article#58#43#^rND^sKaiser^nJ#Gene therapy: RAC's advice: proceed with ca
ution^len#Science#20020000#2002#298#2113-2115#20070500#6541.htm#0036-8075#Scienc
e##
00470000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120049000910300
00700140065000900147064000500156031000400161014000400165865000900169002000900178
035001000187801000700197#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
180#44#article#58#44#^rND^sCheck^nE#Second cancer case halts gene-therapy trials
^len#Nature#20020000#2003#421#305#20070500#6541.htm#0028-0836#Nature##
00489000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120068000910300
00700159065000900166064000500175031000400180014000400184865000900188002000900197
035001000206801000700216#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
181#45#article#58#45#^rND^sCheck^nE#Gene therapists hopeful as trials resume wit
h childhood disease^len#Nature#20040000#2004#429#587#20070500#6541.htm#0028-0836
#Nature##
00480000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120082000950300
00900177710000200186065000900188064000500197031000200202014000400204865000900208
002000900217#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#182#46#artic
le#58#46#^rND^sFriedmann^nT#Gene therapy's new era: a balance of unequivocal ben
efit and unequivocal harm^len#Mol Ther#2#20030000#2003#8#5-7#20070500#6541.htm##
00534000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01400111012007300125030001400198710000200212065000900214064000500223031000200228
014000800230865000900238002000900247#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#183#47#article#58#47#^rND^sThomas^nCE#^rND^sEhrhardt^nA#^rND^sKay^nM
A#Progress and problems with the use of viral vectors for gene therapy^len#Nat R
ev Genet#2#20030000#2003#4#346-358#20070500#6541.htm##
00533000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
02100112012006600133030000900199710000200208065000900210064000500219031000300224
014001000227865000900237002000900246#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#184#48#article#58#48#^rND^sNienhuis^nAW#^rND^sDunbar^nCE#^rND^sSorre
ntino^nBP#Genotoxicity of retroviral integration in hematopoietic cells^len#Mol 
Ther#2#20060000#2006#13#1031-1049#20070500#6541.htm##
00709000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
01700110010001400127010001900141010001900160810000600179012014400185030000900329
71000020033806500090034006400050034903100030035401400080035786500090036500200090
0374#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#185#49#article#58#49
#^rND^sSchambach^nA#^rND^sBohne^nJ#^rND^sChandra^nS#^rND^sWill^nE#^rND^sMargison
^nGP#^rND^sWilliams^nDA#et al#Equal potency of gammaretroviral and lentiviral SI
N vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoie
tic cells^len#Mol Ther#2#20060000#2006#13#391-400#20070500#6541.htm##
00509000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920120
04700108030001100155065000900166064000500175031000400180014000800184865000900192
002000900201035001000210801001100220#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#186#50#article#58#50#^rND^sGroth^nAC#^rND^sCalos^nMP#Phage integrase
s: biology and applications^len#J Mol Biol#20040000#2004#335#667-678#20070500#65
41.htm#0022-2836#J Mol Biol##
00689000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01800110010001800128010001600146010001800162810000600180012012200186030001100308
71000020031906500090032106400050033003100020033501400080033786500090034500200090
0354#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#187#51#article#58#51
#^rND^sIshikawa^nY#^rND^sTanaka^nN#^rND^sMurakami^nK#^rND^sUchiyama^nT#^rND^sKum
aki^nS#^rND^sTsuchiya^nS#et al#Phage phiC31 integrase-mediated genomic integrati
on of the common cytokine receptor gamma chain in human T-cell lines^len#J Gene 
Med#2#20060000#2006#8#646-653#20070500#6541.htm##
00680000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01400109010002100123010001500144010001800159810000600177012009100183030000700274
06500090028106400050029003100040029501400080029986500090030700200090031603500100
0325801000700335#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#188#52#a
rticle#58#52#^rND^sUrnov^nFD#^rND^sMiller^nJC#^rND^sLee^nYL#^rND^sBeausejour^nCM
#^rND^sRock^nJM#^rND^sAugustus^nS#et al#Highly efficient endogenous human gene c
orrection using designed zinc-finger nucleases^len#Nature#20050000#2005#435#646-
651#20070500#6541.htm#0028-0836#Nature##
00495000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120070000910300
00700161065000900168064000500177031000400182014000800186865000900194002000900203
035001000212801000700222#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#
189#53#article#58#53#^rND^sCheck^nE#Harmful potential of viral vectors fuels dou
bts over gene therapy^len#Nature#20030000#2003#423#573-574#20070500#6541.htm#002
8-0836#Nature##
00676000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100021000920100
01700113010001900130010001400149010001800163810000600181012010900187030000900296
71000020030506500090030706400050031603100030032101400080032486500090033200200090
0341#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#190#54#article#58#54
#^rND^sThemis^nM#^rND^sWaddington^nSN#^rND^sSchmidt^nM#^rND^sVon Kalle^nC#^rND^s
Wang^nY#^rND^sAl-Allaf^nF#et al#Oncogenesis following delivery of a nonprimate l
entiviral gene therapy vector to fetal and neonatal mice^len#Mol Ther#2#20050000
#2005#12#763-771#20070500#6541.htm##
00738000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01700109010001700126010001700143010002100160810000600181012013000187030001500317
06500090033206400050034103100030034601400080034986500090035700200090036603500100
0375801001500385#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6541.htm#S#c#191#55#a
rticle#58#55#^rND^sMontini^nE#^rND^sCesana^nD#^rND^sSchmidt^nM#^rND^sSanvito^nF#
^rND^sPonzoni^nM#^rND^sBartholomae^nC#et al#Hematopoietic stem cell gene transfe
r in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector in
tegration^len#Nat Biotechnol#20060000#2006#24#687-696#20070500#6541.htm#1087-015
6#Nat Biotechnol##
00533000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900100
01500109010001500124012004800139030000900187710000200196065000900198064000500207
031000300212014001000215865000900225002000900234#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6541.htm#S#c#192#56#article#58#56#^rND^sBaum^nC#^rND^sSchambach^nA#^r
ND^sBohne^nJ#^rND^sGalla^nM#Retrovirus vectors: toward the plentivirus?^len#Mol 
Ther#2#20060000#2006#13#1050-1063#20070500#6541.htm##
00512000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100026000940120
04200120030000900162065000900171064000500180031000400185014000800189865000900197
002000900206035001000215801000900225#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
541.htm#S#c#193#57#article#58#57#^rND^sStrauss^nBE#^rND^sCostanzi-Strauss^nE#pCL
PG: a p53-driven retroviral system^len#Virology#20040000#2004#321#165-172#200705
00#6541.htm#0042-6822#Virology##
00635000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100020000940100
02600114012011800140030001700258065000900275064000500284031000300289014000800292
865000900300002000900309035001000318801001700328#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6541.htm#S#c#194#58#article#58#58#^rND^sStrauss^nBE#^rND^sBajgelman^n
MC#^rND^sCostanzi-Strauss^nE#A novel gene transfer strategy that combines promot
er and transgene activities for improved tumor cell inhibition^len#Cancer Gene T
her#20050000#2005#12#935-946#20070500#6541.htm#0929-1903#Cancer Gene Ther##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#o#1#1#article#1#20
080212#125709#6542.htm#127##
03117000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120161001790100030003400100022003700100024003920100022004160700113004380700
09700551070016300648083139200811085000802203085003702211085003702248085002202285
08500290230708500270233608500300236311700060239307200030239905800070240211200090
2409111001302418114000902431113001802440881002402458002000902482#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB
#10#BJMBR070#FAPESP#Braz J Med Biol Res#40#5#20070500#^f671^l677#0100-879X#20070
405#Effect of metabolic control on interferon-gamma and interleukin-10 productio
n by peripheral blood mononuclear cells from type 1 and type 2 diabetic patients
^len#^rND^1A01^nM.C.^sFoss-Freitas#^rND^1A02^nN.T.^sFoss#^rND^1A03^nE.A.^sDonadi
#^rND^1A01^nM.C.^sFoss#Universidade de São Paulo^iA01^1Faculdade de Medicina de 
Ribeirão Preto^2Divisão de Endocrinologia e Metabolismo#Universidade de São Paul
o^iA02^1Faculdade de Medicina de Ribeirão Preto^2Divisão de Dermatologia#Univers
idade de São Paulo^iA03^1Faculdade de Medicina de Ribeirão Preto^2Departamento d
e Clínica Médica^3Divisão de Imunologia Clínica^cRibeirão Preto^sSP^pBrasil#^len
^aThe objective of the present study was to evaluate the production of cytokines
, interferon-g (INF-g) and interleukin-10 (IL-10), in cultures of peripheral blo
od mononuclear cells (PBMC) from type 1 and type 2 diabetic patients and to corr
elate it with inadequate and adequate metabolic control. We studied 11 type 1 an
d 13 type 2 diabetic patients and 21 healthy individuals divided into two groups
 (N = 11 and 10) paired by sex and age with type 1 and type 2 diabetic patients.
 The PBMC cultures were stimulated with concanavalin-A to measure INF-g and IL-1
0 supernatant concentration by ELISA. For patients with inadequate metabolic con
trol, the cultures were performed on the first day of hospitalization and again 
after intensive treatment to achieve adequate control. INF-g levels in the super
natants of type 1 diabetic patient cultures were higher compared to type 2 diabe
tic patients with adequate metabolic control (P < 0.001). Additionally, INF-g an
d IL-10 tended to increase the liberation of PBMC from type 1 and 2 diabetic pat
ients with adequate metabolic control (P = 0.009 and 0.09, respectively). The in
creased levels of INF-g and IL-10 released from PBMC of type 1 and 2 diabetic pa
tients with adequate metabolic control suggest that diabetic control improves th
e capacity of activation and maintenance of the immune response, reducing the su
sceptibility to infections.#^dnd^i1#^tm^len^kType 1 diabetes mellitus^i1#^tm^len
^kType 2 diabetes mellitus^i1#^tm^len^kCytokines^i1#^tm^len^kInterferon-gamma^i1
#^tm^len^kInterleukin-10^i1#^tm^len^kMetabolic control^i1#other#38#FAPESP#200607
01#July 1, 2006#20070227#February 27, 2007#S0100-879X2006005000107#6542.htm##
03130000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120184001790100030003630100022003930100024004150100022004390700113004610700
09700574070016300671083139500834085000802229085003702237085003702274085002202311
08500520233308500270238508500300241211700060244207200030244805800070245111200090
2458111001302467114000902480113001802489002000902507#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6542.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#10#BJMBR070
#FAPESP#Braz J Med Biol Res#40#5#20070500#^f671^l677#0100-879X#20070405#Effect o
f metabolic control on interferon-<FONT FACE="Symbol">g</FONT> and interleukin-1
0 production by peripheral blood mononuclear cells from type 1 and type 2 diabet
ic patients^len#^rND^1A01^nM.C.^sFoss-Freitas#^rND^1A02^nN.T.^sFoss#^rND^1A03^nE
.A.^sDonadi#^rND^1A01^nM.C.^sFoss#Universidade de São Paulo^iA01^1Faculdade de M
edicina de Ribeirão Preto^2Divisão de Endocrinologia e Metabolismo#Universidade 
de São Paulo^iA02^1Faculdade de Medicina de Ribeirão Preto^2Divisão de Dermatolo
gia#Universidade de São Paulo^iA03^1Faculdade de Medicina de Ribeirão Preto^2Dep
artamento de Clínica Médica^3Divisão de Imunologia Clínica^cRibeirão Preto^sSP^p
Brasil#^len^aThe objective of the present study was to evaluate the production o
f cytokines, interferon-g (INF-g) and interleukin-10 (IL-10), in cultures of per
ipheral blood mononuclear cells (PBMC) from type 1 and type 2 diabetic patients 
and to correlate it with inadequate and adequate metabolic control. We studied 1
1 type 1 and 13 type 2 diabetic patients and 21 healthy individuals divided into
 two groups (N = 11 and 10) paired by sex and age with type 1 and type 2 diabeti
c patients. The PBMC cultures were stimulated with concanavalin-A to measure INF
-g and IL-10 supernatant concentration by ELISA. For patients with inadequate me
tabolic control, the cultures were performed on the first day of hospitalization
 and again after intensive treatment to achieve adequate control. INF-g levels i
n the supernatants of type 1 diabetic patient cultures were higher compared to t
ype 2 diabetic patients with adequate metabolic control (P &lt; 0.001). Addition
ally, INF-g and IL-10 tended to increase the liberation of PBMC from type 1 and 
2 diabetic patients with adequate metabolic control (P = 0.009 and 0.09, respect
ively). The increased levels of INF-g and IL-10 released from PBMC of type 1 and
 2 diabetic patients with adequate metabolic control suggest that diabetic contr
ol improves the capacity of activation and maintenance of the immune response, r
educing the susceptibility to infections.#^dnd^i1#^tm^len^kType 1 diabetes melli
tus^i1#^tm^len^kType 2 diabetes mellitus^i1#^tm^len^kCytokines^i1#^tm^len^kInter
feron-<FONT FACE="Symbol">g</FONT>^i1#^tm^len^kInterleukin-10^i1#^tm^len^kMetabo
lic control^i1#other#38#FAPESP#20060701#July 1, 2006#20070227#February 27, 2007#
6542.htm##
03272000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762230009001860120161001950100030003560100022003860100024004080100022004320700
14300454070012700597070016500724083139200889085000802281085003702289085003702326
08500220236308500290238508500270241408500300244111700060247107200030247705800070
2480112000902487111001302496114000902509113001802518002000902536008008902545#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#l#4#1#article#1#^mMay^a2007#oa
#en#bjmbr#1#3.1#ilus#tab#10#BJMBR070#FAPESP#Braz. j. med. biol. res#40#5#2007050
0#^f671^l677#0100-879X#20070405#Effect of metabolic control on interferon-gamma 
and interleukin-10 production by peripheral blood mononuclear cells from type 1 
and type 2 diabetic patients^len#^rND^1A01^nM. C^sFoss-Freitas#^rND^1A02^nN. T^s
Foss#^rND^1A03^nE. A^sDonadi#^rND^1A01^nM. C^sFoss#^iA01^1Universidade de São Pa
ulo^2Faculdade de Medicina de Ribeirão Preto^3Divisão de Endocrinologia e Metabo
lismo^cRibeirão Preto^sSP^pBrasil#^iA02^1Universidade de São Paulo^2Faculdade de
 Medicina de Ribeirão Preto^3Divisão de Dermatologia^cRibeirão Preto^sSP^pBrasil
#^iA03^1Universidade de São Paulo^2Faculdade de Medicina de Ribeirão Preto^3Depa
rtamento de Clínica Médica. Divisão de Imunologia Clínica^cRibeirão Preto^sSP^pB
rasil#^len^aThe objective of the present study was to evaluate the production of
 cytokines, interferon-g (INF-g) and interleukin-10 (IL-10), in cultures of peri
pheral blood mononuclear cells (PBMC) from type 1 and type 2 diabetic patients a
nd to correlate it with inadequate and adequate metabolic control. We studied 11
 type 1 and 13 type 2 diabetic patients and 21 healthy individuals divided into 
two groups (N = 11 and 10) paired by sex and age with type 1 and type 2 diabetic
 patients. The PBMC cultures were stimulated with concanavalin-A to measure INF-
g and IL-10 supernatant concentration by ELISA. For patients with inadequate met
abolic control, the cultures were performed on the first day of hospitalization 
and again after intensive treatment to achieve adequate control. INF-g levels in
 the supernatants of type 1 diabetic patient cultures were higher compared to ty
pe 2 diabetic patients with adequate metabolic control (P < 0.001). Additionally
, INF-g and IL-10 tended to increase the liberation of PBMC from type 1 and 2 di
abetic patients with adequate metabolic control (P = 0.009 and 0.09, respectivel
y). The increased levels of INF-g and IL-10 released from PBMC of type 1 and 2 d
iabetic patients with adequate metabolic control suggest that diabetic control i
mproves the capacity of activation and maintenance of the immune response, reduc
ing the susceptibility to infections.#^dnd^i1#^tm^len^kType 1 diabetes mellitus^
i1#^tm^len^kType 2 diabetes mellitus^i1#^tm^len^kCytokines^i1#^tm^len^kInterfero
n-gamma^i1#^tm^len^kInterleukin-10^i1#^tm^len^kMetabolic control^i1#other#38#FAP
ESP#20060701#July 1, 2006#20070227#February 27, 2007#6542.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500010##
00370000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014500070002000900215#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#5#1#article#85#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, May 2007, Volume
 40(5) 671-677</B> </font></P>      ^cY#6542.htm##
00483000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704025800070002000900328#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#6#2#article#85#<P><B><font size="5" face
="Arial, Helvetica, sans-serif">Effect of metabolic control on interferon-<font 
face="Symbol">g</font> and interleukin-10 production by peripheral blood mononuc
lear cells from type 1 and type 2 diabetic patients</font></B>       ^cY#6542.ht
m##
00598000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704037300070002000900443#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#7#3#article#85#<P><font face="Arial, Hel
vetica, sans-serif">M.C. Foss-Freitas<SUP>1</SUP>, N.T.    Foss<SUP>2</SUP>, E.A
. Donadi<SUP>3</SUP> and <b><a href="#Correspondence"><img src="/img/revistas/bj
mbr/v40n5/recor.gif" border="0"></a></b>    <a href="mailto:mcfoss@fmrp.usp.br">
<img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a>    M.C. Foss<S
UP>1</SUP> </font>      ^cY#6542.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704038500070002000900455#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#8#4#article#85#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Divis&atilde;o de Endocrinologia e Metabolismo, 
<SUP>2</SUP>Divis&atilde;o de Dermatologia, <SUP>3</SUP>Divis&atilde;o de Imunol
ogia Cl&iacute;nica, Departamento de Cl&iacute;nica M&eacute;dica, Faculdade de 
Medicina de Ribeir&atilde;o Preto, Universidade de S&atilde;o Paulo, Ribeir&atil
de;o Preto, SP, Brasil</font>       ^cY#6542.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019000070002000900260#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#9#5#article#85#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#6542.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#10#6#article#85#<BR>   <A HREF="#Introdu
ction"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6542.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#11#7#article#85#<BR>   <A HREF="#Materia
l"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Subjects and Methods</strong></A>    ^
cY#6542.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704017200071002000900243#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#12#8#article#85#<BR>   <A HREF="#Results
"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6542.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018100071002000900252#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#13#9#article#85#<BR>   <A HREF="#Discuss
ion"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#654
2.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#14#10#article#85#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6542.htm##
00436000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704020900072002000900281#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#15#11#article#85#<br>   </strong></A><A 
HREF="#Acknowledgments"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#6542.htm##
00445000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021800072002000900290#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#16#12#article#85#<BR>   <A HREF="#Corres
pondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#6542.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#17#13#article#85#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6542.htm##
00545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031800072002000900390#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#18#14#article#85#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif"> </font>      ^cY#6542.htm##
01885000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704165800072002000901730#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#19#15#article#85#<P><font face="Arial, H
elvetica, sans-serif">The objective of the present study was to evaluate the pro
duction of cytokines, interferon-<font face="Symbol">g</font> (INF-<font face="S
ymbol">g</font>) and interleukin-10 (IL-10), in cultures of peripheral blood mon
onuclear cells (PBMC) from type 1 and type 2 diabetic patients and to correlate 
it with inadequate and adequate metabolic control. We studied 11 type 1 and 13 t
ype 2 diabetic patients and 21 healthy individuals divided into two groups (N = 
11 and 10) paired by sex and age with type 1 and type 2 diabetic patients. The P
BMC cultures were stimulated with concanavalin-A to measure INF-<font face="Symb
ol">g</font> and IL-10 supernatant concentration by ELISA. For patients with ina
dequate metabolic control, the cultures were performed on the first day of hospi
talization and again after intensive treatment to achieve adequate control. INF-
<font face="Symbol">g</font> levels in the supernatants of type 1 diabetic patie
nt cultures were higher compared to type 2 diabetic patients with adequate metab
olic control (P &lt; 0.001). Additionally, INF-<font face="Symbol">g</font> and 
IL-10 tended to increase the liberation of PBMC from type 1 and 2 diabetic patie
nts with adequate metabolic control (P = 0.009 and 0.09, respectively). The incr
eased levels of INF-<font face="Symbol">g</font> and IL-10 released from PBMC of
 type 1 and 2 diabetic patients with adequate metabolic control suggest that dia
betic control improves the capacity of activation and maintenance of the immune 
response, reducing the susceptibility to infections. </font>   <font face="Arial
, Helvetica, sans-serif">      ^cY#6542.htm##
00443000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021600072002000900288#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#20#16#article#85#<P><B>Key words: </B> T
ype 1 diabetes mellitus, Type 2 diabetes mellitus, Cytokines, Interferon-<font f
ace="Symbol">g</font>, Interleukin-10, Metabolic control     </font>  <HR ALIGN=
LEFT WIDTH=100% SIZE=2>      ^cY#6542.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038600072002000900458#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#21#17#article#85#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Introduction</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-se
rif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gi
f" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font fac
e="Arial, Helvetica, sans-serif">      ^cY#6542.htm##
01128000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704090100072002000900973#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#22#18#article#85#<P>Cytokines are produc
ed in response to infection with microorganisms or other antigens and are known 
to be important immune modulators in host defense against aggressors (1). They a
lso regulate cell functions in other systems, being implicated in the developmen
t of chronic complications of diabetes mellitus, which involve neurological and 
vascular processes (2,3). Chronic hyperglycemia, more specifically due to the in
crease of glycated proteins, can stimulate the production of cytokines (2) invol
ved in the activation of the immune system. The duration and metabolic control o
f diabetes mellitus seem to be important for the onset and progression of these 
complications (4-6). Besides vascular and neurological complications, a high sus
ceptibility to infection has been described in diabetic patients (7-14), which m
ay be caused by several defects of the immunological defense system.      ^cY#65
42.htm##
00851000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704062400072002000900696#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#23#19#article#85#<P>Impairment of polymo
rphonuclear leukocyte phagocytosis and reduction in granulocyte phagocytic capac
ity have been reported with the increase of plasma glucose concentration in diab
etic patients, and these abnormalities are reversed after insulin therapy (15-20
). The most dramatic defect that occurs in diabetes mellitus is related to abnor
malities of T cell function (21,22). The reason for these alterations in the imm
une cellular behavior of diabetic patients is still undefined, with few studies 
of lymphocyte proliferation and none regarding the influence of metabolic contro
l in diabetic patients. </font>      ^cY#6542.htm##
01544000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704131700072002000901389#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#24#20#article#85#<P><font face="Arial, H
elvetica, sans-serif">Therefore, it seems important to determine the immune cell
ular behavior of diabetic patients focusing on T cell functionality with the obj
ective to study the mechanisms that determine high susceptibility to infections 
in these patients. A high frequency of cutaneous dermatophytosis has been observ
ed (23) in diabetic patients under inadequate metabolic control, suggesting that
 metabolic control is an important tool in the defense against these infections.
 In a previous study, we observed increased proliferation capacity of type 1 dia
betic T lymphocytes (24) and a tendency towards increased tumor necrosis factor-
<font face="Symbol">a</font> and interleukin-6 (IL-6) levels after metabolic con
trol of type 1 and 2 diabetic patients, suggesting that the control of diabetes 
improves the capacity of activation and maintenance of the pro-inflammatory immu
ne response (25). On this basis, in the present investigation we studied the pro
duction of the cytokines interferon-<font face="Symbol">g</font> (IFN-<font face
="Symbol">g</font>) and IL-10 in cultures of peripheral blood mononuclear cells 
(PBMC) from type 1 and type 2 diabetic patients in order to correlate it with in
adequate and adequate metabolic control. </font>   <HR ALIGN=LEFT WIDTH=100% SIZ
E=2>      ^cY#6542.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039000072002000900462#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#25#21#article#85#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Subjects and Methods</B></FONT></FONT></font> <font face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font
 face="Arial, Helvetica, sans-serif">      ^cY#6542.htm##
01698000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704147100072002000901543#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#26#22#article#85#<P>Twenty-four diabetic
 patients were selected from the Outpatient Clinics of the University Hospital o
f the Medical School of Ribeir&atilde;o Preto, USP, Ribeir&atilde;o Preto, SP, B
razil (<a href="#Tab1">Table 1</a>). We also studied 21 healthy individuals pair
ed for sex, age and body mass index with type 1 and type 2 diabetic patients. Th
e patients presented inadequate metabolic control (fasting glucose higher than 2
00 mg/dL and glycated hemoglobin higher than 11%), but did not present any infec
tious disease or were using any drugs that might interfere with the results. The
 patients were hospitalized for 2-3 weeks to obtain adequate metabolic control b
y using an intensive protocol with capillary blood glucose measurements at 7, 11
, 17, and 23 h, and regular administration of insulin injections until a reducti
on of at least 100 mg/dL in mean daily glycemic level was reached. In addition t
o the neurological examination, the presence of microvascular complications was 
evaluated by ophthalmologic examination and urine protein measurement and the pr
esence of macrovascular complications by clinical and electrocardiographic evalu
ation. BMI was calculated as weight (kg)/height (m)<SUP>2</SUP>. The protocol wa
s approved by the Ethics Committee of the University Hospital (FMRP, USP) and th
e volunteers were carefully informed about the nature, purpose and possible risk
s of the study before giving written informed consent to participate.  </font>  
    ^cY#6542.htm##
01584000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704135700072002000901429#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#27#23#article#85#<P><font face="Arial, H
elvetica, sans-serif">Blood samples were obtained on the first and last days of 
hospitalization. Further blood samples were obtained for the measurement of glyc
ated hemoglobin (Labtest Diagn&oacute;stica, Lagoa Santa, MG, Brazil) (20). PBMC
 were isolated by gradient density using Ficoll-Hypaque<SUP>&#174;</SUP> (26). P
BMC at the concentration of 2.5 x 10<SUP>6</SUP> cells/mL were cultivated in tri
plicate in the presence or absence of concanavalin-A. After a 72-h culture at 37
&#186;C in a humid environment with approximately 5% CO<SUB>2</SUB>, the superna
tant was collected for cytokine measurements. IL-10 and IFN-<font face="Symbol">
g</font> were assayed in cell culture supernatants by ELISA. Monoclonal anti-hum
an IL-10 and IFN-<font face="Symbol">g</font> antibody (Pharmingen International
, San Diego, CA, USA) was used as capture antibody and biotinylated anti-human I
L-10 and IFN-<font face="Symbol">g</font> (Pharmingen) as the detecting antibody
. Binding was determined with peroxidase-labeled streptavidin (DAKO, Glostrup, D
enmark) and O-phenylenediamine-2HCl/substrate (Sigma, St. Louis, MO, USA). The i
ntra- and interassay variation was below 10%. The ELISA detection limits were 0.
07 pg/mL for INF-<font face="Symbol">g</font> and 0.03 pg/mL for IL-10. </font> 
  <font face="Arial, Helvetica, sans-serif">      ^cY#6542.htm##
00760000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053300072002000900605#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#28#24#article#85#<P>Data are reported as
 median, mean and standard deviation. The GraphPad Prism program (San Diego, CA,
 USA) was used for statistical analysis. The Kruskal-Wallis test was used to ana
lyze differences between the three groups (type 1 and type 2 patients, and contr
ols), and the Wilcoxon test was used to compare the diabetic groups before and a
fter metabolic control. The Spearman test was used to calculate all correlations
. A P value &lt;0.05 was considered to be significant.    </font>  <HR ALIGN=LEF
T WIDTH=100% SIZE=2>      ^cY#6542.htm##
00603000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037600072002000900448#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#29#25#article#85#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT SIZE=4><FONT COLOR=#00007F><B>
Results</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"><A HR
EF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font face="Arial, 
Helvetica, sans-serif">      ^cY#6542.htm##
00833000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060600072002000900678#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#30#26#article#85#<P>The four groups stud
ied, i.e., type 1 and type 2 diabetic patients and healthy individuals, were sta
tistically similar in age, sex and body mass index (<a href="#Tab1">Table 1</a>)
. The patients did not present chronic macro- or microvascular or neurological c
omplications. The metabolic control evaluated by the daily mean glycemic profile
 during the hospitalization period showed a significant improvement with treatme
nt between the first and last days of hospitalization in type 1 and type 2 diabe
tic patients (P = 0.0002 and P = 0.0001, respectively; <a href="#Fig1">Figure 1<
/a>). </font>      ^cY#6542.htm##
01787000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704156000072002000901632#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#31#27#article#85#<P><font face="Arial, H
elvetica, sans-serif">IFN-<font face="Symbol">g</font> levels were higher in the
 supernatants of stimulated cultures from type 1 diabetic patients compared to t
ype 2 diabetic patients, both with adequate metabolic control (P &lt; 0.001; <a 
href="#Fig2">Figure 2</a>). Additionally, the improvement of metabolic control i
ncreased the concentrations of IFN-<font face="Symbol">g</font> in the stimulate
d culture supernatants of type 1 diabetic patients when compared to type 1 diabe
tic patients with inadequate metabolic control (P = 0.009; <a href="#Fig2">Figur
e 2</a>). However, metabolic control did not influence the IFN-<font face="Symbo
l">g</font> production by PBMC of type 2 diabetic patients. In contrast, IL-10 l
evels were similar in the supernatants of cultures from type 1 and 2 diabetic pa
tients with inadequate and adequate metabolic control compared with their respec
tive paired control groups. However, this cytokine showed a nonsignificant incre
ase in the supernatants of type 2 diabetic patient cultures with adequate metabo
lic control compared to the respective normal control group (P = 0.09; <a href="
#Fig3">Figure 3</a>).       </font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <font f
ace="Arial, Helvetica, sans-serif"></font>  <table width="100%"  border="0">    
<tr align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr
/v40n5/html/6542i01.htm"><img src="/img/revistas/bjmbr/v40n5/6542i01peq.jpg" bor
der="2"></a></td>      <td width="87%"><font face="Arial, Helvetica, sans-serif"
>            ^cY#6542.htm##
00657000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043000072002000900502#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#32#28#article#85#<P><a name="Fig1"></a>F
igure 1<B>.</B> Daily mean glucose levels of type 1 and type 2 diabetic patients
 on the first (sample 1, S1) and last (sample 2, S2) days of hospitalization. Th
ere was a significant reduction in the daily mean blood glucose levels in both t
ype 1 and 2 diabetic groups. The Student <I>t</I>-test was used. The horizontal 
lines indicate the mean for each group.       </font></td>    </tr>  </table>   
   ^cY#6542.htm##
01390000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704116300072002000901235#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#33#29#article#85#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (50 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
0n5/html/6542i02.htm"><img src="/img/revistas/bjmbr/v40n5/6542i02peq.jpg" border
="2"></a></td>           <td width="87%"><font face="Arial, Helvetica, sans-seri
f"><a name="Fig2"></a>Figure        2<B>. </B>INF-<font face="Symbol">g</font> l
evels in culture supernatants        of peripheral blood mononuclear cells from 
type 1 and 2 diabetic patients        having inadequate (NA) or adequate (A) met
abolic control and normal individuals        (control 1 (C1) and control 2 (C2) 
paired by sex and age with type 1 and        2 diabetic patients, respectively).
 INF-<font face="Symbol">g</font> levels        were higher in the A type 1 diab
etic group compared to the A type 2 and        NA type 1 diabetic groups (P &lt;
 0.001 and 0.009, respectively; Kruskal-Wallis        and Wilcoxon tests). The h
orizontal lines indicate the median for each group.        </font></td>    </tr>
  </table>      ^cY#6542.htm##
00662000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043500072002000900507#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#34#30#article#85#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (48 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
0n5/html/6542i03.htm"><img src="/img/revistas/bjmbr/v40n5/6542i03peq.jpg" border
="2"></a></td>      <td width="87%"><font face="Arial, Helvetica, sans-serif">  
        ^cY#6542.htm##
00837000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704061000072002000900682#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#35#31#article#85#<P><a name="Fig3"></a>F
igure 3. IL-10 levels in culture supernatants of peripheral blood mononuclear ce
lls (PBMC) from type 1 and 2 diabetic patients having inadequate (NA) or adequat
e (A) metabolic control and normal individuals (control 1 (C1) and control 2 (C2
) paired by sex and age with type 1 and 2 diabetic patients, respectively). The 
increase in IL-10 levels in the PBMC culture supernatants of A type 2 diabetic p
atients compared to C2 was not statistically significant (P = 0.09; Kruskal-Wall
is test). The horizontal lines indicate the median for each group.</font></td>  
  </tr>  </table>      ^cY#6542.htm##
00831000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060400072002000900676#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#36#32#article#85#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (39 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
0n5/html/6542t01.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2">
</a></td>      <td width="87%"><font face="Arial, Helvetica, sans-serif"><a name
="Tab1"></a>Table 1. Characteristics of type 1 and type 2 diabetic patients and 
healthy individuals paired with type 1 and type 2 patients. </font></td>    </tr
>  </table>      ^cY#6542.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011800072002000900190#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#37#33#article#85#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (110 K JPG file)]</font
></P>      ^cY#6542.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#38#34#article#85#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6542.htm##
00541000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031400072002000900386#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#39#35#article#85#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <
font face="Arial, Helvetica, sans-serif">      ^cY#6542.htm##
00702000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047500072002000900547#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#40#36#article#85#<P>Hyperglycemia is con
sidered to have a negative influence on immune-competent cells, a hypothesis sup
ported by the evidence of improvement in the immune-cellular response of diabeti
c patients after metabolic control (27). However, the insulinopenic state may be
 the reason for these immunological defects (28). Current studies (29,30) sugges
t an anti-inflammatory effect of insulin even in situations of acute compensatio
n of hyperglycemic metabolic disturbances.      ^cY#6542.htm##
00653000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704042600072002000900498#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#41#37#article#85#<P>Plasma levels of cyt
okines in type 1 diabetic patients can be different from those of non-diabetic p
atients (31,32), but it is well known that the plasma concentrations of cytokine
s suffer interference from many factors and can be produced by several types of 
cells. Thus, we used PBMC cultures to evaluate cells of the immunological system
, focusing on the susceptibility to infections of these patients. </font>      ^
cY#6542.htm##
01553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704132600072002000901398#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#42#38#article#85#<P><font face="Arial, H
elvetica, sans-serif">IFN-<font face="Symbol">g</font> is an important cytokine 
involved in the immunological defense against intracellular microorganisms which
 determines a Th1 pattern of the adaptive immune response. According to Faresj&o
uml; et al. (33), IFN-<font face="Symbol">g</font> levels are increased in the s
upernatants of PBMC cultures from type 1 diabetic patients during the first mont
h after the diagnosis. In the present investigation, we studied type 1 diabetic 
patients several years after diagnosis and we observed increased levels of IFN-<
font face="Symbol">g</font> in comparison to type 2 diabetic patients. This sugg
ests that the immunological characteristics observed in early stages of this typ
e of diabetes may further persist. Finally, it cannot be excluded that "hypergly
cemic memory" confounds the relationship between cell function and concomitant b
lood glucose concentration, i.e., hyperglycemia-induced changes in gene expressi
on and biological reactions such as advanced glycation-end products in long-live
d macromolecules may not be reversed when glycemia returns to normal, so that po
or control is progressively "imprinted" on the cells (34), resulting in impairme
nt of cellular immune activity. </font>   <font face="Arial, Helvetica, sans-ser
if">  </font>      ^cY#6542.htm##
01233000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704100600072002000901078#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#43#39#article#85#<P><font face="Arial, H
elvetica, sans-serif">Furthermore, metabolic control increased IFN-g concentrati
on in the supernatants of cell cultures from type 1 diabetic patients, showing t
hat an adequate metabolic control may positively influence lymphocyte activity. 
This increase in lymphocyte activity may have implications not only in the immun
ological defense against infection but also in the pathological process of type 
1 diabetes mellitus, suggesting that adequate metabolic control might stimulate 
the pancreatic injury in earlier stages of this disease. In contrast, metabolic 
control did not influence the production of this cytokine in type 2 diabetic pat
ients despite the lower IFN-<font face="Symbol">g</font> levels in the type 2 di
abetic groups compared to the normal paired control group. These data may be ass
ociated with an immunological defect originating from the chronic disease and th
e older age of type 2 diabetic patients. </font>   <font face="Arial, Helvetica,
 sans-serif">      ^cY#6542.htm##
00779000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704055200072002000900624#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#44#40#article#85#<P>Traditionally, IL-10
 is an anti-inflammatory cytokine that can regulate the Th1 pattern of the cellu
lar immune response, but the biological activity of this cytokine seems to be mo
re complex and there is evidence of a pro-inflammatory effect (35-37). In agreem
ent with Geerlings et al. (38), we did not find significant differences in PBMC 
production of IL-10 between our diabetic and normal individuals, but we observed
 a tendency to an increase in IL-10 levels in type 2 diabetic patients after the
y obtained adequate metabolic control.       ^cY#6542.htm##
00817000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704059000072002000900662#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#45#41#article#85#<P>The increased supern
atant levels of IFN-<font face="Symbol">g</font>  in PBMC cultures from type 1 d
iabetic patients with adequate metabolic control suggest a pattern of inflammato
ry response in patients with good metabolic control. Additionally, the tendency 
to an increase in supernatant IL-10 levels in type 2 diabetic patients with adeq
uate metabolic control suggests that the control of diabetes improves the capaci
ty of activation and maintenance of the immune response, probably diminishing th
e susceptibility to infections.    </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>   
   ^cY#6542.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038200072002000900454#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#46#42#article#85#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>References</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"
><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font face="A
rial, Helvetica, sans-serif">      ^cY#6542.htm##
00409000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016800074002000900242#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#47#43#article#85#1#<P>1. Cur
fs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources, receptors
, effects, and inducers. <I>Clin Microbiol Rev</I> 1997; 10: 742-780.      ^cY#6
542.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020900074002000900283#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#48#44#article#85#2#<P>2. Vla
ssara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-
1 induced by glucose-modified proteins: role in normal tissue remodeling. <I>Sci
ence</I> 1988; 240: 1546-1548.      ^cY#6542.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019600074002000900270#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#49#45#article#85#3#<P>3. Sha
nmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proi
nflammatory cytokine and chemokine genes in monocytic cells. <I>Diabetes</I> 200
3; 52: 1256-1264.      ^cY#6542.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026400074002000900338#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#50#46#article#85#4#<P>4. The
 effect of intensive treatment of diabetes on the development and progression of
 long-term complications in insulin-dependent diabetes mellitus. The Diabetes Co
ntrol and Complications Trial Research Group. <I>N Engl J Med</I> 1993; 329: 977
-986.      ^cY#6542.htm##
00506000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026500074002000900339#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#51#47#article#85#5#<P>5. Int
ensive blood-glucose control with sulphonylureas or insulin compared with conven
tional treatment and risk of complications in patients with type 2 diabetes (UKP
DS 33). UK Prospective Diabetes Study (UKPDS) Group. <I>Lancet</I> 1998; 352: 83
7-853.      ^cY#6542.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022400074002000900298#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#52#48#article#85#6#<P>6. Eff
ect of intensive blood-glucose control with metformin on complications in overwe
ight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UK
PDS) Group. <I>Lancet</I> 1998; 352: 854-865.      ^cY#6542.htm##
00392000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015100074002000900225#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#53#49#article#85#7#<P>7. Jos
hi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes
 mellitus. <I>N Engl J Med</I> 1999; 341: 1906-1912.      ^cY#6542.htm##
00383000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704014200074002000900216#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#54#50#article#85#8#<P>8. Sha
h BR, Hux JE. Quantifying the risk of infectious diseases for people with diabet
es. <I>Diabetes Care</I> 2003; 26: 510-513.      ^cY#6542.htm##
00427000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018600074002000900260#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#55#51#article#85#9#<P>9. Ben
field T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on
 infectious disease hospitalisation and outcome. <I>Diabetologia</I> 2007; 50: 5
49-554.      ^cY#6542.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022900075002000900304#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#56#52#article#85#10#<P>10. L
eibovici L, Yehezkelli Y, Porter A, Regev A, Krauze I, Harell D. Influence of di
abetes mellitus and glycaemic control on the characteristics and outcome of comm
on infections. <I>Diabet Med</I> 1996; 13: 457-463.      ^cY#6542.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021800075002000900293#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#57#53#article#85#11#<P>11. G
olden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control
 and the risk of infectious complications in a cohort of adults with diabetes. <
I>Diabetes Care</I> 1999; 22: 1408-1414.      ^cY#6542.htm##
00410000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016800075002000900243#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#58#54#article#85#12#<P>12. T
abor CA, Parlette EC. Cutaneous manifestations of diabetes. Signs of poor glycem
ic control or new-onset disease. <I>Postgrad Med</I> 2006; 119: 38-44.      ^cY#
6542.htm##
00395000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015300075002000900228#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#59#55#article#85#13#<P>13. S
zalai G, Fellegi V, Szabo Z, Vitez LC. Mucormycosis mimicks sinusitis in a diabe
tic adult. <I>Ann N Y Acad Sci</I> 2006; 1084: 520-530.      ^cY#6542.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021800075002000900293#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#60#56#article#85#14#<P>14. R
odrigues DC, Taba MJ, Novaes AB, Souza SL, Grisi MF. Effect of non-surgical peri
odontal therapy on glycemic control in patients with type 2 diabetes mellitus. <
I>J Periodontol</I> 2003; 74: 1361-1367.      ^cY#6542.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017800075002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#61#57#article#85#15#<P>15. B
ybee JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obta
ined from patients with diabetes mellitus. <I>J Lab Clin Med</I> 1964; 64: 1-13.
      ^cY#6542.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017900075002000900254#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#62#58#article#85#16#<P>16. B
agdade JD, Nielson KL, Bulger RJ. Reversible abnormalities in phagocytic functio
n in poorly controlled diabetic patients. <I>Am J Med Sci</I> 1972; 263: 451-456
.      ^cY#6542.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023000075002000900305#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#63#59#article#85#17#<P>17. S
tevens DL, Bryant AE, Huffman J, Thompson K, Allen RC. Analysis of circulating p
hagocyte activity measured by whole blood luminescence: correlations with clinic
al status. <I>J Infect Dis</I> 1994; 170: 1463-1472.      ^cY#6542.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025000075002000900325#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#64#60#article#85#18#<P>18. S
aeed FA, Castle GE. Neutrophil chemiluminescence during phagocytosis is inhibite
d by abnormally elevated levels of acetoacetate: implications for diabetic susce
ptibility to infections. <I>Clin Diagn Lab Immunol</I> 1998; 5: 740-743.      ^c
Y#6542.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023300075002000900308#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#65#61#article#85#19#<P>19. G
allacher SJ, Thomson G, Fraser WD, Fisher BM, Gemmell CG, MacCuish AC. Neutrophi
l bactericidal function in diabetes mellitus: evidence for association with bloo
d glucose control. <I>Diabet Med</I> 1995; 12: 916-920.      ^cY#6542.htm##
00415000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017300075002000900248#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#66#62#article#85#20#<P>20. D
elamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired l
eucocyte functions in diabetic patients. <I>Diabet Med</I> 1997; 14: 29-34.     
 ^cY#6542.htm##
00397000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015500075002000900230#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#67#63#article#85#21#<P>21. D
olkart RE, Halpern B, Perlman J. Comparison of antibody responses in normal and 
alloxan diabetic mice. <I>Diabetes</I> 1971; 20: 162-167.      ^cY#6542.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027100075002000900346#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#68#64#article#85#22#<P>22. M
ahmoud AA, Rodman HM, Mandel MA, Warren KS. Induced and spontaneous diabetes mel
litus and suppression of cell-mediated immunologic responses. Granuloma formatio
n, delayed dermal reactivity and allograft rejection. <I>J Clin Invest</I> 1976;
 57: 362-367.      ^cY#6542.htm##
00407000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016500075002000900240#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#69#65#article#85#23#<P>23. F
oss NT, Polon DP, Takada MH, Foss-Freitas MC, Foss MC. Skin lesions in diabetic 
patients. <I>Rev Sa&uacute;de P&uacute;blica</I> 2005; 39: 677-682.      ^cY#654
2.htm##
00497000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025500075002000900330#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#70#66#article#85#24#<P>24. F
oss-Freitas MC, Foss NT, Donadi EA, Foss MC. Effect of metabolic control on the 
<I>in vitro</I> proliferation of peripheral blood mononuclear cells in type 1 an
d type 2 diabetic patients. <I>S&atilde;o Paulo Med J </I>2006; 124: 219-222.   
   ^cY#6542.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029500075002000900370#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#71#67#article#85#25#<P>25. F
oss-Freitas MC, Foss NT, Donadi EA, Foss MC. <I>In vitro</I> TNF-alpha and IL-6 
production by adherent peripheral blood mononuclear cells obtained from type 1 a
nd type 2 diabetic patients evaluated according to the metabolic control. <I>Ann
 NY Acad Sci</I> 2006; 1079: 177-180.      ^cY#6542.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028000075002000900355#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#72#68#article#85#26#<P>26. F
oss NT, de Oliveira EB, Silva CL. Correlation between TNF production, increase o
f plasma C-reactive protein level and suppression of T lymphocyte response to co
ncanavalin A during erythema nodosum leprosum. <I>Int J Lepr Other Mycobact Dis<
/I> 1993; 61: 218-226.      ^cY#6542.htm##
00399000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015700075002000900232#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#73#69#article#85#27#<P>27. G
eerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus
 (DM). <I>FEMS Immunol Med Microbiol</I> 1999; 26: 259-265.      ^cY#6542.htm##
00520000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027800075002000900353#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#74#70#article#85#28#<P>28. M
outschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes melli
tus: analysis of the factors and mechanisms involved. Relevance to the increased
 susceptibility of diabetic patients to specific infections. <I>Diabete Metab</I
> 1992; 18: 187-201.      ^cY#6542.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024100075002000900316#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#75#71#article#85#29#<P>29. S
tentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, marker
s of cardiovascular risks, oxidative stress, and lipid peroxidation in patients 
with hyperglycemic crises. <I>Diabetes</I> 2004; 53: 2079-2086.      ^cY#6542.ht
m##
00417000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017500075002000900250#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#76#72#article#85#30#<P>30. D
andona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atheroge
nic effect of insulin: a new paradigm. <I>Diabetologia</I> 2002; 45: 924-930.   
   ^cY#6542.htm##
00422000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018000075002000900255#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#77#73#article#85#31#<P>31. F
oss MC, Foss NT, Paccola GM, Silva CL. Serum levels of tumor necrosis factor in 
insulin-dependent diabetic patients. <I>Braz J Med Biol Res</I> 1992; 25: 239-24
2.      ^cY#6542.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022800075002000900303#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#78#74#article#85#32#<P>32. M
ysliwska J, Zorena K, Bakowska A, Skuratowicz-Kubica A, Mysliwski A. Significanc
e of tumor necrosis factor alpha in patients with long-standing type-I diabetes 
mellitus. <I>Horm Metab Res</I> 1998; 30: 158-161.      ^cY#6542.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020000075002000900275#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#79#75#article#85#33#<P>33. K
arlsson Faresjo MG, Ernerudh J, Ludvigsson J. Cytokine profile in children durin
g the first 3 months after the diagnosis of type 1 diabetes. <I>Scand J Immunol<
/I> 2004; 59: 517-526.      ^cY#6542.htm##
00398000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015600075002000900231#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#80#76#article#85#34#<P>34. L
orenzi M. Glucose toxicity in the vascular complications of diabetes: the cellul
ar perspective. <I>Diabetes Metab Rev</I> 1992; 8: 85-103.      ^cY#6542.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022700075002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#81#77#article#85#35#<P>35. M
ocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship
 between IL-10 and adaptive immunity: putting together the pieces of a puzzle. <
I>Cytokine Growth Factor Rev</I> 2004; 15: 61-76.      ^cY#6542.htm##
00444000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020200075002000900277#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#82#78#article#85#36#<P>36. L
anger JA, Cutrone EC, Kotenko S. The class II cytokine receptor (CRF2) family: o
verview and patterns of receptor-ligand interactions. <I>Cytokine Growth Factor 
Rev</I> 2004; 15: 33-48.      ^cY#6542.htm##
00521000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027900075002000900354#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#83#79#article#85#37#<P>37. T
iittanen M, Huupponen JT, Knip M, Vaarala O. Insulin treatment in patients with 
type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral 
blood mononuclear cells stimulated with insulin <I>in vitro</I>. <I>Diabetes</I>
 2006; 55: 3446-3454.      ^cY#6542.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#p#84#80#article#85#38#<P>38. G
eerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI. Cytok
ine secretion is impaired in women with diabetes mellitus. <I>Eur J Clin Invest<
/I> 2000; 30: 995-1001.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#654
2.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040100072002000900473#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#85#81#article#85#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=#00
007F><B>Acknowledgments</B></FONT></FONT></font> <font face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></font>
</P>  <font face="Arial, Helvetica, sans-serif">      ^cY#6542.htm##
00412000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018500072002000900257#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#86#82#article#85#<P>The authors are grat
eful to Maria Aparecida Nunes Ferreira and Sebasti&atilde;o L. Brand&atilde;o Fi
lho for technical assistance. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^c
Y#6542.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034800072002000900420#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#87#83#article#85#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      
 ^cY#6542.htm##
00642000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041500072002000900487#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#88#84#article#85#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/rec
or.gif" border="0"></a>    Address for correspondence:</b> M.C. Foss, Departamen
to de Cl&iacute;nica M&eacute;dica,    FMRP, USP, Av. Bandeirantes, 3900, 14049-
900 Ribeir&atilde;o Preto, SP, Brasil.    Fax: +55-16-3633-6695. E-mail: <a href
="mailto:mcfoss@fmrp.usp.br">mcfoss@fmrp.usp.br</a></font></p>      ^cY#6542.htm
##
00373000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014600072002000900218#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6542.htm#S#p#89#85#article#85#<P><font face="Arial, H
elvetica, sans-serif">Publication supported by FAPESP. Received July 1, 2006. Ac
cepted February 27, 2007. </font>      ^cY#6542.htm##
00583000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100015000890100
02900104012006900133030001900202065000900221064000500230031000300235014000800238
865000900246002000900255035001000264801001900274#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#90#1#article#38#1#^rND^sCurfs^nJH#^rND^sMeis^nJF#^rND^sH
oogkamp-Korstanje^nJA#A primer on cytokines: sources, receptors, effects, and in
ducers^len#Clin Microbiol Rev#19970000#1997#10#742-780#20070500#6542.htm#0893-85
12#Clin Microbiol Rev##
00649000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100018000910100
01800109010002000127010001800147012009800165030000800263065000900271064000500280
031000400285014001000289865000900299002000900308035001000317801000800327#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#91#2#article#38#2#^rND^sVlassara
^nH#^rND^sBrownlee^nM#^rND^sManogue^nKR#^rND^sDinarello^nCA#^rND^sPasagian^nA#Ca
chectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue
 remodeling^len#Science#19880000#1988#240#1546-1548#20070500#6542.htm#0036-8075#
Science##
00619000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100016000920100
01400108010001900122012010300141030000900244065000900253064000500262031000300267
014001000270865000900280002000900289035001000298801000900308#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#92#3#article#38#3#^rND^sShanmugam^nN#^rND^sR
eddy^nMA#^rND^sGuha^nM#^rND^sNatarajan^nR#High glucose-induced expression of pro
inflammatory cytokine and chemokine genes in monocytic cells^len#Diabetes#200300
00#2003#52#1256-1264#20070500#6542.htm#0012-1797#Diabetes##
00637000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100154000730120064002270300
01300291065000900304064000500313031000400318014000800322865000900330002000900339
035001000348801001300358#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#
93#4#article#38#4#^rND^sThe^neffect of intensive treatment of diabetes on the de
velopment and progression of long-term complications in insulin-dependent diabet
es mellitus#The Diabetes Control and Complications Trial Research Group^len#N En
gl J Med#19930000#1993#329#977-986#20070500#6542.htm#0028-4793#N Engl J Med##
00626000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710120175000730110044002480300
00700292065000900299064000500308031000400313014000800317865000900325002000900334
035001000343801000700353#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#
94#5#article#38#5#Intensive blood-glucose control with sulphonylureas or insulin
 compared with conventional treatment and risk of complications in patients with
 type 2 diabetes (UKPDS 33).^len#UK Prospective Diabetes Study (UKPDS) Group#Lan
cet#19980000#1998#352#837-853#20070500#6542.htm#0099-5355#Lancet##
00585000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710120134000730110044002070300
00700251065000900258064000500267031000400272014000800276865000900284002000900293
035001000302801000700312#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#
95#6#article#38#6#Effect of intensive blood-glucose control with metformin on co
mplications in overweight patients with type 2 diabetes (UKPDS 34).^len#UK Prosp
ective Diabetes Study (UKPDS) Group#Lancet#19980000#1998#352#854-865#20070500#65
42.htm#0099-5355#Lancet##
00578000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100017000880100
02000105010001900125012005000144030001300194065000900207064000500216031000400221
014001000225865000900235002000900244035001000253801001300263#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#96#7#article#38#7#^rND^sJoshi^nN#^rND^sCaput
o^nGM#^rND^sWeitekamp^nMR#^rND^sKarchmer^nAW#Infections in patients with diabete
s mellitus^len#N Engl J Med#19990000#1999#341#1906-1912#20070500#6542.htm#0028-4
793#N Engl J Med##
00534000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100014000880120
07300102030001400175065000900189064000500198031000300203014000800206865000900214
002000900223035001000232801001400242#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
542.htm#S#c#97#8#article#38#8#^rND^sShah^nBR#^rND^sHux^nJE#Quantifying the risk 
of infectious diseases for people with diabetes^len#Diabetes Care#20030000#2003#
26#510-513#20070500#6542.htm#0149-5992#Diabetes Care##
00595000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910100
02300108012009500131030001300226065000900239064000500248031000300253014000800256
865000900264002000900273035001000282801001300292#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#98#9#article#38#9#^rND^sBenfield^nT#^rND^sJensen^nJS#^rN
D^sNordestgaard^nBG#Influence of diabetes and hyperglycaemia on infectious disea
se hospitalisation and outcome^len#Diabetologia#20070000#2007#50#549-554#2007050
0#6542.htm#0012-186X#Diabetologia##
00691000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100020000940100
01600114010001500130010001600145010001600161012011300177030001100290065000900301
06400050031003100030031501400080031886500090032600200090033503500100034480100110
0354#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#99#10#article#38#10#
^rND^sLeibovici^nL#^rND^sYehezkelli^nY#^rND^sPorter^nA#^rND^sRegev^nA#^rND^sKrau
ze^nI#^rND^sHarell^nD#Influence of diabetes mellitus and glycaemic control on th
e characteristics and outcome of common infections^len#Diabet Med#19960000#1996#
13#457-463#20070500#6542.htm#0742-3071#Diabet Med##
00648000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100025000930100
01400118010001900132012011200151030001400263065000900277064000500286031000300291
014001000294865000900304002000900313035001000322801001400332#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#100#11#article#38#11#^rND^sGolden^nSH#^rND^s
Peart-Vigilance^nC#^rND^sKao^nWH#^rND^sBrancati^nFL#Perioperative glycemic contr
ol and the risk of infectious complications in a cohort of adults with diabetes^
len#Diabetes Care#19990000#1999#22#1408-1414#20070500#6542.htm#0149-5992#Diabete
s Care##
00561000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920120
09400111030001300205065000900218064000500227031000400232014000600236865000900242
002000900251035001000260801001300270#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
542.htm#S#c#101#12#article#38#12#^rND^sTabor^nCA#^rND^sParlette^nEC#Cutaneous ma
nifestations of diabetes: Signs of poor glycemic control or new-onset disease^le
n#Postgrad Med#20060000#2006#119#38-44#20070500#6542.htm#0032-5481#Postgrad Med#
#
00586000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01500109010001600124012005500140030001700195065000900212064000500221031000500226
014000800231865000900239002000900248035001000257801001700267#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#102#13#article#38#13#^rND^sSzalai^nG#^rND^sF
ellegi^nV#^rND^sSzabo^nZ#^rND^sVitez^nLC#Mucormycosis mimicks sinusitis in a dia
betic adult^len#Ann N Y Acad Sci#20060000#2006#1084#520-530#20070500#6542.htm#00
77-8923#Ann N Y Acad Sci##
00666000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100015000960100
01700111010001600128010001600144012010900160030001400269065000900283064000500292
031000300297014001000300865000900310002000900319035001000328801001400338#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#103#14#article#38#14#^rND^sRodri
gues^nDC#^rND^sTaba^nMJ#^rND^sNovaes^nAB#^rND^sSouza^nSL#^rND^sGrisi^nMF#Effect 
of non-surgical periodontal therapy on glycemic control in patients with type 2 
diabetes mellitus^len#J Periodontol#20030000#2003#74#1361-1367#20070500#6542.htm
#0022-3492#J Periodontol##
00573000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920120
10600109030001500215065000900230064000500239031000300244014000500247865000900252
002000900261035001000270801001500280#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
542.htm#S#c#104#15#article#38#15#^rND^sBybee^nJD#^rND^sRogers^nDE#The phagocytic
 activity of polymorphonuclear leukocytes obtained from patients with diabetes m
ellitus^len#J Lab Clin Med#19640000#1964#64#1-13#20070500#6542.htm#0022-2143#J L
ab Clin Med##
00590000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01700112012009100129030001300220065000900233064000500242031000400247014000800251
865000900259002000900268035001000277801001300287#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#105#16#article#38#16#^rND^sBagdade^nJD#^rND^sNielson^nKL
#^rND^sBulger^nRJ#Reversible abnormalities in phagocytic function in poorly cont
rolled diabetic patients^len#Am J Med Sci#19720000#1972#263#451-456#20070500#654
2.htm#0002-9629#Am J Med Sci##
00677000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01700111010001800128010001600146012011900162030001300281065000900294064000500303
031000400308014001000312865000900322002000900331035001000340801001300350#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#106#17#article#38#17#^rND^sSteve
ns^nDL#^rND^sBryant^nAE#^rND^sHuffman^nJ#^rND^sThompson^nK#^rND^sAllen^nRC#Analy
sis of circulating phagocyte activity measured by whole blood luminescence: corr
elations with clinical status^len#J Infect Dis#19940000#1994#170#1463-1472#20070
500#6542.htm#0022-1899#J Infect Dis##
00653000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920120
16800109030002300277065000900300064000500309031000200314014000800316865000900324
002000900333035001000342801002300352#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
542.htm#S#c#107#18#article#38#18#^rND^sSaeed^nFA#^rND^sCastle^nGE#Neutrophil che
miluminescence during phagocytosis is inhibited by abnormally elevated levels of
 acetoacetate: implications for diabetic susceptibility to infections^len#Clin D
iagn Lab Immunol#19980000#1998#5#740-743#20070500#6542.htm#1071-412X#Clin Diagn 
Lab Immunol##
00696000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01700113010001700130010001800147010001900165012011100184030001100295065000900306
06400050031503100030032001400080032386500090033100200090034003500100034980100110
0359#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#108#19#article#38#19
#^rND^sGallacher^nSJ#^rND^sThomson^nG#^rND^sFraser^nWD#^rND^sFisher^nBM#^rND^sGe
mmell^nCG#^rND^sMacCuish^nAC#Neutrophil bactericidal function in diabetes mellit
us: evidence for association with blood glucose control^len#Diabet Med#19950000#
1995#12#916-920#20070500#6542.htm#0742-3071#Diabet Med##
00636000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01600114010001800130010001800148010001700166012005400183030001100237065000900248
06400050025703100030026201400060026586500090027100200090028003500100028980100110
0299#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#109#20#article#38#20
#^rND^sDelamaire^nM#^rND^sMaugendre^nD#^rND^sMoreno^nM#^rND^sLe^nGoff MC#^rND^sA
llannic^nH#^rND^sGenetet^nB#Impaired leucocyte functions in diabetic patients^le
n#Diabet Med#19970000#1997#14#29-34#20070500#6542.htm#0742-3071#Diabet Med##
00562000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01700111012007300128030000900201065000900210064000500219031000300224014000800227
865000900235002000900244035001000253801000900263#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#110#21#article#38#21#^rND^sDolkart^nRE#^rND^sHalpern^nB#
^rND^sPerlman^nJ#Comparison of antibody responses in normal and alloxan diabetic
 mice^len#Diabetes#19710000#1971#20#162-167#20070500#6542.htm#0012-1797#Diabetes
##
00701000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01700111010001700128012017300145030001400318065000900332064000500341031000300346
014000800349865000900357002000900366035001000375801001400385#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#111#22#article#38#22#^rND^sMahmoud^nAA#^rND^
sRodman^nHM#^rND^sMandel^nMA#^rND^sWarren^nKS#Induced and spontaneous diabetes m
ellitus and suppression of cell-mediated immunologic responses: Granuloma format
ion, delayed dermal reactivity and allograft rejection^len#J Clin Invest#1976000
0#1976#57#362-367#20070500#6542.htm#0021-9738#J Clin Invest##
00565000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01700107010002300124010001500147012003800162030001800200710000200218065000900220
064000500229031000300234014000800237865000900245002000900254#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#112#23#article#38#23#^rND^sFoss^nNT#^rND^sPo
lon^nDP#^rND^sTakada^nMH#^rND^sFoss-Freitas^nMC#^rND^sFoss^nMC#Skin lesions in d
iabetic patients^len#Rev Saúde Pública#2#20050000#2005#39#677-682#20070500#6542.
htm##
00637000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100015000990100
01700114010001500131012013900146030001600285710000200301065000900303064000500312
031000400317014000800321865000900329002000900338#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#113#24#article#38#24#^rND^sFoss-Freitas^nMC#^rND^sFoss^n
NT#^rND^sDonadi^nEA#^rND^sFoss^nMC#Effect of metabolic control on the in vitro p
roliferation of peripheral blood mononuclear cells in type 1 and type 2 diabetic
 patients^len#São Paulo Med J#2#20060000#2006#124#219-222#20070500#6542.htm##
00684000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100015000990100
01700114010001500131012018500146030001600331710000200347065000900349064000500358
031000500363014000800368865000900376002000900385#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#114#25#article#38#25#^rND^sFoss-Freitas^nMC#^rND^sFoss^n
NT#^rND^sDonadi^nEA#^rND^sFoss^nMC#In vitro TNF-alpha and IL-6 production by adh
erent peripheral blood mononuclear cells obtained from type 1 and type 2 diabeti
c patients evaluated according to the metabolic control^len#Ann NY Acad Sci#2#20
060000#2006#1079#177-180#20070500#6542.htm##
00708000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100022000910100
01600113012017600129030003000305065000900335064000500344031000300349014000800352
865000900360002000900369035001000378801003000388#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#115#26#article#38#26#^rND^sFoss^nNT#^rND^sde^nOliveira E
B#^rND^sSilva^nCL#Correlation between TNF production, increase of plasma C-react
ive protein level and suppression of T lymphocyte response to concanavalin A dur
ing erythema nodosum leprosum^len#Int J Lepr Other Mycobact Dis#19930000#1993#61
#218-226#20070500#6542.htm#0148-916X#Int J Lepr Other Mycobact Dis##
00564000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100020000960120
06300116030002700179065000900206064000500215031000300220014000800223865000900231
002000900240035001000249801002700259#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
542.htm#S#c#116#27#article#38#27#^rND^sGeerlings^nSE#^rND^sHoepelman^nAI#Immune 
dysfunction in patients with diabetes mellitus (DM)^len#FEMS Immunol Med Microbi
ol#19990000#1999#26#259-265#20070500#6542.htm#0928-8244#FEMS Immunol Med Microbi
ol##
00656000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01900113012010000132030010100232710000200333065000900335064000500344031000300349
014000800352865000900360002000900369#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
542.htm#S#c#117#28#article#38#28#^rND^sMoutschen^nMP#^rND^sScheen^nAJ#^rND^sLefe
bvre^nPJ#Impaired immune responses in diabetes mellitus: analysis of the factors
 and mechanisms involved^len#Relevance to the increased susceptibility of diabet
ic patients to specific infections. Diabete Metab#2#19920000#1992#18#187-201#200
70500#6542.htm##
00666000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01600113010001900129012014300148030000900291065000900300064000500309031000300314
014001000317865000900327002000900336035001000345801000900355#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#118#29#article#38#29#^rND^sStentz^nFB#^rND^s
Umpierrez^nGE#^rND^sCuervo^nR#^rND^sKitabchi^nAE#Proinflammatory cytokines, mark
ers of cardiovascular risks, oxidative stress, and lipid peroxidation in patient
s with hyperglycemic crises^len#Diabetes#20040000#2004#53#2079-2086#20070500#654
2.htm#0012-1797#Diabetes##
00586000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01700109012009100126030001300217065000900230064000500239031000300244014000800247
865000900255002000900264035001000273801001300283#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#119#30#article#38#30#^rND^sDandona^nP#^rND^sAljada^nA#^r
ND^sMohanty^nP#The anti-inflammatory and potential anti-atherogenic effect of in
sulin: a new paradigm^len#Diabetologia#20020000#2002#45#924-930#20070500#6542.ht
m#0012-186X#Diabetologia##
00616000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
01800106010001600124012008100140030002000221065000900241064000500250031000300255
014000800258865000900266002000900275035001000284801002000294#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#120#31#article#38#31#^rND^sFoss^nMC#^rND^sFo
ss^nNT#^rND^sPaccola^nGM#^rND^sSilva^nCL#Serum levels of tumor necrosis factor i
n insulin-dependent diabetic patients^len#Braz J Med Biol Res#19920000#1992#25#2
39-242#20070500#6542.htm#0100-879X#Braz J Med Biol Res##
00677000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
01800111010002800129010001900157012010400176030001500280065000900295064000500304
031000300309014000800312865000900320002000900329035001000338801001500348#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#121#32#article#38#32#^rND^sMysli
wska^nJ#^rND^sZorena^nK#^rND^sBakowska^nA#^rND^sSkuratowicz-Kubica^nA#^rND^sMysl
iwski^nA#Significance of tumor necrosis factor alpha in patients with long-stand
ing type-I diabetes mellitus^len#Horm Metab Res#19980000#1998#30#158-161#2007050
0#6542.htm#0018-5043#Horm Metab Res##
00614000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100027000760100018001030100
02000121012009800141030001600239065000900255064000500264031000300269014000800272
865000900280002000900289035001000298801001600308#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#122#33#article#38#33#^rND^sKarlsson^nFaresjo MG#^rND^sEr
nerudh^nJ#^rND^sLudvigsson^nJ#Cytokine profile in children during the first 3 mo
nths after the diagnosis of type 1 diabetes^len#Scand J Immunol#20040000#2004#59
#517-526#20070500#6542.htm#0300-9475#Scand J Immunol##
00537000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120089000930300
01900182065000900201064000500210031000200215014000700217865000900224002000900233
035001000242801001900252#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#
123#34#article#38#34#^rND^sLorenzi^nM#Glucose toxicity in the vascular complicat
ions of diabetes: the cellular perspective^len#Diabetes Metab Rev#19920000#1992#
8#85-103#20070500#6542.htm#0742-4221#Diabetes Metab Rev##
00688000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01600113010001500129010001400144012011100158030002700269065000900296064000500305
031000300310014000600313865000900319002000900328035001000337801002700347#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#124#35#article#38#35#^rND^sMocel
lin^nS#^rND^sMarincola^nF#^rND^sRossi^nCR#^rND^sNitti^nD#^rND^sLise^nM#The multi
faceted relationship between IL-10 and adaptive immunity: putting together the p
ieces of a puzzle^len#Cytokine Growth Factor Rev#20040000#2004#15#61-76#20070500
#6542.htm#1359-6101#Cytokine Growth Factor Rev##
00627000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01700111012010400128030002700232065000900259064000500268031000300273014000600276
865000900282002000900291035001000300801002700310#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6542.htm#S#c#125#36#article#38#36#^rND^sLanger^nJA#^rND^sCutrone^nEC#
^rND^sKotenko^nS#The class II cytokine receptor (CRF2) family: overview and patt
erns of receptor-ligand interactions^len#Cytokine Growth Factor Rev#20040000#200
4#15#33-48#20070500#6542.htm#1359-6101#Cytokine Growth Factor Rev##
00697000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100020000950100
01400115010001700129012017600146030000900322065000900331064000500340031000300345
014001000348865000900358002000900367035001000376801000900386#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6542.htm#S#c#126#37#article#38#37#^rND^sTiittanen^nM#^rND
^sHuupponen^nJT#^rND^sKnip^nM#^rND^sVaarala^nO#Insulin treatment in patients wit
h type 1 diabetes induces upregulation of regulatory T-cell markers in periphera
l blood mononuclear cells stimulated with insulin in vitro^len#Diabetes#20060000
#2006#55#3446-3454#20070500#6542.htm#0012-1797#Diabetes##
00671000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100018000960100
02100114010001700135010001600152010002000168012006700188030001800255065000900273
06400050028203100030028701400090029086500090029900200090030803500100031780100180
0327#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6542.htm#S#c#127#38#article#38#38
#^rND^sGeerlings^nSE#^rND^sBrouwer^nEC#^rND^sVan^nKessel KC#^rND^sGaastra^nW#^rN
D^sStolk^nRP#^rND^sHoepelman^nAI#Cytokine secretion is impaired in women with di
abetes mellitus^len#Eur J Clin Invest#20000000#2000#30#995-1001#20070500#6542.ht
m#0014-2972#Eur J Clin Invest##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#o#1#1#article#1#20
080212#125711#6557.htm#76##
03065000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400110014003500100015122300090016101200920
01700100023002620100030002850100031003150100031003460100033003770700136004100831
62600546085000802172085003202180085002902212085002902241085002702270085002202297
08500290231911700060234807200030235405800050235705800070236211200090236911100140
2378114000902392113001702401881002402418002000902442#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6557.htm#S#h#2#1#article#1#sc#en#bjmbr#1#3.1#TAB#08#BJMBR070#nd#B
raz J Med Biol Res#40#5#20070500#^f657^l662#0100-879X#20070322#Activity of liver
 microsomal enzymes during the chronic phase of murine schistosomiasis^len#^rND^
1A01^nF.P.^sConte#^rND^1A01^nA.A.^sFidalgo-Neto#^rND^1A01^nD.A.^sManhães-Rocha#^
rND^1A01^nF.J.R.^sPaumgartten#^rND^1A01^nA.C.A.X.^sDe-Oliveira#Fundação Oswaldo 
Cruz^iA01^1Escola Nacional de Saúde Pública^2Departamento de Ciências Biológicas
^3Laboratório de Toxicologia Ambiental#^len^aThe effects of schistosomiasis on m
icrosomal enzymes were studied on post-infection day 90 when accumulated damage 
and fibrosis are most intense but granulomatous reaction around the eggs harbore
d in the liver is smaller than during the earlier phases. Swiss Webster (SW) and
 DBA/2 mice of either sex (N = 12 per sex per group) were infected with 100 Schi
stosoma mansoni cercariae on postnatal day 10 and killed on post-infection day 9
0. Cytochrome P-450 (CYP) concentration and alkoxyresorufin-O-dealkylases (EROD,
 MROD, BROD, and PROD), p-nitrophenol-hydroxylase (PNPH), coumarin-7-hydroxylase
 (COH), and UDP-glucuronosyltransferase (UGT) activities were measured in hepati
c microsomes. Age-matched mice of the same sex and strain were used as controls.
 In S. mansoni-infected mice, CYP1A- and 2B-mediated activities (control = 100%)
 were reduced in SW (EROD: male (M) 36%, female (F) 38%; MROD: M 38%, F 39%; BRO
D: M 46%, F 19%; PROD: M 50%, F 28%) and DBA/2 mice (EROD: M 64%, F 58%; MROD: M
 60%; BROD: F 49%; PROD: M 73%) while PNPH (CYP2E1) was decreased in SW (M 31%, 
F 38%) but not in DBA/2 mice. COH did not differ between infected and control DB
A/2 and UGT, a phase-2 enzyme, was not altered by infection. In conclusion, chro
nic S. mansoni infection reduced total CYP content and all CYP-mediated activiti
es evaluated in SW mice, including those catalyzed by CYP2E1 (PNPH), CYP1A (EROD
, MROD) and 2B (BROD, PROD). In DBA/2 mice, however, CYP2A5- and 2E1-mediated ac
tivities remained unchanged while total CYP content and activities mediated by o
ther CYP isoforms were depressed during chronic schistosomiasis.#^dnd^i1#^tm^len
^kSchistosoma mansoni^i1#^tm^len^kPharmacokinetics^i1#^tm^len^kCytochrome P-450^
i1#^tm^len^kMonooxygenases^i1#^tm^len^kGranuloma^i1#^tm^len^kLiver microsomes^i1
#other#20#CNPq#FAPERJ#20060711#July 11, 2006#20070131#January 31, 2007#S0100-879
X2006005000091#6557.htm##
03036000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400110014003500100015122300090016101200920
01700100023002620100030002850100031003150100031003460100033003770700136004100831
62600546085000802172085003902180085002902219085002902248085002702277085002202304
08500290232611700060235507200030236105800050236405800070236911200090237611100140
2385114000902399113001702408002000902425#v40n5#v:\scielo\serial\bjmbr\v40n5\mark
up\6557.htm#S#f#3#1#article#1#sc#en#bjmbr#1#3.1#TAB#08#BJMBR070#nd#Braz J Med Bi
ol Res#40#5#20070500#^f657^l662#0100-879X#20070322#Activity of liver microsomal 
enzymes during the chronic phase of murine schistosomiasis^len#^rND^1A01^nF.P.^s
Conte#^rND^1A01^nA.A.^sFidalgo-Neto#^rND^1A01^nD.A.^sManhães-Rocha#^rND^1A01^nF.
J.R.^sPaumgartten#^rND^1A01^nA.C.A.X.^sDe-Oliveira#Fundação Oswaldo Cruz^iA01^1E
scola Nacional de Saúde Pública^2Departamento de Ciências Biológicas^3Laboratóri
o de Toxicologia Ambiental#^len^aThe effects of schistosomiasis on microsomal en
zymes were studied on post-infection day 90 when accumulated damage and fibrosis
 are most intense but granulomatous reaction around the eggs harbored in the liv
er is smaller than during the earlier phases. Swiss Webster (SW) and DBA/2 mice 
of either sex (N = 12 per sex per group) were infected with 100 Schistosoma mans
oni cercariae on postnatal day 10 and killed on post-infection day 90. Cytochrom
e P-450 (CYP) concentration and alkoxyresorufin-O-dealkylases (EROD, MROD, BROD,
 and PROD), p-nitrophenol-hydroxylase (PNPH), coumarin-7-hydroxylase (COH), and 
UDP-glucuronosyltransferase (UGT) activities were measured in hepatic microsomes
. Age-matched mice of the same sex and strain were used as controls. In S. manso
ni-infected mice, CYP1A- and 2B-mediated activities (control = 100%) were reduce
d in SW (EROD: male (M) 36%, female (F) 38%; MROD: M 38%, F 39%; BROD: M 46%, F 
19%; PROD: M 50%, F 28%) and DBA/2 mice (EROD: M 64%, F 58%; MROD: M 60%; BROD: 
F 49%; PROD: M 73%) while PNPH (CYP2E1) was decreased in SW (M 31%, F 38%) but n
ot in DBA/2 mice. COH did not differ between infected and control DBA/2 and UGT,
 a phase-2 enzyme, was not altered by infection. In conclusion, chronic S. manso
ni infection reduced total CYP content and all CYP-mediated activities evaluated
 in SW mice, including those catalyzed by CYP2E1 (PNPH), CYP1A (EROD, MROD) and 
2B (BROD, PROD). In DBA/2 mice, however, CYP2A5- and 2E1-mediated activities rem
ained unchanged while total CYP content and activities mediated by other CYP iso
forms were depressed during chronic schistosomiasis.#^dnd^i1#^tm^len^k<i>Schisto
soma mansoni</i>^i1#^tm^len^kPharmacokinetics^i1#^tm^len^kCytochrome P-450^i1#^t
m^len^kMonooxygenases^i1#^tm^len^kGranuloma^i1#^tm^len^kLiver microsomes^i1#othe
r#20#CNPq#FAPERJ#20060711#July 11, 2006#20070131#January 31, 2007#6557.htm##
03275000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000400099121000300103049000900106158000300115
03000240011803100030014203200020014506500090014701400110015603500100016722300090
01770120092001860100023002780100030003010100031003310100032003620100035003940700
13800429083173800567085000802305085003202313085002902345085002902374085002702403
08500220243008500290245211700060248107200030248705800050249005800070249511200090
2502111001402511114000902525113001702534002000902551008008902560#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#l#4#1#article#1#^mMay^a2007#sc#en#bjmbr#1#
3.1#tab#08#BJMBR070#nd#Braz. j. med. biol. res#40#5#20070500#^f657^l662#0100-879
X#20070322#Activity of liver microsomal enzymes during the chronic phase of muri
ne schistosomiasis^len#^rND^1A01^nF. P^sConte#^rND^1A01^nA. A^sFidalgo-Neto#^rND
^1A01^nD. A^sManhães-Rocha#^rND^1A01^nF. J. R^sPaumgartten#^rND^1A01^nA. C. A. X
^sDe-Oliveira#^iA01^1Fundação Oswaldo Cruz^2Escola Nacional de Saúde Pública^3De
partamento de Ciências Biológicas. Laboratório de Toxicologia Ambiental#^len^aTh
e effects of schistosomiasis on microsomal enzymes were studied on post-infectio
n day 90 when accumulated damage and fibrosis are most intense but granulomatous
 reaction around the eggs harbored in the liver is smaller than during the earli
er phases. Swiss Webster (SW) and DBA/2 mice of either sex (N = 12 per sex per g
roup) were infected with 100 Schistosoma mansoni cercariae on postnatal day 10 a
nd killed on post-infection day 90. Cytochrome P-450 (CYP) concentration and alk
oxyresorufin-O-dealkylases (EROD, MROD, BROD, and PROD), p-nitrophenol-hydroxyla
se (PNPH), coumarin-7-hydroxylase (COH), and UDP-glucuronosyltransferase (UGT) a
ctivities were measured in hepatic microsomes. Age-matched mice of the same sex 
and strain were used as controls. In S. mansoni-infected mice, CYP1A- and 2B-med
iated activities (control = 100 percent) were reduced in SW (EROD: male (M) 36 p
ercent, female (F) 38 percent; MROD: M 38 percent, F 39 percent; BROD: M 46 perc
ent, F 19 percent; PROD: M 50 percent, F 28 percent) and DBA/2 mice (EROD: M 64 
percent, F 58 percent; MROD: M 60 percent; BROD: F 49 percent; PROD: M 73 percen
t) while PNPH (CYP2E1) was decreased in SW (M 31 percent, F 38 percent) but not 
in DBA/2 mice. COH did not differ between infected and control DBA/2 and UGT, a 
phase-2 enzyme, was not altered by infection. In conclusion, chronic S. mansoni 
infection reduced total CYP content and all CYP-mediated activities evaluated in
 SW mice, including those catalyzed by CYP2E1 (PNPH), CYP1A (EROD, MROD) and 2B 
(BROD, PROD). In DBA/2 mice, however, CYP2A5- and 2E1-mediated activities remain
ed unchanged while total CYP content and activities mediated by other CYP isofor
ms were depressed during chronic schistosomiasis.#^dnd^i1#^tm^len^kSchistosoma m
ansoni^i1#^tm^len^kPharmacokinetics^i1#^tm^len^kCytochrome P-450^i1#^tm^len^kMon
ooxygenases^i1#^tm^len^kGranuloma^i1#^tm^len^kLiver microsomes^i1#other#20#CNPq#
FAPERJ#20060711#July 11, 2006#20070131#January 31, 2007#6557.htm#Internet^ihttp:
//www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500008##
00414000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018900070002000900259#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#5#1#article#52#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 657-662</B> </font> (Short Communication)</B></P>      
^cY#6557.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018200070002000900252#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#6#2#article#52#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">Activity of liver microsomal enzymes durin
g the chronic phase of murine schistosomiasis </font></B> </font>        ^cY#655
7.htm##
00676000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704045100070002000900521#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#7#3#article#52#<P><font face="Arial, Hel
vetica, sans-serif">F.P. Conte, A.A. Fidalgo-Neto, D.A.    Manh&atilde;es-Rocha,
 F.J.R. Paumgartten and <span class="style4"><a href="#Correspondence"><img src=
"/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a href="mailto:ana.oli
veira@ensp.fiocruz.br"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border=
"0"></a></span></font>    <font face="Arial, Helvetica, sans-serif">A.C.A.X. De-
Oliveira </font>      ^cY#6557.htm##
00495000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704027000070002000900340#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#8#4#article#52#<P><font face="Arial, Hel
vetica, sans-serif">Laborat&oacute;rio de Toxicologia Ambiental, Departamento de
 Ci&ecirc;ncias Biol&oacute;gicas, Escola Nacional de Sa&uacute;de P&uacute;blic
a, Funda&ccedil;&atilde;o Oswaldo Cruz, Rio de Janeiro, RJ, Brasil</font>       
 ^cY#6557.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#9#5#article#52#<P class="style4"> <A HRE
F="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6557.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#10#6#article#52#<BR>   <A HREF="#Text"><
img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6557.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#11#7#article#52#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6557.htm##
00483000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704025700071002000900328#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#12#8#article#52#<br>  </strong></A><font
 face="Arial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><img src="/img/r
evistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HR
EF="#Acknowledgments"><strong>Acknowledgments</strong></A></font>    ^cY#6557.ht
m##
00490000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704026400071002000900335#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#13#9#article#52#<BR>   <A HREF="#Corresp
ondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font face="Arial, Helv
etica, sans-serif">Correspondence    and Footnotes</font></strong></a>      ^cY#
6557.htm##
00291000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704006400072002000900136#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#14#10#article#52#<P class="style4">  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6557.htm##
00619000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039200072002000900464#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#15#11#article#52#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <fo
nt face="Arial, Helvetica, sans-serif">      ^cY#6557.htm##
01888000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704166100072002000901733#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#16#12#article#52#<P>The effects of schis
tosomiasis on microsomal enzymes were studied on post-infection day 90 when accu
mulated damage and fibrosis are most intense but granulomatous reaction around t
he eggs harbored in the liver is smaller than during the earlier phases. Swiss W
ebster (SW) and DBA/2 mice of either sex (N = 12 per sex per group) were infecte
d with 100 <I>Schistosoma mansoni</I> cercariae on postnatal day 10 and killed o
n post-infection day 90. Cytochrome P-450 (CYP) concentration and alkoxyresorufi
n-<I>O</I>-dealkylases (EROD, MROD, BROD, and PROD), p-nitrophenol-hydroxylase (
PNPH), coumarin-7-hydroxylase (COH), and UDP-glucuronosyltransferase (UGT) activ
ities were measured in hepatic microsomes. Age-matched mice of the same sex and 
strain were used as controls. In <I>S. mansoni</I>-infected mice, CYP1A- and 2B-
mediated activities (control = 100%) were reduced in SW (EROD: male (M) 36%, fem
ale (F) 38%; MROD: M 38%, F 39%; BROD: M 46%, F 19%; PROD: M 50%, F 28%) and DBA
/2 mice (EROD: M 64%, F 58%; MROD: M 60%; BROD: F 49%; PROD: M 73%) while PNPH (
CYP2E1) was decreased in SW (M 31%, F 38%) but not in DBA/2 mice. COH did not di
ffer between infected and control DBA/2 and UGT, a phase-2 enzyme, was not alter
ed by infection. In conclusion, chronic <I>S. mansoni</I> infection reduced tota
l CYP content and all CYP-mediated activities evaluated in SW mice, including th
ose catalyzed by CYP2E1 (PNPH), CYP1A (EROD, MROD) and 2B (BROD, PROD). In DBA/2
 mice, however, CYP2A5- and 2E1-mediated activities remained unchanged while tot
al CYP content and activities mediated by other CYP isoforms were depressed duri
ng chronic schistosomiasis.       ^cY#6557.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018100072002000900253#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#17#13#article#52#<P><B>Key words: </B> <
I>Schistosoma mansoni</I>, Pharmacokinetics, Cytochrome P-450, Monooxygenases, G
ranuloma, Liver microsomes </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#65
57.htm##
00630000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040300072002000900475#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#18#14#article#52#<P class="style4"><A NA
ME="Text"></A> <span class="style3"><font color="#00007F" face="Arial, Helvetica
, sans-serif" size="4"><b>Text</b></font></span><A HREF="#Home"><FONT SIZE=4><B>
<img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0 LOOP="0"></B></FONT></A>    <font face="Arial, Helvetica, sans-serif"></fo
nt></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6557.htm##
01904000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704167700072002000901749#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#19#15#article#52#<P>It has been reported
 that activities and levels of expression of cytochrome P-450 (CYP) isoforms are
 altered by inflammatory stimuli and by a variety of infections including some h
elminthic infections. In rats and sheep, for instance, the liver fluke <I>Fascio
la hepatica</I> causes a marked depression of various CYP monooxygenases (1,2). 
In contrast to the down-regulation of most CYP isoforms, CYP2A5 was induced in m
ice infected with <I>F. hepatica</I> (3). Similarly, <I>Opisthorchis viverrini</
I> enhanced the expression of hepatic CYP2A5 in male hamsters (4) and the expres
sion of CYP2A6, an isoform orthologous to rodent CYP2A5, in humans (5). As obser
ved with other trematode infections, it has also been reported that liver monoox
ygenase activities are modulated by <I>Schistosoma mansoni</I>. During the early
 phase of murine schistosomiasis, when the liver is still largely devoid of gran
ulomas, infection causes only minor changes in monooxygenase activities, the dir
ection and magnitude of which depend on the mouse strain and sex. Increased acti
vity of some hepatic monooxygenases has been detected in male BALB/c mice 33 day
s after infection with <I>S. mansoni</I> (6). However, a study on male and femal
e Swiss Webster (SW) and DBA/2 mice detected no change in CYP-mediated activitie
s on post-infection day 15 (PID15), and only strain- and gender-specific minor c
hanges of monooxygenase activities on PID30 (7). At this early stage of infectio
n, Manh&atilde;es-Rocha et al. (7) also noted that there was no alteration of co
umarin 7-hydroxylase, a marker of CYP2A5 activity, in male and female DBA/2 mice
 infected with <I>S. mansoni</I> cercariae.       ^cY#6557.htm##
00746000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051900072002000900591#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#20#16#article#52#<P>A marked decline of 
several CYP-mediated activities has been found at a more advanced stage of infec
tion (i.e., 48-55 days after infection) (6,8,9), when worms are sexually mature 
and the immune reaction to parasite eggs as well as the size of hepatic granulom
as are maximal (10). There are almost no data on the activities of microsomal en
zymes at even more advanced phases when accumulated damage and fibrosis are inte
nse but the immune reaction to parasite eggs harbored in the liver is down-modul
ated.       ^cY#6557.htm##
00484000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025700072002000900329#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#21#17#article#52#<P>In the present study
, we evaluated the effects of <I>S. mansoni</I> infection on the activities of C
YP2A5 and other microsomal enzymes on PID90, when granulomas around newly deposi
ted eggs are smaller than those observed during earlier phases.       ^cY#6557.h
tm##
01159000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704093200072002000901004#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#22#18#article#52#<P>SW and DBA/2 mice of
 either sex from the Oswaldo Cruz Foundation breeding stock were used. The anima
ls were housed in standard plastic cages covered with stainless steel lids and c
ontaining wood shavings as bedding. Room temperature (23 &#177; 2&#186;C), air r
elative humidity (approximately 70%) and light/dark cycle (lights on from 8:00 a
m to 8:00 pm) were controlled in the animal facilities. Tap water and a commerci
al diet for rats and mice (Nuvital CR1, Nuvilab<SUP>&#174;</SUP>, Curitiba, PR, 
Brazil) were provided <I>ad libitum</I>. The experiments were conducted in accor
dance with Brazilian animal protection and welfare laws and the research project
 was approved by the Ethics Committee on the Use of Animals, Oswaldo Cruz Founda
tion. Statistical comparisons within each mouse strain were made by the Kruskal-
Wallis test followed by the Mann-Whitney U-test, with the level of significance 
set at P &lt; 0.05.      ^cY#6557.htm##
02595000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704236800072002000902440#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#23#19#article#52#<P>SW and DBA/2 mice we
re infected with <I>S. mansoni</I> (BH strain) cercariae as described in detail 
elsewhere (11). Briefly, 10-day-old pups were transferred to Petri dishes (5 cm 
in diameter, one pup per dish) containing 3 mL dechlorinated water with 100 cerc
ariae. Pups were kept warm while infection took place by 60-W tungsten lamps loc
ated close to the Petri dishes. Under these conditions, the pup's tail and paws 
as well as all the ventral part of their body were exposed to cercarial penetrat
ion for 20 min. Immediately after being infected, the pups were returned to the 
cage of their mothers. A few drops of Lugol's iodine were then added to each dis
h and the number of cercariae that failed to penetrate the skin of the mice (i.e
., separated cercarial heads and intact cercariae) was counted under a stereomic
roscope. Skin penetration by the cercariae was very efficient (97 to 100%) irres
pective of mouse sex and strain. Control (sham-treated) mice were treated exactl
y as infected animals except that no cercaria was added to the Petri dish water.
 Infected mice and their age-matched controls were killed by cervical dislocatio
n on PID90, i.e., on postnatal day 100. Livers were removed as quickly as possib
le, freed from fat and extra tissue, weighed and frozen in liquid nitrogen until
 further use. Hepatic microsomes (pools of two organs) were prepared as describe
d by Manh&atilde;es-Rocha et al. (7). Microsomal protein concentration was deter
mined by the method of Bradford and total CYP content and the activities of pent
oxy- (PROD), benzyloxy- (BROD), methoxy- (MROD), and ethoxy- (EROD) resorufin-<I
>O</I>-dealkylases, coumarin 7-hydroxylase (COH), and UDP-glucuronosyltransferas
e (UGT) were determined as reported elsewhere (7). Nitrophenol-hydroxylase activ
ity in the mouse liver microsomal fraction was determined by the real-time kinet
ic method described in detail by Allis and Robinson (12). Serum alanine aminotra
nsferase (ALT) was assayed by a colorimetric method using a commercially availab
le kit (Bioclin<SUP>&#174;</SUP>, Belo Horizonte, MG, Brazil) and a microplate s
pectrophotometer reader (Spectramax Plus<SUP>&#174;</SUP>, Molecular Devices Co.
, Sunnyvale, CA, USA). Blood was taken from the periorbital venous sinus at the 
time of sacrifice on PID90. ALT activity was reported as international units per
 liter (IU/L).       ^cY#6557.htm##
02144000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704191700072002000901989#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#24#20#article#52#<P>As shown in <a href=
"#Tab1">Table 1</a>, infection with <I>S. mansoni</I> (PID90) markedly depressed
 total CYP content in the liver of SW and DBA/2 mice irrespective of sex. Monoox
ygenase activities catalyzed by CYP1A (MROD and EROD) and 2B (BROD and PROD) sub
family isoforms were decreased by chronic infection in both strains and genders 
(M: male, F: female) but, in these cases, reductions (control: 100%) were more p
ronounced among SW mice (EROD: M 36%, F 38%; MROD: M 38%, F 39%; BROD: M 46%, F 
19%; PROD: M 50%, F 28%) than among DBA/2 mice (EROD: M 64%, F 58%; MROD: M 60%;
 BROD: F, 49%; PROD: M 73%) (<a href="#Tab1">Table 1</a>). In non-infected SW an
d DBA/2 mice, PROD and BROD activities were higher in females than in males, a f
inding consistent with the higher expression of CYP2B9/10 in females. This sex-r
elated difference regarding CYP2B activity was not apparent in infected SW mice 
(<a href="#Tab1">Table 1</a>). CYP2E1-mediated activity (nitrophenol-hydroxylase
) was also depressed among infected SW mice of either sex (M 31%, F 38%) but it 
remained unchanged among infected male and female DBA/2 mice (<a href="#Tab1">Ta
ble 1</a>). These results indicate that CYP-mediated activities were depressed i
n chronically infected mice on PID90 and that the effects of <I>S. mansoni </I>i
nfection were more intense on SW than on DBA/2 mice. The differences between the
 two strains could be explained at least in part by differences in the number of
 parasite eggs harbored in the liver parenchyma. As demonstrated by Fidalgo-Neto
 et al. (11) in mice infected with 100 cercariae on postnatal day 10, although s
kin penetration by cercariae was very effective and did not differ between the S
W and DBA/2 strains, the proportion of penetrating cercariae that further develo
ped into adult worms - and thus the number of eggs trapped in the host's liver o
n PID90 - was higher in the former strain.        ^cY#6557.htm##
00693000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704046600072002000900538#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#25#21#article#52#<P>The levels of CYP2A5
 expression vary among mouse strains, some of which either do not express a func
tional CYP2A5 or express it at very low levels. Since COH, a CYP2A5-mediated act
ivity, is rather low in SW, the effects of infection on CYP2A5 were determined o
nly in DBA/2 mice. As expected, COH activity was higher in females than in males
. <I>S. mansoni</I> infection, however, did not alter COH in males or in females
 (<a href="#Tab1">Table 1</a>).        ^cY#6557.htm##
00657000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043000072002000900502#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#26#22#article#52#<P>The effects of chron
ic schistosomiasis on the activity of UGT, a phase II microsomal enzyme, were al
so evaluated. As shown in <a href="#Tab1">Table 1</a>, UGT activity was somewhat
 higher in non-infected male SW mice than in females, a difference between gende
rs that was not apparent in the DBA/2 strain. <I>S. mansoni</I> infection, on th
e other hand, did not cause any change in UGT activity in SW or DBA/2 mice.     
   ^cY#6557.htm##
01892000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704166500072002000901737#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#27#23#article#52#<P>The mechanisms by wh
ich <I>S. mansoni</I> and some other parasitic infections modify the expression 
and activity of various CYP isoforms are still far from being entirely understoo
d. The down-regulation of liver CYPs during murine schistosomiasis seems to depe
nd on the development of a granuloma around the parasite's eggs since no changes
 in enzyme activities were observed in athymic nude mice (13) or in cases of uni
sexual<I> S. mansoni</I> infection (14). This view of the importance of circumov
al granulomas for the down-modulation of CYPs is additionally supported by the f
act that liver microsomal enzyme activities remain unchanged on PID15, when worm
s are not yet sexually mature, and only minor changes are found on PID30, when v
ery few eggs, if any, are found in the hepatic tissue (7,11). It remains unclear
, however, how pathophysiological changes associated with schistosomal granuloma
s alter the expression and activity of CYP enzymes. Based mainly on studies usin
g bacterial lipopolysaccharide as well as other immunostimulants, it has been pr
oposed that an increase in the levels of nitric oxide (NO) due to the induction 
of nitric oxide synthase (NOS2 or iNOS) is a major factor mediating the suppress
ion of CYP expression and activity by infections and pro-inflammatory stimuli (1
5). Morgan (16), however, has failed to demonstrate that overproduction of NO is
 an essential link between lipopolysaccharide treatment and suppression of CYPs.
 Whether NO and a variety of cytokines produced in the vicinity of schistosomal 
granulomas play a role in the down-modulation of CYP isoforms by the infection r
emains to be further elucidated.      ^cY#6557.htm##
02515000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704228800072002000902360#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#28#24#article#52#<P>The mechanism by whi
ch CYP2A5 is modulated by infections apparently differs from that of most CYP is
oforms. In rodent models, expression of CYP2A5 was induced by trematode infectio
ns such as those caused by <I>F. hepatica</I> and <I>O. viverrini</I> (3,4,17), 
as well as by malaria (18) and by bacterial (<I>Helicobacter hepaticus</I>) and 
viral (HBV) hepatitis. It is noteworthy that CYP2A5 was specifically induced in 
these infection models, whereas total-CYP content was decreased and CYP isoforms
 other than CYP2A5 were either depressed or unaffected. Recently, Gilmore et al.
 (17) suggested that the induction of CYP2A5 may be mediated by direct cellular 
damage rather than by an indirect pathway involving pro-inflammatory cytokines. 
This hypothesis seems to be supported by the fact that CYP2A5 is overexpressed i
n infections that cause a rather extensive damage to liver cells, such as fascio
liasis, opisthorchiasis, and hepatitis. Gilmore et al. (17) also reported that i
nduction of CYP2A5 by pyrazole is associated with a chemically produced hepatoce
llular injury. Recently, De-Oliveira et al. (18) showed that the induction of CY
P2A5 by <I>Plasmodium berghei</I> (ANKA) infection was also associated with an i
ncrease of ALT and aspartate aminotransferase (AST) levels in blood serum. In th
e present study, blood serum ALT activity did not differ between infected and no
n-infected DBA/2 mice on PID90 (<a href="#Tab1">Table 1</a>), indicating that <I
>S. mansoni</I> infection did not produce a biochemically detectable liver injur
y. As pointed out by Brunet et al. (19), while granulomas themselves are clearly
 pathogenic, they also sequester molecules released by parasite eggs and in so d
oing they protect the hepatocytes from toxic miracidial secretions that otherwis
e could lead to cell injury and liver failure. <I>F. hepatica</I>, on the other 
hand, causes extensive liver cell destruction, thereby producing marked elevatio
ns of plasma ALT and AST levels, as the juvenile flukes migrate through the orga
n (20). The induction of CYP2A5 by fascioliasis but not by <I>S. mansoni</I> inf
ection is thus consistent with the view that up-regulation of this isoenzyme dep
ends on the intensity of cellular damage and that there is a threshold for this 
effect (17).         ^cY#6557.htm##
01650000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704142300072002000901495#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#29#25#article#52#<P>The results of the p
resent study show that, during chronic schistosomiasis (PID90), except for CYP2E
1 that remained unchanged in the DBA/2 strain, total CYP levels and the activiti
es mediated by CYP1A1/2, 2B and 2E1 are depressed in the liver of SW and DBA/2 m
ice. <I>S. mansoni</I> infection, on the other hand, did not cause any change in
 CYP2A5 or UGT, a phase 2 microsomal enzyme. These results indicate that decline
 of liver CYP activities caused by <I>S. mansoni</I> is still present when infec
tion evolves to a phase characterized by fibrosis, accumulated damage and a less
 intense host immune response to the parasite egg antigens.</font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>  <font face="Arial, Helvetica, sans-serif">  </font>  <tab
le width="100%"  border="0">    <tr align="left" valign="top">      <td width="1
3%"><a href="/img/revistas/bjmbr/v40n5/html/6557t01.htm"><img src="/img/revistas
/bjmbr/v40n5/table.jpg" border="2"></a></td>      <td width="87%"><font face="Ar
ial, Helvetica, sans-serif"><a name="Tab1"></a>Table 1. Cytochrome P450 (total C
YP) and activities of alkoxyresorufin-<I>O</I>-dealkylases (EROD, MROD, BROD, PR
OD), p-nitrophenol-hydroxylase (PNPH), and UDP-glucuronosyltransferase (UGT) in 
liver microsomes of Swiss Webster and DBA/2 mice 90 days after infection with <I
>Schistosoma mansoni</I>. </font></td>    </tr>  </table>  <font face="Arial, He
lvetica, sans-serif">  </font>      ^cY#6557.htm##
00382000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015500072002000900227#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#30#26#article#52#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (195 K JPG file)]</font
>       <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6557.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#31#27#article#52#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6557.htm##
00425000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018400074002000900258#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#32#28#article#52#1#<P>1. Gal
tier P, Battaglia A, More J, Franc M. Impairment of drug metabolism by the liver
 in experimental fascioliasis in the rat. <I>J Pharm Pharmacol</I> 1983; 35: 729
-733.      ^cY#6557.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027800074002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#33#29#article#52#2#<P>2. Cal
leja C, Bigot K, Eeckhoutte C, Sibille P, Boulard C, Galtier P. Comparison of he
patic and renal drug-metabolising enzyme activities in sheep given single or two
-fold challenge infections with <I>Fasciola hepatica</I>. <I>Int J Parasitol</I>
 2000; 30: 953-958.      ^cY#6557.htm##
00441000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020000074002000900274#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#34#30#article#52#3#<P>3. Mon
tero R, Gentile GJ, Frederick L, McMannis J, Murphy T, Silva G, et al. Induced e
xpression of CYP2A5 in inflamed trematode-infested mouse liver. <I>Mutagenesis</
I> 1999; 14: 217-220.      ^cY#6557.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028100074002000900355#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#35#31#article#52#4#<P>4. Kir
by GM, Pelkonen P, Vatanasapt V, Camus AM, Wild CP, Lang MA. Association of live
r fluke (<I>Opisthorchis viverrini</I>) infestation with increased expression of
 cytochrome P450 and carcinogen metabolism in male hamster liver. <I>Mol Carcino
g</I> 1994; 11: 81-89.      ^cY#6557.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028100074002000900355#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#36#32#article#52#5#<P>5. Sat
arug S, Lang MA, Yongvanit P, Sithithaworn P, Mairiang E, Mairiang P, et al. Ind
uction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite 
infection, <I>Opisthorchiasis viverrini</I>. <I>Cancer Epidemiol Biomarkers Prev
</I> 1996; 5: 795-800.      ^cY#6557.htm##
00434000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019300074002000900267#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#37#33#article#52#6#<P>6. She
weita SA, Mangoura SA, el-Shemi AG. Different levels of <I>Schistosoma mansoni</
I> infection induce changes in drug-metabolizing enzymes. <I>J Helminthol</I> 19
98; 72: 71-77.      ^cY#6557.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023200074002000900306#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#38#34#article#52#7#<P>7. Man
haes-Rocha DA, Conte FP, Fidalgo-Neto AA, De-Oliveira AC, Ribeiro-Pinto LF, Paum
gartten FJ. Alterations of hepatic microsomal enzymes in the early phase of muri
ne schistosomiasis. <I>Acta Trop</I> 2005; 95: 58-66.      ^cY#6557.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018000074002000900254#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#39#35#article#52#8#<P>8. Cha
 YN, Edwards R. Effect of <I>Schistosoma mansoni</I> infection on the hepatic dr
ug-metabolizing capacity of mice. <I>J Pharmacol Exp Ther</I> 1976; 199: 432-440
.      ^cY#6557.htm##
00527000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028600074002000900360#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#40#36#article#52#9#<P>9. She
weita SA, Mubark J, Doenhofe MJ, Mostafa MH, Margison GP, O'Connor PJ, et al. Ch
anges in the expression of cytochrome P450 isozymes and related carcinogen metab
olizing enzyme activities in <I>Schistosoma mansoni</I>-infected mice. <I>J Helm
inthol</I> 2002; 76: 71-78.      ^cY#6557.htm##
00411000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016900075002000900244#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#41#37#article#52#10#<P>10. C
heever AW, Lenzi JA, Lenzi HL, Andrade ZA. Experimental models of <I>Schistosoma
 mansoni</I> infection. <I>Mem Inst Oswaldo Cruz</I> 2002; 97: 917-940.      ^cY
#6557.htm##
00499000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025700075002000900332#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#42#38#article#52#11#<P>11. F
idalgo-Neto AA, De-Carvalho RR, De-Oliveira ACAX, Manh&atilde;es-Rocha DA, Paumg
artten FJR. Penetration and maturation of <I>Schistosoma mansoni</I> in suckling
 and adult Swiss Webster and DBA/2 mice. <I>J Exp Anim Sci</I> 2004; 43: 29-38. 
     ^cY#6557.htm##
00390000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014800075002000900223#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#43#39#article#52#12#<P>12. A
llis JW, Robinson BL. A kinetic assay for p-nitrophenol hydroxylase in rat liver
 microsomes. <I>Anal Biochem</I> 1994; 219: 49-52.      ^cY#6557.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020600075002000900281#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#44#40#article#52#13#<P>13. C
ha YN, Byram JE, Heine HS, Bueding E. Effect of <I>Schistosoma mansoni</I> infec
tion on hepatic drug-metabolizing capacity of athymic nude mice. <I>Am J Trop Me
d Hyg</I> 1980; 29: 234-238.      ^cY#6557.htm##
00425000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018300075002000900258#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#45#41#article#52#14#<P>14. C
ha YN, Heine HS, Bueding E. Effect of unisexual <I>Schistosoma mansoni</I> infec
tions on hepatic drug metabolism of mice. <I>Am J Trop Med Hyg</I> 1980; 29: 227
-233.      ^cY#6557.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022700075002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#46#42#article#52#15#<P>15. K
hatsenko OG, Gross SS, Rifkind AB, Vane JR. Nitric oxide is a mediator of the de
crease in cytochrome P450-dependent metabolism caused by immunostimulants. <I>Pr
oc Natl Acad Sci U S A</I> 1993; 90: 11147-11151.      ^cY#6557.htm##
00383000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014100075002000900216#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#47#43#article#52#16#<P>16. M
organ ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? 
<I>Drug Metab Dispos</I> 2001; 29: 207-212.      ^cY#6557.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025300075002000900328#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#48#44#article#52#17#<P>17. G
ilmore WJ, Hartmann G, Piquette-Miller M, Marriott J, Kirby GM. Effects of lipop
olysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injur
y on mouse hepatic Cyp2a5 expression. <I>Toxicology</I> 2003; 184: 211-226.     
 ^cY#6557.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022500075002000900300#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#49#45#article#52#18#<P>18. D
e-Oliveira AC, Da-Matta AC, Paumgartten FJ. <I>Plasmodium berghei</I> (ANKA): in
fection induces CYP2A5 and 2E1 while depressing other CYP isoforms in the mouse 
liver. <I>Exp Parasitol</I> 2006; 113: 256-261.      ^cY#6557.htm##
00419000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017700075002000900252#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#50#46#article#52#19#<P>19. B
runet LR, Dunne DW, Pearce EJ. Cytokine interaction and immune responses during 
<I>Schistosoma mansoni</I> infection. <I>Parasitol Today</I> 1998; 14: 422-427. 
     ^cY#6557.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023900075002000900314#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#p#51#47#article#52#20#<P>20. K
olodziejczyk L, Siemieniuk E, Skrzydlewska E. Antioxidant potential of rat liver
 in experimental infection with <I>Fasciola hepatica</I>. <I>Parasitol Res</I> 2
005; 96: 367-372.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6557.htm#
#
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040100072002000900473#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#52#48#article#52#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=#00
007F><B>Acknowledgments</B></FONT></FONT></font> <font face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></font>
</P>  <font face="Arial, Helvetica, sans-serif">      ^cY#6557.htm##
00469000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704024200072002000900314#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#53#49#article#52#<P>The authors are grat
eful to the staff of the Department of Malacology of the Oswaldo Cruz Institute 
for the generous supply of <I>Schistosoma mansoni</I> cercariae throughout the s
tudy. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6557.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#54#50#article#52#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, H
elvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT> <
A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6557
.htm##
00778000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704055100072002000900623#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#55#51#article#52#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence:</B><font face="Arial, Helvetica, sans-serif"> A.C.A.
X.    De-Oliveira, Laborat&oacute;rio de Toxicologia Ambiental, Departamento de 
Ci&ecirc;ncias    Biol&oacute;gicas, Escola Nacional de Sa&uacute;de P&uacute;bl
ica, FIOCRUZ,    Av. Brasil, 4036, 21040-361 Rio de Janeiro, RJ, Brasil. Fax: +5
5-21-2270-4427.    E_mail: <a href="mailto:ana.oliveira@ensp.fiocruz.br">ana.oli
veira@ensp.fiocruz.br</a></font>  </P>      ^cY#6557.htm##
00513000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028600072002000900358#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6557.htm#S#p#56#52#article#52#<P><font face="Arial, H
elvetica, sans-serif">Research supported by CNPq and FAPERJ. F.P. Conte (PIBIC) 
and F.J.R. Paumgartten were recipients of fellowships from CNPq. Received July 1
1, 2006. Accepted January 31, 2007.</font><font face="Arial, Helvetica, sans-ser
if"> </font>       ^cY#6557.htm##
00616000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100019000900100
01400109010001500123012008700138030001800225065000900243064000500252031000300257
014000800260865000900268002000900277035001000286801001800296#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6557.htm#S#c#57#1#article#20#1#^rND^sGaltier^nP#^rND^sBat
taglia^nA#^rND^sMore^nJ#^rND^sFranc^nM#Impairment of drug metabolism by the live
r in experimental fascioliasis in the rat^len#J Pharm Pharmacol#19830000#1983#35
#729-733#20070500#6557.htm#0022-3573#J Pharm Pharmacol##
00737000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100015000900100
02000105010001700125010001700142010001700159012015000176030001600326065000900342
06400050035103100030035601400080035986500090036700200090037603500100038580100160
0395#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#58#2#article#20#2#^r
ND^sCalleja^nC#^rND^sBigot^nK#^rND^sEeckhoutte^nC#^rND^sSibille^nP#^rND^sBoulard
^nC#^rND^sGaltier^nP#Comparison of hepatic and renal drug-metabolising enzyme ac
tivities in sheep given single or two-fold challenge infections with Fasciola he
patica^len#Int J Parasitol#20000000#2000#30#953-958#20070500#6557.htm#0020-7519#
Int J Parasitol##
00673000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100018000900100
01900108010001800127010001600145010001500161810000600176012007600182030001200258
06500090027006400050027903100030028401400080028786500090029500200090030403500100
0313801001200323#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#59#3#art
icle#20#3#^rND^sMontero^nR#^rND^sGentile^nGJ#^rND^sFrederick^nL#^rND^sMcMannis^n
J#^rND^sMurphy^nT#^rND^sSilva^nG#et al#Induced expression of CYP2A5 in inflamed 
trematode-infested mouse liver^len#Mutagenesis#19990000#1999#14#217-220#20070500
#6557.htm#0267-8257#Mutagenesis##
00737000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100018000890100
02000107010001600127010001500143010001500158012016100173030001300334065000900347
06400050035603100030036101400060036486500090037000200090037903500100038880100130
0398#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#60#4#article#20#4#^r
ND^sKirby^nGM#^rND^sPelkonen^nP#^rND^sVatanasapt^nV#^rND^sCamus^nAM#^rND^sWild^n
CP#^rND^sLang^nMA#Association of liver fluke (Opisthorchis viverrini) infestatio
n with increased expression of cytochrome P450 and carcinogen metabolism in male
 hamster liver^len#Mol Carcinog#19940000#1994#11#81-89#20070500#6557.htm#0899-19
87#Mol Carcinog##
00768000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100015000900100
01900105010002200124010001800146010001800164810000600182012012400188030003300312
06500090034506400050035403100020035901400080036186500090036900200090037803500100
0387801003300397#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#61#5#art
icle#20#5#^rND^sSatarug^nS#^rND^sLang^nMA#^rND^sYongvanit^nP#^rND^sSithithaworn^
nP#^rND^sMairiang^nE#^rND^sMairiang^nP#et al#Induction of cytochrome P450 2A6 ex
pression in humans by the carcinogenic parasite infection, Opisthorchiasis viver
rini^len#Cancer Epidemiol Biomarkers Prev#19960000#1996#5#795-800#20070500#6557.
htm#1055-9965#Cancer Epidemiol Biomarkers Prev##
00595000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100019000920100
01900111012009800130030001300228065000900241064000500250031000300255014000600258
865000900264002000900273035001000282801001300292#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6557.htm#S#c#62#6#article#20#6#^rND^sSheweita^nSA#^rND^sMangoura^nSA#
^rND^sel-Shemi^nAG#Different levels of Schistosoma mansoni infection induce chan
ges in drug-metabolizing enzymes^len#J Helminthol#19980000#1998#72#71-77#2007050
0#6557.htm#0022-149X#J Helminthol##
00692000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100024000730100016000970100
02300113010002200136010002400158010002200182012009100204030001000295065000900305
06400050031403100030031901400060032286500090032800200090033703500100034680100100
0356#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#63#7#article#20#7#^r
ND^sManhaes-Rocha^nDA#^rND^sConte^nFP#^rND^sFidalgo-Neto^nAA#^rND^sDe-Oliveira^n
AC#^rND^sRibeiro-Pinto^nLF#^rND^sPaumgartten^nFJ#Alterations of hepatic microsom
al enzymes in the early phase of murine schistosomiasis^len#Acta Trop#20050000#2
005#95#58-66#20070500#6557.htm#0001-706X#Acta Trop##
00572000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100017000870120
09400104030002100198065000900219064000500228031000400233014000800237865000900245
002000900254035001000263801002100273#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
557.htm#S#c#64#8#article#20#8#^rND^sCha^nYN#^rND^sEdwards^nR#Effect of Schistoso
ma mansoni infection on the hepatic drug-metabolizing capacity of mice^len#J Pha
rmacol Exp Ther#19760000#1976#199#432-440#20070500#6557.htm#0022-3565#J Pharmaco
l Exp Ther##
00753000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100016000920100
01900108010001800127010001900145010001900164810000600183012014900189030001300338
06500090035106400050036003100030036501400060036886500090037400200090038303500100
0392801001300402#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#65#9#art
icle#20#9#^rND^sSheweita^nSA#^rND^sMubark^nJ#^rND^sDoenhofe^nMJ#^rND^sMostafa^nM
H#^rND^sMargison^nGP#^rND^sO'Connor^nPJ#et al#Changes in the expression of cytoc
hrome P450 isozymes and related carcinogen metabolizing enzyme activities in Sch
istosoma mansoni-infected mice^len#J Helminthol#20020000#2002#76#71-78#20070500#
6557.htm#0022-149X#J Helminthol##
00599000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100016000930100
01600109010001800125012005700143030002200200065000900222064000500231031000300236
014000800239865000900247002000900256035001000265801002200275#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6557.htm#S#c#66#10#article#20#10#^rND^sCheever^nAW#^rND^s
Lenzi^nJA#^rND^sLenzi^nHL#^rND^sAndrade^nZA#Experimental models of Schistosoma m
ansoni infection^len#Mem Inst Oswaldo Cruz#20020000#2002#97#917-940#20070500#655
7.htm#0074-0276#Mem Inst Oswaldo Cruz##
00691000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100023000750100022000980100
02400120010002400144010002300168012010500191030001500296065000900311064000500320
031000300325014000600328865000900334002000900343035001000352801001500362#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#67#11#article#20#11#^rND^sFidalg
o-Neto^nAA#^rND^sDe-Carvalho^nRR#^rND^sDe-Oliveira^nACAX#^rND^sManhães-Rocha^nDA
#^rND^sPaumgartten^nFJR#Penetration and maturation of Schistosoma mansoni in suc
kling and adult Swiss Webster and DBA/2 mice^len#J Exp Anim Sci#20040000#2004#43
#29-38#20070500#6557.htm#0939-8600#J Exp Anim Sci##
00540000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100019000910120
07400110030001300184065000900197064000500206031000400211014000600215865000900221
002000900230035001000239801001300249#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
557.htm#S#c#68#12#article#20#12#^rND^sAllis^nJW#^rND^sRobinson^nBL#A kinetic ass
ay for p-nitrophenol hydroxylase in rat liver microsomes^len#Anal Biochem#199400
00#1994#219#49-52#20070500#6557.htm#0003-2697#Anal Biochem##
00632000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100016000890100
01600105010001700121012010300138030001800241065000900259064000500268031000300273
014000800276865000900284002000900293035001000302801001800312#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6557.htm#S#c#69#13#article#20#13#^rND^sCha^nYN#^rND^sByra
m^nJE#^rND^sHeine^nHS#^rND^sBueding^nE#Effect of Schistosoma mansoni infection o
n hepatic drug-metabolizing capacity of athymic nude mice^len#Am J Trop Med Hyg#
19800000#1980#29#234-238#20070500#6557.htm#0002-9637#Am J Trop Med Hyg##
00591000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100016000890100
01700105012009000122030001800212065000900230064000500239031000300244014000800247
865000900255002000900264035001000273801001800283#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6557.htm#S#c#70#14#article#20#14#^rND^sCha^nYN#^rND^sHeine^nHS#^rND^s
Bueding^nE#Effect of unisexual Schistosoma mansoni infections on hepatic drug me
tabolism of mice^len#Am J Trop Med Hyg#19800000#1980#29#227-233#20070500#6557.ht
m#0002-9637#Am J Trop Med Hyg##
00667000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100016000950100
01800111010001500129012011400144030002500258065000900283064000500292031000300297
014001200300865000900312002000900321035001000330801002500340#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6557.htm#S#c#71#15#article#20#15#^rND^sKhatsenko^nOG#^rND
^sGross^nSS#^rND^sRifkind^nAB#^rND^sVane^nJR#Nitric oxide is a mediator of the d
ecrease in cytochrome P450-dependent metabolism caused by immunostimulants^len#P
roc Natl Acad Sci U S A#19930000#1993#90#11147-11151#20070500#6557.htm#0027-8424
#Proc Natl Acad Sci U S A##
00521000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750120074000920300
01800166065000900184064000500193031000300198014000800201865000900209002000900218
035001000227801001800237#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#
72#16#article#20#16#^rND^sMorgan^nET#Regulation of cytochrome p450 by inflammato
ry mediators: why and how?^len#Drug Metab Dispos#20010000#2001#29#207-212#200705
00#6557.htm#0090-9556#Drug Metab Dispos##
00697000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100018000930100
02500111010001800136010001600154012013700170030001100307065000900318064000500327
031000400332014000800336865000900344002000900353035001000362801001100372#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6557.htm#S#c#73#17#article#20#17#^rND^sGilmor
e^nWJ#^rND^sHartmann^nG#^rND^sPiquette-Miller^nM#^rND^sMarriott^nJ#^rND^sKirby^n
GM#Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated h
epatocellular injury on mouse hepatic Cyp2a5 expression^len#Toxicology#20030000#
2003#184#211-226#20070500#6557.htm#0300-483X#Toxicology##
00629000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100022000750100019000970100
02200116012011900138030001400257065000900271064000500280031000400285014000800289
865000900297002000900306035001000315801001400325#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6557.htm#S#c#74#18#article#20#18#^rND^sDe-Oliveira^nAC#^rND^sDa-Matta
^nAC#^rND^sPaumgartten^nFJ#Plasmodium berghei (ANKA): infection induces CYP2A5 a
nd 2E1 while depressing other CYP isoforms in the mouse liver^len#Exp Parasitol#
20060000#2006#113#256-261#20070500#6557.htm#0014-4894#Exp Parasitol##
00583000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100016000920100
01700108012008300125030001600208065000900224064000500233031000300238014000800241
865000900249002000900258035001000267801001600277#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6557.htm#S#c#75#19#article#20#19#^rND^sBrunet^nLR#^rND^sDunne^nDW#^rN
D^sPearce^nEJ#Cytokine interaction and immune responses during Schistosoma manso
ni infection^len#Parasitol Today#19980000#1998#14#422-427#20070500#6557.htm#0169
-4758#Parasitol Today##
00599000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100023000750100020000980100
02200118012008800140030001400228065000900242064000500251031000300256014000800259
865000900267002000900276035001000285801001400295#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6557.htm#S#c#76#20#article#20#20#^rND^sKolodziejczyk^nL#^rND^sSiemien
iuk^nE#^rND^sSkrzydlewska^nE#Antioxidant potential of rat liver in experimental 
infection with Fasciola hepatica^len#Parasitol Res#20050000#2005#96#367-372#2007
0500#6557.htm#0044-3255#Parasitol Res##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#o#1#1#article#1#20
080213#155322#6597.htm#126##
03472000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000700103030002000110
03100030013003200020013306500090013501400110014403500100015501201360016501000270
03010100023003280100032003510100030003830100025004130700127004380700101005650700
11800666083165400784085000802438085004402446085003402490085002202524085002802546
08500360257411700060261007200030261605300370261905500120265605400280266805800070
26960600011027030580007027140600011027210580005027321120009027371110016027461140
00902762113001802771002000902789#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.
htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#TAB#06#BJMBR060#FAPESP#Braz J Med Biol R
es#40#5#20070500#^f639^l647#0100-879X#Dimensionality of the premenstrual syndrom
e: confirmatory factor analysis of premenstrual dysphoric symptoms among college
 students^len#^rND^1A01 A02^nY.-P.^sWang#^rND^1A01^nC.-T.^sTeng#^rND^1A01^nA.H.G
.^sVieira Filho#^rND^1A01 A03^nC.^sGorenstein#^rND^1A01^nL.H.^sAndrade#Universid
ade de São Paulo^iA01^1Faculdade de Medicina^2Departamento e Instituto de Psiqui
atria (LIM-23)^cSão Paulo^sSP^pBrasil#UNISA^iA02^1Faculdade de Medicina de Santo
 Amaro^2Departamento de Psiquiatria^cSão Paulo^sSP^pBrasil#Universidade de São P
aulo^iA03^1Instituto de Ciências Biomédicas^2Departamento de Farmacologia^cSão P
aulo^sSP^pBrasil#^len^aPremenstrual syndrome and premenstrual dysphoric disorder
 (PMDD) seem to form a severity continuum with no clear-cut boundary. However, s
ince the American Psychiatric Association proposed the research criteria for PMD
D in 1994, there has been no agreement about the symptomatic constellation that 
constitutes this syndrome. The objective of the present study was to establish t
he core latent structure of PMDD symptoms in a non-clinical sample. Data concern
ing PMDD symptoms were obtained from 632 regularly menstruating college students
 (mean age 24.4 years, SD 5.9, range 17 to 49). For the first random half (N = 3
16), we performed principal component analysis (PCA) and for the remaining half 
(N = 316), we tested three theory-derived competing models of PMDD by confirmato
ry factor analysis. PCA allowed us to extract two correlated factors, i.e., dysp
horic-somatic and behavioral-impairment factors. The two-dimensional latent mode
l derived from PCA showed the best overall fit among three models tested by conf
irmatory factor analysis (c²53 = 64.39, P = 0.13; goodness-of-fit indices = 0.96
; adjusted goodness-of-fit indices = 0.95; root mean square residual = 0.05; roo
t mean square error of approximation = 0.03; 90%CI = 0.00 to 0.05; Akaike's info
rmation criterion = -41.61). The items "out of control" and "physical symptoms" 
loaded conspicuously on the first factor and "interpersonal impairment" loaded h
igher on the second factor. The construct validity for PMDD was accounted for by
 two highly correlated dimensions. These results support the argument for focusi
ng on the core psychopathological dimension of PMDD in future studies.#^dnd^i1#^
tm^len^kPremenstrual dysphoric disorder^i1#^tm^len^kPremenstrual syndrome^i1#^tm
^len^kDysphoria^i1#^tm^len^kFactor analysis^i1#^tm^len^kPsychometric properties^
i1#other#24#XIII World Congress of Psychiatry^i1#20050910^i1#September 10 to 15,
 2005^i1#FAPESP#93/04997-4#FAPESP#98/00307-7#CNPq#20060812#August 12, 2006#20070
216#February 16, 2007#6597.htm##
03536000000000697000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000700103030002000110
03100030013003200020013306500090013501400110014403500100015501201360016501000270
03010100023003280100032003510100030003830100025004130700127004380700101005650700
11800666083167600784085000802460085004402468085003402512085002202546085002802568
08500360259611700060263207200030263805300370264105600090267805700090268705500120
26960540028027080580007027360600011027430580007027540600011027610580005027721120
00902777111001602786114000902802113001802811002000902829#v40n5#v:\scielo\serial\
bjmbr\v40n5\markup\6597.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#TAB#06#BJMBR060#
FAPESP#Braz J Med Biol Res#40#5#20070500#^f639^l647#0100-879X#Dimensionality of 
the premenstrual syndrome: confirmatory factor analysis of premenstrual dysphori
c symptoms among college students^len#^rND^1A01 A02^nY.-P.^sWang#^rND^1A01^nC.-T
.^sTeng#^rND^1A01^nA.H.G.^sVieira Filho#^rND^1A01 A03^nC.^sGorenstein#^rND^1A01^
nL.H.^sAndrade#Universidade de São Paulo^iA01^1Faculdade de Medicina^2Departamen
to e Instituto de Psiquiatria (LIM-23)^cSão Paulo^sSP^pBrasil#UNISA^iA02^1Faculd
ade de Medicina de Santo Amaro^2Departamento de Psiquiatria^cSão Paulo^sSP^pBras
il#Universidade de São Paulo^iA03^1Instituto de Ciências Biomédicas^2Departament
o de Farmacologia^cSão Paulo^sSP^pBrasil#^len^aPremenstrual syndrome and premens
trual dysphoric disorder (PMDD) seem to form a severity continuum with no clear-
cut boundary. However, since the American Psychiatric Association proposed the r
esearch criteria for PMDD in 1994, there has been no agreement about the symptom
atic constellation that constitutes this syndrome. The objective of the present 
study was to establish the core latent structure of PMDD symptoms in a non-clini
cal sample. Data concerning PMDD symptoms were obtained from 632 regularly menst
ruating college students (mean age 24.4 years, SD 5.9, range 17 to 49). For the 
first random half (N = 316), we performed principal component analysis (PCA) and
 for the remaining half (N = 316), we tested three theory-derived competing mode
ls of PMDD by confirmatory factor analysis. PCA allowed us to extract two correl
ated factors, i.e., dysphoric-somatic and behavioral-impairment factors. The two
-dimensional latent model derived from PCA showed the best overall fit among thr
ee models tested by confirmatory factor analysis (c<sup>2</sup><sub>53</sub> = 6
4.39, P = 0.13; goodness-of-fit indices = 0.96; adjusted goodness-of-fit indices
 = 0.95; root mean square residual = 0.05; root mean square error of approximati
on = 0.03; 90%CI = 0.00 to 0.05; Akaike's information criterion = -41.61). The i
tems "out of control" and "physical symptoms" loaded conspicuously on the first 
factor and "interpersonal impairment" loaded higher on the second factor. The co
nstruct validity for PMDD was accounted for by two highly correlated dimensions.
 These results support the argument for focusing on the core psychopathological 
dimension of PMDD in future studies.#^dnd^i1#^tm^len^kPremenstrual dysphoric dis
order^i1#^tm^len^kPremenstrual syndrome^i1#^tm^len^kDysphoria^i1#^tm^len^kFactor
 analysis^i1#^tm^len^kPsychometric properties^i1#other#24#XIII World Congress of
 Psychiatry^i1#Cairo^i1#Egypt^i1#20050910^i1#September 10 to 15, 2005^i1#FAPESP#
93/04997-4#FAPESP#98/00307-7#CNPq#20060812#August 12, 2006#20070216#February 16,
 2007#6597.htm##
03656000000000721000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000400099121000300103049000900106158000700115
03000240012203100030014603200020014906500090015101400110016003500100017101201360
01810100027003170100023003440100033003670100029004000100025004290700129004540700
10300583070012000686083166100806085000802467085004402475085003402519085002202553
08500280257508500360260311700060263907200030264505300370264805600090268505700090
26940550012027030540028027150580007027430600011027500580007027610600011027680580
00502779112000902784111001602793114000902809113001802818002000902836008008902845
#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#l#4#1#article#1#^mMay^a200
7#oa#en#bjmbr#1#3.1#tab#06#BJMBR060#FAPESP#Braz. j. med. biol. res#40#5#20070500
#^f639^l647#0100-879X#Dimensionality of the premenstrual syndrome: confirmatory 
factor analysis of premenstrual dysphoric symptoms among college students^len#^r
ND^1A01 A02^nY. -P^sWang#^rND^1A01^nC. -T^sTeng#^rND^1A01^nA. H. G^sVieira Filho
#^rND^1A01 A03^nC^sGorenstein#^rND^1A01^nL. H^sAndrade#^iA01^1Universidade de Sã
o Paulo^2Faculdade de Medicina^3Departamento e Instituto de Psiquiatria (LIM-23)
^cSão Paulo^sSP^pBrasil#^iA02^1UNISA^2Faculdade de Medicina de Santo Amaro^3Depa
rtamento de Psiquiatria^cSão Paulo^sSP^pBrasil#^iA03^1Universidade de São Paulo^
2Instituto de Ciências Biomédicas^3Departamento de Farmacologia^cSão Paulo^sSP^p
Brasil#^len^aPremenstrual syndrome and premenstrual dysphoric disorder (PMDD) se
em to form a severity continuum with no clear-cut boundary. However, since the A
merican Psychiatric Association proposed the research criteria for PMDD in 1994,
 there has been no agreement about the symptomatic constellation that constitute
s this syndrome. The objective of the present study was to establish the core la
tent structure of PMDD symptoms in a non-clinical sample. Data concerning PMDD s
ymptoms were obtained from 632 regularly menstruating college students (mean age
 24.4 years, SD 5.9, range 17 to 49). For the first random half (N = 316), we pe
rformed principal component analysis (PCA) and for the remaining half (N = 316),
 we tested three theory-derived competing models of PMDD by confirmatory factor 
analysis. PCA allowed us to extract two correlated factors, i.e., dysphoric-soma
tic and behavioral-impairment factors. The two-dimensional latent model derived 
from PCA showed the best overall fit among three models tested by confirmatory f
actor analysis (c²53 = 64.39, P = 0.13; goodness-of-fit indices = 0.96; adjusted
 goodness-of-fit indices = 0.95; root mean square residual = 0.05; root mean squ
are error of approximation = 0.03; 90 percentCI = 0.00 to 0.05; Akaike's informa
tion criterion = -41.61). The items "out of control" and "physical symptoms" loa
ded conspicuously on the first factor and "interpersonal impairment" loaded high
er on the second factor. The construct validity for PMDD was accounted for by tw
o highly correlated dimensions. These results support the argument for focusing 
on the core psychopathological dimension of PMDD in future studies.#^dnd^i1#^tm^
len^kPremenstrual dysphoric disorder^i1#^tm^len^kPremenstrual syndrome^i1#^tm^le
n^kDysphoria^i1#^tm^len^kFactor analysis^i1#^tm^len^kPsychometric properties^i1#
other#24#XIII World Congress of Psychiatry^i1#Cairo^i1#Egypt^i1#20050910^i1#Sept
ember 10 to 15, 2005^i1#FAPESP#93/04997-4#FAPESP#98/00307-7#CNPq#20060812#August
 12, 2006#20070216#February 16, 2007#6597.htm#Internet^ihttp://www.scielo.br/sci
elo.php?script=sci_arttext&pid=S0100-879X2007000500006##
00370000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014500070002000900215#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#5#1#article#99#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, May 2007, Volume
 40(5) 639-647</B> </font></P>      ^cY#6597.htm##
00436000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704021100070002000900281#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#6#2#article#99#<P><B><font size="5" face
="Arial, Helvetica, sans-serif">Dimensionality of the premenstrual syndrome: con
firmatory factor analysis of premenstrual dysphoric symptoms among college stude
nts </font></B>       ^cY#6597.htm##
00638000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704041300070002000900483#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#7#3#article#99#<P><font face="Arial, Hel
vetica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v
40n5/recor.gif" border="0"></a></b>    <a href="mailto:gnap_inbox@hotmail.com"><
img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a>    Y.-P. Wang<S
UP>1,2</SUP>, C.-T. Teng<SUP>1</SUP>, A.H.G. Vieira Filho<SUP>1</SUP>,    C. Gor
enstein<SUP>1,3 </SUP>and L.H. Andrade<SUP>1</SUP> </font>      ^cY#6597.htm##
00426000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704020100070002000900271#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#8#4#article#99#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento e Instituto de Psiquiatria (LIM-23)
, Faculdade de Medicina, Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP,
 Brasil     ^cY#6597.htm##
00360000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704013500070002000900205#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#9#5#article#99#<br>        <SUP>2</SUP>D
epartamento de Psiquiatria, Faculdade de Medicina de Santo Amaro, UNISA, S&atild
e;o Paulo, SP, Brasil     ^cY#6597.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018100071002000900252#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#10#6#article#99#<br>        <SUP>3</SUP>
Departamento de Farmacologia, Instituto de Ci&ecirc;ncias Biom&eacute;dicas, Uni
versidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil</font>       ^cY#659
7.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019000071002000900261#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#11#7#article#99#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6597.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#12#8#article#99#<BR>   <A HREF="#Introdu
ction"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6597.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#13#9#article#99#<BR>   <A HREF="#Materia
l"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Subjects and Methods</strong></A>    ^
cY#6597.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017200072002000900244#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#14#10#article#99#<BR>   <A HREF="#Result
s"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6597.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018100072002000900253#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#15#11#article#99#<BR>   <A HREF="#Discus
sion"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#65
97.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#16#12#article#99#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6597.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023400072002000900306#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#17#13#article#99#<br>   </strong></A>   
<A HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#6597.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#18#14#article#99#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6597.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031900072002000900391#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#19#15#article#99#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">  </font>      ^cY#6597.htm##
02031000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704180400072002000901876#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#20#16#article#99#<P><font face="Arial, H
elvetica, sans-serif">Premenstrual syndrome and premenstrual dysphoric disorder 
(PMDD) seem to form a severity continuum with no clear-cut boundary. However, si
nce the American Psychiatric Association proposed the research criteria for PMDD
 in 1994, there has been no agreement about the symptomatic constellation that c
onstitutes this syndrome. The objective of the present study was to establish th
e core latent structure of PMDD symptoms in a non-clinical sample. Data concerni
ng PMDD symptoms were obtained from 632 regularly menstruating college students 
(mean age 24.4 years, SD 5.9, range 17 to 49). For the first random half (N = 31
6), we performed principal component analysis (PCA) and for the remaining half (
N = 316), we tested three theory-derived competing models of PMDD by confirmator
y factor analysis. PCA allowed us to extract two correlated factors, i.e., dysph
oric-somatic and behavioral-impairment factors. The two-dimensional latent model
 derived from PCA showed the best overall fit among three models tested by confi
rmatory factor analysis (<font face="Symbol">c</font><SUP>2</SUP><SUB>53</SUB> =
 64.39, P = 0.13; goodness-of-fit indices = 0.96; adjusted goodness-of-fit indic
es = 0.95; root mean square residual = 0.05; root mean square error of approxima
tion = 0.03; 90%CI = 0.00 to 0.05; Akaike's information criterion = -41.61). The
 items "out of control" and "physical symptoms" loaded conspicuously on the firs
t factor and "interpersonal impairment" loaded higher on the second factor. The 
construct validity for PMDD was accounted for by two highly correlated dimension
s. These results support the argument for focusing on the core psychopathologica
l dimension of PMDD in future studies. </font>   <font face="Arial, Helvetica, s
ans-serif">      ^cY#6597.htm##
00410000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018300072002000900255#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#21#17#article#99#<P><B>Key words: </B> P
remenstrual dysphoric disorder, Premenstrual syndrome, Dysphoria, Factor analysi
s, Psychometric properties  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#
6597.htm##
00664000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043700072002000900509#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#22#18#article#99#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Introduction</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-se
rif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gi
f" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font fac
e="Arial, Helvetica, sans-serif"></font>  <font face="Arial, Helvetica, sans-ser
if">      ^cY#6597.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038900072002000900461#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#23#19#article#99#<P>Premenstrual dysphor
ic disorder (PMDD) and premenstrual syndrome (PMS) are considered to be similar 
premenstrual conditions, although they differ in several respects. However, sinc
e the American Psychiatric Association (APA) proposed the research criteria for 
PMDD in 1994, there has been no agreement about the symptomatic constellation th
at constitutes this syndrome (1).         ^cY#6597.htm##
01257000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704103000072002000901102#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#24#20#article#99#<P>According to the DSM
-IV (1), PMDD presents a characteristic pattern of symptoms, severity and result
ing impairment, i.e., PMDD is regarded as an affective syndrome with social and 
interpersonal impairment. To meet the diagnosis of PMDD, a woman should present 
a symptomatic pattern change from the follicular to the luteal phase, with the m
arked presence of at least one affective symptom (depressive mood, anxiety or te
nsion, affect lability, and anger or irritability) among the 5 symptoms required
 by the DSM-IV criteria. The change should also include a symptom-free period in
 the postmenstrual week. Regarded as accessory symptoms, "sense of being out of 
control" or "sense of being overwhelmed" has been incorporated into the DSM-IV b
ecause of its frequency in premenstrual conditions (2). Conversely, interpersona
l and social impairment is a criterion of clinical significance that is mandator
y for the diagnosis of PMDD. Indeed, there is much uncertainty about the nature 
of self-reported impairment in PMDD.       ^cY#6597.htm##
00856000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704062900072002000900701#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#25#21#article#99#<P>A number of scales h
ave been used to rate PMS symptoms and many of them have been validated and exam
ined for their factorial structure (3-7). A review of the literature on PMS reve
aled wide variability of its construct validity. Demonstrations of its underlyin
g latent structure relied on exploratory factor analysis and researchers identif
ied from 2 to 8 factors to describe its multidimensionality (3,8-11). Only three
 studies evaluated PMDD according to the APA's criteria (10-12). Indeed, the var
iability of their scope, symptom items and clinical utility in different setting
s precludes meaningful comparisons.       ^cY#6597.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031900072002000900391#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#26#22#article#99#<P>The aims of the pres
ent study were to investigate the factor structure of PMDD symptoms as derived f
rom DSM-IV criteria by exploratory factor analysis and subsequent cross-validati
on by confirmatory factor analysis of theoretically sound factor models for PMDD
.   </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6597.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039000072002000900462#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#27#23#article#99#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Subjects and Methods</B></FONT></FONT></font> <font face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font
 face="Arial, Helvetica, sans-serif">      ^cY#6597.htm##
00264000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704003700072002000900109#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#28#24#article#99#<P><b>Subjects</b>  </f
ont>      ^cY#6597.htm##
00922000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069500072002000900767#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#29#25#article#99#<P><font face="Arial, H
elvetica, sans-serif">The original pool of subjects consisted of 865 Brazilian f
emale students from the University of S&atilde;o Paulo in the city of S&atilde;o
 Paulo, attending courses with a high-female to male student ratio, and mostly f
rom Mathematics, Literature and Language courses. Exclusion criteria were a) wom
en in amenorrhea (non-menstruating, including pregnancy) and b) women with menst
rual cycles shorter than 25 days or longer than 35 days, or irregular menstrual 
cycles. A provisional PMDD diagnosis was not required for an individual to be in
cluded in the study, since we were studying the symptomatic profile of premenstr
ual condition. </font>      ^cY#6597.htm##
00993000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704076600072002000900838#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#30#26#article#99#<P><font face="Arial, H
elvetica, sans-serif">The final sample consisted of 632 regularly menstruating w
omen, with a mean age of 24.4 years (SD = 5.9, range 17 to 49 years). We exclude
d 233 women from the original sample because 217 (25%) had reported irregular me
nstrual cycles and 16 (1.8%) were non-menstruating. The majority (86%) of women 
were single, 13% of the respondents were married and the remaining 1% was either
 separated or a widow. Most students also had a part-time job (73%) and 27% of t
hem only studied. Almost one third of the sample (27%) was using oral contracept
ives, and 12.2% had children. There was no refusal to fill out the questionnaire
, and 91% of the respondents were blind to the study intent at the end of assess
ment. </font>      ^cY#6597.htm##
00661000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043400072002000900506#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#31#27#article#99#<P><font face="Arial, H
elvetica, sans-serif">The whole sample was split into two random halves for stat
istical purposes. The first half of the data was used for exploratory factor ana
lysis and the second half for confirmatory factor analysis of the cross-validati
on procedure. The first and second sample halves did not differ significantly in
 terms of sociodemographic profile, parity or use of oral contraceptives. </font
>      ^cY#6597.htm##
00307000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008000072002000900152#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#32#28#article#99#<P><font face="Arial, H
elvetica, sans-serif"><B>Procedures</B> </font>      ^cY#6597.htm##
01243000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704101600072002000901088#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#33#29#article#99#<P><font face="Arial, H
elvetica, sans-serif">In the planning phase, we tested a self-reporting question
naire on 20 female students to evaluate PMDD symptoms in the previous twelve mon
ths (11). PMDD symptoms, as extracted from DSM-IV criteria, were listed as 22 se
parate items. Item 3 was split into affective lability and sensitivity to reject
ion, item 4 as anger/irritability and interpersonal conflicts, item 10 as being 
overwhelmed and out of control, and item 11 as breast tenderness, swelling, head
ache, joint pain, muscle pain, bloating, and weight gain. Criterion B was split 
into social avoidance and decreased productivity and efficiency. In order to det
ect changes between the follicular and luteal phases and to avoid symptom overre
porting in the premenstrual phase, respondents were asked to mark the absence (0
) or presence (1) of each symptom in the menstrual phase in which it occurred. T
he 22 items were merged as the original 12 items listed in the DSM-IV for statis
tical analysis. </font>      ^cY#6597.htm##
01441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704121400072002000901286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#34#30#article#99#<P><font face="Arial, H
elvetica, sans-serif">Blinding procedures were included in the questionnaire. A 
generic introductory remark explained that the study aimed to evaluate the "phys
ical and emotional changes related to some natural events" so as not to disclose
 the intention of the study. Questions concerning sociodemographic, gynecologica
l and obstetric information were also included. The Seasonal Pattern Assessment 
Questionnaire (13) was added to cover up the real research purpose. At the end o
f the questionnaire, an open question was included to control for respondent bli
ndness. To be considered as having correctly guessed the research intent, studen
ts would have to mention "menstruation", "menstrual cycle" and/or "premenstrual"
 in their answer. Furthermore, to avoid any additional hint about the purpose of
 the study, questionnaires were applied in evening classes attended by both fema
le and male students. The participants were asked to voluntarily answer a set of
 questions in their classrooms at the beginning of their regular classes. There 
was no refusal to fill out the questionnaire, and 91% of the respondents were bl
ind to the study intent at the end of the assessment. </font>      ^cY#6597.htm#
#
00516000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028900072002000900361#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#35#31#article#99#<P><font face="Arial, H
elvetica, sans-serif">The study was approved by the University of S&atilde;o Pau
lo Ethics Committee and was conducted in accordance with the Helsinki Declaratio
n of 1975. Written informed consent was obtained from the participants before th
e study. </font>      ^cY#6597.htm##
00317000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009000072002000900162#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#36#32#article#99#<P><font face="Arial, H
elvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6597.htm##
01151000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704092400072002000900996#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#37#33#article#99#<P><font face="Arial, H
elvetica, sans-serif">First, we calculated full-scale internal consistency (Cron
bach's <font face="Symbol">a</font> coefficient) as well as item-total correlati
on. For the random half of the sample (N = 316) we performed principal component
 analysis (PCA) to explore the factor structure of PMDD. The correlation matrix 
for the 12 items was computed first, and the data met the Kaiser-Meyer-Olkin's s
ample adequacy criteria (0.83, minimum acceptable level 0.60), as well as those 
for Bartlett's test of sphericity (<font face="Symbol">c</font><SUP>2</SUP><SUB>
66</SUB> = 837.74, P &lt; 0.0001) for the appropriateness of using factorial mod
els. Scree plot criteria were used to determine the number of factors to extract
. Loadings higher than 0.40 were retained in a factor. Oblique Oblimin rotation 
was performed to help interpretation. We used SPSS for exploratory factor analys
is. </font>      ^cY#6597.htm##
00556000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032900072002000900401#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#38#34#article#99#<P><font face="Arial, H
elvetica, sans-serif">For the remaining half sample (N = 316), we tested the fac
tor structure of three competing hypothetical models. Data of the tetrachoric ma
trix were analyzed by unweighted least square procedure in confirmatory factor a
nalysis (CFA). The following models were tested: </font>      ^cY#6597.htm##
00427000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704020000072002000900272#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#39#35#article#99#<P><font face="Arial, H
elvetica, sans-serif">The one latent dimension model, in which all 12 symptoms f
or PMDD are assumed to reflect one common factor of general distress (model 1). 
</font>      ^cY#6597.htm##
00736000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704050900072002000900581#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#40#36#article#99#<P><font face="Arial, H
elvetica, sans-serif">The second model was based on DSM-IV research criteria for
 PMDD, whereby two latent dimensions are assumed to depict its factorial structu
re. The first dimension, called here affective dimension, covered the affective 
symptoms (depressive mood, affective lability, irritability, tension), and the s
econd behavioral dimension covered sleep, appetite and physical symptoms, as wel
l as out of control and interpersonal impairment symptoms (model 2). </font>    
  ^cY#6597.htm##
00601000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037400072002000900446#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#41#37#article#99#<P><font face="Arial, H
elvetica, sans-serif">The third model was derived from the PCA model of explorat
ory factor analysis. For this alternative model, the first factor also covered t
he "out of control" and physical symptoms in addition to affective symptoms. The
 second latent dimension included behavioral symptoms and interpersonal impairme
nt (model 3). </font>      ^cY#6597.htm##
00796000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056900072002000900641#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#42#38#article#99#<P><font face="Arial, H
elvetica, sans-serif">Model fitting was evaluated by multi-indicator criteria: <
font face="Symbol">c</font><SUP>2</SUP> statistics, goodness-of-fit indices (GFI
), adjusted GFI (AGFI), root mean square residual (RMSR), and RMS error of appro
ximation (RMSEA). Akaike's information criterion (AIC) was used to compare the f
itness of the three models. The model that yields the smallest value of AIC is c
onsidered to be the best compromise between goodness-of-fit and parsimony. CFA w
as carried out using the SAS PROC CALIS package. </font>      ^cY#6597.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004900072002000900121#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#43#39#article#99#<P>   <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6597.htm##
00559000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033200072002000900404#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#44#40#article#99#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT SIZE=4><FONT COLOR=#00007F><B>
Results</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"><A HR
EF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6597.htm##
00312000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008500072002000900157#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#45#41#article#99#<P><b><font face="Arial
, Helvetica, sans-serif">Reliability</font></b> </P>      ^cY#6597.htm##
01255000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704102800072002000901100#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#46#42#article#99#<P><font face="Arial, H
elvetica, sans-serif">Cronbach's <font face="Symbol">a</font> coefficient was 0.
81, indicating good internal consistency and appropriate item homogeneity. The m
ean, standard deviation and corrected item-total correlation of the 12 PMDD item
s for 632 college students are presented in <a href="#Tab1">Table 1</a>. The ite
m-total correlation showed acceptable coefficients for all variables (P &lt; 0.0
5 and higher), ranging from 0.33 to 0.62. The following items, affect lability (
item 4) and anger or irritability (item 3), yielded the highest correlation coef
ficient. Physical symptoms (item 11) and affective symptoms (items 1, 2, 3, 4) w
ere the major complaints of respondents (ranging from 43 to 73%). Behavioral sym
ptoms (items 5, 6, 7, 8, 9) and interpersonal impairment (item 12) were the leas
t endorsed items; nevertheless they were significantly correlated (P &lt; 0.05) 
with the underlying construct. Therefore, this indicates their relative specific
ity for the PMDD construct. </font>      ^cY#6597.htm##
00324000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009700072002000900169#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#47#43#article#99#<P><font face="Arial, H
elvetica, sans-serif"><B>Exploratory factor analysis</B> </font>      ^cY#6597.h
tm##
00791000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056400072002000900636#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#48#44#article#99#<P><font face="Arial, H
elvetica, sans-serif">We performed PCA with the first half of the sample (N = 31
6) to explore the factor structure of PMDD symptoms among students. The examinat
ion of the eigen value &gt;1.0 criteria allowed up to 3 factors, but the scree p
lot identified 2 factors to be extracted. For the non-rotated solution, two comp
onents accounted for 44.91% of the total variance. After Oblimin rotation, all i
tems showed salient standardized regression coefficients for one of the two reta
ined factors (<a href="#Tab2">Table 2</a>). </font>      ^cY#6597.htm##
01015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078800072002000900860#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#49#45#article#99#<P><font face="Arial, H
elvetica, sans-serif">The first factor explained 31.2% of data variance and the 
second 13.72%. The pattern matrix presented a structure that can be interpreted 
as a dysphoric-somatic dimension and a behavioral-impairment dimension. The corr
elation between the two factors was 0.37. Large factor loadings could be observe
d across all PMDD items, except for hypersomnia/insomnia and physical symptoms (
both at 0.42). Inspection of communality estimates (<I>h</I><SUP>2</SUP>) reveal
ed a lower value (&lt;0.30) for appetite change, hypersomnia/insomnia and physic
al symptoms. The items "sense of out of control" and "physical symptoms" loaded 
high on the first component, and the item "interpersonal impairment" loaded high
er on the second component. </font>      ^cY#6597.htm##
00325000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009800072002000900170#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#50#46#article#99#<P><font face="Arial, H
elvetica, sans-serif"><B>Confirmatory factor analysis</B> </font>      ^cY#6597.
htm##
00649000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704042200072002000900494#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#51#47#article#99#<P><font face="Arial, H
elvetica, sans-serif">CFA was performed using the data set for the second half o
f the sample (N = 316) to compare the fitness of the present model derived from 
exploratory factor analysis for the first half of the sample and two plausible m
odels (unidimensional and DSM-IV model). The model fit statistics for the three 
competing models is presented in <a href="#Tab3">Table 3</a>. </font>      ^cY#6
597.htm##
00942000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704071500072002000900787#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#52#48#article#99#<P><font face="Arial, H
elvetica, sans-serif">All three models tested yielded excellent goodness-of-fit 
indices (GFI, AGFI, RMSR, and RMSEA). Results revealed the best fit for model 3,
 derived from the PCA of the first half sample, which achieved the only non-sign
ificant <font face="Symbol">c</font><SUP>2</SUP> value (<font face="Symbol">c</f
ont><SUP>2</SUP><SUB>53</SUB> = 64.39, P = 0.13), confirming the null hypothesis
 (<I>H</I><SUB>o</SUB>) for model 3. The superiority of model 3 was also support
ed by the highest GFI and AGFI values (0.96 and 0.95, respectively), the lowest 
RMSR and RMSEA values (0.05 and 0.03, respectively, with 90%CI = 0.00 to 0.05), 
and the lowest AIC value (-41.61). </font>      ^cY#6597.htm##
00667000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044000072002000900512#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#53#49#article#99#<P><font face="Arial, H
elvetica, sans-serif"><a href="#Tab4">Table 4</a> presents parameter estimates o
f the relationship between the dysphoric-somatic and behavioral-impairment facto
r for model 3. Large factor loadings can be observed across all PMDD items, exce
pt for appetite change (0.44), hypersomnia/insomnia (0.45), and physical symptom
s (0.46). The correlation between the two factors was strong at the 0.66 level. 
</font>      ^cY#6597.htm##
00505000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027800072002000900350#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#54#50#article#99#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="to
p">      <td width="13%"><a href="/img/revistas/bjmbr/v40n5/html/6597t01.htm"><i
mg src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"></a></td>      <td width
="87%">    ^cY#6597.htm##
00478000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025100072002000900323#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#55#51#article#99#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab1"></a>Table 1. Frequency, item-total correlat
ion and internal consistency of premenstrual symptoms in a population of college
 students (N = 632). </font>      </td>    </tr>  </table>      ^cY#6597.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038300072002000900455#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#56#52#article#99#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (143 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
40n5/html/6597t02.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"
></a></td>      <td width="87%">    ^cY#6597.htm##
00534000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030700072002000900379#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#57#53#article#99#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab2"></a>Table 2. Component pattern matrix after
 direct Oblimin rotation from principal component analysis of premenstrual dysph
oric disorder (PMDD) symptoms in a population of college students (N = 316). </f
ont>      </td>    </tr>  </table>      ^cY#6597.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038300072002000900455#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#58#54#article#99#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (159 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
40n5/html/6597t03.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"
></a></td>      <td width="87%">    ^cY#6597.htm##
00426000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704019900072002000900271#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#59#55#article#99#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab3"></a>Table 3. Fit indices of three models te
sted on the second half of the sample (N = 316). </font>      </td>    </tr>  </
table>      ^cY#6597.htm##
00917000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069000072002000900762#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#60#56#article#99#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (125 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
40n5/html/6597t04.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"
></a></td>      <td width="87%"><font face="Arial, Helvetica, sans-serif"><a nam
e="Tab4"></a>Table 4. Parameter estimates from the results of confirmatory facto
r analysis of premenstrual dysphoric disorder (PMDD) symptoms in a population of
 college students (N = 316), alternative two-dimensional model 3. </font></td>  
  </tr>  </table>      ^cY#6597.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011800072002000900190#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#61#57#article#99#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (124 K JPG file)]</font
></P>      ^cY#6597.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#62#58#article#99#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6597.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027000072002000900342#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#63#59#article#99#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#6597.htm##
00842000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704061500072002000900687#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#64#60#article#99#<P><font face="Arial, H
elvetica, sans-serif">Reliability analysis revealed good homogeneity and interna
l consistency for the PMDD scale. Affect lability and anger or irritability were
 the items most correlated with the construct of PMDD. Conversely, appetite chan
ge and sleep disturbance had the weakest item-total correlation, as these items 
are also nonspecific markers of some mental disorders. Physical symptoms (item 1
1) and affective symptoms (items 1, 2, 3, 4) were the major complaints of respon
dents. These two sets of symptoms are regarded as the most stable ones across PM
S cycles (14). </font>      ^cY#6597.htm##
00907000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704068000072002000900752#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#65#61#article#99#<P><font face="Arial, H
elvetica, sans-serif">Until this point, there was no consistent confirmation of 
the factorial structure of PMS. Previous studies have reported 2 to 8 dimensions
 for PMS. The number of identified factors can be attributed primarily to sampli
ng and measure differences across studies rather than true differences in sympto
matic manifestations themselves (14-17). This discrepancy of results may be attr
ibuted to methodological differences such as use of different scales to record p
remenstrual symptoms, recruitment method, retrospective <I>vs</I> prospective de
sign, and technical difference in the distinct factor analytic methods employed.
</font>      ^cY#6597.htm##
01459000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704123200072002000901304#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#66#62#article#99#<P><font face="Arial, H
elvetica, sans-serif">The PCA results suggest that our questionnaire assesses tw
o symptom clusters, and that most of the explained variance was due to a common 
dysphoric-somatic factor (31.2%) rather than to a behavioral-impairment factor. 
The highest factor loadings (&gt;0.70) of the dysphoric-somatic dimension were f
ound for the items anxiety or tension, anger or irritability, affect lability, a
nd depressive mood. Interestingly, two secondary symptoms for the diagnosis of P
MDD in DSM-IV - sense of out of control and physical symptoms - also loaded sign
ificantly on the first factor, together with emotional symptoms. This may sugges
t that both affective symptoms and physical distress could result from the same 
endocrine change or physiological pathway in PMDD (16). Irrespective of the pres
ence of depressed mood, previous studies (17) have regarded some correlated symp
toms, such as anger, irritability, tension, and nervousness, as the core element
s of PMS. Disregarding the sample's cultural background, PMDD could be viewed as
 a distinct diagnostic entity, with irritability and affect lability rather than
 depressed mood and anxiety being its most characteristic features (6). </font> 
     ^cY#6597.htm##
00992000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704076500072002000900837#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#67#63#article#99#<P><font face="Arial, H
elvetica, sans-serif">Behavioral symptoms and interpersonal impairment loaded hi
gher on the second dimension, and explained 13.7% of data variance. Although sel
f-reported social and interpersonal relationship impairment is mandatory for the
 diagnosis of PMDD in the DSM-IV system, this item loaded conspicuously on the s
econdary factor. In agreement with this suggested structure, Bloch et al. (14) h
ave demonstrated that dysphoric mood is strongly associated with functional impa
irment, so that the latter symptom should be viewed as correlated to the former.
 The majority of PMS sufferers will report low subjective distress (17), while p
ure PMDD sufferers will complain of dysphoric mood and severe functional impairm
ent. </font>      ^cY#6597.htm##
01142000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704091500072002000900987#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#68#64#article#99#<P><font face="Arial, H
elvetica, sans-serif">Neglected in previous validity studies of PMS, the dysphor
ic-somatic and behavioral-impairment dimension seemed to be correlated. The vast
 majority of factor analytic studies on this topic have assumed an independent r
elationship between postulated multidimensional constructs, performing orthogona
l rotation without testing an alternative oblique solution that may better descr
ibe their relationship. Our PCA yielded a substantial correlation of 0.37 after 
oblique rotation. In a previous study, we also tested the orthogonal structure o
f the PMDD construct, which yielded a similar factor loading distribution (11). 
Indeed, some researchers have claimed that the oblique structure should always b
e tested because it might be closer to the observed population's latent structur
e. Only four studies have tested the oblique structure for PMS (4,5,8,15). </fon
t>      ^cY#6597.htm##
00633000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040600072002000900478#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#69#65#article#99#<P><font face="Arial, H
elvetica, sans-serif">While the PCA identifies possible factors that account for
 co-variation among items, this technique may only give a very rough idea of the
 true underlying dimensions in the population. On the other hand, CFA is a robus
t multivariate method and has the advantage of allowing a structural comparison 
between theoretically sound competing models. </font>      ^cY#6597.htm##
01289000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704106200072002000901134#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#70#66#article#99#<P><font face="Arial, H
elvetica, sans-serif">The results of our CFA indicated that model 3, a two-facto
r model derived from exploratory factor analysis, produced an excellent fit to t
he data on several indicators. In other words, model 3 produced an estimated co-
variance matrix very close to the observed co-variance matrix for this selected 
population. Statistically speaking, all three models tested displayed pretty goo
d results, with close goodness-of-fit indices. Model 1 (unidimensional) and mode
l 2 (DSM-IV model) also yielded acceptable fit to the data, but the <font face="
Symbol">c</font><SUP>2</SUP> difference and AIC revealed that model 3 had a bett
er overall fit. This means that all tested models may be representative of the o
bserved symptom co-variance structure in this population, but model 3 should be 
viewed as more plausible among them. Previous structural exploratory studies (9,
12,18), which described a similar two-dimensional structure for PMS and late lut
eal premenstrual dysphoric disorder, agree with our findings. </font>      ^cY#6
597.htm##
01956000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704172900072002000901801#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#71#67#article#99#<P><font face="Arial, H
elvetica, sans-serif">Although cultural variability in the factor structure of P
MS could be expected, well-conducted factor analysis was used to replicate a sim
ilar structure. Probably, different factor structures found in previous studies 
on North-American (5,6,10,15,18), Asian (19), European (12,20), and Australian p
opulations (9) were due to technical differences in sample collection and statis
tical approach (17). The premenstrual symptom structure in culturally diverse sa
mples may be slightly different, but the findings in the present Brazilian sampl
e are consistent with some previous factor analytic studies reported in the lite
rature. de la G&aacute;ndara-Martin and de Diego-Herrero (12) extracted two mean
ingful common factors for a stratified community sample in Spain (N = 225), with
 a retrospective questionnaire based on the DSM-III-R criteria for late luteal p
remenstrual dysphoric disorder. The authors concluded that dysphoria (43.5% vari
ance explanation) represented the first general factor and physical exhaustion (
11%) was a secondary factor. Focusing on PMS and using different symptom scales,
 Condon (9) and York et al. (18), in studies on the US and Australian population
s, respectively, also extracted 2 factors in their exploratory factor analysis. 
They described a first strong emotional-dysphoric factor and a second behavioral
-physical symptom factor. Different from DSM-IV criteria, the data analysis of t
he present Latin-American sample indicated that physical symptoms loaded higher 
on the first common factor together with dysphoric symptoms. This indicates that
 complaints of physical symptoms may be more important for premenstrual Brazilia
n women. </font>      ^cY#6597.htm##
00859000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063200072002000900704#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#72#68#article#99#<P><font face="Arial, H
elvetica, sans-serif">An important finding of our CFA, however, was that dysphor
ic-somatic and behavioral-impairment latent factors were highly related (correla
tion = 0.66). Consistent with clinical experience, this is an elegant demonstrat
ion that within the dimensions of the PMDD construct there is probably no strong
 line to be drawn (17,21,22). Previous investigations have attempted to subtype 
PMS in terms of spasmodic and congestive dysmenorrhea (3,23). Searching for core
 psychological dimensions of PMDD may prove more fruitful than searching for dif
ferences between PMDD subtypes. </font>      ^cY#6597.htm##
01112000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704088500072002000900957#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#73#69#article#99#<P><font face="Arial, H
elvetica, sans-serif">The dimensional construct of the present PMDD model has un
covered the relative importance of each symptom for its clinical picture. In add
ition, using structural equation modeling or dimensional models offers considera
ble methodological and analytical advantages in the analysis of the core psychop
athological structure of PMDD since it is no longer necessary to resort to commo
n but problematic research strategies like analyzing specific samples (e.g., ana
lyzing "pure PMDD cases", low prevalence disorders in the community) to avoid co
nfounding, or disregarding, comorbidity when analyzing particular disorders. Fut
ure research may greatly benefit from using such a dimensional approach, where P
MS and PMDD might be regarded as distinct endpoints of the same premenstrual con
dition continuum with no clear-cut boundary. </font>      ^cY#6597.htm##
01149000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704092200072002000900994#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#74#70#article#99#<P><font face="Arial, H
elvetica, sans-serif">The methodological limitations of the present results shou
ld be pointed out. First, our data were collected from a retrospective self-repo
rting questionnaire, which could only detect provisional cases of PMDD. A very t
ime-consuming prospective study of a large sample is warranted (6,8,24). Second,
 we did not recruit the subjects by a random sampling method from the community 
and our sample was representative of regularly menstruating women. Last, whether
 our questionnaire can detect PMDD in the general population is yet to be confir
med. Considering that our questionnaire has been developed to agree with DSM-IV'
s criteria, once its validity (sensitivity, specificity, misclassification rate)
 as a screening instrument is established, this kind of retrospective instrument
 will be a useful tool for the detection of PMDD in a variety of situations (22)
. </font>      ^cY#6597.htm##
01262000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704103500072002000901107#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#75#71#article#99#<P><font face="Arial, H
elvetica, sans-serif">In the present study, we examined the core factor structur
e of DSM-IV PMDD symptoms in a non-clinical student sample in Brazil and sought 
to establish the model that provided the best fit for the diagnostic category of
 PMDD. This is a demonstration of the construct validity of the alternative two-
factor model derived from PCA. The construct validity of PMDD may be represented
 by two highly interrelated common factors. The confirmatory factor analytic cro
ss-validation revealed a broad dimension of dysphoric-somatic symptoms, in which
 the symptom "sense of out of control" was included, and a secondary behavioral-
impairment latent factor, on which interpersonal impairment loaded high. Replica
tion studies with more inclusive sampling would be necessary to strengthen the r
esults of the present hypothesis testing in a CFA study of non-clinical women, a
nd to indicate the necessity to further revise the diagnostic criteria of PMDD. 
</font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6597.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#76#72#article#99#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>References</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"
><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6597.
htm##
00455000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021400074002000900288#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#77#73#article#99#1#<P><font 
face="Arial, Helvetica, sans-serif">1. American Psychiatric Association. <I>Diag
nostic and statistical manual of mental disorder</I>. 4th edn. Washington: Ameri
can Psychiatry Press; 1994. </font>      ^cY#6597.htm##
00516000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027500074002000900349#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#78#74#article#99#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Hurt SW, Schnurr PP, Severino SK, Freeman
 EW, Gise LH, Rivera-Tovar A, et al. Late luteal phase dysphoric disorder in 670
 women evaluated for premenstrual complaints. <I>Am J Psychiatry</I> 1992; 149: 
525-530. </font>      ^cY#6597.htm##
00400000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015900074002000900233#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#79#75#article#99#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Moos RH. Typology of menstrual cycle symp
toms. <I>Am J Obstet Gynecol</I> 1969; 103: 390-402. </font>      ^cY#6597.htm##
00510000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028300072002000900355#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#80#76#article#99#<P><font face="Arial, H
elvetica, sans-serif">4. Cumming DC, Cumming CE, Krausher RJ, Fox EE. Towards a 
definition of PMS.II: A factor analytic evaluation of premenstrual change in wom
en with symptomatic premenstrual change. <I>J Psychosom Res</I> 1991; 35: 713-72
0. </font>      ^cY#6597.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021500074002000900289#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#81#77#article#99#4#<P><font 
face="Arial, Helvetica, sans-serif">5. Rivera-Tovar AD, Pilkonis P, Frank E. Sym
ptom patterns in late luteal phase dysphoric disorder. <I>J Psychopathol Behav A
ssess</I> 1992; 34: 189-199. </font>      ^cY#6597.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021000074002000900284#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#82#78#article#99#5#<P><font 
face="Arial, Helvetica, sans-serif">6. Freeman EW, DeRubeis RJ, Rickels K. Relia
bility and validity of a daily diary for premenstrual syndrome. <I>Psychiatry Re
s</I> 1996; 65: 97-106. </font>      ^cY#6597.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023300074002000900307#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#83#79#article#99#6#<P><font 
face="Arial, Helvetica, sans-serif">7. Feuerstein M, Shaw WS. Measurement proper
ties of the calendar of premenstrual experience in patients with premenstrual sy
ndrome. <I>J Reprod Med</I> 2002; 47: 279-289. </font>      ^cY#6597.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021200074002000900286#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#84#80#article#99#7#<P><font 
face="Arial, Helvetica, sans-serif">8. Endicott J, Nee J, Cohen J, Halbreich U. 
Premenstrual changes: patterns and correlates of daily ratings. <I>J Affect Diso
rd</I> 1986; 10: 127-135. </font>      ^cY#6597.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023600074002000900310#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#85#81#article#99#8#<P><font 
face="Arial, Helvetica, sans-serif">9. Condon JT. Investigation of the reliabili
ty and factor structure of a questionnaire for assessment of the premenstrual sy
ndrome. <I>J Psychosom Res</I> 1993; 37: 543-551. </font>      ^cY#6597.htm##
00507000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026600074002000900340#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#86#82#article#99#9#<P><font 
face="Arial, Helvetica, sans-serif">10. Gehlert S, Chang CH, Hartlage S. Symptom
 patterns of premenstrual dysphoric disorder as defined in the Diagnostic and St
atistical Manual of Mental Disorders-IV. <I>J Womens Health</I> 1999; 8: 75-85. 
</font>      ^cY#6597.htm##
00545000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030300075002000900378#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#87#83#article#99#10#<P><font
 face="Arial, Helvetica, sans-serif">11. Teng CT, Filho AH, Artes R, Gorenstein 
C, Andrade LH, Wang YP. Premenstrual dysphoric symptoms amongst Brazilian colleg
e students: factor structure and methodological appraisal. <I>Eur Arch Psychiatr
y Clin Neurosci</I> 2005; 255: 51-56. </font>      ^cY#6597.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024100075002000900316#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#88#84#article#99#11#<P><font
 face="Arial, Helvetica, sans-serif">12. de la Gandara Martin JJ, de Diego Herre
ro E. Premenstrual dysphoric disorder: an epidemiological study. <I>Actas Luso E
sp Neurol Psiquiatr Cienc Afines</I> 1996; 24: 111-117. </font>      ^cY#6597.ht
m##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029900075002000900374#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#89#85#article#99#12#<P><font
 face="Arial, Helvetica, sans-serif">13. Christensen EM, Larsen JK, Gjerris A. T
he stability of the Seasonal Pattern Assessment Questionnaire score index over t
ime and the validity compared to classification according to DSM-III-R. <I>J Aff
ect Disord</I> 2003; 74: 167-172. </font>      ^cY#6597.htm##
00455000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021300075002000900288#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#90#86#article#99#13#<P><font
 face="Arial, Helvetica, sans-serif">14. Bloch M, Schmidt PJ, Rubinow DR. Premen
strual syndrome: evidence for symptom stability across cycles. <I>Am J Psychiatr
y</I> 1997; 154: 1741-1746. </font>      ^cY#6597.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026700075002000900342#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#91#87#article#99#14#<P><font
 face="Arial, Helvetica, sans-serif">15. Yuk VJ, Jugdutt AV, Cumming CE, Fox EE,
 Cumming DC. Towards a definition of PMS: a factor analytic evaluation of premen
strual change in non-complaining women. <I>J Psychosom Res</I> 1990; 34: 439-446
. </font>      ^cY#6597.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022300075002000900298#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#92#88#article#99#15#<P><font
 face="Arial, Helvetica, sans-serif">16. Mira M, Abraham S, McNeil D, Vizzard J,
 Macaskill P, Fraser I, et al. The inter-relationship of premenstrual symptoms. 
<I>Psychol Med</I> 1995; 25: 947-955. </font>      ^cY#6597.htm##
00461000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021900075002000900294#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#93#89#article#99#16#<P><font
 face="Arial, Helvetica, sans-serif">17. Angst J, Sellaro R, Merikangas KR, Endi
cott J. The epidemiology of perimenstrual psychological symptoms. <I>Acta Psychi
atr Scand</I> 2001; 104: 110-116. </font>      ^cY#6597.htm##
00436000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019400075002000900269#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#94#90#article#99#17#<P><font
 face="Arial, Helvetica, sans-serif">18. York R, Freeman E, Lowery B, Strauss JF
 III. Characteristics of premenstrual syndrome. <I>Obstet Gynecol</I> 1989; 73: 
601-605. </font>      ^cY#6597.htm##
00514000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027200075002000900347#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#95#91#article#99#18#<P><font
 face="Arial, Helvetica, sans-serif">19. Chaturvedi SK, Chandra PS, Issac MK, Su
darshan CY, Beena MB, Sarmukkadam SB, et al. Premenstrual experiences: the four 
profiles and factorial patterns. <I>J Psychosom Obstet Gynaecol</I> 1993; 14: 22
3-235. </font>      ^cY#6597.htm##
00434000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019200075002000900267#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#96#92#article#99#19#<P><font
 face="Arial, Helvetica, sans-serif">20. van der Ploeg HM. The factor structure 
of the Menstrual Distress Questionnaire - Dutch. <I>Psychol Rep</I> 1990; 66: 70
7-714. </font>      ^cY#6597.htm##
00476000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023400075002000900309#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#97#93#article#99#20#<P><font
 face="Arial, Helvetica, sans-serif">21. Wittchen HU, Becker E, Lieb R, Krause P
. Prevalence, incidence and stability of premenstrual dysphoric disorder in the 
community. <I>Psychol Med</I> 2002; 32: 119-132. </font>      ^cY#6597.htm##
00455000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021300075002000900288#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#98#94#article#99#21#<P><font
 face="Arial, Helvetica, sans-serif">22. Steiner M, MacDougall M, Brown E. The p
remenstrual symptoms screening tool (PSST) for clinicians. <I>Arch Womens Ment H
ealth</I> 2003; 6: 203-209. </font>      ^cY#6597.htm##
00379000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013700075002000900212#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#99#95#article#99#22#<P><font
 face="Arial, Helvetica, sans-serif">23. Dalton K. <I>The premenstrual syndrome<
/I>. Springfield: Thomas; 1964. </font>      ^cY#6597.htm##
00588000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070888000300073704034500076002000900421#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#p#100#96#article#99#23#<P><fon
t face="Arial, Helvetica, sans-serif">24. Cohen LS, Soares CN, Otto MW, Sweeney 
BH, Liberman RF, Harlow BL. Prevalence and predictors of premenstrual dysphoric 
disorder (PMDD) in older premenopausal women. The Harvard study of moods and cyc
les. <I>J Affect Disord</I> 2002; 70: 125-132.</font>  <HR ALIGN=LEFT WIDTH=100%
 SIZE=2>      ^cY#6597.htm##
00576000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070704034800073002000900421#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#101#97#article#99#<P><FONT SIZE=4 face="
Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><
B>Correspondence and Footnotes</B></FONT></FONT> <font face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>     
  ^cY#6597.htm##
00783000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070704055500073002000900628#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#102#98#article#99#<p><font face="Arial, 
Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/re
cor.gif" border="0"></a>    Address for correspondence:</b> </font><font face="A
rial, Helvetica, sans-serif">Y.-P.    Wang, N&uacute;cleo de Epidemiologia Psiqu
i&aacute;trica, Instituto de Psiquiatria,    Hospital das Cl&iacute;nicas, FM, U
SP, Rua Dr. Ov&iacute;dio Pires de Campos,    785, 05403-010 S&atilde;o Paulo, S
P, Brasil. Fax: +55-11-3069-6976. E-mail:    <a href="mailto:gnap_inbox@hotmail.
com">gnap_inbox@hotmail.com</a></font> </p>      ^cY#6597.htm##
00576000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070704034800073002000900421#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6597.htm#S#p#103#99#article#99#<P><font face="Arial, 
Helvetica, sans-serif">Presented at the XIII World Congress of Psychiatry, Cairo
, Egypt, September 10 to 15, 2005. Research supported by FAPESP (No. 93/04997-4)
. C.-T. Teng was supported by FAPESP (No. 98/00307-7) and C. Gorenstein was supp
orted by CNPq. Received August 12, 2006. Accepted February 16, 2007. </font>    
  ^cY#6597.htm##
00483000000000241000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720170033000740180057001070630
00800164066001100172062002600183065000900209064000500218865000900223002000900232
#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#104#1#article#23#1#Ameri
can Psychiatric Association#Diagnostic and statistical manual of mental disorder
^len#4th edn#Washington#American Psychiatry Press#19940000#1994#20070500#6597.ht
m##
00703000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100018000890100
01900107010001800126010001500144010002200159810000600181012009200187030001600279
06500090029506400050030403100040030901400080031386500090032100200090033003500100
0339801001600349#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#105#2#ar
ticle#23#2#^rND^sHurt^nSW#^rND^sSchnurr^nPP#^rND^sSeverino^nSK#^rND^sFreeman^nEW
#^rND^sGise^nLH#^rND^sRivera-Tovar^nA#et al#Late luteal phase dysphoric disorder
 in 670 women evaluated for premenstrual complaints^len#Am J Psychiatry#19920000
#1992#149#525-530#20070500#6597.htm#0002-953X#Am J Psychiatry##
00490000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740120041000890300
02000130065000900150064000500159031000400164014000800168865000900176002000900185
035001000194801002000204#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#
106#3#article#23#3#^rND^sMoos^nRH#Typology of menstrual cycle symptoms^len#Am J 
Obstet Gynecol#19690000#1969#103#390-402#20070500#6597.htm#0002-9378#Am J Obstet
 Gynecol##
00543000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100023000740100018000970100
01500115012006200130030002800192710000200220065000900222064000500231031000300236
014000800239865000900247002000900256#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
597.htm#S#c#107#4#article#23#5#^rND^sRivera-Tovar^nAD#^rND^sPilkonis^nP#^rND^sFr
ank^nE#Symptom patterns in late luteal phase dysphoric disorder.^len#J Psychopat
hol Behav Assess#2#19920000#1992#34#189-199#20070500#6597.htm##
00572000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100019000920100
01700111012007200128030001500200065000900215064000500224031000300229014000700232
865000900239002000900248035001000257801001500267#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6597.htm#S#c#108#5#article#23#6#^rND^sFreeman^nEW#^rND^sDeRubeis^nRJ#
^rND^sRickels^nK#Reliability and validity of a daily diary for premenstrual synd
rome^len#Psychiatry Res#19960000#1996#65#97-106#20070500#6597.htm#0165-1781#Psyc
hiatry res##
00575000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100015000940120
10900109030001300218065000900231064000500240031000300245014000800248865000900256
002000900265035001000274801001300284#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
597.htm#S#c#109#6#article#23#7#^rND^sFeuerstein^nM#^rND^sShaw^nWS#Measurement pr
operties of the calendar of premenstrual experience in patients with premenstrua
l syndrome^len#J Reprod Med#20020000#2002#47#279-289#20070500#6597.htm#0024-7758
#J Reprod Med##
00593000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100013000920100
01500105010001900120012006700139030001600206065000900222064000500231031000300236
014000800239865000900247002000900256035001000265801001600275#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6597.htm#S#c#110#7#article#23#8#^rND^sEndicott^nJ#^rND^sN
ee^nJ#^rND^sCohen^nJ#^rND^sHalbreich^nU#Premenstrual changes: patterns and corre
lates of daily ratings^len#J Affect Disord#19860000#1986#10#127-135#20070500#659
7.htm#0165-0327#J Affect Disord##
00563000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740120121000910300
01600212065000900228064000500237031000300242014000800245865000900253002000900262
035001000271801001600281#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#
111#8#article#23#9#^rND^sCondon^nJT#Investigation of the reliability and factor 
structure of a questionnaire for assessment of the premenstrual syndrome^len#J P
sychosom Res#19930000#1993#37#543-551#20070500#6597.htm#0022-3999#J Psychosom Re
s##
00629000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180003000720100017000750100016000920100
01800108012013100126030001600257065000900273064000500282031000200287014000600289
865000900295002000900304035001000313801001600323#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6597.htm#S#c#112#9#article#23#10#^rND^sGehlert^nS#^rND^sChang^nCH#^rN
D^sHartlage^nS#Symptom patterns of premenstrual dysphoric disorder as defined in
 the Diagnostic and Statistical Manual of Mental Disorders-IV^len#J Womens Healt
h#19990000#1999#8#75-85#20070500#6597.htm#1059-7115#J Womens Health##
00739000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01500107010002000122010001800142010001500160012011800175030003400293065000900327
06400050033603100040034101400060034586500090035100200090036003500100036980100340
0379#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#113#10#article#23#11
#^rND^sTeng^nCT#^rND^sFilho^nAH#^rND^sArtes^nR#^rND^sGorenstein^nC#^rND^sAndrade
^nLH#^rND^sWang^nYP#Premenstrual dysphoric symptoms amongst Brazilian college st
udents: factor structure and methodological appraisal^len#Eur Arch Psychiatry Cl
in Neurosci#20050000#2005#255#51-56#20070500#6597.htm#0940-1334#Eur Arch Psychia
try Clin Neurosci##
00616000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100031000760100026001070120
06200133030004500195065000900240064000500249031000300254014000800257865000900265
002000900274035001000283801004500293#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
597.htm#S#c#114#11#article#23#12#^rND^sde^nla Gandara Martin JJ#^rND^sde^nDiego 
Herrero E#Premenstrual dysphoric disorder: an epidemiological study^len#Actas Lu
so Esp Neurol Psiquiatr Cienc Afines#19960000#1996#24#111-117#20070500#6597.htm#
0300-5062#Actas Luso Esp Neurol Psiquiatr Cienc Afines##
00663000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100017000980100
01700115012015600132030001600288065000900304064000500313031000300318014000800321
865000900329002000900338035001000347801001600357#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6597.htm#S#c#115#12#article#23#13#^rND^sChristensen^nEM#^rND^sLarsen^
nJK#^rND^sGjerris^nA#The stability of the Seasonal Pattern Assessment Questionna
ire score index over time and the validity compared to classification according 
to DSM-III-R^len#J Affect Disord#20030000#2003#74#167-172#20070500#6597.htm#0165
-0327#J Affect Disord##
00577000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01800109012007200127030001600199065000900215064000500224031000400229014001000233
865000900243002000900252035001000261801001600271#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6597.htm#S#c#116#13#article#23#14#^rND^sBloch^nM#^rND^sSchmidt^nPJ#^r
ND^sRubinow^nDR#Premenstrual syndrome: evidence for symptom stability across cyc
les^len#Am J Psychiatry#19970000#1997#154#1741-1746#20070500#6597.htm#0002-953X#
Am J Psychiatry##
00667000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100018000900100
01800108010001400126010001800140012011000158030001600268065000900284064000500293
031000300298014000800301865000900309002000900318035001000327801001600337#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#117#14#article#23#15#^rND^sYuk^n
VJ#^rND^sJugdutt^nAV#^rND^sCumming^nCE#^rND^sFox^nEE#^rND^sCumming^nDC#Towards a
 definition of PMS: a factor analytic evaluation of premenstrual change in non-c
omplaining women^len#J Psychosom Res#19900000#1990#34#439-446#20070500#6597.htm#
0022-3999#J Psychosom Res##
00648000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900100
01600107010001700123010001900140010001600159810000600175012005200181030001200233
06500090024506400050025403100030025901400080026286500090027000200090027903500100
0288801001200298#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#118#15#a
rticle#23#16#^rND^sMira^nM#^rND^sAbraham^nS#^rND^sMcNeil^nD#^rND^sVizzard^nJ#^rN
D^sMacaskill^nP#^rND^sFraser^nI#et al#The inter-relationship of premenstrual sym
ptoms^len#Psychol Med#19950000#1995#25#947-955#20070500#6597.htm#0033-2917#Psych
ol Med##
00606000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
02100108010001800129012006100147030002100208065000900229064000500238031000400243
014000800247865000900255002000900264035001000273801002100283#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6597.htm#S#c#119#16#article#23#17#^rND^sAngst^nJ#^rND^sSe
llaro^nR#^rND^sMerikangas^nKR#^rND^sEndicott^nJ#The epidemiology of perimenstrua
l psychological symptoms^len#Acta Psychiatr Scand#20010000#2001#104#110-116#2007
0500#6597.htm#0001-690X#Acta Psychiatr Scand##
00575000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900100
01600107010002200123012004500145030001500190065000900205064000500214031000300219
014000800222865000900230002000900239035001000248801001500258#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6597.htm#S#c#120#17#article#23#18#^rND^sYork^nR#^rND^sFre
eman^nE#^rND^sLowery^nB#^rND^sStrauss^nJF III#Characteristics of premenstrual sy
ndrome^len#Obstet Gynecol#19890000#1989#73#601-605#20070500#6597.htm#0029-7844#O
bstet Gynecol##
00713000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100018000970100
01600115010002000131010001600151010002200167810000600189012007100195030002800266
06500090029406400050030303100030030801400080031186500090031900200090032803500100
0337801002800347#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#121#18#a
rticle#23#19#^rND^sChaturvedi^nSK#^rND^sChandra^nPS#^rND^sIssac^nMK#^rND^sSudars
han^nCY#^rND^sBeena^nMB#^rND^sSarmukkadam^nSB#et al#Premenstrual experiences: th
e four profiles and factorial patterns^len#J Psychosom Obstet Gynaecol#19930000#
1993#14#223-235#20070500#6597.htm#0167-482X#J Psychosom Obstet Gynaecol##
00516000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760120073001000300
01200173065000900185064000500194031000300199014000800202865000900210002000900219
035001000228801001200238#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#
122#19#article#23#20#^rND^svan^nder Ploeg HM#The factor structure of the Menstru
al Distress Questionnaire - Dutch^len#Psychol Rep#19900000#1990#66#707-714#20070
500#6597.htm#0033-2941#Psychol Rep##
00612000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
01400111010001600125012009200141030001200233065000900245064000500254031000300259
014000800262865000900270002000900279035001000288801001200298#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6597.htm#S#c#123#20#article#23#21#^rND^sWittchen^nHU#^rND
^sBecker^nE#^rND^sLieb^nR#^rND^sKrause^nP#Prevalence, incidence and stability of
 premenstrual dysphoric disorder in the community^len#Psychol Med#20020000#2002#
32#119-132#20070500#6597.htm#0033-2917#Psychol Med##
00541000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01500113012006700128030002400195710000200219065000900221064000500230031000200235
014000800237865000900245002000900254#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
597.htm#S#c#124#21#article#23#22#^rND^sSteiner^nM#^rND^sMacDougall^nM#^rND^sBrow
n^nE#The premenstrual symptoms screening tool (PSST) for clinicians^len#Arch Wom
ens Ment Health#2#20030000#2003#6#203-209#20070500#6597.htm##
00403000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160016000760180030000920660
01200122062000700134065000900141064000500150865000900155002000900164#v40n5#v:\sc
ielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#125#22#article#23#23#^rND^sDalton^nK
#The premenstrual syndrome^len#Springfield#Thomas#19640000#1964#20070500#6597.ht
m##
00729000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01500109010001800124010001900142010001700161012014000178030001600318065000900334
06400050034303100030034801400080035186500090035900200090036803500100037780100160
0387#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6597.htm#S#c#126#23#article#23#24
#^rND^sCohen^nLS#^rND^sSoares^nCN#^rND^sOtto^nMW#^rND^sSweeney^nBH#^rND^sLiberma
n^nRF#^rND^sHarlow^nBL#Prevalence and predictors of premenstrual dysphoric disor
der (PMDD) in older premenopausal women: The Harvard study of moods and cycles^l
en#J Affect Disord#20020000#2002#70#125-132#20070500#6597.htm#0165-0327#J Affect
 Disord##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#o#1#1#article#1#20
080212#125715#6620.htm#81##
02799000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015622300090016601201060
01750100022002810100026003030100021003290100027003500100021003770700122003980831
39800520085000801918085003001926085001901956085002401975085002101999085003702020
08500230205711700060208007200030208605800050208905800070209411200090210111100160
2110114000902126113001702135881002402152002000902176#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6620.htm#S#h#2#1#article#1#sc#en#bjmbr#1#3.1#ILUS#05#BJMBR050#FAP
ESP#Braz J Med Biol Res#40#5#20070500#^f633^l637#0100-879X#20070314#Sleep depriv
ation reduces the lymphocyte count in a non-obese mouse model of type 1 diabetes
 mellitus^len#^rND^1A01^nF.S.^sRuiz#^rND^1A01^nM.L.^sAndersen#^rND^1A01^nA.^sZag
er#^rND^1A01^nR.C.S.^sMartins#^rND^1A01^nS.^sTufik#Universidade Federal de São P
aulo^iA01^1Escola Paulista de Medicina^2Departamento de Psicobiologia^cSão Paulo
^sSP^pBrasil#^len^aThe objective of the present study was to determine whether s
leep deprivation (SD) would promote changes in lymphocyte numbers in a type 1 di
abetes model (non-obese diabetic, NOD, mouse strain) and to determine whether SD
 would affect female and male NOD compared to Swiss mice. The number of lymphocy
tes in peripheral blood after 24 and 96 h of SD (by multiple platform method) or
 equivalent period of time in home-cage controls was examined prior to the onset
 of diabetes. SD for 96 h significantly reduced lymphocytes in male Swiss mice c
ompared to control (8.6 ± 2.1 vs 4.1 ± 0.7 10³/µL; P < 0.02). In male NOD animal
s, 24- and 96-h SD caused a significant decrease of lymphocytes compared to cont
rol (4.4 ± 0.3 vs 1.6 ± 0.5; P < 0.001 and 4.4 ± 0.3 vs 0.9 ± 0.1 10³/µL; P < 0.
00001, respectively). Both 24- and 96-h SD induced a reduction in the number of 
lymphocytes in female Swiss (7.5 ± 0.5 vs 4.5 ± 0.5, 4.4 ± 0.6 10³/µL; P < 0.001
, respectively) and NOD mice (4 ± 0.6 vs 1.8 ± 0.2, 1.2 ± 0.4 10³/µL; P < 0.01, 
respectively) compared to the respective controls. Loss of sleep induced lymphop
enia in peripheral blood in both genders and strains used. Since many cases of a
utoimmunity present reduced numbers of lymphocytes and, in this study, it was mo
re evident in the NOD strain, our results suggest that SD should be considered a
 risk factor in the onset of autoimmune disorders.#^dnd^i1#^tm^len^kSleep depriv
ation^i1#^tm^len^kStress^i1#^tm^len^kLymphopenia^i1#^tm^len^kDiabetes^i1#^tm^len
^kNon-obese diabetic mouse^i1#^tm^len^kSwiss mice^i1#other#19#AFIP#FAPESP#200608
31#August 31, 2006#20070122#January 22, 2007#S0100-879X2006005000086#6620.htm##
02822000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015622300090016601201060
01750100022002810100026003030100021003290100027003500100021003770700122003980831
45700520085000801977085003001985085001902015085002402034085002102058085003702079
08500230211611700060213907200030214505800050214805800070215311200090216011100160
2169114000902185113001702194002000902211#v40n5#v:\scielo\serial\bjmbr\v40n5\mark
up\6620.htm#S#f#3#1#article#1#sc#en#bjmbr#1#3.1#ILUS#05#BJMBR050#FAPESP#Braz J M
ed Biol Res#40#5#20070500#^f633^l637#0100-879X#20070314#Sleep deprivation reduce
s the lymphocyte count in a non-obese mouse model of type 1 diabetes mellitus^le
n#^rND^1A01^nF.S.^sRuiz#^rND^1A01^nM.L.^sAndersen#^rND^1A01^nA.^sZager#^rND^1A01
^nR.C.S.^sMartins#^rND^1A01^nS.^sTufik#Universidade Federal de São Paulo^iA01^1E
scola Paulista de Medicina^2Departamento de Psicobiologia^cSão Paulo^sSP^pBrasil
#^len^aThe objective of the present study was to determine whether sleep depriva
tion (SD) would promote changes in lymphocyte numbers in a type 1 diabetes model
 (non-obese diabetic, NOD, mouse strain) and to determine whether SD would affec
t female and male NOD compared to Swiss mice. The number of lymphocytes in perip
heral blood after 24 and 96 h of SD (by multiple platform method) or equivalent 
period of time in home-cage controls was examined prior to the onset of diabetes
. SD for 96 h significantly reduced lymphocytes in male Swiss mice compared to c
ontrol (8.6 ± 2.1 vs 4.1 ± 0.7 10<sup>3</sup>/µL; P &lt; 0.02). In male NOD anim
als, 24- and 96-h SD caused a significant decrease of lymphocytes compared to co
ntrol (4.4 ± 0.3 vs 1.6 ± 0.5; P &lt; 0.001 and 4.4 ± 0.3 vs 0.9 ± 0.1 10<sup>3<
/sup>/µL; P &lt; 0.00001, respectively). Both 24- and 96-h SD induced a reductio
n in the number of lymphocytes in female Swiss (7.5 ± 0.5 vs 4.5 ± 0.5, 4.4 ± 0.
6 10<sup>3</sup>/µL; P &lt; 0.001, respectively) and NOD mice (4 ± 0.6 vs 1.8 ± 
0.2, 1.2 ± 0.4 10<sup>3</sup>/µL; P &lt; 0.01, respectively) compared to the res
pective controls. Loss of sleep induced lymphopenia in peripheral blood in both 
genders and strains used. Since many cases of autoimmunity present reduced numbe
rs of lymphocytes and, in this study, it was more evident in the NOD strain, our
 results suggest that SD should be considered a risk factor in the onset of auto
immune disorders.#^dnd^i1#^tm^len^kSleep deprivation^i1#^tm^len^kStress^i1#^tm^l
en^kLymphopenia^i1#^tm^len^kDiabetes^i1#^tm^len^kNon-obese diabetic mouse^i1#^tm
^len^kSwiss mice^i1#other#19#AFIP#FAPESP#20060831#August 31, 2006#20070122#Janua
ry 22, 2007#6620.htm##
02893000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000700116
03000240012303100030014703200020015006500090015201400110016103500100017222300090
01820120106001910100022002970100026003190100020003450100028003650100020003930700
12400413083139800537085000801935085003001943085001901973085002401992085002102016
08500370203708500230207411700060209707200030210305800050210605800070211111200090
2118111001602127114000902143113001702152002000902169008008902178#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#l#4#1#article#1#^mMay^a2007#sc#en#bjmbr#1#
3.1#ilus#05#BJMBR050#FAPESP#Braz. j. med. biol. res#40#5#20070500#^f633^l637#010
0-879X#20070314#Sleep deprivation reduces the lymphocyte count in a non-obese mo
use model of type 1 diabetes mellitus^len#^rND^1A01^nF. S^sRuiz#^rND^1A01^nM. L^
sAndersen#^rND^1A01^nA^sZager#^rND^1A01^nR. C. S^sMartins#^rND^1A01^nS^sTufik#^i
A01^1Universidade Federal de São Paulo^2Escola Paulista de Medicina^3Departament
o de Psicobiologia^cSão Paulo^sSP^pBrasil#^len^aThe objective of the present stu
dy was to determine whether sleep deprivation (SD) would promote changes in lymp
hocyte numbers in a type 1 diabetes model (non-obese diabetic, NOD, mouse strain
) and to determine whether SD would affect female and male NOD compared to Swiss
 mice. The number of lymphocytes in peripheral blood after 24 and 96 h of SD (by
 multiple platform method) or equivalent period of time in home-cage controls wa
s examined prior to the onset of diabetes. SD for 96 h significantly reduced lym
phocytes in male Swiss mice compared to control (8.6 ± 2.1 vs 4.1 ± 0.7 10³/µL; 
P < 0.02). In male NOD animals, 24- and 96-h SD caused a significant decrease of
 lymphocytes compared to control (4.4 ± 0.3 vs 1.6 ± 0.5; P < 0.001 and 4.4 ± 0.
3 vs 0.9 ± 0.1 10³/µL; P < 0.00001, respectively). Both 24- and 96-h SD induced 
a reduction in the number of lymphocytes in female Swiss (7.5 ± 0.5 vs 4.5 ± 0.5
, 4.4 ± 0.6 10³/µL; P < 0.001, respectively) and NOD mice (4 ± 0.6 vs 1.8 ± 0.2,
 1.2 ± 0.4 10³/µL; P < 0.01, respectively) compared to the respective controls. 
Loss of sleep induced lymphopenia in peripheral blood in both genders and strain
s used. Since many cases of autoimmunity present reduced numbers of lymphocytes 
and, in this study, it was more evident in the NOD strain, our results suggest t
hat SD should be considered a risk factor in the onset of autoimmune disorders.#
^dnd^i1#^tm^len^kSleep deprivation^i1#^tm^len^kStress^i1#^tm^len^kLymphopenia^i1
#^tm^len^kDiabetes^i1#^tm^len^kNon-obese diabetic mouse^i1#^tm^len^kSwiss mice^i
1#other#19#AFIP#FAPESP#20060831#August 31, 2006#20070122#January 22, 2007#6620.h
tm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X20
07000500005##
00414000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018900070002000900259#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#5#1#article#58#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 633-637</B> </font> (Short Communication)</B></P>      
^cY#6620.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704020000070002000900270#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#6#2#article#58#<P class="style2"><B><fon
t size="5" face="Arial, Helvetica, sans-serif">Sleep deprivation reduces the lym
phocyte count in a non-obese mouse model of type 1 diabetes mellitus</font></B> 
</P>       ^cY#6620.htm##
00635000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704041000070002000900480#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#7#3#article#58#<P><font face="Arial, Hel
vetica, sans-serif">F.S. Ruiz, <span class="style4"><a href="#Correspondence"><i
mg src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a href="mailto:
mandersen@psicobio.epm.br"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" bor
der="0"></a></span></font>    <font face="Arial, Helvetica, sans-serif">M.L. And
ersen, A. Zager, R.C.S. Martins    and S. Tufik </font>      ^cY#6620.htm##
00419000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019400070002000900264#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#8#4#article#58#<P><font face="Arial, Hel
vetica, sans-serif">Departamento de Psicobiologia, Escola Paulista de Medicina, 
Universidade Federal de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil</font>   
     ^cY#6620.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#9#5#article#58#<P class="style4"> <A HRE
F="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6620.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#10#6#article#58#<BR>   <A HREF="#Text"><
img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6620.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#11#7#article#58#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6620.htm##
00483000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704025700071002000900328#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#12#8#article#58#<br>  </strong></A><font
 face="Arial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><img src="/img/r
evistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HR
EF="#Acknowledgments"><strong>Acknowledgments</strong></A></font>    ^cY#6620.ht
m##
00490000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704026400071002000900335#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#13#9#article#58#<BR>   <A HREF="#Corresp
ondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font face="Arial, Helv
etica, sans-serif">Correspondence    and Footnotes</font></strong></a>      ^cY#
6620.htm##
00291000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704006400072002000900136#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#14#10#article#58#<P class="style4">  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6620.htm##
00619000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039200072002000900464#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#15#11#article#58#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <fo
nt face="Arial, Helvetica, sans-serif">      ^cY#6620.htm##
01806000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704157900072002000901651#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#16#12#article#58#<P>The objective of the
 present study was to determine whether sleep deprivation (SD) would promote cha
nges in lymphocyte numbers in a type 1 diabetes model (non-obese diabetic, NOD, 
mouse strain) and to determine whether SD would affect female and male NOD compa
red to Swiss mice. The number of lymphocytes in peripheral blood after 24 and 96
 h of SD (by multiple platform method) or equivalent period of time in home-cage
 controls was examined prior to the onset of diabetes. SD for 96 h significantly
 reduced lymphocytes in male Swiss mice compared to control (8.6 &#177; 2.1 <I>v
s</I> 4.1 &#177; 0.7 10<SUP>3</SUP>/&#181;L; P &lt; 0.02). In male NOD animals, 
24- and 96-h SD caused a significant decrease of lymphocytes compared to control
 (4.4 &#177; 0.3 <I>vs </I>1.6 &#177; 0.5; P &lt; 0.001 and 4.4 &#177; 0.3 <I>vs
 </I>0.9 &#177; 0.1 10<SUP>3</SUP>/&#181;L; P &lt; 0.00001, respectively). Both 
24- and 96-h SD induced a reduction in the number of lymphocytes in female Swiss
 (7.5 &#177; 0.5 <I>vs </I>4.5 &#177; 0.5, 4.4 &#177; 0.6 10<SUP>3</SUP>/&#181;L
; P &lt; 0.001, respectively) and NOD mice (4 &#177; 0.6 <I>vs </I>1.8 &#177; 0.
2, 1.2 &#177; 0.4 10<SUP>3</SUP>/&#181;L; P &lt; 0.01, respectively) compared to
 the respective controls. Loss of sleep induced lymphopenia in peripheral blood 
in both genders and strains used. Since many cases of autoimmunity present reduc
ed numbers of lymphocytes and, in this study, it was more evident in the NOD str
ain, our results suggest that SD should be considered a risk factor in the onset
 of autoimmune disorders.       ^cY#6620.htm##
00387000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016000072002000900232#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#17#13#article#58#<P><B>Key words: </B> S
leep deprivation, Stress, Lymphopenia, Diabetes, Non-obese diabetic mouse, Swiss
 mice </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6620.htm##
00579000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035200072002000900424#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#18#14#article#58#<P class="style4"><A NA
ME="Text"></A> <span class="style3"><font color="#00007F" face="Arial, Helvetica
, sans-serif" size="4"><b>Text</b></font></span><A HREF="#Home"><FONT SIZE=4><B>
<img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0 LOOP="0"></B></FONT></A>  </P> <font face="Arial, Helvetica, sans-serif"> 
     ^cY#6620.htm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047000072002000900542#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#19#15#article#58#<P>The non-obese diabet
ic (NOD) mouse spontaneously develops type 1 diabetes mellitus that has many sim
ilarities to the human type 1 diabetes. This strain has become particularly usef
ul as an important model of autoimmune disease which typically results from the 
deregulation of fundamental processes designed to maintain self-tolerance. Type 
1 diabetes occurs as a consequence of progressive destruction of pancreatic &szl
ig; cells by autoimmune T-cells (1).       ^cY#6620.htm##
00842000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704061500072002000900687#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#20#16#article#58#<P>Of particular intere
st is the fact that a significant portion of the conditions that lead to type 1 
diabetes occurs in the presence of a reduced number of immune cells or lymphocyt
es (lymphopenia) (2). It is a fact that animal models of autoimmunity often invo
lve the induction of lymphopenia by genetic or experimental means (3). Type 1 di
abetes occurs earlier and more often in female mice, with prevalence reaching 30
 to 70% compared to males, in which the overall incidence remains under 20% (4).
 Moreover, the prevalence of diabetes may also vary depending upon environmental
 factors like stress.       ^cY#6620.htm##
00764000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053700072002000900609#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#21#17#article#58#<P>The close associatio
n of stress and sleep deprivation (SD) can be viewed as the outcome of the press
ure exerted by society on an individual with repercussions on his health and wel
l-being. Indeed, SD is an inherently stressful procedure, and all SD techniques 
involve some degree of stress. Nevertheless, sleep is essential for the recovery
 from illness and, conversely, lack of sleep impairs host defense (5). SD is a c
ondition that is now perceived to have some influence on the proper functioning 
of host defense systems.      ^cY#6620.htm##
00887000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066000072002000900732#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#22#18#article#58#<P>An association betwe
en sleep duration and increased risk of developing diabetes has been reported by
 several investigators (6). However, further research is needed to elucidate thi
s association, and to determine whether the etiology of habitual short sleeping 
time affects long-term health (7). In this context, a recent study demonstrated 
that the alterations occurred during SD suggest an activation of nonspecific imm
une parameters on the short-term periods (e.g., SD for 24 and 96 h) and a signif
icant impairment of cellular response during long-term sleep restriction (Zager 
A, Andersen ML, Ruiz FS, Antunes IB, Tufik S, unpublished results).      ^cY#662
0.htm##
00527000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030000072002000900372#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#23#19#article#58#<P>Thus, the objective 
of the present study was to first assess whether loss of sleep, as a stressor, c
ould induce changes in circulating peripheral lymphocytes in a type 1 diabetes m
odel strain, and then to determine whether SD could exert different influences o
n female and male NOD mice.      ^cY#6620.htm##
00738000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051100072002000900583#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#24#20#article#58#<P>Three-month-old male
 and female Swiss and NOD mice were obtained from CEDEME (UNIFESP). The study wa
s conducted in accordance with the Ethics and Practical Principles of the Use of
 Laboratory Animals. The minimum number of animals was used to obtain statistica
lly meaningful results and all attempts were made to mitigate any suffering. Sin
ce NOD mice are susceptible to the development of autoimmune disorders, we exten
ded our study by comparing the effects of SD on a normal strain (Swiss mice).   
    ^cY#6620.htm##
01017000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704079000072002000900862#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#25#21#article#58#<P>Naive male and femal
e mice were distributed randomly into two groups: home-cage control and SD group
s, according to gender and strain. Based on previous studies, the SD groups were
 subjected to SD for 24 or 96 h (8). According to Velazquez-Moctezuma et al. (9)
, 24 h of SD significantly decrease the total number of lymphocytes in rats. The
 experimental groups were submitted to SD using the modified multiple platform m
ethod, which consists of placing 5 mice inside cages (38 x 31 x 17 cm) containin
g 14 circular platforms (3.5 cm in diameters) with water up to 1 cm of their upp
er surface. At the onset of each paradoxical sleep episode, the animal experienc
es a loss of muscle tonus and falls into the water, thus awakening. Food and wat
er were available <I>ad libitum</I>.       ^cY#6620.htm##
00559000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033200072002000900404#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#26#22#article#58#<P>After being housed i
n the water cages (SD groups) or home-cages (control group), mice were brought t
o an adjacent room and decapitated at 9:00 am and at noon. Differential leukocyt
e counts were determined in blood using an automatic blood cell counter (Advia 1
20 Hematology System, Tarrytown, NY, USA) on the same day.       ^cY#6620.htm##
00475000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704024800072002000900320#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#27#23#article#58#<P>The lymphocyte count
s of the control and SD groups of both sexes are reported as means &#177; SEM an
d were analyzed by the Student <I>t</I>-test to compare differences between grou
ps. The level of significance was set at P &lt; 0.05.        ^cY#6620.htm##
01321000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704109400072002000901166#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#28#24#article#58#<P>SD for 96 h signific
antly reduced lymphocytes in male Swiss mice compared with    control (8.6 &#177
; 2.1 <I>vs</I> 4.1 &#177; 0.7 10<SUP>3</SUP>/&#181;L; P &lt;    0.02, <a href="
#Fig1">Figure 1A</a>), and 24- and 96-h SD significantly reduced    lymphocytes 
in NOD mice compared to control (4.4 &#177; 0.3 <I>vs </I>1.6 &#177;    0.5; P &
lt; 0.001 and 4.4&#177; 0.3 <I>vs </I>0.9 &#177; 0.1 10<SUP>3</SUP>/&#181;L;    
P &lt; 0.00001, respectively). After 96 h of SD, lymphocytes were reduced by    
79.5% compared to control (4.4 &#177; 0.3 <I>vs</I> 0.9 &#177; 0.1 10<SUP>3</SUP
>/&#181;L;    P &lt; 0.00001). Further analyses were conducted to compare Swiss 
and NOD mice.    The Student <I>t</I>-test revealed that lymphocytes were signif
icantly reduced    in the NOD strain in both SD groups compared to Swiss mice at
 the same times    of SD (24 h: 7.1 &#177; 1.0 <I>vs </I>1.6&#177; 0.5 and 96 h:
 4.1 &#177; 0.7    <I>vs </I>0.9&#177; 0.1 10<SUP>3</SUP>/&#181;L; P &lt; 0.001,
 respectively).    Among controls, the differences between groups were not stati
stically significant.      ^cY#6620.htm##
01350000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704112300072002000901195#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#29#25#article#58#<P>In female Swiss mice
, both 24-h and 96-h SD induced a significant reduction    in lymphocytes compar
ed to control (7.5 &#177; 0.5 <I>vs </I>4.5&#177; 0.5,    4.4 &#177; 0.6 10<SUP>
3</SUP>/&#181;L; P &lt; 0.001, respectively, <a href="#Fig1">Figure    1B</a>). 
Similar results were observed for NOD mice, with animals submitted    to 24- and
 96-h SD differing from their respective controls (4 &#177; 0.6 <I>vs    </I>1.8
 &#177; 0.2, 1.2 &#177; 0.4 10<SUP>3</SUP>/&#181;L; P &lt; 0.01, respectively). 
   In the 96-h SD NOD group, the reduction in lymphocytes reached 70% compared  
  to control (4.0 &#177; 0.6 <I>vs</I> 1.2 &#177; 0.4 10<SUP>3</SUP>/&#181;L;   
 P &lt; 0.01). The Student <I>t</I>-test indicated that for all conditions [cont
rol    (7.5 &#177; 0.5 <I>vs </I>4.0 &#177; 0.6 10<SUP>3</SUP>/&#181;L; P &lt; 0
.001)    and 24- (4.5 &#177; 0.5 <I>vs </I>1.8 &#177; 0.2 10<SUP>3</SUP>/&#181;L
; P &lt;    0.001) or 96-h (4.4 &#177; 0.6 <I>vs </I>1.2 &#177; 0.4 10<SUP>3</SU
P>/&#181;L;    P &lt; 0.01) SD] the lymphocyte counts of NOD animals were signif
icantly decreased    compared to the Swiss strain.      ^cY#6620.htm##
01188000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704096100072002000901033#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#30#26#article#58#<P>We examined the effe
cts of a short (24 h) and prolonged (96 h) SD period on the profile of periphera
l lymphocytes and found that SD was effective in markedly reducing the number of
 lymphocytes in NOD mice of both genders. In contrast, control NOD males did not
 differ significantly from control Swiss mice, whereas NOD females showed a sign
ificant reduction in lymphocytes compared to control Swiss mice. When submitted 
to the SD paradigm, regardless of the duration of sleep loss, both genders of th
e NOD strain had significantly less lymphocytes than their respective control gr
oups. In Swiss males, 24-h SD did not induce any changes and a 4-day SD period w
as required to significantly reduce lymphocytes. In females, a significant decre
ase in the number of lymphocytes was observed already after 24 h of SD, with low
 counts remaining during the 96-h SD period. Considering the results as a whole,
 lymphopenia was more evident in the NOD strain.      ^cY#6620.htm##
00719000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049200072002000900564#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#31#27#article#58#<P>Many studies have be
en performed to address the nature of the deficiencies that lead to autoimmunity
. The focus of such investigations has been on the lack of immune regulatory cel
ls such as lymphocytes. Lymphopenia, measured by quantifying lymphoid cells, has
 been recognized as a condition that drives the development of autoimmunity (3).
 In humans, several autoimmune diseases, including insulin-dependent diabetes me
llitus, are detected in association with lymphopenia (10).       ^cY#6620.htm##
01070000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084300072002000900915#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#32#28#article#58#<P>SD is an inherently 
stressful condition that is increasingly ubiquitous in many countries. It may no
t be possible to completely extricate the effects of SD from those produced by g
eneral stress. Additionally, SD is considered to be a health risk factor that co
ntributes to several disease processes (11) and leads to behavioral (12,13) and 
hormonal alterations (8,14). All of these variables are known to alter the immun
e response. One of the most compelling findings suggesting that SD compromises h
ost defense is the increased rate of bacteremia in chronically sleep-deprived ra
ts (15). The observation of infection in healthy tissue of sleep-deprived subjec
ts leads one to believe that SD negatively affects the immune response, renderin
g such subjects more prone to disease and to the exacerbation of pre-existing co
nditions.       ^cY#6620.htm##
01468000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704124100072002000901313#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#33#29#article#58#<P>Our data demonstrate
 that even a short SD period may promote reduction in the number of lymphocytes,
 an immune parameter considered to be essential for the proper function of the h
ost defense. Lymphopenia was observed in both healthy (Swiss) and NOD animals. I
t has been shown that housing conditions and degree of emotionality interfere wi
th the incidence of diabetes (16). In Swiss females sleep deprived for 24 h, we 
observed a significant decrease in the number of lymphocytes which remained at l
ow counts during the 96 h of SD, corroborating the effect of SD on steroid hormo
nes in the female reproductive system (13). NOD males are more emotional than NO
D females and the less emotional NOD females become diabetic earlier, suggesting
 that emotionality via neuroendocrine alterations may be a mediating factor that
 modulates the expression of diabetes (17). Despite the existence of evidence th
at SD is detrimental to immunological function, to our knowledge, this is the fi
rst study that reports the effect of different schedules of SD on a type 1 diabe
tic strain compared to a non-diabetic strain. The SD paradigm was applied prior 
to the onset of diabetes, usually occurring between the 12th and 30th week of ag
e (18).       ^cY#6620.htm##
00930000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070300072002000900775#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#34#30#article#58#<P>Our study complement
s and extends other investigations of gender response to SD (13). In contrast to
 males, NOD female mice did present lymphopenia, possibly induced by survival me
chanisms of disrupted T-cells, supporting the occurrence of sexual dimorphism in
 the prevalence of diabetes in NOD in most colonies (4), and showing that SD res
ults in distinct immune outcomes, particularly in terms of the number of cell ty
pes. Women usually present a higher prevalence of autoimmune diseases especially
 during their reproductive years, as evidenced by higher prevalence of systemic 
lupus erythematosus which may result, in part, from stimulation of the immune sy
stem by female hormones (19).       ^cY#6620.htm##
01069000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084200072002000900914#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#35#31#article#58#<P>Our data suggest tha
t SD has a negative impact on the immune response, indicating that sleep should 
be considered a vital part of the immune system. Over the last decades there has
 been a noticeable reduction in the average amount of sleep and such restriction
, whether partial or total, has proved to exert adverse effects on the populatio
n afflicted by this condition. Our results indicate that the life-threatening co
ndition induced by either acute or chronic SD is a breakdown of host defense, wh
ich is distinctly affected by a previous predisposing factor such as diabetes. T
his is a relevant issue in its own right, since sleep loss affects general healt
h. However, the inherent stress that results from the SD method employed in the 
current study should also be considered as a relevant component of the overall f
indings.       ^cY#6620.htm##
01565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704133800072002000901410#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#36#32#article#58#<P>The origins of autoi
mmunity remain unknown; however, it is known that various autoimmune diseases ar
e characterized by a reduction in the number of lymphocytes. Since lymphopenia m
ay facilitate the destructive process that characterizes autoimmunity and that t
he NOD strain proved to be more susceptible to the effects of SD than the Swiss 
strain, our results suggest that SD should be considered a risk factor in the on
set of autoimmune disorders.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table
 width="100%"  border="0">    <tr align="left" valign="top">      <td width="12%
"><a href="/img/revistas/bjmbr/v40n5/html/6620i01.htm"><img src="/img/revistas/b
jmbr/v40n5/6620i01peq.jpg" border="2"></a></td>           <td width="88%"><font 
face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure        1. Effect o
f sleep deprivation for 24 and 96 h on the lymphocyte count of        male (pane
l A) and female (panel B) non-obese diabetic (NOD) and Swiss strain        mice 
submitted to sleep deprivation for 24 (SD24) and 96 h (SD96) or maintained      
  as home-cage control. Data are reported as means &#177; SEM for 4-8 animals   
     per group. *P &lt; 0.05 compared to Swiss mice; <SUP>+</SUP>P &lt; 0.05    
    compared to the control group of each strain (Student <I>t</I>-test). </font
></td>    </tr>  </table>      ^cY#6620.htm##
00376000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014900072002000900221#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#37#33#article#58#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (80 K JPG file)]</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6620.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#38#34#article#58#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6620.htm##
00373000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704013200074002000900206#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#39#35#article#58#1#<P>1. Atk
inson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets?
 <I>Nat Med</I> 1999; 5: 601-604.      ^cY#6620.htm##
00379000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704013800074002000900212#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#40#36#article#58#2#<P>2. Gle
eson PA, Toh BH, Van Driel I. Organ-specific autoimmunity induced by lymphopenia
. <I>Immunol Rev</I> 1996; 149: 97-125.      ^cY#6620.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017300074002000900247#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#41#37#article#58#3#<P>3. Kin
g C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during im
mune insufficiency generates autoimmunity. <I>Cell</I> 2004; 117: 265-277.      
^cY#6620.htm##
00486000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024500074002000900319#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#42#38#article#58#4#<P>4. Fit
zpatrick F, Lepault F, Homo-Delarche F, Bach JF, Dardenne M. Influence of castra
tion, alone or combined with thymectomy, on the development of diabetes in the n
onobese diabetic mouse. <I>Endocrinology</I> 1991; 129: 1382-1390.      ^cY#6620
.htm##
00476000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023500074002000900309#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#43#39#article#58#5#<P>5. Eve
rson CA. Clinical assessment of blood leukocytes, serum cytokines, and serum imm
unoglobulins as responses to sleep deprivation in laboratory rats. <I>Am J Physi
ol Regul Integr Comp Physiol</I> 2005; 289: R1054-R1063.      ^cY#6620.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022300074002000900297#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#44#40#article#58#6#<P>6. Mal
lon L, Broman JE, Hetta J. High incidence of diabetes in men with sleep complain
ts or short sleep duration: a 12-year follow-up study of a middle-aged populatio
n. <I>Diabetes Care</I> 2005; 28: 2762-2767.      ^cY#6620.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021600074002000900290#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#45#41#article#58#7#<P>7. Aya
s NT, White DP, Al-Delaimy WK, Manson JE, Stampfer MJ, Speizer FE, et al. A pros
pective study of self-reported sleep duration and incident diabetes in women. <I
>Diabetes Care</I> 2003; 26: 380-384.      ^cY#6620.htm##
00454000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021300074002000900287#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#46#42#article#58#8#<P>8. And
ersen ML, Martins PJ, D'Almeida V, Bignotto M, Tufik S. Endocrinological and cat
echolaminergic alterations during sleep deprivation and recovery in male rats. <
I>J Sleep Res</I> 2005; 14: 83-90.      ^cY#6620.htm##
00556000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704031500074002000900389#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#47#43#article#58#9#<P>9. Vel
azquez-Moctezuma J, Dominguez-Salazar E, Cortes-Barberena E, Najera-Medina O, Re
tana-Marquez S, Rodriguez-Aguilera E, et al. Differential effects of rapid eye m
ovement sleep deprivation and immobilization stress on blood lymphocyte subsets 
in rats. <I>Neuroimmunomodulation</I> 2004; 11: 261-267.      ^cY#6620.htm##
00392000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015000075002000900225#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#48#44#article#58#10#<P>10. S
leasman JW. The association between immunodeficiency and the development of auto
immune disease. <I>Adv Dent Res</I> 1996; 10: 57-61.      ^cY#6620.htm##
00405000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016300075002000900238#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#49#45#article#58#11#<P>11. M
iller NE, Bartus RT. Sleep, sleep pathology, and psychopathology in later life: 
a new research frontier. <I>Neurobiol Aging</I> 1982; 3: 283-286.      ^cY#6620.
htm##
00426000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018400075002000900259#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#50#46#article#58#12#<P>12. T
ufik S, Lindsey CJ, Carlini EA. Does REM sleep deprivation induce a supersensiti
vity of dopaminergic receptors in the rat brain? <I>Pharmacology</I> 1978; 16: 9
8-105.      ^cY#6620.htm##
00424000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018200075002000900257#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#51#47#article#58#13#<P>13. A
ntunes IB, Andersen ML, Baracat EC, Tufik S. The effects of paradoxical sleep de
privation on estrous cycles of the female rats. <I>Horm Behav</I> 2006; 49: 433-
440.      ^cY#6620.htm##
00389000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014700075002000900222#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#52#48#article#58#14#<P>14. S
piegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocr
ine function. <I>Lancet</I> 1999; 354: 1435-1439.      ^cY#6620.htm##
00391000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014900075002000900224#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#53#49#article#58#15#<P>15. E
verson CA. Sustained sleep deprivation impairs host defense. <I>Am J Physiol Reg
ul Intergr Comp Physiol </I>1993; 265: R1148-R1154.      ^cY#6620.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021100075002000900286#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#54#50#article#58#16#<P>16. A
der DN, Johnson SB, Huang SW, Riley WJ. Group size, cage shelf level, and emotio
nality in non-obese diabetic mice: impact on onset and incidence of IDDM. <I>Psy
chosom Med</I> 1991; 53: 313-321.      ^cY#6620.htm##
00525000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028300075002000900358#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#55#51#article#58#17#<P>17. D
urant S, Coulaud J, Amrani A, El Hasnaoui A, Dardenne M, Homo-Delarche F. Effect
s of various environmental stress paradigms and adrenalectomy on the expression 
of autoimmune type 1 diabetes in the non-obese diabetic (NOD) mouse. <I>J Autoim
mun</I> 1993; 6: 735-751.      ^cY#6620.htm##
00354000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704011200075002000900187#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#56#52#article#58#18#<P>18. T
ochino Y. The NOD mouse as a model of type I diabetes. <I>Crit Rev Immunol</I> 1
987; 8: 49-81.      ^cY#6620.htm##
00426000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018400075002000900259#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#p#57#53#article#58#19#<P>19. M
cMurray RW. Estrogen, prolactin, and autoimmunity: actions and interactions. <I>
Int Immunopharmacol</I> 2001; 1: 995-1008.  </font>  <HR ALIGN=LEFT WIDTH=100% S
IZE=2>      ^cY#6620.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040100072002000900473#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#58#54#article#58#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=#00
007F><B>Acknowledgments</B></FONT></FONT></font> <font face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></font>
</P>  <font face="Arial, Helvetica, sans-serif">      ^cY#6620.htm##
00433000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704020600072002000900278#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#59#55#article#58#<P>The authors would li
ke to express their cordial thanks to Waldemarks Leite, Alice Lima and Andrea Re
gina Opperman for assistance during the project.  </font>  <HR ALIGN=LEFT WIDTH=
100% SIZE=2>       ^cY#6620.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#60#56#article#58#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, H
elvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT> <
A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6620
.htm##
00675000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044800072002000900520#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#61#57#article#58#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence: </B><font face="Arial, Helvetica, sans-serif">M.L.  
  Andersen, Departamento de Psicobiologia, EPM, UNIFESP, Rua Napole&atilde;o de 
   Barros, 925, 04024-002 S&atilde;o Paulo, SP, Brasil. Fax: +55-11-5572-5092.  
  E-mail: <a href="mailto:mandersen@psicobio.epm.br">mandersen@psicobio.epm.br</
a></font>  </P>      ^cY#6620.htm##
00536000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030900072002000900381#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6620.htm#S#p#62#58#article#58#<P><font face="Arial, H
elvetica, sans-serif">Research supported by Associa&ccedil;&atilde;o Fundo de In
centivo &agrave; Psicofarmacologia (AFIP) and FAPESP (CEPID #98/14303-3 to S. Tu
fik). Received August 31, 2006. Accepted January 22, 2007.</font><font face="Ari
al, Helvetica, sans-serif"> </font>       ^cY#6620.htm##
00519000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100017000920120
06400109030000800173065000900181064000500190031000200195014000800197865000900205
002000900214035001000223801000800233#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
620.htm#S#c#63#1#article#19#1#^rND^sAtkinson^nMA#^rND^sLeiter^nEH#The NOD mouse 
model of type 1 diabetes: as good as it gets?^len#Nat Med#19990000#1999#5#601-60
4#20070500#6620.htm#1078-8956#Nat Med##
00546000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100014000910100
01900105012005500124030001200179065000900191064000500200031000400205014000700209
865000900216002000900225035001000234801001200244#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6620.htm#S#c#64#2#article#19#2#^rND^sGleeson^nPA#^rND^sToh^nBH#^rND^s
Van^nDriel I#Organ-specific autoimmunity induced by lymphopenia^len#Immunol Rev#
19960000#1996#149#97-125#20070500#6620.htm#0105-2896#Immunol Rev##
00592000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100014000870100
01700101010002000118012008800138030000500226065000900231064000500240031000400245
014000800249865000900257002000900266035001000275801000500285#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6620.htm#S#c#65#3#article#19#3#^rND^sKing^nC#^rND^sIlic^n
A#^rND^sKoelsch^nK#^rND^sSarvetnick^nN#Homeostatic expansion of T cells during i
mmune insufficiency generates autoimmunity^len#Cell#20040000#2004#117#265-277#20
070500#6620.htm#0092-8674#Cell##
00691000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100021000730100017000940100
02300111010001500134010001800149012012600167030001400293065000900307064000500316
031000400321014001000325865000900335002000900344035001000353801001400363#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#66#4#article#19#4#^rND^sFitzpatr
ick^nF#^rND^sLepault^nF#^rND^sHomo-Delarche^nF#^rND^sBach^nJF#^rND^sDardenne^nM#
Influence of castration, alone or combined with thymectomy, on the development o
f diabetes in the nonobese diabetic mouse^len#Endocrinology#19910000#1991#129#13
82-1390#20070500#6620.htm#0013-7227#Endocrinology##
00575000000000253000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730120141000910300
03900232710000200271065000900273064000500282031000400287014001200291865000900303
002000900312#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#67#5#article
#19#5#^rND^sEverson^nCA#Clinical assessment of blood leukocytes, serum cytokines
, and serum immunoglobulins as responses to sleep deprivation in laboratory rats
^len#Am J Physiol Regul Integr Comp Physiol#2#20050000#2005#289#R1054-R1063#2007
0500#6620.htm##
00633000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100017000890100
01500106012013900121030001400260065000900274064000500283031000300288014001000291
865000900301002000900310035001000319801001400329#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6620.htm#S#c#68#6#article#19#6#^rND^sMallon^nL#^rND^sBroman^nJE#^rND^
sHetta^nJ#High incidence of diabetes in men with sleep complaints or short sleep
 duration: a 12-year follow-up study of a middle-aged population^len#Diabetes Ca
re#20050000#2005#28#2762-2767#20070500#6620.htm#0149-5992#Diabetes Care##
00691000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100016000880100
02100104010001700125010001900142010001800161810000600179012008700185030001400272
06500090028606400050029503100030030001400080030386500090031100200090032003500100
0329801001400339#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#69#7#art
icle#19#7#^rND^sAyas^nNT#^rND^sWhite^nDP#^rND^sAl-Delaimy^nWK#^rND^sManson^nJE#^
rND^sStampfer^nMJ#^rND^sSpeizer^nFE#et al#A prospective study of self-reported s
leep duration and incident diabetes in women^len#Diabetes Care#20030000#2003#26#
380-384#20070500#6620.htm#0149-5992#Diabetes Care##
00657000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100018000920100
01900110010001800129010001500147012010600162030001200268065000900280064000500289
031000300294014000600297865000900303002000900312035001000321801001200331#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#70#8#article#19#8#^rND^sAndersen
^nML#^rND^sMartins^nPJ#^rND^sD'Almeida^nV#^rND^sBignotto^nM#^rND^sTufik^nS#Endoc
rinological and catecholaminergic alterations during sleep deprivation and recov
ery in male rats^len#J Sleep Res#20050000#2005#14#83-90#20070500#6620.htm#0962-1
105#J Sleep Res##
00798000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100029000730100027001020100
02600129010002300155010002400178010002800202810000600230012012700236030002200363
06500090038506400050039403100030039901400080040286500090041000200090041903500100
0428801002200438#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#71#9#art
icle#19#9#^rND^sVelazquez-Moctezuma^nJ#^rND^sDominguez-Salazar^nE#^rND^sCortes-B
arberena^nE#^rND^sNajera-Medina^nO#^rND^sRetana-Marquez^nS#^rND^sRodriguez-Aguil
era^nE#et al#Differential effects of rapid eye movement sleep deprivation and im
mobilization stress on blood lymphocyte subsets in rats^len#Neuroimmunomodulatio
n#20040000#2004#11#261-267#20070500#6620.htm#1021-7401#NEUROIMMUNOMODULATION##
00524000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750120087000940300
01300181065000900194064000500203031000300208014000600211865000900217002000900226
035001000235801001300245#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#
72#10#article#19#10#^rND^sSleasman^nJW#The association between immunodeficiency 
and the development of autoimmune disease^len#Adv Dent Res#19960000#1996#10#57-6
1#20070500#6620.htm#0895-9374#Adv Dent Res##
00558000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100017000920120
08700109030001600196065000900212064000500221031000200226014000800228865000900236
002000900245035001000254801001600264#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
620.htm#S#c#73#11#article#19#11#^rND^sMiller^nNE#^rND^sBartus^nRT#Sleep, sleep p
athology, and psychopathology in later life: a new research frontier^len#Neurobi
ol Aging#19820000#1982#3#283-286#20070500#6620.htm#0197-4580#Neurobiol Aging##
00595000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100018000900100
01800108012010100126030001300227065000900240064000500249031000300254014000700257
865000900264002000900273035001000282801001300292#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6620.htm#S#c#74#12#article#19#12#^rND^sTufik^nS#^rND^sLindsey^nCJ#^rN
D^sCarlini^nEA#Does REM sleep deprivation induce a supersensitivity of dopaminer
gic receptors in the rat brain?^len#Pharmacology#19780000#1978#16#98-105#2007050
0#6620.htm#0031-7012#Pharmacology##
00608000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100019000930100
01800112010001500130012008600145030001100231065000900242064000500251031000300256
014000800259865000900267002000900276035001000285801001100295#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6620.htm#S#c#75#13#article#19#13#^rND^sAntunes^nIB#^rND^s
Andersen^nML#^rND^sBaracat^nEC#^rND^sTufik^nS#The effects of paradoxical sleep d
eprivation on estrous cycles of the female rats^len#Horm Behav#20060000#2006#49#
433-440#20070500#6620.htm#0018-506X#Horm Behav##
00551000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100018000920100
02000110012006100130030000700191065000900198064000500207031000400212014001000216
865000900226002000900235035001000244801000700254#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6620.htm#S#c#76#14#article#19#14#^rND^sSpiegel^nK#^rND^sLeproult^nR#^
rND^sVan^nCauter E#Impact of sleep debt on metabolic and endocrine function^len#
Lancet#19990000#1999#354#1435-1439#20070500#6620.htm#0099-5355#Lancet##
00490000000000253000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750120053000930300
04000146710000200186065000900188064000500197031000400202014001200206865000900218
002000900227#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#77#15#articl
e#19#15#^rND^sEverson^nCA#Sustained sleep deprivation impairs host defense^len#A
m J Physiol Regul Intergr Comp Physiol#2#19930000#1993#265#R1148-R1154#20070500#
6620.htm##
00640000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100018000900100
01600108010001600124012011700140030001400257065000900271064000500280031000300285
014000800288865000900296002000900305035001000314801001400324#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6620.htm#S#c#78#16#article#19#16#^rND^sAder^nDN#^rND^sJoh
nson^nSB#^rND^sHuang^nSW#^rND^sRiley^nWJ#Group size, cage shelf level, and emoti
onality in non-obese diabetic mice: impact on onset and incidence of IDDM^len#Ps
ychosom Med#19910000#1991#53#313-321#20070500#6620.htm#0033-3174#Psychosom Med##
00746000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100017000910100
01600108010002100124010001800145010002300163012015800186030001200344065000900356
06400050036503100020037001400080037286500090038000200090038903500100039880100120
0408#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#79#17#article#19#17#
^rND^sDurant^nS#^rND^sCoulaud^nJ#^rND^sAmrani^nA#^rND^sEl^nHasnaoui A#^rND^sDard
enne^nM#^rND^sHomo-Delarche^nF#Effects of various environmental stress paradigms
 and adrenalectomy on the expression of autoimmune type 1 diabetes in the non-ob
ese diabetic (NOD) mouse^len#J Autoimmun#19930000#1993#6#735-751#20070500#6620.h
tm#0896-8411#J Autoimmun##
00490000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750120048000920300
01700140065000900157064000500166031000200171014000600173865000900179002000900188
035001000197801001700207#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#
80#18#article#19#18#^rND^sTochino^nY#The NOD mouse as a model of type I diabetes
^len#Crit Rev Immunol#19870000#1987#8#49-81#20070500#6620.htm#1040-8401#Crit Rev
 Immunol##
00481000000000253000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750120068000940300
02000162710000200182065000900184064000500193031000200198014000900200865000900209
002000900218#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6620.htm#S#c#81#19#articl
e#19#19#^rND^sMcMurray^nRW#Estrogen, prolactin, and autoimmunity: actions and in
teractions^len#Int Immunopharmacol#2#20010000#2001#1#995-1008#20070500#6620.htm#
#
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#o#1#1#article#1#20
080213#155326#6662.htm#25##
00792000000000421000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000900093158000300102030002000105
03100030012503200020012806500090013001400110013903500100015001200290016001000290
01890700083002181170006003010720002003071120009003091110016003181140009003341130
01800343002000900361#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#h#2#1#
article#1#co#en#bjmbr#1#3.1#ND#01#BJMBR030#nd#Braz J Med Biol Res#40#5#20070500#
^f599^l599#0100-879X#New paradigms and ethics^len#^rND^1A01^nL.A.B. de^sCastro#M
inistério da Ciência e Tecnologia^iA01^1Secretaria Nacional^cBrasília^sDF^pBrasi
l#other#4#20061004#October 4, 2006#20061116#November 16, 2006#6662.htm##
00792000000000421000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000900093158000300102030002000105
03100030012503200020012806500090013001400110013903500100015001200290016001000290
01890700083002181170006003010720002003071120009003091110016003181140009003341130
01800343002000900361#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#f#3#1#
article#1#co#en#bjmbr#1#3.1#ND#01#BJMBR030#nd#Braz J Med Biol Res#40#5#20070500#
^f599^l599#0100-879X#New paradigms and ethics^len#^rND^1A01^nL.A.B. de^sCastro#M
inistério da Ciência e Tecnologia^iA01^1Secretaria Nacional^cBrasília^sDF^pBrasi
l#other#4#20061004#October 4, 2006#20061116#November 16, 2006#6662.htm##
00910000000000433000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095121000300099049000900102158000300111030002400114
03100030013803200020014106500090014301400110015203500100016301200290017301000310
02020700085002331170006003180720002003241120009003261110016003351140009003511130
01800360002000900378008008900387#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.
htm#S#l#4#1#article#1#^mMay^a2007#co#en#bjmbr#1#3.1#01#BJMBR030#nd#Braz. j. med.
 biol. res#40#5#20070500#^f599^l599#0100-879X#New paradigms and ethics^len#^rND^
1A01^nL. A. B. de^sCastro#^iA01^1Ministério da Ciência e Tecnologia^2Secretaria 
Nacional^cBrasília^sDF^pBrasil#other#4#20061004#October 4, 2006#20061116#Novembe
r 16, 2006#6662.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext
&pid=S0100-879X2007000500001##
00413000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018800070002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#5#1#article#17#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 599 </B> </font> (Concepts and Comments)</B></P>      ^
cY#6662.htm##
00343000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704011800070002000900188#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#6#2#article#17#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">New paradigms and ethics</font></B> </font
>        ^cY#6662.htm##
00579000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704035400070002000900424#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#7#3#article#17#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/im
g/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a href="mailto:lbarreto@mc
t.gov.br"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a></spa
n></font>    <font face="Arial, Helvetica, sans-serif">L.A.B. de Castro </font> 
     ^cY#6662.htm##
00384000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704015900070002000900229#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#8#4#article#17#<P><font face="Arial, Hel
vetica, sans-serif">Secretaria Nacional, Minist&eacute;rio da Ci&ecirc;ncia e Te
cnologia, Bras&iacute;lia, DF, Brasil</font>      ^cY#6662.htm##
00510000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704028500070002000900355#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#9#5#article#17#<P class="style4"> <A HRE
F="#Text"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A>    <A HREF="#Text"><strong><font face="Verdana, Arial, Helv
etica, sans-serif"><font face="Arial, Helvetica, sans-serif">Text</font></font><
/strong></A>    ^cY#6662.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#10#6#article#17#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6662.htm##
00540000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704031400071002000900385#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#11#7#article#17#<br>   </strong></A> <A 
HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font fac
e="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></strong>
</a>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6662.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704038700071002000900458#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#12#8#article#17#<P class="style4"><A NAM
E="Text"></A><font face="Arial, Helvetica, sans-serif" size="4"><b><font color="
#00007F">Text</font></b></font><A HREF="#Home"><FONT SIZE=4><B><img src="/img/re
vistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></
B></FONT></A>    <font face="Arial, Helvetica, sans-serif"> </font></P>  <font f
ace="Arial, Helvetica, sans-serif">    ^cY#6662.htm##
03015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704278900071002000902860#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#13#9#article#17#<P>When reading the Edit
orial "The Road to Balanced Oversight" (Science, Volume 313, page 831), one cann
ot help remembering that Oswaldo Cruz, a Brazilian scientist who had to face a w
ar against yellow fever with inadequate scientific tools and who proposed a new 
paradigm - vaccination -, more than a century ago, was publically persecuted for
 his effort. History proved him right. The Hinxton Group (1) rightly concluded t
hat scientists should be free to work in any country as long as they obey the la
ws of the country where they are working. It would be unethical, however, for th
em to take advantage of lack of laws to do their work. If society, as stated abo
ve, should be free to regulate science independently in any country, it is biase
d to say that those laws that are less restrictive are permissive. It is the sam
e as saying that restrictive laws are always right and less restrictive laws are
 always wrong. New paradigms often face negative public reactions not always for
 ethical or sound scientific reasons. The advances in DNA synthesis indicate tha
t science may be able to create microbes <I>in vitro</I> (2). Reinart and then S
teward, half a century ago, produced plant embryos from somatic plant cells (3).
 Now we know that perhaps few genes in animals confer embryonic potential (4). D
evelopmental biology is telling us that soon we will be able to produce animal e
mbryos from somatic cells which may be as totipotent as plant cells. What are we
 going to do if we learn to manipulate human somatic cells so that they become e
mbryonic cells? Should we stop doing science with any human living cells which w
e have been studying for a century? Should we prevent the production of human em
bryos from somatic cells, embryos needed for the advancement of science for ethi
cal reasons? We can of course prevent the use of these embryos to generate human
 beings. Laws must be very restrictive when science goes beyond this threshold. 
A clear difference can be established between a human embryo and a human being, 
this being dictated by cell lineage differentiation and the laws of developmenta
l biology. Perhaps we should focus on what the ethical purpose of science is and
, rather than preventing the flow of scientific knowledge, we should try to reac
h a global scientific consensus on biological concepts. This achievable task may
 turn out to be less difficult than pursuing consensus on moral issues, which ma
y delay the development of new scientific paradigms, historically justifiable to
 assure the survival of humanity. Where should society draw the line that will s
ay no to the flow of scientific knowledge? The route chosen to interfere with th
e safe advancement of science in any field may be extremely dangerous.  </font> 
 <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6662.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#14#10#article#17#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6662.htm##
00441000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020000074002000900274#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#p#15#11#article#17#1#<P>1. Mat
hews DJ, Donovan P, Harris J, Lovell-Badge R, Savulescu J, Faden R. Science and 
law. Integrity in international stem cell research collaborations. <I>Science</I
> 2006; 313: 921-922.      ^cY#6662.htm##
00362000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704012100074002000900195#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#p#16#12#article#17#2#<P>2. Ser
vice RF. Biosecurity. Synthetic biologists debate policing themselves. <I>Scienc
e</I> 2006; 312: 1116.      ^cY#6662.htm##
00377000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704013600074002000900210#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#p#17#13#article#17#3#<P>3. War
eing PF, Phillips IDJ. <I>The control of growth and differentiation in plants</I
>. Oxford: Pergamon Press Ltd.; 1970.      ^cY#6662.htm##
00399000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015800074002000900232#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#p#18#14#article#17#4#<P>4. Vog
el G. Stem cell research. Four genes confer embryonic potential. <I>Science</I> 
2006; 313: 27.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6662.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#19#15#article#17#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, H
elvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT> <
A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6662
.htm##
00688000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704046100072002000900533#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#20#16#article#17#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence:</B><font face="Arial, Helvetica, sans-serif"> L.A.B.
    de Castro, Secretaria Nacional Minist&eacute;rio da Ci&ecirc;ncia e Tecnolog
ia,    Esplanada dos Minist&eacute;rios, Bloco E, 2&#186; andar, 70067-900 Bras&
iacute;lia,    DF, Brasil. E-mail: <a href="mailto:lbarreto@mct.gov.br">lbarreto
@mct.gov.br</a></font>  </P>      ^cY#6662.htm##
00392000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016500072002000900237#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6662.htm#S#p#21#17#article#17#<P><font face="Arial, H
elvetica, sans-serif">Received October 4, 2006. Accepted November 16, 2006.</fon
t><font face="Arial, Helvetica, sans-serif"> </font>      ^cY#6662.htm##
00657000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080002000681180002000700100018000720100017000900100
01600107010002200123010001900145010001500164012008200179030000800261065000900269
06400050027803100040028301400080028786500090029500200090030403500100031380100080
0323#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#c#22#1#article#4#1#^rN
D^sMathews^nDJ#^rND^sDonovan^nP#^rND^sHarris^nJ#^rND^sLovell-Badge^nR#^rND^sSavu
lescu^nJ#^rND^sFaden^nR#Science and law: Integrity in international stem cell re
search collaborations^len#Science#20060000#2006#313#921-922#20070500#6662.htm#00
36-8075#Science##
00488000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080002000681180002000700100018000720120065000900300
00800155065000900163064000500172031000400177014000500181865000900186002000900195
035001000204801000800214#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#c#
23#2#article#4#2#^rND^sService^nRF#Biosecurity: Synthetic biologists debate poli
cing themselves^len#Science#20060000#2006#312#1116#20070500#6662.htm#0036-8075#S
cience##
00466000000000241000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080002000681180002000700160018000720160020000900180
05600110066000700166062001900173065000900192064000500201865000900206002000900215
#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#c#24#3#article#4#3#^rND^sW
areing^nPF#^rND^sPhillips^nIDJ#The control of growth and differentiation in plan
ts^len#Oxford#Pergamon Press Ltd#19700000#1970#20070500#6662.htm##
00480000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080002000681180002000700100015000720120062000870300
00800149065000900157064000500166031000400171014000300175865000900178002000900187
035001000196801000800206#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6662.htm#S#c#
25#4#article#4#4#^rND^sVogel^nG#Stem cell research: Four genes confer embryonic 
potential^len#Science#20060000#2006#313#27#20070500#6662.htm#0036-8075#Science##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#o#1#1#article#1#20
080212#125718#6665.htm#92##
02964000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120080001790100024002590100027002830100024003100100025003340100026003590100
02500385070011800410083156200528085000802090085003802098085002302136085003002159
08500250218908500190221411700060223307200030223905800070224205800050224911200090
2254111001602263114000902279113001702288881002402305002000902329#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB
#07#BJMBR070#FAPESP#Braz J Med Biol Res#40#5#20070500#^f649^l655#0100-879X#20070
314#Functional expression of kinin B1 and B2 receptors in mouse abdominal aorta^
len#^rND^1A01^nS.A.^sFelipe#^rND^1A01^nE.S.^sRodrigues#^rND^1A01^nR.P.^sMartin#^
rND^1A01^nA.C.M.^sPaiva#^rND^1A01^nJ.B.^sPesquero#^rND^1A01^nS.I.^sShimuta#Unive
rsidade Federal de São Paulo^iA01^1Escola Paulista de Medicina^2Departamento de 
Biofísica^cSão Paulo^sSP^pBrasil#^len^aPrevious studies have shown that the vasc
ular reactivity of the mouse aorta differs substantially from that of the rat ao
rta in response to several agonists such as angiotensin II, endothelin-1 and iso
proterenol. However, no information is available about the agonists bradykinin (
BK) and DesArg9BK (DBK). Our aim was to determine the potential expression of ki
nin B1 and B2 receptors in the abdominal mouse aorta isolated from C57BL/6 mice.
 Contraction and relaxation responses to BK and DBK were investigated using isom
etric recordings. The kinins were unable to induce relaxation but concentration-
contraction response curves were obtained by applying increasing concentrations 
of the agonists BK and DBK. These effects were blocked by the antagonists Icatib
ant and R-715, respectively. The potency (pD2) calculated from the curves was 7.
0 ± 0.1 for BK and 7.3 ± 0.2 for DBK. The efficacy was 51 ± 2% for BK and 30 ± 1
% for DBK when compared to 1 µM norepinephrine. The concentration-dependent resp
onses of BK and DBK were markedly inhibited by the arachidonic acid inhibitor in
domethacin (1 µM), suggesting a mediation by the cyclooxygenase pathway. These c
ontractile responses were not potentiated in the presence of the NOS inhibitor L
-NAME (1 mM) or endothelium-denuded aorta, indicating that the NO pathway is not
 involved. We conclude that the mouse aorta constitutively contains B1 and B2 su
btypes of kinin receptors and that stimulation with BK and DBK induces contracti
le effect mediated by endothelium-independent vasoconstrictor prostanoids.#^dnd^
i1#^tm^len^kKinin B1 and B2 receptors^i1#^tm^len^kBradykinin^i1#^tm^len^kDesArg9
bradykinin^i1#^tm^len^kIndomethacin^i1#^tm^len^kL-NAME^i1#other#14#FAPESP#CNPq#2
0061004#October 4, 2006#20070115#January 15, 2007#S0100-879X2006005000087#6665.h
tm##
03049000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120102001790100024002810100027003050100024003320100025003560100026003810100
02500407070011800432083162800550085000802178085006002186085002302246085004102269
08500250231008500190233511700060235407200030236005800070236305800050237011200090
2375111001602384114000902400113001702409002000902426#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6665.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#07#BJMBR070
#FAPESP#Braz J Med Biol Res#40#5#20070500#^f649^l655#0100-879X#20070314#Function
al expression of kinin B<sub>1</sub> and B<sub>2</sub> receptors in mouse abdomi
nal aorta^len#^rND^1A01^nS.A.^sFelipe#^rND^1A01^nE.S.^sRodrigues#^rND^1A01^nR.P.
^sMartin#^rND^1A01^nA.C.M.^sPaiva#^rND^1A01^nJ.B.^sPesquero#^rND^1A01^nS.I.^sShi
muta#Universidade Federal de São Paulo^iA01^1Escola Paulista de Medicina^2Depart
amento de Biofísica^cSão Paulo^sSP^pBrasil#^len^aPrevious studies have shown tha
t the vascular reactivity of the mouse aorta differs substantially from that of 
the rat aorta in response to several agonists such as angiotensin II, endothelin
-1 and isoproterenol. However, no information is available about the agonists br
adykinin (BK) and DesArg<sup>9</sup>BK (DBK). Our aim was to determine the poten
tial expression of kinin B<sub>1</sub> and B<sub>2</sub> receptors in the abdomi
nal mouse aorta isolated from C57BL/6 mice. Contraction and relaxation responses
 to BK and DBK were investigated using isometric recordings. The kinins were una
ble to induce relaxation but concentration-contraction response curves were obta
ined by applying increasing concentrations of the agonists BK and DBK. These eff
ects were blocked by the antagonists Icatibant and R-715, respectively. The pote
ncy (pD<sub>2</sub>) calculated from the curves was 7.0 ± 0.1 for BK and 7.3 ± 0
.2 for DBK. The efficacy was 51 ± 2% for BK and 30 ± 1% for DBK when compared to
 1 µM norepinephrine. The concentration-dependent responses of BK and DBK were m
arkedly inhibited by the arachidonic acid inhibitor indomethacin (1 µM), suggest
ing a mediation by the cyclooxygenase pathway. These contractile responses were 
not potentiated in the presence of the NOS inhibitor L-NAME (1 mM) or endotheliu
m-denuded aorta, indicating that the NO pathway is not involved. We conclude tha
t the mouse aorta constitutively contains B<sub>1</sub> and B<sub>2</sub> subtyp
es of kinin receptors and that stimulation with BK and DBK induces contractile e
ffect mediated by endothelium-independent vasoconstrictor prostanoids.#^dnd^i1#^
tm^len^kKinin B<sub>1</sub> and B<sub>2</sub> receptors^i1#^tm^len^kBradykinin^i
1#^tm^len^kDesArg<sup>9</sup>bradykinin^i1#^tm^len^kIndomethacin^i1#^tm^len^kL-N
AME^i1#other#14#FAPESP#CNPq#20061004#October 4, 2006#20070115#January 15, 2007#6
665.htm##
03074000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762230009001860120080001950100024002750100027002990100024003260100026003500100
02600376010002500402070012000427083157600547085000802123085003802131085002302169
08500300219208500250222208500190224711700060226607200030227205800070227505800050
2282112000902287111001602296114000902312113001702321002000902338008008902347#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#l#4#1#article#1#^mMay^a2007#oa
#en#bjmbr#1#3.1#ilus#tab#07#BJMBR070#FAPESP#Braz. j. med. biol. res#40#5#2007050
0#^f649^l655#0100-879X#20070314#Functional expression of kinin B1 and B2 recepto
rs in mouse abdominal aorta^len#^rND^1A01^nS. A^sFelipe#^rND^1A01^nE. S^sRodrigu
es#^rND^1A01^nR. P^sMartin#^rND^1A01^nA. C. M^sPaiva#^rND^1A01^nJ. B^sPesquero#^
rND^1A01^nS. I^sShimuta#^iA01^1Universidade Federal de São Paulo^2Escola Paulist
a de Medicina^3Departamento de Biofísica^cSão Paulo^sSP^pBrasil#^len^aPrevious s
tudies have shown that the vascular reactivity of the mouse aorta differs substa
ntially from that of the rat aorta in response to several agonists such as angio
tensin II, endothelin-1 and isoproterenol. However, no information is available 
about the agonists bradykinin (BK) and DesArg9BK (DBK). Our aim was to determine
 the potential expression of kinin B1 and B2 receptors in the abdominal mouse ao
rta isolated from C57BL/6 mice. Contraction and relaxation responses to BK and D
BK were investigated using isometric recordings. The kinins were unable to induc
e relaxation but concentration-contraction response curves were obtained by appl
ying increasing concentrations of the agonists BK and DBK. These effects were bl
ocked by the antagonists Icatibant and R-715, respectively. The potency (pD2) ca
lculated from the curves was 7.0 ± 0.1 for BK and 7.3 ± 0.2 for DBK. The efficac
y was 51 ± 2 percent for BK and 30 ± 1 percent for DBK when compared to 1 µM nor
epinephrine. The concentration-dependent responses of BK and DBK were markedly i
nhibited by the arachidonic acid inhibitor indomethacin (1 µM), suggesting a med
iation by the cyclooxygenase pathway. These contractile responses were not poten
tiated in the presence of the NOS inhibitor L-NAME (1 mM) or endothelium-denuded
 aorta, indicating that the NO pathway is not involved. We conclude that the mou
se aorta constitutively contains B1 and B2 subtypes of kinin receptors and that 
stimulation with BK and DBK induces contractile effect mediated by endothelium-i
ndependent vasoconstrictor prostanoids.#^dnd^i1#^tm^len^kKinin B1 and B2 recepto
rs^i1#^tm^len^kBradykinin^i1#^tm^len^kDesArg9bradykinin^i1#^tm^len^kIndomethacin
^i1#^tm^len^kL-NAME^i1#other#14#FAPESP#CNPq#20061004#October 4, 2006#20070115#Ja
nuary 15, 2007#6665.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_art
text&pid=S0100-879X2007000500007##
00370000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014500070002000900215#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#5#1#article#74#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, May 2007, Volume
 40(5) 649-655</B> </font></P>      ^cY#6665.htm##
00417000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019200070002000900262#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#6#2#article#74#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">Functional expression of kinin B<SUB>1</SU
B> and B<SUB>2</SUB> receptors in mouse abdominal aorta </font></B> </font>     
   ^cY#6665.htm##
00581000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704035600070002000900426#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#7#3#article#74#<P><font face="Arial, Hel
vetica, sans-serif">S.A. Felipe, E.S. Rodrigues, R.P.    Martin, A.C.M. Paiva, J
.B. Pesquero and <b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v40n
5/recor.gif" border="0"></a></b>    <a href="mailto:suma@biofis.epm.br"><img src
="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a>    S.I. Shimuta </font
>      ^cY#6665.htm##
00421000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019600070002000900266#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#8#4#article#74#<P><font face="Arial, Hel
vetica, sans-serif">Departamento de Biof&iacute;sica, Escola Paulista de Medicin
a, Universidade Federal de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil</font>
       ^cY#6665.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019000070002000900260#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#9#5#article#74#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#6665.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#10#6#article#74#<BR>   <A HREF="#Introdu
ction"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6665.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#11#7#article#74#<BR>   <A HREF="#Materia
l"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#6665.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704017200071002000900243#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#12#8#article#74#<BR>   <A HREF="#Results
"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6665.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018100071002000900252#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#13#9#article#74#<BR>   <A HREF="#Discuss
ion"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#666
5.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#14#10#article#74#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6665.htm##
00495000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704026800072002000900340#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#15#11#article#74#<br>   </strong></A>   
<A HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A> </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     
 ^cY#6665.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#16#12#article#74#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">      ^cY#6665.htm##
01892000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704166500072002000901737#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#17#13#article#74#<P>Previous studies hav
e shown that the vascular reactivity of the mouse aorta differs substantially fr
om that of the rat aorta in response to several agonists such as angiotensin II,
 endothelin-1 and isoproterenol. However, no information is available about the 
agonists bradykinin (BK) and DesArg<SUP>9</SUP>BK (DBK). Our aim was to determin
e the potential expression of kinin B<SUB>1</SUB> and B<SUB>2</SUB> receptors in
 the abdominal mouse aorta isolated from C57BL/6 mice. Contraction and relaxatio
n responses to BK and DBK were investigated using isometric recordings. The kini
ns were unable to induce relaxation but concentration-contraction response curve
s were obtained by applying increasing concentrations of the agonists BK and DBK
. These effects were blocked by the antagonists Icatibant and R-715, respectivel
y. The potency (pD<SUB>2</SUB>) calculated from the curves was 7.0 &#177; 0.1 fo
r BK and 7.3 &#177; 0.2 for DBK. The efficacy was 51 &#177; 2% for BK and 30 &#1
77; 1% for DBK when compared to 1 &#181;M norepinephrine. The concentration-depe
ndent responses of BK and DBK were markedly inhibited by the arachidonic acid in
hibitor indomethacin (1 &#181;M), suggesting a mediation by the cyclooxygenase p
athway. These contractile responses were not potentiated in the presence of the 
NOS inhibitor L-NAME (1 mM) or endothelium-denuded aorta, indicating that the NO
 pathway is not involved. We conclude that the mouse aorta constitutively contai
ns B<SUB>1</SUB> and B<SUB>2</SUB> subtypes of kinin receptors and that stimulat
ion with BK and DBK induces contractile effect mediated by endothelium-independe
nt vasoconstrictor prostanoids.       ^cY#6665.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018800072002000900260#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#18#14#article#74#<P><B>Key words: </B> K
inin B<SUB>1</SUB> and B<SUB>2</SUB> receptors, Bradykinin, DesArg<SUP>9</SUP>br
adykinin, Indomethacin, L-NAME   </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     
 ^cY#6665.htm##
00664000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043700072002000900509#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#19#15#article#74#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Introduction</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-se
rif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gi
f" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font fac
e="Arial, Helvetica, sans-serif"></font>  <font face="Arial, Helvetica, sans-ser
if">      ^cY#6665.htm##
00728000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704050100072002000900573#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#20#16#article#74#<P>Kinins are proinflam
matory peptides that act as local hormones and activate the release of endotheli
um-derived relaxing factors such as nitric oxide (NO) and prostaglandins, increa
se vascular permeability, relax or contract smooth muscle, and provoke pain (for
 a review, see Ref. 1). Most of these effects of kinins are mediated by the acti
vation of the B<SUB>2</SUB> receptor, which belongs to a family of peptide hormo
ne receptors linked to G proteins, via the agonist bradykinin (BK).       ^cY#66
65.htm##
00754000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704052700072002000900599#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#21#17#article#74#<P>Another kinin recept
or, the B<SUB>1</SUB> receptor, is activated by the agonist DesArg<SUP>9</SUP>BK
 (DBK) and is generally absent or expressed at very low levels in healthy tissue
s but is induced in response to pathological insults and mediates cardiovascular
 and nociceptive responses in these conditions (2). It has been shown that the m
ouse stomach fundus constitutively expresses kinin B<SUB>1</SUB> and B<SUB>2</SU
B> receptors (3) but no data regarding mouse vascular reactivity to kinins have 
been reported.      ^cY#6665.htm##
00851000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704062400072002000900696#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#22#18#article#74#<P>Therefore, our aim w
as to characterize pharmacologically the expression of B<SUB>1</SUB> and B<SUB>2
</SUB> subtypes of kinin receptors in the mouse aorta through isometric contract
ions and using antagonists for these receptors. In this study we demonstrate tha
t BK and DBK did not relax but induced endothelium-independent contractions of m
ouse abdominal aorta in a concentration-dependent fashion. These contractile res
ponses to the kinins in rings of abdominal aorta were associated with the produc
tion of eicosanoids, whereas NO involvement was not demonstrable.    </font>  <H
R ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6665.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039000072002000900462#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#23#19#article#74#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Material and Methods</B></FONT></FONT></font> <font face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font
 face="Arial, Helvetica, sans-serif">      ^cY#6665.htm##
00286000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005900072002000900131#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#24#20#article#74#<P><b>Animals and organ
 preparations</b>  </font>      ^cY#6665.htm##
02425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704219800072002000902270#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#25#21#article#74#<P><font face="Arial, H
elvetica, sans-serif">The protocols used in the present study were in accordance
 with current guidelines for the care of laboratory animals and ethical guidelin
es for investigations, and were approved by the Animal Care Committee of the Fed
eral University of S&atilde;o Paulo. Animals were maintained on standard mouse c
how at 21-23&#186;C and kept on a 12-h light:dark cycle, with free access to foo
d and water. After 12-16 weeks of age, the animals, weighing 26-30 g, were kille
d by cervical dislocation and exsanguination. The thoracic and abdominal aortas 
were removed, cleared of connective tissue and mounted as ring preparations usin
g 40-mm tungsten wire, into 5-mL organ baths. Aortic rings were bathed in carbox
ygenated (95% O<SUB>2</SUB>/5% CO<SUB>2</SUB>) modified Krebs-Ringer solution (1
44 mM NaCl, 5 mM KCl, 1.1 mM MgSO<SUB>4</SUB>, 25 mM NaHCO<SUB>3</SUB>, 1.1 mM N
aH<SUB>2</SUB>PO<SUB>4</SUB>, 1.25 mM CaCl, and 5.5 mM glucose), pH 7.35, at 37&
#186;C. Resting tension was maintained at 0.5 g. Tissues were left to equilibrat
e for 1 h, with frequent changes of bathing solution. Tissue viability was asses
sed by priming with 80 mM KCl and 1 &#181;M norepinephrine (NE). Following a 90-
min washout and recovery period, cumulative or non-cumulative concentration-resp
onse curves to the agonists were determined. Changes in tension produced by the 
stimulants were measured with an isometric transducer (FTA-10) through an amplif
ier (E805, Hewlett-Packard, Palo Alto, CA, USA) and a potentiometric recorder (R
B-102, ECB, S&atilde;o Paulo, SP, Brazil), as described previously (4). Concentr
ation-response curves were constructed for BK and DBK by applying from 0.1 nM to
 1 &#181;M agonist concentrations. In some experiments, these curves were obtain
ed in the absence and in the presence of specific inhibitors. To determine the a
pparent affinity of agonists in terms of pD<SUB>2</SUB> (the negative logarithm 
of the concentration of agonist that produces 50% of the maximal effect) the cur
ve-fitting analysis of the dose-response curves was carried out using the GraphP
ad-Prism software (San Diego, CA, USA). Data are reported as means &#177; SD. </
font>      ^cY#6665.htm##
00325000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009800072002000900170#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#26#22#article#74#<P><font face="Arial, H
elvetica, sans-serif"><B>Analysis of gene expression </B> </font>      ^cY#6665.
htm##
03463000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704323600072002000903308#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#27#23#article#74#<P><font face="Arial, H
elvetica, sans-serif">Analysis of gene expression for kinin B<SUB>1</SUB> and B<
SUB>2</SUB> receptors was carried out using real-time quantitative PCR. Five mic
e were killed and their aortas were isolated, dissected, frozen in liquid nitrog
en and stored at -80&#186;C. Frozen tissue was homogenized in 1 mL TRIzol reagen
t (Invitrogen, Carlsbad, CA, USA) and total RNA was isolated according to manufa
cturer instructions. Samples were submitted to a 20-&#181;L reaction using the T
aqMan<SUP>&#174;</SUP> amplification system with an ABI PRISM<SUP>&#174;</SUP> 7
000 sequence detection system (Applied Biosystems, Foster City, CA, USA). Real-t
ime PCR was performed with a 1:10 dilution sample of cDNA obtained from total RN
A with the SuperScricpt<SUP>&#153;</SUP> III first-strand synthesis SuperMix for
 qRT-PCR (Invitrogen) for kinin B<SUB>1</SUB> and B<SUB>2</SUB> receptors and &s
zlig;-actin was used as an internal standard. Oligonucleotide primer and fluorog
enic probe sets for Taqman&#153; Real-time PCR were designed for kinin receptors
 and &szlig;-actin using the Assays-by-Design Service (Applied Biosystems) to me
et all TaqMan<SUP>&#174;</SUP> design guidelines. Probes were synthesized with t
he reporter dye 6-carboxyfluorescein covalently linked at the 5' end and the que
ncher dye 6-carboxy-tetramethyl-rhodamine was linked to the 3' end of the probe.
 Each reaction was carried out with 10 &#181;L of Master Mix (Applied Biosystems
), 1 &#181;L of a mix containing two primers (18 &#181;M each) and a probe (5 &#
181;M) specific for mRNA of the kinin B<SUB>1</SUB> receptor (probe 5'-CACAGGAAC
 CCCAGACAGA-3', forward primer 5'-CTC CATACAAAACCCCAGCTGAA-3', reverse primer 5'
-CTTTGGTTAGAAGGCTG TAGCTTCA-3'), kinin B<SUB>2</SUB> receptor (probe 5'-CTTTGGCA
TCGAAATGT-3', forward primer 5'-GGTTTCTGTCGGTGCATGA G-3', reverse primer 5'-GGAC
TTGTGTGGTGACGTTGA-3') or &szlig;-actin (probe 5'-CAGATCATGTTTGAGACCTT-3', forwar
d primer 5'-GGCCAACCGTGAAAAGATGA C-3', reverse primer 5'-GCCTGGATGGCT ACGTACATG-
3'), 5 &#181;L of cDNA samples and Milli-Q water (Millipore Corporation, Billeri
ca, MA, USA) to 20 &#181;L. The cycle conditions were: 50&#186;C for 2 min, 95&#
186;C for 10 min, followed by 50 cycles of 95&#186;C for 15 s (melting step), 60
&#186;C for 1 min (anneal/extend step). Increases in the amount of reporter dye 
fluorescence during the 50 amplification cycles were monitored using Sequence De
tector software (SDS version 1.6, Applied Biosystems). The PCR cycle when a give
n fluorescence threshold is crossed by the amplification curve is considered to 
be the first parameter analyzing mRNA expression and is named C<SUB>T</SUB>. The
 larger the initial amount of copies, the lower the C<SUB>T</SUB> number. A norm
alized value is obtained by subtracting C<SUB>T</SUB> of kinin B<SUB>1</SUB> or 
B<SUB>2</SUB> receptor from C<SUB>T</SUB> of &szlig;-actin, resulting in <font f
ace="Symbol">D</font>C<SUB>T</SUB>. Since it is uncommon to use <font face="Symb
ol">D</font>C<SUB>T</SUB> as a relative expression parameter due to this logarit
hmic characteristic, the 2<SUP>-</SUP><font face="Symbol"><sup>D</sup></font><SU
P>CT</SUP> parameter was used to express the relative gene expression data. </fo
nt>      ^cY#6665.htm##
00302000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007500072002000900147#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#28#24#article#74#<P><font face="Arial, H
elvetica, sans-serif"><B>Drugs</B> </font>      ^cY#6665.htm##
01505000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704127800072002000901350#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#29#25#article#74#<P><font face="Arial, H
elvetica, sans-serif">BK and DBK were obtained from Bachem (Torrance, CA, USA); 
Icatibant (Aventis, Frankfurt, Germany) and R-715 were a gift from D. Regoli, Un
iversit&eacute; de Sherbrooke, Quebec (Canada). DesArg<SUP>9</SUP>Leu<SUP>8</SUP
>BK was synthesized in the Department of Biophysics, Federal University of S&ati
lde;o Paulo, S&atilde;o Paulo, SP, Brazil. Other reagents were purchased from Si
gma Chemical Co. (Dorset, UK). TRIzol reagent and SuperScricpt&#153; III First-S
trand Synthesis SuperMix for qRT-PCR were purchased from Invitrogen; TaqMan<SUP>
&#174;</SUP> Real-Time PCR primers and Master Mix for TaqMan<SUP>&#174;</SUP> Re
al-Time PCR were from Applied Biosystems. Concentrated solutions of peptides (1 
mg/mL) and other agents were prepared in water and kept at -20&#186;C until used
. The stock solutions were serially diluted with Krebs-Ringer solution. Indometh
acin solutions were prepared just before use by dissolving the drug in a small v
olume of saturated aqueous sodium carbonate, diluting to the desired volume with
 Krebs-Ringer solution. The vehicle used for the administration of indomethacin 
had no effect on the responses of the isolated tissue to agonists. All solutions
 were adjusted to pH 7.35 before use. </font>      ^cY#6665.htm##
00317000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009000072002000900162#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#30#26#article#74#<P><font face="Arial, H
elvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6665.htm##
00550000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032300072002000900395#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#31#27#article#74#<P><font face="Arial, H
elvetica, sans-serif">Values are reported as means &#177; SD. The Student <I>t</
I>-test or analysis of variance (ANOVA) with multiple comparisons was used to de
termine the statistical differences, with the level of significance set as P &lt
; 0.05. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6665.htm##
00559000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033200072002000900404#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#32#28#article#74#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT SIZE=4><FONT COLOR=#00007F><B>
Results</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"><A HR
EF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6665.htm##
00859000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063200072002000900704#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#33#29#article#74#<P><font face="Arial, H
elvetica, sans-serif">BK and DBK were able to promote contractile responses in t
he aortic rings. The pD<SUB>2</SUB> values of BK and DBK calculated from concent
ration-response curves (<a href="#Fig1">Figure 1</a>) indicated that the potency
 was similar but the efficacy of BK was significantly higher than that of DBK (<
a href="#Tab1">Table 1</a>). These effects of BK and DBK were shown to be indepe
ndent of the presence of the endothelium. The removal of the endothelium was con
firmed by the lack of acetylcholine-induced relaxation of abdominal aorta precon
tracted with 1 &#181;M NE. </font> </P>      ^cY#6665.htm##
00816000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704058900072002000900661#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#34#30#article#74#<P><font face="Arial, H
elvetica, sans-serif">In the presence of 1 &#181;M Icatibant preincubated for 30
 min, BK-induced contraction of abdominal aorta was drastically inhibited, where
as the DBK-induced effect was blocked by 1 &#181;M R-715. A peptide an-tagonist 
of the B<SUB>1</SUB> receptor, 1 &#181;M DesArg<SUP>9</SUP>Leu<SUP>8</SUP>BK pre
incubated for 30 min, had a similar effect (data not shown). Most results were o
btained with R-715 since its effect was rapidly reversible. The results obtained
 with Icatibant and R-715 are shown in <a href="#Fig2">Figure 2</a>. </font>    
  ^cY#6665.htm##
00726000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049900072002000900571#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#35#31#article#74#<P><font face="Arial, H
elvetica, sans-serif">In order to evaluate the gene expression of kinin B<SUB>1<
/SUB> and B<SUB>2</SUB> receptors in the mouse aorta the amount of mRNA for both
 receptors was analyzed using a quantitative RNA assay. Kinin B<SUB>1</SUB> rece
ptor mRNA showed detectable expression. This determination revealed that the lev
el of expression of mRNA for the B<SUB>1</SUB> receptor was lower than that for 
the B<SUB>2</SUB> receptor (<a href="#Fig3">Figure 3</a>). </font>      ^cY#6665
.htm##
00805000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704057800072002000900650#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#36#32#article#74#<P><font face="Arial, H
elvetica, sans-serif">B<SUB>2</SUB> receptors have been shown to mediate endothe
lium-dependent vasodilation as well as vasoconstriction (5,6). Therefore, the BK
-induced relaxing response of mouse aortic rings was investigated. BK did not ca
use any relaxation in the resting aortic preparations with intact endothelium or
 on NE-induced contraction. Instead of relaxation, the administration of BK to N
E-precontracted rings produced further dose-dependent contraction, above the inc
reased tension produced by 1 &#181;M NE (data not shown). </font>      ^cY#6665.
htm##
00707000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704048000072002000900552#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#37#33#article#74#<P><font face="Arial, H
elvetica, sans-serif">To investigate a possible role of NO release in the BK-ind
uced contraction, an inhibitor of NO synthase activity was examined. Pre-incubat
ion with 1 mM L-NAME for 20 min did not enhance the contractions induced by BK a
nd DBK in aortic rings with an intact endothelium. The presence of the endotheli
um was confirmed pharmacologically by the acetylcholine-induced relaxing effect 
on aortic rings precontracted with NE. </font>       ^cY#6665.htm##
00639000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041200072002000900484#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#38#34#article#74#<P><font face="Arial, H
elvetica, sans-serif">The contractions induced by BK in    mouse aortic rings we
re blocked by preincubation with 1 &#181;M indomethacin    for 20 min (<a href="
#Fig4">Figure 4A</a>). This effect was observed in endothelium-intact    as well
 as in endothelium-denuded abdominal aorta. Similar results were observed    for
 the effect of DBK (<a href="#Fig4">Figure 4B</a>). </font>      ^cY#6665.htm##
00911000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704068400072002000900756#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#39#35#article#74#<P><font face="Arial, H
elvetica, sans-serif">Stimulation of mouse aorta with exogenous NO and sodium ni
troprusside (SNP) completely relaxed the NE-increased tone of vascular tissue. S
NP did not induce relaxation of the aorta under resting basal tonus. The concent
ration-response curves for SNP are shown in <a href="#Fig5">Figure 5</a> and the
 pD<SUB>2</SUB> value was calculated (7.7 &#177; 0.2).</font>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="t
op">      <td width="14%"><a href="/img/revistas/bjmbr/v40n5/html/6665i01.htm"><
img src="/img/revistas/bjmbr/v40n5/6665i01peq.jpg" border="2"></a></td>      <td
 width="86%">    ^cY#6665.htm##
00828000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060100072002000900673#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#40#36#article#74#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Cumulative concentration-resp
onse curves for the effects of bradykinin (BK) and Des-Arg<SUP>9</SUP>BK (DBK), 
agonists of kinin B<SUB>2</SUB> and B<SUB>1</SUB> receptors, respectively, on ri
ngs of abdominal aorta isolated from mice. The isometric contraction responses w
ere calculated in relation to the maximal effect of 1 &#181;M norepinephrine (NE
) which was considered to be 100%. Data are reported as the means &#177; SD of 5
 experiments. *P &lt; 0.05 compared to BK (ANOVA). </font>      </td>    </tr>  
</table>      ^cY#6665.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038700072002000900459#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#41#37#article#74#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (51 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v4
0n5/html/6665i02.htm"><img src="/img/revistas/bjmbr/v40n5/6665i02peq.jpg" border
="2"></a></td>      <td width="86%">    ^cY#6665.htm##
00954000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704072700072002000900799#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#42#38#article#74#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2. Effect of antagonists of the 
kinin B<SUB>2</SUB> receptor, 1 &#181;M Icatibant and of the B<SUB>1</SUB> recep
tor, 1 &#181;M R-715, on abdominal aortic rings isolated from mice. Cumulative c
oncentration-response curves for bradykinin (BK) (A) and Des-Arg<SUP>9</SUP>BK (
DBK) (B) were determined in the presence and absence of the respective antagonis
ts. The isometric contraction responses were calculated in relation to the maxim
al effect of 1 &#181;M norepinephrine (NE) which was considered to be 100%. Data
 are reported as the means &#177; SD of 5 experiments. *P &lt; 0.05 compared to 
control (ANOVA). </font>      </td>    </tr>  </table>      ^cY#6665.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038700072002000900459#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#43#39#article#74#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (60 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v4
0n5/html/6665i03.htm"><img src="/img/revistas/bjmbr/v40n5/6665i03peq.jpg" border
="2"></a></td>      <td width="86%">    ^cY#6665.htm##
00750000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704052300072002000900595#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#44#40#article#74#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig3"></a>Figure 3. Expression of mRNA for kinin 
B<SUB>1</SUB> and B<SUB>2</SUB> receptors. Gene expression of kinin B<SUB>1</SUB
> and B<SUB>2</SUB> receptors was determined by real-time quantitative PCR. &szl
ig;-Actin was used as an internal standard. The 2<SUP>-<font face="Symbol">D</fo
nt>CT</SUP> parameter was used to express the relative gene expression data. *P 
&lt; 0.05 compared to B<SUB>1</SUB> (<I>t</I>-test). </font>      </td>    </tr>
  </table>      ^cY#6665.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038700072002000900459#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#45#41#article#74#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (42 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v4
0n5/html/6665i04.htm"><img src="/img/revistas/bjmbr/v40n5/6665i04peq.jpg" border
="2"></a></td>      <td width="86%">    ^cY#6665.htm##
00835000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060800072002000900680#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#46#42#article#74#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig4"></a>Figure 4. Effect of indomethacin on the
 effect of bradykinin (BK) and Des-Arg<SUP>9</SUP>BK (DBK) in preparations of ao
rtic rings. Cumulative concentration-response curves for BK (A) and DBK (B) were
 obtained in the absence and in the presence of 1 &#181;M indomethacin, a cycloo
xygenase inhibitor. Percent contraction was calculated from the steady-state ten
sion induced by norepinephrine (NE). Data are reported as the means &#177; SD of
 4 experiments. *P &lt; 0.05 compared to control (ANOVA). </font>      </td>    
</tr>  </table>      ^cY#6665.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038700072002000900459#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#47#43#article#74#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (87 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v4
0n5/html/6665i05.htm"><img src="/img/revistas/bjmbr/v40n5/6665i05peq.jpg" border
="2"></a></td>      <td width="86%">    ^cY#6665.htm##
00603000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037600072002000900448#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#48#44#article#74#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig5"></a>Figure 5. Sodium nitroprusside-induced 
relaxation in norepinephrine-precontracted rings of mouse aorta. Percent relaxat
ion was calculated from the steady-state tension induced by norepinephrine. Data
 are reported as means &#177; SD of 5 independent determinations. </font>      <
/td>    </tr>  </table>      ^cY#6665.htm##
00819000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704059200072002000900664#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#49#45#article#74#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (45 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">           <td width="14%"><a href="/img/revistas/bjm
br/v40n5/6665t01.jpg"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="0">
</a></td>      <td width="86%"><font face="Arial, Helvetica, sans-serif"><a name
="Tab1"></a>Table 1. Effect of indomethacin on the potency and maximal effect in
duced by kinins on mouse abdominal aorta rings. </font></td>    </tr>  </table> 
     ^cY#6665.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011800072002000900190#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#50#46#article#74#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (171 K JPG file)]</font
></P>      ^cY#6665.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#51#47#article#74#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6665.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027000072002000900342#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#52#48#article#74#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#6665.htm##
00722000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049500072002000900567#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#53#49#article#74#<P><font face="Arial, H
elvetica, sans-serif">We assessed the role of B<SUB>1</SUB> and B<SUB>2</SUB> re
ceptors in mouse abdominal aorta using isometric force measurements. Our prelimi
nary studies had revealed a low responsiveness of the thoracic aorta to the agon
ists BK and DBK. The poor response to BK by the thoracic aorta in comparison wit
h the response of abdominal aorta was also observed in the contractions induced 
by angiotensin II and endothelin-1 in this tissue (6). </font>      ^cY#6665.htm
##
01301000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704107400072002000901146#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#54#50#article#74#<P><font face="Arial, H
elvetica, sans-serif">The present study showed that BK induced a potent contract
ile response in the abdominal aorta (51% of that induced by 1 &#181;M NE) that w
as significantly inhibited by the B<SUB>2</SUB> receptor antagonist Icatibant, i
ndicating that this agonist depends specifically on the activation of this recep
tor. On the other hand, DBK-induced contraction, whose efficacy was lower than t
hat of BK (30% of NE), was shown to be specifically mediated by the B<SUB>1</SUB
> receptor which was antagonized by the R-715 and DesArg<SUP>9</SUP>Leu<SUP>8</S
UP>BK. By analyzing the gene expression of B<SUB>1</SUB> and B<SUB>2</SUB> recep
tors we could demonstrate B<SUB>1</SUB> receptor mRNA expression in freshly isol
ated mouse aorta which indicated that DBK-induced contractile responses were due
 to activation of the constitutive B<SUB>1</SUB> receptor rather than to its up-
regulation. The lower expression of B<SUB>1</SUB> receptor than B<SUB>2</SUB> re
ceptor mRNA was correlated with the lower efficacy of DBK compared to BK. </font
>      ^cY#6665.htm##
00564000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033700072002000900409#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#55#51#article#74#<P><font face="Arial, H
elvetica, sans-serif">The contractile responses induced by BK and DBK in the mou
se aorta were similar to those reported by Allogho et al. (3), who showed that t
he mouse stomach contains functional B<SUB>1</SUB> and B<SUB>2</SUB> receptors a
nd that the efficacy of BK was greater than that of DBK. </font>      ^cY#6665.h
tm##
00861000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063400072002000900706#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#56#52#article#74#<P><font face="Arial, H
elvetica, sans-serif">In contrast, the rat aorta has been reported to be insensi
tive to DBK<I> in vitro</I>, even after bacterial lipopolysaccharide pre-treatme
nt (7). More recent studies have shown that rat aortic smooth muscle cells bind 
the tritiated B<SUB>1</SUB> receptor agonist <SUP>3</SUP>H-DBK and that B<SUB>1 
</SUB>receptor mRNA was detected (8). According to these observations, rat aorti
c smooth muscle cells have the potential to express B<SUB>1</SUB> receptors but 
the expression level may not be high enough to induce detectable contractile res
ponses in the isolated rat aorta. </font>      ^cY#6665.htm##
01031000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704080400072002000900876#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#57#53#article#74#<P><font face="Arial, H
elvetica, sans-serif">Our finding that BK-induced contractions were not affected
 by endothelium removal indicates that, in contrast to the vasodilator effect (9
,10), the vasoconstriction induced by kinins results from a direct action on iso
lated mouse aortic smooth muscle. In agreement with this result, BK-induced cont
raction was not altered when the abdominal aorta was treated with L-NAME. This r
esult suggests that NO-dependent vasodilation, which would antagonize part of th
e vasoconstrictive effect of BK, can be ruled out. It is noteworthy that endothe
lin-1-induced contraction of the same preparation was significantly reduced when
 L-NAME was absent from the medium (11), whereas this effect was not observed wi
th angiotensin II-induced contraction (12). </font>      ^cY#6665.htm##
01023000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704079600072002000900868#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#58#54#article#74#<P><font face="Arial, H
elvetica, sans-serif">The finding that the contractile responses to BK and DBK w
ere significantly reduced by indomethacin in mouse endothelium-denuded abdominal
 aorta indicates that these responses are mostly mediated by vasoconstrictor pro
stanoids. In this regard, it is interesting to note that, as previously reported
, the prostanoids derived from the arachidonic acid-cyclooxygenase pathway can b
e produced within the vascular smooth muscle (13). Since the BK- and DBK-induced
 effect was not completely blocked by the cyclooxygenase inhibitor, the remainin
g response could be ascribed to a direct rather than a mediated effect of the pe
ptides. However, a possible involvement of other signaling pathways in this cont
ractile effect cannot be ruled out. </font>      ^cY#6665.htm##
00829000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060200072002000900674#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#59#55#article#74#<P><font face="Arial, H
elvetica, sans-serif">In contrast to the mouse abdominal aorta, where kinins wer
e unable to induce relaxation of NE-pre-contracted preparations, BK induced conc
entration-dependent relaxation in phenylephrine-pre-contracted rings of rat aort
a, which was inhibited by Icatibant. This vasorelaxation of endothelium-denuded 
rat aorta was ascribed to the generation of cyclooxygenase products through acti
vation of B<SUB>2</SUB> receptors on smooth muscle cells (14). These results ind
icate that the effect of kinins on vessels may differ considerably among species
. </font>      ^cY#6665.htm##
00600000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037300072002000900445#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#60#56#article#74#<P><font face="Arial, H
elvetica, sans-serif">The present study showed for the first time that mouse aor
tic tissues express functional constitutive kinin B<SUB>1</SUB> and B<SUB>2</SUB
> receptors localized within the vascular wall and that BK and DBK induce contra
ctile responses which are mostly mediated by prostanoids. </font>  <HR ALIGN=LEF
T WIDTH=100% SIZE=2>      ^cY#6665.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#61#57#article#74#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>References</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"
><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6665.
htm##
00563000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704032200074002000900396#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#62#58#article#74#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Leeb-Lundberg LM, Marceau F, Muller-Ester
l W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classific
ation of the kinin receptor family: from molecular mechanisms to pathophysiologi
cal consequences. <I>Pharmacol Rev</I> 2005; 57: 27-77. </font>      ^cY#6665.ht
m##
00409000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016800074002000900242#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#63#59#article#74#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Marceau F, Hess JF, Bachvarov DR. The B1 
receptors for kinins. <I>Pharmacol Rev</I> 1998; 50: 357-386. </font>      ^cY#6
665.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022700074002000900301#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#64#60#article#74#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Allogho SN, Gobeil F, Pheng LH, Nguyen-Le
 XK, Neugebauer W, Regoli D. Kinin B1 and B2 receptors in the mouse. <I>Can J Ph
ysiol Pharmacol</I> 1995; 73: 1759-1764. </font>      ^cY#6665.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024100074002000900315#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#65#61#article#74#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Shimuta SI, Barbosa AM, Borges AC, Paiva 
TB. Pharmacological characterization of RMP-7, a novel bradykinin agonist in smo
oth muscle. <I>Immunopharmacology</I> 1999; 45: 63-67. </font>      ^cY#6665.htm
##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022500074002000900299#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#66#62#article#74#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Briner VA, Tsai P, Schrier RW. Bradykinin
: potential for vascular constriction in the presence of endothelial injury. <I>
Am J Physiol</I> 1993; 264: F322-F327. </font>      ^cY#6665.htm##
00444000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020300074002000900277#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#67#63#article#74#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Russell A, Watts S. Vascular reactivity o
f isolated thoracic aorta of the C57BL/6J mouse. <I>J Pharmacol Exp Ther</I> 200
0; 294: 598-604. </font>      ^cY#6665.htm##
00389000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704014800074002000900222#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#68#64#article#74#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Marceau F. Kinin B1 receptors: a review. 
<I>Immunopharmacology</I> 1995; 30: 1-26. </font>      ^cY#6665.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024900074002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#69#65#article#74#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Schaeffer P, Laplace MC, Savi P, Prabonna
ud V, Salel V, Herbert JM. Detection of bradykinin B1 receptors in rat aortic sm
ooth muscle cells. <I>Biochem Pharmacol</I> 2001; 61: 291-298. </font>      ^cY#
6665.htm##
00454000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021300074002000900287#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#70#66#article#74#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Siragy HM, Jaffa AA, Margolius HS. Bradyk
inin B2 receptor modulates renal prostaglandin E2 and nitric oxide. <I>Hypertens
ion</I> 1997; 29: 757-762. </font>      ^cY#6665.htm##
00534000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029200075002000900367#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#71#67#article#74#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Kichuk MR, Seyedi N, Zhang X, Marboe CC
, Michler RE, Addonizio LJ, et al. Regulation of nitric oxide production in huma
n coronary microvessels and the contribution of local kinin formation. <I>Circul
ation</I> 1996; 94: 44-51. </font>      ^cY#6665.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027600075002000900351#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#72#68#article#74#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Zhou Y, Dirksen WP, Zweier JL, Periasam
y M. Endothelin-1-induced responses in isolated mouse vessels: the expression an
d function of receptor types. <I>Am J Physiol Heart Circ Physiol</I> 2004; 287: 
H573-H578. </font>      ^cY#6665.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030100075002000900376#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#73#69#article#74#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Zhou Y, Dirksen WP, Babu GJ, Periasamy 
M. Differential vasoconstrictions induced by angiotensin II: role of AT1 and AT2
 receptors in isolated C57BL/6J mouse blood vessels. <I>Am J Physiol Heart Circ 
Physiol</I> 2003; 285: H2797-H2803. </font>      ^cY#6665.htm##
00529000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028700075002000900362#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#74#70#article#74#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Stanke-Labesque F, Mallaret M, Lefebvre
 B, Hardy G, Caron F, Bessard G. 2-Arachidonoyl glycerol induces contraction of 
isolated rat aorta: role of cyclooxygenase-derived products. <I>Cardiovasc Res</
I> 2004; 63: 155-160. </font>      ^cY#6665.htm##
00547000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030500075002000900380#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#p#75#71#article#74#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Fukada SY, Tirapelli CR, de Godoy MA, d
e Oliveira AM. Mechanisms underlying the endothelium-independent relaxation indu
ced by angiotensin II in rat aorta. <I>J Cardiovasc Pharmacol</I> 2005; 45: 136-
143. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6665.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034800072002000900420#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#76#72#article#74#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      
 ^cY#6665.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040100072002000900473#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#77#73#article#74#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/rec
or.gif" border="0"></a>    Address for correspondence:</b> </font><font face="Ar
ial, Helvetica, sans-serif">S.I.    Shimuta, Rua Botucatu, 862, 04023-062 S&atil
de;o Paulo, SP, Brasil. Fax: +55-11-5571-5780.    E-mail: <a href="mailto:suma@b
iofis.epm.br">suma@biofis.epm.br</a></font> </p>      ^cY#6665.htm##
00381000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015400072002000900226#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6665.htm#S#p#78#74#article#74#<P><font face="Arial, H
elvetica, sans-serif">Research supported by FAPESP and CNPq. Received October 4,
 2006. Accepted January 15, 2007. </font>      ^cY#6665.htm##
00718000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100024000730100017000970100
02300114010002000137010001600157012015200173030001400325065000900339064000500348
031000300353014000600356865000900362002000900371035001000380801001400390#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#c#79#1#article#14#1#^rND^sLeeb-Lun
dberg^nLM#^rND^sMarceau^nF#^rND^sMuller-Esterl^nW#^rND^sPettibone^nDJ#^rND^sZura
w^nBL#International union of pharmacology. XLV. Classification of the kinin rece
ptor family: from molecular mechanisms to pathophysiological consequences^len#Ph
armacol Rev#20050000#2005#57#27-77#20070500#6665.htm#0031-6997#Pharmacol Rev##
00528000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100015000900100
02000105012003200125030001400157065000900171064000500180031000300185014000800188
865000900196002000900205035001000214801001400224#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6665.htm#S#c#80#2#article#14#2#^rND^sMarceau^nF#^rND^sHess^nJF#^rND^s
Bachvarov^nDR#The B1 receptors for kinins^len#Pharmacol Rev#19980000#1998#50#357
-386#20070500#6665.htm#0031-6997#Pharmacol Rev##
00651000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100016000910100
01600107010002000123010002000143010001600163012004300179030002400222065000900246
06400050025503100030026001400100026386500090027300200090028203500100029180100240
0301#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#c#81#3#article#14#3#^r
ND^sAllogho^nSN#^rND^sGobeil^nF#^rND^sPheng^nLH#^rND^sNguyen-Le^nXK#^rND^sNeugeb
auer^nW#^rND^sRegoli^nD#Kinin B1 and B2 receptors in the mouse^len#Can J Physiol
 Pharmacol#19950000#1995#73#1759-1764#20070500#6665.htm#0008-4212#Can J Physiol 
Pharmacol##
00624000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100018000910100
01700109010001600126012009100142030001900233065000900252064000500261031000300266
014000600269865000900275002000900284035001000293801001900303#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6665.htm#S#c#82#4#article#14#4#^rND^sShimuta^nSI#^rND^sBa
rbosa^nAM#^rND^sBorges^nAC#^rND^sPaiva^nTB#Pharmacological characterization of R
MP-7, a novel bradykinin agonist in smooth muscle^len#Immunopharmacology#1999000
0#1999#45#63-67#20070500#6665.htm#0162-3109#Immunopharmacology##
00584000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100014000900100
01800104012009000122030001300212065000900225064000500234031000400239014001000243
865000900253002000900262035001000271801001300281#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6665.htm#S#c#83#5#article#14#5#^rND^sBriner^nVA#^rND^sTsai^nP#^rND^sS
chrier^nRW#Bradykinin: potential for vascular constriction in the presence of en
dothelial injury^len#Am J Physiol#19930000#1993#264#F322-F327#20070500#6665.htm#
0002-9513#Am J Physiol##
00552000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100015000900120
07300105030002100178065000900199064000500208031000400213014000800217865000900225
002000900234035001000243801002100253#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
665.htm#S#c#84#6#article#14#6#^rND^sRussell^nA#^rND^sWatts^nS#Vascular reactivit
y of isolated thoracic aorta of the C57BL/6J mouse^len#J Pharmacol Exp Ther#2000
0000#2000#294#598-604#20070500#6665.htm#0022-3565#J Pharmacol Exp Ther##
00477000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730120033000900300
01900123065000900142064000500151031000300156014000500159865000900164002000900173
035001000182801001900192#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#c#
85#7#article#14#7#^rND^sMarceau^nF#Kinin B1 receptors: a review^len#Immunopharma
cology#19950000#1995#30#1-26#20070500#6665.htm#0162-3109#Immunopharmacology##
00667000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100018000920100
01400110010002000124010001500144010001800159012007500177030001800252065000900270
06400050027903100030028401400080028786500090029500200090030403500100031380100180
0323#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#c#86#8#article#14#8#^r
ND^sSchaeffer^nP#^rND^sLaplace^nMC#^rND^sSavi^nP#^rND^sPrabonnaud^nV#^rND^sSalel
^nV#^rND^sHerbert^nJM#Detection of bradykinin B1 receptors in rat aortic smooth 
muscle cells^len#Biochem Pharmacol#20010000#2001#61#291-298#20070500#6665.htm#00
06-2952#Biochem Pharmacol##
00572000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100016000900100
02000106012007700126030001300203065000900216064000500225031000300230014000800233
865000900241002000900250035001000259801001300269#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6665.htm#S#c#87#9#article#14#9#^rND^sSiragy^nHM#^rND^sJaffa^nAA#^rND^
sMargolius^nHS#Bradykinin B2 receptor modulates renal prostaglandin E2 and nitri
c oxide^len#Hypertension#19970000#1997#29#757-762#20070500#6665.htm#0194-911X#Hy
pertension##
00716000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100016000920100
01500108010001700123010001800140010002000158810000600178012011900184030001200303
06500090031506400050032403100030032901400060033286500090033800200090034703500100
0356801001200366#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#c#88#10#ar
ticle#14#10#^rND^sKichuk^nMR#^rND^sSeyedi^nN#^rND^sZhang^nX#^rND^sMarboe^nCC#^rN
D^sMichler^nRE#^rND^sAddonizio^nLJ#et al#Regulation of nitric oxide production i
n human coronary microvessels and the contribution of local kinin formation^len#
Circulation#19960000#1996#94#44-51#20070500#6665.htm#0009-7322#Circulation##
00621000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100018000890100
01700107010001900124012010800143030003200251710000200283065000900285064000500294
031000400299014001000303865000900313002000900322#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6665.htm#S#c#89#11#article#14#11#^rND^sZhou^nY#^rND^sDirksen^nWP#^rND
^sZweier^nJL#^rND^sPeriasamy^nM#Endothelin-1-induced responses in isolated mouse
 vessels: the expression and function of receptor types^len#Am J Physiol Heart C
irc Physiol#2#20040000#2004#287#H573-H578#20070500#6665.htm##
00646000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100018000890100
01500107010001900122012013300141030003200274710000200306065000900308064000500317
031000400322014001200326865000900338002000900347#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6665.htm#S#c#90#12#article#14#12#^rND^sZhou^nY#^rND^sDirksen^nWP#^rND
^sBabu^nGJ#^rND^sPeriasamy^nM#Differential vasoconstrictions induced by angioten
sin II: role of AT1 and AT2 receptors in isolated C57BL/6J mouse blood vessels^l
en#Am J Physiol Heart Circ Physiol#2#20030000#2003#285#H2797-H2803#20070500#6665
.htm##
00703000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100025000750100018001000100
01800118010001500136010001500151010001700166012011100183030001500294065000900309
06400050031803100030032301400080032686500090033400200090034303500100035280100150
0362#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6665.htm#S#c#91#13#article#14#13#
^rND^sStanke-Labesque^nF#^rND^sMallaret^nM#^rND^sLefebvre^nB#^rND^sHardy^nG#^rND
^sCaron^nF#^rND^sBessard^nG#2-Arachidonoyl glycerol induces contraction of isola
ted rat aorta: role of cyclooxygenase-derived products^len#Cardiovasc Res#200400
00#2004#63#155-160#20070500#6665.htm#0008-6363#Cardiovasc Res##
00658000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100020000920100
01900112010002200131012010400153030002300257065000900280064000500289031000300294
014000800297865000900305002000900314035001000323801002300333#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6665.htm#S#c#92#14#article#14#14#^rND^sFukada^nSY#^rND^sT
irapelli^nCR#^rND^sde^nGodoy MA#^rND^sde^nOliveira AM#Mechanisms underlying the 
endothelium-independent relaxation induced by angiotensin II in rat aorta^len#J 
Cardiovasc Pharmacol#20050000#2005#45#136-143#20070500#6665.htm#0160-2446#J Card
iovasc Pharmacol##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#o#1#1#article#1#20
080212#125721#6678.htm#149##
02619000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120119001790100028002980100028003260100027003540100029003810100023004100100
02300433010002400456070010200480070013200582083104500714085000801759085003001767
08500240179708500310182108500280185208500210188011700060190107200030190711200090
1910111001701919114000901936113001501945881002401960002000901984#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#h#2#1#article#1#ra#en#bjmbr#1#3.1#ILUS#TAB
#15#BJMBR700#FAPESP#Braz J Med Biol Res#40#5#20070500#^f707^l712#0100-879X#20070
405#Water deprivation and the double- depletion hypothesis: common neural mechan
isms underlie thirst and salt appetite^len#^rND^1A01^nL.A. Jr^sDe Luca#^rND^1A02
^nR.C.^sVendramini#^rND^1A01^nD.T.B.^sPereira#^rND^1A01^nD.A.S.^sColombari#^rND^
1A01^nR.B.^sDavid#^rND^1A01^nP.M.^sPaula#^rND^1A01^nJ.V.^sMenani#Universidade Es
tadual Paulista^iA01^1Faculdade de Odontologia^2Departamento de Fisiologia e Pat
ologia#Universidade Estadual Paulista^iA02^1Faculdade de Ciências Farmacêuticas^
2Departamento de Análises Clínicas^cAraraquara^sSP^pBrasil#^len^aWater deprivati
on-induced thirst is explained by the double-depletion hypothesis, which predict
s that dehydration of the two major body fluid compartments, the extracellular a
nd intracellular compartments, activates signals that combine centrally to induc
e water intake. However, sodium appetite is also elicited by water deprivation. 
In this brief review, we stress the importance of the water-depletion and partia
l extracellular fluid-repletion protocol which permits the distinction between s
odium appetite and thirst. Consistent enhancement or a de novo production of sod
ium intake induced by deactivation of inhibitory nuclei (e.g., lateral parabrach
ial nucleus) or hormones (oxytocin, atrial natriuretic peptide), in water-depriv
ed, extracellular-dehydrated or, contrary to tradition, intracellular-dehydrated
 rats, suggests that sodium appetite and thirst share more mechanisms than previ
ously thought. Water deprivation has physiological and health effects in humans 
that might be related to the salt craving shown by our species.#^dnd^i1#^tm^len^
kWater deprivation^i1#^tm^len^kDehydration^i1#^tm^len^kMineral preference^i1#^tm
^len^kSodium appetite^i1#^tm^len^kCravings^i1#other#50#20061011#October 11, 2006
#20070329#March 29, 2007#S0100-879X2006005000101#6678.htm##
02583000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120119001790100028002980100028003260100027003540100029003810100023004100100
02300433010002400456070010200480070013200582083104500714085000801759085003001767
08500240179708500310182108500280185208500210188011700060190107200030190711200090
1910111001701919114000901936113001501945002000901960#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6678.htm#S#f#3#1#article#1#ra#en#bjmbr#1#3.1#ILUS#TAB#15#BJMBR700
#FAPESP#Braz J Med Biol Res#40#5#20070500#^f707^l712#0100-879X#20070405#Water de
privation and the double- depletion hypothesis: common neural mechanisms underli
e thirst and salt appetite^len#^rND^1A01^nL.A. Jr^sDe Luca#^rND^1A02^nR.C.^sVend
ramini#^rND^1A01^nD.T.B.^sPereira#^rND^1A01^nD.A.S.^sColombari#^rND^1A01^nR.B.^s
David#^rND^1A01^nP.M.^sPaula#^rND^1A01^nJ.V.^sMenani#Universidade Estadual Pauli
sta^iA01^1Faculdade de Odontologia^2Departamento de Fisiologia e Patologia#Unive
rsidade Estadual Paulista^iA02^1Faculdade de Ciências Farmacêuticas^2Departament
o de Análises Clínicas^cAraraquara^sSP^pBrasil#^len^aWater deprivation-induced t
hirst is explained by the double-depletion hypothesis, which predicts that dehyd
ration of the two major body fluid compartments, the extracellular and intracell
ular compartments, activates signals that combine centrally to induce water inta
ke. However, sodium appetite is also elicited by water deprivation. In this brie
f review, we stress the importance of the water-depletion and partial extracellu
lar fluid-repletion protocol which permits the distinction between sodium appeti
te and thirst. Consistent enhancement or a de novo production of sodium intake i
nduced by deactivation of inhibitory nuclei (e.g., lateral parabrachial nucleus)
 or hormones (oxytocin, atrial natriuretic peptide), in water-deprived, extracel
lular-dehydrated or, contrary to tradition, intracellular-dehydrated rats, sugge
sts that sodium appetite and thirst share more mechanisms than previously though
t. Water deprivation has physiological and health effects in humans that might b
e related to the salt craving shown by our species.#^dnd^i1#^tm^len^kWater depri
vation^i1#^tm^len^kDehydration^i1#^tm^len^kMineral preference^i1#^tm^len^kSodium
 appetite^i1#^tm^len^kCravings^i1#other#50#20061011#October 11, 2006#20070329#Ma
rch 29, 2007#6678.htm##
02743000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762230009001860120119001950100029003140100028003430100028003710100030003990100
02300429010002300452010002400475070012800499070013400627083104500761085000801806
08500300181408500240184408500310186808500280189908500210192711700060194807200030
1954112000901957111001701966114000901983113001501992002000902007008008902016#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#l#4#1#article#1#^mMay^a2007#ra
#en#bjmbr#1#3.1#ilus#tab#15#BJMBR700#FAPESP#Braz. j. med. biol. res#40#5#2007050
0#^f707^l712#0100-879X#20070405#Water deprivation and the double- depletion hypo
thesis: common neural mechanisms underlie thirst and salt appetite^len#^rND^1A01
^nL. A. Jr^sDe Luca#^rND^1A02^nR. C^sVendramini#^rND^1A01^nD. T. B^sPereira#^rND
^1A01^nD. A. S^sColombari#^rND^1A01^nR. B^sDavid#^rND^1A01^nP. M^sPaula#^rND^1A0
1^nJ. V^sMenani#^iA01^1Universidade Estadual Paulista^2Faculdade de Odontologia^
3Departamento de Fisiologia e Patologia^cAraraquara^sSP^pBrasil#^iA02^1Universid
ade Estadual Paulista^2Faculdade de Ciências Farmacêuticas^3Departamento de Anál
ises Clínicas^cAraraquara^sSP^pBrasil#^len^aWater deprivation-induced thirst is 
explained by the double-depletion hypothesis, which predicts that dehydration of
 the two major body fluid compartments, the extracellular and intracellular comp
artments, activates signals that combine centrally to induce water intake. Howev
er, sodium appetite is also elicited by water deprivation. In this brief review,
 we stress the importance of the water-depletion and partial extracellular fluid
-repletion protocol which permits the distinction between sodium appetite and th
irst. Consistent enhancement or a de novo production of sodium intake induced by
 deactivation of inhibitory nuclei (e.g., lateral parabrachial nucleus) or hormo
nes (oxytocin, atrial natriuretic peptide), in water-deprived, extracellular-deh
ydrated or, contrary to tradition, intracellular-dehydrated rats, suggests that 
sodium appetite and thirst share more mechanisms than previously thought. Water 
deprivation has physiological and health effects in humans that might be related
 to the salt craving shown by our species.#^dnd^i1#^tm^len^kWater deprivation^i1
#^tm^len^kDehydration^i1#^tm^len^kMineral preference^i1#^tm^len^kSodium appetite
^i1#^tm^len^kCravings^i1#other#50#20061011#October 11, 2006#20070329#March 29, 2
007#6678.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0
100-879X2007000500015##
00401000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704017600070002000900246#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#5#1#article#95#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 707-712</B> </font> (Review)</B></P>      ^cY#6678.htm#
#
00438000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704021300070002000900283#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#6#2#article#95#<P class="style2"><B><fon
t size="5" face="Arial, Helvetica, sans-serif">Water deprivation and the double-
 depletion hypothesis: common neural mechanisms underlie thirst and salt appetit
e</font></B> </P>       ^cY#6678.htm##
00899000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704067400070002000900744#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#7#3#article#95#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/im
g/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a href="mailto:lucajr@foar
.unesp.br"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a></sp
an></font>    <font face="Arial, Helvetica, sans-serif">L.A. De Luca Jr.<SUP>1</
SUP>, R.C.    Vendramini<SUP>2</SUP><a href="#These"><font size="4">*</font></a>
, D.T.B. Pereira<SUP>1</SUP><a href="#These"><font size="4">*</font></a>,    D.A
.S. Colombari<SUP>1</SUP>, R.B. David<SUP>1</SUP><a href="#These"><font size="4"
>*</font></a>,    P.M. de Paula<SUP>1</SUP> and J.V. Menani<SUP>1</SUP> </font> 
     ^cY#6678.htm##
00531000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704030600070002000900376#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#8#4#article#95#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento de Fisiologia e Patologia, Faculdad
e de Odontologia, <SUP>2</SUP>Departamento de An&aacute;lises Cl&iacute;nicas, F
aculdade de Ci&ecirc;ncias Farmac&ecirc;uticas, Universidade Estadual Paulista, 
Araraquara, SP, Brasil</font>        ^cY#6678.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#9#5#article#95#<P class="style4"> <A HRE
F="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6678.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#10#6#article#95#<BR>   <A HREF="#Text"><
img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6678.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#11#7#article#95#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6678.htm##
00483000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704025700071002000900328#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#12#8#article#95#<br>  </strong></A><font
 face="Arial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><img src="/img/r
evistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HR
EF="#Acknowledgments"><strong>Acknowledgments</strong></A></font>    ^cY#6678.ht
m##
00490000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704026400071002000900335#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#13#9#article#95#<BR>   <A HREF="#Corresp
ondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font face="Arial, Helv
etica, sans-serif">Correspondence    and Footnotes</font></strong></a>      ^cY#
6678.htm##
00291000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704006400072002000900136#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#14#10#article#95#<P class="style4">  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6678.htm##
00612000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038500072002000900457#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#15#11#article#95#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4">Abstract</font><FONT COLOR=#00007F>    </FONT></span>
<A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" AL
IGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face
="Arial, Helvetica, sans-serif">      ^cY#6678.htm##
01285000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704105800072002000901130#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#16#12#article#95#<P>Water deprivation-in
duced thirst is explained by the double-depletion hypothesis, which predicts tha
t dehydration of the two major body fluid compartments, the extracellular and in
tracellular compartments, activates signals that combine centrally to induce wat
er intake. However, sodium appetite is also elicited by water deprivation. In th
is brief review, we stress the importance of the water-depletion and partial ext
racellular fluid-repletion protocol which permits the distinction between sodium
 appetite and thirst. Consistent enhancement or a <I>de novo</I> production of s
odium intake induced by deactivation of inhibitory nuclei (e.g., lateral parabra
chial nucleus) or hormones (oxytocin, atrial natriuretic peptide), in water-depr
ived, extracellular-dehydrated or, contrary to tradition, intracellular-dehydrat
ed rats, suggests that sodium appetite and thirst share more mechanisms than pre
viously thought. Water deprivation has physiological and health effects in human
s that might be related to the salt craving shown by our species.      ^cY#6678.
htm##
00378000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015100072002000900223#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#17#13#article#95#<P><B>Key words: </B> W
ater deprivation, Dehydration, Mineral preference, Sodium appetite, Cravings </f
ont>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6678.htm##
00578000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035100072002000900423#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#18#14#article#95#<P class="style4"><A NA
ME="Text"></A><A HREF="#Home"><FONT SIZE=4><span class="style3"><font color="#00
007F">Text</font></span><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>    <font face="Arial, 
Helvetica, sans-serif"></font></P>  <font face="Arial, Helvetica, sans-serif">  
    ^cY#6678.htm##
00545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031800072002000900390#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#19#15#article#95#<P>Sodium appetite and 
thirst are recognized complementary motivational states that drive a dehydrated 
animal to refill its major fluid compartments. Here we review the fact that wate
r deprivation, the most common and natural form of inducing dehydration, activat
es not only thirst, but also sodium appetite.      ^cY#6678.htm##
00304000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007700072002000900149#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#20#16#article#95#<P><B>Thirst and sodium
 appetite results from water deprivation</B>      ^cY#6678.htm##
01428000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704120100072002000901273#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#21#17#article#95#<P>The double-depletion
 hypothesis of thirst predicts that water intake occurs as a response to a water
 deficit generated by liquid loss from the two major body compartments, i.e., th
e intra- and extracellular compartments (1). Thus, combined contraction and incr
eased tonicity of the extracellular fluid (ECF) generates signals through the re
nin-angiotensin system and osmoreceptors, respectively, that in turn combine cen
trally to produce thirst (1,2). The double-depletion hypothesis is seminal to li
nk these two mechanisms once considered separate to explain thirst in water-depr
ived animals. An early crucial set of experiments testing such a link was the at
tempt to suppress thirst by providing an intragastric or intravenous preload of 
the appropriate fluid in volumes predicted to be sufficient to refill each compa
rtment, i.e., water for the intracellular compartment, and 0.15 M NaCl (i.e., is
otonic solution) for the extracellular one (3,4). Under carefully controlled con
ditions, the experiments essentially showed that thirst induced by water depriva
tion, as measured by the amount of water intake, is not completely suppressed by
 either preload alone, but by the two combined.       ^cY#6678.htm##
01719000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704149200072002000901564#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#22#18#article#95#<P>However, water-depri
ved rats ingested large amounts of isotonic NaCl after they received water prelo
ads equivalent to the total volume of water they normally ingest. The authors co
ncluded that intracellular overhydration, as induced by the ingestion of only wa
ter, did not reduce thirst, but only the desire to ingest water (4). The authors
 apparently assumed that isotonic NaCl intake is related to thirst, as also prop
osed by others to explain why cell-dehydrated rats also ingest isotonic NaCl (5,
6). The main implication of this conclusion is that thirst drives a rat to inges
t not only water, but also salt. One may agree in part with this view, because w
ater is not always the most preferred liquid compared to mineral solutions under
 conditions of selective acute dehydration of either the extracellular or the in
tracellular compartment occurring within hours (7). Moreover, the total amount o
f fluid ingested by water-deprived rats is strongly influenced by taste (8,9). H
owever, there are two caveats about the view that thirst induces a desire to ing
est water and salt, even if the salt is at isotonic concentration. First, accord
ing to what appears to be common sense, other investigators have related the exp
ression of thirst only to water intake (10,11). Second, the early experiments mi
ght have overlooked the possibility that sodium appetite, or the selective inges
tion of sodium solutions and increased hypertonic NaCl intake, also results from
 water deprivation.      ^cY#6678.htm##
01346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704111900072002000901191#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#23#19#article#95#<P>Several hours of wat
er deprivation lead to appropriate physiological alterations that initiate a typ
ical sodium appetite. For example, water-deprived rats, rabbits, sheep, or human
s have not only contraction of the ECF, but also a negative sodium balance that 
results from a mechanism to buffer the increase in extracellular tonicity (12,13
). The first suggestion that water deprivation induces sodium appetite was based
 on these findings. When offered different types of mineral solutions simultaneo
usly, water-deprived rats showed preference for sodium compared to other mineral
 solutions (14). This led us to ask whether angiotensin II mediates water depriv
ation-induced sodium appetite (15), as it does in the classic sodium depletion m
odels such as adrenalectomy or diuretic injection combined with sodium-free food
 (16,17). However, water-deprived rats may behave non-specifically by ingesting 
any type of fluid that becomes immediately available to them, as suggested by pi
lot experiments in our laboratory and the literature (8), making it hard to know
 when thirst ends and sodium appetite begins.       ^cY#6678.htm##
01192000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704096500072002000901037#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#24#20#article#95#<P>In order to properly
 distinguish thirst from sodium appetite, we developed a protocol, the water-dep
letion and partial ECF-repletion protocol or WD-PR, in which thirst is quenched 
by allowing the rat to drink from a burette filled with water prior to any acces
s to sodium (15). Then, as water intake fades to nil, a solution of NaCl is prov
ided in another burette and a sodium appetite test begins. The intake of 0.3 M N
aCl in the sodium appetite test increases as a function of water deprivation per
iod as shown at <a href="#Fig1">Figure 1</a>. Animals that are not water deprive
d ingest less than 0.5 mL of this salt solution during the test. Preliminary unp
ublished data from our laboratory (Leite AS, Pereira DTB, Menani JV, De Luca LA 
Jr)  are also consistent with the earlier proposal that water deprivation induce
s a preference for sodium (14) because mineral ingestion during this sodium appe
tite test is much in the form of sodium solutions.        ^cY#6678.htm##
01420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704119300072002000901265#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#25#21#article#95#<P>Crucial physiologica
l and neurological alterations in WD-PR associated with the subsequent ingestion
 of a sodium solution, in the sodium appetite test, are listed in <a href="#Tab1
">Table 1</a> (18). Notice the negative sodium balance that results from reduced
 standard-food intake and from intracellular dehydration-induced natriuresis. Th
e increase in plasma renin activity induced by hypovolemia remains elevated afte
r thirst satiation; this elevation correlates with c-Fos expression in the subfo
rnical organ and, partially, in the lamina terminalis. Neurons in these two stru
ctures are activated by angiotensin II and belong to encephalic circuits that su
bserve sodium appetite mediated by angiotensin II (19-24). The WD-PR protocol is
 instrumental for the execution of acute tests aimed at understanding the mechan
isms of sodium appetite because it allows one to distinguish thirst from sodium 
appetite originating from the same treatment, i.e., water deprivation. Under the
se conditions, we have shown that blockade of converting enzyme or central angio
tensin II receptors strongly inhibits the ingestion of hypertonic sodium solutio
n during the sodium appetite test (15).       ^cY#6678.htm##
00409000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018200072002000900254#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#26#22#article#95#<P>Therefore, water dep
rivation relates not only to thirst, but also to sodium appetite, thus leading t
o a new equation where water deprivation = thirst + sodium appetite.       ^cY#6
678.htm##
00302000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007500072002000900147#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#27#23#article#95#<P><B>Thirst and sodium
 appetite: two sides of the same coin?</B>      ^cY#6678.htm##
00666000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043900072002000900511#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#28#24#article#95#<P>So much for water de
privation, but, considering water deprivation = double depletion, can one also c
onclude that double depletion = thirst + sodium appetite? The classical findings
 in this field of study say no, because, whereas extracellular dehydration facil
itates, intracellular dehydration inhibits sodium appetite. However, the combina
tion of earlier data with more recent experiments may impose a challenging "perh
aps".       ^cY#6678.htm##
01072000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084500072002000900917#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#29#25#article#95#<P>As mentioned above, 
since the early experiments testing the double-depletion hypothesis it has been 
known that animals in the early stages of dehydration, whether extra- or intrace
llular, ingest both water and isotonic NaCl. However, ingestion of isotonic NaCl
 is not traditionally considered to represent sodium appetite. First, because an
imals in early extracellular or intracellular dehydration also ingest water, but
 reject hypertonic NaCl (4,7,25,26). Second, neither water nor sodium solution i
s preferred by early extracellularly or intracellularly dehydrated rats; whereas
 the former may ingest equal amounts of sodium and non-sodium solutions, as well
 as water, the latter show an uncanny preference for a potassium solution (7). T
hird, ECF hypertonicity is classically linked to inhibition of hypertonic NaCl i
ntake (27).       ^cY#6678.htm##
01326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704109900072002000901171#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#30#26#article#95#<P>Nevertheless, ECF hy
pertonicity might also induce hypertonic NaCl intake under special conditions. T
his was first suggested by studies showing enhanced hypertonic NaCl intake in an
imals either made hyponatremic with systemic hypertonic mannitol or injected sys
temically with hypertonic NaCl when hypovolemic (28,29). Central inactivation or
 blockade of either central oxytocin or atrial natriuretic peptide receptors of 
these animals not only reduced the inhibition of hypertonic NaCl intake, but als
o induced hypertonic NaCl intake at amounts far above control. This enhanced hyp
ertonic NaCl intake is similar to that shown by hypovolemic animals that have al
so their central oxytocin receptors blocked (29, but also see 30). More recently
, it has been shown that enhanced hypertonic NaCl intake also occurs when seroto
nin receptors are blocked in the lateral parabrachial nucleus of either water-de
prived, selectively extracellularly dehydrated or selectively intracellularly de
hydrated rats; no hypertonic NaCl intake occurs in hydrated animals bearing this
 type of blockade (31-33).      ^cY#6678.htm##
01349000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704112200072002000901194#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#31#27#article#95#<P>Taken together, thes
e data regarding inhibitory hormones and an inhibitory nucleus suggest that inhi
bitory circuits are a determinant factor of hypertonic NaCl intake, particularly
 in hyperosmotic animals. If so, it is possible that ECF hypertonicity and angio
tensin II activate circuits that subserve thirst, and, contrary to common sense 
about ECF hypertonicity, also induce sodium appetite in the water-deprived rat, 
but the inhibitory factors activated by hypertonicity also produce strong inhibi
tion of sodium appetite. Thus, a water-deprived rat that has immediate access to
 a salty solution may ingest it because it is searching for a liquid. If the ani
mal first ingests only water instead, the inhibitory hypertonicity is removed, l
eaving only the facilitatory mechanisms, like angiotensin II, to act on sodium a
ppetite. In addition, the more a salty solution is diluted, the less an inhibito
ry system interferes, thus allowing, for example, a cell-dehydrated rat with an 
intact lateral parabrachial nucleus to ingest isotonic NaCl as the most concentr
ated sodium solution in addition to water (4,34).      ^cY#6678.htm##
00655000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704042800072002000900500#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#32#28#article#95#<P>The possibility that
 hypertonicity and angiotensin II induce thirst and sodium appetite in the rat r
esembles the behavior of marine fish that respond to both types of dehydration b
y ingesting salty water (35) and thus one may ask whether some of the neural bas
is of hydromineral intake in mammals was not inherited from their marine ancesto
rs, and whether thirst and sodium appetite were the same thing in the past.     
 ^cY#6678.htm##
00299000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007200072002000900144#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#33#29#article#95#<P><B>Water deprivation
, emergency reactions and addiction</B>      ^cY#6678.htm##
00881000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704065400072002000900726#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#34#30#article#95#<P>Water deprivation in
duces global responses involving not only the drive to ingest water and salt, bu
t also activation of systems that act to conserve volume and guarantee normal ti
ssue perfusion. Enhanced circulating angiotensin II, vasopressin and sympathetic
 tone contribute to avoid a decrease in arterial pressure under reduced extracel
lular volume (36,37). Again, hormones may interact positively with hypertonicity
. The increase in plasma osmotic pressure during water deprivation is not only i
mportant for vasopressin secretion, but also necessary for the increased sympath
etic output that helps to sustain arterial pressure (38,39).       ^cY#6678.htm#
#
01173000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094600072002000901018#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#35#31#article#95#<P>Water deprivation al
so enhances the secretion of glucocorticoid, a hormone that helps the animals to
 cope with stress and that is likely to interact with angiotensin II to increase
 water and sodium intake (40-42). Water-deprived humans have similar physiologic
al alterations and this species has learned that a guarantee against dehydration
 is to secure water resources and to adjust water and salt intake in order to av
oid excessive water-lack hypovolemia or water-overconsumption hyponatremia (43-4
5). Some societies may still take water, and even salt, for granted, but this is
 not the rule all over the world because of either regional scarcity or reduced 
economic power (44). Nevertheless, whatever society is considered, a phenomenon 
called voluntary dehydration may be chronic in humans, and one can only speculat
e as to what consequences this phenomenon plus recurrent water deprivation may h
ave for health and disease (46).       ^cY#6678.htm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047000072002000900542#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#36#32#article#95#<P>One guess is that wa
ter deprivation may contribute to the human craving for salt. Salt preference in
creases in humans subjected acutely to a protocol similar to the WD-PR (47). Rep
eated episodes of sodium depletion in rats lead to an enhanced sodium consumptio
n that may share neural mechanisms with addiction (48,49) and recently we have s
hown that rats with a history of repeated episodes of water deprivation have inc
reased daily sodium consumption (50).      ^cY#6678.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704003100072002000900103#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#37#33#article#95#<P><B>Conclusion </B>  
    ^cY#6678.htm##
01058000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704083100072002000900903#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#38#34#article#95#<P>Water homeostasis ha
s had a major survival role in the terrestrial environment. The same is true for
 sodium homeostasis. Water deprivation challenges both and thereby elicits appro
priate mechanisms that assure the replacement of water and sodium. Therefore, wh
en studying dehydration-related states we should not forget that sodium appetite
 is elicited by water deprivation. Perhaps the application of WD-PR protocols in
 humans and animals may provide novel insights for this type of study. </font>  
<HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align
="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n5/ht
ml/6678i01.htm"><img src="/img/revistas/bjmbr/v40n5/6678i01peq.jpg" border="2"><
/a></td>      <td width="85%"><font face="Arial, Helvetica, sans-serif">        
    ^cY#6678.htm##
00822000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704059500072002000900667#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#39#35#article#95#<P><a name="Fig1"></a>F
igure 1. Cumulative 0.3 M NaCl intake during a sodium appetite test by rats that
 had previous access only to water (partial extracellular fluid repletion, PR) a
fter 24- (WD 24-PR) or 36-h (WD 36-PR) water deprivation (WD). WD 24-PR (filled 
circles, N = 10) and WD 36-PR (open circles, N = 12). Hydrated animals ingest le
ss than 0.5 mL 0.3 M NaCl during a period equivalent to the sodium appetite test
. P &lt; 0.05 compared to WD 24-PR (F(1,80) two-way repeated measures ANOVA and 
<I>post hoc </I>Student-Newman Keuls test).        </font></td>    </tr>  </tabl
e>      ^cY#6678.htm##
00978000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704075100072002000900823#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#40#36#article#95#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (42 K JPG file)]</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr ali
gn="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n5/
html/6678t01.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"></a>
</td>      <td width="85%"><font face="Arial, Helvetica, sans-serif"><a name="Ta
b1"></a>Table 1. Fluid-electrolyte balance, hormonal activity, neuronal activity
, blood pressure, and behavior of water-deprived rats prior to and after ingesti
on of water in the water-depletion and partial extracellular fluid-repletion (WD
-PR) protocol (from Ref. 18, with permission).</font> </td>    </tr>  </table>  
    ^cY#6678.htm##
00377000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015000072002000900222#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#41#37#article#95#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (169 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6678.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#42#38#article#95#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6678.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024300074002000900317#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#43#39#article#95#1#<P>1. Eps
tein AN. Epilogue: retrospect and prognosis. In: Epstein AN, Kissileff HR, Stell
ar E (Editors), <I>The neuropsychology of thirst: new findings and advances in c
oncepts</I>. Washington: V.H. Winston and Sons; 1973. p 315-332.      ^cY#6678.h
tm##
00355000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704011400074002000900188#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#44#40#article#95#2#<P>2. Wil
son KM, Rowland N, Fregly MJ. Drinking: a final common pathway? <I>Appetite</I> 
1984; 5: 31-38.      ^cY#6678.htm##
00394000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015300074002000900227#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#45#41#article#95#3#<P>3. Ram
say DJ, Rolls BJ, Wood RJ. Body fluid changes which influence drinking in the wa
ter deprived rat. <I>J Physiol</I> 1977; 266: 453-469.      ^cY#6678.htm##
00412000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017100074002000900245#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#46#42#article#95#4#<P>4. Bla
ss EM, Hall WG. Drinking termination: interactions among hydrational, orogastric
, and behavioral controls in rats. <I>Psychol Rev</I> 1976; 83: 356-374.      ^c
Y#6678.htm##
00391000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015000074002000900224#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#47#43#article#95#5#<P>5. Smi
th DF, Stricker EM. The influence of need on the rat's preference for dilute NaC
l solutions. <I>Physiol Behav</I> 1969; 4: 407-410.      ^cY#6678.htm##
00387000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704014600074002000900220#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#48#44#article#95#6#<P>6. Str
icker EM, Wolf G. Hypovolemic thirst in comparison with thirst induced by hypero
smolality. <I>Physiol Behav</I> 1967; 2: 33-37.      ^cY#6678.htm##
00400000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015900074002000900233#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#49#45#article#95#7#<P>7. Per
eira DT, David RB, Vendramini RC, Menani JV, De Luca LA Jr. Potassium intake dur
ing cell dehydration. <I>Physiol Behav</I> 2005; 85: 99-106.      ^cY#6678.htm##
00398000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015700074002000900231#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#50#46#article#95#8#<P>8. Sca
lera G. Taste preference and acceptance in thirsty and rehydrated [correction of
 dehydrated] rats. <I>Physiol Behav</I> 2000; 71: 457-468.      ^cY#6678.htm##
00336000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704009500074002000900169#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#51#47#article#95#9#<P>9. Rol
ls BJ, Rolls ET. <I>Thirst</I>. Cambridge: Cambridge University Press; 1982.    
  ^cY#6678.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022400075002000900299#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#52#48#article#95#10#<P>10. E
pstein AN. Prospectus: thirst and salt appetite. In: Stricker EM (Editor), <I>Ne
urobiology of food and fluid intake </I>(<I>Handbook of behavioral neurobiology<
/I>). New York: Plenum Press; 1990. p 489-512.      ^cY#6678.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020600075002000900281#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#53#49#article#95#11#<P>11. J
ohnson AK, Thunhorst RL. The neuroendocrinology of thirst and salt appetite: vis
ceral sensory signals and mechanisms of central integration. <I>Front Neuroendoc
rinol</I> 1997; 18: 292-353.      ^cY#6678.htm##
00415000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017300075002000900248#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#54#50#article#95#12#<P>12. M
cKinley MJ, Denton DA, Nelson JF, Weisinger RS. Dehydration induces sodium deple
tion in rats, rabbits, and sheep. <I>Am J Physiol</I> 1983; 245: R287-R292.     
 ^cY#6678.htm##
00416000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017400075002000900249#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#55#51#article#95#13#<P>13. S
choorlemmer GH, Evered MD. Water and solute balance in rats during 10 h water de
privation and rehydration. <I>Can J Physiol Pharmacol</I> 1993; 71: 379-386.    
  ^cY#6678.htm##
00390000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014800075002000900223#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#56#52#article#95#14#<P>14. W
eisinger RS, Denton DA, McKinley MJ, Nelson JF. Dehydration-induced sodium appet
ite in rats. <I>Physiol Behav</I> 1985; 34: 45-50.      ^cY#6678.htm##
00427000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018500075002000900260#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#57#53#article#95#15#<P>15. S
ato MA, Yada MM, De Luca LA Jr. Antagonism of the renin-angiotensin system and w
ater deprivation-induced NaCl intake in rats. <I>Physiol Behav</I> 1996; 60: 109
9-1104.      ^cY#6678.htm##
00431000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018900075002000900264#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#58#54#article#95#16#<P>16. S
akai RR, Epstein AN. Dependence of adrenalectomy-induced sodium appetite on the 
action of angiotensin II in the brain of the rat. <I>Behav Neurosci</I> 1990; 10
4: 167-176.      ^cY#6678.htm##
00440000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019800075002000900273#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#59#55#article#95#17#<P>17. R
owland NE, Rozelle A, Riley PJ, Fregly MJ. Effect of nonpeptide angiotensin rece
ptor antagonists on water intake and salt appetite in rats. <I>Brain Res Bull</I
> 1992; 29: 389-393.      ^cY#6678.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027100075002000900346#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#60#56#article#95#18#<P>18. D
e Luca LA Jr, Xu Z, Schoorlemmer GH, Thunhorst RL, Beltz TG, Menani JV, et al. W
ater deprivation-induced sodium appetite: humoral and cardiovascular mediators a
nd immediate early genes. <I>Am J Physiol Regul Integr Comp Physiol</I> 2002; 28
2: R552-R559.      ^cY#6678.htm##
00419000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017700075002000900252#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#61#57#article#95#19#<P>19. F
itts DA, Tjepkes DS, Bright RO. Salt appetite and lesions of the ventral part of
 the ventral median preoptic nucleus. <I>Behav Neurosci</I> 1990; 104: 818-827. 
     ^cY#6678.htm##
00458000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021600075002000900291#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#62#58#article#95#20#<P>20. W
eisinger RS, Denton DA, Di Nicolantonio R, Hards DK, McKinley MJ, Oldfield B, et
 al. Subfornical organ lesion decreases sodium appetite in the sodium-depleted r
at. <I>Brain Res</I> 1990; 526: 23-30.      ^cY#6678.htm##
00480000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023800075002000900313#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#63#59#article#95#21#<P>21. D
e Luca LA Jr, Galaverna O, Schulkin J, Yao SZ, Epstein AN. The anteroventral wal
l of the third ventricle and the angiotensinergic component of need-induced sodi
um intake in the rat. <I>Brain Res Bull</I> 1992; 28: 73-87.      ^cY#6678.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023200075002000900307#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#64#60#article#95#22#<P>22. V
ivas L, Chiaraviglio E. The effects of reversible lidocaine-induced lesion of th
e tissue surrounding the anterior ventral wall of the third ventricle on drinkin
g in rats. <I>Behav Neural Biol</I> 1992; 57: 124-130.      ^cY#6678.htm##
00399000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015700075002000900232#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#65#61#article#95#23#<P>23. R
owland NE, Fregly MJ, Li BH, Han L. Angiotensin-related induction of immediate e
arly genes in rat brain. <I>Regul Pept</I> 1996; 66: 25-29.      ^cY#6678.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023700075002000900312#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#66#62#article#95#24#<P>24. M
cKinley MJ, Allen AM, May CN, McAllen RM, Oldfield BJ, Sly D, et al. Neural path
ways from the lamina terminalis influencing cardiovascular and body fluid homeos
tasis. <I>Clin Exp Pharmacol Physiol</I> 2001; 28: 990-992.      ^cY#6678.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017600075002000900251#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#67#63#article#95#25#<P>25. S
tricker EM, Gannon KS, Smith JC. Thirst and salt appetite induced by hypovolemia
 in rats: analysis of drinking behavior. <I>Physiol Behav</I> 1992; 51: 27-37.  
    ^cY#6678.htm##
00376000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013400075002000900209#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#68#64#article#95#26#<P>26. S
tricker EM, Verbalis JG. Central inhibition of salt appetite by oxytocin in rats
. <I>Regul Pept</I> 1996; 66: 83-85.      ^cY#6678.htm##
00527000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028500075002000900360#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#69#65#article#95#27#<P>27. F
itzsimons JT, Wirth JB. The neuroendocrinology of thirst and sodium appetite. In
: Kaufmann W, Krause DK (Editors), <I>Central nervous control of Na<SUP>+</SUP> 
balance - relations to the renin-angiotensin system</I>. Stuttgart: Georg Thieme
 Publishers; 1976. p 80-93.      ^cY#6678.htm##
00494000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025200075002000900327#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#70#66#article#95#28#<P>28. B
lackburn RE, Samson WK, Fulton RJ, Stricker EM, Verbalis JG. Central oxytocin in
hibition of salt appetite in rats: evidence for differential sensing of plasma s
odium and osmolality. <I>Proc Natl Acad Sci USA</I> 1993; 90: 10380-10384.      
^cY#6678.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020800075002000900283#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#71#67#article#95#29#<P>29. B
lackburn RE, Samson WK, Fulton RJ, Stricker EM, Verbalis JG. Central oxytocin an
d ANP receptors mediate osmotic inhibition of salt appetite in rats. <I>Am J Phy
siol</I> 1995; 269: R245-R251.      ^cY#6678.htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028400075002000900359#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#72#68#article#95#30#<P>30. F
itts DA, Thornton SN, Ruhf AA, Zierath DK, Johnson AK, Thunhorst RL. Effects of 
central oxytocin receptor blockade on water and saline intake, mean arterial pre
ssure, and c-Fos expression in rats. <I>Am J Physiol Regul Integr Comp Physiol</
I> 2003; 285: R1331-R1339.      ^cY#6678.htm##
00435000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019300075002000900268#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#73#69#article#95#31#<P>31. M
enani JV, Thunhorst RL, Johnson AK. Lateral parabrachial nucleus and serotonergi
c mechanisms in the control of salt appetite in rats. <I>Am J Physiol</I> 1996; 
270: R162-R168.      ^cY#6678.htm##
00438000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019600075002000900271#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#74#70#article#95#32#<P>32. M
enani JV, De Luca LA Jr, Johnson AK. Lateral parabrachial nucleus serotonergic m
echanisms and salt appetite induced by sodium depletion. <I>Am J Physiol</I> 199
8; 274: R555-R560.      ^cY#6678.htm##
00400000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015800075002000900233#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#75#71#article#95#33#<P>33. D
e Luca LA Jr, Barbosa SP, Menani JV. Brain serotonin blockade and paradoxical sa
lt intake in rats. <I>Neuroscience</I> 2003; 121: 1055-1061.      ^cY#6678.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017600075002000900251#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#76#72#article#95#34#<P>34. P
ereira DT, Vendramini RC, David RB, Nozaki PN, Menani JV, De Luca LA Jr. Isotoni
c NaCl intake by cell-dehydrated rats. <I>Physiol Behav</I> 2002; 76: 501-505.  
    ^cY#6678.htm##
00415000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017300075002000900248#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#77#73#article#95#35#<P>35. T
akei Y. Comparative physiology of body fluid regulation in vertebrates with spec
ial reference to thirst regulation. <I>Jpn J Physiol</I> 2000; 50: 171-186.     
 ^cY#6678.htm##
00461000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021900075002000900294#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#78#74#article#95#36#<P>36. D
e Luca LA Jr, Sugawara AM, Menani JV. Brain versus peripheral angiotensin II rec
eptors in hypovolaemia: behavioural and cardiovascular implications. <I>Clin Exp
 Pharmacol Physiol</I> 2000; 27: 437-442.      ^cY#6678.htm##
00394000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015200075002000900227#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#79#75#article#95#37#<P>37. S
chrier RW. Water and sodium retention in edematous disorders: role of vasopressi
n and aldosterone. <I>Am J Med</I> 2006; 119: S47-S53.      ^cY#6678.htm##
00411000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016900075002000900244#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#80#76#article#95#38#<P>38. S
tricker EM, Sved AF. Controls of vasopressin secretion and thirst: similarities 
and dissimilarities in signals. <I>Physiol Behav</I> 2002; 77: 731-736.      ^cY
#6678.htm##
00400000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015800075002000900233#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#81#77#article#95#39#<P>39. T
oney GM, Chen QH, Cato MJ, Stocker SD. Central osmotic regulation of sympathetic
 nerve activity. <I>Acta Physiol Scand</I> 2003; 177: 43-55.      ^cY#6678.htm##
00486000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024400075002000900319#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#82#78#article#95#40#<P>40. B
rooks VL, Qi Y, O'Donaughy TL. Increased osmolality of conscious water-deprived 
rats supports arterial pressure and sympathetic activity via a brain action. <I>
Am J Physiol Regul Integr Comp Physiol</I> 2005; 288: R1248-R1255.      ^cY#6678
.htm##
00385000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014300075002000900218#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#83#79#article#95#41#<P>41. G
anesan R, Sumners C. Glucocorticoids potentiate the dipsogenic action of angiote
nsin II. <I>Brain Res</I> 1989; 499: 121-130.      ^cY#6678.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017200075002000900247#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#84#80#article#95#42#<P>42. M
a LY, McEwen BS, Sakai RR, Schulkin J. Glucocorticoids facilitate mineralocortic
oid-induced sodium intake in the rat. <I>Horm Behav</I> 1993; 27: 240-250.      
^cY#6678.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022300075002000900298#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#85#81#article#95#43#<P>43. C
onvertino VA, Armstrong LE, Coyle EF, Mack GW, Sawka MN, Senay LC Jr, et al. Ame
rican College of Sports Medicine position stand. Exercise and fluid replacement.
 <I>Med Sci Sports Exerc</I> 1996; 28: i-vii.      ^cY#6678.htm##
00371000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704012900075002000900204#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#86#82#article#95#44#<P>44. W
ard DR. <I>Water wars: drought, flood, folly, and the politics of thirst</I>. Ne
w York: Riverhead Books; 2002.       ^cY#6678.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027700075002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#87#83#article#95#45#<P>45. B
oscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the    Unit
ed States. <I>Cost Eff Resour Alloc</I> <a href="http://www.resource-allocation.
com/content/4/1/10" target="_blank">http://www.resource-allocation.com/content/4
/1/10</a>;    2006.      ^cY#6678.htm##
00357000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704011500075002000900190#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#88#84#article#95#46#<P>46. K
leiner SM. Water: an essential but overlooked nutrient. <I>J Am Diet Assoc</I> 1
999; 99: 200-206.      ^cY#6678.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021000075002000900285#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#89#85#article#95#47#<P>47. T
akamata A, Mack GW, Gillen CM, Nadel ER. Sodium appetite, thirst, and body fluid
 regulation in humans during rehydration without sodium replacement. <I>Am J Phy
siol</I> 1994; 266: R1493-R1502.      ^cY#6678.htm##
00424000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018200075002000900257#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#90#86#article#95#48#<P>48. S
akai RR, Fine WB, Epstein AN, Frankmann SP. Salt appetite is enhanced by one pri
or episode of sodium depletion in the rat. <I>Behav Neurosci</I> 1987; 101: 724-
731.      ^cY#6678.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020000075002000900275#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#91#87#article#95#49#<P>49. C
lark JJ, Bernstein IL. A role for D2 but not D1 dopamine receptors in the cross-
sensitization between amphetamine and salt appetite. <I>Pharmacol Biochem Behav<
/I> 2006; 83: 277-284.      ^cY#6678.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023000075002000900305#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#p#92#88#article#95#50#<P>50. P
ereira DT, David RB, Menani JV, De Luca LA Jr. Episodes of water deprivation enh
ance daily hypertonic NaCl intake in rats. <I>Braz J Med Biol Res</I> 2002; 35: 
465-468.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6678.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040100072002000900473#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#93#89#article#95#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=#00
007F><B>Acknowledgments</B></FONT></FONT></font> <font face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></font>
</P>  <font face="Arial, Helvetica, sans-serif">      ^cY#6678.htm##
00363000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704013600072002000900208#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#94#90#article#95#<P>The authors thank Si
lvana A.D. Malavolta for excellent secretarial assistance.  </font>  <HR ALIGN=L
EFT WIDTH=100% SIZE=2>       ^cY#6678.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#95#91#article#95#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, H
elvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT> <
A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6678
.htm##
00680000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704045300072002000900525#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#96#92#article#95#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence:</B><font face="Arial, Helvetica, sans-serif"> L.A.  
  De Luca Jr., Departamento de Fisiologia e Patologia, Faculdade de Odontologia,
    UNESP, Rua Humait&aacute;, 1680, 14801-903 Araraquara, SP, Brasil. Fax: +55-
16-3301-6488.    E-mail: <a href="mailto:lucajr@foar.unesp.br">lucajr@foar.unesp
.br</a></font>  </P>      ^cY#6678.htm##
00486000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025900072002000900331#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#97#93#article#95#<P><font face="Arial, H
elvetica, sans-serif">Presented at the International Symposium of Neuroendocrino
logy "Neuroendocrine control of body fluid homeostasis: past, present and future
". Ribeir&atilde;o Preto, SP, Brazil, September 1-3, 2006. </font>      ^cY#6678
.htm##
00530000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030300072002000900375#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#98#94#article#95#<P><font face="Arial, H
elvetica, sans-serif"><a name="These"></a>*These authors were enrolled in the Jo
int UFSCar/UNESP Graduate Program in Physiological Sciences. Research supported 
by CNPq and FAPESP. R.B. David and D.T.B. Pereira were recipients of graduate fe
llowships from FAPESP. </font>      ^cY#6678.htm##
00389000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016200072002000900234#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6678.htm#S#p#99#95#article#95#<P><font face="Arial, H
elvetica, sans-serif">Received October 11, 2006. Accepted March 29, 2007.</font>
<font face="Arial, Helvetica, sans-serif"> </font>     ^cY#6678.htm##
00624000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740120039000920160
01800131016002000149016001700169018007300186066001100259062002200270065000900292
064000500301061001000306865000900316002000900325#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#100#1#article#50#1#^rND^sEpstein^nAN#Epilogue: retrospec
t and prognosis^len#^rND^sEpstein^nAN#^rND^sKissileff^nHR#^rND^sStellar^nE#The n
europsychology of thirst: new findings and advances in concepts^len#Washington#V
.H. Winston and Sons#19730000#1973#p 315-332#20070500#6678.htm##
00520000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100017000910100
01700108012003700125030000900162065000900171064000500180031000200185014000600187
865000900193002000900202035001000211801000900221#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#101#2#article#50#2#^rND^sWilson^nKM#^rND^sRowland^nN#^rN
D^sFregly^nMJ#Drinking: a final common pathway^len#Appetite#19840000#1984#5#31-3
8#20070500#6678.htm#0195-6663#Appetite##
00530000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100016000910100
01500107012007400122030001000196710000200206065000900208064000500217031000400222
014000800226865000900234002000900243#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#102#3#article#50#3#^rND^sRamsay^nDJ#^rND^sRolls^nBJ#^rND^sWood^nRJ#B
ody fluid changes which influence drinking in the water deprived rat^len#J Physi
ol#2#19770000#1977#266#453-469#20070500#6678.htm##
00562000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100015000900120
10200105030001200207065000900219064000500228031000300233014000800236865000900244
002000900253035001000262801001200272#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#103#4#article#50#4#^rND^sBlass^nEM#^rND^sHall^nWG#Drinking terminati
on: interactions among hydrational, orogastric, and behavioral controls in rats^
len#Psychol Rev#19760000#1976#83#356-374#20070500#6678.htm#0033-295X#Psychol Rev
##
00543000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100019000900120
07600109030001400185065000900199064000500208031000200213014000800215865000900223
002000900232035001000241801001400251#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#104#5#article#50#5#^rND^sSmith^nDF#^rND^sStricker^nEM#The influence 
of need on the rat's preference for dilute NaCl solutions^len#Physiol Behav#1969
0000#1969#4#407-410#20070500#6678.htm#0031-9384#Physiol Behav##
00539000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100014000930120
07600107030001400183065000900197064000500206031000200211014000600213865000900219
002000900228035001000237801001400247#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#105#6#article#50#6#^rND^sStricker^nEM#^rND^sWolf^nG#Hypovolemic thir
st in comparison with thirst induced by hyperosmolality^len#Physiol Behav#196700
00#1967#2#33-37#20070500#6678.htm#0031-9384#Physiol Behav##
00606000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920100
02100108010001700129010002100146012004500167030001400212065000900226064000500235
031000300240014000700243865000900250002000900259035001000268801001400278#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#106#7#article#50#7#^rND^sPereira
^nDT#^rND^sDavid^nRB#^rND^sVendramini^nRC#^rND^sMenani^nJV#^rND^sDe^nLuca LA Jr#
Potassium intake during cell dehydration^len#Physiol Behav#20050000#2005#85#99-1
06#20070500#6678.htm#0031-9384#Physiol Behav##
00532000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740120094000910300
01400185065000900199064000500208031000300213014000800216865000900224002000900233
035001000242801001400252#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#
107#8#article#50#8#^rND^sScalera^nG#Taste preference and acceptance in thirsty a
nd rehydrated [correction of dehydrated] rats^len#Physiol Behav#20000000#2000#71
#457-468#20070500#6678.htm#0031-9384#Physiol Behav##
00428000000000241000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720160016000740160016000900180
01100106066001000117062002700127065000900154064000500163865000900168002000900177
#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#108#9#article#50#9#^rND^
sRolls^nBJ#^rND^sRolls^nET#Thirst^len#Cambridge#Cambridge University Press#19820
000#1982#20070500#6678.htm##
00562000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120041000940160
01900135018008000154066000900234062001300243065000900256064000500265014000800270
865000900278002000900287#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#
109#10#article#50#10#^rND^sEpstein^nAN#Prospectus: thirst and salt appetite^len#
^rND^sStricker^nEM#Neurobiology of food and fluid intake (Handbook of behavioral
 neurobiology)^len#New York#Plenum Press#19900000#1990#489-512#20070500#6678.htm
##
00608000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100020000940120
11900114030002200233065000900255064000500264031000300269014000800272865000900280
002000900289035001000298801002200308#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#110#11#article#50#11#^rND^sJohnson^nAK#^rND^sThunhorst^nRL#The neuro
endocrinology of thirst and salt appetite: visceral sensory signals and mechanis
ms of central integration^len#Front Neuroendocrinol#19970000#1997#18#292-353#200
70500#6678.htm#0091-3022#Front Neuroendocrinol##
00602000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
01700112010002000129012006900149030001300218065000900231064000500240031000400245
014001000249865000900259002000900268035001000277801001300287#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#111#12#article#50#12#^rND^sMcKinley^nMJ#^rND
^sDenton^nDA#^rND^sNelson^nJF#^rND^sWeisinger^nRS#Dehydration induces sodium dep
letion in rats, rabbits, and sheep^len#Am J Physiol#19830000#1983#245#R287-R292#
20070500#6678.htm#0002-9513#Am J Physiol##
00578000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100017000990120
08300116030002400199065000900223064000500232031000300237014000800240865000900248
002000900257035001000266801002400276#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#112#13#article#50#13#^rND^sSchoorlemmer^nGH#^rND^sEvered^nMD#Water a
nd solute balance in rats during 10 h water deprivation and rehydration^len#Can 
J Physiol Pharmacol#19930000#1993#71#379-386#20070500#6678.htm#0008-4212#Can J P
hysiol Pharmacol##
00578000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01900113010001700132012004800149030001400197065000900211064000500220031000300225
014000600228865000900234002000900243035001000252801001400262#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#113#14#article#50#14#^rND^sWeisinger^nRS#^rN
D^sDenton^nDA#^rND^sMcKinley^nMJ#^rND^sNelson^nJF#Dehydration-induced sodium app
etite in rats^len#Physiol Behav#19850000#1985#34#45-50#20070500#6678.htm#0031-93
84#Physiol Behav##
00597000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
02100106012009700127030001400224065000900238064000500247031000300252014001000255
865000900265002000900274035001000283801001400293#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#114#15#article#50#15#^rND^sSato^nMA#^rND^sYada^nMM#^rND^
sDe^nLuca LA Jr#Antagonism of the renin-angiotensin system and water deprivation
-induced NaCl intake in rats^len#Physiol Behav#19960000#1996#60#1099-1104#200705
00#6678.htm#0031-9384#Physiol Behav##
00584000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
11200110030001500222065000900237064000500246031000400251014000800255865000900263
002000900272035001000281801001500291#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#115#16#article#50#16#^rND^sSakai^nRR#^rND^sEpstein^nAN#Dependence of
 adrenalectomy-induced sodium appetite on the action of angiotensin II in the br
ain of the rat^len#Behav Neurosci#19900000#1990#104#167-176#20070500#6678.htm#07
35-7044#Behav Neurosci##
00629000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01600111010001700127012010000144030001500244065000900259064000500268031000300273
014000800276865000900284002000900293035001000302801001500312#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#116#17#article#50#17#^rND^sRowland^nNE#^rND^
sRozelle^nA#^rND^sRiley^nPJ#^rND^sFregly^nMJ#Effect of nonpeptide angiotensin re
ceptor antagonists on water intake and salt appetite in rats^len#Brain Res Bull#
19920000#1992#29#389-393#20070500#6678.htm#0361-9230#Brain Res Bull##
00714000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100012000970100
02300109010002000132010001600152010001700168810000600185012011000191030003900301
71000020034006500090034206400050035103100040035601400100036086500090037000200090
0379#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#117#18#article#50#18
#^rND^sDe^nLuca LA Jr#^rND^sXu^nZ#^rND^sSchoorlemmer^nGH#^rND^sThunhorst^nRL#^rN
D^sBeltz^nTG#^rND^sMenani^nJV#et al#Water deprivation-induced sodium appetite: h
umoral and cardiovascular mediators and immediate early genes^len#Am J Physiol R
egul Integr Comp Physiol#2#20020000#2002#282#R552-R559#20070500#6678.htm##
00590000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01700110012008900127030001500216065000900231064000500240031000400245014000800249
865000900257002000900266035001000275801001500285#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#118#19#article#50#19#^rND^sFitts^nDA#^rND^sTjepkes^nDS#^
rND^sBright^nRO#Salt appetite and lesions of the ventral part of the ventral med
ian preoptic nucleus^len#Behav Neurosci#19900000#1990#104#818-827#20070500#6678.
htm#0735-7044#Behav Neurosci##
00689000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
02500113010001600138010001900154010001800173810000600191012008200197030001000279
06500090028906400050029803100040030301400060030786500090031300200090032203500100
0331801001000341#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#119#20#a
rticle#50#20#^rND^sWeisinger^nRS#^rND^sDenton^nDA#^rND^sDi^nNicolantonio R#^rND^
sHards^nDK#^rND^sMcKinley^nMJ#^rND^sOldfield^nB#et al#Subfornical organ lesion d
ecreases sodium appetite in the sodium-depleted rat^len#Brain Res#19900000#1990#
526#23-30#20070500#6678.htm#0006-8993#Brain res##
00687000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100019000970100
01800116010001400134010001800148012012600166030001500292065000900307064000500316
031000300321014000600324865000900330002000900339035001000348801001500358#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#120#21#article#50#21#^rND^sDe^nL
uca LA Jr#^rND^sGalaverna^nO#^rND^sSchulkin^nJ#^rND^sYao^nSZ#^rND^sEpstein^nAN#T
he anteroventral wall of the third ventricle and the angiotensinergic component 
of need-induced sodium intake in the rat^len#Brain Res Bull#19920000#1992#28#73-
87#20070500#6678.htm#0361-9230#Brain Res Bull##
00630000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100022000910120
15000113030001800263065000900281064000500290031000300295014000800298865000900306
002000900315035001000324801001800334#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#121#22#article#50#22#^rND^sVivas^nL#^rND^sChiaraviglio^nE#The effect
s of reversible lidocaine-induced lesion of the tissue surrounding the anterior 
ventral wall of the third ventricle on drinking in rats^len#Behav Neural Biol#19
920000#1992#57#124-130#20070500#6678.htm#0163-1047#Behav Neural Biol##
00584000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01300111010001300124012007200137030001100209065000900220064000500229031000300234
014000600237865000900243002000900252035001000261801001100271#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#122#23#article#50#23#^rND^sRowland^nNE#^rND^
sFregly^nMJ#^rND^sLi^nBH#^rND^sHan^nL#Angiotensin-related induction of immediate
 early genes in rat brain^len#Regul Pept#19960000#1996#66#25-29#20070500#6678.ht
m#0167-0115#Regul Pept##
00734000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
01400111010001800125010001900143010001300162010001300175012010100188030002700289
06500090031606400050032503100030033001400080033386500090034100200090035003500100
0359801002700369#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#123#24#a
rticle#50#24#^rND^sMcKinley^nMJ#^rND^sAllen^nAM#^rND^sMay^nCN#^rND^sMcAllen^nRM#
^rND^sOldfield^nBJ#^rND^sSly^nD#^rND^set^nal#Neural pathways from the lamina ter
minalis influencing cardiovascular and body fluid homeostasis^len#Clin Exp Pharm
acol Physiol#20010000#2001#28#990-992#20070500#6678.htm#0305-1870#Clin Exp Pharm
acol Physiol##
00588000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
01600112012009100128030001400219065000900233064000500242031000300247014000600250
865000900256002000900265035001000274801001400284#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#124#25#article#50#25#^rND^sStricker^nEM#^rND^sGannon^nKS
#^rND^sSmith^nJC#Thirst and salt appetite induced by hypovolemia in rats: analys
is of drinking behavior^len#Physiol Behav#19920000#1992#51#27-37#20070500#6678.h
tm#0031-9384#Physiol Behav##
00525000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950120
06000114030001100174065000900185064000500194031000300199014000600202865000900208
002000900217035001000226801001100236#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#125#26#article#50#26#^rND^sStricker^nEM#^rND^sVerbalis^nJG#Central i
nhibition of salt appetite by oxytocin in rats^len#Regul Pept#19960000#1996#66#8
3-85#20070500#6678.htm#0167-0115#Regul Pept##
00654000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100016000970120
05700113016001800170016001700188018008700205066001000292062002400302065000900326
064000500335014000600340865000900346002000900355#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#126#27#article#50#27#^rND^sFitzsimons^nJT#^rND^sWirth^nJ
B#The neuroendocrinology of thirst and sodium appetite^len#^rND^sKaufmann^nW#^rN
D^sKrause^nDK#Central nervous control of Na+ balance - relations to the renin-an
giotensin system^len#Stuttgart#Georg Thieme Publishers#19760000#1976#80-93#20070
500#6678.htm##
00709000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01700113010001900130010001900149012012400168030002300292065000900315064000500324
031000300329014001200332865000900344002000900353035001000362801002300372#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#127#28#article#50#28#^rND^sBlack
burn^nRE#^rND^sSamson^nWK#^rND^sFulton^nRJ#^rND^sStricker^nEM#^rND^sVerbalis^nJG
#Central oxytocin inhibition of salt appetite in rats: evidence for differential
 sensing of plasma sodium and osmolality^len#Proc Natl Acad Sci USA#19930000#199
3#90#10380-10384#20070500#6678.htm#0027-8424#Proc Natl Acad Sci USA##
00655000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01700113010001900130010001900149012009100168030001300259065000900272064000500281
031000400286014001000290865000900300002000900309035001000318801001300328#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#128#29#article#50#29#^rND^sBlack
burn^nRE#^rND^sSamson^nWK#^rND^sFulton^nRJ#^rND^sStricker^nEM#^rND^sVerbalis^nJG
#Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite 
in rats^len#Am J Physiol#19950000#1995#269#R245-R251#20070500#6678.htm#0002-9513
#Am J Physiol##
00716000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
01500111010001800126010001800144010002000162012013100182030003900313710000200352
065000900354064000500363031000400368014001200372865000900384002000900393#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#129#30#article#50#30#^rND^sFitts
^nDA#^rND^sThornton^nSN#^rND^sRuhf^nAA#^rND^sZierath^nDK#^rND^sJohnson^nAK#^rND^
sThunhorst^nRL#Effects of central oxytocin receptor blockade on water and saline
 intake, mean arterial pressure, and c-Fos expression in rats^len#Am J Physiol R
egul Integr Comp Physiol#2#20030000#2003#285#R1331-R1339#20070500#6678.htm##
00604000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01800113012010100131030001300232065000900245064000500254031000400259014001000263
865000900273002000900282035001000291801001300301#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#130#31#article#50#31#^rND^sMenani^nJV#^rND^sThunhorst^nR
L#^rND^sJohnson^nAK#Lateral parabrachial nucleus and serotonergic mechanisms in 
the control of salt appetite in rats^len#Am J Physiol#19960000#1996#270#R162-R16
8#20070500#6678.htm#0002-9513#Am J Physiol##
00607000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100021000930100
01800114012010300132030001300235065000900248064000500257031000400262014001000266
865000900276002000900285035001000294801001300304#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#131#32#article#50#32#^rND^sMenani^nJV#^rND^sDe^nLuca LA 
Jr#^rND^sJohnson^nAK#Lateral parabrachial nucleus serotonergic mechanisms and sa
lt appetite induced by sodium depletion^len#Am J Physiol#19980000#1998#274#R555-
R560#20070500#6678.htm#0002-9513#Am J Physiol##
00569000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100018000970100
01700115012006500132030001300197065000900210064000500219031000400224014001000228
865000900238002000900247035001000256801001300266#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#132#33#article#50#33#^rND^sDe^nLuca LA Jr#^rND^sBarbosa^
nSP#^rND^sMenani^nJV#Brain serotonin blockade and paradoxical salt intake in rat
s^len#Neuroscience#20030000#2003#121#1055-1061#20070500#6678.htm#0306-4522#Neuro
science##
00642000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100021000940100
01600115010001700131010001700148010002100165012004900186030001400235065000900249
06400050025803100030026301400080026686500090027400200090028303500100029280100140
0302#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#133#34#article#50#34
#^rND^sPereira^nDT#^rND^sVendramini^nRC#^rND^sDavid^nRB#^rND^sNozaki^nPN#^rND^sM
enani^nJV#^rND^sDe^nLuca LA Jr#Isotonic NaCl intake by cell-dehydrated rats^len#
Physiol Behav#20020000#2002#76#501-505#20070500#6678.htm#0031-9384#Physiol Behav
##
00549000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120111000910300
01400202065000900216064000500225031000300230014000800233865000900241002000900250
035001000259801001400269#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#
134#35#article#50#35#^rND^sTakei^nY#Comparative physiology of body fluid regulat
ion in vertebrates with special reference to thirst regulation^len#Jpn J Physiol
#20000000#2000#50#171-186#20070500#6678.htm#0021-521X#Jpn J Physiol##
00644000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100019000970100
01700116012011400133030002700247065000900274064000500283031000300288014000800291
865000900299002000900308035001000317801002700327#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6678.htm#S#c#135#36#article#50#36#^rND^sDe^nLuca LA Jr#^rND^sSugawara
^nAM#^rND^sMenani^nJV#Brain versus peripheral angiotensin II receptors in hypovo
laemia: behavioural and cardiovascular implications^len#Clin Exp Pharmacol Physi
ol#20000000#2000#27#437-442#20070500#6678.htm#0305-1870#Clin Exp Pharmacol Physi
ol##
00523000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120091000940300
00900185065000900194064000500203031000400208014000800212865000900220002000900229
035001000238801000900248#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#
136#37#article#50#37#^rND^sSchrier^nRW#Water and sodium retention in edematous d
isorders: role of vasopressin and aldosterone^len#Am J Med#20060000#2006#119#S47
-S53#20070500#6678.htm#0002-9343#Am J Med##
00563000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950120
09400110030001400204065000900218064000500227031000300232014000800235865000900243
002000900252035001000261801001400271#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#137#38#article#50#38#^rND^sStricker^nEM#^rND^sSved^nAF#Controls of v
asopressin secretion and thirst: similarities and dissimilarities in signals^len
#Physiol Behav#20020000#2002#77#731-736#20070500#6678.htm#0031-9384#Physiol Beha
v##
00593000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01500107010001800122012006100140030001900201065000900220064000500229031000400234
014000600238865000900244002000900253035001000262801001900272#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#138#39#article#50#39#^rND^sToney^nGM#^rND^sC
hen^nQH#^rND^sCato^nMJ#^rND^sStocker^nSD#Central osmotic regulation of sympathet
ic nerve activity^len#Acta Physiol Scand#20030000#2003#177#43-55#20070500#6678.h
tm#0001-6772#Acta Physiol Scand##
00622000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100012000930100
02100105012012900126030003900255710000200294065000900296064000500305031000400310
014001200314865000900326002000900335#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#139#40#article#50#40#^rND^sBrooks^nVL#^rND^sQi^nY#^rND^sO'Donaughy^n
TL#Increased osmolality of conscious water-deprived rats supports arterial press
ure and sympathetic activity via a brain action^len#Am J Physiol Regul Integr Co
mp Physiol#2#20050000#2005#288#R1248-R1255#20070500#6678.htm##
00533000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930120
07100110030001000181065000900191064000500200031000400205014000800209865000900217
002000900226035001000235801001000245#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#140#41#article#50#41#^rND^sGanesan^nR#^rND^sSumners^nC#Glucocorticoi
ds potentiate the dipsogenic action of angiotensin II^len#Brain Res#19890000#198
9#499#121-130#20070500#6678.htm#0006-8993#Brain res##
00599000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100017000890100
01600106010001800122012008200140030001100222065000900233064000500242031000300247
014000800250865000900258002000900267035001000276801001100286#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#141#42#article#50#42#^rND^sMa^nLY#^rND^sMcEw
en^nBS#^rND^sSakai^nRR#^rND^sSchulkin^nJ#Glucocorticoids facilitate mineralocort
icoid-induced sodium intake in the rat^len#Horm Behav#19930000#1993#27#240-250#2
0070500#6678.htm#0018-506X#Horm Behav##
00707000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100020000970100
01600117010001500133010001600148010001900164810000600183012008700189030002100276
06500090029706400050030603100030031101400060031486500090032000200090032903500100
0338801002100348#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#142#43#a
rticle#50#43#^rND^sConvertino^nVA#^rND^sArmstrong^nLE#^rND^sCoyle^nEF#^rND^sMack
^nGW#^rND^sSawka^nMN#^rND^sSenay^nLC Jr#et al#American College of Sports Medicin
e position stand: Exercise and fluid replacement^len#Med Sci Sports Exerc#199600
00#1996#28#i-vii#20070500#6678.htm#0195-9131#Med Sci Sports Exerc##
00444000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160015000760180066000910660
00900157062001600166065000900182064000500191865000900196002000900205#v40n5#v:\sc
ielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#143#44#article#50#44#^rND^sWard^nDR#
Water wars: drought, flood, folly, and the politics of thirst^len#New York#River
head Books#20020000#2002#20070500#6678.htm##
00558000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01900110012005700129030002200186710000200208062005000210065000900260064000500269
865000900274002000900283#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#
144#45#article#50#45#^rND^sBoscoe^nA#^rND^sParamore^nC#^rND^sVerbalis^nJG#Cost o
f illness of hyponatremia in the United States^len#Cost Eff Resour Alloc#2#http:
//www.resource-allocation.com/content/4/1/10#20060000#2006#20070500#6678.htm##
00493000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120048000940300
01600142065000900158064000500167031000300172014000800175865000900183002000900192
035001000201801001600211#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6678.htm#S#c#
145#46#article#50#46#^rND^sKleiner^nSM#Water: an essential but overlooked nutrie
nt^len#J Am Diet Assoc#19990000#1999#99#200-206#20070500#6678.htm#0002-8223#J Am
 Diet Assoc##
00639000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01700109010001600126012011100142030001300253065000900266064000500275031000400280
014001200284865000900296002000900305035001000314801001300324#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#146#47#article#50#47#^rND^sTakamata^nA#^rND^
sMack^nGW#^rND^sGillen^nCM#^rND^sNadel^nER#Sodium appetite, thirst, and body flu
id regulation in humans during rehydration without sodium replacement^len#Am J P
hysiol#19940000#1994#266#R1493-R1502#20070500#6678.htm#0002-9513#Am J Physiol##
00613000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01800107010002000125012008200145030001500227065000900242064000500251031000400256
014000800260865000900268002000900277035001000286801001500296#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#147#48#article#50#48#^rND^sSakai^nRR#^rND^sF
ine^nWB#^rND^sEpstein^nAN#^rND^sFrankmann^nSP#Salt appetite is enhanced by one p
rior episode of sodium depletion in the rat^len#Behav Neurosci#19870000#1987#101
#724-731#20070500#6678.htm#0735-7044#Behav Neurosci##
00604000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100020000920120
11300112030002400225065000900249064000500258031000300263014000800266865000900274
002000900283035001000292801002400302#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
678.htm#S#c#148#49#article#50#49#^rND^sClark^nJJ#^rND^sBernstein^nIL#A role for 
D2 but not D1 dopamine receptors in the cross-sensitization between amphetamine 
and salt appetite^len#Pharmacol Biochem Behav#20060000#2006#83#277-284#20070500#
6678.htm#0091-3057#Pharmacol Biochem Behav##
00622000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01700110010002100127012007900148030002000227065000900247064000500256031000300261
014000800264865000900272002000900281035001000290801002000300#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6678.htm#S#c#149#50#article#50#50#^rND^sPereira^nDT#^rND^
sDavid^nRB#^rND^sMenani^nJV#^rND^sDe Luca^nLA Jr#Episodes of water deprivation e
nhance daily hypertonic NaCl intake in rats^len#Braz J Med Biol Res#20020000#200
2#35#465-468#20070500#6678.htm#0100-879X#Braz J Med Biol Res##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#o#1#1#article#1#20
080212#125723#6679.htm#122##
03249000000000589000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000900093158000300102030002000105
03100030012503200020012806500090013001400110013903500100015022300090016001201160
01690100026002850100026003110100026003370700084003630831848004470850008022950850
02402303085001602327085001702343085001702360085002602377117000602403072000302409
05301260241205500120253805400230255011200090257311100170258211400090259911300180
2608881002402626002000902650#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#
S#h#2#1#article#1#ra#en#bjmbr#1#3.1#ND#14#BJMBR700#nd#Braz J Med Biol Res#40#5#2
0070500#^f699^l705#0100-879X#20070326#Mineralocorticoid modulation of central an
giotensin-induced neuronal activity, water intake and sodium appetite^len#^rND^1
A01^nS.N.^sThornton#^rND^1A01^nS.T.^sOmouessi#^rND^1A01^nC.^sFalconetti#Universi
té Henri Poincaré^iA01^1Faculté de Médecine^2U684 UHP-INSERM^cNancy^pFrance#^len
^aCentral angiotensin II (AngII) stimulates water and salt solution intake. Pret
reatment with low-dose mineralocorticoid (DOCA) enhances this AngII-induced inta
ke of salt solutions (the synergy theory) in Wistar and Sprague Dawley rats but 
not in Fischer rats. This response is mediated via the AT-1 receptor. Electrophy
siological experiments using iontophoretic application of AngII and the AT-1 rec
eptor-specific non-peptide antagonist losartan showed excitation of neurons in t
he preoptic/medial septum region of urethane-anesthetized male Wistar rats. DOCA
 pretreatment further enhances this neuronal excitation in response to AngII and
 reduces the responses to losartan. This generated the hypothesis that DOCA-enha
nced AngII-induced neuronal excitation is the neural support for the synergy the
ory. AT-2 receptors modulate these intake responses depending on sodium in the d
iet, and diuretic-induced dehydration during pregnancy produces a higher salt in
take in the offspring. AngII-induced salt and water intakes were tested in offsp
ring from Sprague Dawley mothers with only 1.8% NaCl to drink in which half were
 treated with furosemide. The important observations were a) the AT-1 antagonist
 alone suppressed intakes in offspring from mothers not treated with furosemide,
 b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemi
de-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists 
greatly suppressed water intake in offspring from mothers not treated with furos
emide. These results suggest that AT-1 and AT-2 receptors have variable properti
es (receptor number and/or second messengers). Furthermore, the activity and fun
ction of these central AngII receptors depend on the background mineralocorticoi
d levels. The exact mechanism of this influence, however, remains to be determin
ed.#^dnd^i1#^tm^len^kAldosterone^i1#^tm^len^kRat^i1#^tm^len^kAT-1^i1#^tm^len^kAT
-2^i1#^tm^len^kIontophoresis^i1#other#39#International Symposium of Neuroendocri
nology "Neuroendocrine control of body fluid homeostasis: past, present and futu
re"^i1#20060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#20070213#Feb
ruary 13, 2007#S0100-879X2006005000092#6679.htm##
03272000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000900093158000300102030002000105
03100030012503200020012806500090013001400110013903500100015022300090016001201160
01690100026002850100026003110100026003370700084003630831848004470850008022950850
02402303085001602327085001702343085001702360085002602377117000602403072000302409
05301260241205600250253805700100256305500120257305400230258511200090260811100170
2617114000902634113001802643002000902661#v40n5#v:\scielo\serial\bjmbr\v40n5\mark
up\6679.htm#S#f#3#1#article#1#ra#en#bjmbr#1#3.1#ND#14#BJMBR700#nd#Braz J Med Bio
l Res#40#5#20070500#^f699^l705#0100-879X#20070326#Mineralocorticoid modulation o
f central angiotensin-induced neuronal activity, water intake and sodium appetit
e^len#^rND^1A01^nS.N.^sThornton#^rND^1A01^nS.T.^sOmouessi#^rND^1A01^nC.^sFalcone
tti#Université Henri Poincaré^iA01^1Faculté de Médecine^2U684 UHP-INSERM^cNancy^
pFrance#^len^aCentral angiotensin II (AngII) stimulates water and salt solution 
intake. Pretreatment with low-dose mineralocorticoid (DOCA) enhances this AngII-
induced intake of salt solutions (the synergy theory) in Wistar and Sprague Dawl
ey rats but not in Fischer rats. This response is mediated via the AT-1 receptor
. Electrophysiological experiments using iontophoretic application of AngII and 
the AT-1 receptor-specific non-peptide antagonist losartan showed excitation of 
neurons in the preoptic/medial septum region of urethane-anesthetized male Wista
r rats. DOCA pretreatment further enhances this neuronal excitation in response 
to AngII and reduces the responses to losartan. This generated the hypothesis th
at DOCA-enhanced AngII-induced neuronal excitation is the neural support for the
 synergy theory. AT-2 receptors modulate these intake responses depending on sod
ium in the diet, and diuretic-induced dehydration during pregnancy produces a hi
gher salt intake in the offspring. AngII-induced salt and water intakes were tes
ted in offspring from Sprague Dawley mothers with only 1.8% NaCl to drink in whi
ch half were treated with furosemide. The important observations were a) the AT-
1 antagonist alone suppressed intakes in offspring from mothers not treated with
 furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring f
rom furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 
antagonists greatly suppressed water intake in offspring from mothers not treate
d with furosemide. These results suggest that AT-1 and AT-2 receptors have varia
ble properties (receptor number and/or second messengers). Furthermore, the acti
vity and function of these central AngII receptors depend on the background mine
ralocorticoid levels. The exact mechanism of this influence, however, remains to
 be determined.#^dnd^i1#^tm^len^kAldosterone^i1#^tm^len^kRat^i1#^tm^len^kAT-1^i1
#^tm^len^kAT-2^i1#^tm^len^kIontophoresis^i1#other#39#International Symposium of 
Neuroendocrinology "Neuroendocrine control of body fluid homeostasis: past, pres
ent and future"^i1#Ribeirão Preto^i1^eSP^i1#Brazil^i1#20060901^i1#September 1-3,
 2006^i1#20061011#October 11, 2006#20070213#February 13, 2007#6679.htm##
03394000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095121000300099049000900102158000300111030002400114
03100030013803200020014106500090014301400110015203500100016322300090017301201160
01820100026002980100026003240100025003500700086003750831855004610850008023160850
02402324085001602348085001702364085001702381085002602398117000602424072000302430
05301260243305600250255905700100258405500120259405400230260611200090262911100170
2638114000902655113001802664002000902682008008902691#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6679.htm#S#l#4#1#article#1#^mMay^a2007#ra#en#bjmbr#1#3.1#14#BJMBR
700#nd#Braz. j. med. biol. res#40#5#20070500#^f699^l705#0100-879X#20070326#Miner
alocorticoid modulation of central angiotensin-induced neuronal activity, water 
intake and sodium appetite^len#^rND^1A01^nS. N^sThornton#^rND^1A01^nS. T^sOmoues
si#^rND^1A01^nC^sFalconetti#^iA01^1Université Henri Poincaré^2Faculté de Médecin
e^3U684 UHP-INSERM^cNancy^pFrance#^len^aCentral angiotensin II (AngII) stimulate
s water and salt solution intake. Pretreatment with low-dose mineralocorticoid (
DOCA) enhances this AngII-induced intake of salt solutions (the synergy theory) 
in Wistar and Sprague Dawley rats but not in Fischer rats. This response is medi
ated via the AT-1 receptor. Electrophysiological experiments using iontophoretic
 application of AngII and the AT-1 receptor-specific non-peptide antagonist losa
rtan showed excitation of neurons in the preoptic/medial septum region of uretha
ne-anesthetized male Wistar rats. DOCA pretreatment further enhances this neuron
al excitation in response to AngII and reduces the responses to losartan. This g
enerated the hypothesis that DOCA-enhanced AngII-induced neuronal excitation is 
the neural support for the synergy theory. AT-2 receptors modulate these intake 
responses depending on sodium in the diet, and diuretic-induced dehydration duri
ng pregnancy produces a higher salt intake in the offspring. AngII-induced salt 
and water intakes were tested in offspring from Sprague Dawley mothers with only
 1.8 percent NaCl to drink in which half were treated with furosemide. The impor
tant observations were a) the AT-1 antagonist alone suppressed intakes in offspr
ing from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists 
suppressed intakes in offspring from furosemide-treated mothers, and c) combined
 administration of AT-1 and AT-2 antagonists greatly suppressed water intake in 
offspring from mothers not treated with furosemide. These results suggest that A
T-1 and AT-2 receptors have variable properties (receptor number and/or second m
essengers). Furthermore, the activity and function of these central AngII recept
ors depend on the background mineralocorticoid levels. The exact mechanism of th
is influence, however, remains to be determined.#^dnd^i1#^tm^len^kAldosterone^i1
#^tm^len^kRat^i1#^tm^len^kAT-1^i1#^tm^len^kAT-2^i1#^tm^len^kIontophoresis^i1#oth
er#39#International Symposium of Neuroendocrinology "Neuroendocrine control of b
ody fluid homeostasis: past, present and future"^i1#Ribeirão Preto^i1^eSP^i1#Bra
zil^i1#20060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#20070213#Feb
ruary 13, 2007#6679.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_art
text&pid=S0100-879X2007000500014##
00401000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704017600070002000900246#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#5#1#article#79#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 699-705</B> </font> (Review)</B></P>      ^cY#6679.htm#
#
00431000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704020600070002000900276#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#6#2#article#79#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">Mineralocorticoid modulation of central an
giotensin-induced neuronal activity, water intake and sodium appetite </font></B
> </font>        ^cY#6679.htm##
00571000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704034600070002000900416#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#7#3#article#79#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/im
g/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a href="mailto:simon.thorn
ton@nancy.inserm.fr"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0
"></a></span>    S.N. Thornton, S.T. Omouessi and C. Falconetti </font>      ^cY
#6679.htm##
00394000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704016900070002000900239#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#8#4#article#79#<P><font face="Arial, Hel
vetica, sans-serif">U684 UHP-INSERM, Facult&eacute; de M&eacute;decine, Universi
t&eacute; Henri Poincar&eacute;, Nancy, France</font>       ^cY#6679.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#9#5#article#79#<P class="style4"> <A HRE
F="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6679.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#10#6#article#79#<BR>   <A HREF="#Text"><
img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6679.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#11#7#article#79#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6679.htm##
00504000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704027800071002000900349#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#12#8#article#79#<br>   </strong></A> <A 
HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font fac
e="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></strong>
</a>      ^cY#6679.htm##
00290000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704006400071002000900135#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#13#9#article#79#<P class="style4">  <HR 
ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6679.htm##
00619000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039200072002000900464#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#14#10#article#79#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" size="4" face="Ari
al, Helvetica, sans-serif"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <fo
nt face="Arial, Helvetica, sans-serif">      ^cY#6679.htm##
02082000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704185500072002000901927#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#15#11#article#79#<P>Central angiotensin 
II (AngII) stimulates water and salt solution intake. Pretreatment with low-dose
 mineralocorticoid (DOCA) enhances this AngII-induced intake of salt solutions (
the synergy theory) in Wistar and Sprague Dawley rats but not in Fischer rats. T
his response is mediated via the AT-1 receptor. Electrophysiological experiments
 using iontophoretic application of AngII and the AT-1 receptor-specific non-pep
tide antagonist losartan showed excitation of neurons in the preoptic/medial sep
tum region of urethane-anesthetized male Wistar rats. DOCA pretreatment further 
enhances this neuronal excitation in response to AngII and reduces the responses
 to losartan. This generated the hypothesis that DOCA-enhanced AngII-induced neu
ronal excitation is the neural support for the synergy theory. AT-2 receptors mo
dulate these intake responses depending on sodium in the diet, and diuretic-indu
ced dehydration during pregnancy produces a higher salt intake in the offspring.
 AngII-induced salt and water intakes were tested in offspring from Sprague Dawl
ey mothers with only 1.8% NaCl to drink in which half were treated with furosemi
de. The important observations were a) the AT-1 antagonist alone suppressed inta
kes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2
 antagonists suppressed intakes in offspring from furosemide-treated mothers, an
d c) combined administration of AT-1 and AT-2 antagonists greatly suppressed wat
er intake in offspring from mothers not treated with furosemide. These results s
uggest that AT-1 and AT-2 receptors have variable properties (receptor number an
d/or second messengers). Furthermore, the activity and function of these central
 AngII receptors depend on the background mineralocorticoid levels. The exact me
chanism of this influence, however, remains to be determined.       ^cY#6679.htm
##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011900072002000900191#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#16#12#article#79#<P><B>Key words: </B> A
ldosterone, Rat, AT-1, AT-2, Iontophoresis </font>  <HR ALIGN=LEFT WIDTH=100% SI
ZE=2>       ^cY#6679.htm##
00602000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037500072002000900447#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#17#13#article#79#<P class="style4"><A NA
ME="Text"></A><font face="Arial, Helvetica, sans-serif" size="4" color="#00007F"
><b>Text</b></font><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr
/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A
>    <font face="Arial, Helvetica, sans-serif"></font></P>  <font face="Arial, H
elvetica, sans-serif">      ^cY#6679.htm##
00983000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704075600072002000900828#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#18#14#article#79#<P>Behavior is a very g
ood example of a motivated state and drinking behavior is perhaps one of the bes
t examples. Not only is this particular behavior motivated by internal physiolog
ical signals but it can be initiated using components of these physiological sig
nals. Drinking is just one aspect of body fluid regulation, an integrated physio
logical regulatory system that implicates nearly all the main organ networks of 
the body for a vital function, i.e., survival. It has even been postulated that 
without this integrated approach which includes the brain and a memory function,
 perhaps related to the physiological response to a disturbance in the body hydr
ation state, the initial development of terrestrial life may not have occurred (
1).      ^cY#6679.htm##
00896000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066900072002000900741#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#19#15#article#79#<P>Ever since the first
 unicellular organisms formed on earth regulation of cellular water content, i.e
., cellular volume, has been a never-ending problem. Water molecules move down a
long a concentration gradient until an equilibrium is reached or movement is pre
vented. Organisms living in an aqueous environment have to fight against either 
too much liquid coming in or loss of liquid to the outside depending on the osmo
lality of the surrounding fluids. Organisms, both plant and animal, living in fr
esh or sea water have developed mechanisms to combat these imposed movements of 
water across the various membranes in contact with the outside environment.     
  ^cY#6679.htm##
00967000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704074000072002000900812#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#20#16#article#79#<P>Land animals, and pl
ants for that matter, have another problem, i.e., getting enough water in and ke
eping it there. As far as animals are concerned, water comes into the body from 
drinking and from the metabolism of ingested food, and then the renal system, an
d to some extent the respiratory system, are responsible for keeping it there. O
nce the water is in, the internal distribution must be assured by yet another sy
stem, i.e., the cardiovascular one, with all its inherent control mechanisms. Ho
wever, many other regulatory physiological systems depend also on the water inge
sted and all need separate control mechanisms. The interplay between all of thes
e mechanisms gives a fascinating picture of physiological control.       ^cY#667
9.htm##
00482000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025500072002000900327#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#21#17#article#79#<P>In his early work on
 rats James Fitzsimons (2) described two major thirst states, primary and second
ary, the former being a state of physiological need and thus regulatory in natur
e, and the latter being not principally regulatory in nature.       ^cY#6679.htm
##
00923000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069600072002000900768#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#22#18#article#79#<P>Primary thirst was s
ubsequently further divided into thirst of intracellular origin and thirst of ex
tracellular origin. Under ideal conditions where all physiological systems funct
ion correctly, the osmolality of all fluid compartments is the same and water is
 distributed proportionally (two thirds intracellular and one third extracellula
r). Another element that plays a key role in the regulation of body fluids is th
e sodium ion. Sodium is the principal cation of the extracellular fluids (potass
ium being that of the intracellular compartment) and thus plays an essential rol
e in the regulation of body fluid osmolality, i.e., the gradient that regulates 
the movement of water.       ^cY#6679.htm##
01731000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704150400072002000901576#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#23#19#article#79#<P>As far as extracellu
lar thirst is concerned, in an ideal state, fluid would be lost initially from t
he vasculature leading to a decrease in blood volume. As the volume loss increas
es fluid would also move out of the interstitial compartment into the vasculatur
e. The overall regulation of blood volume and blood pressure is complex. In the 
case of thirst and fluid regulation it could be simplified initially to the cont
rol of blood volume. There are detectors in the great veins for a decrease in vo
lume that signal to the brain to search for water and to increase the release of
 antidiuretic hormone. These receptors also cause an increase in sodium appetite
 and reflex release of renin through sympathetic activation. Furthermore, in the
 kidney other volume/pressure detectors sense the decrease in perfusion pressure
 of the kidney and cause further release of renin. This enzyme acts on circulati
ng angiotensinogen, an a<SUB>2</SUB>-globulin released from the liver, forming t
he decapeptide angiotensin I. Angiotensin-converting enzyme in the lung converts
 this to the octapeptide angiotensin II (AngII) that has several actions. It is 
vasoconstrictive (via a direct and indirect action on the vascular wall) thus re
ducing the diameter of the vasculature to fit the lower blood volume and to faci
litate blood flow, it stimulates the thirst centers in the brain to search out a
nd ingest water, and it stimulates the release of the mineralocorticoid hormone 
aldosterone from the adrenals.       ^cY#6679.htm##
00599000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037200072002000900444#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#24#20#article#79#<P>Aldosterone is the h
ormone of sodium regulation and has two principal actions, one to increase sodiu
m absorption in the kidney via an action on the distal tubule and the other to s
ensitize certain specific areas of the brain (especially the hypothalamus) to th
e circulating levels of AngII, the combined effect of which is to stimulate sodi
um appetite (2,3).       ^cY#6679.htm##
00743000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051600072002000900588#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#25#21#article#79#<P>The ingestion of wat
er and sodium together restores the lost blood volume to the initial values (2).
 As blood volume increases, the signals to stimulate thirst, antidiuretic hormon
e release and the release of renin are thus decreased. The action of aldosterone
, on the other hand, appears to continue for some time, even after its levels in
 the blood have decreased to normal values, as is the case for most steroid horm
ones, since they activate many intracellular pathways including protein synthesi
s.       ^cY#6679.htm##
00540000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031300072002000900385#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#26#22#article#79#<P>The homeostatic regu
lation of hydromineral balance is thus designed to cope perfectly well with vari
ations in water intake through regulation of blood vessel caliber, regulation of
 water and sodium excretion through the kidneys and regulation of the behavioral
 act, i.e., thirst and sodium appetite.       ^cY#6679.htm##
00774000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704054700072002000900619#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#27#23#article#79#<P>One of the key compo
nents of this physiologically regulated system is AngII which, when administered
 into the brain either directly into various brain structures or into the cerebr
o-ventricular system, stimulates the intake of water and of concentrated NaCl so
lution. This action is mediated via angiotensin type 1 receptors (AT-1) (3,4) pr
esent throughout the hypothalamus and specifically in the circumventricular orga
ns around the 3rd cerebral ventricle, structures implicated in the brain sensing
 of the body's hydrational state.       ^cY#6679.htm##
00602000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037500072002000900447#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#28#24#article#79#<P>Electrophysiological
 studies of neurons with these receptors have shown a multitude of responses. In
 patch clamp studies with bath application AngII increases the spontaneous activ
ity of these neurons (5). Iontophoretic application directly onto neurons has sh
own both an increase and a decrease in activity (6-8), as well as an increase in
 field potentials (9).      ^cY#6679.htm##
01068000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084100072002000900913#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#29#25#article#79#<P>Treatment with aldos
terone had been shown to increase the number of binding sites for AngII centrall
y (10-12) and a short treatment (3 to 4 days) with a low dose of the synthetic m
ineralocorticoid (DOCA) enhances AngII-induced drinking of hypertonic salt solut
ions (13). These results came to form the basis of the synergy theory developed 
by Epstein and his colleagues (14), whereby it was the uniquely central interact
ion of these two hormones that led to the enhancement of the appetite for sodium
. This was found to be the case in Wistar and Sprague Dawley rats but not in Fis
cher (15) or Zucker obese rats (Omouessi ST, personal communication), suggesting
 that perhaps the mechanism was not applicable to all rats. The use of receptor-
specific antagonists showed that this response was mediated via the AT-1 recepto
r (16).       ^cY#6679.htm##
01411000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704118400072002000901256#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#30#26#article#79#<P>Electrophysiological
 experiments using iontophoretic application of AngII and the AT-1 receptor-spec
ific non-peptide antagonist losartan, showed that both substances increased exci
tation of neurons in the preoptic/medial septum region of urethane-anesthetized 
male Wistar rats (8). The increase in activity in response to losartan was inter
preted as the inhibition of an AngII-induced inhibition (7), yielding excitation
 (8). DOCA pretreatment further enhanced this neuronal excitation in response to
 AngII but reduced the responses to losartan (17). This generated the hypothesis
 that DOCA-enhanced AngII-induced neuronal excitation was the neural support for
 the synergy theory's-enhanced salt intake. Furthermore, it has been taken as ev
idence that there is possibly more than just one type, or functional state, of t
he AT-1 receptor (17) since the response to locally applied losartan went from f
requent short- and long-term neuronal excitation before DOCA to infrequent short
-term excitation only, and in rare cases inhibition, afterwards (8). As if the m
ineralocorticoid treatment had modified the type of AngII receptor responding, o
r its functional state (18,19).      ^cY#6679.htm##
01724000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704149700072002000901569#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#31#27#article#79#<P>Li&eacute;nard et al
. (20) took this one step further by using behavioral experiments with losartan 
and DOCA. They argued that iontophoretic application would have put very small q
uantities of losartan around the neurons, similar to what occurs with AngII, and
 that therefore very low doses of this particular antagonist should be used. The
 results showed that in animals already tested with central injections of 10 pmo
l AngII, which generated a significant intake of water and a small intake of 2% 
salt solution, losartan at the same Mol for Mol dose generated an appetite for s
odium over the 2 days following administration. Once again suggesting that inhib
ition of a local inhibition could generate an intake. Furthermore, treatment of 
these rats with DOCA given peripherally after the central administration of losa
rtan produced an appetite for the concentrated salt solution, something which di
d not happen if DOCA was given before losartan. This was interpreted to indicate
 that the normal action of the mineralocorticoid was to modify the central funct
ioning of AngII receptors such that those responsible for the inhibition were no
 longer functioning. This would be in agreement with the findings of a reduced a
ction of losartan in DOCA-treated rats (17), again suggesting that there is a to
nic inhibitory signal against a salt appetite but when this is removed, either w
ith DOCA pretreatment or with central losartan, then AngII can stimulate an incr
eased intake of sodium.       ^cY#6679.htm##
01552000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704132500072002000901397#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#32#28#article#79#<P>This was tested furt
her in Fischer rats known to have a reduced appetite for sodium and who respond 
minimally to challenges that would normally increase sodium appetite. Using the 
electrophysiological approach with iontophoretic application we observed that ne
urons in the forebrain of these rats were much less responsive to locally applie
d AngII than in Wistar rats (21). Furthermore, local application of losartan pro
duced inhibition only and never excitation, as has been observed in Wistar rats 
(8,17). These results suggested once again that it could be the state of activit
y, or excitability to local AngII that is the neuronal basis of sodium appetite.
 The Fischer rats with a very much reduced excitability had a reduced appetite. 
However, in the same experiments reported by Falconetti et al. (21), the authors
 observed that central injection of AngII into conscious behaving animals produc
ed equivalent intakes of concentrated sodium solution in Fischer and Wistar rats
. This would suggest that motivated behavior is not so simple to analyze and tha
t, although the forebrain may be the center of body fluid intake regulation, the
 neuronal substrate of this regulation is slightly more complex than analysis of
 the activity of just one area (relatively large as it might appear; see Ref. 22
, page 171).      ^cY#6679.htm##
00924000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069700072002000900769#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#33#29#article#79#<P>In a subsequent stud
y on Fischer rats, again looking at behavior of both the intact, non-anesthetize
d animal and neurons in the forebrain of anesthetized animals, it was observed t
hat DOCA pretreatment could increase the responsiveness of forebrain neurons to 
AngII, as reported previously in Wistar rats, but that the salt drinking respons
es to centrally applied AngII were not enhanced (23). Thus, the two phenomena ca
n be separated and perhaps enhancement can be observed depending on the degree o
f increased excitability, or degree of decreased inhibition, of the forebrain ne
urons. Experiments using increasing doses of DOCA pretreatment of Fischer rat re
main to be carried out.       ^cY#6679.htm##
01464000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704123700072002000901309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#34#30#article#79#<P>Two major subtypes o
f the AngII receptors have been identified, AngII type-1 (AT-1) and AngII type-2
 (AT-2), with the development of specific non-peptide antagonists (24-27). These
 receptors have been shown to have different distributions and functions within 
the central nervous system (28-30). Although, as mentioned previously, all major
 functions attributed to central administration of AngII have been shown to be m
ediated through the AT-1 receptor, the possible role of the AT-2 receptor as a m
ediator of AT-1 function has been suggested by several experiments. In adrenalec
tomized rats, having no plasma aldosterone, central losartan injection decreased
 sodium intake in a dose-response manner (31). The AT-2 specific antagonist PD 1
23319 was not effective by itself, but when combined with losartan, both at a lo
w dose, there was synergy of action and a more pronounced antagonism of the appe
tite than simple addition of the effect of the individual doses (31). This was o
ne of the first suggestions that the two receptor subtypes could have an interac
tion in the central nervous system. Subsequent research has even gone so far as 
to indicate that the AT-2 receptor could be an antagonist of the AT-1 receptor (
32).      ^cY#6679.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036700072002000900439#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#35#31#article#79#<P>The distribution and
 function of AngII receptors in the brain has been shown to be influenced by pla
sma aldosterone levels (10, 11,17), as well as by the sodium content of the diet
 (33,34). The latter finding suggests that sodium in the food would have an infl
uence on plasma aldosterone levels which could thus influence central AngII rece
ptor function.      ^cY#6679.htm##
00813000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704058600072002000900658#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#36#32#article#79#<P>Furthermore, an extr
acellular dehydration event during pregnancy in both rats and humans predisposes
 the offspring to a higher preference for sodium in later life (35,36). This eff
ect is dependent on the dehydration-induced maternal aldosterone crossing the pl
acental barrier and altering the sensitivity of the fetal brain angiotensin rece
ptors (37). Although it has been hypothesized that the sensitivity of brain AngI
I receptors of these offspring is altered by the dehydration event in the mother
, few studies have been undertaken to investigate animals thus produced.       ^
cY#6679.htm##
01242000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704101500072002000901087#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#37#33#article#79#<P>In recent as yet unp
ublished study, it has been shown that in male offspring from pregnant Sprague D
awley rats given only 1.8% NaCl solution to drink (in order to reduce blood aldo
sterone levels), with half of the pregnant dams receiving extracellular dehydrat
ion by injection of furosemide twice towards the end of pregnancy, AngII-induced
 intakes of water and a concentrated salt solution were modulated by prior injec
tion of AT-1 and/or AT-2 receptor-specific antagonists; a) AT-1 but not AT-2 rec
eptor blockade alone suppressed water and 1.8% NaCl intake in male offspring fro
m mothers not treated with furosemide; b) both AT-1 and AT-2 receptor antagonist
s suppressed water and 1.8% NaCl intake in offspring from furosemide-treated mot
hers, and c) combined administration of AT-1 and AT-2 receptor antagonists great
ly suppressed water (and to a lesser extent salt) intake only in offspring from 
mothers not treated with furosemide (Falconetti C, Omouessi ST and Thornton SN, 
unpublished results).       ^cY#6679.htm##
00895000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066800072002000900740#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#38#34#article#79#<P>It would thus appear
 that the absence of mineralocorticoids during pregnancy permitted an interactio
n of both AT-1 and AT-2 receptors, perhaps in the form of a heterodimer, suggest
ing that, under these particular conditions, AT-2 could well be a modulator of A
T-1 activity. Furthermore, the transient increase in mineralocorticoids during p
regnancy appeared to be sufficient to modulate the function of the two receptors
 so that they now were observed to play an equal role in the response to central
ly administered AngII. Again it could be suggested that a dimer structure is pos
sible but this time antagonism of one of the pair inhibits also the other.      
 ^cY#6679.htm##
00805000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704057800072002000900650#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#39#35#article#79#<P>At least two studies
 have indicated that the G protein activated or the second messengers used can v
ary depending on the AT-1 receptor activated (38,39) or more precisely the type 
of neuron stimulated, so that the possibilities of modulation become very comple
x. It would thus appear that mineralocorticoids are able to modulate not only re
ceptor expression but also receptor function. Suffice it to say that the interac
tion of the brain angiotensin receptor system with the mineralocorticoids is com
plex and will lead to some interesting discoveries in the future.      ^cY#6679.
htm##
01326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704109900072002000901171#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#40#36#article#79#<P>In conclusion, the r
egulation of body fluids is an integrated organization of various systems to bri
ng water and sodium in, to keep the substances there and to distribute them thro
ughout all fluid compartments of the body. These systems are known and have been
 studied intensely over the past 30 years or so. The hormones implicated in this
 vital regulatory function are also known but their complexity of interaction is
 beginning to shed light on as yet unstudied physiological mechanisms that are a
lso part of this regulation. This review has dealt with what happens in the cent
ral nervous system but there is also an interaction of mineralocorticoids with t
he peripheral renin angiotensin system that may be just as complex, if not more 
so, and probably responsible for the cardiovascular dysfunction seen in many hyp
ertensive disease states. The presence therein of elevated levels of these two p
articular hormones, AngII and aldosterone, may very well be the consequence of t
he normal physiological response to long-term mild hypovolemia.</font>  <HR ALIG
N=LEFT WIDTH=100% SIZE=2>       ^cY#6679.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#41#37#article#79#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6679.htm##
00398000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015700074002000900231#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#42#38#article#79#1#<P>1. Den
ton DA, McKinley MJ, Weisinger RS. Hypothalamic integration of body fluid regula
tion. <I>Proc Natl Acad Sci U S A</I> 1996; 93: 7397-7404.      ^cY#6679.htm##
00351000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704011000074002000900184#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#43#39#article#79#2#<P>2. Fit
zsimons JT. Angiotensin, thirst, and sodium appetite. <I>Physiol Rev</I> 1998; 7
8: 583-686.      ^cY#6679.htm##
00506000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026500074002000900339#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#44#40#article#79#3#<P>3. Joh
nson AK. Brain mechanisms in the control of body fluid homeostasis. In: Gisolfi 
CV, Lamb DR (Editors), <I>Perspectives in exercise science and sports medicine, 
fluid homeostasis during exercise</I>. Indianapolis: Benchmark Press; 1990. p 34
7-419.      ^cY#6679.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027000074002000900344#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#45#41#article#79#4#<P>4. Ber
esford MJ, Fitzsimons JT. Intracerebroventricular angiotensin II-induced thirst 
and sodium appetite in rat are blocked by the AT1 receptor antagonist, Losartan 
(DuP 753), but not by the AT2 antagonist, CGP 42112B. <I>Exp Physiol</I> 1992; 7
7: 761-764.      ^cY#6679.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017300074002000900247#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#46#42#article#79#5#<P>5. Li 
Z, Ferguson AV. Angiotensin II responsiveness of rat paraventricular and subforn
ical organ neurons <I>in vitro</I>. <I>Neuroscience</I> 1993; 55: 197-207.      
^cY#6679.htm##
00374000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704013300074002000900207#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#47#43#article#79#6#<P>6. Huw
yler T, Felix D. Angiotensin II-sensitive neurons in septal areas of the rat. <I
>Brain Res</I> 1980; 195: 187-195.      ^cY#6679.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021800074002000900292#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#48#44#article#79#7#<P>7. Sim
onnet G, Bioulac B, Rodriguez F, Vincent JD. Evidence of a direct action of angi
otensin II on neurones in the septum and in the medial preoptic area. <I>Pharmac
ol Biochem Behav</I> 1980; 13: 359-363.      ^cY#6679.htm##
00438000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019700074002000900271#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#49#45#article#79#8#<P>8. Tho
rnton SN, Nicolaidis S. Long-term mineralocorticoid-induced changes in rat neuro
n properties plus interaction of aldosterone and ANG II. <I>Am J Physiol</I> 199
4; 266: R564-R571.      ^cY#6679.htm##
00371000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704013000074002000900204#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#50#46#article#79#9#<P>9. von
 Bohlen Und Halbach O, Albrecht D. The CNS renin-angiotensin system. <I>Cell Tis
sue Res</I> 2006; 326: 599-616.      ^cY#6679.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017800075002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#51#47#article#79#10#<P>10. G
utkind JS, Kurihara M, Saavedra JM. Increased angiotensin II receptors in brain 
nuclei of DOCA-salt hypertensive rats. <I>Am J Physiol</I> 1988; 255: H646-H650.
      ^cY#6679.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017600075002000900251#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#52#48#article#79#11#<P>11. K
ing SJ, Harding JW, Moe KE. Elevated salt appetite and brain binding of angioten
sin II in mineralocorticoid-treated rats. <I>Brain Res</I> 1988; 448: 140-149.  
    ^cY#6679.htm##
00478000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023600075002000900311#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#53#49#article#79#12#<P>12. S
helat SG, King JL, Flanagan-Cato LM, Fluharty SJ. Mineralocorticoids and glucoco
rticoids cooperatively increase salt intake and angiotensin II receptor binding 
in rat brain. <I>Neuroendocrinology</I> 1999; 69: 339-351.      ^cY#6679.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023500075002000900310#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#54#50#article#79#13#<P>13. F
luharty SJ, Epstein AN. Sodium appetite elicited by intracerebroventricular infu
sion of angiotensin II in the rat: II. Synergistic interaction with systemic min
eralocorticoids. <I>Behav Neurosci</I> 1983; 97: 746-758.      ^cY#6679.htm##
00417000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017500075002000900250#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#55#51#article#79#14#<P>14. S
akai RR, Nicolaidis S, Epstein AN. Salt appetite is suppressed by interference w
ith angiotensin II and aldosterone. <I>Am J Physiol</I> 1986; 251: R762-R768.   
   ^cY#6679.htm##
00405000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016300075002000900238#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#56#52#article#79#15#<P>15. R
owland NE, Fregly MJ. Behavioral and physiological aspects of body fluid homeost
asis in Fischer 344 rats. <I>Physiol Behav</I> 1988; 42: 499-505.      ^cY#6679.
htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019700075002000900272#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#57#53#article#79#16#<P>16. C
ooney AS, Fitzsimons JT. The effect of the putative AT2 agonist, p-aminophenylal
anine6 angiotensin II, on thirst and sodium appetite in rats. <I>Exp Physiol</I>
 1993; 78: 767-774.      ^cY#6679.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025100075002000900326#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#58#54#article#79#17#<P>17. M
artial FP, Thornton SN, Lienard F, Mousseau MC, Nicolaidis S. Tonic neuronal inh
ibition by AII revealed by iontophoretic application of Losartan, a specific ant
agonist of AII type-1 receptors. <I>Brain Res Bull</I> 1994; 34: 533-539.      ^
cY#6679.htm##
00408000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016600075002000900241#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#59#55#article#79#18#<P>18. W
ilson KM, Sumners C, Hathaway S, Fregly MJ. Mineralocorticoids modulate central 
angiotensin II receptors in rats. <I>Brain Res</I> 1986; 382: 87-96.      ^cY#66
79.htm##
00446000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020400075002000900279#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#60#56#article#79#19#<P>19. N
oda K, Feng YH, Liu XP, Saad Y, Husain A, Karnik SS. The active state of the AT1
 angiotensin receptor is generated by angiotensin II induction. <I>Biochemistry<
/I> 1996; 35: 16435-16442.      ^cY#6679.htm##
00454000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021200075002000900287#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#61#57#article#79#20#<P>20. L
ienard F, Thornton SN, Martial FP, Mousseau MC, Nicolaidis S. Angiotensin II rec
eptor subtype antagonists can both stimulate and inhibit salt appetite in rats. 
<I>Regul Pept</I> 1996; 66: 87-94.      ^cY#6679.htm##
00545000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030300075002000900378#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#62#58#article#79#21#<P>21. F
alconetti C, Chapleur M, Fernette B, Thornton SN. Central AII evokes a normal so
dium appetite in the Fischer rat, but its low spontaneous sodium intake may be r
elated to reduced excitation and increased inhibition in septo-preoptic AII neur
ons. <I>Brain Res Bull</I> 2004; 62: 405-412.      ^cY#6679.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#63#59#article#79#22#<P>22. M
ousseau MC, Thornton SN, Lienard F, Martial FP, Nicolaidis S. Water versus salty
 taste and iontophoretic ANGII responses of septopreoptic neurons in dehydrated 
and euhydrated awake rats. <I>Brain Res Bull</I> 1996; 41: 167-173.      ^cY#667
9.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025100075002000900326#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#64#60#article#79#23#<P>23. O
mouessi ST, Falconetti C, Chapleur M, Fernette B, Thornton SN. Mineralocorticoid
 pretreatment enhances angiotensin II-induced neuronal excitation but not salt d
rinking in male Fischer rats. <I>J Neuroendocrinol</I> 2007; 19: 109-115.      ^
cY#6679.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019500075002000900270#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#65#61#article#79#24#<P>24. C
hiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, et al. Identifi
cation of angiotensin II receptor subtypes. <I>Biochem Biophys Res Commun</I> 19
89; 165: 196-203.      ^cY#6679.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020300075002000900278#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#66#62#article#79#25#<P>25. D
udley DT, Panek RL, Major TC, Lu GH, Bruns RF, Klinkefus BA, et al. Subclasses o
f angiotensin II binding sites and their functional significance. <I>Mol Pharmac
ol</I> 1990; 38: 370-377.      ^cY#6679.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022900075002000900304#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#67#63#article#79#26#<P>26. K
akar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-1 rece
ptor subtype cDNAs: differential tissue expression and hormonal regulation. <I>B
iochem Biophys Res Commun</I> 1992; 183: 1090-1096.      ^cY#6679.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019700075002000900272#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#68#64#article#79#27#<P>27. T
immermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiot
ensin II receptors and angiotensin II receptor antagonists. <I>Pharmacol Rev</I>
 1993; 45: 205-251.      ^cY#6679.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024000075002000900315#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#69#65#article#79#28#<P>28. C
hang RS, Lotti VJ, Chen TB, Faust KA. Two angiotensin II binding sites in rat br
ain revealed using [125I]Sar1, Ile8-angiotensin II and selective nonpeptide anta
gonists. <I>Biochem Biophys Res Commun</I> 1990; 171: 813-817.      ^cY#6679.htm
##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017200075002000900247#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#70#66#article#79#29#<P>29. S
ong K, Allen AM, Paxinos G, Mendelsohn FA. Mapping of angiotensin II receptor su
btype heterogeneity in rat brain. <I>J Comp Neurol</I> 1992; 316: 467-484.      
^cY#6679.htm##
00476000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023400075002000900309#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#71#67#article#79#30#<P>30. T
oney GM, Porter JP. Functional roles of brain AT1 and AT2 receptors in the centr
al angiotensin II pressor response in conscious young spontaneously hypertensive
 rats. <I>Brain Res Dev Brain Res</I> 1993; 71: 193-199.      ^cY#6679.htm##
00478000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023600075002000900311#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#72#68#article#79#31#<P>31. G
alaverna O, Polidori C, Sakai RR, Lienard F, Chow SY, Fluharty SJ. Blockade of c
entral angiotensin II type 1 and type 2 receptors suppresses adrenalectomy-induc
ed NaCl intake in rats. <I>Regul Pept</I> 1996; 66: 47-50.      ^cY#6679.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017200075002000900247#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#73#69#article#79#32#<P>32. A
bdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor
 is an AT1 receptor antagonist. <I>J Biol Chem</I> 2001; 276: 39721-39726.      
^cY#6679.htm##
00419000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017700075002000900252#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#74#70#article#79#33#<P>33. S
andberg K, Ji H, Catt KJ. Regulation of angiotensin II receptors in rat brain du
ring dietary sodium changes. <I>Hypertension</I> 1994; 23 (Suppl): I-137-I-141. 
     ^cY#6679.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023700075002000900312#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#75#71#article#79#34#<P>34. C
amara AK, Osborn J. Central AT1 and AT2 receptors mediate chronic intracerebrove
ntricular angiotensin II-induced drinking in rats fed high sodium chloride diet 
from weaning. <I>Acta Physiol Scand</I> 2001; 171: 195-201.      ^cY#6679.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017800075002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#76#72#article#79#35#<P>35. N
icolaidis S, Galaverna O, Metzler CH. Extracellular dehydration during pregnancy
 increases salt appetite of offspring. <I>Am J Physiol</I> 1990; 258: R281-R283.
      ^cY#6679.htm##
00374000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013200075002000900207#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#77#73#article#79#36#<P>36. C
rystal SR, Bernstein IL. Morning sickness: impact on offspring salt preference. 
<I>Appetite</I> 1995; 25: 231-240.      ^cY#6679.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022500075002000900300#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#78#74#article#79#37#<P>37. G
alaverna O, Nicolaidis S, Yao SZ, Sakai RR, Epstein AN. Endocrine consequences o
f prenatal sodium depletion prepare rats for high need-free NaCl intake in adult
hood. <I>Am J Physiol</I> 1995; 269: R578-R583.      ^cY#6679.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021000075002000900285#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#79#75#article#79#38#<P>38. C
rawford KW, Frey EA, Cote TE. Angiotensin II receptor recognized by DuP753 regul
ates two distinct guanine nucleotide-binding protein signaling pathways. <I>Mol 
Pharmacol</I> 1992; 41: 154-162.      ^cY#6679.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023900075002000900314#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#p#80#76#article#79#39#<P>39. D
aniels D, Yee DK, Faulconbridge LF, Fluharty SJ. Divergent behavioral roles of a
ngiotensin receptor intracellular signaling cascades. <I>Endocrinology</I> 2005;
 146: 5552-5560.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6679.htm#
#
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#81#77#article#79#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, H
elvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT> <
A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6679
.htm##
00710000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704048300072002000900555#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#82#78#article#79#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence:</B><font face="Arial, Helvetica, sans-serif"> S.N.  
  Thornton, U684 UHP-INSERM, Facult&eacute; de M&eacute;decine, 9, Avenue de la 
   for&ecirc;t de Haye, B.P. 184, 54505 Vand&#156;uvre , Les Nancy cedex, France
.    Fax: +33-3-8368-3639. E-mail: <a href="mailto:simon.thornton@nancy.inserm.f
r">simon.thornton@nancy.inserm.fr</a></font>  </P>      ^cY#6679.htm##
00591000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036400072002000900436#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6679.htm#S#p#83#79#article#79#<P><font face="Arial, H
elvetica, sans-serif">Presented at the International Symposium of Neuroendocrino
logy "Neuroendocrine control of body fluid homeostasis: past, present and future
". Ribeir&atilde;o Preto, SP, Brazil, September 1-3, 2006. Received October 11, 
2006. Accepted February 13, 2007.</font><font face="Arial, Helvetica, sans-serif
"> </font>       ^cY#6679.htm##
00578000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100019000900100
02000109012005400129030002500183065000900208064000500217031000300222014001000225
865000900235002000900244035001000253801002500263#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6679.htm#S#c#84#1#article#39#1#^rND^sDenton^nDA#^rND^sMcKinley^nMJ#^r
ND^sWeisinger^nRS#Hypothalamic integration of body fluid regulation^len#Proc Nat
l Acad Sci U S A#19960000#1996#93#7397-7404#20070500#6679.htm#0027-8424#Proc Nat
l Acad Sci U S A##
00482000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100021000730120045000940300
01200139065000900151064000500160031000300165014000800168865000900176002000900185
035001000194801001200204#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#
85#2#article#39#2#^rND^sFitzsimons^nJT#Angiotensin, thirst, and sodium appetite^
len#Physiol Rev#19980000#1998#78#583-686#20070500#6679.htm#0031-9333#Physiol Rev
##
00625000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730120062000910160
01800153016001500171018009200186066001300278062001600291065000900307064000500316
014000800321865000900329002000900338#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#86#3#article#39#3#^rND^sJohnson^nAK#Brain mechanisms in the control 
of body fluid homeostasis^len#^rND^sGisolfi^nCV#^rND^sLamb^nDR#Perspectives in e
xercise science and sports medicine, fluid homeostasis during exercise^len#India
napolis#Benchmark Press#19900000#1990#347-419#20070500#6679.htm##
00660000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100021000930120
19100114030001200305065000900317064000500326031000300331014000800334865000900342
002000900351035001000360801001200370#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#87#4#article#39#4#^rND^sBeresford^nMJ#^rND^sFitzsimons^nJT#Intracere
broventricular angiotensin II-induced thirst and sodium appetite in rat are bloc
ked by the AT1 receptor antagonist, Losartan (DuP 753), but not by the AT2 antag
onist, CGP 42112B^len#Exp Physiol#19920000#1992#77#761-764#20070500#6679.htm#095
8-0670#Exp Physiol##
00557000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100012000730100019000850120
09600104030001300200065000900213064000500222031000300227014000800230865000900238
002000900247035001000256801001300266#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#88#5#article#39#5#^rND^sLi^nZ#^rND^sFerguson^nAV#Angiotensin II resp
onsiveness of rat paraventricular and subfornical organ neurons in vitro^len#Neu
roscience#19930000#1993#55#197-207#20070500#6679.htm#0306-4522#Neuroscience##
00521000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100015000900120
06400105030001000169065000900179064000500188031000400193014000800197865000900205
002000900214035001000223801001000233#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#89#6#article#39#6#^rND^sHuwyler^nT#^rND^sFelix^nD#Angiotensin II-sen
sitive neurons in septal areas of the rat^len#Brain Res#19800000#1980#195#187-19
5#20070500#6679.htm#0006-8993#Brain res##
00656000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910100
01900108010001800127012010800145030002400253065000900277064000500286031000300291
014000800294865000900302002000900311035001000320801002400330#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#90#7#article#39#7#^rND^sSimonnet^nG#^rND^sBi
oulac^nB#^rND^sRodriguez^nF#^rND^sVincent^nJD#Evidence of a direct action of ang
iotensin II on neurones in the septum and in the medial preoptic area^len#Pharma
col Biochem Behav#19800000#1980#13#359-363#20070500#6679.htm#0091-3057#Pharmacol
 Biochem Behav##
00588000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100020000920120
11600112030001300228065000900241064000500250031000400255014001000259865000900269
002000900278035001000287801001300297#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#91#8#article#39#8#^rND^sThornton^nSN#^rND^sNicolaidis^nS#Long-term m
ineralocorticoid-induced changes in rat neuron properties plus interaction of al
dosterone and ANG II^len#Am J Physiol#19940000#1994#266#R564-R571#20070500#6679.
htm#0002-9513#Am J Physiol##
00524000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100032000730100018001050120
03700123030001600160065000900176064000500185031000400190014000800194865000900202
002000900211035001000220801001600230#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#92#9#article#39#9#^rND^svon^nBohlen Und Halbach O#^rND^sAlbrecht^nD#
The CNS renin-angiotensin system^len#Cell Tissue Res#20060000#2006#326#599-616#2
0070500#6679.htm#0302-766X#Cell tissue res##
00588000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100018000930100
01900111012008600130030001300216065000900229064000500238031000400243014001000247
865000900257002000900266035001000275801001300285#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6679.htm#S#c#93#10#article#39#10#^rND^sGutkind^nJS#^rND^sKurihara^nM#
^rND^sSaavedra^nJM#Increased angiotensin II receptors in brain nuclei of DOCA-sa
lt hypertensive rats^len#Am J Physiol#19880000#1988#255#H646-H650#20070500#6679.
htm#0002-9513#Am J Physiol##
00583000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100018000900100
01400108012009700122030001000219065000900229064000500238031000400243014000800247
865000900255002000900264035001000273801001000283#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6679.htm#S#c#94#11#article#39#11#^rND^sKing^nSJ#^rND^sHarding^nJW#^rN
D^sMoe^nKE#Elevated salt appetite and brain binding of angiotensin II in mineral
ocorticoid-treated rats^len#Brain Res#19880000#1988#448#140-149#20070500#6679.ht
m#0006-8993#Brain res##
00670000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100015000920100
02400107010001900131012012700150030001900277065000900296064000500305031000300310
014000800313865000900321002000900330035001000339801001900349#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#95#12#article#39#12#^rND^sShelat^nSG#^rND^sK
ing^nJL#^rND^sFlanagan-Cato^nLM#^rND^sFluharty^nSJ#Mineralocorticoids and glucoc
orticoids cooperatively increase salt intake and angiotensin II receptor binding
 in rat brain^len#Neuroendocrinology#19990000#1999#69#339-351#20070500#6679.htm#
0028-3835#Neuroendocrinology##
00594000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100018000940120
09800112030007300210710000200283065000900285064000500294031000300299014000800302
865000900310002000900319#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#
96#13#article#39#13#^rND^sFluharty^nSJ#^rND^sEpstein^nAN#Sodium appetite elicite
d by intracerebroventricular infusion of angiotensin II in the rat: II^len#Syner
gistic interaction with systemic mineralocorticoids. Behav Neurosci#2#19830000#1
983#97#746-758#20070500#6679.htm##
00585000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100020000910100
01800111012008400129030001300213065000900226064000500235031000400240014001000244
865000900254002000900263035001000272801001300282#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6679.htm#S#c#97#14#article#39#14#^rND^sSakai^nRR#^rND^sNicolaidis^nS#
^rND^sEpstein^nAN#Salt appetite is suppressed by interference with angiotensin I
I and aldosterone^len#Am J Physiol#19860000#1986#251#R762-R768#20070500#6679.htm
#0002-9513#Am J Physiol##
00556000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100017000930120
08700110030001400197065000900211064000500220031000300225014000800228865000900236
002000900245035001000254801001400264#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#98#15#article#39#15#^rND^sRowland^nNE#^rND^sFregly^nMJ#Behavioral an
d physiological aspects of body fluid homeostasis in Fischer 344 rats^len#Physio
l Behav#19880000#1988#42#499-505#20070500#6679.htm#0031-9384#Physiol Behav##
00588000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100021000920120
12000113030001200233065000900245064000500254031000300259014000800262865000900270
002000900279035001000288801001200298#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#99#16#article#39#16#^rND^sCooney^nAS#^rND^sFitzsimons^nJT#The effect
 of the putative AT2 agonist, p-aminophenylalanine6 angiotensin II, on thirst an
d sodium appetite in rats^len#Exp Physiol#19930000#1993#78#767-774#20070500#6679
.htm#0958-0670#Exp Physiol##
00700000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01700113010001900130010002000149012013400169030001500303065000900318064000500327
031000300332014000800335865000900343002000900352035001000361801001500371#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#100#17#article#39#17#^rND^sMarti
al^nFP#^rND^sThornton^nSN#^rND^sLienard^nF#^rND^sMousseau^nMC#^rND^sNicolaidis^n
S#Tonic neuronal inhibition by AII revealed by iontophoretic application of Losa
rtan, a specific antagonist of AII type-1 receptors^len#Brain Res Bull#19940000#
1994#34#533-539#20070500#6679.htm#0361-9230#Brain Res Bull##
00592000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01800110010001700128012007300145030001000218065000900228064000500237031000400242
014000600246865000900252002000900261035001000270801001000280#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#101#18#article#39#18#^rND^sWilson^nKM#^rND^s
Sumners^nC#^rND^sHathaway^nS#^rND^sFregly^nMJ#Mineralocorticoids modulate centra
l angiotensin II receptors in rats^len#Brain Res#19860000#1986#382#87-96#2007050
0#6679.htm#0006-8993#Brain res##
00669000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100015000900100
01400105010001400119010001600133010001700149012009400166030001300260065000900273
06400050028203100030028701400120029086500090030200200090031103500100032080100130
0330#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#102#19#article#39#19
#^rND^sNoda^nK#^rND^sFeng^nYH#^rND^sLiu^nXP#^rND^sSaad^nY#^rND^sHusain^nA#^rND^s
Karnik^nSS#The active state of the AT1 angiotensin receptor is generated by angi
otensin II induction^len#Biochemistry#19960000#1996#35#16435-16442#20070500#6679
.htm#0006-2960#Biochemistry##
00657000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01800112010001900130010002000149012010100169030001100270065000900281064000500290
031000300295014000600298865000900304002000900313035001000322801001100332#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#103#20#article#39#20#^rND^sLiena
rd^nF#^rND^sThornton^nSN#^rND^sMartial^nFP#^rND^sMousseau^nMC#^rND^sNicolaidis^n
S#Angiotensin II receptor subtype antagonists can both stimulate and inhibit sal
t appetite in rats^len#Regul Pept#19960000#1996#66#87-94#20070500#6679.htm#0167-
0115#Regul Pept##
00734000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100018000960100
01800114010001900132012019800151030001500349065000900364064000500373031000300378
014000800381865000900389002000900398035001000407801001500417#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#104#21#article#39#21#^rND^sFalconetti^nC#^rN
D^sChapleur^nM#^rND^sFernette^nB#^rND^sThornton^nSN#Central AII evokes a normal 
sodium appetite in the Fischer rat, but its low spontaneous sodium intake may be
 related to reduced excitation and increased inhibition in septo-preoptic AII ne
urons^len#Brain Res Bull#20040000#2004#62#405-412#20070500#6679.htm#0361-9230#Br
ain Res Bull##
00694000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01700114010001800131010002000149012012800169030001500297065000900312064000500321
031000300326014000800329865000900337002000900346035001000355801001500365#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#105#22#article#39#22#^rND^sMouss
eau^nMC#^rND^sThornton^nSN#^rND^sLienard^nF#^rND^sMartial^nFP#^rND^sNicolaidis^n
S#Water versus salty taste and iontophoretic ANGII responses of septopreoptic ne
urons in dehydrated and euhydrated awake rats^len#Brain Res Bull#19960000#1996#4
1#167-173#20070500#6679.htm#0361-9230#Brain Res Bull##
00703000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100020000950100
01800115010001800133010001900151012013000170030001800300065000900318064000500327
031000300332014000800335865000900343002000900352035001000361801001800371#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#106#23#article#39#23#^rND^sOmoue
ssi^nST#^rND^sFalconetti^nC#^rND^sChapleur^nM#^rND^sFernette^nB#^rND^sThornton^n
SN#Mineralocorticoid pretreatment enhances angiotensin II-induced neuronal excit
ation but not salt drinking in male Fischer rats^len#J Neuroendocrinol#20070000#
2007#19#109-115#20070500#6679.htm#0953-8194#J Neuroendocrinol##
00685000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01700109010001800126010001700144010001700161810000600178012005500184030002700239
06500090026606400050027503100040028001400080028486500090029200200090030103500100
0310801002700320#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#107#24#a
rticle#39#24#^rND^sChiu^nAT#^rND^sHerblin^nWF#^rND^sMcCall^nDE#^rND^sArdecky^nRJ
#^rND^sCarini^nDJ#^rND^sDuncia^nJV#et al#Identification of angiotensin II recept
or subtypes^len#Biochem Biophys Res Commun#19890000#1989#165#196-203#20070500#66
79.htm#0006-291X#Biochem Biophys Res Commun##
00680000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01600109010001300125010001600138010002000154810000600174012008100180030001400261
06500090027506400050028403100030028901400080029286500090030000200090030903500100
0318801001400328#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#108#25#a
rticle#39#25#^rND^sDudley^nDT#^rND^sPanek^nRL#^rND^sMajor^nTC#^rND^sLu^nGH#^rND^
sBruns^nRF#^rND^sKlinkefus^nBA#et al#Subclasses of angiotensin II binding sites 
and their functional significance^len#Mol Pharmacol#19900000#1990#38#370-377#200
70500#6679.htm#0026-895X#Mol Pharmacol##
00690000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01600110010001900126010001600145012010500161030002700266065000900293064000500302
031000400307014001000311865000900321002000900330035001000339801002700349#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#109#26#article#39#26#^rND^sKakar
^nSS#^rND^sSellers^nJC#^rND^sDevor^nDC#^rND^sMusgrove^nLC#^rND^sNeill^nJD#Angiot
ensin II type-1 receptor subtype cDNAs: differential tissue expression and hormo
nal regulation^len#Biochem Biophys Res Commun#19920000#1992#183#1090-1096#200705
00#6679.htm#0006-291X#Biochem Biophys Res Commun##
00674000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100015000970100
01500112010001800127010001800145010001700163810000600180012006900186030001400255
06500090026906400050027803100030028301400080028686500090029400200090030303500100
0312801001400322#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#110#27#a
rticle#39#27#^rND^sTimmermans^nPB#^rND^sWong^nPC#^rND^sChiu^nAT#^rND^sHerblin^nW
F#^rND^sBenfield^nP#^rND^sCarini^nDJ#et al#Angiotensin II receptors and angioten
sin II receptor antagonists^len#Pharmacol Rev#19930000#1993#45#205-251#20070500#
6679.htm#0031-6997#Pharmacol Rev##
00683000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01500108010001600123012013400139030002700273065000900300064000500309031000400314
014000800318865000900326002000900335035001000344801002700354#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#111#28#article#39#28#^rND^sChang^nRS#^rND^sL
otti^nVJ#^rND^sChen^nTB#^rND^sFaust^nKA#Two angiotensin II binding sites in rat 
brain revealed using [125I]Sar1, Ile8-angiotensin II and selective nonpeptide an
tagonists^len#Biochem Biophys Res Commun#19900000#1990#171#813-817#20070500#6679
.htm#0006-291X#Biochem Biophys Res Commun##
00602000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01700106010002100123012007400144030001400218065000900232064000500241031000400246
014000800250865000900258002000900267035001000276801001400286#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#112#29#article#39#29#^rND^sSong^nK#^rND^sAll
en^nAM#^rND^sPaxinos^nG#^rND^sMendelsohn^nFA#Mapping of angiotensin II receptor 
subtype heterogeneity in rat brain^len#J Comp Neurol#19920000#1992#316#467-484#2
0070500#6679.htm#0021-9967#J Comp Neurol##
00638000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920120
15000109030002400259065000900283064000500292031000300297014000800300865000900308
002000900317035001000326801002400336#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#113#30#article#39#30#^rND^sToney^nGM#^rND^sPorter^nJP#Functional rol
es of brain AT1 and AT2 receptors in the central angiotensin II pressor response
 in conscious young spontaneously hypertensive rats^len#Brain Res Dev Brain Res#
19930000#1993#71#193-199#20070500#6679.htm#0165-3806#Brain Res Dev Brain Res##
00699000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01600113010001700129010001500146010001900161012012000180030001100300065000900311
06400050032003100030032501400060032886500090033400200090034303500100035280100110
0362#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#114#31#article#39#31
#^rND^sGalaverna^nO#^rND^sPolidori^nC#^rND^sSakai^nRR#^rND^sLienard^nF#^rND^sCho
w^nSY#^rND^sFluharty^nSJ#Blockade of central angiotensin II type 1 and type 2 re
ceptors suppresses adrenalectomy-induced NaCl intake in rats^len#Regul Pept#1996
0000#1996#66#47-50#20070500#6679.htm#0167-0115#Regul Pept##
00600000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
02200109010001900131012006600150030001200216065000900228064000500237031000400242
014001200246865000900258002000900267035001000276801001200286#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#115#32#article#39#32#^rND^sAbdAlla^nS#^rND^s
Lother^nH#^rND^sAbdel-tawab^nAM#^rND^sQuitterer^nU#The angiotensin II AT2 recept
or is an AT1 receptor antagonist^len#J Biol Chem#20010000#2001#276#39721-39726#2
0070500#6679.htm#0021-9258#J Biol Chem##
00600000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100012000940100
01500106012008600121030001300207065000900220064000500229031000300234032000800237
014001200245865000900257002000900266035001000275801001300285#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#116#33#article#39#33#^rND^sSandberg^nK#^rND^
sJi^nH#^rND^sCatt^nKJ#Regulation of angiotensin II receptors in rat brain during
 dietary sodium changes^len#Hypertension#19940000#1994#23#^sSuppl#I-137-I-141#20
070500#6679.htm#0194-911X#Hypertension##
00636000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930120
15700109030001900266065000900285064000500294031000400299014000800303865000900311
002000900320035001000329801001900339#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#117#34#article#39#34#^rND^sCamara^nAK#^rND^sOsborn^nJ#Central AT1 an
d AT2 receptors mediate chronic intracerebroventricular angiotensin II-induced d
rinking in rats fed high sodium chloride diet from weaning^len#Acta Physiol Scan
d#20010000#2001#171#195-201#20070500#6679.htm#0001-6772#Acta Physiol Scand##
00589000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960100
01800115012008400133030001300217065000900230064000500239031000400244014001000248
865000900258002000900267035001000276801001300286#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6679.htm#S#c#118#35#article#39#35#^rND^sNicolaidis^nS#^rND^sGalaverna
^nO#^rND^sMetzler^nCH#Extracellular dehydration during pregnancy increases salt 
appetite of offspring^len#Am J Physiol#19900000#1990#258#R281-R283#20070500#6679
.htm#0002-9513#Am J Physiol##
00521000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100020000940120
05800114030000900172065000900181064000500190031000300195014000800198865000900206
002000900215035001000224801000900234#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
679.htm#S#c#119#36#article#39#36#^rND^sCrystal^nSR#^rND^sBernstein^nIL#Morning s
ickness: impact on offspring salt preference^len#Appetite#19950000#1995#25#231-2
40#20070500#6679.htm#0195-6663#Appetite##
00672000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100020000950100
01400115010001600129010001800145012011300163030001300276065000900289064000500298
031000400303014001000307865000900317002000900326035001000335801001300345#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6679.htm#S#c#120#37#article#39#37#^rND^sGalav
erna^nO#^rND^sNicolaidis^nS#^rND^sYao^nSZ#^rND^sSakai^nRR#^rND^sEpstein^nAN#Endo
crine consequences of prenatal sodium depletion prepare rats for high need-free 
NaCl intake in adulthood^len#Am J Physiol#19950000#1995#269#R578-R583#20070500#6
679.htm#0002-9513#Am J Physiol##
00622000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
01500110012012600125030001400251065000900265064000500274031000300279014000800282
865000900290002000900299035001000308801001400318#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6679.htm#S#c#121#38#article#39#38#^rND^sCrawford^nKW#^rND^sFrey^nEA#^
rND^sCote^nTE#Angiotensin II receptor recognized by DuP753 regulates two distinc
t guanine nucleotide-binding protein signaling pathways^len#Mol Pharmacol#199200
00#1992#41#154-162#20070500#6679.htm#0026-895X#Mol Pharmacol##
00624000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930100
02400107010001900131012008800150030001400238065000900252064000500261031000400266
014001000270865000900280002000900289035001000298801001400308#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6679.htm#S#c#122#39#article#39#39#^rND^sDaniels^nD#^rND^s
Yee^nDK#^rND^sFaulconbridge^nLF#^rND^sFluharty^nSJ#Divergent behavioral roles of
 angiotensin receptor intracellular signaling cascades^len#Endocrinology#2005000
0#2005#146#5552-5560#20070500#6679.htm#0013-7227#Endocrinology##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#o#1#1#article#1#20
080212#125726#6680.htm#117##
03007000000000577000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120080001790100025002590700075002840831679003590850008020380850023020460850
02902069085003002098085002402128085002202152117000602174072000302180053012602183
05500120230905400230232111200090234411100170235311400090237011300170237988100240
2396002000902420#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#h#2#1#arti
cle#1#ra#en#bjmbr#1#3.1#ILUS#TAB#16#BJMBR700#FAPESP#Braz J Med Biol Res#40#5#200
70500#^f713^l720#0100-879X#20070314#Matching salt intake to physiological need i
n rats using foraging protocols^len#^rND^1A01^nN.E.^sRowland#University of Flori
da^iA01^1Department of Psychology^cGainesville^sFL^pUSA#^len^aSeveral studies of
 the quantitative relationship between sodium need and sodium intake in rats are
 reviewed. Using acute diuretic treatment 24 h beforehand, intake matches need f
airly accurately when intake is spread out in time by using a hypotonic solution
 of NaCl. In contrast, using a hypertonic solution, intake is typically double t
he need. Using the same diuretic treatment, although the natriuresis occurs with
in ~1 h, the appetite appears only slowly over 24 h. Increased plasma levels of 
aldosterone parallel the increased intake; however, treatment with metyrapone bl
ocks the rise in aldosterone but has no effect on appetite. Satiation of sodium 
appetite was studied in rats using sodium loss induced by chronic diuretic treat
ment and daily salt consumption sessions. When a simulated foraging cost was imp
osed on NaCl access in the form of a progressive ratio lever press task, rats sh
owed satiation for NaCl (break point) after consuming an amount close to their e
stimated deficit. The chronic diuretic regimen produced hypovolemia and large in
creases in plasma aldosterone concentration and renin activity. These parameters
 were reversed to or toward non-depleted control values at the time of behaviora
l satiation in the progressive ratio protocol. Satiation mechanisms for sodium a
ppetite thus do appear to exist. However, they do not operate quantitatively whe
n concentrated salt is available at no effort, but instead allow overconsumption
. There are reasons to believe that such a bias toward overconsumption may have 
been beneficial over evolutionary time, but such biasing for salt and other comm
odities is maladaptive in a resource-rich environment.#^dnd^i1#^tm^len^kFurosemi
de^i1#^tm^len^kSodium depletion^i1#^tm^len^kProgressive ratio^i1#^tm^len^kAldost
erone^i1#^tm^len^kSatiation^i1#other#25#International Symposium of Neuroendocrin
ology "Neuroendocrine control of body fluid homeostasis: past, present and futur
e"^i1#20060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#20070201#Febr
uary 1, 2007#S0100-879X2006005000088#6680.htm##
03030000000000589000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120080001790100025002590700075002840831679003590850008020380850023020460850
02902069085003002098085002402128085002202152117000602174072000302180053012602183
05600250230905700100233405500120234405400230235611200090237911100170238811400090
2405113001702414002000902431#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#
S#f#3#1#article#1#ra#en#bjmbr#1#3.1#ILUS#TAB#16#BJMBR700#FAPESP#Braz J Med Biol 
Res#40#5#20070500#^f713^l720#0100-879X#20070314#Matching salt intake to physiolo
gical need in rats using foraging protocols^len#^rND^1A01^nN.E.^sRowland#Univers
ity of Florida^iA01^1Department of Psychology^cGainesville^sFL^pUSA#^len^aSevera
l studies of the quantitative relationship between sodium need and sodium intake
 in rats are reviewed. Using acute diuretic treatment 24 h beforehand, intake ma
tches need fairly accurately when intake is spread out in time by using a hypoto
nic solution of NaCl. In contrast, using a hypertonic solution, intake is typica
lly double the need. Using the same diuretic treatment, although the natriuresis
 occurs within ~1 h, the appetite appears only slowly over 24 h. Increased plasm
a levels of aldosterone parallel the increased intake; however, treatment with m
etyrapone blocks the rise in aldosterone but has no effect on appetite. Satiatio
n of sodium appetite was studied in rats using sodium loss induced by chronic di
uretic treatment and daily salt consumption sessions. When a simulated foraging 
cost was imposed on NaCl access in the form of a progressive ratio lever press t
ask, rats showed satiation for NaCl (break point) after consuming an amount clos
e to their estimated deficit. The chronic diuretic regimen produced hypovolemia 
and large increases in plasma aldosterone concentration and renin activity. Thes
e parameters were reversed to or toward non-depleted control values at the time 
of behavioral satiation in the progressive ratio protocol. Satiation mechanisms 
for sodium appetite thus do appear to exist. However, they do not operate quanti
tatively when concentrated salt is available at no effort, but instead allow ove
rconsumption. There are reasons to believe that such a bias toward overconsumpti
on may have been beneficial over evolutionary time, but such biasing for salt an
d other commodities is maladaptive in a resource-rich environment.#^dnd^i1#^tm^l
en^kFurosemide^i1#^tm^len^kSodium depletion^i1#^tm^len^kProgressive ratio^i1#^tm
^len^kAldosterone^i1#^tm^len^kSatiation^i1#other#25#International Symposium of N
euroendocrinology "Neuroendocrine control of body fluid homeostasis: past, prese
nt and future"^i1#Ribeirão Preto^i1^eSP^i1#Brazil^i1#20060901^i1#September 1-3, 
2006^i1#20061011#October 11, 2006#20070201#February 1, 2007#6680.htm##
03161000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762230009001860120080001950100025002750700077003000831679003770850008020560850
02302064085002902087085003002116085002402146085002202170117000602192072000302198
05301260220105600250232705700100235205500120236205400230237411200090239711100170
2406114000902423113001702432002000902449008008902458#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6680.htm#S#l#4#1#article#1#^mMay^a2007#ra#en#bjmbr#1#3.1#ilus#tab
#16#BJMBR700#FAPESP#Braz. j. med. biol. res#40#5#20070500#^f713^l720#0100-879X#2
0070314#Matching salt intake to physiological need in rats using foraging protoc
ols^len#^rND^1A01^nN. E^sRowland#^iA01^1University of Florida^2Department of Psy
chology^cGainesville^sFL^pUSA#^len^aSeveral studies of the quantitative relation
ship between sodium need and sodium intake in rats are reviewed. Using acute diu
retic treatment 24 h beforehand, intake matches need fairly accurately when inta
ke is spread out in time by using a hypotonic solution of NaCl. In contrast, usi
ng a hypertonic solution, intake is typically double the need. Using the same di
uretic treatment, although the natriuresis occurs within ~1 h, the appetite appe
ars only slowly over 24 h. Increased plasma levels of aldosterone parallel the i
ncreased intake; however, treatment with metyrapone blocks the rise in aldostero
ne but has no effect on appetite. Satiation of sodium appetite was studied in ra
ts using sodium loss induced by chronic diuretic treatment and daily salt consum
ption sessions. When a simulated foraging cost was imposed on NaCl access in the
 form of a progressive ratio lever press task, rats showed satiation for NaCl (b
reak point) after consuming an amount close to their estimated deficit. The chro
nic diuretic regimen produced hypovolemia and large increases in plasma aldoster
one concentration and renin activity. These parameters were reversed to or towar
d non-depleted control values at the time of behavioral satiation in the progres
sive ratio protocol. Satiation mechanisms for sodium appetite thus do appear to 
exist. However, they do not operate quantitatively when concentrated salt is ava
ilable at no effort, but instead allow overconsumption. There are reasons to bel
ieve that such a bias toward overconsumption may have been beneficial over evolu
tionary time, but such biasing for salt and other commodities is maladaptive in 
a resource-rich environment.#^dnd^i1#^tm^len^kFurosemide^i1#^tm^len^kSodium depl
etion^i1#^tm^len^kProgressive ratio^i1#^tm^len^kAldosterone^i1#^tm^len^kSatiatio
n^i1#other#25#International Symposium of Neuroendocrinology "Neuroendocrine cont
rol of body fluid homeostasis: past, present and future"^i1#Ribeirão Preto^i1^eS
P^i1#Brazil^i1#20060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#2007
0201#February 1, 2007#6680.htm#Internet^ihttp://www.scielo.br/scielo.php?script=
sci_arttext&pid=S0100-879X2007000500016##
00401000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704017600070002000900246#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#5#1#article#88#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 713-720</B> </font> (Review)</B></P>      ^cY#6680.htm#
#
00394000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704016900070002000900239#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#6#2#article#88#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">Matching salt intake to physiological need
 in rats using foraging protocols</font></B> </font>        ^cY#6680.htm##
00600000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704037500070002000900445#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#7#3#article#88#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style2"><font face="Arial, Helvetica, sans-seri
f"><span class="style4"><a href="#Correspondence"><img src="/img/revistas/bjmbr/
v40n5/recor.gif" border="0"></a>    <a href="mailto:nrowland@ufl.edu"><img src="
/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a></span></font></span>    
N.E. Rowland </font>      ^cY#6680.htm##
00358000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704013300070002000900203#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#8#4#article#88#<P><font face="Arial, Hel
vetica, sans-serif">Department of Psychology, University of Florida, Gainesville
, FL, USA </font>       ^cY#6680.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#9#5#article#88#<P class="style4"> <A HRE
F="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6680.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#10#6#article#88#<BR>   <A HREF="#Text"><
img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6680.htm##
00474000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704024800071002000900319#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#11#7#article#88#<br>      <font face="Ar
ial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><img src="/img/revistas/b
jmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Ackn
owledgments"><strong>Discussion</strong></A></font>         ^cY#6680.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#12#8#article#88#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6680.htm##
00504000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704027800071002000900349#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#13#9#article#88#<br>   </strong></A> <A 
HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font fac
e="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></strong>
</a>      ^cY#6680.htm##
00291000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704006400072002000900136#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#14#10#article#88#<P class="style4">  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6680.htm##
00619000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039200072002000900464#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#15#11#article#88#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <fo
nt face="Arial, Helvetica, sans-serif">      ^cY#6680.htm##
01912000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704168500072002000901757#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#16#12#article#88#<P>Several studies of t
he quantitative relationship between sodium need and sodium intake in rats are r
eviewed. Using acute diuretic treatment 24 h beforehand, intake matches need fai
rly accurately when intake is spread out in time by using a hypotonic solution o
f NaCl. In contrast, using a hypertonic solution, intake is typically double the
 need. Using the same diuretic treatment, although the natriuresis occurs within
 ~1 h, the appetite appears only slowly over 24 h. Increased plasma levels of al
dosterone parallel the increased intake; however, treatment with metyrapone bloc
ks the rise in aldosterone but has no effect on appetite. Satiation of sodium ap
petite was studied in rats using sodium loss induced by chronic diuretic treatme
nt and daily salt consumption sessions. When a simulated foraging cost was impos
ed on NaCl access in the form of a progressive ratio lever press task, rats show
ed satiation for NaCl (break point) after consuming an amount close to their est
imated deficit. The chronic diuretic regimen produced hypovolemia and large incr
eases in plasma aldosterone concentration and renin activity. These parameters w
ere reversed to or toward non-depleted control values at the time of behavioral 
satiation in the progressive ratio protocol. Satiation mechanisms for sodium app
etite thus do appear to exist. However, they do not operate quantitatively when 
concentrated salt is available at no effort, but instead allow overconsumption. 
There are reasons to believe that such a bias toward overconsumption may have be
en beneficial over evolutionary time, but such biasing for salt and other commod
ities is maladaptive in a resource-rich environment.      ^cY#6680.htm##
00372000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014500072002000900217#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#17#13#article#88#<P><B>Key words: </B> F
urosemide, Sodium depletion, Progressive ratio, Aldosterone, Satiation </font>  
<HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6680.htm##
00564000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033700072002000900409#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#18#14#article#88#<P class="style4"><A NA
ME="Text"></A> <font face="Arial, Helvetica, sans-serif" size="4"><b><font color
="#00007F">Text</font></b></font><A HREF="#Home"><FONT SIZE=4><B><img src="/img/
revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0">
</B></FONT></A>  </P> <font face="Arial, Helvetica, sans-serif">      ^cY#6680.h
tm##
01161000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704093400072002000901006#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#19#15#article#88#<P>In the laboratory, s
odium appetite most usually is studied using rats and access to hypertonic solut
ions of NaCl that normally would be unpalatable. This ensures that the behavior 
is `motivated' because, under comparable control conditions, intake would be min
imal. Several models of sodium appetite have been developed. Some of these use n
atural sodium deficiency while others emulate one or more of the hormonal condit
ions associated with natural deficiency, such as elevated circulating mineraloco
rticoid and/or angiotensin II concentrations (1). Such models and procedures hav
e focused largely on the initiating conditions for sodium appetite, and there ar
e relatively few studies on the termination of sodium appetite. Only depletion m
odels, in which there is a true and quantifiable need, allow us to assess whethe
r the appetite (i.e., amount consumed in a designated elapsed time) is commensur
ate with the need.         ^cY#6680.htm##
00960000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073300072002000900805#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#20#16#article#88#<P>The most widely used
 model of sodium depletion was introduced by Jalowiec (2) and involves administr
ation of the loop diuretic, furosemide. This produces a quite rapid (complete wi
thin 2 h) diuresis of near isotonic urine, and adult rats typically lose ~2 mEq 
of sodium during this time. The sodium appetite that develops as a result of thi
s abrupt depletion has several important characteristics: it is taste-guided and
 relatively specific for the taste of sodium; it matures over several hours to r
each a maximal level after 12-24 h (provided that the animals receive sodium-fre
e food so they cannot replete in the interim); the maximal level reached is exce
ssive, typically two to three times the actual sodium loss.       ^cY#6680.htm##
00589000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036200072002000900434#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#21#17#article#88#<P>The first of these c
haracteristics is most likely due to the presence of specific sodium-sensitive f
ibers in the gustatory system (3). The second is probably a result of genomic or
 other non-immediate actions of the hormones that are elevated soon after sodium
 loss (1), and the third has no good explanation and is the topic of the present
 review.       ^cY#6680.htm##
01350000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704112300072002000901195#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#22#18#article#88#<P>Sodium appetite has 
often been considered a `model drive' (4) because of its relatively simple physi
ological underpinnings and few commodities that will satisfy that appetite. Addi
tionally, sodium depletion can be quantified accurately and any repletion of tha
t deficit likewise can be measured easily. This is due in part to the fact that 
there is no significant storage for sodium in the body, a situation that is cons
iderably simpler than the relation between food and energy status. Thus, most of
 the sodium is in a relatively exchangeable form - extracellular fluid - that is
 subject to rapid loss, as with furosemide, and gain, as after drinking sodium s
alts. This makes it an ideal system in which to study whether the induced appeti
te is in fact matched to physiological need. We already know, from the list in t
he previous paragraph, that this is not the case - depleted rats consume excessi
ve amounts of sodium, at least under some conditions. We will consider three con
ditions that affect the amount of sodium consumed, and therefore the matching of
 intake to need: concentration, time, and effort.       ^cY#6680.htm##
00278000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005100072002000900123#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#23#19#article#88#<P><B>Concentration of 
sodium offered</B>      ^cY#6680.htm##
01506000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704127900072002000901351#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#24#20#article#88#<P>Animals show charact
eristic preference-aversion intake functions as a function of the concentration 
of sodium salt (usually NaCl) offered. In the absence of sodium depletion, these
 functions differ between species and between strains within a species (5-7), an
d sometimes between brief and long access tests that assess taste only and taste
 plus post-ingestive effects, respectively. Functions for two strains of rats te
sted in 24-h two-bottle choice tests (water and salt) are shown in <a href="#Fig
1">Figure 1</a> (redrawn from original data published by Fregly (8) and Rowland 
and Fregly (6)). Under need-free conditions, Sprague-Dawley rats show preference
s for NaCl in the 30-150 mM range, and aversion at 350 mM, while Fisher 344 rats
 show no preference and only an aversion above 150 mM. In contrast, during chron
ic dietary administration of angiotensin-converting enzyme inhibitors, all of wh
ich induce comparable sodium appetite (5), both strains show greatly increased i
ntakes of NaCl at all concentrations (and slightly decreased water intake; data 
not shown) and a resultant expansion in the range of preferred NaCl concentratio
ns. Note also that the absolute increase of NaCl intake is comparable in the two
 strains across the full concentration range.       ^cY#6680.htm##
01732000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704150500072002000901577#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#25#21#article#88#<P>Nonetheless, the mos
t usual procedure to ensure a specific appetite in a depleted rat is to offer a 
concentrated solution of NaCl so that most if not all of the intake that occurs 
cannot be ascribed to a basal preference. It is this type of procedure that has 
led investigators to report overconsumption after depletion (2). However, rats l
ose ~2 mEq of sodium after furosemide, so that repletion would correspond to ing
estion of only ~4 mL 450 mM NaCl, and this intake often occurs within less than 
5 min after presentation of salt. Possibly slowing the intake (9) or offering a 
less "solute dense" (i.e., diluted) version of NaCl might allow rats to exhibit 
appropriate intake. To determine this, we examined the characteristics of intake
 of a high (300 mM) and low (30 mM) NaCl solution in rats treated 24 h previousl
y with furosemide, timed so that the test began at lights out (10). Repletion wo
uld correspond to ingestion of 6-7 mL 300 mM and 60-70 mL 30 mM NaCl. Rats clear
ly cannot consume the latter amount within a short period of time. The results a
re shown in <a href="#Tab1">Table 1</a>. Rats with access to 300 mM NaCl consume
d about two times their deficit in the first hour of access, went into a positiv
e sodium balance, and continued to drink NaCl throughout the night, thus sustain
ing an even higher positive balance. There was no further increase in the intake
 of 300 mM NaCl when the test was repeated one week later, a finding that has al
so been reported by others (11).      ^cY#6680.htm##
00605000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037800072002000900450#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#26#22#article#88#<P>In contrast, rats wi
th access to 30 mM NaCl were unable to consume the high volume required to repai
r their deficit in the first hour, but first-hour intake was increased on the se
cond week compared with the first. In the first test, after 12 h rats were still
 in negative balance, but had repaired their deficit within 12 h at the second t
est one week later (10).       ^cY#6680.htm##
00969000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704074200072002000900814#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#27#23#article#88#<P>A parallel study of 
plasma markers of sodium depletion in rats drinking 30 mM NaCl (<a href="#Tab2">
Table 2</a>) showed that the elevations in hematocrit ratio, plasma protein conc
entration, and renin activity were restored to normal after intake of 60-80 mL o
r ~2 mEq 30 mM NaCl; this intake took place within the 6- to 12-h time frame. In
 contrast, plasma levels of aldosterone were decreased to normal after 1 h when 
the rats were still in a negative sodium balance, and were reduced to levels wel
l below normal after 6 and 12 h. This suggests that pre-absorptive factors such 
as taste may be important in reducing aldosterone synthesis, an idea also sugges
ted by Tordoff and McCaughey (9) on the basis of sham intake studies.      ^cY#6
680.htm##
00568000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034100072002000900413#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#28#24#article#88#<P>To summarize this st
udy, the satiation of sodium appetite after ~12 h in rats drinking diluted NaCl 
suggests that spreading the ingestion out in time may contribute to satiation. T
his idea is not inconsistent with the results of studies reporting intake of con
centrated NaCl in rats after either gavage or oral preloads (9,12).       ^cY#66
80.htm##
00278000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005100072002000900123#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#29#25#article#88#<P><B>Temporal maturati
on of appetite</B>      ^cY#6680.htm##
01129000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704090200072002000900974#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#30#26#article#88#<P>Jalowiec (2) origina
lly noted that the intake of hypertonic NaCl studied 24 h after depletion with f
urosemide exceeded physiological need. Since that need is fully realized within 
2 h and does not increase appreciably thereafter (2), it follows that over the c
ourse of 24 h the appetite must mature and at some time shorter than 24 h must h
ave equaled physiological need. To examine this, Rowland and Morian (13) studied
 intake 3, 12, and 24 h after injection of furosemide and on three consecutive t
ests held at 1-week intervals so that animals might have the opportunity to lear
n an earlier appetite. The mean intakes of 300 mM NaCl in a 1-h test after these
 time delays are shown in the left panel of <a href="#Fig2">Figure 2</a>. The in
take reached estimated sodium loss after about 12-h injection-to-test interval, 
and there was no conditioning to consume sooner on subsequent weeks.       ^cY#6
680.htm##
00915000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704068800072002000900760#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#31#27#article#88#<P>Measures of plasma a
ldosterone concentration and plasma renin activity (PRA), using the same protoco
l, are shown in <a href="#Fig2">Figure 2</a>B. Aldosterone levels did not peak f
or ~12 h, and so correlated with the growth of appetite. In contrast, PRA peaked
 at the earliest point and decreased at the later times, and therefore was not c
orrelated with appetite. This temporal correlation between aldosterone and sodiu
m appetite does not reflect causality because we found that treatment with metyr
apone, a selective inhibitor of aldosterone synthesis that was fully effective t
o block elevations in plasma aldosterone, was without effect on the induced sodi
um appetite.         ^cY#6680.htm##
01397000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704117000072002000901242#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#32#28#article#88#<P>Several conclusions 
may be drawn from these data as they relate to overconsumption: overconsumption 
(of 300 mM NaCl) occurs after &gt;12 h have elapsed since furosemide administrat
ion; at this time, aldosterone levels have peaked, but PRA is declining; however
, blocking the rise in aldosterone with metyrapone did not affect appetite; whil
e this study failed to identify any one "excitatory" factor for sodium appetite,
 we raised the possibility that maturation/sensitization may reflect dissipation
 of an inhibitory factor (14). Scholars of sodium appetite have argued that sinc
e mature appetite in the face of an acute need takes hours to develop, then one 
might expect that the appetite would wane with a similar time course. Wolf et al
. (12) reported studies consistent with this interpretation, and in the Rowland 
and Fregly study (10) reported above, appetite stopped after 12 h regardless of 
sodium balance. However, in both cases the interpretation was confounded because
 the offset of appetite often coincides with the onset of the light phase. In ot
her studies, light or circadian rhythm has been shown to modulate sodium appetit
e strongly (15).       ^cY#6680.htm##
00933000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070600072002000900778#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#33#29#article#88#<P>We note that the "sl
ow offset" argument makes little ecological sense - why would natural selection 
have retained a behavior that puts the animal in danger by foraging for a commod
ity long after the need was met? Perhaps the problem is not with the sensing (or
 deficiency therein) of sodium balance but rather with the environment in which 
we test appetite. While animals at natural risk for sodium depletion (e.g., herb
ivores) may find concentrated mineral deposits (salt licks), these locations not
 only require effort to reach but also are quite likely to become a magnet for p
otential predators. The environment may provide significant inhibitory factors, 
and we now turn to that analysis.      ^cY#6680.htm##
00281000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005400072002000900126#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#34#30#article#88#<P><B>Effort-operant re
sponding for salt</B>      ^cY#6680.htm##
01391000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704116400072002000901236#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#35#31#article#88#<P>We initially drew on
 protocols from the domain of food and in particular the continuous access close
d economy work of Collier (16). To translate this to sodium appetite, we needed 
to use a protocol in which an "on" signal would be present most of the time, and
 we could then examine the temporal self-organization of salt appetite. We (17) 
chose chronic administration of DOCA. Rats were tested in a protocol with three 
procurement cost phases (1, 80, 300 presses), three NaCl concentration phases (4
0, 150, 400 mM), and two treatment phases (baseline and DOCA), with each phase l
asting 1-3 weeks. Rats were required to emit the designated procurement cost on 
one of two levers. One lever delivered distilled water and the other NaCl of the
 designated concentration. Completion of the cost ratio caused the relevant spou
t to be moved on a motor-driven platform into reach of the rat through a slot ab
ove the lever. The rat could then lick and drink as much as it chose but with th
e caveat that whenever 10 min elapsed without a lick (detected by a contact sens
or) the motor moved the bottle out of reach until the next procurement ratio was
 completed.      ^cY#6680.htm##
00667000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044000072002000900512#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#36#32#article#88#<P>In terms of preferen
ce for water compared with NaCl, the baseline data showed a typical preference a
version function, with greatest NaCl choice at 150 mM. As procurement cost incre
ased, rats took fewer and larger bouts of either NaCl or water (<a href="#Tab3">
Table 3</a>). Comparing baseline to DOCA phases, rats took more NaCl during the 
DOCA phase. In other words, rats initiated more salt bouts during the DOCA phase
 (17).       ^cY#6680.htm##
01176000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094900072002000901021#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#37#33#article#88#<P>Despite this encoura
ging result, this protocol is not very useful in terms of examining our goal of 
studying intake in relationship to defined physiological need - i.e., a true "ec
onomic decision". Thus, our next approach was to use this protocol but with a ch
ronic natriuretic regimen. We (Colbert CL and Rowland NE, unpublished data) used
 hydrochlorothiazide (HCZ) in the diet. Fregly and Kim (18) had reported that HC
Z induces higher intakes of NaHCO<SUB>3</SUB> than NaCl, an event which we verif
ied in a proof-of-principle experiment (19). In the foraging protocol, the resul
t was similar to the DOCA study, with rats initiating more salt bouts under HCZ 
than at baseline, and with bout sizes increasing at higher procurement costs (<a
 href="#Tab3">Table 3</a>). But it proved difficult to predict or control the ti
ming and magnitude of the physiological deficit induced by the HCZ, hence to mak
e arguments about satiation of need.      ^cY#6680.htm##
00643000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041600072002000900488#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#38#34#article#88#<P>Thus, in our most re
cent studies (20) we returned to the furosemide protocol discussed earlier but i
nstead of using continuous access procurement costs we used a time-limited acces
s with imposed consummatory cost and a closed economy since this was the only sa
lt the animals could obtain to alleviate their need. The protocol, in which furo
semide was injected once every day, is sketched below.  </font>      ^cY#6680.ht
m##
00240000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001300072002000900085#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#39#35#article#88#<P>      ^cY#6680.htm##
00597000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037000072002000900442#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#40#36#article#88#<P><font face="Arial, H
elvetica, sans-serif">Furosemide <SUP><img src="/img/revistas/bjmbr/v40n5/6680se
ta1.jpg"> </SUP> Operant (PR) NaCl session </font><font face="Arial, Helvetica, 
sans-serif"><SUP><img src="/img/revistas/bjmbr/v40n5/6680seta2.jpg"> </SUP> Furo
semide, </font><font face="Arial, Helvetica, sans-serif">where PR is a progressi
ve ratio. </font>      ^cY#6680.htm##
00240000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001300072002000900085#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#41#37#article#88#<P>      ^cY#6680.htm##
01124000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704089700072002000900969#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#42#38#article#88#<P><font face="Arial, H
elvetica, sans-serif">This protocol allows for an accurate timing of the sodium 
loss, and 18 h is sufficient to allow complete maturation of the appetite. A few
 hours after the operant session in which NaCl was available, furosemide was inj
ected and the cycle began again. Rats were fed a low sodium diet throughout. We 
chose PR schedules to study satiation by analogy with their use as a particularl
y sensitive metric of motivation for drug taking (21). In a PR, each successive 
reinforcer costs more (i.e., incrementing consummatory cost), so this is really 
a special instance of a variable ratio schedule, but one in which rats show a br
eak point when they cease responding. In terms of food, this is analogous to for
aging causing resource depletion in a patch, when animals are forced to make `op
timal' decisions about staying versus leaving the patch. </font>      ^cY#6680.h
tm##
01005000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704077800072002000900850#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#43#39#article#88#<P><font face="Arial, H
elvetica, sans-serif">We chose two PR schedules differing in step size for succe
ssive reinforcers but the intakes were similar and so have been combined for pre
sentation. Additionally, using the motor-driven salt bottles mentioned above, ac
cess was granted for either a short (7.5 s) or a long (15 s) duration: continuou
s licking for these durations would yield ~0.3 and 0.6 mL, respectively. Only da
ta for the short duration are shown: these were approximately 73% of the intakes
 in the long duration and so represent the lowest intakes that we observed. Furt
her, we ran two studies, one using 300 mM NaCl and the other 450 mM NaCl. As a c
ontrol, animals with free access to either 300 or 450 mM were run in the same de
pletion protocol. </font>      ^cY#6680.htm##
01187000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704096000072002000901032#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#44#40#article#88#<P><font face="Arial, H
elvetica, sans-serif">The results are shown in <a href="#Fig3">Figure 3</a>. Con
trol rats with free access consumed a greater volume of 300 than 450 mM NaCl, an
d slightly more when converted to solute. Both intakes were considerably in exce
ss of the 1.5-2.0 mEq deficit that we estimated. The intakes of rats tested in t
he PR were less than 50% those in the free drink condition, and when converted t
o mEq. Note that rats with the longer access PR reinforcer consumed ~2 mEq. In a
nother study, we determined that the actual sodium loss in this protocol was 1-2
 mEq and therefore we concluded that the PR rats showed a break point near their
 physiological need. We again emphasize that the break point was not imposed eit
her by experimenter or time: the criterion for ending the session was 15 min ela
psed since the last reinforcer. Thus, rats showed satiation by a standard criter
ion for establishing meals and satiety. </font>      ^cY#6680.htm##
01076000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084900072002000900921#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#45#41#article#88#<P><font face="Arial, H
elvetica, sans-serif">To determine whether this intake in the PR session caused 
physiological changes by the time that satiation occurred, blood was taken from 
rats either before their PR session (pre) or after satiating in the PR session (
post; run in the 300 mM short protocol as in <a href="#Fig3">Figure 3</a>), or w
hen not depleted (control). It can be seen in <a href="#Tab4">Table 4</a> that d
epleted (pre-session) rats had expected significant elevations in hematocrit rat
io, plasma protein, PRA, and aldosterone. Each of these parameters was significa
ntly reduced by the end of the PR session. It is also noteworthy that aldosteron
e was normalized fully at this time while PRA was not, a result similar to the m
ore rapid drop of aldosterone in the 30 mM NaCl free drinking study reported abo
ve (10). </font>      ^cY#6680.htm##
00858000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063100072002000900703#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#46#42#article#88#<P><font face="Arial, H
elvetica, sans-serif">Thus, behavioral satiation by the PR break point criterion
 occurs when physiological need, assessed by hematocrit ratio, protein, and aldo
sterone, is largely alleviated. There is no hint of overconsumption (<a href="#F
ig2">Figure 2</a>, and verified in this particular blood sampling study).</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>    <table width="100%"  border="0">      <tr
 align="left" valign="top">        <td width="14%"><a href="/img/revistas/bjmbr/
v40n5/html/6680i01.htm"><img src="/img/revistas/bjmbr/v40n5/6680i01peq.jpg" bord
er="2"></a></td>        <td width="86%">    ^cY#6680.htm##
01336000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704110900072002000901181#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#47#43#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Mean daily intake of NaCl sol
ution of various concentrations, available in a two-bottle choice with water. Da
ta are averaged over several days for each concentration. <I>A</I>, Redrawn from
 Fregly (8) Figure 1, shows data from female Sprague-Dawley (SD) rats under base
line conditions or with the angiotensin-converting enzyme (ACE) inhibitor captop
ril added to the food (1.05 g/kg). *P &lt; 0.05 higher, <SUP>+</SUP>P &lt; 0.05 
lower than concurrent water intakes (the latter are not shown; <I>t</I>-test). C
aptopril induced a net preference for NaCl at both low and high concentrations c
ompared to baseline. <I>B</I>, Redrawn from Rowland and Fregly (6), shows data f
rom male Fisher 344 rats under baseline conditions and when the ACE inhibitor, r
amipril (0.05 g/kg), was added to the food. Note that ramipril induced a net pre
ference for NaCl across most of the concentration range, and that the ACE-induce
d increase from baseline was comparable to that in SD rats shown in A. </font>  
      </td>      </tr>    </table>        ^cY#6680.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039400072002000900466#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#48#44#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (104 K JPG file)]</font
>    <HR ALIGN=LEFT WIDTH=100% SIZE=2>    <table width="100%"  border="0">      
<tr align="left" valign="top">        <td width="14%"><a href="/img/revistas/bjm
br/v40n5/html/6680i02.htm"><img src="/img/revistas/bjmbr/v40n5/6680i02peq.jpg" b
order="2"></a></td>        <td width="86%">    ^cY#6680.htm##
00622000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039500072002000900467#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#49#45#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2. Temporal changes in sodium ap
petite (A) and plasma aldosterone or plasma renin activity (PRA; B) following a 
single injection of furosemide in rats. Data are reported as means for 6 male SD
 rats. Data are redrawn from Rowland and Morian (13). Ang I = angiotensin I. </f
ont>        </td>      </tr>    </table>        ^cY#6680.htm##
00620000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039300072002000900465#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#50#46#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (92 K JPG file)]</font>
    <HR ALIGN=LEFT WIDTH=100% SIZE=2>    <table width="100%"  border="0">      <
tr align="left" valign="top">        <td width="14%"><a href="/img/revistas/bjmb
r/v40n5/html/6680i03.htm"><img src="/img/revistas/bjmbr/v40n5/6680i03peq.jpg" bo
rder="2"></a></td>        <td width="86%">    ^cY#6680.htm##
00787000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056000072002000900632#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#51#47#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig3"></a>Figure 3. Intake in mL (A) and mEq (B) 
of rats drinking either 300 or 450 mM NaCl ~18 h after sodium depletion with fur
osemide and either drinking freely (1-h session) or under progressive ratio (PR)
 session conditions (terminated after 15 min of no responding, typically after ~
1 h). Data are reported as means &#177; SEM. The estimated sodium loss prior to 
the drinking session is 1-2 mEq; intake approximates the need in the PR protocol
. </font>        </td>      </tr>    </table>        ^cY#6680.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038800072002000900460#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#52#48#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (88 K JPG file)]</font>
    <HR ALIGN=LEFT WIDTH=100% SIZE=2>    <table width="100%"  border="0">      <
tr align="left" valign="top">        <td width="14%"><a href="/img/revistas/bjmb
r/v40n5/html/6680t01.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border=
"2"></a></td>        <td width="86%">    ^cY#6680.htm##
00410000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018300072002000900255#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#53#49#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab1"></a>Table 1. Intakes of 30 and 300 mM NaCl 
by sodium-depleted rats. </font>        </td>      </tr>    </table>        ^cY#
6680.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038900072002000900461#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#54#50#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (106 K JPG file)]</font
>    <HR ALIGN=LEFT WIDTH=100% SIZE=2>    <table width="100%"  border="0">      
<tr align="left" valign="top">        <td width="14%"><a href="/img/revistas/bjm
br/v40n5/html/6680t02.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border
="2"></a></td>        <td width="86%">    ^cY#6680.htm##
00458000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023100072002000900303#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#55#51#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab2"></a>Table 2. Changes in mean plasma paramet
ers during slow repletion of sodium deficit in rats drinking 30 mM NaCl. </font>
        </td>      </tr>    </table>        ^cY#6680.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038900072002000900461#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#56#52#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (140 K JPG file)]</font
>    <HR ALIGN=LEFT WIDTH=100% SIZE=2>    <table width="100%"  border="0">      
<tr align="left" valign="top">        <td width="14%"><a href="/img/revistas/bjm
br/v40n5/html/6680t03.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border
="2"></a></td>        <td width="86%">    ^cY#6680.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021300072002000900285#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#57#53#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab3"></a>Table 3. Performance of rats in a close
d economy procurement foraging task for salt solution. </font>        </td>     
 </tr>    </table>        ^cY#6680.htm##
00852000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704062500072002000900697#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#58#54#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (181 K JPG file)]</font
>    <HR ALIGN=LEFT WIDTH=100% SIZE=2>    <table width="100%"  border="0">      
<tr align="left" valign="top">        <td width="14%"><a href="/img/revistas/bjm
br/v40n5/html/6680t04.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border
="2"></a></td>        <td width="86%"><font face="Arial, Helvetica, sans-serif">
<a name="Tab4"></a>Table 4. Plasma parameters of furosemide-treated rats taken e
ither before (pre) or after (post) satiation in the plasma renin protocol. </fon
t></td>      </tr>    </table>        ^cY#6680.htm##
00378000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015100072002000900223#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#59#55#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (127 K JPG file)]</font
>    <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6680.htm##
00579000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035200072002000900424#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#60#56#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT SIZE=4><FONT COLOR=#00
007F><B>Discussion</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-s
erif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></font></P> 
     ^cY#6680.htm##
00973000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704074600072002000900818#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#61#57#article#88#<P><font face="Arial, H
elvetica, sans-serif">Collectively, the data presented above show that behaviora
l satiation for salt depends on the circumstances under which salt is presented,
 and not on some immutable target amount of solute. In particular, the developme
nt of the repeated furosemide model allows us to make an accurate assessment of 
physiological need. Using a PR schedule, we showed that behavioral satiation is 
critically dependent on motivational and economic factors that are imparted in a
 PR. It appears that the motive force to consume when there is little or no cost
 involved in obtaining the commodity leads to overconsumption, whereas under har
der conditions the intake matches the need reasonably accurately. </font>      ^
cY#6680.htm##
00931000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070400072002000900776#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#62#58#article#88#<P><font face="Arial, H
elvetica, sans-serif">The term motivation implies the effort of an organism in t
he face of environmental adversity (22) and quite early studies of sodium appeti
te in rats modeled adversity in the form of operant lever pressing. At that time
, the understanding of the physiology of sodium appetite was rudimentary and pro
cedures for producing sodium appetite were either painful (formalin injection) o
r induced an irreversible condition (adrenalectomy). Almost all recent studies h
ave used unpalatable hypertonic solutions of sodium salts as the adversity, in p
art because this is procedurally easier and requires little or no training compa
red with operant tasks. </font>      ^cY#6680.htm##
01773000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704154600072002000901618#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#63#59#article#88#<P><font face="Arial, H
elvetica, sans-serif">Consumption of a commodity is inversely related to environ
mental adversity or effort (23), so it follows that a control system so construc
ted could produce consumption in excess of need when the environment was favorab
le and in the absence of a strong endogenous signal for satiation. The results o
f the present PR experiment, as well as a few literature reports, are consistent
 with this perspective. Thus, McCutcheon and Levy (24) found that formalin-treat
ed rats bar pressing in a variable interval 20-s schedule for 400 mM NaCl soluti
on showed a defined temporal onset and satiation of behavior when NaCl was avail
able <I>ad libitum</I>. Economidou et al. (25) recently reported a protocol simi
lar to our own using chronic furosemide treatment and daily operant access to Na
Cl. Their rats consumed ~18 mL 2% NaCl (~3.6 mEq), well in excess of need, when 
it was available in 0.1-mL reinforcements on an FR1. But this is a very easy sch
edule of procurement and therefore, together with the data reviewed above, we su
ggest that the propensity of rats to overconsume in foraging protocols may be cr
itically dependent on how difficult the task is and/or how it is structured in t
ime. Satiation and satiety then may be considered to be variable constructs, dep
endent on both internal and economic factors (16). The salt depletion protocol h
ere developed allows for a quantitative investigation of this hypothesis as it r
elates to physiological need. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^
cY#6680.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031900072002000900391#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#64#60#article#88#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>      ^cY#6680.htm##
00412000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017100074002000900245#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#65#61#article#88#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Daniels D, Fluharty SJ. Salt appetite: a 
neurohormonal viewpoint. <I>Physiol Behav</I> 2004; 81: 319-337. </font>      ^c
Y#6680.htm##
00441000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020000074002000900274#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#66#62#article#88#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Jalowiec JE. Sodium appetite elicited by 
furosemide: effects of differential dietary maintenance. <I>Behav Biol</I> 1974;
 10: 313-327. </font>      ^cY#6680.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021100074002000900285#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#67#63#article#88#3#<P><font 
face="Arial, Helvetica, sans-serif">3. DeSimone JA, Ferrell F. Analysis of amilo
ride inhibition of chorda tympani taste response of rat to NaCl. <I>Am J Physiol
</I> 1985; 249: R52-R61. </font>      ^cY#6680.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021500074002000900289#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#68#64#article#88#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Wolf G, McGovern JF, Dicara LV. Sodium ap
petite: some conceptual and methodologic aspects of a model drive system. <I>Beh
av Biol</I> 1974; 10: 27-42. </font>      ^cY#6680.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022100074002000900295#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#69#65#article#88#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Rowland NE, Fregly MJ. Sodium appetite: s
pecies and strain differences and role of renin-angiotensin-aldosterone system. 
<I>Appetite</I> 1988; 11: 143-178. </font>      ^cY#6680.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024200074002000900316#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#70#66#article#88#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Rowland NE, Fregly MJ. Regulation of inta
kes of water and NaCl solutions in Fischer 344 rats: contrasts and comparisons b
etween strains. <I>Physiol Behav</I> 1988; 44: 461-467. </font>      ^cY#6680.ht
m##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024900074002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#71#67#article#88#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Bachmanov AA, Beauchamp GK, Tordoff MG. V
oluntary consumption of NaCl, KCl, CaCl<SUB>2</SUB>, and NH<SUB>4</SUB>Cl soluti
ons by 28 mouse strains. <I>Behav Genet</I> 2002; 32: 445-457. </font>      ^cY#
6680.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021600074002000900290#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#72#68#article#88#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Fregly MJ. Effect of the angiotensin conv
erting enzyme inhibitor, captopril, on NaCl appetite of rats. <I>J Pharmacol Exp
 Ther</I> 1980; 215: 407-412. </font>      ^cY#6680.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026700074002000900341#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#73#69#article#88#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Tordoff MG, McCaughey SA. Influence of or
al and gastric NaCl preloads on NaCl intake and gastric emptying of sodium-defic
ient rats. <I>Am J Physiol Regul Integr Comp Physiol</I> 2001; 281: R1152-R1160.
 </font>      ^cY#6680.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#74#70#article#88#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Rowland NE, Fregly MJ. Repletion of acu
te sodium deficit in rats drinking either low or high concentrations of sodium c
hloride solution. <I>Am J Physiol</I> 1992; 262: R419-R425. </font>      ^cY#668
0.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027700075002000900352#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#75#71#article#88#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Leshem M, Kavushansky A, Devys JM, Thor
nton S. Enhancement revisited: the effects of multiple depletions on sodium inta
ke in rats vary with strain, substrain, and gender. <I>Physiol Behav</I> 2004; 8
2: 571-580. </font>      ^cY#6680.htm##
00432000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019000075002000900265#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#76#72#article#88#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Wolf G, Schulkin J, Simson PE. Multiple
 factors in the satiation of salt appetite. <I>Behav Neurosci</I> 1984; 98: 661-
673. </font>      ^cY#6680.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023100075002000900306#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#77#73#article#88#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Rowland NE, Morian KR. Roles of aldoste
rone and angiotensin in maturation of sodium appetite in furosemide-treated rats
. <I>Am J Physiol</I> 1999; 276: R1453-R1460. </font>      ^cY#6680.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026600075002000900341#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#78#74#article#88#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Verbalis JG, Blackburn RE, Olson BR, St
ricker EM. Central oxytocin inhibition of food and salt ingestion: a mechanism f
or intake regulation of solute homeostasis. <I>Regul Pept</I> 1993; 45: 149-154.
 </font>      ^cY#6680.htm##
00443000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020100075002000900276#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#79#75#article#88#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Rowland NE, Bellush LL, Fregly MJ. Nyct
hemeral rhythms and sodium chloride appetite in rats. <I>Am J Physiol</I> 1985; 
249: R375-R378. </font>      ^cY#6680.htm##
00397000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015500075002000900230#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#80#76#article#88#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Collier GH. Satiety: an ecological pers
pective. <I>Brain Res Bull</I> 1985; 14: 693-700. </font>      ^cY#6680.htm##
00435000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019300075002000900268#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#81#77#article#88#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Colbert CL, Rowland NE. Sodium preferen
ce and appetite in rats in an operant protocol. <I>Physiol Behav</I> 2005; 83: 7
15-721. </font>      ^cY#6680.htm##
00447000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020500075002000900280#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#82#78#article#88#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Fregly MJ, Kim KJ. Specificity of the s
odium chloride appetite of hydrochlorothiazide-treated rats. <I>Physiol Behav</I
> 1970; 5: 595-599. </font>      ^cY#6680.htm##
00454000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021200075002000900287#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#83#79#article#88#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Rowland NE, Colbert CL. Sodium appetite
 induced in rats by chronic administration of a thiazide diuretic. <I>Physiol Be
hav</I> 2003; 79: 613-619. </font>      ^cY#6680.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024800075002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#84#80#article#88#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Starr LJ, Rowland NE. Characteristics o
f salt appetite in chronically sodium-depleted rats using a progressive ratio sc
hedule of procurement. <I>Physiol Behav</I> 2006; 88: 433-442. </font>      ^cY#
6680.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#85#81#article#88#21#<P><font
 face="Arial, Helvetica, sans-serif">21. Stafford D, LeSage MG, Glowa JR. Progre
ssive-ratio schedules of drug delivery in the analysis of drug self-administrati
on: a review. <I>Psychopharmacology</I> 1998; 139: 169-184. </font>      ^cY#668
0.htm##
00498000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025600075002000900331#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#86#82#article#88#22#<P><font
 face="Arial, Helvetica, sans-serif">22. Epstein AN. Instinct and motivation as 
explanations for complex behavior. In: Pfaff DW (Editor), <I>The physiological m
echanisms of motivation</I>. New York: Springer-Verlag; 1982. p 25-58. </font>  
    ^cY#6680.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018700075002000900262#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#87#83#article#88#23#<P><font
 face="Arial, Helvetica, sans-serif">23. Houston AI, McNamara JM. The value of f
ood: effects of open and closed economies. <I>Animal Behav</I> 1989; 37: 546-562
. </font>      ^cY#6680.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021000075002000900285#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#88#84#article#88#24#<P><font
 face="Arial, Helvetica, sans-serif">24. McCutcheon B, Levy C. Relationship betw
een NaCl rewarded bar-pressing and duration of sodium deficiency. <I>Physiol Beh
av</I> 1972; 8: 761-763. </font>      ^cY#6680.htm##
00593000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704035100075002000900426#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#p#89#85#article#88#25#<P><font
 face="Arial, Helvetica, sans-serif">25. Economidou D, Mattioli L, Cifani C, Per
fumi M, Massi M, Cuomo V, et al. Effect of the cannabinoid CB1 receptor antagoni
st SR-141716A on ethanol self-administration and ethanol-seeking behaviour in ra
ts. <I>Psychopharmacology</I> 2006; 183: 394-403.</font>   <HR ALIGN=LEFT WIDTH=
100% SIZE=2>       ^cY#6680.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#90#86#article#88#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, H
elvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT> <
A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6680
.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#91#87#article#88#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence: </B><font face="Arial, Helvetica, sans-serif">N.E.  
  Rowland, Department of Psychology, University of Florida, Gainesville, FL 3261
1-2250,    USA. E-mail: <a href="mailto:nrowland@ufl.edu">nrowland@ufl.edu</a></
font> </P>      ^cY#6680.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6680.htm#S#p#92#88#article#88#<P><font face="Arial, H
elvetica, sans-serif">Presented at the International Symposium of Neuroendocrino
logy "Neuroendocrine control of body fluid homeostasis: past, present and future
". Ribeir&atilde;o Preto, SP, Brazil, September 1-3, 2006. Received October 11, 
2006. Accepted February 1, 2007.</font><font face="Arial, Helvetica, sans-serif"
> </font>       ^cY#6680.htm##
00513000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100019000900120
04500109030001400154065000900168064000500177031000300182014000800185865000900193
002000900202035001000211801001400221#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#93#1#article#25#1#^rND^sDaniels^nD#^rND^sFluharty^nSJ#Salt appetite:
 a neurohormonal viewpoint^len#Physiol Behav#20040000#2004#81#319-337#20070500#6
680.htm#0031-9384#Physiol Behav##
00521000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730120088000920300
01100180065000900191064000500200031000300205014000800208865000900216002000900225
035001000234801001100244#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#c#
94#2#article#25#2#^rND^sJalowiec^nJE#Sodium appetite elicited by furosemide: eff
ects of differential dietary maintenance^len#Behav Biol#19740000#1974#10#313-327
#20070500#6680.htm#0091-6773#Behav Biol##
00552000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100017000920120
08500109030001300194065000900207064000500216031000400221014000800225865000900233
002000900242035001000251801001300261#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#95#3#article#25#3#^rND^sDeSimone^nJA#^rND^sFerrell^nF#Analysis of am
iloride inhibition of chorda tympani taste response of rat to NaCl^len#Am J Phys
iol#19850000#1985#249#R52-R61#20070500#6680.htm#0002-9513#Am J Physiol##
00572000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100019000870100
01700106012008600123030001100209065000900220064000500229031000300234014000600237
865000900243002000900252035001000261801001100271#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6680.htm#S#c#96#4#article#25#4#^rND^sWolf^nG#^rND^sMcGovern^nJF#^rND^
sDicara^nLV#Sodium appetite: some conceptual and methodologic aspects of a model
 drive system^len#Behav Biol#19740000#1974#10#27-42#20070500#6680.htm#0091-6773#
Behav Biol##
00558000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910120
10100108030000900209065000900218064000500227031000300232014000800235865000900243
002000900252035001000261801000900271#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#97#5#article#25#5#^rND^sRowland^nNE#^rND^sFregly^nMJ#Sodium appetite
: species and strain differences and role of renin-angiotensin-aldosterone syste
m^len#Appetite#19880000#1988#11#143-178#20070500#6680.htm#0195-6663#Appetite##
00584000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910120
11700108030001400225065000900239064000500248031000300253014000800256865000900264
002000900273035001000282801001400292#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#98#6#article#25#6#^rND^sRowland^nNE#^rND^sFregly^nMJ#Regulation of i
ntakes of water and NaCl solutions in Fischer 344 rats: contrasts and comparison
s between strains^len#Physiol Behav#19880000#1988#44#461-467#20070500#6680.htm#0
031-9384#Physiol Behav##
00585000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100020000930100
01800113012008700131030001200218065000900230064000500239031000300244014000800247
865000900255002000900264035001000273801001200283#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6680.htm#S#c#99#7#article#25#7#^rND^sBachmanov^nAA#^rND^sBeauchamp^nG
K#^rND^sTordoff^nMG#Voluntary consumption of NaCl, KCl, CaCl2, and NH4Cl solutio
ns by 28 mouse strains^len#Behav Genet#20020000#2002#32#445-457#20070500#6680.ht
m#0001-8244#Behav Genet##
00548000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740120095000910300
02100186065000900207064000500216031000400221014000800225865000900233002000900242
035001000251801002100261#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#c#
100#8#article#25#8#^rND^sFregly^nMJ#Effect of the angiotensin converting enzyme 
inhibitor, captopril, on NaCl appetite of rats^len#J Pharmacol Exp Ther#20020000
#1980#215#407-412#20070500#6680.htm#0022-3565#J Pharmacol Exp Ther##
00576000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100020000920120
10900112030003900221710000200260065000900262064000500271031000400276014001200280
865000900292002000900301#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#c#
101#9#article#25#9#^rND^sTordoff^nMG#^rND^sMcCaughey^nSA#Influence of oral and g
astric NaCl preloads on NaCl intake and gastric emptying of sodium-deficient rat
s^len#Am J Physiol Regul Integr Comp Physiol#2#20010000#2001#281#R1152-R1160#200
70500#6680.htm##
00588000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940120
11700111030001300228065000900241064000500250031000400255014001000259865000900269
002000900278035001000287801001300297#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#102#10#article#25#10#^rND^sRowland^nNE#^rND^sFregly^nMJ#Repletion of
 acute sodium deficit in rats drinking either low or high concentrations of sodi
um chloride solution^len#Am J Physiol#19920000#1992#262#R419-R425#20070500#6680.
htm#0002-9513#Am J Physiol##
00657000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100021000920100
01600113010001800129012012700147030001400274065000900288064000500297031000300302
014000800305865000900313002000900322035001000331801001400341#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6680.htm#S#c#103#11#article#25#11#^rND^sLeshem^nM#^rND^sK
avushansky^nA#^rND^sDevys^nJM#^rND^sThornton^nS#Enhancement revisited: the effec
ts of multiple depletions on sodium intake in rats vary with strain, substrain, 
and gender^len#Physiol Behav#20040000#2004#82#571-580#20070500#6680.htm#0031-938
4#Physiol Behav##
00553000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100018000900100
01700108012005500125030001500180065000900195064000500204031000300209014000800212
865000900220002000900229035001000238801001500248#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6680.htm#S#c#104#12#article#25#12#^rND^sWolf^nG#^rND^sSchulkin^nJ#^rN
D^sSimson^nPE#Multiple factors in the satiation of salt appetite^len#Behav Neuro
sci#19840000#1984#98#661-673#20070500#6680.htm#0735-7044#Behav Neurosci##
00574000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940120
10100111030001300212065000900225064000500234031000400239014001200243865000900255
002000900264035001000273801001300283#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#105#13#article#25#13#^rND^sRowland^nNE#^rND^sMorian^nKR#Roles of ald
osterone and angiotensin in maturation of sodium appetite in furosemide-treated 
rats^len#Am J Physiol#19990000#1999#276#R1453-R1460#20070500#6680.htm#0002-9513#
Am J Physiol##
00643000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100020000950100
01600115010001900131012011600150030001100266065000900277064000500286031000300291
014000800294865000900302002000900311035001000320801001100330#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6680.htm#S#c#106#14#article#25#14#^rND^sVerbalis^nJG#^rND
^sBlackburn^nRE#^rND^sOlson^nBR#^rND^sStricker^nEM#Central oxytocin inhibition o
f food and salt ingestion: a mechanism for intake regulation of solute homeostas
is^len#Regul Pept#19930000#1993#45#149-154#20070500#6680.htm#0167-0115#Regul Pep
t##
00562000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01700112012006100129030001300190065000900203064000500212031000400217014001000221
865000900231002000900240035001000249801001300259#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6680.htm#S#c#107#15#article#25#15#^rND^sRowland^nNE#^rND^sBellush^nLL
#^rND^sFregly^nMJ#Nycthemeral rhythms and sodium chloride appetite in rats^len#A
m J Physiol#19850000#1985#249#R375-R378#20070500#6680.htm#0002-9513#Am J Physiol
##
00482000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120039000940300
01500133065000900148064000500157031000300162014000800165865000900173002000900182
035001000191801001500201#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#c#
108#16#article#25#16#^rND^sCollier^nGH#Satiety: an ecological perspective^len#Br
ain Res Bull#19850000#1985#14#693-700#20070500#6680.htm#0361-9230#Brain Res Bull
##
00537000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940120
06600112030001400178065000900192064000500201031000300206014000800209865000900217
002000900226035001000235801001400245#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#109#17#article#25#17#^rND^sColbert^nCL#^rND^sRowland^nNE#Sodium pref
erence and appetite in rats in an operant protocol^len#Physiol Behav#20050000#20
05#83#715-721#20070500#6680.htm#0031-9384#Physiol Behav##
00549000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930120
08400107030001400191065000900205064000500214031000200219014000800221865000900229
002000900238035001000247801001400257#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#110#18#article#25#18#^rND^sFregly^nMJ#^rND^sKim^nKJ#Specificity of t
he sodium chloride appetite of hydrochlorothiazide-treated rats^len#Physiol Beha
v#19700000#1970#5#595-599#20070500#6680.htm#0031-9384#Physiol Behav##
00556000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940120
08500112030001400197065000900211064000500220031000300225014000800228865000900236
002000900245035001000254801001400264#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#111#19#article#25#19#^rND^sRowland^nNE#^rND^sColbert^nCL#Sodium appe
tite induced in rats by chronic administration of a thiazide diuretic^len#Physio
l Behav#20030000#2003#79#613-619#20070500#6680.htm#0031-9384#Physiol Behav##
00592000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
12300110030001400233065000900247064000500256031000300261014000800264865000900272
002000900281035001000290801001400300#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#112#20#article#25#20#^rND^sStarr^nLJ#^rND^sRowland^nNE#Characteristi
cs of salt appetite in chronically sodium-depleted rats using a progressive rati
o schedule of procurement^len#Physiol Behav#20030000#2006#88#433-442#20070500#66
80.htm#0031-9384#Physiol Behav##
00612000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01600111012010300127030001900230065000900249064000500258031000400263014000800267
865000900275002000900284035001000293801001900303#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6680.htm#S#c#113#21#article#25#21#^rND^sStafford^nD#^rND^sLeSage^nMG#
^rND^sGlowa^nJR#Progressive-ratio schedules of drug delivery in the analysis of 
drug self-administration: a review^len#Psychopharmacology#19980000#1998#139#169-
184#20070500#6680.htm#0033-3158#Psychopharmacology##
00553000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120065000940160
01600159018004700175066000900222062001600231065000900247064000500256014000800261
865000900269002000900278#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#c#
114#22#article#25#22#^rND^sEpstein^nAN#Instinct and motivation as explanations f
or complex behavior^len#^rED^sPfaff^nDW#The physiological mechanisms of motivati
on^len#New York#Springer-Verlag#19820000#1982#p 25-58#20070500#6680.htm##
00497000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940120
06000113030001300173710000200186065000900188064000500197031000300202014000800205
865000900213002000900222#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#c#
115#23#article#25#23#^rND^sHouston^nAI#^rND^sMcNamara^nJM#The value of food: eff
ects of open and closed economies^len#Animal Behav#2#19890000#1989#37#546-562#20
070500#6680.htm##
00554000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100014000960120
08600110030001400196065000900210064000500219031000200224014000800226865000900234
002000900243035001000252801001400262#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
680.htm#S#c#116#24#article#25#24#^rND^sMcCutcheon^nB#^rND^sLevy^nC#Relationship 
between NaCl rewarded bar-pressing and duration of sodium deficiency^len#Physiol
 Behav#19720000#1972#8#761-763#20070500#6680.htm#0031-9384#Physiol Behav##
00747000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100018000960100
01600114010001700130010001500147010001500162810000600177012013400183030001900317
06500090033606400050034503100040035001400080035486500090036200200090037103500100
0380801001900390#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6680.htm#S#c#117#25#a
rticle#25#25#^rND^sEconomidou^nD#^rND^sMattioli^nL#^rND^sCifani^nC#^rND^sPerfumi
^nM#^rND^sMassi^nM#^rND^sCuomo^nV#et al#Effect of the cannabinoid CB1 receptor a
ntagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviou
r in rats^len#Psychopharmacology#20060000#2006#183#394-403#20070500#6680.htm#003
3-3158#Psychopharmacology##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#o#1#1#article#1#20
080212#125728#6681.htm#126##
03392000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015601200780016601000250
02440100022002690100022002910100024003130100024003370100023003610700083003840700
11300467083178600580085000802366085002102374085002502395085004002420085003502460
08500220249508500200251711700060253707200030254305301260254605500120267205400230
2684112000902707111001702716114000902733113001502742002000902757#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#h#2#1#article#1#ra#en#bjmbr#1#3.1#ILUS#17#
BJMBR700#FAPESP#Braz J Med Biol Res#40#5#20070500#^f721^l726#0100-879X#Sodium ta
ste threshold in children and its relationship to blood pressure^len#^rND^1A01^n
J.^sArguelles#^rND^1A02^nJ.J.^sDiaz#^rND^1A02^nI.^sMalaga#^rND^1A01^nC.^sPerilla
n#^rND^1A01^nM.^sCostales#^rND^1A01^nM.^sVijande#Universidad de Oviedo^iA01^1Are
a de Fisiología^2Departamento de Biología Funcional#Universidad de Oviedo^iA02^1
Hospital Universitario Central de Asturias^2Departamento de Pediatría^cOviedo^pS
pain#^len^aPopular science has emphasized the risks of high sodium intake and ma
ny studies have confirmed that salt intake is closely related to hypertension. T
he present mini-review summarizes experiments about salt taste sensitivity and i
ts relationship with blood pressure (BP) and other variables of clinical and fam
ilial relevance. Children and adolescents from control parents (N = 72) or with 
at least one essential hypertensive (EHT) parent (N = 51) were investigated. Mat
ernal questionnaires on eating habits and vomiting episodes were collected. Offs
pring, anthropometric, BP, and salt taste sensitivity values were recorded and b
lood samples analyzed. Most mothers declared that they added "little salt" when 
cooking. Salt taste sensitivity was inversely correlated with systolic BP (SBP) 
in control youngsters (r = -0.33; P = 0.015). In the EHT group, SBP values were 
similar to control and a lower salt taste sensitivity threshold. Obese offspring
 of EHT parents showed higher SBP and C-reactive protein values but no differenc
es in renin-angiotensin-aldosterone system activity. Salt taste sensitivity was 
correlated with SBP only in the non-obese EHT group (N = 41; r = 0.37; P = 0.02)
. Salt taste sensitivity was correlated with SBP in healthy, normotensive childr
en and adolescents whose mothers reported significant vomiting during the first 
trimester (N = 18; r = -0.66; P < 0.005), but not in "non-vomiter offspring" (N 
= 54; r = -0.18; nonsignificant). There is evidence for a linkage between high b
lood pressure, salt intake and sensitivity, perinatal environment and obesity, w
ith potential physiopathological implications in humans. This relationship has n
ot been studied comprehensively using homogeneous methods and therefore more res
earch is needed in this field.#^dnd^i1#^tm^len^kChildren^i1#^tm^len^kHypertensio
n^i1#^tm^len^kCardiovascular risk factors^i1#^tm^len^kSalt taste sensitivity^i1#
^tm^len^kPregnancy^i1#^tm^len^kObesity^i1#other#38#International Symposium of Ne
uroendocrinology "Neuroendocrine control of body fluid homeostasis: past, presen
t and future"^i1#20060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#20
070314#March 14, 2007#6681.htm##
03454000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015601200780016601000250
02440100022002690100022002910100024003130100024003370100023003610700083003840700
11300467083178900580085000802369085002102377085002502398085004002423085003502463
08500220249808500200252011700060254007200030254605301260254905600250267505700100
27000550012027100540023027221120009027451110017027541140009027711130015027800020
00902795#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#f#3#1#article#1#ra
#en#bjmbr#1#3.1#ILUS#17#BJMBR700#FAPESP#Braz J Med Biol Res#40#5#20070500#^f721^
l726#0100-879X#Sodium taste threshold in children and its relationship to blood 
pressure^len#^rND^1A01^nJ.^sArguelles#^rND^1A02^nJ.J.^sDiaz#^rND^1A02^nI.^sMalag
a#^rND^1A01^nC.^sPerillan#^rND^1A01^nM.^sCostales#^rND^1A01^nM.^sVijande#Univers
idad de Oviedo^iA01^1Area de Fisiología^2Departamento de Biología Funcional#Univ
ersidad de Oviedo^iA02^1Hospital Universitario Central de Asturias^2Departamento
 de Pediatría^cOviedo^pSpain#^len^aPopular science has emphasized the risks of h
igh sodium intake and many studies have confirmed that salt intake is closely re
lated to hypertension. The present mini-review summarizes experiments about salt
 taste sensitivity and its relationship with blood pressure (BP) and other varia
bles of clinical and familial relevance. Children and adolescents from control p
arents (N = 72) or with at least one essential hypertensive (EHT) parent (N = 51
) were investigated. Maternal questionnaires on eating habits and vomiting episo
des were collected. Offspring, anthropometric, BP, and salt taste sensitivity va
lues were recorded and blood samples analyzed. Most mothers declared that they a
dded "little salt" when cooking. Salt taste sensitivity was inversely correlated
 with systolic BP (SBP) in control youngsters (r = -0.33; P = 0.015). In the EHT
 group, SBP values were similar to control and a lower salt taste sensitivity th
reshold. Obese offspring of EHT parents showed higher SBP and C-reactive protein
 values but no differences in renin-angiotensin-aldosterone system activity. Sal
t taste sensitivity was correlated with SBP only in the non-obese EHT group (N =
 41; r = 0.37; P = 0.02). Salt taste sensitivity was correlated with SBP in heal
thy, normotensive children and adolescents whose mothers reported significant vo
miting during the first trimester (N = 18; r = -0.66; P &lt; 0.005), but not in 
"non-vomiter offspring" (N = 54; r = -0.18; nonsignificant). There is evidence f
or a linkage between high blood pressure, salt intake and sensitivity, perinatal
 environment and obesity, with potential physiopathological implications in huma
ns. This relationship has not been studied comprehensively using homogeneous met
hods and therefore more research is needed in this field.#^dnd^i1#^tm^len^kChild
ren^i1#^tm^len^kHypertension^i1#^tm^len^kCardiovascular risk factors^i1#^tm^len^
kSalt taste sensitivity^i1#^tm^len^kPregnancy^i1#^tm^len^kObesity^i1#other#38#In
ternational Symposium of Neuroendocrinology "Neuroendocrine control of body flui
d homeostasis: past, present and future"^i1#Ribeirão Preto^i1^eSP^i1#Brazil^i1#2
0060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#20070314#March 14, 2
007#6681.htm##
03594000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000700116
03000240012303100030014703200020015006500090015201400110016103500100017201200780
01820100024002600100022002840100021003060100023003270100023003500100022003730700
10000395070011500495083178600610085000802396085002102404085002502425085004002450
08500350249008500220252508500200254711700060256707200030257305301260257605600250
27020570010027270550012027370540023027491120009027721110017027811140009027981130
01502807002000902822008008902831#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.
htm#S#l#4#1#article#1#^mMay^a2007#ra#en#bjmbr#1#3.1#ilus#17#BJMBR700#FAPESP#Braz
. j. med. biol. res#40#5#20070500#^f721^l726#0100-879X#Sodium taste threshold in
 children and its relationship to blood pressure^len#^rND^1A01^nJ^sArguelles#^rN
D^1A02^nJ. J^sDiaz#^rND^1A02^nI^sMalaga#^rND^1A01^nC^sPerillan#^rND^1A01^nM^sCos
tales#^rND^1A01^nM^sVijande#^iA01^1Universidad de Oviedo^2Area de Fisiología^3De
partamento de Biología Funcional^cOviedo^pSpain#^iA02^1Universidad de Oviedo^2Ho
spital Universitario Central de Asturias^3Departamento de Pediatría^cOviedo^pSpa
in#^len^aPopular science has emphasized the risks of high sodium intake and many
 studies have confirmed that salt intake is closely related to hypertension. The
 present mini-review summarizes experiments about salt taste sensitivity and its
 relationship with blood pressure (BP) and other variables of clinical and famil
ial relevance. Children and adolescents from control parents (N = 72) or with at
 least one essential hypertensive (EHT) parent (N = 51) were investigated. Mater
nal questionnaires on eating habits and vomiting episodes were collected. Offspr
ing, anthropometric, BP, and salt taste sensitivity values were recorded and blo
od samples analyzed. Most mothers declared that they added "little salt" when co
oking. Salt taste sensitivity was inversely correlated with systolic BP (SBP) in
 control youngsters (r = -0.33; P = 0.015). In the EHT group, SBP values were si
milar to control and a lower salt taste sensitivity threshold. Obese offspring o
f EHT parents showed higher SBP and C-reactive protein values but no differences
 in renin-angiotensin-aldosterone system activity. Salt taste sensitivity was co
rrelated with SBP only in the non-obese EHT group (N = 41; r = 0.37; P = 0.02). 
Salt taste sensitivity was correlated with SBP in healthy, normotensive children
 and adolescents whose mothers reported significant vomiting during the first tr
imester (N = 18; r = -0.66; P < 0.005), but not in "non-vomiter offspring" (N = 
54; r = -0.18; nonsignificant). There is evidence for a linkage between high blo
od pressure, salt intake and sensitivity, perinatal environment and obesity, wit
h potential physiopathological implications in humans. This relationship has not
 been studied comprehensively using homogeneous methods and therefore more resea
rch is needed in this field.#^dnd^i1#^tm^len^kChildren^i1#^tm^len^kHypertension^
i1#^tm^len^kCardiovascular risk factors^i1#^tm^len^kSalt taste sensitivity^i1#^t
m^len^kPregnancy^i1#^tm^len^kObesity^i1#other#38#International Symposium of Neur
oendocrinology "Neuroendocrine control of body fluid homeostasis: past, present 
and future"^i1#Ribeirão Preto^i1^eSP^i1#Brazil^i1#20060901^i1#September 1-3, 200
6^i1#20061011#October 11, 2006#20070314#March 14, 2007#6681.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500017##
00401000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704017600070002000900246#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#5#1#article#84#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 721-726</B> </font> (Review)</B></P>      ^cY#6681.htm#
#
00392000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704016700070002000900237#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#6#2#article#84#<P><font face="Arial, Hel
vetica, sans-serif"><B><font size="5">Sodium taste threshold in children and its
 relationship to blood pressure</font></B> </font>        ^cY#6681.htm##
00710000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704048500070002000900555#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#7#3#article#84#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/im
g/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a href="mailto:jal@uniovi.
es"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a></span></fo
nt>    <font face="Arial, Helvetica, sans-serif">J. Arguelles<SUP>1</SUP>, J.J. 
Diaz<SUP>2</SUP>,    I. Malaga<SUP>2</SUP>, C. Perillan<SUP>1</SUP>, M. Costales
<SUP>1</SUP> and    M. Vijande<SUP>1</SUP> </font>      ^cY#6681.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704027200070002000900342#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#8#4#article#84#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento de Biolog&iacute;a Funcional, Area 
de Fisiolog&iacute;a, <SUP>2</SUP>Departamento de Pediatr&iacute;a, Hospital Uni
versitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain</font>     
   ^cY#6681.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#9#5#article#84#<P class="style4"> <A HRE
F="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6681.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#10#6#article#84#<BR>   <A HREF="#Text"><
img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6681.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#11#7#article#84#<BR>   <A HREF="#Referen
ces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6681.htm##
00504000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704027800071002000900349#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#12#8#article#84#<br>   </strong></A> <A 
HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font fac
e="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></strong>
</a>      ^cY#6681.htm##
00290000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704006400071002000900135#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#13#9#article#84#<P class="style4">  <HR 
ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6681.htm##
00612000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038500072002000900457#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#14#10#article#84#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4">Abstract</font><FONT COLOR=#00007F>    </FONT></span>
<A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" AL
IGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face
="Arial, Helvetica, sans-serif">      ^cY#6681.htm##
02035000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704180800072002000901880#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#15#11#article#84#<P>Popular science has 
emphasized the risks of high sodium intake and many studies have confirmed that 
salt intake is closely related to hypertension. The present mini-review summariz
es experiments about salt taste sensitivity and its relationship with blood pres
sure (BP) and other variables of clinical and familial relevance. Children and a
dolescents from control parents (N = 72) or with at least one essential hyperten
sive (EHT) parent (N = 51) were investigated. Maternal questionnaires on eating 
habits and vomiting episodes were collected. Offspring, anthropometric, BP, and 
salt taste sensitivity values were recorded and blood samples analyzed. Most mot
hers declared that they added "little salt" when cooking. Salt taste sensitivity
 was inversely correlated with systolic BP (SBP) in control youngsters (r = -0.3
3; P = 0.015). In the EHT group, SBP values were similar to control and a lower 
salt taste sensitivity threshold was found. Obese offspring of EHT parents showe
d higher SBP and C-reactive protein values but no differences in renin-angiotens
in-aldosterone system activity. Salt taste sensitivity was correlated with SBP o
nly in the non-obese EHT group (N = 41; r = 0.37; P = 0.02). Salt taste sensitiv
ity was correlated with SBP in healthy, normotensive children and adolescents wh
ose mothers reported significant vomiting during the first trimester (N = 18; r 
= -0.66; P &lt; 0.005), but not in "non-vomiter offspring" (N = 54; r =    -0.18
; nonsignificant). There is evidence for a linkage between high blood pressure, 
salt intake and sensitivity, perinatal environment and obesity, with potential p
hysiopathological implications in humans. This relationship has not been studied
 comprehensively using homogeneous methods and therefore more research is needed
 in this field.      ^cY#6681.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017100072002000900243#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#16#12#article#84#<P><B>Key words: </B> C
hildren, Hypertension, Cardiovascular risk factors, Salt taste sensitivity, Preg
nancy, Obesity </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6681.htm##
00586000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035900072002000900431#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#17#13#article#84#<P class="style4"><A NA
ME="Text"></A><A HREF="#Home"><FONT SIZE=4><B><font face="Arial, Helvetica, sans
-serif" color="#00007F">Text</font><img src="/img/revistas/bjmbr/v40n5/back.gif"
 ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>    <font face=
"Arial, Helvetica, sans-serif"></font></P>  <font face="Arial, Helvetica, sans-s
erif">      ^cY#6681.htm##
00488000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704026100072002000900333#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#18#14#article#84#<P>Blood pressure is a 
major physiological variable which is maintained within a narrow range by strong
 homeostatic mechanisms operating throughout the life span. Many factors influen
ce blood pressure and its increase has severe deleterious effects.        ^cY#66
81.htm##
00513000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028600072002000900358#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#19#15#article#84#<P>This article summari
zes several studies carried out by our group and others on humans and rats which
 dealt with some of the factors related to blood pressure homeostasis: salt sens
itivity and intake, obesity and perinatal and genetic factors (<a href="#Fig1">F
igure 1</a>).      ^cY#6681.htm##
00270000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004300072002000900115#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#20#16#article#84#<P><B>Salt and blood pr
essure</B>      ^cY#6681.htm##
01108000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704088100072002000900953#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#21#17#article#84#<P>Epidemiological rese
arch has shown that dietary sodium is an important contributor to the pathogenes
is of hypertension (1). While higher blood pressure values are being currently o
bserved in populations with higher salt intake (2), treatment strategies based o
n lowering salt ingestion have demonstrated their effectiveness in lowering bloo
d pressure (3). Nevertheless, only a limited proportion of individuals - 5 to 16
% - classified as "salt-dependent" would benefit from dietary salt restriction (
4). On the other hand, it seems obvious that the amount of salt intake by an ind
ividual should be related in one way or another to his conscious or unconscious 
ability to recognize it (salt sensitivity). A significant positive relationship 
between blood pressure and sodium intake has also been reported in pediatric pop
ulations (5) and confirmed by meta-analysis (6).      ^cY#6681.htm##
00833000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060600072002000900678#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#22#18#article#84#<P>One important aspect
 to be considered is the possible association between salt perception and blood 
pressure and its possible variation in normotensive and hypertensive subjects. B
ecause hypertension is typically an adult disease, only minor pathological signs
 or alterations could be expected during the early years of life. However, these
 could be significant markers or tracking signals for subjects that eventually w
ill develop hypertension and therefore they would be useful as tools for identif
ying subjects who could be treated prophylactically or advised about healthy hab
its early on.      ^cY#6681.htm##
00534000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030700072002000900379#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#23#19#article#84#<P>The relationship bet
ween salt taste sensitivity (gustatory perception) and blood pressure has been s
tudied to different extents by several investigators, with differing findings. S
ome of them revealed a positive correlation between salt perception and blood pr
essure while others did not (7,8).      ^cY#6681.htm##
00764000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053700072002000900609#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#24#20#article#84#<P>Our group has studie
d a cohort of Spanish children and adolescents (42 boys and 30 girls) for their 
familial salt habits, individual salt taste sensitivity and blood pressure (9). 
Most of the families (84%) declared that they cook with little salt, which indic
ates the strong bias of declared salt consumption, perhaps induced by media reco
mmendations on health. These values did not match well the range of fractional s
odium excretion found in our subjects which was well within the range of normali
ty (0.65 &#177; 0.03%).       ^cY#6681.htm##
01286000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704105900072002000901131#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#25#21#article#84#<P>A behavioral test ad
apted from Cornsweet (10) was used to assess the salt taste sensitivity, i.e., t
he lowest Na concentration detected when compared to distilled/deionized water (
<a href="#Fig2">Figure 2</a>). This test consisted of a forced-choice staircase 
protocol in which subjects received a series of successive pairs of solutions. W
ithin each pair one sample was the unsalted control (distilled deionized water),
 and the other contained in order one of the following NaCl solutions: 13.7, 12.
2, 10.7, 9.2, 7.7, 6.2, 4.7, 3.2, 1.7, 0.2 mM. Each concentration was presented 
twice. Subjects tasted both samples and chose the saltier within each pair. Afte
r a successful detection of the salty cup twice in the same trial, the next less
 intense stimulus was presented. A failure in any of the trials forced to try th
e next more intense stimulus (reversal). The procedure was continued until three
 reversals occurred. The geometric mean of the three reversal concentrations was
 deemed as the threshold sodium taste sensitivity for the subject.      ^cY#6681
.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038200072002000900454#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#26#22#article#84#<P>Sodium taste sensiti
vity was 4.55 &#177; 0.6 mM NaCl (11) and was negatively correlated with systoli
c blood pressure (SBP, N = 72; r = -0.33; P &lt; 0.01; <a href="#Fig3">Figure 3<
/a>). Although the mechanism linking these two variables cannot be inferred from
 these data, the correlation suggests common or related causes for salt taste se
nsitivity and blood pressure.      ^cY#6681.htm##
00267000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004000072002000900112#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#27#23#article#84#<P><B>Perinatal influen
ces</B>      ^cY#6681.htm##
00682000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704045500072002000900527#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#28#24#article#84#<P>Epidemiological and 
experimental studies have shown that hypertension is mainly a multifactorial dis
ease, with an important genetic component and possibly affected by some perinata
l influences. Hypertension is about twice as common in subjects who have one or 
both hypertensive parents, and it has been estimated that genetic factors accoun
t for approximately 30% of the variation in blood pressure in various human popu
lations (12).  </font>      ^cY#6681.htm##
00961000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073400072002000900806#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#29#25#article#84#<P><font face="Arial, H
elvetica, sans-serif">In a sample of 51 normotensive adolescents  with at least 
one essential hypertensive (EHT) parent (13), we found blood pressure values sim
ilar to those of the control group, but a lower salt taste sensitivity threshold
 (<a href="#Fig4">Figure 4</a>). When age, sex, and body mass index (BMI) were i
ncluded as control variables in a multiple regression model, the salt taste sens
itivity threshold was significantly correlated with SBP (&szlig; = 0.94; P &lt; 
0.012). Interestingly, the regression slope between salt taste sensitivity thres
hold and SBP in control and in EHT (both statistically significant) had the oppo
site sign.  </font>  <font face="Arial, Helvetica, sans-serif">    ^cY#6681.htm#
#
01181000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704095400072002000901026#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#30#26#article#84#<P>Long-lasting effects
 induced by challenges to body fluid homeostasis during gestation have been test
ed in different species. Concerning these perinatal influences in pregnant rats,
 Nicolaidis et al. (14) showed that episodes of extracellular dehydration by pol
yethylene-glycol administration led to an increased salt appetite in adult offsp
ring. A few years later the same group found an increase in salt appetite in the
 offspring when acute and repeated mineralofluid losses had occurred during preg
nancy after diuretic-natriuretic treatment (15). In both cases the subjects unde
rwent dehydration accompanied by an activation of the renin angiotensin system. 
Leshem (16), working with humans, suggested that episodes of mineralofluid losse
s during pregnancy or in early infancy could increase salt preference when inves
tigated in late childhood, and that more sensitive tests of salt preference woul
d be required to reveal these influences.      ^cY#6681.htm##
00475000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704024800072002000900320#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#31#27#article#84#<P>During the last deca
de, our group has been studying the changes in need-free and stimulated NaCl int
ake in newborn and adult rats by manipulations of the levels of NaCl ingestion d
uring gestation and the early postnatal period (17-20).      ^cY#6681.htm##
00585000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035800072002000900430#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#32#28#article#84#<P>Recent studies sugge
st that maternal angiotensin II may affect the neural substrate in the fetus sin
ce angiotensin receptors have been shown to mediate several ontogenic effects in
cluding growth, differentiation and apoptosis among others, and especially the A
T2 subtype which is abundant in the fetal brain and disappears soon after birth 
(21).      ^cY#6681.htm##
00772000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704054500072002000900617#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#33#29#article#84#<P>Human studies focuse
d on salt appetite are complicated by the lack of uniformity in the experimental
 protocols. Crystal and Bernstein (22) found a greater preference for saltier fo
od in young college students whose mothers reported morning sickness during preg
nancy when compared to those with asymptomatic mothers. They also demonstrated t
hat infants from mothers vomiting excessively during early pregnancy drank more 
concentrated salt solutions than controls and showed less aversive facial reacti
ons to the salty solutions (23).      ^cY#6681.htm##
00918000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069100072002000900763#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#34#30#article#84#<P>Results from our wor
k (24) have proved a significant correlation between blood pressure and salt tas
te perception in a healthy and normotensive adolescent Spanish population (N = 1
8; r = -0.66; P &lt; 0.005) whose mothers reported significant vomiting during t
he 1st trimester of gestation, i.e., indicating that those subjects with higher 
SBP values had lower detection thresholds (being more salt sensitive). These dat
a agree with the "Barker hypothesis" (25) applied to the important health field 
of hypertension, adding new evidence to the emerging programming hypothesis that
 links early episodes in fetal and neonatal life to the development of disease r
isk in adult life.      ^cY#6681.htm##
00286000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005900072002000900131#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#35#31#article#84#<P><B>Obesity and cardi
ovascular risk factors</B>      ^cY#6681.htm##
00884000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704065700072002000900729#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#36#32#article#84#<P>The trend towards ov
erweight in adult populations is common in the developed world (26,27). Still mo
re alarming is the progressive rate of obesity detected in pediatric populations
 in these countries (28-30). All this is related to increasing blood pressure va
lues and even to the prevalence of hypertension and other cardiovascular risk fa
ctors, including dyslipidemia, insulin resistance and metabolic syndrome (31,32)
. The concurrence of some or all of these factors amplifies their potential dele
terious cardiovascular effects (33). Although the metabolic syndrome was initial
ly described in adults, it is also often found in children (34).      ^cY#6681.h
tm##
01101000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704087400072002000900946#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#37#33#article#84#<P>There are an increas
ing number of studies indicating that other factors could also be involved in ca
rdiovascular pathology. These are often named as novel or emerging cardiovascula
r risk factors. A low grade of inflammatory disease affecting the arterial vesse
ls which can be revealed by discrete elevations in C-reactive protein (CRP), onl
y detectable by using high sensitivity methods, is one of these and could start 
in childhood (35). CRP is related to age, sex, ethnicity, anthropometric variabl
es, lipid profile, and insulin sensitivity (36), and its values increase in para
llel with BMI (37). The discovery of adipocytokines has led to an increased unde
rstanding of the role of fatty tissue both in normal homeostasis and in patholog
ical states because they may correspond to an important mechanistic link between
 obesity and cardiovascular disease (38).      ^cY#6681.htm##
01626000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704139900072002000901471#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#38#34#article#84#<P>In this respect, we 
found a 20% prevalence of obesity in young and adolescent offspring of EHT patie
nts (28 boys and 24 girls, with at least 1 parent with EHT) and studied its rela
tionship to other pathogenic factors for hypertension such as renin-angiotensin-
aldosterone system components and CRP (9). Body weight and height significantly 
correlated with SBP both in obese (N = 10; r = 0.70; P = 0.03 and r = 0.66; P = 
0.04) and non-obese offspring of EHT patients (N = 41; r = 0.51; P = 0.001 and r
 = 0.49; P = 0.001). In contrast, SBP correlated significantly with BMI only in 
non-obese subjects (N = 41; r = 0.33; P = 0.03). Although salt taste threshold w
as similar in both groups (obese and non-obese), it correlated significantly wit
h SBP only in the non-obese group (N = 41; r = 0.37; P = 0.02). Obese offspring 
of EHT patients showed SBP values 10 mmHg higher than non-obese offspring (P = 0
.004) and also higher CRP (when adjusted by age and SBP, P = 0.024). No differen
ces were found in diastolic blood pressure, kidney function tests, aldosterone, 
renin activity, or angiotensin-converting enzyme between groups. Therefore, the 
obese offspring of EHT parents showed a high prevalence of obesity and higher SB
P and CRP values than the non-obese offspring but no differences in renin-angiot
ensin-aldosterone system activity and only limited salt taste sensitivity differ
ences.      ^cY#6681.htm##
00876000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704064900072002000900721#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#39#35#article#84#<P>On the basis of thes
e considerations, there are some links between high blood pressure, salt intake,
 perinatal environment and obesity, with potential physiopathological implicatio
ns in humans, which have not been comprehensively studied using homogeneous meth
ods, thus requiring more research in this field. </font>  <HR ALIGN=LEFT WIDTH=1
00% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="top"> 
     <td width="15%"><a href="/img/revistas/bjmbr/v40n5/html/6681i01.htm"><img s
rc="/img/revistas/bjmbr/v40n5/6681i01peq.jpg" border="2"></a></td>      <td widt
h="85%"><font face="Arial, Helvetica, sans-serif">            ^cY#6681.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021900072002000900291#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#40#36#article#84#<P><a name="Fig1"></a>F
igure 1. Relations between hypertension and cardiovascular risk factors (CRF). E
stablished (solid lines) and unestablished (dotted lines) relations.       </fon
t></td>    </tr>  </table>      ^cY#6681.htm##
00660000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043300072002000900505#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#41#37#article#84#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (61 K JPG file)]</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr ali
gn="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n5/
html/6681i02.htm"><img src="/img/revistas/bjmbr/v40n5/6681i02peq.jpg" border="2"
></a></td>      <td width="85%"><font face="Arial, Helvetica, sans-serif">      
      ^cY#6681.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017100072002000900243#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#42#38#article#84#<P><a name="Fig2"></a>F
igure 2. Forced-choice staircase method for the detection    of threshold for sa
lt taste sensitivity.      </font></td>    </tr>  </table>      ^cY#6681.htm##
00660000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043300072002000900505#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#43#39#article#84#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (73 K JPG file)]</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr ali
gn="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n5/
html/6681i03.htm"><img src="/img/revistas/bjmbr/v40n5/6681i03peq.jpg" border="2"
></a></td>      <td width="85%"><font face="Arial, Helvetica, sans-serif">      
      ^cY#6681.htm##
00401000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017400072002000900246#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#44#40#article#84#<P><a name="Fig3"></a>F
igure 3. Negative correlation between sodium chloride detection threshold and sy
stolic blood pressure.        </font></td>    </tr>  </table>      ^cY#6681.htm#
#
01159000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704093200072002000901004#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#45#41#article#84#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (74 K JPG file)]</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr ali
gn="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v40n5/
html/6681i04.htm"><img src="/img/revistas/bjmbr/v40n5/6681i04peq.jpg" border="2"
></a></td>      <td width="85%"><font face="Arial, Helvetica, sans-serif"><a nam
e="Fig4"></a>Figure 4. Salt detection threshold in the offspring of control and 
hypertensive parents. Box vertical sides represent the lower and upper quartile 
(enclosing the middle half of the sample); the sample median, as the vertical li
ne inside; whiskers sprout from the two ends of the box until they reach the sam
ple maximum and minimum, excluding outliers - black symbols (cases with the valu
es between 1.5 and 3 box-lengths from the 75th or 25th percentile).</font> </td>
    </tr>  </table>      ^cY#6681.htm##
00376000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014900072002000900221#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#46#42#article#84#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (44 K JPG file)]</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6681.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036300072002000900435#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#47#43#article#84#<P class="style4"> <A N
AME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Helv
etica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT 
SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6681.htm##
00354000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704011300074002000900187#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#48#44#article#84#1#<P>1. Key
s AE. Coronary heart disease in seven countries. <I>Circulation</I> 1970; 41 (Su
ppl 4): 1-211.      ^cY#6681.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019600074002000900270#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#49#45#article#84#2#<P>2. Hor
an MJ, Blaustein MP, Dunbar JB, Grundy S, Kachadorian W, Kaplan NM, et al. NIH r
eport on research challenges in nutrition and hypertension. <I>Hypertension</I> 
1985; 7: 818-823.      ^cY#6681.htm##
00430000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018900074002000900263#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#50#46#article#84#3#<P>3. Law
 MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pres
sure? III - Analysis of data from trials of salt reduction. <I>BMJ</I> 1991; 302
: 819-824.      ^cY#6681.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018000074002000900254#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#51#47#article#84#4#<P>4. Duc
her M, Fauvel JP, Maurin M, Laville M, Maire P, Paultre CZ, et al. Sodium intake
 and blood pressure in healthy individuals. <I>J Hypertens</I> 2003; 21: 289-294
.      ^cY#6681.htm##
00433000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019200074002000900266#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#52#48#article#84#5#<P>5. del
 Negro MC, Oliver M, Arocha I, Arias F. Arterial hypertension in the adolescent:
 its possible relation to the salt taste threshold. <I>Rev Esp Cardiol</I> 1992;
 45: 227-231.      ^cY#6681.htm##
00382000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704014100074002000900215#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#53#49#article#84#6#<P>6. Sim
ons-Morton DG, Obarzanek E. Diet and blood pressure in children and adolescents.
 <I>Pediatr Nephrol</I> 1997; 11: 244-249.      ^cY#6681.htm##
00426000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018500074002000900259#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#54#50#article#84#7#<P>7. Oko
ro EO, Uroghide GE, Jolayemi ET. Salt taste sensitivity and blood pressure in ad
olescent school children in southern Nigeria. <I>East Afr Med J</I> 1998; 75: 19
9-203.      ^cY#6681.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019800074002000900272#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#55#51#article#84#8#<P>8. Zum
kley H, Vetter H, Mandelkow T, Spieker C. Taste sensitivity for sodium chloride 
in hypotensive, normotensive and hypertensive subjects. <I>Nephron</I> 1987; 47 
(Suppl 1): 132-134.      ^cY#6681.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024600074002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#56#52#article#84#9#<P>9. Dia
z Martin JJ, Malaga Dieguez I, Arguelles LJ, Dieguez Junquera MA, Vijande VM, Ma
laga GS. Clustering of cardiovascular risk factors in obese offspring of parents
 with essential hypertension. <I>Ann Pediatr </I>2005; 63: 238-243.      ^cY#668
1.htm##
00350000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704010800075002000900183#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#57#53#article#84#10#<P>10. C
ornsweet TN. The staircase-method in psychophysics. <I>Am J Psychol</I> 1962; 75
: 485-491.      ^cY#6681.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020900075002000900284#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#58#54#article#84#11#<P>11. M
alaga S, Diaz JJ, Arguelles J, Perillan C, Malaga I, Vijande M. Blood pressure r
elates to sodium taste sensitivity and discrimination in adolescents. <I>Pediatr
 Nephrol</I> 2003; 18: 431-434.      ^cY#6681.htm##
00377000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013500075002000900210#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#59#55#article#84#12#<P>12. B
eevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of hyperte
nsion. <I>BMJ</I> 2001; 322: 912-916.      ^cY#6681.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022800075002000900303#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#60#56#article#84#13#<P>13. A
rguelles J, Perillan C, D&iacute;az JJ, M&aacute;laga I, Vijande M, Malaga S. Al
teraciones de la sensibilidad gustativa a la sal en hijos de hipertensos esencia
les. <I>Hipertensi&oacute;n</I> 2005; 22: 311-317.      ^cY#6681.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017800075002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#61#57#article#84#14#<P>14. N
icolaidis S, Galaverna O, Metzler CH. Extracellular dehydration during pregnancy
 increases salt appetite of offspring. <I>Am J Physiol</I> 1990; 258: R281-R283.
      ^cY#6681.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022500075002000900300#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#62#58#article#84#15#<P>15. G
alaverna O, Nicolaidis S, Yao SZ, Sakai RR, Epstein AN. Endocrine consequences o
f prenatal sodium depletion prepare rats for high need-free NaCl intake in adult
hood. <I>Am J Physiol</I> 1995; 269: R578-R583.      ^cY#6681.htm##
00405000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016300075002000900238#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#63#59#article#84#16#<P>16. L
eshem M. Salt preference in adolescence is predicted by common prenatal and infa
ntile mineralofluid loss. <I>Physiol Behav</I> 1998; 63: 699-704.      ^cY#6681.
htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019500075002000900270#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#64#60#article#84#17#<P>17. A
rguelles J, Brime JI, Lopez-Sela P, Perillan C, Vijande M. Adult offspring long-
term effects of high salt and water intake during pregnancy. <I>Horm Behav</I> 2
000; 37: 156-162.      ^cY#6681.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023000075002000900305#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#65#61#article#84#18#<P>18. A
rguelles J, Lopez-Sela P, Brime JI, Costales M, Vijande M. Changes of blood pres
sure responsiveness in rats exposed <I>in utero</I> and perinatally to a high-sa
lt environment. <I>Regul Pept</I> 1996; 66: 113-115.      ^cY#6681.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017800075002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#66#62#article#84#19#<P>19. P
erillan C, Costales M, Diaz F, Vijande M, Arguelles J. Thirst changes in offspri
ng of hyperreninemic rat dams. <I>Pharmacol Biochem Behav</I> 2004; 79: 709-713.
      ^cY#6681.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022700075002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#67#63#article#84#20#<P>20. V
ijande M, Brime JI, Lopez-Sela P, Costales M, Arguelles J. Increased salt prefer
ence in adult offspring raised by mother rats consuming excessive amounts of sal
t and water. <I>Regul Pept</I> 1996; 66: 105-108.      ^cY#6681.htm##
00402000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016000075002000900235#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#68#64#article#84#21#<P>21. D
inh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution
, signalling and function. <I>Clin Sci </I>2001; 100: 481-492.      ^cY#6681.htm
##
00374000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013200075002000900207#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#69#65#article#84#22#<P>22. C
rystal SR, Bernstein IL. Morning sickness: impact on offspring salt preference. 
<I>Appetite</I> 1995; 25: 231-240.      ^cY#6681.htm##
00373000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013100075002000900206#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#70#66#article#84#23#<P>23. C
rystal SR, Bernstein IL. Infant salt preference and mother's morning sickness. <
I>Appetite</I> 1998; 30: 297-307.      ^cY#6681.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020800075002000900283#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#71#67#article#84#24#<P>24. M
alaga I, Arguelles J, Diaz JJ, Perillan C, Vijande M, Malaga S. Maternal pregnan
cy vomiting and offspring salt taste sensitivity and blood pressure. <I>Pediatr 
Nephrol</I> 2005; 20: 956-960.      ^cY#6681.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021100075002000900286#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#72#68#article#84#25#<P>25. B
arker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth <I>in utero</I>, bloo
d pressure in childhood and adult life, and mortality from cardiovascular diseas
e. <I>BMJ</I> 1989; 298: 564-567.      ^cY#6681.htm##
00413000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017100075002000900246#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#73#69#article#84#26#<P>26. J
ames PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future p
revention strategies. <I>Eur J Cardiovasc Prev Rehabil</I> 2004; 11: 3-8.      ^
cY#6681.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027000075002000900345#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#74#70#article#84#27#<P>27. A
nonymous. Executive Summary of the Third Report of the National Cholesterol Educ
ation Program (NCEP) expert panel on detection, evaluation, and treatment of hig
h blood cholesterol in adults (adult treatment panel III). <I>JAMA</I> 2001; 285
: 2486-2497.      ^cY#6681.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023100075002000900306#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#75#71#article#84#28#<P>28. D
aniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S, et al. Overw
eight in children and adolescents: pathophysiology, consequences, prevention, an
d treatment. <I>Circulation</I> 2005; 111: 1999-2012.      ^cY#6681.htm##
00458000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021600075002000900291#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#76#72#article#84#29#<P>29. M
oreno LA, Mesana MI, Fleta J, Ruiz JR, Gonzalez-Gross M, Sarria A, et al. Overwe
ight, obesity and body fat composition in Spanish adolescents. The AVENA Study. 
<I>Ann Nutr Metab</I> 2005; 49: 71-76.      ^cY#6681.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020900075002000900284#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#77#73#article#84#30#<P>30. H
edley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of 
overweight and obesity among US children, adolescents, and adults, 1999-2002. <I
>JAMA</I> 2004; 291: 2847-2850.      ^cY#6681.htm##
00440000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019800075002000900273#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#78#74#article#84#31#<P>31. W
eiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesi
ty and the metabolic syndrome in children and adolescents. <I>N Engl J Med</I> 2
004; 350: 2362-2374.      ^cY#6681.htm##
00350000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704010800075002000900183#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#79#75#article#84#32#<P>32. E
ckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. <I>Lancet</I> 2005; 365: 
1415-1428.      ^cY#6681.htm##
00444000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020200075002000900277#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#80#76#article#84#33#<P>33. L
urbe E, Torro I, Alvarez V, Nawrot T, Paya R, Redon J, et al. Prevalence, persis
tence, and clinical significance of masked hypertension in youth. <I>Hypertensio
n</I> 2005; 45: 493-498.      ^cY#6681.htm##
00366000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704012400075002000900199#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#81#77#article#84#34#<P>34. C
ruz ML, Goran MI. The metabolic syndrome in children and adolescents. <I>Curr Di
ab Rep</I> 2004; 4: 53-62.      ^cY#6681.htm##
00374000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013200075002000900207#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#82#78#article#84#35#<P>35. B
elay B, Belamarich P, Racine AD. Pediatric precursors of adult atherosclerosis. 
<I>Pediatr Rev</I> 2004; 25: 4-16.      ^cY#6681.htm##
00380000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013800075002000900213#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#83#79#article#84#36#<P>36. K
oenig W. Update on C-reactive protein as a risk marker in cardiovascular disease
. <I>Kidney Int Suppl</I> 2003; S58-S61.      ^cY#6681.htm##
00404000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016200075002000900237#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#84#80#article#84#37#<P>37. V
isser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflam
mation in overweight children. <I>Pediatrics</I> 2001; 107: E13.      ^cY#6681.h
tm##
00433000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019100075002000900266#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#p#85#81#article#84#38#<P>38. S
kilton MR, Celermajer DS. The effects of obesity-related peptides on the vascula
ture. <I>Curr Vasc Pharmacol</I> 2006; 4: 79-85.  </font>  <HR ALIGN=LEFT WIDTH=
100% SIZE=2>       ^cY#6681.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#86#82#article#84#<P class="style4"><A NA
ME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, H
elvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT> <
A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6681
.htm##
00657000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043000072002000900502#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#87#83#article#84#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    
Address for correspondence:</B><font face="Arial, Helvetica, sans-serif"> J.    
Arguelles, Departamento de Biologia Funcional, Area de Fisiologia, Universidad  
  de Oviedo, Julian Claveria, 6, 33006 - Oviedo, Espa&ntilde;a. Fax: +34-985-10-
6285.    E-mail: <a href="mailto:jal@uniovi.es">jal@uniovi.es</a></font> </P>   
   ^cY#6681.htm##
00588000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036100072002000900433#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6681.htm#S#p#88#84#article#84#<P><font face="Arial, H
elvetica, sans-serif">Presented at the International Symposium of Neuroendocrino
logy "Neuroendocrine control of body fluid homeostasis: past, present and future
". Ribeir&atilde;o Preto, SP, Brazil, September 1-3, 2006. Received October 11, 
2006. Accepted March 14, 2007.</font><font face="Arial, Helvetica, sans-serif"> 
</font>       ^cY#6681.htm##
00497000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730120046000880300
01200134065000900146064000500155031000300160032001000163014000600173865000900179
002000900188035001000197801001200207#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
681.htm#S#c#89#1#article#38#1#^rND^sKeys^nAE#Coronary heart disease in seven cou
ntries^len#Circulation#19700000#1970#41#^sSuppl 4#1-211#20070500#6681.htm#0009-7
322#Circulation##
00670000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100020000890100
01700109010001600126010002100142010001700163810000600180012006800186030001300254
06500090026706400050027603100020028101400080028386500090029100200090030003500100
0309801001300319#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#90#2#art
icle#38#2#^rND^sHoran^nMJ#^rND^sBlaustein^nMP#^rND^sDunbar^nJB#^rND^sGrundy^nS#^
rND^sKachadorian^nW#^rND^sKaplan^nNM#et al#NIH report on research challenges in 
nutrition and hypertension^len#Hypertension#19850000#1985#7#818-823#20070500#668
1.htm#0194-911X#Hypertension##
00589000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100016000870100
01500103012011900118030000400237065000900241064000500250031000400255014000800259
865000900267002000900276035001000285801000400295#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6681.htm#S#c#91#3#article#38#3#^rND^sLaw^nMR#^rND^sFrost^nCD#^rND^sWa
ld^nNJ#By how much does dietary salt reduction lower blood pressure: III - Analy
sis of data from trials of salt reduction^len#BMJ#19910000#1991#302#819-824#2007
0500#6681.htm#0959-8138#BMJ##
00653000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100017000890100
01600106010001700122010001500139010001800154810000600172012006000178030001200238
06500090025006400050025903100030026401400080026786500090027500200090028403500100
0293801001200303#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#92#4#art
icle#38#4#^rND^sDucher^nM#^rND^sFauvel^nJP#^rND^sMaurin^nM#^rND^sLaville^nM#^rND
^sMaire^nP#^rND^sPaultre^nCZ#et al#Sodium intake and blood pressure in healthy i
ndividuals^len#J Hypertens#20030000#2003#21#289-294#20070500#6681.htm#0263-6352#
J Hypertens##
00622000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100016000930100
01600109010001500125012009500140030001600235065000900251064000500260031000300265
014000800268865000900276002000900285035001000294801001600304#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6681.htm#S#c#93#5#article#38#5#^rND^sdel^nNegro MC#^rND^s
Oliver^nM#^rND^sArocha^nI#^rND^sArias^nF#Arterial hypertension in the adolescent
: its possible relation to the salt taste threshold^len#Rev Esp Cardiol#19920000
#1992#45#227-231#20070500#6681.htm#0300-8932#Rev Esp Cardiol##
00535000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100024000730100019000970120
05600116030001600172065000900188064000500197031000300202014000800205865000900213
002000900222035001000231801001600241#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
681.htm#S#c#94#6#article#38#6#^rND^sSimons-Morton^nDG#^rND^sObarzanek^nE#Diet an
d blood pressure in children and adolescents^len#Pediatr Nephrol#19970000#1997#1
1#244-249#20070500#6681.htm#0097-5257#Pediatr Nephrol##
00596000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100019000890100
01900108012009600127030001500223065000900238064000500247031000300252014000800255
865000900263002000900272035001000281801001500291#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6681.htm#S#c#95#7#article#38#7#^rND^sOkoro^nEO#^rND^sUroghide^nGE#^rN
D^sJolayemi^nET#Salt taste sensitivity and blood pressure in adolescent school c
hildren in southern Nigeria^len#East Afr Med J#19980000#1998#75#199-203#20070500
#6681.htm#0012-835X#East Afr Med J##
00632000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100016000900100
01900106010001700125012009700142030000800239065000900247064000500256031000300261
032001000264014000800274865000900282002000900291035001000300801000800310#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#96#8#article#38#8#^rND^sZumkley^
nH#^rND^sVetter^nH#^rND^sMandelkow^nT#^rND^sSpieker^nC#Taste sensitivity for sod
ium chloride in hypotensive, normotensive and hypertensive subjects^len#Nephron#
19870000#1987#47#^sSuppl 1#132-134#20070500#6681.htm#0028-2766#Nephron##
00676000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100022000730100024000950100
02000119010002700139010001800166010001700184012010400201030001200305710000200317
065000900319064000500328031000300333014000800336865000900344002000900353#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#97#9#article#38#9#^rND^sDiaz^nMa
rtin JJ#^rND^sMalaga^nDieguez I#^rND^sArguelles^nLJ#^rND^sDieguez^nJunquera MA#^
rND^sVijande^nVM#^rND^sMalaga^nGS#Clustering of cardiovascular risk factors in o
bese offspring of parents with essential hypertension^len#Ann Pediatr#2#20050000
#2005#63#238-243#20070500#6681.htm##
00482000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750120042000950300
01300137065000900150064000500159031000300164014000800167865000900175002000900184
035001000193801001300203#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#
98#10#article#38#10#^rND^sCornsweet^nTN#The staircase-method in psychophysics^le
n#Am J Psychol#19620000#1962#75#485-491#20070500#6681.htm#0002-9556#Am J Psychol
##
00676000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100015000910100
01900106010001800125010001600143010001700159012008900176030001600265065000900281
06400050029003100030029501400080029886500090030600200090031503500100032480100160
0334#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#99#11#article#38#11#
^rND^sMalaga^nS#^rND^sDiaz^nJJ#^rND^sArguelles^nJ#^rND^sPerillan^nC#^rND^sMalaga
^nI#^rND^sVijande^nM#Blood pressure relates to sodium taste sensitivity and disc
rimination in adolescents^len#Pediatr Nephrol#20030000#2003#18#431-434#20070500#
6681.htm#0097-5257#Pediatr Nephrol##
00537000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930100
01700107012006100124030000400185065000900189064000500198031000400203014000800207
865000900215002000900224035001000233801000400243#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6681.htm#S#c#100#12#article#38#12#^rND^sBeevers^nG#^rND^sLip^nGY#^rND
^sO'Brien^nE#ABC of hypertension: The pathophysiology of hypertension^len#BMJ#20
010000#2001#322#912-916#20070500#6681.htm#0959-8138#BMJ##
00639000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01500113010001600128010001700144010001600161012009000177030001300267710000200280
065000900282064000500291031000300296014000800299865000900307002000900316#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#101#13#article#38#13#^rND^sArgue
lles^nJ#^rND^sPerillan^nC#^rND^sDíaz^nJJ#^rND^sMálaga^nI#^rND^sVijande^nM#^rND^s
Malaga^nS#Alteraciones de la sensibilidad gustativa a la sal en hijos de hiperte
nsos esenciales^les#Hipertensión#2#20050000#2005#22#311-317#20070500#6681.htm##
00589000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960100
01800115012008400133030001300217065000900230064000500239031000400244014001000248
865000900258002000900267035001000276801001300286#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6681.htm#S#c#102#14#article#38#14#^rND^sNicolaidis^nS#^rND^sGalaverna
^nO#^rND^sMetzler^nCH#Extracellular dehydration during pregnancy increases salt 
appetite of offspring^len#Am J Physiol#19900000#1990#258#R281-R283#20070500#6681
.htm#0002-9513#Am J Physiol##
00672000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100020000950100
01400115010001600129010001800145012011300163030001300276065000900289064000500298
031000400303014001000307865000900317002000900326035001000335801001300345#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#103#15#article#38#15#^rND^sGalav
erna^nO#^rND^sNicolaidis^nS#^rND^sYao^nSZ#^rND^sSakai^nRR#^rND^sEpstein^nAN#Endo
crine consequences of prenatal sodium depletion prepare rats for high need-free 
NaCl intake in adulthood^len#Am J Physiol#19950000#1995#269#R578-R583#20070500#6
681.htm#0002-9513#Am J Physiol##
00539000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120100000920300
01400192065000900206064000500215031000300220014000800223865000900231002000900240
035001000249801001400259#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#
104#16#article#38#16#^rND^sLeshem^nM#Salt preference in adolescence is predicted
 by common prenatal and infantile mineralofluid loss^len#Physiol Behav#19980000#
1998#63#699-704#20070500#6681.htm#0031-9384#Physiol Behav##
00640000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
02000111010001800131010001700149012008500166030001100251065000900262064000500271
031000300276014000800279865000900287002000900296035001000305801001100315#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#105#17#article#38#17#^rND^sArgue
lles^nJ#^rND^sBrime^nJI#^rND^sLopez-Sela^nP#^rND^sPerillan^nC#^rND^sVijande^nM#A
dult offspring long-term effects of high salt and water intake during pregnancy^
len#Horm Behav#20000000#2000#37#156-162#20070500#6681.htm#0018-506X#Horm Behav##
00668000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100020000950100
01600115010001800131010001700149012011300166030001100279065000900290064000500299
031000300304014000800307865000900315002000900324035001000333801001100343#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#106#18#article#38#18#^rND^sArgue
lles^nJ#^rND^sLopez-Sela^nP#^rND^sBrime^nJI#^rND^sCostales^nM#^rND^sVijande^nM#C
hanges of blood pressure responsiveness in rats exposed in utero and perinatally
 to a high-salt environment^len#Regul Pept#19960000#1996#66#113-115#20070500#668
1.htm#0167-0115#Regul Pept##
00636000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01400112010001700126010001900143012005900162030002400221065000900245064000500254
031000300259014000800262865000900270002000900279035001000288801002400298#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#107#19#article#38#19#^rND^sPeril
lan^nC#^rND^sCostales^nM#^rND^sDiaz^nF#^rND^sVijande^nM#^rND^sArguelles^nJ#Thirs
t changes in offspring of hyperreninemic rat dams^len#Pharmacol Biochem Behav#20
040000#2004#79#709-713#20070500#6681.htm#0091-3057#Pharmacol Biochem Behav##
00672000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
02000109010001800129010001900147012011700166030001100283065000900294064000500303
031000300308014000800311865000900319002000900328035001000337801001100347#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#108#20#article#38#20#^rND^sVijan
de^nM#^rND^sBrime^nJI#^rND^sLopez-Sela^nP#^rND^sCostales^nM#^rND^sArguelles^nJ#I
ncreased salt preference in adult offspring raised by mother rats consuming exce
ssive amounts of salt and water^len#Regul Pept#19960000#1996#66#105-108#20070500
#6681.htm#0167-0115#Regul Pept##
00585000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01900109010001800128012006500146030000900211065000900220064000500229031000400234
014000800238865000900246002000900255035001000264801000900274#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6681.htm#S#c#109#21#article#38#21#^rND^sDinh^nDT#^rND^sFr
auman^nAG#^rND^sJohnston^nCI#^rND^sFabiani^nME#Angiotensin receptors: distributi
on, signalling and function^len#Clin Sci#20010000#2001#100#481-492#20070500#6681
.htm#0009-9287#Clin Sci##
00521000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100020000940120
05800114030000900172065000900181064000500190031000300195014000800198865000900206
002000900215035001000224801000900234#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
681.htm#S#c#110#22#article#38#22#^rND^sCrystal^nSR#^rND^sBernstein^nIL#Morning s
ickness: impact on offspring salt preference^len#Appetite#19950000#1995#25#231-2
40#20070500#6681.htm#0195-6663#Appetite##
00520000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100020000940120
05700114030000900171065000900180064000500189031000300194014000800197865000900205
002000900214035001000223801000900233#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
681.htm#S#c#111#23#article#38#23#^rND^sCrystal^nSR#^rND^sBernstein^nIL#Infant sa
lt preference and mother's morning sickness^len#Appetite#19980000#1998#30#297-30
7#20070500#6681.htm#0195-6663#Appetite##
00676000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
01500111010001800126010001700144010001600161012008800177030001600265065000900281
06400050029003100030029501400080029886500090030600200090031503500100032480100160
0334#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#112#24#article#38#24
#^rND^sMalaga^nI#^rND^sArguelles^nJ#^rND^sDiaz^nJJ#^rND^sPerillan^nC#^rND^sVijan
de^nM#^rND^sMalaga^nS#Maternal pregnancy vomiting and offspring salt taste sensi
tivity and blood pressure^len#Pediatr Nephrol#20050000#2005#20#956-960#20070500#
6681.htm#0097-5257#Pediatr Nephrol##
00642000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01700109010001300126010002000139012010700159030000400266065000900270064000500279
031000400284014000800288865000900296002000900305035001000314801000400324#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#113#25#article#38#25#^rND^sBarke
r^nDJ#^rND^sOsmond^nC#^rND^sGolding^nJ#^rND^sKuh^nD#^rND^sWadsworth^nME#Growth i
n utero, blood pressure in childhood and adult life, and mortality from cardiova
scular disease^len#BMJ#19890000#1989#298#564-567#20070500#6681.htm#0959-8138#BMJ
##
00549000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01500107012007800122030003000200710000200230065000900232064000500241031000300246
014000400249865000900253002000900262#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
681.htm#S#c#114#26#article#38#26#^rND^sJames^nPT#^rND^sRigby^nN#^rND^sLeach^nR#T
he obesity epidemic, metabolic syndrome and future prevention strategies^len#Eur
 J Cardiovasc Prev Rehabil#2#20040000#2004#11#3-8#20070500#6681.htm##
00648000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100005000760100010000810120
21300091030000500304065000900309064000500318031000400323014001000327865000900337
002000900346035001000355801000500365#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
681.htm#S#c#115#27#article#38#27#^rND#Anonymous#Executive Summary of the Third R
eport of the National Cholesterol Education Program (NCEP) expert panel on detec
tion, evaluation, and treatment of high blood cholesterol in adults (adult treat
ment panel III).^len#JAMA#20010000#2001#285#2486-2497#20070500#6681.htm#0098-748
4#JAMA##
00706000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01600111010001800127010001700145010001900162810000600181012010100187030001200288
06500090030006400050030903100040031401400100031886500090032800200090033703500100
0346801001200356#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#116#28#a
rticle#38#28#^rND^sDaniels^nSR#^rND^sArnett^nDK#^rND^sEckel^nRH#^rND^sGidding^nS
S#^rND^sHayman^nLL#^rND^sKumanyika^nS#et al#Overweight in children and adolescen
ts: pathophysiology, consequences, prevention, and treatment^len#Circulation#200
50000#2005#111#1999-2012#20070500#6681.htm#0009-7322#Circulation##
00694000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01500110010001500125010002400140010001600164810000600180012008900186030001500275
06500090029006400050029903100030030401400060030786500090031300200090032203500100
0331801001500341#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#117#29#a
rticle#38#29#^rND^sMoreno^nLA#^rND^sMesana^nMI#^rND^sFleta^nJ#^rND^sRuiz^nJR#^rN
D^sGonzalez-Gross^nM#^rND^sSarria^nA#et al#Overweight, obesity and body fat comp
osition in Spanish adolescents: The AVENA Study^len#Ann Nutr Metab#20050000#2005
#49#71-76#20070500#6681.htm#0250-6807#Ann Nutr Metab##
00666000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01800109010001800127010001700145010001700162012009500179030000500274065000900279
06400050028803100040029301400100029786500090030700200090031603500100032580100050
0335#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#118#30#article#38#30
#^rND^sHedley^nAA#^rND^sOgden^nCL#^rND^sJohnson^nCL#^rND^sCarroll^nMD#^rND^sCurt
in^nLR#^rND^sFlegal^nKM#Prevalence of overweight and obesity among US children, 
adolescents, and adults, 1999-2002^len#JAMA#20040000#2004#291#2847-2850#20070500
#6681.htm#0098-7484#JAMA##
00674000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01800107010002100125010001800146010001700164810000600181012006700187030001300254
06500090026706400050027603100040028101400100028586500090029500200090030403500100
0313801001300323#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#119#31#a
rticle#38#31#^rND^sWeiss^nR#^rND^sDziura^nJ#^rND^sBurgert^nTS#^rND^sTamborlane^n
WV#^rND^sTaksali^nSE#^rND^sYeckel^nCW#et al#Obesity and the metabolic syndrome i
n children and adolescents^len#N Engl J Med#20040000#2004#350#2362-2374#20070500
#6681.htm#0028-4793#N Engl J Med##
00513000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01700109012002700126030000700153065000900160064000500169031000400174014001000178
865000900188002000900197035001000206801000700216#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6681.htm#S#c#120#32#article#38#32#^rND^sEckel^nRH#^rND^sGrundy^nSM#^r
ND^sZimmet^nPZ#The metabolic syndrome^len#Lancet#20050000#2005#365#1415-1428#200
70500#6681.htm#0099-5355#Lancet##
00678000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
01700106010001600123010001400139010001500153810000600168012008700174030001300261
06500090027406400050028303100030028801400080029186500090029900200090030803500100
0317801001300327#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#121#33#a
rticle#38#33#^rND^sLurbe^nE#^rND^sTorro^nI#^rND^sAlvarez^nV#^rND^sNawrot^nT#^rND
^sPaya^nR#^rND^sRedon^nJ#et al#Prevalence, persistence, and clinical significanc
e of masked hypertension in youth^len#Hypertension#20050000#2005#45#493-498#2007
0500#6681.htm#0194-911X#Hypertension##
00484000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910120
05500107030001400162710000200176065000900178064000500187031000200192014000600194
865000900200002000900209#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#
122#34#article#38#34#^rND^sCruz^nML#^rND^sGoran^nMI#The metabolic syndrome in ch
ildren and adolescents^len#Curr Diab Rep#2#20040000#2004#4#53-62#20070500#6681.h
tm##
00542000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100020000910100
01700111012005000128030001200178065000900190064000500199031000300204014000500207
865000900212002000900221035001000230801001200240#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6681.htm#S#c#123#35#article#38#35#^rND^sBelay^nB#^rND^sBelamarich^nP#
^rND^sRacine^nAD#Pediatric precursors of adult atherosclerosis^len#Pediatr Rev#2
0040000#2004#25#4-16#20070500#6681.htm#0191-9601#Pediatr Rev##
00506000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120076000920300
01700168065000900185064000500194014000800199865000900207002000900216035001000225
801001700235#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#124#36#artic
le#38#36#^rND^sKoenig^nW#Update on C-reactive protein as a risk marker in cardio
vascular disease^len#Kidney Int Suppl#20030000#2003#S58-S61#20070500#6681.htm#00
98-6577#Kidney Int Suppl##
00607000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
02000109010001600129010001700145012005900162030001100221065000900232064000500241
031000400246014000400250865000900254002000900263035001000272801001100282#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#125#37#article#38#37#^rND^sVisse
r^nM#^rND^sBouter^nLM#^rND^sMcQuillan^nGM#^rND^sWener^nMH#^rND^sHarris^nTB#Low-g
rade systemic inflammation in overweight children^len#Pediatrics#20010000#2001#1
07#E13#20070500#6681.htm#0031-4005#Pediatrics##
00506000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100021000940120
06300115030002000178710000200198065000900200064000500209031000200214014000600216
865000900222002000900231#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6681.htm#S#c#
126#38#article#38#38#^rND^sSkilton^nMR#^rND^sCelermajer^nDS#The effects of obesi
ty-related peptides on the vasculature^len#Curr Vasc Pharmacol#2#20060000#2006#4
#79-85#20070500#6681.htm##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#o#1#1#article#1#20
080212#125731#6682.htm#172##
03319000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015222300090016201200600
01710100019002310100037002500100027002870700075003140700050003890700062004390700
05200501070006700553083148100620085000802101085002702109085002102136085003902157
08500250219608500360222108500250225711700060228207200030228805301260229105500120
24170540023024290580042024520580065024941120009025591110017025681140009025851130
01802594881002402612002000902636#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.
htm#S#h#2#1#article#1#ra#en#bjmbr#1#3.1#ILUS#18#BJMBR700#nd#Braz J Med Biol Res#
40#5#20070500#^f727^l734#0100-879X#20070326#Sex differences in angiotensin II- i
nduced hypertension^len#^rND^1A02^nB.^sXue#^rND^1A02 A03 A04 A05^nA.K.^sJohnson#
^rND^1A01 A02 A05^nM.^sHay#University of Iowa^iA01^1Department of Molecular Phys
iology and Biophysics#University of Iowa^iA02^1Department of Psychology#Universi
ty of Iowa^iA03^1Department of Integrative Physiology#University of Iowa^iA04^1D
epartment of Pharmacology#University of Iowa^iA05^1Cardiovascular Center^cIowa C
ity^sIA^pUSA#^len^aSex differences in the development of hypertension and cardio
vascular disease have been described in humans and in animal models. In this pap
er we will review some of our studies which have as their emphasis the examinati
on of the role of sex differences and sex steroids in modulating the central act
ions of angiotensin II (ANG II) via interactions with free radicals and nitric o
xide, generating pathways within brain circumventricular organs and in central s
ympathomodulatory systems. Our studies indicate that low-dose infusions of ANG I
I result in hypertension in wild-type male mice but not in intact wild-type fema
les. Furthermore, we have demonstrated that ANG II-induced hypertension in males
 is blocked by central infusions of the androgen receptor antagonist, flutamide,
 and by central infusions of the superoxide dismutase mimetic, tempol. We have a
lso found that, in comparison to females, males show greater levels of intracell
ular reactive oxygen species in circumventricular organ neurons following long-t
erm ANG II infusions. In female mice, ovariectomy, central blockade of estrogen 
receptors or total knockout of estrogen a receptors augments the pressor effects
 of ANG II. Finally, in females but not in males, central blockade of nitric oxi
de synthase increases the pressor effects of ANG II. Taken together, these resul
ts suggest that sex differences and estrogen and testosterone play important rol
es in the development of ANG II-induced hypertension.#^dnd^i1#^tm^len^kAngiotens
in II^i1#^tm^len^kEstrogen^i1#^tm^len^kEstrogen a and ß receptors^i1#^tm^len^kNi
tric oxide^i1#^tm^len^kReactive oxygen species^i1#^tm^len^kTestosterone^i1#other
#59#International Symposium of Neuroendocrinology "Neuroendocrine control of bod
y fluid homeostasis: past, present and future"^i1#20060901^i1#September 1-3, 200
6^i1#National Heart, Lung, and Blood Institute#National Institute of Diabetes an
d Digestive and Kidney Diseases#20061011#October 11, 2006#20070222#February 22, 
2007#S0100-879X2006005000093#6682.htm##
03342000000000685000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015222300090016201200600
01710100019002310100037002500100027002870700075003140700050003890700062004390700
05200501070006700553083148100620085000802101085002702109085002102136085003902157
08500250219608500360222108500250225711700060228207200030228805301260229105600250
24170570010024420550012024520540023024640580042024870580065025291120009025941110
01702603114000902620113001802629002000902647#v40n5#v:\scielo\serial\bjmbr\v40n5\
markup\6682.htm#S#f#3#1#article#1#ra#en#bjmbr#1#3.1#ILUS#18#BJMBR700#nd#Braz J M
ed Biol Res#40#5#20070500#^f727^l734#0100-879X#20070326#Sex differences in angio
tensin II- induced hypertension^len#^rND^1A02^nB.^sXue#^rND^1A02 A03 A04 A05^nA.
K.^sJohnson#^rND^1A01 A02 A05^nM.^sHay#University of Iowa^iA01^1Department of Mo
lecular Physiology and Biophysics#University of Iowa^iA02^1Department of Psychol
ogy#University of Iowa^iA03^1Department of Integrative Physiology#University of 
Iowa^iA04^1Department of Pharmacology#University of Iowa^iA05^1Cardiovascular Ce
nter^cIowa City^sIA^pUSA#^len^aSex differences in the development of hypertensio
n and cardiovascular disease have been described in humans and in animal models.
 In this paper we will review some of our studies which have as their emphasis t
he examination of the role of sex differences and sex steroids in modulating the
 central actions of angiotensin II (ANG II) via interactions with free radicals 
and nitric oxide, generating pathways within brain circumventricular organs and 
in central sympathomodulatory systems. Our studies indicate that low-dose infusi
ons of ANG II result in hypertension in wild-type male mice but not in intact wi
ld-type females. Furthermore, we have demonstrated that ANG II-induced hypertens
ion in males is blocked by central infusions of the androgen receptor antagonist
, flutamide, and by central infusions of the superoxide dismutase mimetic, tempo
l. We have also found that, in comparison to females, males show greater levels 
of intracellular reactive oxygen species in circumventricular organ neurons foll
owing long-term ANG II infusions. In female mice, ovariectomy, central blockade 
of estrogen receptors or total knockout of estrogen a receptors augments the pre
ssor effects of ANG II. Finally, in females but not in males, central blockade o
f nitric oxide synthase increases the pressor effects of ANG II. Taken together,
 these results suggest that sex differences and estrogen and testosterone play i
mportant roles in the development of ANG II-induced hypertension.#^dnd^i1#^tm^le
n^kAngiotensin II^i1#^tm^len^kEstrogen^i1#^tm^len^kEstrogen a and ß receptors^i1
#^tm^len^kNitric oxide^i1#^tm^len^kReactive oxygen species^i1#^tm^len^kTestoster
one^i1#other#59#International Symposium of Neuroendocrinology "Neuroendocrine co
ntrol of body fluid homeostasis: past, present and future"^i1#Ribeirão Preto^i1^
eSP^i1#Brazil^i1#20060901^i1#September 1-3, 2006^i1#National Heart, Lung, and Bl
ood Institute#National Institute of Diabetes and Digestive and Kidney Diseases#2
0061011#October 11, 2006#20070222#February 22, 2007#6682.htm##
03559000000000709000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000300116
03000240011903100030014303200020014606500090014801400110015703500100016822300090
01780120060001870100018002470100037002650100026003020700097003280700072004250700
08400497070007400581070006900655083148100724085000802205085002702213085002102240
08500390226108500250230008500360232508500250236111700060238607200030239205301260
23950560025025210570010025460550012025560540023025680580042025910580065026331120
00902698111001702707114000902724113001802733002000902751008008902760#v40n5#v:\sc
ielo\serial\bjmbr\v40n5\markup\6682.htm#S#l#4#1#article#1#^mMay^a2007#ra#en#bjmb
r#1#3.1#ilus#18#BJMBR700#nd#Braz. j. med. biol. res#40#5#20070500#^f727^l734#010
0-879X#20070326#Sex differences in angiotensin II- induced hypertension^len#^rND
^1A02^nB^sXue#^rND^1A02 A03 A04 A05^nA. K^sJohnson#^rND^1A01 A02 A05^nM^sHay#^iA
01^1University of Iowa^2Department of Molecular Physiology and Biophysics^cIowa 
City^sIA^pUSA#^iA02^1University of Iowa^2Department of Psychology^cIowa City^sIA
^pUSA#^iA03^1University of Iowa^2Department of Integrative Physiology^cIowa City
^sIA^pUSA#^iA04^1University of Iowa^2Department of Pharmacology^cIowa City^sIA^p
USA#^iA05^1University of Iowa^2Cardiovascular Center^cIowa City^sIA^pUSA#^len^aS
ex differences in the development of hypertension and cardiovascular disease hav
e been described in humans and in animal models. In this paper we will review so
me of our studies which have as their emphasis the examination of the role of se
x differences and sex steroids in modulating the central actions of angiotensin 
II (ANG II) via interactions with free radicals and nitric oxide, generating pat
hways within brain circumventricular organs and in central sympathomodulatory sy
stems. Our studies indicate that low-dose infusions of ANG II result in hyperten
sion in wild-type male mice but not in intact wild-type females. Furthermore, we
 have demonstrated that ANG II-induced hypertension in males is blocked by centr
al infusions of the androgen receptor antagonist, flutamide, and by central infu
sions of the superoxide dismutase mimetic, tempol. We have also found that, in c
omparison to females, males show greater levels of intracellular reactive oxygen
 species in circumventricular organ neurons following long-term ANG II infusions
. In female mice, ovariectomy, central blockade of estrogen receptors or total k
nockout of estrogen a receptors augments the pressor effects of ANG II. Finally,
 in females but not in males, central blockade of nitric oxide synthase increase
s the pressor effects of ANG II. Taken together, these results suggest that sex 
differences and estrogen and testosterone play important roles in the developmen
t of ANG II-induced hypertension.#^dnd^i1#^tm^len^kAngiotensin II^i1#^tm^len^kEs
trogen^i1#^tm^len^kEstrogen a and ß receptors^i1#^tm^len^kNitric oxide^i1#^tm^le
n^kReactive oxygen species^i1#^tm^len^kTestosterone^i1#other#59#International Sy
mposium of Neuroendocrinology "Neuroendocrine control of body fluid homeostasis:
 past, present and future"^i1#Ribeirão Preto^i1^eSP^i1#Brazil^i1#20060901^i1#Sep
tember 1-3, 2006^i1#National Heart, Lung, and Blood Institute#National Institute
 of Diabetes and Digestive and Kidney Diseases#20061011#October 11, 2006#2007022
2#February 22, 2007#6682.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sc
i_arttext&pid=S0100-879X2007000500018##
00402000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017600071002000900247#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#5#1#article#109#<P class="style4"> <A NA
ME="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">
<B>May 2007, Volume 40(5) 727-734</B> </font> (Review)</B></P>      ^cY#6682.htm
##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#6#2#article#109#<P><font face="Arial, He
lvetica, sans-serif"><B><font size="5">Sex differences in angiotensin II- induce
d hypertension</font></B> </font>        ^cY#6682.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704042100071002000900492#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#7#3#article#109#<P><font face="Arial, He
lvetica, sans-serif">B. Xue<SUP>2</SUP>, A.K. Johnson<SUP>2,3,4,5</SUP>    and <
span class="style4"><a href="#Correspondence"><img src="/img/revistas/bjmbr/v40n
5/recor.gif" border="0"></a>    <a href="mailto:meredith-hay@uiowa.edu"><img src
="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0"></a></span></font>    <font
 face="Arial, Helvetica, sans-serif">M. Hay<sup>1,2,5</sup> </font>      ^cY#668
2.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704032700071002000900398#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#8#4#article#109#<P><font face="Arial, He
lvetica, sans-serif"><sup>1</sup>Department of Molecular Physiology and Biophysi
cs, <SUP>2</SUP>Department of Psychology, <SUP>3</SUP>Department of Integrative 
Physiology, <SUP>4</SUP>Department of Pharmacology, <SUP>5</SUP>Cardiovascular C
enter, University of Iowa, Iowa City, IA, USA</font>       ^cY#6682.htm##
00465000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704023900071002000900310#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#9#5#article#109#<P class="style4"> <A HR
EF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER
=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helv
etica, sans-serif">Abstract</font></strong></A>    ^cY#6682.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021500072002000900287#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#10#6#article#109#<BR>   <A HREF="#Text">
<img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">
Text</font></strong></A>    ^cY#6682.htm##
00447000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704022000072002000900292#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#11#7#article#109#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, 
sans-serif">References</font>    ^cY#6682.htm##
00505000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704027800072002000900350#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#12#8#article#109#<br>   </strong></A> <A
 HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font fa
ce="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></strong
></a>      ^cY#6682.htm##
00291000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704006400072002000900136#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#13#9#article#109#<P class="style4">  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6682.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038500073002000900458#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#14#10#article#109#<P class="style4"> <A 
NAME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helv
etica, sans-serif" size="4">Abstract</font><FONT COLOR=#00007F>    </FONT></span
><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font fac
e="Arial, Helvetica, sans-serif">      ^cY#6682.htm##
01723000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704149500073002000901568#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#15#11#article#109#<P>Sex differences in 
the development of hypertension and cardiovascular disease have been described i
n humans and in animal models. In this paper we will review some of our studies 
which have as their emphasis the examination of the role of sex differences and 
sex steroids in modulating the central actions of angiotensin II (ANG II) via in
teractions with free radicals and nitric oxide, generating pathways within brain
 circumventricular organs and in central sympathomodulatory systems. Our studies
 indicate that low-dose infusions of ANG II result in hypertension in wild-type 
male mice but not in intact wild-type females. Furthermore, we have demonstrated
 that ANG II-induced hypertension in males is blocked by central infusions of th
e androgen receptor antagonist, flutamide, and by central infusions of the super
oxide dismutase mimetic, tempol. We have also found that, in comparison to femal
es, males show greater levels of intracellular reactive oxygen species in circum
ventricular organ neurons following long-term ANG II infusions. In female mice, 
ovariectomy, central blockade of estrogen receptors or total knockout of estroge
n a receptors augments the pressor effects of ANG II. Finally, in females but no
t in males, central blockade of nitric oxide synthase increases the pressor effe
cts of ANG II. Taken together, these results suggest that sex differences and es
trogen and testosterone play important roles in the development of ANG II-induce
d hypertension. </font>      ^cY#6682.htm##
00483000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704025500073002000900328#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#16#12#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><B>Key words: </B> Angiotensin II, Estrogen, Estrogen <fo
nt face="Symbol">a</font> and &szlig; receptors, Nitric oxide, Reactive oxygen s
pecies, Testosterone </font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6682.ht
m##
00624000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039600073002000900469#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#17#13#article#109#<P class="style4"><A N
AME="Text"></A> <span class="style3"><font color="#00007F" face="Arial, Helvetic
a, sans-serif" size="4">Text</font></span><A HREF="#Home"><FONT SIZE=4><B><img s
rc="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 
LOOP="0"></B></FONT></A>    <font face="Arial, Helvetica, sans-serif"></font></P
> <font face="Arial, Helvetica, sans-serif">      ^cY#6682.htm##
01896000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704166800073002000901741#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#18#14#article#109#<P>In general, men are
 at greater risk for cardiovascular disease and hypertension than premenopausal 
women of the same age (1,2). Ambulatory blood pressure measurements have consist
ently found that men aged 50-60 years have higher blood pressures than premenopa
usal, age-matched women (3,4). In animal models of hypertension, studies have al
so shown that males have higher blood pressure than females (5-7). Angiotensin I
I (ANG II) is an important factor in many forms of clinical and experimental hyp
ertension. In animals, low doses of ANG II are known to induce neurogenic hypert
ension via the central nervous system by acting through brain circumventricular 
organs (8,9). An increasing body of evidence has shown that the central and peri
pheral effects of ANG II involve activation of reactive oxygen (10,11). Similarl
y, central and peripheral studies with estrogen (E2) and testosterone have shown
 that many of their cardiovascular-related effects may involve modulation of the
 generation of reactive oxygen species (ROS) and nitric oxide (NO) (12-14). In m
any systems, cardiovascular homeostasis is maintained by the balance between the
 ROS and NO systems. Therefore, understanding the nature of any imbalance in NO/
ROS signaling activated by ANG II and the contribution of sex differences and se
x steroids to such dysfunction will be of key importance for developing new trea
tments for ANG II-related cardiovascular disease. The purpose of this review is 
to summarize recent developments that implicate a role for sex-related mechanism
s modulating the central actions of ANG II and, in particular, the role of free 
radical- and NO-generating pathways.      ^cY#6682.htm##
00302000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007400073002000900147#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#19#15#article#109#<P><B>Sex differences 
in angiotensin II-induced hypertension</B>      ^cY#6682.htm##
01323000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704109500073002000901168#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#20#16#article#109#<P>Central actions of 
ANG II increase sympathetic nerve activity and modulate reflex regulation of hea
rt rate through actions of the peptide on sensory circumventricular organs (15) 
such as the area postrema, subfornical organ and organum vasculosum of the lamin
a terminalis (8,16-20). It has been reported that chronic low-dose ANG II-induce
d hypertension, which develops over a period of days, is not due to the peripher
al vasoconstrictor activity of ANG II, but is most likely the result of excitati
on of the sympathetic nerve activity (8,17). Recent studies from our laboratory 
have shown in mice that decreases in blood pressure induced by ganglionic blocka
de are much smaller on day 1 as compared to day 7 of ANG II infusion, thus sugge
sting that an enhancement of sympathetic outflow contributes to the ANG II-induc
ed progressive increase in blood pressure (21). The results obtained by Hendel a
nd Collister (18) confirm that the chronic phase of ANG II hypertension has a si
gnificant neurogenic component and that this sympathoexcitation is mediated via 
the subfornical organ.       ^cY#6682.htm##
01526000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704129800073002000901371#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#21#17#article#109#<P>There is increasing
 evidence that the actions of ANG II on the central nervous    system may differ
 between sexes. Doursout et al. (22) have reported that the    blood pressure an
d dipsogenic responses to centrally administered ANG II in    conscious dogs are
 substantially augmented in males relative to females. Recent    studies from ou
r laboratory have shown that 1) low-dose infusion of ANG II increases    blood p
ressure in male but not female mice (<a href="#Fig1">Figure 1A</a>),    and 2) g
onadectomy attenuates ANG II-induced hypertension in male mice and augments    h
ypertension in females (<a href="#Fig1">Figure 1B</a>). Furthermore, we have    
reported that ganglionic blockade produces greater reductions in blood pressure 
   in males compared to females during ANG II infusion, and reflex bradycardic  
  responses are blunted in males but not in females during chronic ANG II infusi
on.    These results suggest that female mice are protected against the developm
ent    of ANG II-induced hypertension and that sex hormones play an important mo
dulatory    role in the pathogenesis of ANG II-induced hypertension. Furthermore
, attenuated    baroreflex sensitivity and increases in sympathetic outflow appe
ar to contribute    to the hypertension observed in the male (21).      ^cY#6682
.htm##
01093000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704086500073002000900938#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#22#18#article#109#<P>Although the mechan
isms underlying the sex differences in ANG II-induced hypertension are unknown, 
substantial evidence has accumulated to show that sex differences and sex hormon
es affect components of the renin-angiotensin system (23). For example, testoste
rone treatment in ovariectomized (OVX) female rats increases plasma renin activi
ty, while plasma renin activity, plasma angiotensin-converting enzyme activity a
nd angiotensinogen mRNA decrease after castration of males (24,25). In contrast,
 E2 may decrease components of the renin-angiotensin system (23). E2 has been sh
own to reduce angiotensin type 1 (AT<SUB>1</SUB>) receptor binding and mRNA in t
he subfornical organ in female rats (26); this may indicate that E2 might attenu
ate ANG II activation of subfornical organ neurons and the development of ANG II
-induced hypertension in females.      ^cY#6682.htm##
00339000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011100073002000900184#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#23#19#article#109#<P><B>The role of sex 
hormones and their central receptors in angiotensin II-induced hypertension</B> 
     ^cY#6682.htm##
01008000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078000073002000900853#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#24#20#article#109#<P>Physiologically rel
evant concentrations of E2 have both rapid and long-term positive cardiovascular
 effects which are mediated by two types of estrogen receptors (ER), ER<font fac
e="Symbol">a</font>  and ER&szlig; (27). Crucial roles for ER<font face="Symbol"
>a</font>  in the protection against vascular injury, activation of endothelial 
NO synthase (NOS) and anti-atherosclerotic effects have been amply documented (2
8,29). Genetic deletion of ER&szlig; results in the development of hypertension 
in middle-aged female and male mice due to multiple abnormalities of ion channel
 function in blood vessels (30). However, very little is known about the role of
 ER in the central nervous system regarding the mediation of the cardiovascular 
protective effects of E2.         ^cY#6682.htm##
01344000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704111600073002000901189#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#25#21#article#109#<P>Saleh et al. (31,32
) have shown that in OVX female rats, E2 administration into several hindbrain n
uclei, such as the nucleus of the solitary tract, nucleus ambiguous and parabrac
hial nucleus, and into the intrathecal space inhibits sympathetic efferent activ
ity but enhances parasympathetic efferent activity. These effects of E2 were blo
cked by pretreatment with the ER antagonist, ICI182,780. Moreover, central injec
tion of ICI182,780 blocked increased vagal nerve activity and decreased renal ne
rve activity induced by bolus injections of E2 (<I>iv</I>), thereby indicating t
hat peripherally administered E2 modulates baseline autonomic tone via the activ
ation of central ERs (33). Studies from our laboratory have shown that 17&szlig;
-estradiol facilitates area postrema calcium-activated K<SUP>+</SUP> currents an
d inhibits area postrema neuronal activity (34). 17&szlig;-estradiol also inhibi
ts an increase in (Ca<SUP>2+</SUP>)<SUB>i</SUB> induced by application of ANG II
 to cultured area postrema neurons (35). This evidence reinforces the importance
 of a central antihypertensive action of E2.      ^cY#6682.htm##
00717000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704048900073002000900562#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#26#22#article#109#<P>Recently, we report
ed that central infusion of the ER antagonist ICI182,780 facilitates ANG II-indu
ced hypertension in females. Furthermore, we have shown that in female ER<font f
ace="Symbol">a</font>  knockout mice ANG II increases blood pressure in a simila
r manner to that seen in OVX, wild-type females (<a href="#Fig2">Figure 2</a>), 
suggesting that E2 protects against ANG II-induced hypertension in females via a
ctions on the ER<font face="Symbol">a</font>  (36,37).         ^cY#6682.htm##
01526000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704129800073002000901371#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#27#23#article#109#<P>Studies in humans a
nd animals suggest that testosterone is a pro-hypertensive hormone (38). Studies
 using ambulatory blood pressure monitoring techniques in children have shown th
at with increasing age, blood pressure increases in both young boys and girls. H
owever, after the onset of puberty, boys have higher blood pressure than age-mat
ched girls (39). These data show that in adolescence and puberty, when androgen 
levels are increasing, blood pressure is higher in males than in females. In ani
mal models, blood pressure is higher in male spontaneously hypertensive, Dahl sa
lt-sensitive, and deoxycorticosterone acetate-salt hypertensive rats as compared
 to the same hypertensive models when females are studied (7,40, 41). Treatment 
of OVX normotensive females or castrated males with testosterone increases blood
 pressure to levels similar to those of intact males, and testosterone increases
 blood pressure in OVX female spontaneously hypertensive rats. Moreover, chronic
 blockade of androgen receptors with the antagonist flutamide reduces blood pres
sure in male spontaneously hypertensive rats to the level found in female sponta
neously hypertensive animals (42). Thus, increases in androgens in humans and in
 normotensive and hypertensive rats lead to higher blood pressure.      ^cY#6682
.htm##
01170000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704094200073002000901015#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#28#24#article#109#<P>The mechanisms by w
hich testosterone affects blood pressure are multifaceted and involve direct eff
ects on vascular, renal and heart cells (38,43). However, there are very few stu
dies on the central effects of androgen as well as its receptor on blood pressur
e and cardiovascular regulation, and this is just beginning to be investigated. 
Data from our laboratory show that the use of intracerebroventricular flutamide 
infusion to block androgen receptors in the central nervous system significantly
 attenuates the development of ANG II-induced hypertension in male mice (<a href
="#Fig3">Figure 3</a>). These results indicate that central androgen receptors m
ight mediate the hypertensive effects of sex hormones during infusions of ANG II
 in mice (44). The mechanisms underlying the role of male sex hormones and andro
gen receptors in altering ANG II activation of the central nervous system need t
o be studied further.  </font>      ^cY#6682.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704021300073002000900286#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#29#25#article#109#<P> <font face="Arial,
 Helvetica, sans-serif"><B>Reactive oxygen species and nitric oxide in sex diffe
rences in angiotensin II-induced hypertension Reactive oxygen species and sex di
fferences</B> </font>      ^cY#6682.htm##
01551000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704132300073002000901396#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#30#26#article#109#<P><font face="Arial, 
Helvetica, sans-serif">Oxidative stress can be characterized by an imbalance bet
ween the generation and the scavenging of oxide radicals (e.g., O<SUB>2</SUB><SU
P>-</SUP> or hydrogen peroxide) and has been identified as a key component of th
e pathogenesis of central and peripheral diseases (45). Recent studies have show
n that superoxide radicals are critical determinants of the central actions of A
NG II (11,46,47). These studies demonstrate that overexpression of superoxide di
smutase (SOD) within the region of the subfornical organ by administration of an
 adenoviral vector containing the gene coding human MnSOD and CuZnSOD blocks the
 pressor, bradycardic and dipsogenic effects of centrally administered ANG II. F
urther, these investigators also found that MnSOD is co-expressed with AT<SUB>1<
/SUB> receptors in the subfornical organ, thus supporting the hypothesis that ce
ntral ANG II-induced hypertension involves ROS activation within ANG II-sensitiv
e circumventricular organs. Recent data from our laboratory have shown that late
ral <I>icv</I> infusion of tempol, a SOD mimetic, blocks systemic ANG II-induced
 hypertension in male mice (48,49). This suggests that central ROS activation is
 required for ANG II-induced hypertension in males (<a href="#Fig4">Figure 4</a>
). </font>       ^cY#6682.htm##
01381000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704115300073002000901226#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#31#27#article#109#<P><font face="Arial, 
Helvetica, sans-serif">Testosterone and E2 have been shown    to alter oxidative
 stress at both peripheral and central sites. In endothelial    cells E2 has rec
ently been shown to inhibit ANG II-induced increases in expression    of nicotin
amide adenine dinucleotide phosphate, the reduced form (NADPH) and    NOS (13). 
In vascular smooth muscle cells, E2 decreases ANG II-induced free    radical pro
duction and up-regulates MnSOD and extracellular SOD, suggesting    that the car
diovascular protection of E2 against peripheral ANG II-induced oxidative    stre
ss is due to an increase in SOD activity induced by E2 (12). Using real-time    
measurements of reactive oxygen generation with dihydroethidium in living brain 
   slices, our laboratory has shown that ANG II increases ROS production in subf
ornical    organ neurons and that this effect is blocked by tempol (<a href="#Fi
g5">Figure    5A</a>). Importantly, incubation of the slices in E2 blocks ANG II
-induced increases    in ROS (<a href="#Fig5">Figure 5B</a>), suggesting that E2
 may inhibit central    ANG II effects by inhibiting ROS production (50). </font
>      ^cY#6682.htm##
00330000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010200073002000900175#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#32#28#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><B>Nitric oxide and sex differences</B> </font>      ^cY#
6682.htm##
01046000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704081800073002000900891#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#33#29#article#109#<P><font face="Arial, 
Helvetica, sans-serif">NO synthesized from its precursor L-arginine by the enzym
e NOS is an important mediator of intracellular signaling in various tissues. Ne
uronal NOS (nNOS) activity has been demonstrated in central and peripheral auton
omic nervous system sites that are involved in the control of blood pressure reg
ulation (51). There are a large number of studies examining the central effects 
of NO on sympathetic outflow. For example, within the hypothalamus, the largest 
population of NO cells is found within the paraventricular nucleus. Increases in
 NO within the paraventricular nucleus result in decreases of sympathetic outflo
w and blood pressure, and NO plays an important central role in reducing arteria
l pressure during recovery from psychological stress (52). </font>      ^cY#6682
.htm##
01645000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704141700073002000901490#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#34#30#article#109#<P><font face="Arial, 
Helvetica, sans-serif">A differential modulation of nNOS expression and/or activ
ity has been proposed to be related to observed sex differences in NO release. R
ecent studies demonstrate that E2 up-regulates endothelial NOS in endothelial ce
lls (53) and nNOS in the brain (54, 55). Many of the actions of E2 on the brain 
have been suggested to be through an NO-mediated mechanism (54,55). Castration i
ncreases and androgen treatment decreases nNOS activity in the brain (56). Immun
ohistochemical studies from our laboratory also revealed co-localization of nNOS
 and ER<font face="Symbol">a</font> in the subfornical organ of female mice (57)
. Moreover, Wang et al. (58) recently reported that there are sex differences in
 the development of long-term N<SUP><font face="Symbol">w</font></SUP>-nitro-L-a
rginine methyl ester (L-NAME)-induced hypertension in rats. L-NAME-treated femal
es exhibited a significantly higher elevation of blood pressure than males. Resu
lts from our laboratory have demonstrated that the increases in blood pressure i
nduced by ANG II are significantly greater in female mice given central infusion
s of L-NAME than in control mice (57) (<a href="#Fig6">Figure 6</a>). This raise
s the possibility that activation of the endogenous NO system may buffer the sti
mulatory effects of ANG II on central sympathetic nervous system activity, espec
ially in females. </font>      ^cY#6682.htm##
00940000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704071200073002000900785#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#35#31#article#109#<P><font face="Arial, 
Helvetica, sans-serif">In many systems the harmful effects of ROS are offset by 
NO production (45). When these systems are out of balance, an increase in produc
tion of ROS results in a decreased bioavailability of NO (59). Increased product
ion of superoxide radicals results in the scavenging of NO and an increased prod
uction of peroxynitrite. Preliminary data from our laboratory show that, in male
 mice, L-NAME had no effect on ANG II-induced hypertension. However, the depress
or effect of tempol was inhibited by central co-administration of L-NAME, sugges
ting that NO may modulate the depressor effect of tempol in the development of A
NG II-induced hypertension (49). </font>      ^cY#6682.htm##
00310000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008200073002000900155#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#36#32#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><B>Conclusions </B> </font>      ^cY#6682.htm##
01689000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704146100073002000901534#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#37#33#article#109#<P><font face="Arial, 
Helvetica, sans-serif">Our studies have demonstrated that there are sex differen
ces in ANG II-induced hypertension in conscious mice, and that sex hormones such
 as androgen and E2 as well as their central receptors modulate this form of ANG
 II-induced hypertension. Our studies have also indicated that the interactions 
among sex hormones and ROS/NO within the circumventricular organs significantly 
influence ANG II-induced hypertension. Thus, given the links between NO and ROS 
and the role of sex hormones and ANG II in neurohumoral activation, it can be hy
pothesized that sex hormones, ANG II, NO, and ROS work in concert to regulate au
tonomic function. <a href="#Fig7">Figure 7</a> illustrates the balance between R
OS and NO which is suggested to be involved in activation of the AT<SUB>1</SUB> 
receptor. Both E2 and testosterone are hypothesized to modulate the effects of A
T<SUB>1</SUB> receptor activation by modulating the ROS/NO balance. The interact
ions of these factors are likely to contribute to cardiovascular protection or i
mpairment. Ongoing studies in our laboratory focus on this hypothesis and are ex
ploring the related mechanisms.</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <tab
le width="100%"  border="0">    <tr align="left" valign="top">      <td width="1
3%"><a href="/img/revistas/bjmbr/v40n5/html/6682i01.htm"><img src="/img/revistas
/bjmbr/v40n5/6682i01peq.jpg" border="2"></a></td>      <td width="87%">    ^cY#6
682.htm##
01063000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704083500073002000900908#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#38#34#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. <I>A</I>, Telemetry measurem
ent (TA11PA-C20, Data Sciences International, St. Paul, MN, USA) of mean arteria
l pressure (MAP) before and during infusion of angiotensin II (ANG II, 800 ng kg
<SUP>-1</SUP> min<SUP>-1</SUP>) in male and female mice. Control days are denote
d by C, followed by the 7 days of ANG II infusion. *P &lt; 0.05 compared to base
line, <SUP>+</SUP>P &lt; 0.05 compared to females (two-way ANOVA). <I>B</I>, Ave
raged increases in MAP induced by ANG II infusion in intact and gonadectomized m
ice. Data are reported as means &#177; SEM for 6 mice in each group. <SUP>**</SU
P>P &lt; 0.05 compared to castrated males, <SUP>++</SUP>P &lt; 0.05 compared to 
ovariectomized (OVX) females (one-way ANOVA). </font>      </td>    </tr>  </tab
le>      ^cY#6682.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038300073002000900456#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#39#35#article#109#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (82 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr al
ign="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n5
/html/6682i02.htm"><img src="/img/revistas/bjmbr/v40n5/6682i02peq.jpg" border="2
"></a></td>      <td width="87%">    ^cY#6682.htm##
00837000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704060900073002000900682#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#40#36#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. Comparison of increases in m
ean arterial pressure (<font face="Symbol">D</font>MAP) induced by angiotensin I
I (ANG II, 800 ng kg<SUP>-1</SUP> min<SUP>-1</SUP>) infusion in intact, central 
ICI182,780 (ICI, 1.5 &#181;g kg<SUP>-1</SUP> day<SUP>-1</SUP>)-treated, ovariect
omized (OVX), and estrogen receptor alpha knockout (ER<font face="Symbol">a</fon
t>KO) female mice. Data are reported as means &#177; SEM for 6 mice in each grou
p. *P &lt; 0.05 compared to intact females (one-way ANOVA). </font>      </td>  
  </tr>  </table>      ^cY#6682.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038300073002000900456#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#41#37#article#109#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (52 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr al
ign="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n5
/html/6682i03.htm"><img src="/img/revistas/bjmbr/v40n5/6682i03peq.jpg" border="2
"></a></td>      <td width="87%">    ^cY#6682.htm##
00745000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704051700073002000900590#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#42#38#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure 3. Averaged change in mean arte
rial pressure (<font face="Symbol">D</font>MAP) induced by angiotensin II (ANG I
I, 800 ng kg<SUP>-1</SUP> min<SUP>-1</SUP>) infusion in intact, castrated (Cas),
 and central flutamide (Flu, 0.8 mg kg<SUP>-1</SUP> day<SUP>-1</SUP>)-treated ma
le mice. Data are reported as means &#177; SEM for 5 mice in each group. *P &lt;
 0.05 compared to intact males (one-way ANOVA). </font>      </td>    </tr>  </t
able>      ^cY#6682.htm##
00624000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039600073002000900469#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#43#39#article#109#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (43 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr al
ign="left" valign="top">      <td width="13%" height="104"><a href="/img/revista
s/bjmbr/v40n5/html/6682i04.htm"><img src="/img/revistas/bjmbr/v40n5/6682i04peq.j
pg" border="2"></a></td>      <td width="87%">    ^cY#6682.htm##
00922000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069400073002000900767#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#44#40#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig4"></a>Figure 4. Mean blood pressures (MAP) d
uring infusion of tempol (200 nM kg<SUP>-1</SUP> min<SUP>-1</SUP>) into the late
ral ventricles were not significantly different from baseline blood pressure; ho
wever, central administration of tempol during subcutaneous infusion of angioten
sin II (ANG II, 800 ng kg<SUP>-1</SUP> min<SUP>-1</SUP>) attenuated the increase
s in blood pressure observed with infusion of ANG II alone. Data are reported as
 means &#177; SEM for 7 mice in each group. *P &lt; 0.05 compared to baseline; <
SUP>+</SUP>P &lt; 0.05 compared to ANG II alone (one-way ANOVA). </font>      </
td>    </tr>  </table>      ^cY#6682.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038300073002000900456#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#45#41#article#109#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (68 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr al
ign="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n5
/html/6682i05.htm"><img src="/img/revistas/bjmbr/v40n5/6682i05peq.jpg" border="2
"></a></td>      <td width="87%">    ^cY#6682.htm##
01160000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704093200073002000901005#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#46#42#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig5"></a>Figure 5. <I>A</I>, Pseudocolor images
 showing increases in ethidium fluorescence intensity in the subfornical organ d
uring superfusion of slices with angiotensin II (ANG II). Arrows indicate cells 
in which intensity increased. <I>B</I>, Changes in ethidium fluorescence evoked 
by superfusion of ANG II (100 nM) in the absence and presence of tempol (1 mM). 
ANG II-evoked increases in intracellular reactive oxygen species (ROS) in the su
bfornical organ brain slice are blocked by tempol. <I>C</I>, The effects of 17&s
zlig;-estradiol (E2, 100 nM) on ANG II (100 nM)-induced intracellular generation
 of ROS. In the presence of E2, ANG II-induced percent increase of fluorescence 
intensity is significantly inhibited. Data are reported as means &#177; SEM. *P 
&lt; 0.05 compared to E2 alone or E2 + ANG II (one-way ANOVA). </font>      </td
>    </tr>  </table>      ^cY#6682.htm##
00612000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038400073002000900457#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#47#43#article#109#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (152 K JPG file)]</fon
t>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr a
lign="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n
5/html/6682i06.htm"><img src="/img/revistas/bjmbr/v40n5/6682i06peq.jpg" border="
2"></a></td>      <td width="87%">    ^cY#6682.htm##
00944000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704071600073002000900789#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#48#44#article#109#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig6"></a>Figure 6. Mean blood pressures (MAP) d
uring infusion of N<SUP><font face="Symbol">w</font></SUP>-nitro-L-arginine meth
yl ester (L-NAME, 0.5 mg kg<SUP>-1</SUP> day<SUP>-1</SUP>) into the lateral vent
ricles were not significantly different from baseline blood pressures in female 
mice; however, central administration of L-NAME augmented an angiotensin II (ANG
 II, 800 ng kg<SUP>-1</SUP> min<SUP>-1</SUP>)-induced increase in blood pressure
. Data are reported as means &#177; SEM for 6 mice in each group. *P &lt; 0.05 c
ompared to baseline, <SUP>+</SUP>P &lt; 0.05 compared to ANG II alone (one-way A
NOVA). </font>      </td>    </tr>  </table>      ^cY#6682.htm##
01271000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104300073002000901116#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#49#45#article#109#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (70 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr al
ign="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n5
/html/6682i07.htm"><img src="/img/revistas/bjmbr/v40n5/6682i07peq.jpg" border="2
"></a></td>      <td width="87%"><font face="Arial, Helvetica, sans-serif"><a na
me="Fig7"></a>Figure 7. Schematic representations of the hypothetical mechanisms
 of interaction of sex hormones, angiotensin II (ANG II), nitric oxide (NO), and
 reactive oxygen species (ROS). Both estrogen and testosterone are assumed to ha
ve actions in the central nervous system that modulate the activity of ROS and n
euronal NO synthase (nNOS) pathways, thereby modulating the hypertensive effects
 of central angiotensin type 1 (AT<SUB>1</SUB>) receptor activation by ANG II. S
OD = superoxide dismutase; NAD(P)H = nicotinamide adenine dinucleotide phosphate
, the reduced form. </font></td>    </tr>  </table>      ^cY#6682.htm##
00378000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015000073002000900223#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#50#46#article#109#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (91 K JPG file)]</font
>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6682.htm##
00547000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031900073002000900392#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#51#47#article#109#<P class="style4"> <A 
NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Hel
vetica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT
 SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>      ^cY#6682.htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704026800075002000900343#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#52#48#article#109#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Messerli FH, Garavaglia GE, Schmieder RE
, Sundgaard-Riise K, Nunez BD, Amodeo C. Disparate cardiovascular findings in me
n and women with essential hypertension. <I>Ann Intern Med</I> 1987; 107: 158-16
1. </font>      ^cY#6682.htm##
00534000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704029200075002000900367#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#53#49#article#109#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Stampfer MJ, Colditz GA, Willett WC, Man
son JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiov
ascular disease. Ten-year follow-up from the nurses' health study. <I>N Engl J M
ed</I> 1991; 325: 756-762. </font>      ^cY#6682.htm##
00556000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704031400075002000900389#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#54#50#article#109#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Burt VL, Whelton P, Roccella EJ, Brown C
, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult popula
tion. Results from the Third National Health and Nutrition Examination Survey, 1
988-1991. <I>Hypertension</I> 1995; 25: 305-313. </font>      ^cY#6682.htm##
00430000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018800075002000900263#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#55#51#article#109#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Staessen J, Fagard R, Lijnen P, Amery A.
 The influence of menopause on blood pressure. <I>Arch Belg</I> 1989; 47: 118-12
2. </font>      ^cY#6682.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025900075002000900334#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#56#52#article#109#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Brosnihan KB, Li P, Ganten D, Ferrario C
M. Estrogen protects transgenic hypertensive rats by shifting the vasoconstricto
r-vasodilator balance of RAS. <I>Am J Physiol</I> 1997; 273: R1908-R1915. </font
>      ^cY#6682.htm##
00404000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704016200075002000900237#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#57#53#article#109#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Chen YF. Sexual dimorphism of hypertensi
on. <I>Curr Opin Nephrol Hypertens</I> 1996; 5: 181-185. </font>      ^cY#6682.h
tm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020800075002000900283#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#58#54#article#109#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Rowland NE, Fregly MJ. Role of gonadal h
ormones in hypertension in the Dahl salt-sensitive rat. <I>Clin Exp Hypertens A<
/I> 1992; 14: 367-375. </font>      ^cY#6682.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704021000075002000900285#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#59#55#article#109#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Fink GD, Bruner CA, Mangiapane ML. Area 
postrema is critical for angiotensin-induced hypertension in rats. <I>Hypertensi
on</I> 1987; 9: 355-361. </font>      ^cY#6682.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022700075002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#60#56#article#109#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Matsukawa S, Reid IA. Role of the area p
ostrema in the modulation of the baroreflex control of heart rate by angiotensin
 II. <I>Circ Res</I> 1990; 67: 1462-1473. </font>      ^cY#6682.htm##
00554000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031100076002000900387#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#61#57#article#109#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Chabrashvili T, Kitiyakara C, Blau J, 
Karber A, Aslam S, Welch WJ, et al. Effects of ANG II type 1 and 2 receptors on 
oxidative stress, renal NADPH oxidase, and SOD expression. <I>Am J Physiol Regul
 Integr Comp Physiol</I> 2003; 285: R117-R124. </font>      ^cY#6682.htm##
00504000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026100076002000900337#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#62#58#article#109#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Zimmerman MC, Lazartigues E, Lang JA, 
Sinnayah P, Ahmad IM, Spitz DR, et al. Superoxide mediates the actions of angiot
ensin II in the central nervous system. <I>Circ Res</I> 2002; 91: 1038-1045. </f
ont>      ^cY#6682.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023800076002000900314#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#63#59#article#109#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Strehlow K, Rotter S, Wassmann S, Adam
 O, Grohe C, Laufs K, et al. Modulation of antioxidant enzyme expression and fun
ction by estrogen. <I>Circ Res</I> 2003; 93: 170-177. </font>      ^cY#6682.htm#
#
00530000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028700076002000900363#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#64#60#article#109#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Gragasin FS, Xu Y, Arenas IA, Kainth N
, Davidge ST. Estrogen reduces angiotensin II-induced nitric oxide synthase and 
NAD(P)H oxidase expression in endothelial cells. <I>Arterioscler Thromb Vasc Bio
l</I> 2003; 23: 38-44. </font>      ^cY#6682.htm##
00504000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026100076002000900337#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#65#61#article#109#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Hawk T, Zhang YQ, Rajakumar G, Day AL,
 Simpkins JW. Testosterone increases and estradiol decreases middle cerebral art
ery occlusion lesion size in male rats. <I>Brain Res</I> 1998; 796: 296-298. </f
ont>      ^cY#6682.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018600076002000900262#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#66#62#article#109#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Johnson AK, Gross PM. Sensory circumve
ntricular organs and brain homeostatic pathways. <I>FASEB J</I> 1993; 7: 678-686
. </font>      ^cY#6682.htm##
00521000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027800076002000900354#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#67#63#article#109#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Xue B, Gole H, Pamidimukkala J, Hay M.
 Role of the area postrema in angiotensin II modulation of baroreflex control of
 heart rate in conscious mice. <I>Am J Physiol Heart Circ Physiol</I> 2003; 284:
 H1003-H1007. </font>      ^cY#6682.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024000076002000900316#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#68#64#article#109#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Fink GD. Long-term sympatho-excitatory
 effect of angiotensin II: a mechanism of spontaneous and renovascular hypertens
ion. <I>Clin Exp Pharmacol Physiol</I> 1997; 24: 91-95. </font>      ^cY#6682.ht
m##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023000076002000900306#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#69#65#article#109#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Hendel MD, Collister JP. Contribution 
of the subfornical organ to angiotensin II-induced hypertension. <I>Am J Physiol
 Heart Circ Physiol</I> 2005; 288: H680-H685. </font>      ^cY#6682.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026900076002000900345#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#70#66#article#109#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. De Luca LA Jr, Sugawara AM, Menani JV.
 Brain versus peripheral angiotensin II receptors in hypovolaemia: behavioural a
nd cardiovascular implications. <I>Clin Exp Pharmacol Physiol</I> 2000; 27: 437-
442. </font>      ^cY#6682.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022800076002000900304#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#71#67#article#109#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. Bealer SL. Anteroventral third ventric
le periventricular tissue contributes to cardiac baroreflex responses. <I>Clin E
xp Pharmacol Physiol</I> 2000; 27: 460-464. </font>      ^cY#6682.htm##
00496000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025300076002000900329#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#72#68#article#109#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. Xue B, Pamidimukkala J, Hay M. Sex dif
ferences in the development of angiotensin II-induced hypertension in conscious 
mice. <I>Am J Physiol Heart Circ Physiol</I> 2005; 288: H2177-H2184. </font>    
  ^cY#6682.htm##
00496000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025300076002000900329#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#73#69#article#109#22#<P><fon
t face="Arial, Helvetica, sans-serif">22. Doursout MF, Chelly JE, Wouters P, Law
rence C, Liang YY, Buckley JP. Effect of gender in centrally induced angiotensin
 II hypertension in dogs. <I>Hypertension</I> 1990; 15: I-117-I-120. </font>    
  ^cY#6682.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022100076002000900297#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#74#70#article#109#23#<P><fon
t face="Arial, Helvetica, sans-serif">23. Fischer M, Baessler A, Schunkert H. Re
nin angiotensin system and gender differences in the cardiovascular system. <I>C
ardiovasc Res</I> 2002; 53: 672-677. </font>      ^cY#6682.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022900076002000900305#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#75#71#article#109#24#<P><fon
t face="Arial, Helvetica, sans-serif">24. Chen YF, Naftilan AJ, Oparil S. Androg
en-dependent angiotensinogen and renin messenger RNA expression in hypertensive 
rats. <I>Hypertension</I> 1992; 19: 456-463. </font>      ^cY#6682.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021700076002000900293#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#76#72#article#109#25#<P><fon
t face="Arial, Helvetica, sans-serif">25. Lim YK, Retnam L, Bhagavath B, Sethi S
K, bin Ali A, Lim SK. Gonadal effects on plasma ACE activity in mice. <I>Atheros
clerosis</I> 2002; 160: 311-316. </font>      ^cY#6682.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023100076002000900307#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#77#73#article#109#26#<P><fon
t face="Arial, Helvetica, sans-serif">26. Kisley LR, Sakai RR, Fluharty SJ. Estr
ogen decreases hypothalamic angiotensin II AT1 receptor binding and mRNA in the 
female rat. <I>Brain Res</I> 1999; 844: 34-42. </font>      ^cY#6682.htm##
00438000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704019500076002000900271#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#78#74#article#109#27#<P><fon
t face="Arial, Helvetica, sans-serif">27. Mendelsohn ME, Karas RH. Molecular and
 cellular basis of cardiovascular gender differences. <I>Science</I> 2005; 308: 
1583-1587. </font>      ^cY#6682.htm##
00446000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020300076002000900279#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#79#75#article#109#28#<P><fon
t face="Arial, Helvetica, sans-serif">28. Huang A, Kaley G. Gender-specific regu
lation of cardiovascular function: estrogen as key player. <I>Microcirculation</
I> 2004; 11: 9-38. </font>      ^cY#6682.htm##
00507000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026400076002000900340#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#80#76#article#109#29#<P><fon
t face="Arial, Helvetica, sans-serif">29. Pare G, Krust A, Karas RH, Dupont S, A
ronovitz M, Chambon P, et al. Estrogen receptor-alpha mediates the protective ef
fects of estrogen against vascular injury. <I>Circ Res</I> 2002; 90: 1087-1092. 
</font>      ^cY#6682.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024200076002000900318#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#81#77#article#109#30#<P><fon
t face="Arial, Helvetica, sans-serif">30. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, 
Cox D, et al. Abnormal vascular function and hypertension in mice deficient in e
strogen receptor beta. <I>Science</I> 2002; 295: 505-508. </font>      ^cY#6682.
htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024200076002000900318#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#82#78#article#109#31#<P><fon
t face="Arial, Helvetica, sans-serif">31. Saleh MC, Connell BJ, Saleh TM. Autono
mic and cardiovascular reflex responses to central estrogen injection in ovariec
tomized female rats. <I>Brain Res</I> 2000; 879: 105-114. </font>      ^cY#6682.
htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021400076002000900290#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#83#79#article#109#32#<P><fon
t face="Arial, Helvetica, sans-serif">32. Saleh TM, Connell BJ. Centrally mediat
ed effect of 17beta-estradiol on parasympathetic tone in male rats. <I>Am J Phys
iol</I> 1999; 276: R474-R481. </font>      ^cY#6682.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021700076002000900293#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#84#80#article#109#33#<P><fon
t face="Arial, Helvetica, sans-serif">33. Saleh TM, Connell BJ. 17beta-estradiol
 modulates baroreflex sensitivity and autonomic tone of female rats. <I>J Auton 
Nerv Syst</I> 2000; 80: 148-161. </font>      ^cY#6682.htm##
00431000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018800076002000900264#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#85#81#article#109#34#<P><fon
t face="Arial, Helvetica, sans-serif">34. Li Z, Hay M. 17-beta-estradiol modulat
ion of area postrema potassium currents. <I>J Neurophysiol</I> 2000; 84: 1385-13
91. </font>      ^cY#6682.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023100076002000900307#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#86#82#article#109#35#<P><fon
t face="Arial, Helvetica, sans-serif">35. Pamidimukkala J, Hay M. 17beta-estradi
ol inhibits angiotensin II activation of area postrema neurons. <I>Am J Physiol 
Heart Circ Physiol</I> 2003; 285: H1515-H1520. </font>      ^cY#6682.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023600076002000900312#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#87#83#article#109#36#<P><fon
t face="Arial, Helvetica, sans-serif">36. Xue B, Pamidimukkala J, Hay M. Role of
 estrogen receptor alpha in angiotensin II-induced hypertension in conscious fem
ale mice. <I>FASEB J</I> 2005; 19: A617 (Abstract). </font>      ^cY#6682.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030000076002000900376#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#88#84#article#109#37#<P><fon
t face="Arial, Helvetica, sans-serif">37. Xue B, Johnson RF, Beltz T, Johnson AK
, Hay M. Central estrogen attenuates ANG II-induced hypertension in ovariectomiz
ed female mice. <I>Experimental Biology 2006</I>. April 1-5; San Francisco. 2006
. p 37. Late Breaking Abstract 164. </font>      ^cY#6682.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017800076002000900254#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#89#85#article#109#38#<P><fon
t face="Arial, Helvetica, sans-serif">38. Reckelhoff JF. Gender differences in t
he regulation of blood pressure. <I>Hypertension</I> 2001; 37: 1199-1208. </font
>      ^cY#6682.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022800076002000900304#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#90#86#article#109#39#<P><fon
t face="Arial, Helvetica, sans-serif">39. Harshfield GA, Alpert BS, Pulliam DA, 
Somes GW, Wilson DK. Ambulatory blood pressure recordings in children and adoles
cents. <I>Pediatrics</I> 1994; 94: 180-184. </font>      ^cY#6682.htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026700076002000900343#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#91#87#article#109#40#<P><fon
t face="Arial, Helvetica, sans-serif">40. Reckelhoff JF, Zhang H, Srivastava K. 
Gender differences in development of hypertension in spontaneously hypertensive 
rats: role of the renin-angiotensin system. <I>Hypertension</I> 2000; 35: 480-48
3. </font>      ^cY#6682.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024200076002000900318#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#92#88#article#109#41#<P><fon
t face="Arial, Helvetica, sans-serif">41. Ouchi Y, Share L, Crofton JT, Iitake K
, Brooks DP. Sex difference in the development of deoxycorticosterone-salt hyper
tension in the rat. <I>Hypertension</I> 1987; 9: 172-177. </font>      ^cY#6682.
htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026700076002000900343#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#93#89#article#109#42#<P><fon
t face="Arial, Helvetica, sans-serif">42. Reckelhoff JF, Zhang H, Srivastava K, 
Granger JP. Gender differences in hypertension in spontaneously hypertensive rat
s: role of androgens and androgen receptor. <I>Hypertension</I> 1999; 34: 920-92
3. </font>      ^cY#6682.htm##
00424000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018100076002000900257#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#94#90#article#109#43#<P><fon
t face="Arial, Helvetica, sans-serif">43. Dubey RK, Oparil S, Imthurn B, Jackson
 EK. Sex hormones and hypertension. <I>Cardiovasc Res</I> 2002; 53: 688-708. </f
ont>      ^cY#6682.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022700076002000900303#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#95#91#article#109#44#<P><fon
t face="Arial, Helvetica, sans-serif">44. Xue B, Skala K, Pamidimukkala J, Hay M
. Androgens modulate angiotensin II-induced hypertension in conscious male mice.
 <I>FASEB J</I> 2004; 18: A649 (Abstract). </font>      ^cY#6682.htm##
00432000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018900076002000900265#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#96#92#article#109#45#<P><fon
t face="Arial, Helvetica, sans-serif">45. Mates JM, Perez-Gomez C, Nunez de Cast
ro I. Antioxidant enzymes and human diseases. <I>Clin Biochem</I> 1999; 32: 595-
603. </font>      ^cY#6682.htm##
00516000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027300076002000900349#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#97#93#article#109#46#<P><fon
t face="Arial, Helvetica, sans-serif">46. Zimmerman MC, Lazartigues E, Sharma RV
, Davisson RL. Hypertension caused by angiotensin II infusion involves increased
 superoxide production in the central nervous system. <I>Circ Res</I> 2004; 95: 
210-216. </font>      ^cY#6682.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021400076002000900290#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#98#94#article#109#47#<P><fon
t face="Arial, Helvetica, sans-serif">47. Zimmerman MC, Davisson RL. Redox signa
ling in central neural regulation of cardiovascular function. <I>Prog Biophys Mo
l Biol</I> 2004; 84: 125-149. </font>      ^cY#6682.htm##
00539000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029600076002000900372#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#99#95#article#109#48#<P><fon
t face="Arial, Helvetica, sans-serif">48. Pamidimukkala J, Xue B, Hay M. Role of
 ROS in angiotensin II-activation of area postrema (AP) neurons and systemic hyp
ertension. <I>Experimental Biology 2004</I>. April 17-21; Washington. 2004. p A1
03. Late Breaking Abstract 501. </font>      ^cY#6682.htm##
00486000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704024200077002000900319#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#100#96#article#109#49#<P><fo
nt face="Arial, Helvetica, sans-serif">49. Xue B, Zhao Y, Beltz T, Johnson RF, J
ohnson AK, Hay M. The effects of L-NAME and tempol in Ang II induced hypertensio
n in male mice. <I>FASEB J</I> 2006; 20: A1207 (Abstract). </font>      ^cY#6682
.htm##
00500000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704025600077002000900333#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#101#97#article#109#50#<P><fo
nt face="Arial, Helvetica, sans-serif">50. Zhao Y, Pamidimukkala J, Hay M. Angio
tensin II evoked increases in reactive oxygen species in subfornical organ neuro
ns in the living brain slice. <I>FASEB J</I> 2005; 19: A1291 (Abstract). </font>
      ^cY#6682.htm##
00436000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704019200077002000900269#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#102#98#article#109#51#<P><fo
nt face="Arial, Helvetica, sans-serif">51. Vincent SR, Kimura H. Histochemical m
apping of nitric oxide synthase in the rat brain. <I>Neuroscience</I> 1992; 46: 
755-784. </font>      ^cY#6682.htm##
00431000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704018700077002000900264#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#103#99#article#109#52#<P><fo
nt face="Arial, Helvetica, sans-serif">52. Patel KP, Li YF, Hirooka Y. Role of n
itric oxide in central sympathetic outflow. <I>Exp Biol Med</I> 2001; 226: 814-8
24. </font>      ^cY#6682.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026300078002000900341#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#104#100#article#109#53#<P><f
ont face="Arial, Helvetica, sans-serif">53. Hodgin JB, Knowles JW, Kim HS, Smith
ies O, Maeda N. Interactions between endothelial nitric oxide synthase and sex h
ormones in vascular protection in mice. <I>J Clin Invest</I> 2002; 109: 541-548.
 </font>      ^cY#6682.htm##
00561000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031600078002000900394#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#105#101#article#109#54#<P><f
ont face="Arial, Helvetica, sans-serif">54. Rachman IM, Unnerstall JR, Pfaff DW,
 Cohen RS. Regulation of neuronal nitric oxide synthase mRNA in lordosis-relevan
t neurons of the ventromedial hypothalamus following short-term estrogen treatme
nt. <I>Brain Res Mol Brain Res</I> 1998; 59: 105-108. </font>      ^cY#6682.htm#
#
00484000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023900078002000900317#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#106#102#article#109#55#<P><f
ont face="Arial, Helvetica, sans-serif">55. Ceccatelli S, Grandison L, Scott RE,
 Pfaff DW, Kow LM. Estradiol regulation of nitric oxide synthase mRNAs in rat hy
pothalamus. <I>Neuroendocrinology</I> 1996; 64: 357-363. </font>      ^cY#6682.h
tm##
00531000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028600078002000900364#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#107#103#article#109#56#<P><f
ont face="Arial, Helvetica, sans-serif">56. Singh R, Pervin S, Shryne J, Gorski 
R, Chaudhuri G. Castration increases and androgens decrease nitric oxide synthas
e activity in the brain: physiologic implications. <I>Proc Natl Acad Sci U S A</
I> 2000; 97: 3672-3677. </font>      ^cY#6682.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026000078002000900338#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#108#104#article#109#57#<P><f
ont face="Arial, Helvetica, sans-serif">57. Xue B, Skala K, Pamidimukkala J, Hay
 M. Protective effect of central nitric oxide (NO) in angiotensin II-induced hyp
ertension in conscious female mice. <I>FASEB J</I> 2005; 19: A617 (Abstract). </
font>      ^cY#6682.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024200078002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#109#105#article#109#58#<P><f
ont face="Arial, Helvetica, sans-serif">58. Wang YR, Yen CH, Sun YF, Laun YT. Ge
nder-dependent response in blood pressure changes following the inhibition of ni
tric oxide synthase. <I>Chin J Physiol</I> 2003; 46: 91-94. </font>      ^cY#668
2.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029800078002000900376#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#p#110#106#article#109#59#<P><f
ont face="Arial, Helvetica, sans-serif">59. Darley-Usmar VM, McAndrew J, Patel R
, Moellering D, Lincoln TM, Jo H, et al. Nitric oxide, free radicals and cell si
gnalling in cardiovascular disease. <I>Biochem Soc Trans</I> 1997; 25: 925-929.<
/font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6682.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033900075002000900414#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#111#107#article#109#<P class="style4"><A
 NAME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial
, Helvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT
> <A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6
682.htm##
00632000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704040200075002000900477#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#112#108#article#109#<P class="style4"><B
><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a> 
   Address for correspondence: </B><font face="Arial, Helvetica, sans-serif">M. 
   Hay, Vice President for Research University of Iowa, 201 Gilmore Hall, Iowa  
  City, IA 52242, USA. Fax: +1-319-335-2104. E-mail: <a href="mailto:meredith-ha
y@uiowa.edu">meredith-hay@uiowa.edu</a></font>  </P>      ^cY#6682.htm##
00824000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704059400075002000900669#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6682.htm#S#p#113#109#article#109#<P><font face="Arial
, Helvetica, sans-serif">Presented at the International Symposium of Neuroendocr
inology "Neuroendocrine control of body fluid homeostasis: past, present and fut
ure". Ribeir&atilde;o Preto, SP, Brazil, September 1-3, 2006. Research supported
 by the National Heart, Lung, and Blood Institute (HL-59676 and HL-62261 for M. 
Hay), (HL-14388 and HL-57472) and the National Institute of Diabetes and Digesti
ve and Kidney Diseases (DK-66086 for A.K. Johnson). Received October 11, 2006. A
ccepted February 22, 2007.</font><font face="Arial, Helvetica, sans-serif"> </fo
nt>       ^cY#6682.htm##
00684000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100021000930100
02000114010002500134010001600159010001600175012008300191030001500274065000900289
06400050029803100040030301400080030786500090031500200090032403500100033380100150
0343#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#114#1#article#59#1#^
rND^sMesserli^nFH#^rND^sGaravaglia^nGE#^rND^sSchmieder^nRE#^rND^sSundgaard-Riise
^nK#^rND^sNunez^nBD#^rND^sAmodeo^nC#Disparate cardiovascular findings in men and
 women with essential hypertension^len#Ann Intern Med#19870000#1987#107#158-161#
20070500#6682.htm#0003-4819#Ann Intern Med##
00717000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100018000930100
01800111010001700129010001600146010001800162810000600180012011300186030001300299
06500090031206400050032103100040032601400080033086500090033800200090034703500100
0356801001300366#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#115#2#ar
ticle#59#2#^rND^sStampfer^nMJ#^rND^sColditz^nGA#^rND^sWillett^nWC#^rND^sManson^n
JE#^rND^sRosner^nB#^rND^sSpeizer^nFE#et al#Postmenopausal estrogen therapy and c
ardiovascular disease: Ten-year follow-up from the nurses' health study^len#N En
gl J Med#19910000#1991#325#756-762#20070500#6682.htm#0028-4793#N Engl J Med##
00739000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100017000890100
01900106010001500125010001700140010001700157810000600174012014200180030001300322
06500090033506400050034403100030034901400080035286500090036000200090036903500100
0378801001300388#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#116#3#ar
ticle#59#3#^rND^sBurt^nVL#^rND^sWhelton^nP#^rND^sRoccella^nEJ#^rND^sBrown^nC#^rN
D^sCutler^nJA#^rND^sHiggins^nM#et al#Prevalence of hypertension in the US adult 
population: Results from the Third National Health and Nutrition Examination Sur
vey, 1988-1991^len#Hypertension#19950000#1995#25#305-313#20070500#6682.htm#0194-
911X#Hypertension##
00533000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920100
01600108010001500124012004900139030001000188710000200198065000900200064000500209
031000300214014000800217865000900225002000900234#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#117#4#article#59#4#^rND^sStaessen^nJ#^rND^sFagard^nR#^rN
D^sLijnen^nP#^rND^sAmery^nA#The influence of menopause on blood pressure^len#Arc
h Belg#2#19890000#1989#47#118-122#20070500#6682.htm##
00637000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100012000940100
01600106010001900122012011000141030001300251065000900264064000500273031000400278
014001200282865000900294002000900303035001000312801001300322#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#118#5#article#59#5#^rND^sBrosnihan^nKB#^rND^
sLi^nP#^rND^sGanten^nD#^rND^sFerrario^nCM#Estrogen protects transgenic hypertens
ive rats by shifting the vasoconstrictor-vasodilator balance of RAS^len#Am J Phy
siol#19970000#1997#273#R1908-R1915#20070500#6682.htm#0002-9513#Am J Physiol##
00501000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740120038000890300
02800127065000900155064000500164031000200169014000800171865000900179002000900188
035001000197801002800207#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#
119#6#article#59#6#^rND^sChen^nYF#Sexual dimorphism of hypertension^len#Curr Opi
n Nephrol Hypertens#19960000#1996#5#181-185#20070500#6682.htm#1062-4821#Curr Opi
n Nephrol Hypertens##
00558000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100017000920120
07600109030002100185065000900206064000500215031000300220014000800223865000900231
002000900240035001000249801002100259#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#120#7#article#59#7#^rND^sRowland^nNE#^rND^sFregly^nMJ#Role of gonada
l hormones in hypertension in the Dahl salt-sensitive rat^len#Clin Exp Hypertens
 A#19920000#1992#14#367-375#20070500#6682.htm#0730-0077#Clin Exp Hypertens A##
00570000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100017000890100
02100106012007500127030001300202065000900215064000500224031000200229014000800231
865000900239002000900248035001000257801001300267#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#121#8#article#59#8#^rND^sFink^nGD#^rND^sBruner^nCA#^rND^
sMangiapane^nML#Area postrema is critical for angiotensin-induced hypertension i
n rats^len#Hypertension#19870000#1987#9#355-361#20070500#6682.htm#0194-911X#Hype
rtension##
00565000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100015000930120
10600108030000900214065000900223064000500232031000300237014001000240865000900250
002000900259035001000268801000900278#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#122#9#article#59#9#^rND^sMatsukawa^nS#^rND^sReid^nIA#Role of the are
a postrema in the modulation of the baroreflex control of heart rate by angioten
sin II^len#Circ Res#19900000#1990#67#1462-1473#20070500#6682.htm#0009-7330#Circ 
Res##
00704000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100020000980100
01400118010001600132010001500148010001600163810000600179012010600185030003900291
71000020033006500090033206400050034103100040034601400100035086500090036000200090
0369#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#123#10#article#59#10
#^rND^sChabrashvili^nT#^rND^sKitiyakara^nC#^rND^sBlau^nJ#^rND^sKarber^nA#^rND^sA
slam^nS#^rND^sWelch^nWJ#et al#Effects of ANG II type 1 and 2 receptors on oxidat
ive stress, renal NADPH oxidase, and SOD expression^len#Am J Physiol Regul Integ
r Comp Physiol#2#20030000#2003#285#R117-R124#20070500#6682.htm##
00683000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100021000960100
01500117010001800132010001600150010001600166810000600182012008400188030000900272
06500090028106400050029003100030029501400100029886500090030800200090031703500100
0326801000900336#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#124#11#a
rticle#59#11#^rND^sZimmerman^nMC#^rND^sLazartigues^nE#^rND^sLang^nJA#^rND^sSinna
yah^nP#^rND^sAhmad^nIM#^rND^sSpitz^nDR#et al#Superoxide mediates the actions of 
angiotensin II in the central nervous system^len#Circ Res#20020000#2002#91#1038-
1045#20070500#6682.htm#0009-7330#Circ Res##
00660000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01800110010001400128010001500142010001500157810000600172012007300178030000900251
06500090026006400050026903100030027401400080027786500090028500200090029403500100
0303801000900313#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#125#12#a
rticle#59#12#^rND^sStrehlow^nK#^rND^sRotter^nS#^rND^sWassmann^nS#^rND^sAdam^nO#^
rND^sGrohe^nC#^rND^sLaufs^nK#et al#Modulation of antioxidant enzyme expression a
nd function by estrogen^len#Circ Res#20030000#2003#93#170-177#20070500#6682.htm#
0009-7330#Circ Res##
00701000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100012000950100
01700107010001600124010001800140012011800158030003000276065000900306064000500315
031000300320014000600323865000900329002000900338035001000347801003000357#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#126#13#article#59#13#^rND^sGraga
sin^nFS#^rND^sXu^nY#^rND^sArenas^nIA#^rND^sKainth^nN#^rND^sDavidge^nST#Estrogen 
reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase express
ion in endothelial cells^len#Arterioscler Thromb Vasc Biol#20030000#2003#23#38-4
4#20070500#6682.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00655000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01900106010001400125010001900139012010900158030001000267065000900277064000500286
031000400291014000800295865000900303002000900312035001000321801001000331#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#127#14#article#59#14#^rND^sHawk^
nT#^rND^sZhang^nYQ#^rND^sRajakumar^nG#^rND^sDay^nAL#^rND^sSimpkins^nJW#Testoster
one increases and estradiol decreases middle cerebral artery occlusion lesion si
ze in male rats^len#Brain Res#19980000#1998#796#296-298#20070500#6682.htm#0006-8
993#Brain res##
00524000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
06800110030000800178065000900186064000500195031000200200014000800202865000900210
002000900219035001000228801000800238#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#128#15#article#59#15#^rND^sJohnson^nAK#^rND^sGross^nPM#Sensory circu
mventricular organs and brain homeostatic pathways^len#FASEB J#19930000#1993#7#6
78-686#20070500#6682.htm#0892-6638#FASEB j##
00624000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100014000890100
02300103010001300126012011300139030003200252710000200284065000900286064000500295
031000400300014001200304865000900316002000900325#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#129#16#article#59#16#^rND^sXue^nB#^rND^sGole^nH#^rND^sPa
midimukkala^nJ#^rND^sHay^nM#Role of the area postrema in angiotensin II modulati
on of baroreflex control of heart rate in conscious mice^len#Am J Physiol Heart 
Circ Physiol#2#20030000#2003#284#H1003-H1007#20070500#6682.htm##
00579000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120117000910300
02700208065000900235064000500244031000300249014000600252865000900258002000900267
035001000276801002700286#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#
130#17#article#59#17#^rND^sFink^nGD#Long-term sympatho-excitatory effect of angi
otensin II: a mechanism of spontaneous and renovascular hypertension^len#Clin Ex
p Pharmacol Physiol#19970000#1997#24#91-95#20070500#6682.htm#0305-1870#Clin Exp 
Pharmacol Physiol##
00540000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930120
08100113030003200194710000200226065000900228064000500237031000400242014001000246
865000900256002000900265#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#
131#18#article#59#18#^rND^sHendel^nMD#^rND^sCollister^nJP#Contribution of the su
bfornical organ to angiotensin II-induced hypertension^len#Am J Physiol Heart Ci
rc Physiol#2#20050000#2005#288#H680-H685#20070500#6682.htm##
00644000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100019000970100
01700116012011400133030002700247065000900274064000500283031000300288014000800291
865000900299002000900308035001000317801002700327#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#132#19#article#59#19#^rND^sDe^nLuca LA Jr#^rND^sSugawara
^nAM#^rND^sMenani^nJV#Brain versus peripheral angiotensin II receptors in hypovo
laemia: behavioural and cardiovascular implications^len#Clin Exp Pharmacol Physi
ol#20000000#2000#27#437-442#20070500#6682.htm#0305-1870#Clin Exp Pharmacol Physi
ol##
00567000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120101000930300
02700194065000900221064000500230031000300235014000800238865000900246002000900255
035001000264801002700274#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#
133#20#article#59#20#^rND^sBealer^nSL#Anteroventral third ventricle periventricu
lar tissue contributes to cardiac baroreflex responses^len#Clin Exp Pharmacol Ph
ysiol#20000000#2000#27#460-464#20070500#6682.htm#0305-1870#Clin Exp Pharmacol Ph
ysiol##
00581000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100023000890100
01300112012009600125030003200221710000200253065000900255064000500264031000400269
014001200273865000900285002000900294#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#134#21#article#59#21#^rND^sXue^nB#^rND^sPamidimukkala^nJ#^rND^sHay^n
M#Sex differences in the development of angiotensin II-induced hypertension in c
onscious mice^len#Am J Physiol Heart Circ Physiol#2#20050000#2005#288#H2177-H218
4#20070500#6682.htm##
00668000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
01700112010001800129010001600147010001800163012007800181030001300259065000900272
06400050028103100030028601400120028986500090030100200090031003500100031980100130
0329#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#135#22#article#59#22
#^rND^sDoursout^nMF#^rND^sChelly^nJE#^rND^sWouters^nP#^rND^sLawrence^nC#^rND^sLi
ang^nYY#^rND^sBuckley^nJP#Effect of gender in centrally induced angiotensin II h
ypertension in dogs^len#Hypertension#19900000#1990#15#I-117-I-120#20070500#6682.
htm#0194-911X#Hypertension##
00584000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01900111012008100130030001500211065000900226064000500235031000300240014000800243
865000900251002000900260035001000269801001500279#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#136#23#article#59#23#^rND^sFischer^nM#^rND^sBaessler^nA#
^rND^sSchunkert^nH#Renin angiotensin system and gender differences in the cardio
vascular system^len#Cardiovasc Res#20020000#2002#53#672-677#20070500#6682.htm#00
08-6363#Cardiovasc Res##
00590000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100019000910100
01600110012009500126030001300221065000900234064000500243031000300248014000800251
865000900259002000900268035001000277801001300287#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#137#24#article#59#24#^rND^sChen^nYF#^rND^sNaftilan^nAJ#^
rND^sOparil^nS#Androgen-dependent angiotensinogen and renin messenger RNA expres
sion in hypertensive rats^len#Hypertension#19920000#1992#19#456-463#20070500#668
2.htm#0194-911X#Hypertension##
00635000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01900106010001600125010001700141010001400158012005100172030001600223065000900239
06400050024803100040025301400080025786500090026500200090027403500100028380100160
0293#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#138#25#article#59#25
#^rND^sLim^nYK#^rND^sRetnam^nL#^rND^sBhagavath^nB#^rND^sSethi^nSK#^rND^sbin^nAli
 A#^rND^sLim^nSK#Gonadal effects on plasma ACE activity in mice^len#Atherosclero
sis#20020000#2002#160#311-316#20070500#6682.htm#0021-9150#Atherosclerosis##
00589000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01900109012009900128030001000227065000900237064000500246031000400251014000600255
865000900261002000900270035001000279801001000289#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#139#26#article#59#26#^rND^sKisley^nLR#^rND^sSakai^nRR#^r
ND^sFluharty^nSJ#Estrogen decreases hypothalamic angiotensin II AT1 receptor bin
ding and mRNA in the female rat^len#Brain Res#19990000#1999#844#34-42#20070500#6
682.htm#0006-8993#Brain res##
00533000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100016000970120
07000113030000800183065000900191064000500200031000400205014001000209865000900219
002000900228035001000237801000800247#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#140#27#article#59#27#^rND^sMendelsohn^nME#^rND^sKaras^nRH#Molecular 
and cellular basis of cardiovascular gender differences^len#Science#20050000#200
5#308#1583-1587#20070500#6682.htm#0036-8075#Science##
00550000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910120
08200106030001700188065000900205064000500214031000300219014000500222865000900227
002000900236035001000245801001700255#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#141#28#article#59#28#^rND^sHuang^nA#^rND^sKaley^nG#Gender-specific r
egulation of cardiovascular function: estrogen as key player^len#Microcirculatio
n#20040000#2004#11#9-38#20070500#6682.htm#0275-4177#MICROCIRCULATION##
00686000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100015000900100
01600105010001600121010001900137010001700156810000600173012009600179030000900275
06500090028406400050029303100030029801400100030186500090031100200090032003500100
0329801000900339#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#142#29#a
rticle#59#29#^rND^sPare^nG#^rND^sKrust^nA#^rND^sKaras^nRH#^rND^sDupont^nS#^rND^s
Aronovitz^nM#^rND^sChambon^nP#et al#Estrogen receptor-alpha mediates the protect
ive effects of estrogen against vascular injury^len#Circ Res#20020000#2002#90#10
87-1092#20070500#6682.htm#0009-7330#Circ Res##
00663000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100014000890100
01200103010001600115010001300131010001300144810000600157012009200163030000800255
06500090026306400050027203100040027701400080028186500090028900200090029803500100
0307801000800317#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#143#30#a
rticle#59#30#^rND^sZhu^nY#^rND^sBian^nZ#^rND^sLu^nP#^rND^sKaras^nRH#^rND^sBao^nL
#^rND^sCox^nD#et al#Abnormal vascular function and hypertension in mice deficien
t in estrogen receptor beta^len#Science#20020000#2002#295#505-508#20070500#6682.
htm#0036-8075#Science##
00600000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01600110012011000126030001000236065000900246064000500255031000400260014000800264
865000900272002000900281035001000290801001000300#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#144#31#article#59#31#^rND^sSaleh^nMC#^rND^sConnell^nBJ#^
rND^sSaleh^nTM#Autonomic and cardiovascular reflex responses to central estrogen
 injection in ovariectomized female rats^len#Brain Res#20000000#2000#879#105-114
#20070500#6682.htm#0006-8993#Brain res##
00557000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
08700110030001300197065000900210064000500219031000400224014001000228865000900238
002000900247035001000256801001300266#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#145#32#article#59#32#^rND^sSaleh^nTM#^rND^sConnell^nBJ#Centrally med
iated effect of 17beta-estradiol on parasympathetic tone in male rats^len#Am J P
hysiol#19990000#1999#276#R474-R481#20070500#6682.htm#0002-9513#Am J Physiol##
00565000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
08800110030001800198065000900216064000500225031000300230014000800233865000900241
002000900250035001000259801001800269#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#146#33#article#59#33#^rND^sSaleh^nTM#^rND^sConnell^nBJ#17beta-estrad
iol modulates baroreflex sensitivity and autonomic tone of female rats^len#J Aut
on Nerv Syst#20000000#2000#80#148-161#20070500#6682.htm#0165-1838#J Auton Nerv S
yst##
00533000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100013000880120
06900101030001500170065000900185064000500194031000300199014001000202865000900212
002000900221035001000230801001500240#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#147#34#article#59#34#^rND^sLi^nZ#^rND^sHay^nM#17-beta-estradiol modu
lation of area postrema potassium currents^len#J Neurophysiol#20000000#2000#84#1
385-1391#20070500#6682.htm#0022-3077#J Neurophysiol##
00541000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100013000990120
08100112030003200193710000200225065000900227064000500236031000400241014001200245
865000900257002000900266#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#
148#35#article#59#35#^rND^sPamidimukkala^nJ#^rND^sHay^nM#17beta-estradiol inhibi
ts angiotensin II activation of area postrema neurons^len#Am J Physiol Heart Cir
c Physiol#2#20030000#2003#285#H1515-H1520#20070500#6682.htm##
00602000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100023000890100
01300112012010000125030000800225065000900233064000500242031000300247014000500250
061000900255865000900264002000900273035001000282801000800292#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#149#36#article#59#36#^rND^sXue^nB#^rND^sPami
dimukkala^nJ#^rND^sHay^nM#Role of estrogen receptor alpha in angiotensin II-indu
ced hypertension in conscious female mice^len#FASEB J#20050000#2005#19#A617#Abst
ract#20070500#6682.htm#0892-6638#FASEB j##
00666000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100018000890100
01500107010001800122010001300140012009000153030002600243710000200269065000900271
064001000280066001400290014000300304061002700307865000900334002000900343#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#150#37#article#59#37#^rND^sXue^n
B#^rND^sJohnson^nRF#^rND^sBeltz^nT#^rND^sJohnson^nAK#^rND^sHay^nM#Central estrog
en attenuates ANG II-induced hypertension in ovariectomized female mice^len#Expe
rimental Biology 2006#2#20060401#April 1-5#San Francisco#37#Late Breaking Abstra
ct 164#20070500#6682.htm##
00503000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760120059000970300
01300156065000900169064000500178031000300183014001000186865000900196002000900205
035001000214801001300224#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#
151#38#article#59#38#^rND^sReckelhoff^nJF#Gender differences in the regulation o
f blood pressure^len#Hypertension#20010000#2001#37#1199-1208#20070500#6682.htm#0
194-911X#Hypertension##
00623000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100017000970100
01800114010001600132010001700148012006900165030001100234065000900245064000500254
031000300259014000800262865000900270002000900279035001000288801001100298#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#152#39#article#59#39#^rND^sHarsh
field^nGA#^rND^sAlpert^nBS#^rND^sPulliam^nDA#^rND^sSomes^nGW#^rND^sWilson^nDK#Am
bulatory blood pressure recordings in children and adolescents^len#Pediatrics#19
940000#1994#94#180-184#20070500#6682.htm#0031-4005#Pediatrics##
00628000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100015000970100
02000112012012700132030001300259065000900272064000500281031000300286014000800289
865000900297002000900306035001000315801001300325#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#153#40#article#59#40#^rND^sReckelhoff^nJF#^rND^sZhang^nH
#^rND^sSrivastava^nK#Gender differences in development of hypertension in sponta
neously hypertensive rats: role of the renin-angiotensin system^len#Hypertension
#20000000#2000#35#480-483#20070500#6682.htm#0194-911X#Hypertension##
00639000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
01800106010001600124010001700140012009000157030001300247065000900260064000500269
031000200274014000800276865000900284002000900293035001000302801001300312#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#154#41#article#59#41#^rND^sOuchi
^nY#^rND^sShare^nL#^rND^sCrofton^nJT#^rND^sIitake^nK#^rND^sBrooks^nDP#Sex differ
ence in the development of deoxycorticosterone-salt hypertension in the rat^len#
Hypertension#19870000#1987#9#172-177#20070500#6682.htm#0194-911X#Hypertension##
00646000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100015000970100
02000112010001800132012011500150030001300265065000900278064000500287031000300292
014000800295865000900303002000900312035001000321801001300331#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#155#42#article#59#42#^rND^sReckelhoff^nJF#^r
ND^sZhang^nH#^rND^sSrivastava^nK#^rND^sGranger^nJP#Gender differences in hyperte
nsion in spontaneously hypertensive rats: role of androgens and androgen recepto
r^len#Hypertension#19990000#1999#34#920-923#20070500#6682.htm#0194-911X#Hyperten
sion##
00562000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01700108010001800125012003400143030001500177065000900192064000500201031000300206
014000800209865000900217002000900226035001000235801001500245#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#156#43#article#59#43#^rND^sDubey^nRK#^rND^sO
paril^nS#^rND^sImthurn^nB#^rND^sJackson^nEK#Sex hormones and hypertension^len#Ca
rdiovasc Res#20020000#2002#53#688-708#20070500#6682.htm#0008-6363#Cardiovasc Res
##
00611000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100015000890100
02300104010001300127012008200140030000800222065000900230064000500239031000300244
014000500247061000900252865000900261002000900270035001000279801000800289#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#157#44#article#59#44#^rND^sXue^n
B#^rND^sSkala^nK#^rND^sPamidimukkala^nJ#^rND^sHay^nM#Androgens modulate angioten
sin II-induced hypertension in conscious male mice^len#FASEB J#20040000#2004#18#
A649#Abstract#20070500#6682.htm#0892-6638#FASEB j##
00550000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100021000920100
02500113012004300138030001300181065000900194064000500203031000300208014000800211
865000900219002000900228035001000237801001300247#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#158#45#article#59#45#^rND^sMates^nJM#^rND^sPerez-Gomez^n
C#^rND^sNunez^nde Castro I#Antioxidant enzymes and human diseases^len#Clin Bioch
em#19990000#1999#32#595-603#20070500#6682.htm#0009-9120#Clin Biochem##
00648000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100021000960100
01700117010001900134012012200153030000900275065000900284064000500293031000300298
014000800301865000900309002000900318035001000327801000900337#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#159#46#article#59#46#^rND^sZimmerman^nMC#^rN
D^sLazartigues^nE#^rND^sSharma^nRV#^rND^sDavisson^nRL#Hypertension caused by ang
iotensin II infusion involves increased superoxide production in the central ner
vous system^len#Circ Res#20040000#2004#95#210-216#20070500#6682.htm#0009-7330#Ci
rc Res##
00566000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960120
07600115030002200191065000900213064000500222031000300227014000800230865000900238
002000900247035001000256801002200266#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#160#47#article#59#47#^rND^sZimmerman^nMC#^rND^sDavisson^nRL#Redox si
gnaling in central neural regulation of cardiovascular function^len#Prog Biophys
 Mol Biol#20040000#2004#84#125-149#20070500#6682.htm#0079-6107#Prog Biophys Mol 
Biol##
00626000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100013000990100
01300112012010100125030002600226710000200252065000900254064001200263066001100275
014000500286061002700291865000900318002000900327#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#161#48#article#59#48#^rND^sPamidimukkala^nJ#^rND^sXue^nB
#^rND^sHay^nM#Role of ROS in angiotensin II-activation of area postrema (AP) neu
rons and systemic hypertension^len#Experimental Biology 2004#2#20040417#April 17
-21#Washington#A103#Late Breaking Abstract 501#20070500#6682.htm##
00662000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100014000890100
01500103010001800118010001800136010001300154012008100167030000800248065000900256
06400050026503100030027001400060027306100090027986500090028800200090029703500100
0306801000800316#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#162#49#a
rticle#59#49#^rND^sXue^nB#^rND^sZhao^nY#^rND^sBeltz^nT#^rND^sJohnson^nRF#^rND^sJ
ohnson^nAK#^rND^sHay^nM#The effects of L-NAME and tempol in Ang II induced hyper
tension in male mice^len#FASEB J#20060000#2006#20#A1207#Abstract#20070500#6682.h
tm#0892-6638#FASEB j##
00622000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100023000900100
01300113012011800126030000800244065000900252064000500261031000300266014000600269
061000900275865000900284002000900293035001000302801000800312#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#163#50#article#59#50#^rND^sZhao^nY#^rND^sPam
idimukkala^nJ#^rND^sHay^nM#Angiotensin II evoked increases in reactive oxygen sp
ecies in subfornical organ neurons in the living brain slice^len#FASEB J#2005000
0#2005#19#A1291#Abstract#20070500#6682.htm#0892-6638#FASEB j##
00535000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
06800110030001300178065000900191064000500200031000300205014000800208865000900216
002000900225035001000234801001300244#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
682.htm#S#c#164#51#article#59#51#^rND^sVincent^nSR#^rND^sKimura^nH#Histochemical
 mapping of nitric oxide synthase in the rat brain^len#Neuroscience#19920000#199
2#46#755-784#20070500#6682.htm#0306-4522#Neuroscience##
00548000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100013000920100
01700105012005600122030001300178065000900191064000500200031000400205014000800209
865000900217002000900226035001000235801001300245#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6682.htm#S#c#165#52#article#59#52#^rND^sPatel^nKP#^rND^sLi^nYF#^rND^s
Hirooka^nY#Role of nitric oxide in central sympathetic outflow^len#Exp Biol Med#
20010000#2001#226#814-824#20070500#6682.htm#0071-3384#Exp Biol Med##
00661000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01400111010001800125010001500143012010700158030001400265065000900279064000500288
031000400293014000800297865000900305002000900314035001000323801001400333#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#166#53#article#59#53#^rND^sHodgi
n^nJB#^rND^sKnowles^nJW#^rND^sKim^nHS#^rND^sSmithies^nO#^rND^sMaeda^nN#Interacti
ons between endothelial nitric oxide synthase and sex hormones in vascular prote
ction in mice^len#J Clin Invest#20020000#2002#109#541-548#20070500#6682.htm#0021
-9738#J Clin Invest##
00706000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100021000940100
01600115010001600131012015600147030002400303065000900327064000500336031000300341
014000800344865000900352002000900361035001000370801002400380#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#167#54#article#59#54#^rND^sRachman^nIM#^rND^
sUnnerstall^nJR#^rND^sPfaff^nDW#^rND^sCohen^nRS#Regulation of neuronal nitric ox
ide synthase mRNA in lordosis-relevant neurons of the ventromedial hypothalamus 
following short-term estrogen treatment^len#Brain Res Mol Brain Res#19980000#199
8#59#105-108#20070500#6682.htm#0169-328X#Brain Res Mol Brain Res##
00642000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960100
01600115010001600131010001400147012007600161030001900237065000900256064000500265
031000300270014000800273865000900281002000900290035001000299801001900309#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#168#55#article#59#55#^rND^sCecca
telli^nS#^rND^sGrandison^nL#^rND^sScott^nRE#^rND^sPfaff^nDW#^rND^sKow^nLM#Estrad
iol regulation of nitric oxide synthase mRNAs in rat hypothalamus^len#Neuroendoc
rinology#19960000#1996#64#357-363#20070500#6682.htm#0028-3835#Neuroendocrinology
##
00695000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01600107010001600123010001900139012011800158030002500276065000900301064000500310
031000300315014001000318865000900328002000900337035001000346801002500356#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#169#56#article#59#56#^rND^sSingh
^nR#^rND^sPervin^nS#^rND^sShryne^nJ#^rND^sGorski^nR#^rND^sChaudhuri^nG#Castratio
n increases and androgens decrease nitric oxide synthase activity in the brain: 
physiologic implications^len#Proc Natl Acad Sci U S A#20000000#2000#97#3672-3677
#20070500#6682.htm#0027-8424#Proc Natl Acad Sci U S A##
00644000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100015000890100
02300104010001300127012011500140030000800255065000900263064000500272031000300277
014000500280061000900285865000900294002000900303035001000312801000800322#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#170#57#article#59#57#^rND^sXue^n
B#^rND^sSkala^nK#^rND^sPamidimukkala^nJ#^rND^sHay^nM#Protective effect of centra
l nitric oxide (NO) in angiotensin II-induced hypertension in conscious female m
ice^len#FASEB J#20050000#2005#19#A617#Abstract#20070500#6682.htm#0892-6638#FASEB
 j##
00623000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100014000910100
01400105010001500119012010600134030001500240065000900255064000500264031000300269
014000600272865000900278002000900287035001000296801001500306#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6682.htm#S#c#171#58#article#59#58#^rND^sWang^nYR#^rND^sYe
n^nCH#^rND^sSun^nYF#^rND^sLaun^nYT#Gender-dependent response in blood pressure c
hanges following the inhibition of nitric oxide synthase^len#Chin J Physiol#2003
0000#2003#46#91-94#20070500#6682.htm#0304-4920#Chin J Physiol##
00693000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100018000990100
01500117010002000132010001800152010001200170810000600182012007800188030001800266
06500090028406400050029303100030029801400080030186500090030900200090031803500100
0327801001800337#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6682.htm#S#c#172#59#a
rticle#59#59#^rND^sDarley-Usmar^nVM#^rND^sMcAndrew^nJ#^rND^sPatel^nR#^rND^sMoell
ering^nD#^rND^sLincoln^nTM#^rND^sJo^nH#et al#Nitric oxide, free radicals and cel
l signalling in cardiovascular disease^len#Biochem Soc Trans#19970000#1997#25#92
5-929#20070500#6682.htm#0300-5127#Biochem Soc Trans##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#o#1#1#article#1#20
080212#125734#6683.htm#167##
03171000000000817000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400110014003500100015122300090016101200680
01700100019002380100018002570100018002750100020002930100018003130100022003310700
05800353070006700411070006100478083115600539085000801695085002601703085004301729
08500180177208500230179008500330181311700060184607200030185205800050185506000090
18600580027018690600012018960580030019080600010019380580034019480600009019820580
03201991060000802023058001702031060000802048058004102056060000902097053012602106
05500120223205400230224411200090226711100170227611400090229311300180230288100240
2320002000902344#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#h#2#1#arti
cle#1#ra#en#bjmbr#1#3.1#TAB#19#BJMBR700#nd#Braz J Med Biol Res#40#5#20070500#^f7
35^l741#0100-879X#20070326#Development of fetal nicotine and muscarinic receptor
s in utero^len#^rND^1A01^nC.^sMao#^rND^1A01^nJ.^sLv#^rND^1A03^nH.^sLi#^rND^1A01^
nY.^sChen#^rND^1A01^nJ.^sWu#^rND^1A01 A02^nZ.^sXu#Soochow University School of M
edicine^iA01^cSuzhou^pChina#Loma Linda University School of Medicine^iA02^cLoma 
Linda^sCA^pUSA#Suzhou Hospital^iA03^1Center for Reproduction^cSuzhou^pChina#^len
^aThe role of acetylcholine in the central and peripheral nervous systems is wel
l established in adults. Cholinergic modulation of vascular functions and body f
luid balance has been extensively studied. In the embryo-fetus, cholinergic rece
ptors are widespread in the peripheral and central systems, including smooth mus
cle and the epithelial lining of the cardiovascular, digestive, and urinary syst
ems, as well as in the brain. Fetal nicotine and muscarinic receptors develop in
 a pattern (e.g., amount and distribution) related to gestational periods. Choli
nergic mechanisms have been found to be relatively intact and functional in the 
control of vascular homeostasis during fetal life in utero at least during the l
ast third of gestation. This review focuses on the development of fetal nicotine
 and muscarinic receptors, and provides information indicating that central chol
inergic systems are well developed in the control of fetal blood pressure and bo
dy fluid balance before birth. Therefore, the development of cholinergic systems
 in utero plays an important role in fetal vascular regulation, gastrointestinal
 motility, and urinary control.#^dnd^i1#^tm^len^kAcetylcholine^i1#^tm^len^kMusca
rinic/nicotinic receptors^i1#^tm^len^kFetus^i1#^tm^len^kSwallowing^i1#^tm^len^kV
ascular homeostasis^i1#other#60#NSFC#30570915#JiangSu High Education NSF#05KJB31
0109#JiangSu NSF Key Project Grant#BK2006703#Soochow University Research Grant#E
E134501#Suzhou Social Development Grant#ssy0632#Suzhou Key Grant#SZS0602#Soochow
 University Program Project Grant#90134602#International Symposium of Neuroendoc
rinology "Neuroendocrine control of body fluid homeostasis: past, present and fu
ture"^i1#20060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#20070213#F
ebruary 13, 2007#S0100-879X2006005000094#6683.htm##
03194000000000829000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400110014003500100015122300090016101200680
01700100019002380100018002570100018002750100020002930100018003130100022003310700
05800353070006700411070006100478083115600539085000801695085002601703085004301729
08500180177208500230179008500330181311700060184607200030185205800050185506000090
18600580027018690600012018960580030019080600010019380580034019480600009019820580
03201991060000802023058001702031060000802048058004102056060000902097053012602106
05600250223205700100225705500120226705400230227911200090230211100170231111400090
2328113001802337002000902355#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#
S#f#3#1#article#1#ra#en#bjmbr#1#3.1#TAB#19#BJMBR700#nd#Braz J Med Biol Res#40#5#
20070500#^f735^l741#0100-879X#20070326#Development of fetal nicotine and muscari
nic receptors in utero^len#^rND^1A01^nC.^sMao#^rND^1A01^nJ.^sLv#^rND^1A03^nH.^sL
i#^rND^1A01^nY.^sChen#^rND^1A01^nJ.^sWu#^rND^1A01 A02^nZ.^sXu#Soochow University
 School of Medicine^iA01^cSuzhou^pChina#Loma Linda University School of Medicine
^iA02^cLoma Linda^sCA^pUSA#Suzhou Hospital^iA03^1Center for Reproduction^cSuzhou
^pChina#^len^aThe role of acetylcholine in the central and peripheral nervous sy
stems is well established in adults. Cholinergic modulation of vascular function
s and body fluid balance has been extensively studied. In the embryo-fetus, chol
inergic receptors are widespread in the peripheral and central systems, includin
g smooth muscle and the epithelial lining of the cardiovascular, digestive, and 
urinary systems, as well as in the brain. Fetal nicotine and muscarinic receptor
s develop in a pattern (e.g., amount and distribution) related to gestational pe
riods. Cholinergic mechanisms have been found to be relatively intact and functi
onal in the control of vascular homeostasis during fetal life in utero at least 
during the last third of gestation. This review focuses on the development of fe
tal nicotine and muscarinic receptors, and provides information indicating that 
central cholinergic systems are well developed in the control of fetal blood pre
ssure and body fluid balance before birth. Therefore, the development of choline
rgic systems in utero plays an important role in fetal vascular regulation, gast
rointestinal motility, and urinary control.#^dnd^i1#^tm^len^kAcetylcholine^i1#^t
m^len^kMuscarinic/nicotinic receptors^i1#^tm^len^kFetus^i1#^tm^len^kSwallowing^i
1#^tm^len^kVascular homeostasis^i1#other#60#NSFC#30570915#JiangSu High Education
 NSF#05KJB310109#JiangSu NSF Key Project Grant#BK2006703#Soochow University Rese
arch Grant#EE134501#Suzhou Social Development Grant#ssy0632#Suzhou Key Grant#SZS
0602#Soochow University Program Project Grant#90134602#International Symposium o
f Neuroendocrinology "Neuroendocrine control of body fluid homeostasis: past, pr
esent and future"^i1#Ribeirão Preto^i1^eSP^i1#Brazil^i1#20060901^i1#September 1-
3, 2006^i1#20061011#October 11, 2006#20070213#February 13, 2007#6683.htm##
03323000000000853000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000400099121000300103049000900106158000300115
03000240011803100030014203200020014506500090014701400110015603500100016722300090
01770120068001860100018002540100017002720100017002890100019003060100017003250100
02100342070006000363070006900423070006300492083115600555085000801711085002601719
08500430174508500180178808500230180608500330182911700060186207200030186805800050
18710600009018760580027018850600012019120580030019240600010019540580034019640600
00901998058003202007060000802039058001702047060000802064058004102072060000902113
05301260212205600250224805700100227305500120228305400230229511200090231811100170
2327114000902344113001802353002000902371008008902380#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6683.htm#S#l#4#1#article#1#^mMay^a2007#ra#en#bjmbr#1#3.1#tab#19#B
JMBR700#nd#Braz. j. med. biol. res#40#5#20070500#^f735^l741#0100-879X#20070326#D
evelopment of fetal nicotine and muscarinic receptors in utero^len#^rND^1A01^nC^
sMao#^rND^1A01^nJ^sLv#^rND^1A03^nH^sLi#^rND^1A01^nY^sChen#^rND^1A01^nJ^sWu#^rND^
1A01 A02^nZ^sXu#^iA01^1Soochow University School of Medicine^cSuzhou^pChina#^iA0
2^1Loma Linda University School of Medicine^cLoma Linda^sCA^pUSA#^iA03^1Suzhou H
ospital^2Center for Reproduction^cSuzhou^pChina#^len^aThe role of acetylcholine 
in the central and peripheral nervous systems is well established in adults. Cho
linergic modulation of vascular functions and body fluid balance has been extens
ively studied. In the embryo-fetus, cholinergic receptors are widespread in the 
peripheral and central systems, including smooth muscle and the epithelial linin
g of the cardiovascular, digestive, and urinary systems, as well as in the brain
. Fetal nicotine and muscarinic receptors develop in a pattern (e.g., amount and
 distribution) related to gestational periods. Cholinergic mechanisms have been 
found to be relatively intact and functional in the control of vascular homeosta
sis during fetal life in utero at least during the last third of gestation. This
 review focuses on the development of fetal nicotine and muscarinic receptors, a
nd provides information indicating that central cholinergic systems are well dev
eloped in the control of fetal blood pressure and body fluid balance before birt
h. Therefore, the development of cholinergic systems in utero plays an important
 role in fetal vascular regulation, gastrointestinal motility, and urinary contr
ol.#^dnd^i1#^tm^len^kAcetylcholine^i1#^tm^len^kMuscarinic/nicotinic receptors^i1
#^tm^len^kFetus^i1#^tm^len^kSwallowing^i1#^tm^len^kVascular homeostasis^i1#other
#60#NSFC#30570915#JiangSu High Education NSF#05KJB310109#JiangSu NSF Key Project
 Grant#BK2006703#Soochow University Research Grant#EE134501#Suzhou Social Develo
pment Grant#ssy0632#Suzhou Key Grant#SZS0602#Soochow University Program Project 
Grant#90134602#International Symposium of Neuroendocrinology "Neuroendocrine con
trol of body fluid homeostasis: past, present and future"^i1#Ribeirão Preto^i1^e
SP^i1#Brazil^i1#20060901^i1#September 1-3, 2006^i1#20061011#October 11, 2006#200
70213#February 13, 2007#6683.htm#Internet^ihttp://www.scielo.br/scielo.php?scrip
t=sci_arttext&pid=S0100-879X2007000500019##
00402000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017600071002000900247#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#5#1#article#103#<P class="style4"> <A NA
ME="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">
<B>May 2007, Volume 40(5) 735-741</B> </font> (Review)</B></P>      ^cY#6683.htm
##
00395000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704016900071002000900240#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#6#2#article#103#<P class="style2"><B><fo
nt size="5" face="Arial, Helvetica, sans-serif">Development of fetal nicotine an
d muscarinic receptors <I>in utero</I></font></B> </P>       ^cY#6683.htm##
00813000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704058700071002000900658#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#7#3#article#103#<P><font face="Arial, He
lvetica, sans-serif">C. Mao<SUP>1</SUP>, J. Lv<SUP>1</SUP>,    H. Li<SUP>3</SUP>
, Y. Chen<SUP>1</SUP>, J. Wu<SUP>1</SUP> and <span class="style4"><a href="#Corr
espondence"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a>    <a
 href="mailto:xuzhice@suda.edu.cn"><img src="/img/revistas/bjmbr/v40n5/email-ca.
gif" border="0"></a></span></font>    <font face="Arial, Helvetica, sans-serif">
<span class="style4"><a href="mailto:zxu@llu.edu"><img src="/img/revistas/bjmbr/
v40n5/email-ca.gif" border="0"></a></span>    Z. Xu<sup>1,2</sup> </font>      ^
cY#6683.htm##
00344000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704011800071002000900189#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#8#4#article#103#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Soochow University School of Medicine, Suzhou, 
China     ^cY#6683.htm##
00320000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704009400071002000900165#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#9#5#article#103#<br>        <SUP>2</SUP>
Loma Linda University School of Medicine, Loma Linda, CA, USA     ^cY#6683.htm##
00324000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704009700072002000900169#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#10#6#article#103#<br>        <SUP>3</SUP
>Center for Reproduction, Suzhou Hospital, Suzhou, China</font>       ^cY#6683.h
tm##
00466000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704023900072002000900311#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#11#7#article#103#<P class="style4"> <A H
REF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Hel
vetica, sans-serif">Abstract</font></strong></A>    ^cY#6683.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021500072002000900287#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#12#8#article#103#<BR>   <A HREF="#Text">
<img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">
Text</font></strong></A>    ^cY#6683.htm##
00447000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704022000072002000900292#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#13#9#article#103#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, 
sans-serif">References</font>    ^cY#6683.htm##
00506000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027800073002000900351#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#14#10#article#103#<br>   </strong></A> <
A HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font f
ace="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></stron
g></a>      ^cY#6683.htm##
00292000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704006400073002000900137#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#15#11#article#103#<P class="style4">  <H
R ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6683.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038500073002000900458#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#16#12#article#103#<P class="style4"> <A 
NAME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helv
etica, sans-serif" size="4">Abstract</font><FONT COLOR=#00007F>    </FONT></span
><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>  <font fac
e="Arial, Helvetica, sans-serif">      ^cY#6683.htm##
01405000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704117700073002000901250#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#17#13#article#103#<P>The role of acetylc
holine in the central and peripheral nervous systems is well established in adul
ts. Cholinergic modulation of vascular functions and body fluid balance has been
 extensively studied. In the embryo-fetus, cholinergic receptors are widespread 
in the peripheral and central systems, including smooth muscle and the epithelia
l lining of the cardiovascular, digestive, and urinary systems, as well as in th
e brain. Fetal nicotine and muscarinic receptors develop in a pattern (e.g., amo
unt and distribution) related to gestational periods. Cholinergic mechanisms hav
e been found to be relatively intact and functional in the control of vascular h
omeostasis during fetal life <I>in utero</I> at least during the last third of g
estation. This review focuses on the development of fetal nicotine and muscarini
c receptors, and provides information indicating that central cholinergic system
s are well developed in the control of fetal blood pressure and body fluid balan
ce before birth. Therefore, the development of cholinergic systems <I>in utero</
I> plays an important role in fetal vascular regulation, gastrointestinal motili
ty, and urinary control.       ^cY#6683.htm##
00388000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016000073002000900233#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#18#14#article#103#<P><B>Key words: </B> 
Acetylcholine, Muscarinic/nicotinic receptors, Fetus, Swallowing, Vascular homeo
stasis </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6683.htm##
00624000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039600073002000900469#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#19#15#article#103#<P class="style4"><A N
AME="Text"></A> <span class="style3"><font color="#00007F" face="Arial, Helvetic
a, sans-serif" size="4">Text</font></span><A HREF="#Home"><FONT SIZE=4><B><img s
rc="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 
LOOP="0"></B></FONT></A>    <font face="Arial, Helvetica, sans-serif"></font></P
> <font face="Arial, Helvetica, sans-serif">      ^cY#6683.htm##
00714000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704048600073002000900559#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#20#16#article#103#<P>Cholinergic systems
 play an important role in body fluid and vascular regulation. Progress has been
 made in demonstrating that <I>in utero</I> development can have an impact on pr
enatal and postnatal health, and certain putative mechanisms, including choliner
gic mechanisms, have been proposed. The present mini-review focuses on the progr
ess in the development of cholinergic receptors and on how cholinergic mechanism
s mediate fetal vascular and body fluid regulation.         ^cY#6683.htm##
00341000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011300073002000900186#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#21#17#article#103#<P><B>Development of p
eripheral cholinergic receptors in the heart, urinary, and digestive systems </B
>      ^cY#6683.htm##
00291000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704006300073002000900136#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#22#18#article#103#<P><b>Fetal cardiovasc
ular systems </b>       </font>      ^cY#6683.htm##
00875000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704064700073002000900720#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#23#19#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Acetylcholine (ACh) acts as a transmitter in the developi
ng heart of humans. Muscarinic responses to ACh can be detected from the 4th pos
t-conception week onwards after the initiation of the first heartbeats. Under <I
>in vitro</I> conditions, muscarinic-cholinergic transmission can be demonstrate
d in 10- to 12-week-old human hearts and the <I>in utero</I> fetal tachycardiac 
response to atropine can be demonstrated within 15-17 weeks. The parasympathetic
-cholinergic control of the developing human heart then becomes functional and p
lays a role in antenatal cardiac functions (1). </font>      ^cY#6683.htm##
02271000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704204300073002000902116#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#24#20#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Muscarinic agonists inhibit the pacemaker current of embr
yonic pig ventricular myocytes and can reverse &szlig;-adrenergic stimulation (2
). Muscarinic ACh receptors (mAChR) in the embryonic cardiomyocytes of rats are 
involved in the inhibition of L-type calcium current (3). Expression of rat chol
ine acetyltransferase (ChAT) and acetylcholinesterase (AChE) mRNA was observed f
rom 15 embryonic days in the neural tissue covering the dorsocranial wall of the
 atria. mAChR subtypes (M<SUB>1</SUB>, M<SUB>2</SUB>, M<SUB>4</SUB>) were observ
ed at the same location as AChE and ChAT mRNA, while M<SUB>1</SUB> and M<SUB>4</
SUB> receptors showed a low level of expression in the atrial myocardium during 
the fetal period. ChAT, AChE, and mAChR (M<SUB>1</SUB>, M<SUB>2</SUB>, M<SUB>4</
SUB>) mRNA are usually co-localized in the rat cardiac ganglia (<a href="#Tab1">
Table 1</a>). M<SUB>1</SUB>, M<SUB>2</SUB>, M<SUB>3</SUB>, and M<SUB>4</SUB> rec
eptors were detected in the cultured neonatal ventricular myocytes of rats (4,5)
. No M<SUB>3 </SUB>or M<SUB>5 </SUB>expression was observed in the embryonic hea
rt. Low concentrations of ACh (<font face="Symbol">&#163;</font>1 nM) increased 
automaticity in the neonatal rat heart, with the excitatory response being media
ted via stimulation of a post-synaptic M<SUB>1</SUB> receptor in non-innervated 
myocytes. Sympathetic innervation prevents the functional expression of the post
-synaptic myocardial M<SUB>1</SUB> receptor. Pharmacological analysis with mAChR
 antagonists has indicated that M<SUB>1</SUB> and M<SUB>2</SUB> receptors are im
portant mediators of the response to carbachol in neonatal atria (6). These data
 suggest that cholinergic mechanisms start to function in the control of fetal h
eart and vascular systems during the prenatal period, at least at 70% of gestati
on in different species observed. In addition, it seems that the cholinergic mec
hanism via M receptors is critical to fetal cardiovascular control <I>in utero</
I>. </font>      ^cY#6683.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011800073002000900191#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#25#21#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><B>Fetal swallowing, digestive and urinary systems </B> <
/font>      ^cY#6683.htm##
02190000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704196200073002000902035#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#26#22#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Fetal swallowing is an important behavior during the peri
od of <I>in utero</I> development. This behavior causes fetal intake of amniotic
 fluid that may influence fetal body fluids and vascular volume. In the digestiv
e tract, cholinergic systems are already present during prenatal life. The devel
opment of cholinergic regulation of upper gastrointestinal motility occurs in ne
ar-term fetal rabbits. Atropine injected into the fetal rabbit during the late g
estational period could suppress upper gastrointestinal motility, indicating tha
t fetal cholinergic mechanisms may be functional in fetal digestive systems duri
ng late gestation (7-9). Many studies conducted on adults have demonstrated that
 cholinergic stimulation such as administration of carbachol plays an important 
role in water intake and body fluid regulation. For example, a previous study su
ggested that this portion of the hypothalamus contains two populations of neural
 elements which participate in the regulation of food and water intake and are p
referentially sensitive to adrenergic and cholinergic stimulation, respectively 
(10). Although several reports have shown that fetal swallowing (fluid intake) c
an be controlled by angiotensin and osmotic mechanisms (11,12), there are very f
ew studies regarding the functional development of fetal swallowing produced by 
cholinergic stimulation or mechanisms <I>in utero</I>. A preliminary study by ou
r group (Mao C, Shi L, Xu Z, Central application of carbachol increased fetal sw
allowing activity in the ovine fetus, unpublished data) indicated that intracere
broventricular injection of carbachol into chronically prepared near-term sheep 
can increase fetal swallowing activity. This has opened intriguing possibilities
 for future studies of the cholinergic system, its antagonists, its receptors, a
nd central pathways in the development of fetal swallowing and body fluid contro
l. </font>      ^cY#6683.htm##
01171000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704094300073002000901016#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#27#23#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Despite the very limited data currently available on chol
inergically stimulated fetal swallowing, many studies have demonstrated choliner
gic development in the digestive tract of the fetus. M<SUB>2</SUB> receptors are
 predominant in the gastric smooth muscle of rabbit fetuses. Administration of c
holinergic agonists or antagonists potentially modulates fetal gastrointestinal 
motility and absorption of amniotic fluid (13,14). Intravenous bethanechol impro
ves electromechanical coordination in the fetal colon. Cholinergic stimulation e
vokes local contractile/expulsive mechanisms in meconium passage in sheep fetuse
s at near-term. Cholinergic mechanisms may be critical to the regulation of colo
nic motility since defects in the cholinergic system have been reported in infan
ts born with Hirschsprung's disease, in which a delay in meconium passage was cl
inically observed (15). </font>      ^cY#6683.htm##
01709000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704148100073002000901554#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#28#24#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The urinary system is also important for water and salt r
eabsorption and excretion in the regulation of body fluids. Cholinergic receptor
s appear very early in the human fetal bladder since contractile responses to be
thanechol, competitively blocked by atropine, were observed in the prepared detr
usor muscle at three months and in the sphincter at four months. Later, the dens
ity of cholinergic receptors increases in the detrusor muscle, whereas there is 
a progressive reduction in the sphincter (16). The density of mAChR was signific
antly greater than the density of <font face="Symbol">a</font>- or &szlig;-adren
ergic receptors in the smooth muscle of the fetal bovine bladder during the mid-
gestational period (17). Voluntary or involuntary contraction of the detrusor mu
scle of the urinary system mainly depends on mAChR stimulated by ACh that is rel
eased from parasympathetic terminals (18). The M<SUB>2</SUB> receptor is the pre
dominant subtype in the bladder and uterus. The bladder of the fetal rabbit has 
been shown to respond to muscarinic stimulation (19,20). The development of shee
p fetuses is associated with increased contractile activation between 65 and 140
 gestational days, and atropine-increased bladder capacity is observed at 120 da
ys' gestation (21-23). M receptor-mediated mechanisms are important in the regul
ation of fetal urinary systems, including the bladder, at pre-term and near-term
. </font>      ^cY#6683.htm##
00999000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704077100073002000900844#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#29#25#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><a href="#Tab1">Table 1</a> shows the development of peri
pheral cholinergic elements in the fetal heart and in the urinary and digestive 
systems during different gestational periods and in different species. In genera
l, cholinergic systems, including their receptors and key enzymes, are developed
 and functional in the cardiovascular, urinary, and digestive systems regarding 
body fluid balance. However, functional development of cholinergic mechanisms in
 the control of fetal swallowing, kidney function, and vascular volume regulatio
n is still unclear. Further studies are needed to clarify the possible contribut
ion of fetal cholinergic mechanisms to the development of systems that control b
ody fluids. </font>      ^cY#6683.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704017100073002000900244#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#30#26#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><B>Development of fetal brain cholinergic receptors and t
heir effects on vascular and body fluid control</B> </font>      ^cY#6683.htm##
01988000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704176000073002000901833#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#31#27#article#103#<P><font face="Arial, 
Helvetica, sans-serif">ACh receptors are differentially expressed throughout the
 central nervous system, where they play a role in the modulation of neurotransm
itter release, neuronal differentiation, regulation of gene expression, and neur
onal pathfinding. The nicotinic AChR (nAChR) are ligand-gated ion channels with 
different <font face="Symbol">a</font> (<font face="Symbol">a</font>2-7) and &sz
lig; (&szlig;2-4) units (<a href="#Tab2">Table 2</a>). It has been demonstrated 
that multiple subtypes of neuronal nAChR can be formed from various combinations
 of subunits, including the <font face="Symbol">a</font>4&szlig;2, <font face="S
ymbol">a</font>3&szlig;2, <font face="Symbol">a</font>4&szlig;4, and <font face=
"Symbol">a</font>7 subtypes. Most nAChR in the brain appear to be heteromeric <f
ont face="Symbol">a</font>4&szlig;2, and homomeric <font face="Symbol">a</font>7
 (24-26). nAChR is present in the human fetal brain as early as the first trimes
ter, gradually increasing up to mid-gestation and then declining in the third tr
imester. <font face="Symbol">a</font>3, 4, 5, 7, and &szlig;2, 3, 4, but not <fo
nt face="Symbol">a</font>2, 6 receptors are expressed in the human fetal brain. 
<font face="Symbol">a</font>5 levels are higher in the cortex, while <font face=
"Symbol">a</font>7 levels are higher in the hindbrain, and &szlig;3 in the cereb
ellum. &szlig;4 is equally distributed in all regions, whereas &szlig;2 levels a
re higher in the cortex and cerebellum. nAChR decrease in all regions of the hum
an brain after birth (27-30). <font face="Symbol">a</font>2, 3, 7 in the cortex 
and <font face="Symbol">a</font>4, 7 in the brainstem are increasingly expressed
 in humans exposed to nicotine (31, 32). </font>      ^cY#6683.htm##
01781000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704155300073002000901626#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#32#28#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Five subtypes of mAChR have been identified: M<SUB>1</SUB
>, M<SUB>3</SUB>, and M<SUB>5</SUB> receptors that are preferentially coupled to
 G-protein and stimulate phospholipase C, and M<SUB>2</SUB> and M<SUB>4</SUB> re
ceptors that are coupled to G-protein associated with the inhibition of adenylat
e cyclase (33). In general, the ontogeny of mAChR in the human fetal brain shows
 two distinct phases during <I>in utero</I> development: first, they appear betw
een 16 and 18 weeks and gradually increase up to 20 weeks. Second, there is a la
g period between 20 and 24 weeks, at which time the receptor density does not ch
ange perceptibly. mAChR decrease in all regions of the human brain after birth (
34,35). mAChR are extensively distributed in the striatum, brainstem, cortex, an
d midbrain, and their levels are relatively lower in the cerebellum and hippocam
pus. M<SUB>1</SUB> receptors are concentrated mainly in the forebrain regions wh
ile M<SUB>2</SUB> receptors dominate in the thalamus (36,37). During middle and 
late gestation, M<SUB>2</SUB> receptors are abundant in the cerebellum of human 
fetuses and M<SUB>3</SUB>, M<SUB>4</SUB> receptors appear to predominate in the 
brainstem (38) (<a href="#Tab3">Table 3</a>). High mAChR densities are noted in 
certain brainstem nuclei that are important for the development of fetal and neo
natal behaviors (39). The development of central N and M receptors in the fetal 
brain provides the basis for central cholinergic actions <I>in utero</I>. </font
>      ^cY#6683.htm##
01054000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704082600073002000900899#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#33#29#article#103#<P><font face="Arial, 
Helvetica, sans-serif">During the early development of the brain, the main proce
sses are proliferation of neuronal stem and progenitor cells, migration of diffe
rent cells to a pre-designated area and differentiation into neurons and glial c
ells. Cholinergic neurons innervate almost the entire neuraxis and mAChR are dis
tributed throughout the central nervous system (40-48). At early stages of embry
ogenesis, fetal neurons are releasing ACh that triggers the depolarization of ad
jacent cells in the spinal cord (49,50). Previous studies have shown that <font 
face="Symbol">a</font>7 receptors play a role in axonogenesis, synaptogenesis, a
nd synaptic plasticity, are also related to developmental neurotoxicants, and in
crease glutamate release onto postsynaptic NMDA receptors (51,52). </font>      
^cY#6683.htm##
01309000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704108100073002000901154#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#34#30#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The major populations of cholinergic neurons in the brain
 include two "projections" located in the pontine reticular formation and in the
 basal forebrain. These two complexes comprise, in part, the anatomical substrat
es for the "ascending reticular activating system". The pontine cholinergic syst
em relays its rostral information mainly through thalamic intralaminar nuclei, b
ut it also connects to the basal forebrain and provides a minor innervation of t
he cortex. The basal forebrain cholinergic complex projects directly to the cort
ex and the hippocampus, and has a minor connection with the thalamus. The basal 
forebrain cholinergic complex acts in tandem or in parallel with the pontine cho
linergic projection to activate the electro-encephalogram, to increase cerebral 
blood flow, to regulate sleep-wake cycling, and to modulate cognitive functions 
(53-55). Abnormal development of the cholinergic basal forebrain has been implic
ated in numerous developmental disorders such as Rett syndrome and Down syndrome
. </font>      ^cY#6683.htm##
00899000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067100073002000900744#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#35#31#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Muscarinic cholinergic neurotransmission is involved in f
etal breathing. Near-term ovine fetal swallowing activity occurs predominantly d
uring low-voltage electrocortical activation. Atropine suppressed fetal swallowi
ng activity in the ovine fetus (56), while carbachol increased high-voltage feta
l sheep electrocortical activity and breathe amplitude. These effects were media
ted by M<SUB>1</SUB> receptors (57). Central cholinergic systems are important i
n the control of fetal cardiovascular activity. Stimulation of central mAChR res
ults in hypertension and a change of heart rate in the fetal lamb (58). </font> 
     ^cY#6683.htm##
00472000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024400073002000900317#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#36#32#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Our recent study demonstrated that intracerebroventricula
r carbachol can increase systolic, diastolic, and mean arterial pressure accompa
nied by a bradycardia in sheep fetuses (59). </font>      ^cY#6683.htm##
01039000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704081100073002000900884#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#37#33#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Neuronal activity labeled with c-fos was significantly en
hanced after central administration of carbachol in the fetal anterior third ven
tricle region of the forebrain, and in the area postrema, lateral parabrachial n
ucleus, nucleus tractus solitarii, and rostral ventrolateral medulla in the hind
brain. This central neural activation labeled with c-fos was associated with car
diovascular changes in sheep fetuses (59). Central cholinergic systems are also 
involved in fetal hormone secretion that may also contribute to vascular regulat
ion. For example, acetylcholine evoked CRH secretion in Lewis rat fetal hypothal
amic cells (60). Notably, hormonal mechanisms may be well developed in the fetal
 brain for the control of fetal vascular functions. </font>      ^cY#6683.htm##
01555000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704132700073002000901400#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#38#34#article#103#<P><font face="Arial, 
Helvetica, sans-serif">In summary, both peripheral and central cholinergic syste
ms, particularly cholinergic receptors, are relatively mature before birth in al
l systems that are linked to the regulation of body fluids. Both N receptors and
 M receptors as well as their subtypes appeared in the fetal cardiovascular, ing
estive, and urinary systems as well as in the fetal brain. Cholinergic mechanism
s are relatively intact and functional in the control of cardiovascular homeosta
sis during fetal life <I>in utero</I> in the last third of gestation. It is appa
rent that central cholinergic systems are well developed in the control of fetal
 blood pressure before birth. Although further studies are required to determine
 the functional development of cholinergic control of fetal body fluid balance a
nd its influence on prenatal and postnatal health, the data obtained so far have
 opened up intriguing possibilities for future studies of the functional develop
ment of drinking behavior regulated by cholinergic mechanisms.</font>   <HR ALIG
N=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" 
valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n5/html/6683t
01.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"></a></td>     
 <td width="87%">    ^cY#6683.htm##
00524000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029600073002000900369#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#39#35#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab1"></a>Table 1. Development of peripheral cho
linergic elements in the fetal heart and in the fetal urinary and digestive syst
ems during different gestational periods and in different species. </font>      
</td>    </tr>  </table>      ^cY#6683.htm##
00607000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037900073002000900452#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#40#36#article#103#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (106 K JPG file)]</fon
t>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr a
lign="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n
5/html/6683t02.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"></
a></td>      <td width="87%">    ^cY#6683.htm##
00453000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704022500073002000900298#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#41#37#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab2"></a>Table 2. Brain nicotinic acetylcholine
 receptor (nAChR) levels of human fetuses at different gestational periods. </fo
nt>      </td>    </tr>  </table>      ^cY#6683.htm##
00801000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704057300073002000900646#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#42#38#article#103#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (79 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr al
ign="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v40n5
/html/6683t03.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"></a
></td>      <td width="87%"><font face="Arial, Helvetica, sans-serif"><a name="T
ab3"></a>Table 3. Brain muscarinic acetylcholine receptors of human fetuses at d
ifferent gestational periods.</font> </td>    </tr>  </table>      ^cY#6683.htm#
#
00377000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014900073002000900222#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#43#39#article#103#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (90 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY#6683.htm##
00547000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031900073002000900392#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#44#40#article#103#<P class="style4"> <A 
NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial, Hel
vetica, sans-serif">References</font></B></FONT></FONT>    <A HREF="#Home"><FONT
 SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>      ^cY#6683.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019500075002000900270#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#45#41#article#103#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Papp JG. Autonomic responses and neurohu
moral control in the human early antenatal heart. <I>Basic Res Cardiol</I> 1988;
 83: 2-9. </font>      ^cY#6683.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024800075002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#46#42#article#103#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Shigenobu K, Tanaka H, Satoh H. Developm
ental changes in the pacemaker current and membrane currents of the guinea pig m
yocardium. <I>Nippon Yakurigaku Zasshi</I> 1996; 107: 259-272. </font>      ^cY#
6683.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704029100075002000900366#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#47#43#article#103#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Liang HM, Tang M, Liu CJ, Luo HY, Song Y
L, Hu XW, et al. Muscarinic cholinergic regulation of L-type calcium channel in 
heart of embryonic mice at different developmental stages. <I>Acta Pharmacol Sin
</I> 2004; 25: 1450-1457. </font>      ^cY#6683.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024300075002000900318#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#48#44#article#103#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Franco D, Moorman AF, Lamers WH. Express
ion of the cholinergic signal-transduction pathway components during embryonic r
at heart development. <I>Anat Rec</I> 1997; 248: 110-120. </font>      ^cY#6683.
htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704026900075002000900344#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#49#45#article#103#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Sun LS, Huber F, Robinson RB, Bilezikian
 JP, Steinberg SF, Vulliemoz Y. Muscarinic receptor heterogeneity in neonatal ra
t ventricular myocytes in culture. <I>J Cardiovasc Pharmacol</I> 1996; 27: 455-4
61. </font>      ^cY#6683.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704028600075002000900361#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#50#46#article#103#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Sun LS, Vulliemoz Y, Huber F, Bilezikian
 JP, Robinson RB. An excitatory muscarinic response in neonatal rat ventricular 
myocytes and its modulation by sympathetic innervation. <I>J Mol Cell Cardiol</I
> 1994; 26: 779-787. </font>      ^cY#6683.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022800075002000900303#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#51#47#article#103#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Vannucchi MG, Faussone-Pellegrini MS. Di
fferentiation of cholinergic cells in the rat gut during pre- and postnatal life
. <I>Neurosci Lett</I> 1996; 206: 105-108. </font>      ^cY#6683.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022200075002000900297#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#52#48#article#103#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Kolivas S, Volombello T, Shulkes A. Expr
ession of receptors regulating gastric acidity in the developing sheep stomach. 
<I>Regul Pept</I> 2001; 101: 93-100. </font>      ^cY#6683.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020800075002000900283#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#53#49#article#103#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Seidel ER, Johnson LR. Ontogeny of gastr
ic mucosal muscarinic receptor and sensitivity to carbachol. <I>Am J Physiol</I>
 1984; 246: G550-G555. </font>      ^cY#6683.htm##
00446000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020300076002000900279#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#54#50#article#103#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Grossman SP. Effects of adrenergic and
 cholinergic blocking agents on hypothalamic mechanisms. <I>Am J Physiol</I> 196
2; 202: 1230-1236. </font>      ^cY#6683.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022200076002000900298#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#55#51#article#103#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Xu Z, Nijland MJ, Ross MG. Plasma osmo
lality dipsogenic thresholds and c-fos expression in the near-term ovine fetus. 
<I>Pediatr Res</I> 2001; 49: 678-685. </font>      ^cY#6683.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026200076002000900338#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#56#52#article#103#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Xu Z, Glenda C, Day L, Yao J, Ross MG.
 Central angiotensin induction of fetal brain c-fos expression and swallowing ac
tivity. <I>Am J Physiol Regul Integr Comp Physiol</I> 2001; 280: R1837-R1843. </
font>      ^cY#6683.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026800076002000900344#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#57#53#article#103#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Acosta R, Lee JJ, Oyachi N, Buchmiller
-Crair TL, Atkinson JB, Ross MG. Anticholinergic suppression of fetal rabbit upp
er gastrointestinal motility. <I>J Matern Fetal Neonatal Med</I> 2002; 11: 153-1
57. </font>      ^cY#6683.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023100076002000900307#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#58#54#article#103#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Tomomasa T, Hyman PE, Hsu CT, Jing J, 
Snape WJ Jr. Development of the muscarinic receptor in rabbit gastric smooth mus
cle. <I>Am J Physiol</I> 1988; 254: G680-G686. </font>      ^cY#6683.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021000076002000900286#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#59#55#article#103#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Oue T, Yoneda A, Shima H, Puri P. Musc
arinic acetylcholine receptor expression in aganglionic bowel. <I>Pediatr Surg I
nt</I> 2000; 16: 267-271. </font>      ^cY#6683.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025800076002000900334#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#60#56#article#103#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Mitolo-Chieppa D, Schonauer S, Grasso 
G, Cicinelli E, Carratu MR. Ontogenesis of autonomic receptors in detrusor muscl
e and bladder sphincter of human fetus. <I>Urology</I> 1983; 21: 599-603. </font
>      ^cY#6683.htm##
00524000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028100076002000900357#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#61#57#article#103#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Lee JG, Macarak E, Coplen D, Wein AJ, 
Levin RM. Distribution and function of the adrenergic and cholinergic receptors 
in the fetal calf bladder during mid-gestational age. <I>Neurourol Urodyn</I> 19
93; 12: 599-607. </font>      ^cY#6683.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017800076002000900254#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#62#58#article#103#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Jimenez Cidre MA. Urinary incontinence
: anticholinergic treatment. <I>Rev Med Univ Navarra</I> 2004; 48: 37-42. </font
>      ^cY#6683.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022700076002000900303#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#63#59#article#103#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. Brandes SB, Ruggieri MR. Muscarinic re
ceptor subtypes in normal, fetal, and gravid rabbit bladder, heart and uterus. <
I>Adv Exp Med Biol</I> 1995; 385: 241-249. </font>      ^cY#6683.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024700076002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#64#60#article#103#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. Baselli EC, Brandes SB, Luthin GR, Rug
gieri MR. The effect of pregnancy and contractile activity on bladder muscarinic
 receptor subtypes. <I>Neurourol Urodyn</I> 1999; 18: 511-520. </font>      ^cY#
6683.htm##
00480000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023700076002000900313#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#65#61#article#103#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. Nyirady P, Thiruchelvam N, Godley ML, 
David A, Cuckow PM, Fry CH. Contractile properties of the developing fetal sheep
 bladder. <I>Neurourol Urodyn</I> 2005; 24: 276-281. </font>      ^cY#6683.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022600076002000900302#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#66#62#article#103#22#<P><fon
t face="Arial, Helvetica, sans-serif">22. Levin RM, Macarak E, Howard P, Horan P
, Kogan BA. The response of fetal sheep bladder tissue to partial outlet obstruc
tion. <I>J Urol</I> 2001; 166: 1156-1160. </font>      ^cY#6683.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025200076002000900328#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#67#63#article#103#23#<P><fon
t face="Arial, Helvetica, sans-serif">23. Kogan BA, Iwamoto HS. Lower urinary tr
act function in the sheep fetus: studies of autonomic control and pharmacologic 
responses of the fetal bladder. <I>J Urol</I> 1989; 141: 1019-1024. </font>     
 ^cY#6683.htm##
00422000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017900076002000900255#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#68#64#article#103#24#<P><fon
t face="Arial, Helvetica, sans-serif">24. Paterson D, Nordberg A. Neuronal nicot
inic receptors in the human brain. <I>Prog Neurobiol</I> 2000; 61: 75-111. </fon
t>      ^cY#6683.htm##
00503000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026000076002000900336#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#69#65#article#103#25#<P><fon
t face="Arial, Helvetica, sans-serif">25. Clementi F. Handbook of experimental p
harmacology, neuronal nicotinic receptors. In: Sargent PB (Editor), <I>The distr
ibution of neuronal nicotinic acetylcholine receptors</I>. 2000. p 163-192. </fo
nt>      ^cY#6683.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704019600076002000900272#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#70#66#article#103#26#<P><fon
t face="Arial, Helvetica, sans-serif">26. Dani JA. Overview of nicotinic recepto
rs and their roles in the central nervous system. <I>Biol Psychiatry</I> 2001; 4
9: 166-174. </font>      ^cY#6683.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017700076002000900253#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#71#67#article#103#27#<P><fon
t face="Arial, Helvetica, sans-serif">27. Gotti C, Fornasari D, Clementi F. Huma
n neuronal nicotinic receptors. <I>Prog Neurobiol</I> 1997; 53: 199-237. </font>
      ^cY#6683.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029000076002000900366#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#72#68#article#103#28#<P><fon
t face="Arial, Helvetica, sans-serif">28. Hellstrom-Lindahl E, Gorbounova O, Sei
ger A, Mousavi M, Nordberg A. Regional distribution of nicotinic receptors durin
g prenatal development of human brain and spinal cord. <I>Brain Res Dev Brain Re
s</I> 1998; 108: 147-160. </font>      ^cY#6683.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023900076002000900315#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#73#69#article#103#29#<P><fon
t face="Arial, Helvetica, sans-serif">29. Falk L, Nordberg A, Seiger A, Kjaeldga
ard A, Hellstrom-Lindahl E. The alpha7 nicotinic receptors in human fetal brain 
and spinal cord. <I>J Neurochem</I> 2002; 80: 457-465. </font>      ^cY#6683.htm
##
00497000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025400076002000900330#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#74#70#article#103#30#<P><fon
t face="Arial, Helvetica, sans-serif">30. Reddy SC, Panigrahy A, White WF, Kinne
y HC. Developmental changes in neurotransmitter receptor binding in the human pe
riaqueductal gray. <I>J Neuropathol Exp Neurol</I> 1996; 55: 409-418. </font>   
   ^cY#6683.htm##
00524000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028100076002000900357#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#75#71#article#103#31#<P><fon
t face="Arial, Helvetica, sans-serif">31. Hellstrom-Lindahl E, Seiger A, Kjaeldg
aard A, Nordberg A. Nicotine-induced alterations in the expression of nicotinic 
receptors in primary cultures from human prenatal brain. <I>Neuroscience</I> 200
1; 105: 527-534. </font>      ^cY#6683.htm##
00585000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704034200076002000900418#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#76#72#article#103#32#<P><fon
t face="Arial, Helvetica, sans-serif">32. Falk L, Nordberg A, Seiger A, Kjaeldga
ard A, Hellstrom-Lindahl E. Smoking during early pregnancy affects the expressio
n pattern of both nicotinic and muscarinic acetylcholine receptors in human firs
t trimester brainstem and cerebellum. <I>Neuroscience</I> 2005; 132: 389-397. </
font>      ^cY#6683.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027900076002000900355#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#77#73#article#103#33#<P><fon
t face="Arial, Helvetica, sans-serif">33. Ravikumar BV, Sastry PS. Muscarinic ch
olinergic receptors in human foetal brain: characterization and ontogeny of [3H]
quinuclidinyl benzilate binding sites in frontal cortex. <I>J Neurochem</I> 1985
; 44: 240-246. </font>      ^cY#6683.htm##
00530000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028700076002000900363#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#78#74#article#103#34#<P><fon
t face="Arial, Helvetica, sans-serif">34. Ravikumar BV, Sastry PS. Cholinergic m
uscarinic receptors in human fetal brain: ontogeny of [3H]quinuclidinyl benzilat
e binding sites in corpus striatum, brainstem, and cerebellum. <I>J Neurochem</I
> 1985; 45: 1948-1950. </font>      ^cY#6683.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029000076002000900366#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#79#75#article#103#35#<P><fon
t face="Arial, Helvetica, sans-serif">35. Bar-Peled O, Israeli M, Ben-Hur H, Hos
kins I, Groner Y, Biegon A. Developmental pattern of muscarinic receptors in nor
mal and Down's syndrome fetal brain - an autoradiographic study. <I>Neurosci Let
t</I> 1991; 133: 154-158. </font>      ^cY#6683.htm##
00553000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031000076002000900386#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#80#76#article#103#36#<P><fon
t face="Arial, Helvetica, sans-serif">36. Egozi Y, Sokolovsky M, Schejter E, Bla
tt I, Zakut H, Matzkel A, et al. Divergent regulation of muscarinic binding site
s and acetylcholinesterase in discrete regions of the developing human fetal bra
in. <I>Cell Mol Neurobiol</I> 1986; 6: 55-70. </font>      ^cY#6683.htm##
00489000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024600076002000900322#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#81#77#article#103#37#<P><fon
t face="Arial, Helvetica, sans-serif">37. Schlumpf M, Palacios JM, Cortes R, Lic
htensteiger W. Regional development of muscarinic cholinergic binding sites in t
he prenatal rat brain. <I>Neuroscience</I> 1991; 45: 347-357. </font>      ^cY#6
683.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026600076002000900342#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#82#78#article#103#38#<P><fon
t face="Arial, Helvetica, sans-serif">38. Aubert I, Cecyre D, Gauthier S, Quirio
n R. Comparative ontogenic profile of cholinergic markers, including nicotinic a
nd muscarinic receptors, in the rat brain. <I>J Comp Neurol</I> 1996; 369: 31-55
. </font>      ^cY#6683.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027500076002000900351#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#83#79#article#103#39#<P><fon
t face="Arial, Helvetica, sans-serif">39. Berger-Sweeney J. The cholinergic basa
l forebrain system during development and its influence on cognitive processes: 
important questions and potential answers. <I>Neurosci Biobehav Rev</I> 2003; 27
: 401-411. </font>      ^cY#6683.htm##
00430000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018700076002000900263#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#84#80#article#103#40#<P><fon
t face="Arial, Helvetica, sans-serif">40. Lauder JM, Schambra UB. Morphogenetic 
roles of acetylcholine. <I>Environ Health Perspect</I> 1999; 107 (Suppl 1): 65-6
9. </font>      ^cY#6683.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024400076002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#85#81#article#103#41#<P><fon
t face="Arial, Helvetica, sans-serif">41. Adams PR, Brown DA. Synaptic inhibitio
n of the M-current: slow excitatory post-synaptic potential mechanism in bullfro
g sympathetic neurones. <I>J Physiol</I> 1982; 332: 263-272.</font>      ^cY#668
3.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022300076002000900299#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#86#82#article#103#42#<P><fon
t face="Arial, Helvetica, sans-serif">42. Fibiger HC, Damsma G, Day JC. Behavior
al pharmacology and biochemistry of central cholinergic neurotransmission. <I>Ad
v Exp Med Biol</I> 1991; 295: 399-414. </font>      ^cY#6683.htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028300076002000900359#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#87#83#article#103#43#<P><fon
t face="Arial, Helvetica, sans-serif">43. Adams CE, Broide RS, Chen Y, Winzer-Se
rhan UH, Henderson TA, Leslie FM, et al. Development of the alpha7 nicotinic cho
linergic receptor in rat hippocampal formation. <I>Brain Res Dev Brain Res</I> 2
002; 139: 175-187. </font>      ^cY#6683.htm##
00488000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024500076002000900321#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#88#84#article#103#44#<P><fon
t face="Arial, Helvetica, sans-serif">44. Adams CE. Comparison of alpha7 nicotin
ic acetylcholine receptor development in the hippocampal formation of C3H and DB
A/2 mice. <I>Brain Res Dev Brain Res</I> 2003; 143: 137-149. </font>      ^cY#66
83.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027000076002000900346#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#89#85#article#103#45#<P><fon
t face="Arial, Helvetica, sans-serif">45. Vizi ES, Lendvai B. Modulatory role of
 presynaptic nicotinic receptors in synaptic and non-synaptic chemical communica
tion in the central nervous system. <I>Brain Res Brain Res Rev</I> 1999; 30: 219
-235. </font>      ^cY#6683.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024800076002000900324#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#90#86#article#103#46#<P><fon
t face="Arial, Helvetica, sans-serif">46. McGehee DS, Heath MJ, Gelber S, Devay 
P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS
 by presynaptic receptors. <I>Science</I> 1995; 269: 1692-1696. </font>      ^cY
#6683.htm##
00506000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026300076002000900339#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#91#87#article#103#47#<P><fon
t face="Arial, Helvetica, sans-serif">47. Edwards JA, Cline HT. Light-induced ca
lcium influx into retinal axons is regulated by presynaptic nicotinic acetylchol
ine receptor activity <I>in vivo</I>. <I>J Neurophysiol</I> 1999; 81: 895-907. <
/font>      ^cY#6683.htm##
00520000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027700076002000900353#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#92#88#article#103#48#<P><fon
t face="Arial, Helvetica, sans-serif">48. Slotkin TA, Cousins MM, Seidler FJ. Ad
ministration of nicotine to adolescent rats evokes regionally selective upregula
tion of CNS alpha 7 nicotinic acetylcholine receptors. <I>Brain Res</I> 2004; 10
30: 159-163. </font>      ^cY#6683.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028500076002000900361#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#93#89#article#103#49#<P><fon
t face="Arial, Helvetica, sans-serif">49. Myers CP, Lewcock JW, Hanson MG, Gosgn
ach S, Aimone JB, Gage FH, et al. Cholinergic input is required during embryonic
 development to mediate proper assembly of spinal locomotor circuits. <I>Neuron<
/I> 2005; 46: 37-49. </font>      ^cY#6683.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027500076002000900351#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#94#90#article#103#50#<P><fon
t face="Arial, Helvetica, sans-serif">50. Phelps PE, Barber RP, Brennan LA, Main
es VM, Salvaterra PM, Vaughn JE. Embryonic development of four different subsets
 of cholinergic neurons in rat cervical spinal cord. <I>J Comp Neurol</I> 1990; 
291: 9-26. </font>      ^cY#6683.htm##
00530000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028700076002000900363#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#95#91#article#103#51#<P><fon
t face="Arial, Helvetica, sans-serif">51. Slotkin TA, Southard MC, Adam SJ, Cous
ins MM, Seidler FJ. Alpha7 nicotinic acetylcholine receptors targeted by choline
rgic developmental neurotoxicants: nicotine and chlorpyrifos. <I>Brain Res Bull<
/I> 2004; 64: 227-235. </font>      ^cY#6683.htm##
00500000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025700076002000900333#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#96#92#article#103#52#<P><fon
t face="Arial, Helvetica, sans-serif">52. Aramakis VB, Metherate R. Nicotine sel
ectively enhances NMDA receptor-mediated synaptic transmission during postnatal 
development in sensory neocortex. <I>J Neurosci</I> 1998; 18: 8485-8495. </font>
      ^cY#6683.htm##
00515000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027200076002000900348#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#97#93#article#103#53#<P><fon
t face="Arial, Helvetica, sans-serif">53. Berger-Sweeney J. The effects of neona
tal basal forebrain lesions on cognition: towards understanding the developmenta
l role of the cholinergic basal forebrain. <I>Int J Dev Neurosci</I> 1998; 16: 6
03-612. </font>      ^cY#6683.htm##
00540000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029700076002000900373#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#98#94#article#103#54#<P><fon
t face="Arial, Helvetica, sans-serif">54. Ricceri L, Minghetti L, Moles A, Popol
i P, Confaloni A, De Simone R, et al. Cognitive and neurological deficits induce
d by early and prolonged basal forebrain cholinergic hypofunction in rats. <I>Ex
p Neurol</I> 2004; 189: 162-172. </font>      ^cY#6683.htm##
00478000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023500076002000900311#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#99#95#article#103#55#<P><fon
t face="Arial, Helvetica, sans-serif">55. Hohmann CF, Berger-Sweeney J. Choliner
gic regulation of cortical development and plasticity. New twists to an old stor
y. <I>Perspect Dev Neurobiol</I> 1998; 5: 401-425. </font>      ^cY#6683.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704020900077002000900286#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#100#96#article#103#56#<P><fo
nt face="Arial, Helvetica, sans-serif">56. Nijland MJ, Chao CR, Ross MG. Anticho
linergic suppression of ovine fetal swallowing activity. <I>Am J Obstet Gynecol<
/I> 1997; 177: 1105-1112. </font>      ^cY#6683.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704022400077002000900301#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#101#97#article#103#57#<P><fo
nt face="Arial, Helvetica, sans-serif">57. Joseph SA, Walker DW. Catecholamine n
eurons in fetal brain: effects on breathing movements and electrocorticogram. <I
>J Appl Physiol</I> 1990; 69: 1903-1911. </font>      ^cY#6683.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704019500077002000900272#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#102#98#article#103#58#<P><fo
nt face="Arial, Helvetica, sans-serif">58. Szeto HH, Hinman DJ. Central muscarin
ic modulation of fetal blood pressure and heart rate. <I>J Dev Physiol</I> 1990;
 13: 17-23. </font>      ^cY#6683.htm##
00530000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704028600077002000900363#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#103#99#article#103#59#<P><fo
nt face="Arial, Helvetica, sans-serif">59. Shi L, Zhang Y, Morrissey P, Yao J, X
u Z. The association of cardiovascular responses with brain c-fos expression aft
er central carbachol in the near-term ovine fetus. <I>Neuropsychopharmacology</I
> 2005; 30: 2162-2168. </font>      ^cY#6683.htm##
00571000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032600078002000900404#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#p#104#100#article#103#60#<P><f
ont face="Arial, Helvetica, sans-serif">60. Wei R, Phillips TM, Sternberg EM. Sp
ecific up-regulation of CRH or AVP secretion by acetylcholine or lipopolysacchar
ide in inflammatory susceptible Lewis rat fetal hypothalamic cells. <I>J Neuroim
munol</I> 2002; 131: 31-40.</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>       ^cY
#6683.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033900075002000900414#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#105#101#article#103#<P class="style4"><A
 NAME="Correspondence"></A><FONT SIZE=4><FONT COLOR=#00007F><B><font face="Arial
, Helvetica, sans-serif">Correspondence    and Footnotes</font></B></FONT></FONT
> <A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>       ^cY#6
683.htm##
00619000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704038900075002000900464#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#106#102#article#103#<P class="style4"><B
><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a> 
   Address for correspondence:</B><font face="Arial, Helvetica, sans-serif">Z.  
  Xu, Soochow University, School of Medicine, Suzhou 215123, China. E-mail: <a h
ref="mailto:xuzhice@suda.edu.cn">xuzhice@suda.edu.cn</a>    or <a href="mailto:z
xu@llu.edu">zxu@llu.edu</a></font> </P>      ^cY#6683.htm##
00920000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704069000075002000900765#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6683.htm#S#p#107#103#article#103#<P><font face="Arial
, Helvetica, sans-serif">Research supported by NSFC (No. 30570915), JiangSu High
 Education NSF (No. 05KJB310109), JiangSu NSF Key Project Grant (No. BK2006703),
 Soochow University Research Grant (No. EE134501), Suzhou Social Development Gra
nt (No. ssy0632), Suzhou Key Grant (No. SZS0602), and Soochow University Program
 Project Grant (No. 90134602). Presented at the International Symposium of Neuro
endocrinology "Neuroendocrine control of body fluid homeostasis: past, present a
nd future". Ribeir&atilde;o Preto, SP, Brazil, September 1-3, 2006. Received Oct
ober 11, 2006. Accepted February 13, 2007.</font><font face="Arial, Helvetica, s
ans-serif"> </font>       ^cY#6683.htm##
00524000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740120084000890300
01800173065000900191064000500200031000300205014000400208865000900212002000900221
035001000230801001800240#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
108#1#article#60#1#^rND^sPapp^nJG#Autonomic responses and neurohumoral control i
n the human early antenatal heart^len#Basic Res Cardiol#19880000#1988#83#2-9#200
70500#6683.htm#0300-8428#Basic Res Cardiol##
00620000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100016000930100
01500109012010200124030002500226065000900251064000500260031000400265014000800269
865000900277002000900286035001000295801002500305#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#109#2#article#60#2#^rND^sShigenobu^nK#^rND^sTanaka^nH#^r
ND^sSatoh^nH#Developmental changes in the pacemaker current and membrane current
s of the guinea pig myocardium^len#Nippon Yakurigaku Zasshi#19960000#1996#107#25
9-272#20070500#6683.htm#0015-5691#Nippon Yakurigaku Zasshi##
00683000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100014000900100
01400104010001400118010001500132010001300147810000600160012012500166030001900291
71000020031006500090031206400050032103100030032601400100032986500090033900200090
0348#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#110#3#article#60#3#^
rND^sLiang^nHM#^rND^sTang^nM#^rND^sLiu^nCJ#^rND^sLuo^nHY#^rND^sSong^nYL#^rND^sHu
^nXW#et al#Muscarinic cholinergic regulation of L-type calcium channel in heart 
of embryonic mice at different developmental stages^len#Acta Pharmacol Sin#2#200
40000#2004#25#1450-1457#20070500#6683.htm##
00599000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100018000900100
01700108012011200125030000900237065000900246064000500255031000400260014000800264
865000900272002000900281035001000290801000900300#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#111#4#article#60#4#^rND^sFranco^nD#^rND^sMoorman^nAF#^rN
D^sLamers^nWH#Expression of the cholinergic signal-transduction pathway componen
ts during embryonic rat heart development^len#Anat Rec#19970000#1997#248#110-120
#20070500#6683.htm#0003-276X#Anat Rec##
00693000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100015000880100
01900103010002100122010002000143010001900163012008600182030002300268065000900291
06400050030003100030030501400080030886500090031600200090032503500100033480100230
0344#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#112#5#article#60#5#^
rND^sSun^nLS#^rND^sHuber^nF#^rND^sRobinson^nRB#^rND^sBilezikian^nJP#^rND^sSteinb
erg^nSF#^rND^sVulliemoz^nY#Muscarinic receptor heterogeneity in neonatal rat ven
tricular myocytes in culture^len#J Cardiovasc Pharmacol#19960000#1996#27#455-461
#20070500#6683.htm#0160-2446#J Cardiovasc Pharmacol##
00688000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100019000880100
01500107010002100122010001900143012012100162030001900283065000900302064000500311
031000300316014000800319865000900327002000900336035001000345801001900355#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#113#6#article#60#6#^rND^sSun^nLS
#^rND^sVulliemoz^nY#^rND^sHuber^nF#^rND^sBilezikian^nJP#^rND^sRobinson^nRB#An ex
citatory muscarinic response in neonatal rat ventricular myocytes and its modula
tion by sympathetic innervation^len#J Mol Cell Cardiol#19940000#1994#26#779-787#
20070500#6683.htm#0022-2828#J Mol Cell Cardiol##
00571000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100030000940120
08700124030001400211065000900225064000500234031000400239014000800243865000900251
002000900260035001000269801001400279#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#114#7#article#60#7#^rND^sVannucchi^nMG#^rND^sFaussone-Pellegrini^nMS
#Differentiation of cholinergic cells in the rat gut during pre- and postnatal l
ife^len#Neurosci Lett#19960000#1996#206#105-108#20070500#6683.htm#0304-3940#Neur
osci Lett##
00580000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100020000910100
01700111012008700128030001100215065000900226064000500235031000400240014000700244
865000900251002000900260035001000269801001100279#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#115#8#article#60#8#^rND^sKolivas^nS#^rND^sVolombello^nT#
^rND^sShulkes^nA#Expression of receptors regulating gastric acidity in the devel
oping sheep stomach^len#Regul Pept#20010000#2001#101#93-100#20070500#6683.htm#01
67-0115#Regul Pept##
00550000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910120
08100109030001300190065000900203064000500212031000400217014001000221865000900231
002000900240035001000249801001300259#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#116#9#article#60#9#^rND^sSeidel^nER#^rND^sJohnson^nLR#Ontogeny of ga
stric mucosal muscarinic receptor and sensitivity to carbachol^len#Am J Physiol#
19840000#1984#246#G550-G555#20070500#6683.htm#0002-9513#Am J Physiol##
00528000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120085000950300
01300180065000900193064000500202031000400207014001000211865000900221002000900230
035001000239801001300249#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
117#10#article#60#10#^rND^sGrossman^nSP#Effects of adrenergic and cholinergic bl
ocking agents on hypothalamic mechanisms^len#Am J Physiol#19620000#1962#202#1230
-1236#20070500#6683.htm#0002-9513#Am J Physiol##
00582000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100018000880100
01500106012009400121030001200215065000900227064000500236031000300241014000800244
865000900252002000900261035001000270801001200280#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#118#11#article#60#11#^rND^sXu^nZ#^rND^sNijland^nMJ#^rND^
sRoss^nMG#Plasma osmolality dipsogenic thresholds and c-fos expression in the ne
ar-term ovine fetus^len#Pediatr Res#20010000#2001#49#678-685#20070500#6683.htm#0
031-3998#Pediatr Res##
00626000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100016000880100
01300104010001300117010001500130012009000145030003900235710000200274065000900276
064000500285031000400290014001200294865000900306002000900315#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6683.htm#S#c#119#12#article#60#12#^rND^sXu^nZ#^rND^sGlend
a^nC#^rND^sDay^nL#^rND^sYao^nJ#^rND^sRoss^nMG#Central angiotensin induction of f
etal brain c-fos expression and swallowing activity^len#Am J Physiol Regul Integ
r Comp Physiol#2#20010000#2001#280#R1837-R1843#20070500#6683.htm##
00650000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100014000920100
01600106010002700122010001900149010001500168012008000183030002800263710000200291
065000900293064000500302031000300307014000800310865000900318002000900327#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#120#13#article#60#13#^rND^sAcost
a^nR#^rND^sLee^nJJ#^rND^sOyachi^nN#^rND^sBuchmiller-Crair^nTL#^rND^sAtkinson^nJB
#^rND^sRoss^nMG#Anticholinergic suppression of fetal rabbit upper gastrointestin
al motility^len#J Matern Fetal Neonatal Med#2#20020000#2002#11#153-157#20070500#
6683.htm##
00628000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01400110010001400124010001900138012007500157030001300232065000900245064000500254
031000400259014001000263865000900273002000900282035001000291801001300301#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#121#14#article#60#14#^rND^sTomom
asa^nT#^rND^sHyman^nPE#^rND^sHsu^nCT#^rND^sJing^nJ#^rND^sSnape^nWJ Jr#Developmen
t of the muscarinic receptor in rabbit gastric smooth muscle^len#Am J Physiol#19
880000#1988#254#G680-G686#20070500#6683.htm#0002-9513#Am J Physiol##
00593000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100016000890100
01500105010001400120012007000134030001700204065000900221064000500230031000300235
014000800238865000900246002000900255035001000264801001700274#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6683.htm#S#c#122#15#article#60#15#^rND^sOue^nT#^rND^sYone
da^nA#^rND^sShima^nH#^rND^sPuri^nP#Muscarinic acetylcholine receptor expression 
in aganglionic bowel^len#Pediatr Surg Int#20000000#2000#16#267-271#20070500#6683
.htm#0179-0358#Pediatr Surg Int##
00650000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760100019001000100
01600119010001900135010001800154012009500172030000800267065000900275064000500284
031000300289014000800292865000900300002000900309035001000318801000800328#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#123#16#article#60#16#^rND^sMitol
o-Chieppa^nD#^rND^sSchonauer^nS#^rND^sGrasso^nG#^rND^sCicinelli^nE#^rND^sCarratu
^nMR#Ontogenesis of autonomic receptors in detrusor muscle and bladder sphincter
 of human fetus^len#Urology#19830000#1983#21#599-603#20070500#6683.htm#0090-4295
#Urology##
00682000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900100
01600107010001500123010001600138012012700154030001700281065000900298064000500307
031000300312014000800315865000900323002000900332035001000341801001700351#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#124#17#article#60#17#^rND^sLee^n
JG#^rND^sMacarak^nE#^rND^sCoplen^nD#^rND^sWein^nAJ#^rND^sLevin^nRM#Distribution 
and function of the adrenergic and cholinergic receptors in the fetal calf bladd
er during mid-gestational age^len#Neurourol Urodyn#19930000#1993#12#599-607#2007
0500#6683.htm#0733-2467#Neurourol Urodyn##
00511000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760120052001000300
02100152065000900173064000500182031000300187014000600190865000900196002000900205
035001000214801002100224#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
125#18#article#60#18#^rND^sJimenez^nCidre MA#Urinary incontinence: anticholinerg
ic treatment^len#Rev Med Univ Navarra#20040000#2004#48#37-42#20070500#6683.htm#0
556-6177#Rev Med Univ Navarra##
00574000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940120
09500113030001700208065000900225064000500234031000400239014000800243865000900251
002000900260035001000269801001700279#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#126#19#article#60#19#^rND^sBrandes^nSB#^rND^sRuggieri^nMR#Muscarinic
 receptor subtypes in normal, fetal, and gravid rabbit bladder, heart and uterus
^len#Adv Exp Med Biol#19950000#1995#385#241-249#20070500#6683.htm#0065-2598#Adv 
Exp Med Biol##
00630000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01700112010001900129012009300148030001700241065000900258064000500267031000300272
014000800275865000900283002000900292035001000301801001700311#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6683.htm#S#c#127#20#article#60#20#^rND^sBaselli^nEC#^rND^
sBrandes^nSB#^rND^sLuthin^nGR#^rND^sRuggieri^nMR#The effect of pregnancy and con
tractile activity on bladder muscarinic receptor subtypes^len#Neurourol Urodyn#1
9990000#1999#18#511-520#20070500#6683.htm#0733-2467#Neurourol Urodyn##
00656000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100022000930100
01700115010001500132010001700147010001400164012006500178030001700243065000900260
06400050026903100030027401400080027786500090028500200090029403500100030380100170
0313#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#128#21#article#60#21
#^rND^sNyirady^nP#^rND^sThiruchelvam^nN#^rND^sGodley^nML#^rND^sDavid^nA#^rND^sCu
ckow^nPM#^rND^sFry^nCH#Contractile properties of the developing fetal sheep blad
der^len#Neurourol Urodyn#20050000#2005#24#276-281#20070500#6683.htm#0733-2467#Ne
urourol Urodyn##
00617000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01600109010001500125010001600140012007700156030000700233065000900240064000500249
031000400254014001000258865000900268002000900277035001000286801000700296#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#129#22#article#60#22#^rND^sLevin
^nRM#^rND^sMacarak^nE#^rND^sHoward^nP#^rND^sHoran^nP#^rND^sKogan^nBA#The respons
e of fetal sheep bladder tissue to partial outlet obstruction^len#J Urol#2001000
0#2001#166#1156-1160#20070500#6683.htm#0022-5347#J Urol##
00589000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
13100110030000700241065000900248064000500257031000400262014001000266865000900276
002000900285035001000294801000700304#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#130#23#article#60#23#^rND^sKogan^nBA#^rND^sIwamoto^nHS#Lower urinary
 tract function in the sheep fetus: studies of autonomic control and pharmacolog
ic responses of the fetal bladder^len#J Urol#19890000#1989#141#1019-1024#2007050
0#6683.htm#0022-5347#J Urol##
00524000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940120
05200112030001500164065000900179064000500188031000300193014000700196865000900203
002000900212035001000221801001500231#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#131#24#article#60#24#^rND^sPaterson^nD#^rND^sNordberg^nA#Neuronal ni
cotinic receptors in the human brain^len#Prog Neurobiol#20000000#2000#61#75-111#
20070500#6683.htm#0301-0082#Prog Neurobiol##
00533000000000241000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120072000940160
01800166018006700184065000900251064000500260014000800265865000900273002000900282
#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#132#25#article#60#25#^rN
D^sClementi^nF#Handbook of experimental pharmacology, neuronal nicotinic recepto
rs^len#^rND^sSargent^nPB#The distribution of neuronal nicotinic acetylcholine re
ceptors^len#20000000#2000#163-192#20070500#6683.htm##
00524000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120082000910300
01600173065000900189064000500198031000300203014000800206865000900214002000900223
035001000232801001600242#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
133#26#article#60#26#^rND^sDani^nJA#Overview of nicotinic receptors and their ro
les in the central nervous system^len#Biol Psychiatry#20010000#2001#49#166-174#2
0070500#6683.htm#0006-3223#Biol Psychiatry##
00540000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100019000910100
01800110012003900128030001500167065000900182064000500191031000300196014000800199
865000900207002000900216035001000225801001500235#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#134#27#article#60#27#^rND^sGotti^nC#^rND^sFornasari^nD#^
rND^sClementi^nF#Human neuronal nicotinic receptors^len#Prog Neurobiol#19970000#
1997#53#199-237#20070500#6683.htm#0301-0082#Prog Neurobiol##
00698000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100027000760100020001030100
01600123010001700139010001800156012010800174030002400282065000900306064000500315
031000400320014000800324865000900332002000900341035001000350801002400360#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#135#28#article#60#28#^rND^sHells
trom-Lindahl^nE#^rND^sGorbounova^nO#^rND^sSeiger^nA#^rND^sMousavi^nM#^rND^sNordb
erg^nA#Regional distribution of nicotinic receptors during prenatal development 
of human brain and spinal cord^len#Brain Res Dev Brain Res#19980000#1998#108#147
-160#20070500#6683.htm#0165-3806#Brain Res Dev Brain Res##
00635000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100018000900100
01600108010002100124010002700145012007200172030001200244065000900256064000500265
031000300270014000800273865000900281002000900290035001000299801001200309#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#136#29#article#60#29#^rND^sFalk^
nL#^rND^sNordberg^nA#^rND^sSeiger^nA#^rND^sKjaeldgaard^nA#^rND^sHellstrom-Lindah
l^nE#The alpha7 nicotinic receptors in human fetal brain and spinal cord^len#J N
eurochem#20020000#2002#80#457-465#20070500#6683.htm#0022-3042#J Neurochem##
00645000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
01600111010001700127012009600144030002500240065000900265064000500274031000300279
014000800282865000900290002000900299035001000308801002500318#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6683.htm#S#c#137#30#article#60#30#^rND^sReddy^nSC#^rND^sP
anigrahy^nA#^rND^sWhite^nWF#^rND^sKinney^nHC#Developmental changes in neurotrans
mitter receptor binding in the human periaqueductal gray^len#J Neuropathol Exp N
eurol#19960000#1996#55#409-418#20070500#6683.htm#0022-3069#J Neuropathol Exp Neu
rol##
00660000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100027000760100016001030100
02100119010001800140012012000158030001300278065000900291064000500300031000400305
014000800309865000900317002000900326035001000335801001300345#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6683.htm#S#c#138#31#article#60#31#^rND^sHellstrom-Lindahl
^nE#^rND^sSeiger^nA#^rND^sKjaeldgaard^nA#^rND^sNordberg^nA#Nicotine-induced alte
rations in the expression of nicotinic receptors in primary cultures from human 
prenatal brain^len#Neuroscience#20010000#2001#105#527-534#20070500#6683.htm#0306
-4522#Neuroscience##
00739000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100018000900100
01600108010002100124010002700145012017300172030001300345065000900358064000500367
031000400372014000800376865000900384002000900393035001000402801001300412#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#139#32#article#60#32#^rND^sFalk^
nL#^rND^sNordberg^nA#^rND^sSeiger^nA#^rND^sKjaeldgaard^nA#^rND^sHellstrom-Lindah
l^nE#Smoking during early pregnancy affects the expression pattern of both nicot
inic and muscarinic acetylcholine receptors in human first trimester brainstem a
nd cerebellum^len#Neuroscience#20050000#2005#132#389-397#20070500#6683.htm#0306-
4522#Neuroscience##
00621000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960120
15300113030001200266065000900278064000500287031000300292014000800295865000900303
002000900312035001000321801001200331#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#140#33#article#60#33#^rND^sRavikumar^nBV#^rND^sSastry^nPS#Muscarinic
 cholinergic receptors in human foetal brain: characterization and ontogeny of [
3H]quinuclidinyl benzilate binding sites in frontal cortex^len#J Neurochem#19850
000#1985#44#240-246#20070500#6683.htm#0022-3042#J Neurochem##
00629000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960120
15900113030001200272065000900284064000500293031000300298014001000301865000900311
002000900320035001000329801001200339#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#141#34#article#60#34#^rND^sRavikumar^nBV#^rND^sSastry^nPS#Cholinergi
c muscarinic receptors in human fetal brain: ontogeny of [3H]quinuclidinyl benzi
late binding sites in corpus striatum, brainstem, and cerebellum^len#J Neurochem
#19850000#1985#45#1948-1950#20070500#6683.htm#0022-3042#J Neurochem##
00706000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
01700112010001700129010001600146010001600162012012000178030001400298065000900312
06400050032103100040032601400080033086500090033800200090034703500100035680100140
0366#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#142#35#article#60#35
#^rND^sBar-Peled^nO#^rND^sIsraeli^nM#^rND^sBen-Hur^nH#^rND^sHoskins^nI#^rND^sGro
ner^nY#^rND^sBiegon^nA#Developmental pattern of muscarinic receptors in normal a
nd Down's syndrome fetal brain - an autoradiographic study^len#Neurosci Lett#199
10000#1991#133#154-158#20070500#6683.htm#0304-3940#Neurosci Lett##
00742000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100020000910100
01800111010001500129010001500144010001700159810000600176012013400182030001900316
06500090033506400050034403100020034901400060035186500090035700200090036603500100
0375801001900385#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#143#36#a
rticle#60#36#^rND^sEgozi^nY#^rND^sSokolovsky^nM#^rND^sSchejter^nE#^rND^sBlatt^nI
#^rND^sZakut^nH#^rND^sMatzkel^nA#et al#Divergent regulation of muscarinic bindin
g sites and acetylcholinesterase in discrete regions of the developing human fet
al brain^len#Cell Mol Neurobiol#19860000#1986#6#55-70#20070500#6683.htm#0272-434
0#Cell Mol Neurobiol##
00625000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01600113010002400129012009100153030001300244065000900257064000500266031000300271
014000800274865000900282002000900291035001000300801001300310#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6683.htm#S#c#144#37#article#60#37#^rND^sSchlumpf^nM#^rND^
sPalacios^nJM#^rND^sCortes^nR#^rND^sLichtensteiger^nW#Regional development of mu
scarinic cholinergic binding sites in the prenatal rat brain^len#Neuroscience#19
910000#1991#45#347-357#20070500#6683.htm#0306-4522#Neuroscience##
00646000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01800108010001700126012012100143030001400264065000900278064000500287031000400292
014000600296865000900302002000900311035001000320801001400330#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6683.htm#S#c#145#38#article#60#38#^rND^sAubert^nI#^rND^sC
ecyre^nD#^rND^sGauthier^nS#^rND^sQuirion^nR#Comparative ontogenic profile of cho
linergic markers, including nicotinic and muscarinic receptors, in the rat brain
^len#J Comp Neurol#19960000#1996#369#31-55#20070500#6683.htm#0021-9967#J Comp Ne
urol##
00609000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760120146001000300
02200246065000900268064000500277031000300282014000800285865000900293002000900302
035001000311801002200321#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
146#39#article#60#39#^rND^sBerger-Sweeney^nJ#The cholinergic basal forebrain sys
tem during development and its influence on cognitive processes: important quest
ions and potential answers^len#Neurosci Biobehav Rev#20030000#2003#27#401-411#20
070500#6683.htm#0149-7634#Neurosci Biobehav Rev##
00553000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930120
04100112030002400153065000900177064000500186031000400191032001000195014000600205
865000900211002000900220035001000229801002400239#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#147#40#article#60#40#^rND^sLauder^nJM#^rND^sSchambra^nUB
#Morphogenetic roles of acetylcholine^len#Environ Health Perspect#19990000#1999#
107#^sSuppl 1#65-69#20070500#6683.htm#0091-6765#Environ Health Perspect##
00555000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920120
12500108030001000233710000200243065000900245064000500254031000400259014000800263
865000900271002000900280#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
148#41#article#60#41#^rND^sAdams^nPR#^rND^sBrown^nDA#Synaptic inhibition of the 
M-current: slow excitatory post-synaptic potential mechanism in bullfrog sympath
etic neurones^len#J Physiol#2#19820000#1982#332#263-272#20070500#6683.htm##
00588000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01400110012008600124030001700210065000900227064000500236031000400241014000800245
865000900253002000900262035001000271801001700281#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#149#42#article#60#42#^rND^sFibiger^nHC#^rND^sDamsma^nG#^
rND^sDay^nJC#Behavioral pharmacology and biochemistry of central cholinergic neu
rotransmission^len#Adv Exp Med Biol#19910000#1991#295#399-414#20070500#6683.htm#
0065-2598#Adv Exp Med Biol##
00720000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01400109010002400123010002000147010001700167810000600184012009000190030002400280
06500090030406400050031303100040031801400080032286500090033000200090033903500100
0348801002400358#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#150#43#a
rticle#60#43#^rND^sAdams^nCE#^rND^sBroide^nRS#^rND^sChen^nY#^rND^sWinzer-Serhan^
nUH#^rND^sHenderson^nTA#^rND^sLeslie^nFM#et al#Development of the alpha7 nicotin
ic cholinergic receptor in rat hippocampal formation^len#Brain Res Dev Brain Res
#20020000#2002#139#175-187#20070500#6683.htm#0165-3806#Brain Res Dev Brain Res##
00581000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120121000920300
02400213065000900237064000500246031000400251014000800255865000900263002000900272
035001000281801002400291#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
151#44#article#60#44#^rND^sAdams^nCE#Comparison of alpha7 nicotinic acetylcholin
e receptor development in the hippocampal formation of C3H and DBA/2 mice^len#Br
ain Res Dev Brain Res#20030000#2003#143#137-149#20070500#6683.htm#0165-3806#Brai
n Res Dev Brain Res##
00624000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910120
13700108030002400245065000900269064000500278031000300283014000800286865000900294
002000900303035001000312801002400322#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#152#45#article#60#45#^rND^sVizi^nES#^rND^sLendvai^nB#Modulatory role
 of presynaptic nicotinic receptors in synaptic and non-synaptic chemical commun
ication in the central nervous system^len#Brain Res Brain Res Rev#19990000#1999#
30#219-235#20070500#6683.htm#0165-0173#Brain Res Brain Res Rev##
00640000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01600110010001500126010001500141012009800156030000800254065000900262064000500271
031000400276014001000280865000900290002000900299035001000308801000800318#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#153#46#article#60#46#^rND^sMcGeh
ee^nDS#^rND^sHeath^nMJ#^rND^sGelber^nS#^rND^sDevay^nP#^rND^sRole^nLW#Nicotine en
hancement of fast excitatory synaptic transmission in CNS by presynaptic recepto
rs^len#Science#19950000#1995#269#1692-1696#20070500#6683.htm#0036-8075#Science##
00601000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
13000110030001500240065000900255064000500264031000300269014000800272865000900280
002000900289035001000298801001500308#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#154#47#article#60#47#^rND^sEdwards^nJA#^rND^sCline^nHT#Light-induced
 calcium influx into retinal axons is regulated by presynaptic nicotinic acetylc
holine receptor activity in vivo^len#J Neurophysiol#19990000#1999#81#895-907#200
70500#6683.htm#0022-3077#J Neurophysiol##
00635000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01800112012014000130030001000270065000900280064000500289031000500294014000800299
865000900307002000900316035001000325801001000335#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#155#48#article#60#48#^rND^sSlotkin^nTA#^rND^sCousins^nMM
#^rND^sSeidler^nFJ#Administration of nicotine to adolescent rats evokes regional
ly selective upregulation of CNS alpha 7 nicotinic acetylcholine receptors^len#B
rain Res#20040000#2004#1030#159-163#20070500#6683.htm#0006-8993#Brain res##
00705000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01700110010001800127010001700145010001500162810000600177012011900183030000700302
06500090030906400050031803100030032301400060032686500090033200200090034103500100
0350801000700360#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#156#49#a
rticle#60#49#^rND^sMyers^nCP#^rND^sLewcock^nJW#^rND^sHanson^nMG#^rND^sGosgnach^n
S#^rND^sAimone^nJB#^rND^sGage^nFH#et al#Cholinergic input is required during emb
ryonic development to mediate proper assembly of spinal locomotor circuits^len#N
euron#20050000#2005#46#37-49#20070500#6683.htm#0896-6273#Neuron##
00691000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01800110010001700128010002100145010001700166012010300183030001400286065000900300
06400050030903100040031401400050031886500090032300200090033203500100034180100140
0351#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#157#50#article#60#50
#^rND^sPhelps^nPE#^rND^sBarber^nRP#^rND^sBrennan^nLA#^rND^sMaines^nVM#^rND^sSalv
aterra^nPM#^rND^sVaughn^nJE#Embryonic development of four different subsets of c
holinergic neurons in rat cervical spinal cord^len#J Comp Neurol#19900000#1990#2
91#9-26#20070500#6683.htm#0021-9967#J Comp Neurol##
00686000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01500113010001800128010001800146012012500164030001500289065000900304064000500313
031000300318014000800321865000900329002000900338035001000347801001500357#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#158#51#article#60#51#^rND^sSlotk
in^nTA#^rND^sSouthard^nMC#^rND^sAdam^nSJ#^rND^sCousins^nMM#^rND^sSeidler^nFJ#Alp
ha7 nicotinic acetylcholine receptors targeted by cholinergic developmental neur
otoxicants: nicotine and chlorpyrifos^len#Brain Res Bull#20040000#2004#64#227-23
5#20070500#6683.htm#0361-9230#Brain Res Bull##
00598000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950120
12900114030001100243065000900254064000500263031000300268014001000271865000900281
002000900290035001000299801001100309#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#159#52#article#60#52#^rND^sAramakis^nVB#^rND^sMetherate^nR#Nicotine 
selectively enhances NMDA receptor-mediated synaptic transmission during postnat
al development in sensory neocortex^len#J Neurosci#19980000#1998#18#8485-8495#20
070500#6683.htm#0270-6474#J Neurosci##
00603000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760120146001000300
01900246065000900265064000500274031000300279014000800282865000900290002000900299
035001000308801001900318#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#
160#53#article#60#53#^rND^sBerger-Sweeney^nJ#The effects of neonatal basal foreb
rain lesions on cognition: towards understanding the developmental role of the c
holinergic basal forebrain^len#Int J Dev Neurosci#19980000#1998#16#603-612#20070
500#6683.htm#0736-5748#Int J Dev Neurosci##
00721000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01500112010001600127010001900143010001900162810000600181012012000187030001100307
06500090031806400050032703100040033201400080033686500090034400200090035303500100
0362801001100372#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#161#54#a
rticle#60#54#^rND^sRicceri^nL#^rND^sMinghetti^nL#^rND^sMoles^nA#^rND^sPopoli^nP#
^rND^sConfaloni^nA#^rND^sDe^nSimone R#et al#Cognitive and neurological deficits 
induced by early and prolonged basal forebrain cholinergic hypofunction in rats^
len#Exp Neurol#20040000#2004#189#162-172#20070500#6683.htm#0014-4886#Exp Neurol#
#
00588000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100024000940120
09400118030002300212065000900235064000500244031000200249014000800251865000900259
002000900268035001000277801002300287#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#162#55#article#60#55#^rND^sHohmann^nCF#^rND^sBerger-Sweeney^nJ#Choli
nergic regulation of cortical development and plasticity: New twists to an old s
tory^len#Perspect Dev Neurobiol#19980000#1998#5#401-425#20070500#6683.htm#1064-0
517#Perspect Dev Neurobiol##
00577000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01500109012006700124030002000191065000900211064000500220031000400225014001000229
865000900239002000900248035001000257801002000267#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#163#56#article#60#56#^rND^sNijland^nMJ#^rND^sChao^nCR#^r
ND^sRoss^nMG#Anticholinergic suppression of ovine fetal swallowing activity^len#
Am J Obstet Gynecol#19970000#1997#177#1105-1112#20070500#6683.htm#0002-9378#Am J
 Obstet Gynecol##
00569000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930120
09600110030001500206065000900221064000500230031000300235014001000238865000900248
002000900257035001000266801001500276#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#164#57#article#60#57#^rND^sJoseph^nSA#^rND^sWalker^nDW#Catecholamine
 neurons in fetal brain: effects on breathing movements and electrocorticogram^l
en#J Appl Physiol#19900000#1990#69#1903-1911#20070500#6683.htm#0021-8987#J Appl 
Physiol##
00539000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920120
07300109030001400182065000900196064000500205031000300210014000600213865000900219
002000900228035001000237801001400247#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
683.htm#S#c#165#58#article#60#58#^rND^sSzeto^nHH#^rND^sHinman^nDJ#Central muscar
inic modulation of fetal blood pressure and heart rate^len#J Dev Physiol#1990000
0#1990#13#17-23#20070500#6683.htm#0141-9846#J Dev Physiol##
00694000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100015000890100
01900104010001300123010001200136012012900148030002400277065000900301064000500310
031000300315014001000318865000900328002000900337035001000346801002400356#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6683.htm#S#c#166#59#article#60#59#^rND^sShi^n
L#^rND^sZhang^nY#^rND^sMorrissey^nP#^rND^sYao^nJ#^rND^sXu^nZ#The association of 
cardiovascular responses with brain c-fos expression after central carbachol in 
the near-term ovine fetus^len#Neuropsychopharmacology#20050000#2005#30#2162-2168
#20070500#6683.htm#0893-133X#Neuropsychopharmacology##
00653000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100019000890100
02000108012015300128030001500281065000900296064000500305031000400310014000600314
865000900320002000900329035001000338801001500348#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6683.htm#S#c#167#60#article#60#60#^rND^sWei^nR#^rND^sPhillips^nTM#^rN
D^sSternberg^nEM#Specific up-regulation of CRH or AVP secretion by acetylcholine
 or lipopolysaccharide in inflammatory susceptible Lewis rat fetal hypothalamic 
cells^len#J Neuroimmunol#20020000#2002#131#31-40#20070500#6683.htm#0165-5728#J N
euroimmunol##
00270000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020012000857030
00300097#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\tribute.htm#S#o#1#1#text#1#20
080212#125736#tribute.htm#30##
01607000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015212300020016201201130
01640100033002770100034003100100024003440100032003680100029004000100023004290100
02700452070010600479070013700585070011400722070008200836070010000918070008301018
002001201101#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\tribute.htm#S#h#2#1#text#
1#sc#en#bjmbr#1#3.1#ILUS#13#BJMBR700#nd#Braz J Med Biol Res#40#5#20070500#^f697^
l698#0100-879X#1#A tribute to Samuel MacDonald McCann (1925-2007): in honor of o
ne of the last pioneers of Neuroendocrinology^len#^rND^1A01^nJ.^sAntunes-Rodrigu
es#^rND^1A03^nJ.C.^sBedran de Castro#^rND^1A01^nC.R.^sFranci#^rND^1A02^nJ.A.^sAn
selmo Franci#^rND^1A04^nC.C.^sPazos Moura#^rND^1A05^nE.G.^sMoura#^rND^1A06^nU.^s
Marubayashi#USP^iA01^1Faculdade de Medicina de Ribeirão Preto^2Departamento de F
isiologia^cRibeirão Preto^sSP^pBrasil#USP^iA02^1Faculdade de Odontologia de Ribe
irão Preto^2Departamento de Morfologia, Estomatologia e Fisiologia^cRibeirão Pre
to^sSP^pBrasil#UNESP^iA03^1Faculdade de Odontologia de Araçatuba^2Departamento d
e Apoio, Produção e Saúde^cAraçatuba^sSP^pBrasil#UFRJ^iA04^1Instituto de Biofísi
ca Carlos Chagas Filho^cRio de Janeiro^sRJ^pBrasil#UERJ^iA05^1Instituto de Biolo
gia^2Departamento de Ciências Fisiológicas^cRio de Janeiro^sRJ^pBrasil#UFMG^iA06
^1ICB^2Departamento de Fisiologia e Biofísica^cBelo Horizonte^sMG^pBrasil#tribut
e.htm##
01607000000000493000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015212300020016201201130
01640100033002770100034003100100024003440100032003680100029004000100023004290100
02700452070010600479070013700585070011400722070008200836070010000918070008301018
002001201101#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\tribute.htm#S#f#3#1#text#
1#sc#en#bjmbr#1#3.1#ILUS#13#BJMBR700#nd#Braz J Med Biol Res#40#5#20070500#^f697^
l698#0100-879X#1#A tribute to Samuel MacDonald McCann (1925-2007): in honor of o
ne of the last pioneers of Neuroendocrinology^len#^rND^1A01^nJ.^sAntunes-Rodrigu
es#^rND^1A03^nJ.C.^sBedran de Castro#^rND^1A01^nC.R.^sFranci#^rND^1A02^nJ.A.^sAn
selmo Franci#^rND^1A04^nC.C.^sPazos Moura#^rND^1A05^nE.G.^sMoura#^rND^1A06^nU.^s
Marubayashi#USP^iA01^1Faculdade de Medicina de Ribeirão Preto^2Departamento de F
isiologia^cRibeirão Preto^sSP^pBrasil#USP^iA02^1Faculdade de Odontologia de Ribe
irão Preto^2Departamento de Morfologia, Estomatologia e Fisiologia^cRibeirão Pre
to^sSP^pBrasil#UNESP^iA03^1Faculdade de Odontologia de Araçatuba^2Departamento d
e Apoio, Produção e Saúde^cAraçatuba^sSP^pBrasil#UFRJ^iA04^1Instituto de Biofísi
ca Carlos Chagas Filho^cRio de Janeiro^sRJ^pBrasil#UERJ^iA05^1Instituto de Biolo
gia^2Departamento de Ciências Fisiológicas^cRio de Janeiro^sRJ^pBrasil#UFMG^iA06
^1ICB^2Departamento de Fisiologia e Biofísica^cBelo Horizonte^sMG^pBrasil#tribut
e.htm##
01746000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000300116
03000240011903100030014303200020014606500090014801400110015703500100016812300020
01780120113001800100032002930100034003250100024003590100032003830100029004150100
02300444010002600467070010800493070013900601070011600740070008400856070010200940
070008501042002001201127008008901139#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\t
ribute.htm#S#l#4#1#text#1#^mMay^a2007#sc#en#bjmbr#1#3.1#ilus#13#BJMBR700#nd#Braz
. j. med. biol. res#40#5#20070500#^f697^l698#0100-879X#1#A tribute to Samuel Mac
Donald McCann (1925-2007): in honor of one of the last pioneers of Neuroendocrin
ology^len#^rND^1A01^nJ^sAntunes-Rodrigues#^rND^1A03^nJ. C^sBedran de Castro#^rND
^1A01^nC. R^sFranci#^rND^1A02^nJ. A^sAnselmo Franci#^rND^1A04^nC. C^sPazos Moura
#^rND^1A05^nE. G^sMoura#^rND^1A06^nU^sMarubayashi#^iA01^1USP^2Faculdade de Medic
ina de Ribeirão Preto^3Departamento de Fisiologia^cRibeirão Preto^sSP^pBrasil#^i
A02^1USP^2Faculdade de Odontologia de Ribeirão Preto^3Departamento de Morfologia
, Estomatologia e Fisiologia^cRibeirão Preto^sSP^pBrasil#^iA03^1UNESP^2Faculdade
 de Odontologia de Araçatuba^3Departamento de Apoio, Produção e Saúde^cAraçatuba
^sSP^pBrasil#^iA04^1UFRJ^2Instituto de Biofísica Carlos Chagas Filho^cRio de Jan
eiro^sRJ^pBrasil#^iA05^1UERJ^2Instituto de Biologia^3Departamento de Ciências Fi
siológicas^cRio de Janeiro^sRJ^pBrasil#^iA06^1UFMG^2ICB^3Departamento de Fisiolo
gia e Biofísica^cBelo Horizonte^sMG^pBrasil#tribute.htm#Internet^ihttp://www.sci
elo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500013##
00394000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704016600070002001200236#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#5#1#text#26#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif"><
B>May 2007, Volume 40(5) 697-698</B></font></B></P>      ^cY#tribute.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012200070002001200192#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#6#2#text#26#<p align="center"><font f
ace="Arial, Helvetica, sans-serif"><B><font size="5">A tribute to Samuel MacDona
ld McCann    ^cY#tribute.htm##
00263000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704003500070002001200105#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#7#3#text#26#<br>   </font> (1925-2007
)     ^cY#tribute.htm##
00320000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704009200070002001200162#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#8#4#text#26#<br>  In honor of one of 
the last pioneers of Neuroendocrinology </B> </font></p>       ^cY#tribute.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704027800070002001200348#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#9#5#text#26#<P><font face="Arial, Hel
vetica, sans-serif">J. Antunes-Rodrigues<SUP>1</SUP>,    J.C. Bedran de Castro<S
UP>3</SUP>, C.R. Franci<SUP>1</SUP>, J.A. Anselmo Franci<SUP>2</SUP>,    C.C. Pa
zos Moura<SUP>4</SUP>, E.G. Moura<SUP>5</SUP> and U. Marubayashi<sup>6</sup></fo
nt>      ^cY#tribute.htm##
00408000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704017900071002001200250#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#10#6#text#26#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Departamento de Fisiologia, Faculdade de Medici
na de Ribeir&atilde;o Preto, USP, Ribeir&atilde;o Preto, SP, Brasil    ^cY#tribu
te.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704017800071002001200249#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#11#7#text#26#<br>        <SUP>2</SUP>
Departamento de Morfologia, Estomatologia e Fisiologia, Faculdade de Odontologia
 de Ribeir&atilde;o Preto, USP, Ribeir&atilde;o Preto, SP, Brasil     ^cY#tribut
e.htm##
00405000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704017600071002001200247#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#12#8#text#26#<br>        <SUP>3</SUP>
Departamento de Apoio, Produ&ccedil;&atilde;o e Sa&uacute;de, Faculdade de Odont
ologia de Ara&ccedil;atuba, UNESP, Ara&ccedil;atuba, SP, Brasil     ^cY#tribute.
htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011100071002001200182#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#13#9#text#26#<br>   <SUP>4</SUP>Insti
tuto de Biof&iacute;sica Carlos Chagas Filho, UFRJ, Rio de Janeiro, RJ, Brasil  
   ^cY#tribute.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704013700072002001200209#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#14#10#text#26#<br>   <SUP>5</SUP>Depa
rtamento de Ci&ecirc;ncias Fisiol&oacute;gicas, Instituto de Biologia, UERJ, , R
io de Janeiro, RJ, Brasil     ^cY#tribute.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704012000072002001200192#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#15#11#text#26#<br>  <SUP>6</SUP>Depar
tamento de Fisiologia e Biof&iacute;sica, ICB, UFMG, Belo Horizonte, MG, Brasil<
/font>       ^cY#tribute.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021600072002001200288#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#16#12#text#26#<P align="right"><font 
size="2" face="Arial, Helvetica, sans-serif"><em>The authors were colleagues who
 worked under the supervision of Prof. McCann in the Department of Physiology of
 the University of Texas,    ^cY#tribute.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011400072002001200186#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#17#13#text#26#<br>    Southwestern Me
dical School, Dallas, Texas, USA</em> </font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2
>      ^cY#tribute.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009500072002001200167#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#18#14#text#26#<P align="center" class
="style4"><img src="/img/revistas/bjmbr/v40n5/mccann.jpg"></P>      ^cY#tribute.
htm##
01064000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704083400072002001200906#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#19#15#text#26#<P class="style4"><font
 face="Arial, Helvetica, sans-serif">Samuel MacDonald McCann was born in Houston
, Texas, USA, on September 8, 1925, the only child of parents dedicated to unive
rsity life. He received his basic education at Rice University, Houston. However
, his interest in science developed during high school at Culver Military Academ
y. He obtained his MD at the Medical School of the University of Pennsylvania in
 1948 in only three years, always as one of the best students in the course. Dur
ing this period he published two papers in the American Journal of Physiology de
monstrating the role of stress and of adrenocortical hormones in triggering hype
rtension. He did his internship and medical residency at Massachusetts General H
ospital, Boston, where he conducted studies on the artificial kidney. </font></P
>      ^cY#tribute.htm##
01205000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704097500072002001201047#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#20#16#text#26#<P class="style4"><font
 face="Arial, Helvetica, sans-serif">Two years later he returned to the Universi
ty of Pennsylvania as a Physiology Instructor and then served in the American Ar
med Forces at Walter Reed Hospital (Army Medical Corps), where he continued his 
studies on stress and on the control of vasopressin secretion. In the Department
 of Physiology of the University of Pennsylvania he started his pioneering studi
es in Neuroendocrinology, demonstrating the existence of neuropeptides secreted 
by the hypothalamus and responsible for the control of adenohypophyseal function
s. He was the first to demonstrate the role of vasopressin in the control of ACT
H secretion, the biological existence of LH-releasing factor (LHRF) in the basal
 middle hypothalamus, and of FSH-RF, GHRF and GHIF, the last known as somatostat
in. At the University of Pennsylvania he held all the academic positions from In
structor to Full Professor of Physiology in 1964. </font> </P>      ^cY#tribute.
htm##
00856000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704062600072002001200698#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#21#17#text#26#<P><font face="Arial, H
elvetica, sans-serif">In 1965 he was invited to be Chairman of the Department of
 Physiology of Tulane University, New Orleans, and of the University of Texas, S
outhwestern Medical School, Dallas. He chose the University of Texas, where he b
uilt one of the best Neuroendocrinology nuclei in the country. At that time, one
 of us (JAR) had the privilege of accompanying him from Philadelphia to Dallas, 
remaining with him for two years working under his supervision in order to isola
te biologically and to purify the hypothalamic factors that control the function
s of the adenohypophysis. </font>      ^cY#tribute.htm##
00786000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055600072002001200628#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#22#18#text#26#<P><font face="Arial, H
elvetica, sans-serif">The scientific career of Dr. McCann was very productive: h
e published more than 700 full papers and many chapters in books, acting as edit
or of several other books. These data represent the profile of a born researcher
, very dynamic and with privileged intellectual capacity. Throughout his life he
 received many prizes, honors and medals. In 1987 he was elected a member of the
 National Academy of Sciences of the United States, one of the positions most so
ught after by scientists worldwide. </font>      ^cY#tribute.htm##
01022000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704079200072002001200864#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#23#19#text#26#<P><font face="Arial, H
elvetica, sans-serif">He had a special gift regarding the stimulation and traini
ng of young investigators. Many of those he trained progressed greatly in their 
countries of origin, thus multiplying his ability to train human resources. To t
he young people who worked at his side he transmitted security and confidence re
garding free thinking, scientific independence and autonomous activity. One of h
is main characteristics was to stimulate the scientific development of each disc
iple, respecting his individuality. He molded students, not in his own likeness,
 but by encouraging them to develop their own scientific abilities. He trained p
eople and not tools for his own work. Many investigators from all over the world
 passed through his laboratory. </font>      ^cY#tribute.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704023300072002001200305#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#24#20#text#26#<P><font face="Arial, H
elvetica, sans-serif">At 70 years of age he was honored by the Pennington Biomed
ical Research Center, Louisiana State University at Baton Rouge, which conferred
 to him the Endowed Chair title. </font>      ^cY#tribute.htm##
00955000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704072500072002001200797#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#25#21#text#26#<P><font face="Arial, H
elvetica, sans-serif">Dr. McCann belonged to many scientific societies and was a
 member of the Council of the American Physiological Society and Endocrine Socie
ty. In addition, he was a member of the National Academy of Science of the Unite
d States and an honorary member of various international scientific societies, a
mong them Sociedade Brasileira de Fisiologia (Brazilian Physiological Society). 
He was the President of the International Neuroendocrine Federation, of the Soci
ety for Experimental Biology and Medicine, of the International Society of Neuro
endocrinology, and of the International Society of Neuroimmunomodulation. He was
 also Editor-in-Chief of Neuroendocrinology. </font>      ^cY#tribute.htm##
00734000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704050400072002001200576#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#26#22#text#26#<P><font face="Arial, H
elvetica, sans-serif">Until his last days, Prof. McCann accompanied the scientif
ic evolution of Brazilian groups and the increasing body of scientific knowledge
 of the Brazilian society, providing guidance to the young with precise attitude
s and opinions inducing the humanistic training complementary to modern scientif
ic qualification. He used to say that "in science there is no substitute for the
 brain". The brain implies intelligence and the heart, charity. </font>      ^cY
#tribute.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704021600072002001200288#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#27#23#text#26#<P><font face="Arial, H
elvetica, sans-serif">He was a pioneer. He delighted in opening new research lin
es, "opening roads". His intellectual ability was impressive, as confirmed by hi
s publications. </font>      ^cY#tribute.htm##
00644000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704041400072002001200486#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#28#24#text#26#<P><font face="Arial, H
elvetica, sans-serif">Prof. McCann died on March 16, 2007. The feeling of loss o
f a Teacher and friend is very painful, but we must look back at all those times
 of pleasure, camaraderie and mutual cooperation that we experienced together. I
t was all worth it! We are sure that he did all he could for Physiology and espe
cially for Neuroendocrinology. Now he rests in peace. </font>      ^cY#tribute.h
tm##
00872000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704064200072002001200714#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#29#25#text#26#<P><font face="Arial, H
elvetica, sans-serif">Last year, during the closing ceremony of the Internationa
l Symposium of Neuroendocrinology "Neuroendocrine control of body fluid homeosta
sis: past, present and future", Ribeir&atilde;o Preto, SP, Brazil, September 1-3
, 2006, we asked the participants to applaud Dr. McCann for all he represented f
or Neuroendocrine Physiology. After the ovation, he addressed Dr. Antunes and sa
id: "Jos&eacute;, this is one of the happiest moments of my life!" The Teacher i
s gone, but he leaves behind that exemplary flame that will light up the path fo
r many young people dedicated to science. </font>      ^cY#tribute.htm##
00718000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704048800072002001200560#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\tribute.htm#S#p#30#26#text#26#<P><font face="Arial, H
elvetica, sans-serif">Prof. McCann will always be remembered as one of the pione
ers in contemporary Neuroendocrinology and as a human being of invaluable worth.
 His wisdom, culture and humanistic vision of science made of him a model to be 
followed by all of us. He built a fundamental opus, of those that mark a time, d
efine paths and serve as an example. To him, our everlasting gratitude. </font> 
   <font face="Arial, Helvetica, sans-serif"> </font>        ^cY#tribute.htm##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#o#1#1#article#1#20
080213#154524#6376.htm#150##
02969000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120047001790100032002260100025002580100022002830700128003050700116004330831
55200549085000802101085002002109085001702129085001602146085002202162085002402184
08500160220811700060222407200030223005800070223305800050224006000150224511200090
2260111001802269114000902287113001402296881002402310002000902334#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB
#12#BJMBR080#FAPESP#Braz J Med Biol Res#40#5#20070500#^f687^l696#0100-879X#20070
405#Cl- and regulation of pH by MDCK-C11 cells^len#^rND^1A01 A02^nA.L.^sTararthu
ch#^rND^1A02^nR.^sFernandez#^rND^1A01^nG.^sMalnic#Universidade de São Paulo^iA01
^1Instituto de Ciências Biomédicas^2Departamento de Fisiologia e Biofísica^cSão 
Paulo^sSP^pBrasil#Universidade Federal do Paraná^iA02^1Departamento de Fisiologi
a^2Setor de Ciências Biológicas^cCuritiba^sPR^pBrasil#^len^aThe interaction betw
een H+ extrusion via H+-ATPase and Cl- conductance was studied in the C11 clone 
of MDCK cells, akin to the intercalated cells of the collecting duct. Cell pH (p
Hi) was measured by fluorescence microscopy using the fluorescein-derived probe 
BCECF-AM. Control recovery rate measured after a 20 mM NH4Cl acid pulse was 0.13
6 ± 0.008 pH units/min (dpHi/dt) in Na+ Ringer and 0.032 ± 0.003 in the absence 
of Na+ (0 Na+). With 0 Na+ plus the Cl- channel inhibitor NPPB (10 µM), recovery
 was reduced to 0.014 ± 0.001 dpHi/dt. 8-Br-cAMP, known to activate CFTR Cl- cha
nnels, increased dpHi/dt in 0 Na+ to 0.061 ± 0.009 and also in the presence of 4
6 nM concanamycin and 50 µM Schering 28080. Since it is thought that the Cl- dep
endence of H+-ATPase might be due to its electrogenic nature and the establishme
nt of a +PD (potential difference) across the cell membrane, the effect of 10 µM
 valinomycin at high (100 mM) K+ was tested in our cells. In Na+ Ringer, dpHi/dt
 was increased, but no effect was detected in 0 Na+ Ringer in the presence of NP
PB, indicating that in intact C11 cells the effect of blocking Cl- channels on d
pHi/dt was not due to an adverse electrical gradient. The effect of 100 µM ATP w
as studied in 0 Na+ Ringer solution; this treatment caused a significant inhibit
ion of dpHi/dt, reversed by 50 µM Bapta. We have shown that H+-ATPase present in
 MDCK C11 cells depends on Cl- ions and their channels, being regulated by cAMP 
and ATP, but not by the electrical gradient established by electrogenic H+ trans
port.#^dnd^i1#^tm^len^kCell pH^i1#^tm^len^kcAMP^i1#^tm^len^kATP^i1#^tm^len^kH+-A
TPase^i1#^tm^len^kValinomycin^i1#^tm^len^kCl-^i1#other#40#FAPESP#CNPq#66.1029/19
98-0#20060215#February 15, 2006#20070302#March 2, 2007#S0100-879X2006005000098#6
376.htm##
03197000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120058001790100032002370100025002690100022002940700128003160700116004440831
78300560085000802343085002002351085001702371085001602388085003302404085002402437
08500270246111700060248807200030249405800070249705800050250406000150250911200090
2524111001802533114000902551113001402560002000902574#v40n5#v:\scielo\serial\bjmb
r\v40n5\markup\6376.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#12#BJMBR080
#FAPESP#Braz J Med Biol Res#40#5#20070500#^f687^l696#0100-879X#20070405#Cl<sup>-
</sup> and regulation of pH by MDCK-C11 cells^len#^rND^1A01 A02^nA.L.^sTararthuc
h#^rND^1A02^nR.^sFernandez#^rND^1A01^nG.^sMalnic#Universidade de São Paulo^iA01^
1Instituto de Ciências Biomédicas^2Departamento de Fisiologia e Biofísica^cSão P
aulo^sSP^pBrasil#Universidade Federal do Paraná^iA02^1Departamento de Fisiologia
^2Setor de Ciências Biológicas^cCuritiba^sPR^pBrasil#^len^aThe interaction betwe
en H<sup>+</sup> extrusion via H<sup>+</sup>-ATPase and Cl<sup>-</sup> conductan
ce was studied in the C11 clone of MDCK cells, akin to the intercalated cells of
 the collecting duct. Cell pH (pHi) was measured by fluorescence microscopy usin
g the fluorescein-derived probe BCECF-AM. Control recovery rate measured after a
 20 mM NH<sub>4</sub>Cl acid pulse was 0.136 ± 0.008 pH units/min (dpHi/dt) in N
a<sup>+</sup> Ringer and 0.032 ± 0.003 in the absence of Na<sup>+</sup> (0 Na<su
p>+</sup>). With 0 Na<sup>+</sup> plus the Cl<sup>-</sup> channel inhibitor NPPB
 (10 µM), recovery was reduced to 0.014 ± 0.001 dpHi/dt. 8-Br-cAMP, known to act
ivate CFTR Cl<sup>-</sup> channels, increased dpHi/dt in 0 Na<sup>+</sup> to 0.0
61 ± 0.009 and also in the presence of 46 nM concanamycin and 50 µM Schering 280
80. Since it is thought that the Cl<sup>-</sup> dependence of H<sup>+</sup>-ATPa
se might be due to its electrogenic nature and the establishment of a +PD (poten
tial difference) across the cell membrane, the effect of 10 µM valinomycin at hi
gh (100 mM) K<sup>+</sup> was tested in our cells. In Na<sup>+</sup> Ringer, dpH
i/dt was increased, but no effect was detected in 0 Na<sup>+</sup> Ringer in the
 presence of NPPB, indicating that in intact C11 cells the effect of blocking Cl
<sup>-</sup> channels on dpHi/dt was not due to an adverse electrical gradient. 
The effect of 100 µM ATP was studied in 0 Na<sup>+</sup> Ringer solution; this t
reatment caused a significant inhibition of dpHi/dt, reversed by 50 µM Bapta. We
 have shown that H<sup>+</sup>-ATPase present in MDCK C11 cells depends on Cl<su
p>-</sup> ions and their channels, being regulated by cAMP and ATP, but not by t
he electrical gradient established by electrogenic H<sup>+</sup> transport.#^dnd
^i1#^tm^len^kCell pH^i1#^tm^len^kcAMP^i1#^tm^len^kATP^i1#^tm^len^kH<sup>+</sup>-
ATPase^i1#^tm^len^kValinomycin^i1#^tm^len^kCl<sup>-</sup>^i1#other#40#FAPESP#CNP
q#66.1029/1998-0#20060215#February 15, 2006#20070302#March 2, 2007#6376.htm##
03064000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762230009001860120047001950100032002420100024002740100021002980700130003190700
11800449083155200567085000802119085002002127085001702147085001602164085002202180
08500240220208500160222611700060224207200030224805800070225105800050225806000150
2263112000902278111001802287114000902305113001402314002000902328008008902337#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#l#4#1#article#1#^mMay^a2007#oa
#en#bjmbr#1#3.1#ilus#tab#12#BJMBR080#FAPESP#Braz. j. med. biol. res#40#5#2007050
0#^f687^l696#0100-879X#20070405#Cl- and regulation of pH by MDCK-C11 cells^len#^
rND^1A01 A02^nA. L^sTararthuch#^rND^1A02^nR^sFernandez#^rND^1A01^nG^sMalnic#^iA0
1^1Universidade de São Paulo^2Instituto de Ciências Biomédicas^3Departamento de 
Fisiologia e Biofísica^cSão Paulo^sSP^pBrasil#^iA02^1Universidade Federal do Par
aná^2Departamento de Fisiologia^3Setor de Ciências Biológicas^cCuritiba^sPR^pBra
sil#^len^aThe interaction between H+ extrusion via H+-ATPase and Cl- conductance
 was studied in the C11 clone of MDCK cells, akin to the intercalated cells of t
he collecting duct. Cell pH (pHi) was measured by fluorescence microscopy using 
the fluorescein-derived probe BCECF-AM. Control recovery rate measured after a 2
0 mM NH4Cl acid pulse was 0.136 ± 0.008 pH units/min (dpHi/dt) in Na+ Ringer and
 0.032 ± 0.003 in the absence of Na+ (0 Na+). With 0 Na+ plus the Cl- channel in
hibitor NPPB (10 µM), recovery was reduced to 0.014 ± 0.001 dpHi/dt. 8-Br-cAMP, 
known to activate CFTR Cl- channels, increased dpHi/dt in 0 Na+ to 0.061 ± 0.009
 and also in the presence of 46 nM concanamycin and 50 µM Schering 28080. Since 
it is thought that the Cl- dependence of H+-ATPase might be due to its electroge
nic nature and the establishment of a +PD (potential difference) across the cell
 membrane, the effect of 10 µM valinomycin at high (100 mM) K+ was tested in our
 cells. In Na+ Ringer, dpHi/dt was increased, but no effect was detected in 0 Na
+ Ringer in the presence of NPPB, indicating that in intact C11 cells the effect
 of blocking Cl- channels on dpHi/dt was not due to an adverse electrical gradie
nt. The effect of 100 µM ATP was studied in 0 Na+ Ringer solution; this treatmen
t caused a significant inhibition of dpHi/dt, reversed by 50 µM Bapta. We have s
hown that H+-ATPase present in MDCK C11 cells depends on Cl- ions and their chan
nels, being regulated by cAMP and ATP, but not by the electrical gradient establ
ished by electrogenic H+ transport.#^dnd^i1#^tm^len^kCell pH^i1#^tm^len^kcAMP^i1
#^tm^len^kATP^i1#^tm^len^kH+-ATPase^i1#^tm^len^kValinomycin^i1#^tm^len^kCl-^i1#o
ther#40#FAPESP#CNPq#66.1029/1998-0#20060215#February 15, 2006#20070302#March 2, 
2007#6376.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S
0100-879X2007000500012##
00371000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014500071002000900216#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#5#1#article#106#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, May 2007, Volum
e 40(5) 687-696</B> </font></P>      ^cY#6376.htm##
00358000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704013200071002000900203#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#6#2#article#106#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">Cl<SUP>-</SUP> and regulation of pH by MDCK-C11
 cells</font></B>       ^cY#6376.htm##
00574000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704034800071002000900419#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#7#3#article#106#<P><font face="Arial, He
lvetica, sans-serif">A.L. Tararthuch<SUP>1,2</SUP>, R.    Fernandez<SUP>2</SUP> 
and <b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/recor.gif" 
border="0"></a></b>    <a href="mailto:gemalnic@usp.br"><img src="/img/revistas/
bjmbr/v40n5/email-ca.gif" border="0"></a>    G. Malnic<SUP>1</SUP> </font>      
^cY#6376.htm##
00448000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704022200071002000900293#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#8#4#article#106#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Departamento de Fisiologia e Biof&iacute;sica, 
Instituto de Ci&ecirc;ncias Biom&eacute;dicas, Universidade de S&atilde;o Paulo,
 S&atilde;o Paulo, SP, Brasil     ^cY#6376.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704016900071002000900240#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#9#5#article#106#<br>     <SUP>2</SUP>Set
or de Ci&ecirc;ncias Biol&oacute;gicas, Departamento de Fisiologia, Universidade
 Federal do Paran&aacute;, Curitiba, PR, Brasil</font>       ^cY#6376.htm##
00417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019000072002000900262#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#10#6#article#106#<P> <font face="Arial, 
Helvetica, sans-serif"><A HREF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/d
own.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A> 
   ^cY#6376.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#11#7#article#106#<BR>   <A HREF="#Introd
uction"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#6376.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#12#8#article#106#<BR>   <A HREF="#Materi
al"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    
^cY#6376.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704017200072002000900244#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#13#9#article#106#<BR>   <A HREF="#Result
s"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6376.htm##
00409000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704018100073002000900254#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#14#10#article#106#<BR>   <A HREF="#Discu
ssion"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#6
376.htm##
00396000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016800073002000900241#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#15#11#article#106#<BR>   <A HREF="#Refer
ences"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6376.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023400073002000900307#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#16#12#article#106#<br>   </strong></A>  
 <A HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspo
ndence and Footnotes</strong></A>  </font>      ^cY#6376.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#17#13#article#106#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6376.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#18#14#article#106#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <fon
t face="Arial, Helvetica, sans-serif">      ^cY#6376.htm##
02062000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704183400073002000901907#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#19#15#article#106#<P>The interaction bet
ween H<SUP>+</SUP> extrusion via H<SUP>+</SUP>-ATPase and Cl<SUP>-</SUP> conduct
ance was studied in the C11 clone of MDCK cells, akin to the intercalated cells 
of the collecting duct. Cell pH (pHi) was measured by fluorescence microscopy us
ing the fluorescein-derived probe BCECF-AM. Control recovery rate measured after
 a 20 mM NH<SUB>4</SUB>Cl acid pulse was 0.136 &#177; 0.008 pH units/min (dpHi/d
t) in Na<SUP>+</SUP> Ringer and 0.032 &#177; 0.003 in the absence of Na<SUP>+</S
UP> (0 Na<SUP>+</SUP>). With 0 Na<SUP>+</SUP> plus the Cl<SUP>-</SUP> channel in
hibitor NPPB (10 &#181;M), recovery was reduced to 0.014 &#177; 0.001 dpHi/dt. 8
-Br-cAMP, known to activate CFTR Cl<SUP>-</SUP> channels, increased dpHi/dt in 0
 Na<SUP>+</SUP> to 0.061 &#177; 0.009 and also in the presence of 46 nM concanam
ycin and 50 &#181;M Schering 28080. Since it is thought that the Cl<SUP>-</SUP> 
dependence of H<SUP>+</SUP>-ATPase might be due to its electrogenic nature and t
he establishment of a +PD (potential difference) across the cell membrane, the e
ffect of 10 &#181;M valinomycin at high (100 mM) K<SUP>+</SUP> was tested in our
 cells. In Na<SUP>+</SUP> Ringer, dpHi/dt was increased, but no effect was detec
ted in 0 Na<SUP>+</SUP> Ringer in the presence of NPPB, indicating that in intac
t C11 cells the effect of blocking Cl<SUP>-</SUP> channels on dpHi/dt was not du
e to an adverse electrical gradient. The effect of 100 &#181;M ATP was studied i
n 0 Na<SUP>+</SUP> Ringer solution; this treatment caused a significant inhibiti
on of dpHi/dt, reversed by 50 &#181;M Bapta. We have shown that H<SUP>+</SUP>-AT
Pase present in MDCK C11 cells depends on Cl<SUP>-</SUP> ions and their channels
, being regulated by cAMP and ATP, but not by the electrical gradient establishe
d by electrogenic H<SUP>+</SUP> transport.      ^cY#6376.htm##
00373000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014500073002000900218#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#20#16#article#106#<P><B>Key words: </B> 
Cell pH, cAMP, ATP, H<SUP>+</SUP>-ATPase, Valinomycin, Cl<SUP>-</SUP>  </font>  
<HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6376.htm##
00665000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043700073002000900510#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#21#17#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT SIZE=4><FONT COLOR=#0000
7F><B>Introduction</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-s
erif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font fa
ce="Arial, Helvetica, sans-serif"></font>  <font face="Arial, Helvetica, sans-se
rif">      ^cY#6376.htm##
01307000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704107900073002000901152#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#22#18#article#106#<P>Various intracellul
ar compartments maintain an acidic pH that is necessary for a number of cellular
 functions, including vesicular trafficking. This is accomplished largely by the
 active transport of protons (H<SUP>+</SUP>) by the vacuolar type of H<SUP>+</SU
P>-ATPase. Active H<SUP>+</SUP>-transport by this pump is electrogenic and gener
ates a voltage gradient by creating an asymmetric distribution of charge across 
the vesicular membrane. The electrical polarization of this membrane can limit t
he maximal level of acidification by introducing a positive charge within the ve
sicle that opposes further movement of protons. The concurrent passive Cl<SUP>-<
/SUP> movement into vesicular compartments is able to restore electroneutrality 
and enables a higher pH gradient to be established (1,2). Several lines of evide
nce for this interaction has been advanced. An association between the ability t
o acidify intracellular organelles (endosomes, lysosomes, Golgi apparatus) and t
he presence of Cl<SUP>-</SUP> ions or Cl<SUP>-</SUP> channels has been observed 
(3,4).       ^cY#6376.htm##
01355000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704112700073002000901200#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#23#19#article#106#<P>Dependence of renal
 H<SUP>+</SUP>-ATPase on Cl<SUP>-</SUP>has also been observed in several studies
. The presence of H<SUP>+</SUP>-ATPase in proximal cells was detected by perfusi
ng these tubules <I>in vitro</I> in Na<SUP>+</SUP>-free medium and subjecting th
em to an acid (NH<SUB>4</SUB>Cl) pulse, observing cell pH recovery that was inhi
bited by n-ethyl-maleimide, an H<SUP>+</SUP>-ATPase blocker (5), or by perfusing
 them <I>in vivo</I> with bafilomycin, a specific H<SUP>+</SUP>-ATPase inhibitor
 (6). It was shown that the proximal H<SUP>+</SUP>-ATPase was dependent on the p
resence of Cl<SUP>-</SUP> and on active Cl<SUP>-</SUP> channels in studies on pe
rfused rabbit proximal tubules, where the recovery of cell pH in Na<SUP>+</SUP>-
free medium was significantly delayed by perfusion with 5-nitro-2 (3-phenylpropy
lamine)-benzoic acid (NPPB), a Cl<SUP>-</SUP> channel blocker (7,8). We also obs
erved a significant reduction of bicarbonate reabsorption (a reduction of the ra
te of H<SUP>+</SUP> secretion) in the late cortical distal tubule of the rat whe
n apical chloride channels were blocked with NPPB (9).       ^cY#6376.htm##
00735000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704050700073002000900580#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#24#20#article#106#<P>The interaction of 
Cl<SUP>-</SUP> ions with H<SUP>+</SUP>-ATPase, however, cannot be explained only
 by the establishment or dissipation of a potential difference (PD) across cellu
lar and subcellular membranes. It has been shown that the presence of ATP activa
tes not only H<SUP>+</SUP>-ATPase, but also the Cl<SUP>-</SUP> channels connecte
d to it (10); and even after dissipating the PD across endosome membranes with v
alinomycin, the ATPase still depends on the presence of Cl<SUP>-</SUP> (3).     
 ^cY#6376.htm##
00756000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704052800073002000900601#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#25#21#article#106#<P>In the present stud
y, we investigated the relationship between H<SUP>+</SUP>-ATPase and Cl<SUP>-</S
UP> ions further by measuring the extrusion of H<SUP>+</SUP> ions into Na<SUP>+<
/SUP>-free medium from cultured MDCK cells, more specifically from their C11 clo
ne, which has several properties similar to those of the intercalated cells of t
he renal distal tubule and collecting duct, using agents known to affect their P
D and the activity of their Cl<SUP>-</SUP> channels.  </font>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6376.htm##
00618000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039000073002000900463#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#26#22#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Material and Methods</B></FONT></FONT></font> <font face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <fon
t face="Arial, Helvetica, sans-serif">      ^cY#6376.htm##
00269000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004100073002000900114#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#27#23#article#106#<P><b>Cell culture</b>
  </font>      ^cY#6376.htm##
01275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104700073002000901120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#28#24#article#106#<P><font face="Arial, 
Helvetica, sans-serif">A subtype (clone) of MDCK cells denominated C11 (MDCK-C11
), obtained from Dr. H. Oberleithner (Department of Physiology, University of M&
uuml;nster, Germany), was used (11). These cells were used from passage 74 to pa
ssage 82. Cultures were maintained in minimum essential medium with Earle's salt
s, nonessential amino acids, and L-glutamine (Gibco, Grand Island, NY, USA) supp
lemented with 10% fetal bovine serum, 26 mM NaHCO<SUB>3</SUB>, 100 IU/mL penicil
lin and 100 &#181;g/mL streptomycin. Cells were grown at 37&#186;C in 95% humidi
fied air and 5% carbon dioxide, pH 7.4, in a CO<SUB>2</SUB> incubator (Lab-Line 
Instruments Inc., Melrose Park, IL, USA). The medium was changed three times a w
eek and the cells were split once a week. The cells were harvested with trypsin 
and then seeded onto sterile permeable filters (Costar, Cambridge, MA, USA) with
 12 mm in diameter and pore size of 3 &#181;m, and then incubated for 48-72 h in
 the same medium until they reached confluence. </font>      ^cY#6376.htm##
00343000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011500073002000900188#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#29#25#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><B>Measurement of pHi by fluorescence microscopy</B> </fo
nt>      ^cY#6376.htm##
01372000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704114400073002000901217#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#30#26#article#106#<P><font face="Arial, 
Helvetica, sans-serif">Cell pH (pHi) was measured using the fluorescent probe 2'
,7'-biscarboxyethyl-5,6-carboxyfluorescein (BCECF) (12,13). Cells grown to confl
uence on permeable filters were loaded with the dye by exposure for 20 min to 12
 &#181;M BCECF-AM in the control solution (solution 1, <a href="#Tab1">Table 1</
a>). The acetoxymethyl ester of BCECF enters the cells and is rapidly converted 
to the anionic free acid form (4 negative charges) by intracellular esterase. Fo
llowing the loading period the filters covered with confluent cell monolayers we
re placed in a thermo-regulated chamber mounted on an inverted epifluorescence m
icroscope (Nikon, Diaphot model TMD, Tokyo, Japan). In all experiments, the solu
tions were the same on both surfaces of the cell layer. The use of permeable fil
ters permits adequate access of the solutions to both cell surfaces. The filters
 were rinsed with the control solution to remove the solution containing BCECF. 
The area measured under the microscope had a diameter of 260 &#181;m and contain
ed up to 200 cells. All experiments were performed at 37&#176;C. </font>      ^c
Y#6376.htm##
01154000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704092600073002000900999#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#31#27#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The cells were alternately excited at 440 or 495 nm with 
two 150-W xenon lamps illuminating the measurement chamber via a bifurcated fibe
r optic glass guide and the fluorescence emission was monitored at 530 nm with a
 photomultiplier-based fluorescence system (PMT-4000, Georgia Instruments, Roswe
ll, GA, USA) at 5-s intervals. At the end of an experiment, the BCECF signal was
 calibrated using the high K<SUP>+</SUP>-nigericin method (13,14). pHi was set a
pproximately equal to pHo by exposing the cells to a solution containing 130 mM 
KCl, 20 mM NaCl, 1 mM CaCl<SUB>2</SUB>, 1 mM MgCl<SUB>2</SUB>, 5 mM HEPES, and 1
0 &#181;M nigericin, at different pH values. The 495/440 ratio was measured at d
ifferent pHo, and the resulting plot of 495/440 ratios <I>vs</I> pH yielded a ca
libration curve which was used to convert the fluorescence ratios (495/440 nm) t
o pHi. </font>      ^cY#6376.htm##
00890000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704066200073002000900735#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#32#28#article#106#<P><font face="Arial, 
Helvetica, sans-serif">To analyze the functional activity of the H<SUP>+</SUP> t
ransporters the intracellular alkalinization following an acute acid load due to
 a 20 mM NH<SUB>4</SUB>Cl pulse was determined (solution 2), allowing us to calc
ulate the initial rate of pHi recovery (dpHi/dt, pH units per min) in the presen
ce of different solutions from the first 2 min of the recovery curve by linear r
egression analysis in the presence of Na<SUP>+</SUP>. In the absence of Na<SUP>+
</SUP>, recovery started 2-3 min after returning to the NH<SUB>4</SUB>Cl-free so
lution, when recovery rates were measured over a 2-min period. </font>      ^cY#
6376.htm##
00320000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009200073002000900165#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#33#29#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><B>Solutions and reagents</B> </font>      ^cY#6376.htm##
00928000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070000073002000900773#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#34#30#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The composition of the solutions used in the present stud
y is shown in <a href="#Tab1">Table 1</a>. The osmolality of the solutions range
d from 295 to 305 mOsm. Na<SUP>+</SUP> concentration in nominally Na<SUP>+</SUP>
-free solutions was less than 1 mEq/L. Concanamycin A, 8-bromo-cAMP, valinomycin
 and nigericin were obtained from Sigma, St. Louis, MO, USA and Schering 28080 (
Sch 28080) was obtained from Schering-Plough (Liberty Corner, NJ, USA). BCECF-AM
 and Bapta-AM were obtained from Molecular Probes Inc., Junction City, OR, USA. 
NPPB was a gift from Dr. R. Greger, Freiburg, Germany. All other chemicals were 
of analytical grade. </font>      ^cY#6376.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#35#31#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6376.htm##
00525000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029700073002000900370#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#36#32#article#106#<P><font face="Arial, 
Helvetica, sans-serif">Data are reported as means &#177; SEM. Statistical compar
isons were made by analysis of variance followed by the Student-Newman-Keuls con
trast test, with the level of significance set at P &lt; 0.05. </font>  <HR ALIG
N=LEFT WIDTH=100% SIZE=2>      ^cY#6376.htm##
00561000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033300073002000900406#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#37#33#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Results</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"><A H
REF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" ALIGN=
BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>       ^cY#6376.htm#
#
02145000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704191700073002000901990#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#38#34#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The MDCK-C11 cells studied in the    present investigatio
n, which have properties similar to collecting duct intercalated    cells, had a
 mean pH of 7.19 &#177; 0.02 (N = 76) in control sodium Ringer solution    (<a h
ref="#Tab1">Table 1</a>, solution 1). In the experimental groups, care    was ta
ken to use cell pH series in which the pH obtained after an acid pulse    reache
d similar values (of the order of 6.4-6.6). <a href="#Fig1">Figure 1</a>    illu
strates the recovery of cell pH after an ammonium pulse in the absence of    Na<
SUP>+</SUP> plus 10 &#181;M NPPB, a Cl<SUP>-</SUP> channel blocker, compared    
to the curve in Na<SUP>+</SUP> Ringer (<a href="#Fig1">Figure 1A</a>), and in   
 the absence of Na<SUP>+</SUP> (0 Na<SUP>+</SUP>) and Cl<SUP>-</SUP> (solution  
  5) compared to 0 Na<SUP>+ </SUP>plus Cl<SUP>-</SUP> (<a href="#Fig1">Figure   
 1B</a>). In the presence of NaCl after cellular acidification, cell pH was reco
vered    at a rate of 0.136 &#177; 0.008 pHi units/min (N = 15). At 0 Na<SUP>+</
SUP>,    with pH recovery starting after only about 2-3 min of the pulse, this r
ate was    0.032 &#177; 0.003 pHi units/min (N = 10), and at 0 Na<SUP>+</SUP>/0 
Cl<SUP>-</SUP>,    the rate was 0.013 &#177; 0.005 pHi units/min (N = 11). When 
NPPB was included    in the 0 Na<SUP>+</SUP> experiment, the recovery was 0.014 
&#177; 0.0007 (N    = 6) pHi/min, a value similar to that observed during superf
usion with 0 Na<SUP>+</SUP>/0    Cl<SUP>-</SUP>. The mean values for these group
s are given in <a href="#Fig1">Figure    1C</a>. It can be seen that the recover
y of pHi at 0 Na<SUP>+</SUP> was significantly    slower than in sodium Ringer s
olution (P &lt; 0.001), and that the recovery    was significantly slower in bot
h 0 Na<SUP>+</SUP>/0 Cl<SUP>-</SUP> and 0 Na<SUP>+</SUP>    + NPPB than in 0 Na<
SUP>+</SUP> alone (P &lt; 0.01). </font> </P>      ^cY#6376.htm##
02637000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704240900073002000902482#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#39#35#article#106#<P><font face="Arial, 
Helvetica, sans-serif">Since the reduction of cell pH recovery observed at low c
hloride levels or after blocking Cl<SUP>-</SUP> channels has been attributed to 
shunting of the PD caused by electrogenic H<SUP>+</SUP> secretion (e.g., by vacu
olar H<SUP>+</SUP>-ATPase) by the Cl<SUP>-</SUP> anions, we investigated the eff
ect of abolishing cell PD by performing the experiments in the presence of 10 &#
181;M valinomycin, a potassium ionophore known to reduce transmembrane PD (15) a
t high external potassium levels (100 mM K<SUP>+</SUP> substituting the cation o
f solutions 1 or 3). <a href="#Fig2">Figure 2</a> shows the mean values of dpHi/
dt (cell pH units/min) for several of these experimental groups. First, valinomy
cin/high K<SUP>+</SUP> was used in 45 mM Na<SUP>+</SUP>-containing solutions. In
 this experiment, the addition of valinomycin/K<SUP>+</SUP> significantly increa
sed dpHi/dt from 0.124 &#177; 0.01 (N = 5) to 0.233 &#177; 0.018 (N = 9). The ca
use of this increase is not clear. It might have been due to the low PD, which m
ight favor Na<SUP>+</SUP> extrusion, lower cell Na<SUP>+</SUP>, and a more favor
able gradient for Na<SUP>+</SUP> influx via the electroneutral exchanger. A simi
lar effect of valinomycin on Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger activity has
 been reported in a different cell model (cheek cells) (16). On the other hand, 
no significant difference was found when comparing valinomycin/K<SUP>+</SUP> wit
h 0 Na<SUP>+</SUP>, with dpHi/dt being 0.032 &#177; 0.003 for 0 Na<SUP>+</SUP> (
N = 10) and 0.030 &#177; 0.003 for 0 Na<SUP>+</SUP> + valinomycin (N = 7). Also,
 no significant difference was observed when comparing the solution containing 1
0 &#181;M NPPB (0.014 &#177; 0.001; N = 6) to the solution containing NPPB + val
inomycin (0.018 &#177; 0.003; P &gt; 0.05; N = 7). Moreover, in the absence of N
a<SUP>+</SUP> + valinomycin but with control levels of K<SUP>+</SUP> (5 mM), dpH
i/dt was 0.034 &#177; 0.008 pH units/min (N = 5), a value not different from tha
t observed with 100mM K<SUP>+</SUP>. The cell membrane potentials found in this 
cell line (C11 MDCK) have been reported by Gekle et al. (17) and similar values 
were expected to be present in our experiments, as shown in <a href="#Tab2">Tabl
e 2</a>. These data suggest that membrane PD was not an important factor respons
ible for the effect of Cl<SUP>-</SUP> on dpHi/dt. </font>      ^cY#6376.htm##
02033000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704180500073002000901878#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#40#36#article#106#<P><font face="Arial, 
Helvetica, sans-serif">One of the important regulators of chloride channels, esp
ecially in the intestinal mucosa, but also in renal tubules, is cAMP (18-20). In
 subsequent experiments, 10 &#181;M 8-Br-cAMP, a membrane-permeant form of cAMP,
 was added to C11 cells incubated in 0 Na<SUP>+</SUP> solution (see <a href="#Fi
g3">Figure 3</a>). Under these conditions, dpHi/dt increased significantly from 
0.032 &#177; 0.003 (N = 6) at 0 Na<SUP>+</SUP> to 0.061 &#177; 0.009 (N = 9) wit
h 8-Br-cAMP. When 46 nM concanamycin, a specific blocker of vacuolar H<SUP>+</SU
P>-ATPase, was added to the 0 Na<SUP>+</SUP> solution, dpHi/dt fell significantl
y to 0.020 &#177; 0.003 (N = 6), but 8-Br-cAMP still increased pH recovery signi
ficantly to 0.034 &#177; 0.005 (N = 8). When 50 &#181;M Sch 28080, an inhibitor 
of H<SUP>+</SUP>-K<SUP>+</SUP>-ATPase, was added to the 0 Na<SUP>+</SUP> solutio
n, dpHi/dt did not change significantly compared to control 0 Na<SUP>+</SUP>, wi
th a value of 0.033 &#177; 0.004 (N = 9), but the addition of 8-Br-cAMP still in
creased pH recovery significantly to 0.046 &#177; 0.003 (N = 10) pH units/min. T
hese data indicate a marked participation of H<SUP>+</SUP>-ATPase in pH recovery
 in these cells, but a minor participation of H<SUP>+</SUP>-K<SUP>+</SUP>-ATPase
, lower than that reported in a previous paper (12). However, 8-Br-cAMP stimulat
ed pH recovery after an acid load in the three situations. When both concanamyci
n and Sch 28080 at the concentrations given above were added to C11 cells incuba
ted in 0 Na<SUP>+</SUP> Ringer, dpHi/dt fell to 0.010 &#177; 0.0091 (N = 6), and
 when 10 &#181;M 8-Br-cAMP was further added, a dpHi/dt of -0.026 &#177; 0.023 (
N = 4) was obtained, with neither value differing significantly from 0 (P &gt; 0
.10). </font>      ^cY#6376.htm##
01353000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704112500073002000901198#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#41#37#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The role of chloride depletion of C11 cells prior to the 
addition of 8-Br-cAMP was investigated in subsequent experiments. <a href="#Fig4
">Figure 4</a> presents the mean values of dpHi/dt in experiments at 0 Na<SUP>+<
/SUP> with and without the addition of 10 &#181;M 8-Br-cAMP in the absence or pr
esence of chloride depletion (solutions 4 or 5). Control values in the presence 
of Na<SUP>+</SUP> were also included. The 0 Na<SUP>+</SUP> +/- 8-Br-cAMP data wi
thout depletion are those given above. In the Cl<SUP>-</SUP> depletion group, be
fore measuring basal pH values the cells were incubated for 10 min in 0 Cl<SUP>-
</SUP> solutions. Here, dpHi/dt was 0.041 &#177; 0.003 in 0 Na<SUP>+</SUP> (N = 
5) and 0.036 &#177; 0.004 (N = 8) after the addition of 8-Br-cAMP, without a sig
nificant difference between these groups. In chloride depletion, the effect of 8
-Br-cAMP on cell pH recovery due to vacuolar H<SUP>+</SUP>-ATPase appeared to ha
ve been abolished due to the absence of Cl<SUP>-</SUP> fluxes across the channel
s present in the cell membranes of C11 cells. </font>      ^cY#6376.htm##
01937000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704170900073002000901782#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#42#38#article#106#<P><font face="Arial, 
Helvetica, sans-serif">An interaction of cystic fibrosis transmembrane conductio
n regulator (CFTR) channels with ATP has been observed; particularly, exit of AT
P from cells via these channels has been reported (21). Purinergic receptors hav
e been detected in C11 cells (22). In addition, it was shown that extracellular 
ATP stimulates Cl<SUP>-</SUP> secretion while increasing cell Ca<SUP>2+</SUP> in
 both renal and digestive epithelial cells (20,23). The activation of Cl<SUP>-</
SUP>conductance may modulate H<SUP>+</SUP>-ATPase in C11 cells. We have investig
ated this possibility by measuring the recovery of cell pH during administration
 of 100 &#181;M ATP to Na<SUP>+</SUP> Ringer or 0 Na<SUP>+</SUP> Ringer solution
. dpH/dt was 0.146 &#177; 0.007 (N = 18) in Na<SUP>+</SUP> Ringer, and, 0.063 &#
177; 0.004 (N = 6) in Na<SUP>+</SUP> Ringer + 100 &#181;M ATP (P &lt; 0.001). dp
Hi/dt was 0.035 &#177; 0.002 (N = 5) in control 0 Na<SUP>+</SUP> Ringer, and 0.0
15 &#177; 0.001 (N = 7) in Ringer with 100 &#181;M ATP (P &lt; 0.01). In order t
o detect a role for cell Ca<SUP>2+</SUP> in this effect, dpHi/dt was measured in
 the presence of 50 &#181;M Bapta-AM, an intracellular Ca<SUP>2+</SUP> chelator.
 The addition of Bapta to 0 Na<SUP>+</SUP> Ringer did not affect dpHi/dt signifi
cantly (0.031 &#177; 0.004, N = 4, P &gt; 0.05), but Bapta + ATP led to the reco
very of dpHi/dt to values not significantly different from 0 Na<SUP>+</SUP> alon
e (0.040 &#177; 0.0095, N = 5, P &gt; 0.05), thus abolishing the effect of ATP o
n pH recovery (see <a href="#Fig5">Figure 5</a>). This finding suggests mediatio
n of Ca<SUP>2+</SUP> in the effect of ATP on H<SUP>+</SUP> transport. </font>   
   ^cY#6376.htm##
00511000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028300073002000900356#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#43#39#article#106#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="t
op">      <td width="14%"><a href="/img/revistas/bjmbr/v40n5/html/6376i01.htm"><
img src="/img/revistas/bjmbr/v40n5/6376i01peq.jpg" border="2"></a></td>      <td
 width="86%">    ^cY#6376.htm##
01322000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704109400073002000901167#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#44#40#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Records of cell pH under con
trol (C), ammonium pulse (NH<SUB>4</SUB>) and experimental conditions in MDCK-C1
1 cells. <I>A</I>, Superfusion with 0 Na<SUP>+</SUP> Ringer solution (solution 3
) + 10 &#181;M NPPB. For comparison, + Na<SUP>+</SUP> was superfused with Na<SUP
>+</SUP> Ringer (solution 1). <I>B</I>, Superfusion with 0 Na<SUP>+</SUP>/0 Cl<S
UP>-</SUP> Ringer solution (solution 5) compared to 0 Na<SUP>+</SUP> alone (solu
tion 3). <I>C</I>, Mean initial rate of pHi recovery following acute intracellul
ar acidification in MDCK-C11 cells. Each bar represents the mean &#177; SEM rate
s of cell pH recovery (dpHi/dt, pH units/min) under different experimental condi
tions (control Na<SUP>+</SUP> Ringer, 0 Na<SUP>+</SUP> Ringer, 0 Na<SUP>+</SUP>/
0 Cl<SUP>-</SUP> Ringer, and 0 Na<SUP>+</SUP> Ringer plus 10 &#181;M NPPB). NPPB
 = 5-nitro-2 (3-phenylpropylamine)-benzoic acid. *P &lt; 0.001 <I>vs</I> control
. <SUP>+</SUP>P &lt; 0.01 <I>vs</I> 0 Na<SUP>+</SUP> (ANOVA). </font>         </
td>    </tr>  </table>      ^cY#6376.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#45#41#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (91 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
40n5/html/6376i02.htm"><img src="/img/revistas/bjmbr/v40n5/6376i02peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6376.htm##
00840000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061200073002000900685#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#46#42#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. Effect of abolishing cell po
tential difference (PD) on the observed reduction of cell pH after blocking Cl<S
UP>-</SUP> channels. Means &#177; SEM of dpHi/dt (pH units/min) in control (Na<S
UP>+</SUP> Ringer) and 0 Na<SUP>+</SUP> Ringer during superfusion with 10 &#181;
M valinomycin (valin)/100 mM K<SUP>+</SUP> and/or 0 Na<SUP>+</SUP>/10 &#181;M 5-
nitro-2 (3-phenylpropylamine)-benzoic acid (NPPB). *P &lt; 0.05 <I>vs</I> contro
l; <SUP>+</SUP>P &lt; 0.05 <I>vs</I> 0 Na<SUP>+</SUP> (ANOVA). </font>      </td
>    </tr>  </table>      ^cY#6376.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#47#43#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (76 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
40n5/html/6376i03.htm"><img src="/img/revistas/bjmbr/v40n5/6376i03peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6376.htm##
00969000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074100073002000900814#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#48#44#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure 3. Effect of 10 &#181;M 8-Br-cA
MP, a membrane-permeant form of cAMP, on the mean initial rate of pHi recovery i
n C11 cells incubated in 0 Na<SUP>+</SUP> solution. Mean &#177; SEM dpHi/dt duri
ng superfusion with 0 Na<SUP>+</SUP> Ringer containing 10 &#181;M 8-Br-cAMP, 46 
nM concanamycin (Conca), an H<SUP>+</SUP>-ATPase blocker, and/or 50 &#181;M Sche
ring 28080 (Sch), an H<SUP>+</SUP>/K<SUP>+</SUP>-ATPase inhibitor. *P &lt; 0.05 
<I>vs</I> control (0 Na<SUP>+</SUP>). **P &lt; 0.01 <I>vs</I> 0 Na<SUP>+</SUP>. 
<SUP>+</SUP>P &lt; 0.05 <I>vs</I> concanamycin. <SUP>++</SUP>P &lt; 0.05 <I>vs</
I> Sch 28080 (unpaired t-test). </font>      </td>    </tr>  </table>      ^cY#6
376.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#49#45#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (77 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
40n5/html/6376i04.htm"><img src="/img/revistas/bjmbr/v40n5/6376i04peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6376.htm##
00644000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041600073002000900489#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#50#46#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig4"></a>Figure 4. Effect of 10 &#181;M 8-Br-cA
MP on dpHi/dt in controls or 0 Na<SUP>+</SUP> Ringer solution in normal and Cl<S
UP>-</SUP>-depleted C11 cells. *P &lt; 0.01 <I>vs</I> control Na<SUP>+</SUP>. **
P &lt; 0.05 <I>vs</I> 0 Na<SUP>+</SUP>; <SUP>+</SUP>P &gt; 0.05 <I>vs</I> 0 Na<B
><SUP>+ </SUP></B>(ANOVA). </font>      </td>    </tr>  </table>      ^cY#6376.h
tm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#51#47#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (63 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
40n5/html/6376i05.htm"><img src="/img/revistas/bjmbr/v40n5/6376i05peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6376.htm##
00668000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044000073002000900513#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#52#48#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig5"></a>Figure 5. Effect of 100 &#181;M ATP on
 dpHi/dt in C11 cells superfused with Na<SUP>+</SUP> or 0 Na<SUP>+ </SUP>Ringer 
solution, and effect of Bapta-AM during superperfusion with 0 Na<SUP>+</SUP> sol
ution. *P &lt; 0.01 <I>vs</I> control Na<SUP>+</SUP>; <SUP>+</SUP>P &lt; 0.01 <I
>vs</I> 0 Na<SUP>+</SUP> (unpaired <I>t</I>-test). </font>      </td>    </tr>  
</table>      ^cY#6376.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038200073002000900455#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#53#49#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (63 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
40n5/html/6376t01.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"
></a></td>      <td width="86%">    ^cY#6376.htm##
00410000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704018200073002000900255#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#54#50#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab1"></a>Table 1. Composition of the solutions 
used in the present experiments. </font>      </td>    </tr>  </table>      ^cY#
6376.htm##
00849000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704062100073002000900694#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#55#51#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (145 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/
v40n5/html/6376t02.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2
"></a></td>      <td width="86%"><font face="Arial, Helvetica, sans-serif"><a na
me="Tab2"></a>Table 2. pH recovery rates after an acid pulse at different extern
al [K<SUP>+</SUP>] concentrations in the presence and absence of valinomycin. </
font></td>    </tr>  </table>      ^cY#6376.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011700073002000900190#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#56#52#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (63 K JPG file)]</font
></P>      ^cY#6376.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#57#53#article#106#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6376.htm##
00498000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027000073002000900343#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#58#54#article#106#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n
5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  
    ^cY#6376.htm##
01869000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704164100073002000901714#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#59#55#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The present paper investigated the role of Cl<SUP>-</SUP>
 ions in H<SUP>+</SUP> ion transport across plasma membranes of a clone of culti
vated MDCK cells, C11 cells, that were obtained by Gekle et al. (11) and charact
erized as a model for renal-collecting duct intercalated cells. Experiments from
 our laboratory have shown that these cells possess Na<SUP>+</SUP>/H<SUP>+</SUP>
 exchangers, H<SUP>+</SUP>-ATPase and H<SUP>+</SUP>-K<SUP>+</SUP>-ATPase in thei
r membranes, the latter transporters being demonstrated during experiments in 0 
Na<SUP>+</SUP> solutions (12). <a href="#Fig3">Figure 3</a> shows that in the pr
esent series of experiments, treatment of the cells with Sch 28080 did not reduc
e dpHi/dt significantly when compared to 0 Na<SUP>+</SUP>, indicating that H<SUP
>+</SUP>/K<SUP>+</SUP>-ATPase did not have a significant participation in our ex
periments. Nevertheless, cAMP stimulation of H<SUP>+</SUP> transport in the pres
ence of the H<SUP>+</SUP>/K<SUP>+</SUP>-ATPase blocker Sch 28080 yielded a lower
 rate than when cAMP was applied to 0 Na<SUP>+</SUP> alone; thus, a role of H<SU
P>+</SUP>/K<SUP>+</SUP>-ATPase in our experiments cannot be entirely excluded. T
he present experiments confirmed the role of Cl<SUP>-</SUP> in H<SUP>+</SUP> sec
retion by vacuolar H<SUP>+</SUP>-ATPase in Na<SUP>+</SUP>-free solutions that ha
d been previously shown in wild-type MDCK cells (24) and in the S3 segment of ra
bbit proximal tubules (7), indicating that intercalated cells (C11 cells) are an
 important site for the expression of H<SUP>+</SUP>-ATPase in the distal nephron
. </font>      ^cY#6376.htm##
01250000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704102200073002000901095#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#60#56#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The interaction of H<SUP>+</SUP>-ATPase and Cl<SUP>-</SUP
> channels has also been observed by other investigators. Colocalization of H<SU
P>+</SUP>-ATPase and ClC5 channels has been observed in renal cells by immunocyt
ochemical analysis using monoclonal antibodies against these transporters. This 
colocalization was seen in proximal tubules and in collecting duct intercalated 
cells, inside subcellular membrane vesicles. The presence of Cl<SUP>-</SUP> has 
been shown to support mechanisms leading to apical membrane insertion of these A
TPases, as well as to filtered protein reabsorption (25-27). ClC3 and CFTR chann
els have also been implicated in this mechanism (2,28). CFTR channels are known 
to be important for Cl<SUP>-</SUP> secretion in intestinal as well as renal epit
helia (29). These channels transport ATP and are known to regulate the activity 
of other channels, including Cl<SUP>-</SUP>, Na<SUP>+</SUP> (ENaC) and K<SUP>+</
SUP> channels (30,31). </font>      ^cY#6376.htm##
02811000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704258300073002000902656#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#61#57#article#106#<P><font face="Arial, 
Helvetica, sans-serif">It has been widely accepted that chloride ions moving alo
ng chloride channels act to dissipate the electrical gradient established by the
 electrogenic transport of H<SUP>+</SUP> ions into subcellular vesicles (endosom
es, lysosomes, Golgi vesicles) (4,32-34). However, evidence for different mechan
isms for the coupling of H<SUP>+</SUP>-ATPase and Cl<SUP>-</SUP> has been obtain
ed. Kaunitz et al. (3) have shown that the acidification of renal medullary endo
somes depends on the presence of Cl<SUP>-</SUP> ions, but the shunting of the PD
 created by H<SUP>+</SUP>-ATPase by valinomycin, a potassium ionophore, at high 
external K<SUP>+</SUP>, did not affect the Cl<SUP>-</SUP> dependence of H<SUP>+<
/SUP> transport. We have followed up this question by incubating C11 cells in a 
medium containing valinomycin and 5 or 100 mM external K<SUP>+</SUP>, and by mea
suring the recovery of cell pH after an acid ammonium pulse. As seen in <a href=
"#Fig2">Figure 2</a>, the presence of valinomycin did not alter dpHi/dt measured
 at 0 Na<SUP>+</SUP> in the presence of NPPB. Under these experimental condition
s, the PD across the cell membrane was expected to fall markedly. Assuming an in
tracellular K<SUP>+</SUP> of 120 mM and an extracellular K<SUP>+</SUP> of 100 mM
, one obtains a cell PD of -4.8 mV by the Nernst equation when the permeability 
of K<SUP>+</SUP> is determinant. This finding indicates that electrical shunting
 is not the main mechanism of the functional coupling between H<SUP>+</SUP> and 
Cl<SUP>-</SUP>transport in C11 cells, as had been suggested by Kaunitz et al. (3
) for renal medullary endosomes. Some other form of coupled H<SUP>+</SUP>/Cl<SUP
>-</SUP> transport should be invoked, such as that suggested for a group of red 
pigments produced by microorganisms, called prodigiosins, that inhibit lysosomal
 acidification and uncouple H<SUP>+</SUP>-ATPase H<SUP>+</SUP> transport without
 affecting ATP hydrolysis (14,35). These molecules are thought to be H<SUP>+</SU
P>/Cl<SUP>-</SUP> symporters and function as H<SUP>+</SUP>-ion ionophores that m
ay lead to dissipation of pH gradients across subcellular vesicle membranes. On 
the other hand, in the present experiments we observed the transfer of a relativ
ely small amount of H<SUP>+</SUP> across the whole cell membrane, a situation qu
ite different from that observed in endosomes, where the density of H<SUP>+</SUP
>-ATPases is certainly much higher. Nevertheless, in both preparations the depen
dence of H<SUP>+</SUP> transport on Cl<SUP>-</SUP> is apparent. </font>      ^cY
#6376.htm##
01935000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704170700073002000901780#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#62#58#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The role of cAMP in the regulation of intestinal chloride
 secretion via CFTR channels has been widely acknowledged, and has also been det
ected in the distal nephron (cortical-collecting duct) (19). In our experiments 
(see <a href="#Fig3">Figures 3</a> and <a href="#Fig4">4</a>), the addition of 8
-Br-cAMP, a membrane permeant form of cAMP, to the incubation medium stimulated 
the recovery of cell pH in 0 Na<SUP>+</SUP> solution, which could suggest that s
timulating Cl<SUP>-</SUP> flux through cAMP-sensitive Cl<SUP>-</SUP> channels co
uld also affect the possibly co-localized H<SUP>+</SUP>-ATPase. In our experimen
ts, 8-Br-cAMP stimulated H<SUP>+</SUP> extrusion in Na<SUP>+</SUP>-free solution
s both after blocking H<SUP>+</SUP>-K<SUP>+</SUP>-ATPase with Sch 28080 and H<SU
P>+</SUP>-ATPase with concanamycin, suggesting that both of these H<SUP>+</SUP>-
transporting molecules may be stimulated by cAMP. This is compatible with the Cl
<SUP>-</SUP>/H<SUP>+</SUP>-ATPase interaction discussed above and agrees with th
e mechanisms proposed for the action of cAMP phosphorylating CFTR channels, ther
eby destabilizing their closed state and thus increasing the membrane conductanc
e to Cl<SUP>-</SUP> (36), which could also lead to activation of H<SUP>+</SUP>-A
TPase. It is not clear if cAMP acts directly on these transporters or via activa
tion of Cl<SUP>-</SUP> channels. It has been proposed that the action of CFTR on
 H<SUP>+</SUP>-ATPase might be indirect, with CFTR activating other Cl<SUP>-</SU
P> channels such as ClC5 which in turn would increase membrane conductance for C
l<SUP>-</SUP>, with this increase stimulating H<SUP>+</SUP>-ATPase. </font>     
 ^cY#6376.htm##
01953000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704172500073002000901798#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#63#59#article#106#<P><font face="Arial, 
Helvetica, sans-serif">We have also shown that in cells preincubated at 0 Cl<SUP
>-</SUP> no effect of 8-Br-cAMP on cell H<SUP>+</SUP> extrusion was found, which
 supports the view that increases of Cl<SUP>-</SUP> fluxes are an integral part 
of the activation of H<SUP>+</SUP>-ATPase. On the other hand, we have demonstrat
ed before that incubation of C11 cells in 0 Cl<SUP>-</SUP> reduces the volume of
 these cells, a process that may stimulate ion transport mechanisms transferring
 ions into them, thus recomposing their volume (13). This process could modify t
he rate of H<SUP>+</SUP> extrusion from the cells. However, it has been proposed
 that, after hypotonic shock, a regulatory volume decrease would cause opening o
f CFTR and their parallel ATP channels, releasing ATP into the extracellular med
ium, which, by interacting with P2 receptors, might increase the probability of 
Cl<SUP>-</SUP> channel opening (37,38). This mechanism would not be active in th
e volume decrease caused by Cl<SUP>-</SUP> depletion, turning volume regulation 
an improbable cause for the activation of dpHi/dt during this depletion. In addi
tion, in the study cited above we had also shown that influx of NH<SUB>4</SUB><S
UP>+</SUP> via the Na<SUP>+</SUP>/K<SUP>+</SUP> ATPase is stimulated in 0 Cl<SUP
>-</SUP> medium, probably due to the volume reduction observed in this medium. T
his process could participate in the change in cell alkalinization; however, the
 magnitude of dpHi/dt in 0 Na<SUP>+</SUP> medium under Cl<SUP>-</SUP> depletion 
was similar to that in Cl<SUP>-</SUP>Ringer solution, suggesting that no major m
odifications in H<SUP>+</SUP> extrusion occurred under these experimental condit
ions. </font>      ^cY#6376.htm##
01103000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704087500073002000900948#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#64#60#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The stimulation of H<SUP>+</SUP>-K<SUP>+</SUP>-ATPase by 
cAMP observed in our experiments was unexpected. However, a similar effect was o
bserved for gastric glands, where it was shown that this ATPase is phosphorylate
d via cAMP/PKA, causing fusion of tubular vesicles with the apical membrane, whi
ch would be compatible with a stimulating effect of cAMP on H<SUP>+</SUP>-K<SUP>
+</SUP>-ATPase in our preparation (39). On the other hand, in the present series
 of experiments, the participation of H<SUP>+</SUP>/K<SUP>+</SUP>-ATPase in H<SU
P>+</SUP> extrusion was minor, as shown in <a href="#Fig3">Figure 3</a>; the red
uction of dpHi/dt upon the addition of Sch 28080 to the medium was small, indica
ting that H<SUP>+</SUP>-ATPase is the major component of H<SUP>+</SUP> transport
 under 0 Na<SUP>+</SUP> conditions. </font>      ^cY#6376.htm##
01748000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704152000073002000901593#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#65#61#article#106#<P><font face="Arial, 
Helvetica, sans-serif">In contrast to the effect of cAMP on H<SUP>+</SUP>-ATPase
, which was stimulatory, extracellular ATP inhibited H<SUP>+</SUP> extrusion fro
m C11 cells via this transporter. The stimulating effect of extracellular ATP on
 Cl<SUP>-</SUP> secretion or conductance has been reported (see Results). In one
 of these studies, performed in <I>Necturus</I> gallbladder, activation of Cl<SU
P>-</SUP> conductance was shown to depend on cAMP/PKA, and not on Ca<SUP>2+</SUP
> (20), while in the other, performed in renal collecting duct cells, treatment 
with Bapta reduced Cl<SUP>- </SUP> current significantly (23). In our study, H<S
UP>+</SUP> extrusion via H<SUP>+</SUP>-ATPase was stimulated by cAMP and reduced
 by ATP in a Ca<SUP>2+</SUP>-dependent manner. It should be kept in mind, howeve
r, that there are at least four different purinergic P1 receptor isoforms and an
 even greater number of P2 isoforms that may interact with ATP, so that a direct
 interaction of ATP with one or more of the different H<SUP>+</SUP> transporters
 cannot be excluded (40). This review also shows that transient activation and d
elayed inhibition of NKCC in ATP-treated C11-MDCK cells is mediated by Ca<SUP>2+
</SUP>/CaM-dependent protein kinase II and by Ca<SUP>2+</SUP>-independent signal
ing triggered by apical P2Y(2) and basolateral P2Y(1) receptors, respectively, d
emonstrating a possible interference of Ca<SUP>2+</SUP> with the effect of ATP o
n cell membrane H<SUP>+</SUP> transport. </font>      ^cY#6376.htm##
00918000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069000073002000900763#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#66#62#article#106#<P><font face="Arial, 
Helvetica, sans-serif">The present data indicate that MDCK-C11 cells, that have 
many properties of collecting duct intercalated cells, possess in their plasma m
embranes H<SUP>+</SUP>-ATPases responsible for part of the recovery of their pH 
after an acid pulse. This mechanism depends on Cl<SUP>-</SUP> for its activation
, but cell PD is not an important factor for the maintenance of its activity, si
nce its abolition by valinomycin/high K<SUP>+</SUP> did not affect the function 
of H<SUP>+</SUP>-ATPase. Other regulatory factors such as cAMP, ATP and chloride
 depletion were also investigated in the present study. </font>  <HR ALIGN=LEFT 
WIDTH=100% SIZE=2>      ^cY#6376.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033800073002000900411#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#67#63#article#106#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>References</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif
"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6376
.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018700075002000900262#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#68#64#article#106#1#<P><font
 face="Arial, Helvetica, sans-serif">1. George AL Jr. Chloride channels and endo
cytosis: ClC-5 makes a dent. <I>Proc Natl Acad Sci U S A</I> 1998; 95: 7843-7845
. </font>      ^cY#6376.htm##
00488000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024600075002000900321#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#69#65#article#106#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Li X, Wang T, Zhao Z, Weinman SA. The Cl
C-3 chloride channel promotes acidification of lysosomes in CHO-K1 and Huh-7 cel
ls. <I>Am J Physiol Cell Physiol</I> 2002; 282: C1483-C1491. </font>      ^cY#63
76.htm##
00496000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025400075002000900329#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#70#66#article#106#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Kaunitz JD, Gunther RD, Sachs G. Charact
erization of an electrogenic ATP and chloride-dependent proton translocating pum
p from rat renal medulla. <I>J Biol Chem</I> 1985; 260: 11567-11573. </font>    
  ^cY#6376.htm##
00547000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704030500075002000900380#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#71#67#article#106#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Sonawane ND, Thiagarajah JR, Verkman AS.
 Chloride concentration in endosomes measured using a ratioable fluorescent Cl<S
UP>-</SUP> indicator: evidence for chloride accumulation during acidification. <
I>J Biol Chem</I> 2002; 277: 5506-5513. </font>      ^cY#6376.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018700075002000900262#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#72#68#article#106#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Geibel J. Apical H<SUP>+</SUP>-ATPase ac
tivity in the rabbit proximal tubule. <I>Cell Physiol Biochem</I> 1993; 3: 34-41
. </font>      ^cY#6376.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704021100075002000900286#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#73#69#article#106#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Ulate G, Fernandez R, Malnic G. Effect o
f bafilomycin on proximal bicarbonate absorption in the rat. <I>Braz J Med Biol 
Res</I> 1993; 26: 773-777.</font>      ^cY#6376.htm##
00461000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704021900075002000900294#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#74#70#article#106#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Malnic G, Geibel JP. Cell pH and H(+) se
cretion by S3 segment of mammalian kidney: role of H(+)-ATPase and Cl(-). <I>J M
embr Biol</I> 2000; 178: 115-125. </font>      ^cY#6376.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024800075002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#75#71#article#106#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Wagner CA, Giebisch G, Lang F, Geibel JP
. Angiotensin II stimulates vesicular H<SUP>+</SUP>-ATPase in rat proximal tubul
ar cells. <I>Proc Natl Acad Sci U S A</I> 1998; 95: 9665-9668. </font>      ^cY#
6376.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023300075002000900308#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#76#72#article#106#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Fernandez R, Bosqueiro JR, Cassola AC, M
alnic G. Role of Cl- in electrogenic H<SUP>+</SUP> secretion by cortical distal 
tubule. <I>J Membr Biol</I> 1997; 157: 193-201. </font>      ^cY#6376.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022700076002000900303#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#77#73#article#106#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Hilden SA, Johns CA, Madias NE. Cl(-)-
dependent ATP-driven H<SUP>+</SUP> transport in rabbit renal cortical endosomes.
 <I>Am J Physiol</I> 1988; 255: F885-F897. </font>      ^cY#6376.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027500076002000900351#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#78#74#article#106#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Gekle M, Wunsch S, Oberleithner H, Sil
bernagl S. Characterization of two MDCK-cell subtypes as a model system to study
 principal cell and intercalated cell properties. <I>Pflugers Arch</I> 1994; 428
: 157-162. </font>      ^cY#6376.htm##
00454000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021100076002000900287#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#79#75#article#106#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Fernandez R, Oliveira-Souza M, Malnic 
G. Na<SUP>+</SUP>-independent proton secretion in MDCK-C11 cells. <I>Pflugers Ar
ch</I> 2000; 441: 287-293. </font>      ^cY#6376.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021900076002000900295#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#80#76#article#106#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Tararthuch AL, Fernandez R, Ramirez MA
, Malnic G. Factors affecting ammonium uptake by C11 clone of MDCK cells. <I>Pfl
ugers Arch</I> 2002; 445: 194-201. </font>      ^cY#6376.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029800076002000900374#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#81#77#article#106#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Konno H, Matsuya H, Okamoto M, Sato T,
 Tanaka Y, Yokoyama K, et al. Prodigiosins uncouple mitochondrial and bacterial 
F-ATPases: evidence for their H<SUP>+</SUP>/Cl<SUP>-</SUP> symport activity. <I>
J Biochem</I> 1998; 124: 547-556. </font>      ^cY#6376.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024800076002000900324#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#82#78#article#106#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Soltoff SP, Mandel LJ. Potassium trans
port in the rabbit renal proximal tubule: effects of barium, ouabain, valinomyci
n, and other ionophores. <I>J Membr Biol</I> 1986; 94: 153-161. </font>      ^cY
#6376.htm##
00557000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031400076002000900390#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#83#79#article#106#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Patten GS, Leifert WR, Burnard SL, Hea
d RJ, McMurchie EJ. Stimulation of human cheek cell Na<SUP>+</SUP>/H<SUP>+</SUP>
 antiporter activity by saliva and salivary electrolytes: amplification by niger
icin. <I>Mol Cell Biochem</I> 1996; 154: 133-141. </font>      ^cY#6376.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024000076002000900316#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#84#80#article#106#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Gekle M, Silbernagl S, Oberleithner H.
 The mineralocorticoid aldosterone activates a proton conductance in cultured ki
dney cells. <I>Am J Physiol</I> 1997; 273: C1673-C1678. </font>      ^cY#6376.ht
m##
00428000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018500076002000900261#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#85#81#article#106#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Begenisich T, Melvin JE. Regulation of
 chloride channels in secretory epithelia. <I>J Membr Biol</I> 1998; 163: 77-85.
 </font>      ^cY#6376.htm##
00534000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029100076002000900367#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#86#82#article#106#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. Bens M, Van Huyen JP, Cluzeaud F, Teul
on J, Vandewalle A. CFTR disruption impairs cAMP-dependent Cl(-) secretion in pr
imary cultures of mouse cortical collecting ducts. <I>Am J Physiol Renal Physiol
</I> 2001; 281: F434-F442. </font>      ^cY#6376.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029000076002000900366#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#87#83#article#106#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. Vank C, Fromter E, Kottra G. Activatio
n of an apical Cl<SUP>-</SUP> conductance by extracellular ATP in <I>Necturus ga
llbladder</I> is mediated by cAMP and not by [Ca<SUP>2+</SUP>]i. <I>Pflugers Arc
h</I> 1999; 438: 486-496. </font>      ^cY#6376.htm##
00524000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028100076002000900357#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#88#84#article#106#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. Cantiello HF, Jackson GR Jr, Grosman C
F, Prat AG, Borkan SC, Wang Y, et al. Electrodiffusional ATP movement through th
e cystic fibrosis transmembrane conductance regulator. <I>Am J Physiol</I> 1998;
 274: C799-C809. </font>      ^cY#6376.htm##
00538000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029500076002000900371#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#89#85#article#106#22#<P><fon
t face="Arial, Helvetica, sans-serif">22. Brindikova TA, Bourcier N, Torres B, P
chejetski D, Gekle M, Maximov GV, et al. Purinergic-induced signaling in C11-MDC
K cells inhibits the secretory Na-K-Cl cotransporter. <I>Am J Physiol Cell Physi
ol</I> 2003; 285: C1445-C1453. </font>      ^cY#6376.htm##
00563000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704032000076002000900396#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#90#86#article#106#23#<P><fon
t face="Arial, Helvetica, sans-serif">23. Cuffe JE, Bielfeld-Ackermann A, Thomas
 J, Leipziger J, Korbmacher C. ATP stimulates Cl<SUP>-</SUP> secretion and reduc
es amiloride-sensitive Na<SUP>+</SUP> absorption in M-1 mouse cortical collectin
g duct cells. <I>J Physiol</I> 2000; 524 (Pt 1): 77-90. </font>      ^cY#6376.ht
m##
00455000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021200076002000900288#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#91#87#article#106#24#<P><fon
t face="Arial, Helvetica, sans-serif">24. Fernandez R, Malnic G. H<SUP>+</SUP> A
TPase and Cl<SUP>-</SUP> interaction in regulation of MDCK cell pH. <I>J Membr B
iol</I> 1998; 163: 137-145. </font>      ^cY#6376.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022000076002000900296#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#92#88#article#106#25#<P><fon
t face="Arial, Helvetica, sans-serif">25. Gunther W, Piwon N, Jentsch TJ. The Cl
C-5 chloride channel knock-out mouse - an animal model for Dent's disease. <I>Pf
lugers Arch</I> 2003; 445: 456-462. </font>      ^cY#6376.htm##
00549000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030600076002000900382#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#93#89#article#106#26#<P><fon
t face="Arial, Helvetica, sans-serif">26. Gunther W, Luchow A, Cluzeaud F, Vande
walle A, Jentsch TJ. ClC-5, the chloride channel mutated in Dent's disease, colo
calizes with the proton pump in endocytotically active kidney cells. <I>Proc Nat
l Acad Sci U S A</I> 1998; 95: 8075-8080. </font>      ^cY#6376.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029000076002000900366#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#94#90#article#106#27#<P><fon
t face="Arial, Helvetica, sans-serif">27. Sakamoto H, Sado Y, Naito I, Kwon TH, 
Inoue S, Endo K, et al. Cellular and subcellular immunolocalization of ClC-5 cha
nnel in mouse kidney: colocalization with H<SUP>+</SUP>-ATPase. <I>Am J Physiol<
/I> 1999; 277: F957-F965. </font>      ^cY#6376.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021900076002000900295#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#95#91#article#106#28#<P><fon
t face="Arial, Helvetica, sans-serif">28. Devuyst O, Guggino WB. Chloride channe
ls in the kidney: lessons learned from knockout animals. <I>Am J Physiol Renal P
hysiol</I> 2002; 283: F1176-F1191. </font>      ^cY#6376.htm##
00531000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028800076002000900364#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#96#92#article#106#29#<P><fon
t face="Arial, Helvetica, sans-serif">29. Vandorpe D, Kizer N, Ciampollilo F, Mo
yer B, Karlson K, Guggino WB, et al. CFTR mediates electrogenic chloride secreti
on in mouse inner medullary collecting duct (mIMCD-K2) cells. <I>Am J Physiol</I
> 1995; 269: C683-C689. </font>      ^cY#6376.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017500076002000900251#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#97#93#article#106#30#<P><fon
t face="Arial, Helvetica, sans-serif">30. Devidas S, Guggino WB. CFTR: domains, 
structure, and function. <I>J Bioenerg Biomembr</I> 1997; 29: 443-451. </font>  
    ^cY#6376.htm##
00461000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021800076002000900294#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#98#94#article#106#31#<P><fon
t face="Arial, Helvetica, sans-serif">31. Jentsch TJ, Stein V, Weinreich F, Zdeb
ik AA. Molecular structure and physiological function of chloride channels. <I>P
hysiol Rev</I> 2002; 82: 503-568. </font>      ^cY#6376.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017100076002000900247#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#99#95#article#106#32#<P><fon
t face="Arial, Helvetica, sans-serif">32. al-Awqati Q. Chloride channels of intr
acellular organelles. <I>Curr Opin Cell Biol</I> 1995; 7: 504-508. </font>      
^cY#6376.htm##
00572000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704032800077002000900405#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#100#96#article#106#33#<P><fo
nt face="Arial, Helvetica, sans-serif">33. Gentzsch M, Cui L, Mengos A, Chang XB
, Chen JH, Riordan JR. The PDZ-binding chloride channel ClC-3B localizes to the 
Golgi and associates with cystic fibrosis transmembrane conductance regulator-in
teracting PDZ proteins. <I>J Biol Chem</I> 2003; 278: 6440-6449. </font>      ^c
Y#6376.htm##
00424000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704018000077002000900257#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#101#97#article#106#34#<P><fo
nt face="Arial, Helvetica, sans-serif">34. Schapiro FB, Grinstein S. Determinant
s of the pH of the Golgi complex. <I>J Biol Chem</I> 2000; 275: 21025-21032. </f
ont>      ^cY#6376.htm##
00534000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704029000077002000900367#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#102#98#article#106#35#<P><fo
nt face="Arial, Helvetica, sans-serif">35. Ohkuma S, Sato T, Okamoto M, Matsuya 
H, Arai K, Kataoka T, et al. Prodigiosins uncouple lysosomal vacuolar-type ATPas
e through promotion of H<SUP>+</SUP>/Cl<SUP>-</SUP> symport. <I>Biochem J</I> 19
98; 334 (Part 3): 731-741. </font>      ^cY#6376.htm##
00403000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704015900077002000900236#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#103#99#article#106#36#<P><fo
nt face="Arial, Helvetica, sans-serif">36. Foskett JK. ClC and CFTR chloride cha
nnel gating. <I>Annu Rev Physiol</I> 1998; 60: 689-717. </font>      ^cY#6376.ht
m##
00502000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025700078002000900335#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#104#100#article#106#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Wang Y, Roman R, Lidofsky SD, Fitz J
G. Autocrine signaling through ATP release represents a novel mechanism for cell
 volume regulation. <I>Proc Natl Acad Sci U S A</I> 1996; 93: 12020-12025. </fon
t>      ^cY#6376.htm##
00602000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704035700078002000900435#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#105#101#article#106#38#<P><f
ont face="Arial, Helvetica, sans-serif">38. Braunstein GM, Roman RM, Clancy JP, 
Kudlow BA, Taylor AL, Shylonsky VG, et al. Cystic fibrosis transmembrane conduct
ance regulator facilitates ATP release by stimulating a separate ATP release cha
nnel for autocrine control of cell volume regulation. <I>J Biol Chem</I> 2001; 2
76: 6621-6630. </font>      ^cY#6376.htm##
00516000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027100078002000900349#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#106#102#article#106#39#<P><f
ont face="Arial, Helvetica, sans-serif">39. Yao XB, Karam SM, Ramilo M, Rong QF,
 Thibodeau A, Forte JG. Stimulation of gastric acid secretion by cAMP in a novel
 a-toxin-permeabilized gland model. <I>Am J Physiol Cell Physiol</I> 1996; 271: 
C61-C73. </font>      ^cY#6376.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022800078002000900306#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#p#107#103#article#106#40#<P><f
ont face="Arial, Helvetica, sans-serif">40. Leipziger J. Control of epithelial t
ransport via luminal P2 receptors. <I>Am J Physiol Renal Physiol</I> 2003; 284: 
F419-F432.</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6376.htm##
00578000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704034800075002000900423#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#108#104#article#106#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence and Footnotes</B></FONT></FONT> <font face="Arial, Helvetica,
 sans-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>   
    ^cY#6376.htm##
00694000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704046400075002000900539#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#109#105#article#106#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/
recor.gif" border="0"></a>    Address for correspondence:</b> </font><font face=
"Arial, Helvetica, sans-serif">G.    Malnic, Departamento de Fisiologia e Biof&i
acute;sica, ICB, USP, Av. Prof. Lineu    Prestes, 1524, 05508-900 S&atilde;o Pau
lo, SP, Brasil. Fax: +55-11-3091-7285.    E-mail: <a href="mailto:gemalnic@usp.b
r">gemalnic@usp.br</a></font> </p>      ^cY#6376.htm##
00411000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704018100075002000900256#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6376.htm#S#p#110#106#article#106#<P><font face="Arial
, Helvetica, sans-serif">Research supported by FAPESP and CNPq (Pronex No. 66.10
29/1998-0). Received February 15, 2006. Accepted March 2, 2007. </font>      ^cY
#6376.htm##
00523000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740120058000940300
02500152065000900177064000500186031000300191014001000194865000900204002000900213
035001000222801002500232#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#
111#1#article#40#1#^rND^sGeorge^nAL Jr#Chloride channels and endocytosis: ClC-5 
makes a dent^len#Proc Natl Acad Sci U S A#19980000#1998#95#7843-7845#20070500#63
76.htm#0027-8424#Proc Natl Acad Sci U S A##
00591000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100012000740100014000860100
01400100010001800114012009300132030002600225710000200251065000900253064000500262
031000400267014001200271865000900283002000900292#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#112#2#article#40#2#^rND^sLi^nX#^rND^sWang^nT#^rND^sZhao^
nZ#^rND^sWeinman^nSA#The ClC-3 chloride channel promotes acidification of lysoso
mes in CHO-K1 and Huh-7 cells^len#Am J Physiol Cell Physiol#2#20020000#2002#282#
C1483-C1491#20070500#6376.htm##
00613000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100018000920100
01500110012011600125030001200241065000900253064000500262031000400267014001200271
865000900283002000900292035001000301801001200311#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#113#3#article#40#3#^rND^sKaunitz^nJD#^rND^sGunther^nRD#^
rND^sSachs^nG#Characterization of an electrogenic ATP and chloride-dependent pro
ton translocating pump from rat renal medulla^len#J Biol Chem#19850000#1985#260#
11567-11573#20070500#6376.htm#0021-9258#J Biol Chem##
00653000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100022000930100
01800115012015000133030001200283065000900295064000500304031000400309014001000313
865000900323002000900332035001000341801001200351#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#114#4#article#40#4#^rND^sSonawane^nND#^rND^sThiagarajah^
nJR#^rND^sVerkman^nAS#Chloride concentration in endosomes measured using a ratio
able fluorescent Cl- indicator: evidence for chloride accumulation during acidif
ication^len#J Biol Chem#20020000#2002#277#5506-5513#20070500#6376.htm#0021-9258#
J Biol Chem##
00508000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740120060000900300
02100150065000900171064000500180031000200185014000600187865000900193002000900202
035001000211801002100221#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#
115#5#article#40#5#^rND^sGeibel^nJ#Apical H+-ATPase activity in the rabbit proxi
mal tubule^len#Cell Physiol Biochem#19930000#1993#3#34-41#20070500#6376.htm#1015
-8987#Cell Physiol Biochem##
00579000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100019000890100
01600108012007200124030002000196065000900216064000500225031000300230014000800233
865000900241002000900250035001000259801002000269#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#116#6#article#40#6#^rND^sUlate^nG#^rND^sFernandez^nR#^rN
D^sMalnic^nG#Effect of bafilomycin on proximal bicarbonate absorption in the rat
^len#Braz J Med Biol Res#19930000#1993#26#773-777#20070500#6376.htm#0100-879X#Br
az J Med Biol Res##
00561000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100017000900120
09600107030001300203065000900216064000500225031000400230014000800234865000900242
002000900251035001000260801001300270#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
376.htm#S#c#117#7#article#40#7#^rND^sMalnic^nG#^rND^sGeibel^nJP#Cell pH and H(+)
 secretion by S3 segment of mammalian kidney: role of H(+)-ATPase and Cl(-)^len#
J Membr Biol#20000000#2000#178#115-125#20070500#6376.htm#0022-2631#J Membr Biol#
#
00627000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910100
01400109010001700123012008000140030002500220065000900245064000500254031000300259
014001000262865000900272002000900281035001000290801002500300#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6376.htm#S#c#118#8#article#40#8#^rND^sWagner^nCA#^rND^sGi
ebisch^nG#^rND^sLang^nF#^rND^sGeibel^nJP#Angiotensin II stimulates vesicular H+-
ATPase in rat proximal tubular cells^len#Proc Natl Acad Sci U S A#19980000#1998#
95#9665-9668#20070500#6376.htm#0027-8424#Proc Natl Acad Sci U S A##
00600000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100020000930100
01800113010001600131012007100147030001300218065000900231064000500240031000400245
014000800249865000900257002000900266035001000275801001300285#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6376.htm#S#c#119#9#article#40#9#^rND^sFernandez^nR#^rND^s
Bosqueiro^nJR#^rND^sCassola^nAC#^rND^sMalnic^nG#Role of Cl- in electrogenic H+ s
ecretion by cortical distal tubule^len#J Membr Biol#19970000#1997#157#193-201#20
070500#6376.htm#0022-2631#J Membr Biol##
00577000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01700109012007900126030001300205065000900218064000500227031000400232014001000236
865000900246002000900255035001000264801001300274#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#120#10#article#40#10#^rND^sHilden^nSA#^rND^sJohns^nCA#^r
ND^sMadias^nNE#Cl(-)-dependent ATP-driven H+ transport in rabbit renal cortical 
endosomes^len#Am J Physiol#19880000#1988#255#F885-F897#20070500#6376.htm#0002-95
13#Am J Physiol##
00655000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
02200107010002000129012012200149030001400271065000900285064000500294031000400299
014000800303865000900311002000900320035001000329801001400339#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6376.htm#S#c#121#11#article#40#11#^rND^sGekle^nM#^rND^sWu
nsch^nS#^rND^sOberleithner^nH#^rND^sSilbernagl^nS#Characterization of two MDCK-c
ell subtypes as a model system to study principal cell and intercalated cell pro
perties^len#Pflugers Arch#19940000#1994#428#157-162#20070500#6376.htm#0031-6768#
Pflugers Arch##
00562000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100024000950100
01600119012005500135030001400190065000900204064000500213031000400218014000800222
865000900230002000900239035001000248801001400258#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#122#12#article#40#12#^rND^sFernandez^nR#^rND^sOliveira-S
ouza^nM#^rND^sMalnic^nG#Na+-independent proton secretion in MDCK-C11 cells^len#P
flugers Arch#20000000#2000#441#287-293#20070500#6376.htm#0031-6768#Pflugers Arch
##
00599000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100019000970100
01800116010001600134012006500150030001400215065000900229064000500238031000400243
014000800247865000900255002000900264035001000273801001400283#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6376.htm#S#c#123#13#article#40#13#^rND^sTararthuch^nAL#^r
ND^sFernandez^nR#^rND^sRamirez^nMA#^rND^sMalnic^nG#Factors affecting ammonium up
take by C11 clone of MDCK cells^len#Pflugers Arch#20020000#2002#445#194-201#2007
0500#6376.htm#0031-6768#Pflugers Arch##
00669000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01700108010001400125010001600139010001800155810000600173012010800179030001000287
71000020029706500090029906400050030803100040031301400080031786500090032500200090
0334#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#124#14#article#40#14
#^rND^sKonno^nH#^rND^sMatsuya^nH#^rND^sOkamoto^nM#^rND^sSato^nT#^rND^sTanaka^nY#
^rND^sYokoyama^nK#et al#Prodigiosins uncouple mitochondrial and bacterial F-ATPa
ses: evidence for their H+/Cl- symport activity^len#J Biochem#2#19980000#1998#12
4#547-556#20070500#6376.htm##
00591000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940120
12300111030001300234065000900247064000500256031000300261014000800264865000900272
002000900281035001000290801001300300#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
376.htm#S#c#125#15#article#40#15#^rND^sSoltoff^nSP#^rND^sMandel^nLJ#Potassium tr
ansport in the rabbit renal proximal tubule: effects of barium, ouabain, valinom
ycin, and other ionophores^len#J Membr Biol#19860000#1986#94#153-161#20070500#63
76.htm#0022-2631#J Membr Biol##
00693000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01800111010001500129010002000144012012700164030001700291065000900308064000500317
031000400322014000800326865000900334002000900343035001000352801001700362#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#126#16#article#40#16#^rND^sPatte
n^nGS#^rND^sLeifert^nWR#^rND^sBurnard^nSL#^rND^sHead^nRJ#^rND^sMcMurchie^nEJ#Sti
mulation of human cheek cell Na+/H+ antiporter activity by saliva and salivary e
lectrolytes: amplification by nigericin^len#Mol Cell Biochem#19960000#1996#154#1
33-141#20070500#6376.htm#0300-8177#Mol Cell Biochem##
00601000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100020000910100
02200111012009400133030001300227065000900240064000500249031000400254014001200258
865000900270002000900279035001000288801001300298#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#127#17#article#40#17#^rND^sGekle^nM#^rND^sSilbernagl^nS#
^rND^sOberleithner^nH#The mineralocorticoid aldosterone activates a proton condu
ctance in cultured kidney cells^len#Am J Physiol#19970000#1997#273#C1673-C1678#2
0070500#6376.htm#0002-9513#Am J Physiol##
00528000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960120
05900113030001300172065000900185064000500194031000400199014000600203865000900209
002000900218035001000227801001300237#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
376.htm#S#c#128#18#article#40#18#^rND^sBegenisich^nT#^rND^sMelvin^nJE#Regulation
 of chloride channels in secretory epithelia^len#J Membr Biol#19980000#1998#163#
77-85#20070500#6376.htm#0022-2631#J Membr Biol##
00655000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100020000900100
01800110010001600128010002000144012011400164030002700278710000200305065000900307
064000500316031000400321014001000325865000900335002000900344#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6376.htm#S#c#129#19#article#40#19#^rND^sBens^nM#^rND^sVan
^nHuyen JP#^rND^sCluzeaud^nF#^rND^sTeulon^nJ#^rND^sVandewalle^nA#CFTR disruption
 impairs cAMP-dependent Cl(-) secretion in primary cultures of mouse cortical co
llecting ducts^len#Am J Physiol Renal Physiol#2#20010000#2001#281#F434-F442#2007
0500#6376.htm##
00623000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900100
01600107012012800123030001400251065000900265064000500274031000400279014000800283
865000900291002000900300035001000309801001400319#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#130#20#article#40#20#^rND^sVank^nC#^rND^sFromter^nE#^rND
^sKottra^nG#Activation of an apical Cl- conductance by extracellular ATP in Nect
urus gallbladder is mediated by cAMP and not by [Ca2+]i^len#Pflugers Arch#199900
00#1999#438#486-496#20070500#6376.htm#0031-6768#Pflugers Arch##
00707000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100021000960100
01800117010001500135010001700150010001400167810000600181012010000187030001300287
06500090030006400050030903100040031401400100031886500090032800200090033703500100
0346801001300356#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#131#21#a
rticle#40#21#^rND^sCantiello^nHF#^rND^sJackson^nGR Jr#^rND^sGrosman^nCF#^rND^sPr
at^nAG#^rND^sBorkan^nSC#^rND^sWang^nY#et al#Electrodiffusional ATP movement thro
ugh the cystic fibrosis transmembrane conductance regulator^len#Am J Physiol#199
80000#1998#274#C799-C809#20070500#6376.htm#0002-9513#Am J Physiol##
00688000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100018000970100
01600115010002000131010001500151010001800166810000600184012009600190030002600286
71000020031206500090031406400050032303100040032801400120033286500090034400200090
0353#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#132#22#article#40#22
#^rND^sBrindikova^nTA#^rND^sBourcier^nN#^rND^sTorres^nB#^rND^sPchejetski^nD#^rND
^sGekle^nM#^rND^sMaximov^nGV#et al#Purinergic-induced signaling in C11-MDCK cell
s inhibits the secretory Na-K-Cl cotransporter^len#Am J Physiol Cell Physiol#2#2
0030000#2003#285#C1445-C1453#20070500#6376.htm##
00674000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100028000920100
01600120010001900136010002000155012012400175030001000299710000200309065000900311
064000500320031000400325061000700329014000600336865000900342002000900351#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#133#23#article#40#23#^rND^sCuffe
^nJE#^rND^sBielfeld-Ackermann^nA#^rND^sThomas^nJ#^rND^sLeipziger^nJ#^rND^sKorbma
cher^nC#ATP stimulates Cl- secretion and reduces amiloride-sensitive Na+ absorpt
ion in M-1 mouse cortical collecting duct cells^len#J Physiol#2#20000000#2000#52
4#(Pt 1)#77-90#20070500#6376.htm##
00533000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950120
06400111030001300175065000900188064000500197031000400202014000800206865000900214
002000900223035001000232801001300242#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
376.htm#S#c#134#24#article#40#24#^rND^sFernandez^nR#^rND^sMalnic^nG#H+ ATPase an
d Cl- interaction in regulation of MDCK cell pH^len#J Membr Biol#19980000#1998#1
63#137-145#20070500#6376.htm#0022-2631#J Membr Biol##
00582000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01800108012008400126030001400210065000900224064000500233031000400238014000800242
865000900250002000900259035001000268801001400278#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6376.htm#S#c#135#25#article#40#25#^rND^sGunther^nW#^rND^sPiwon^nN#^rN
D^sJentsch^nTJ#The ClC-5 chloride channel knock-out mouse - an animal model for 
Dent's disease^len#Pflugers Arch#20030000#2003#445#456-462#20070500#6376.htm#003
1-6768#Pflugers Arch##
00715000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01800109010002000127010001800147012013100165030002500296065000900321064000500330
031000300335014001000338865000900348002000900357035001000366801002500376#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#136#26#article#40#26#^rND^sGunth
er^nW#^rND^sLuchow^nA#^rND^sCluzeaud^nF#^rND^sVandewalle^nA#^rND^sJentsch^nTJ#Cl
C-5, the chloride channel mutated in Dent's disease, colocalizes with the proton
 pump in endocytotically active kidney cells^len#Proc Natl Acad Sci U S A#199800
00#1998#95#8075-8080#20070500#6376.htm#0027-8424#Proc Natl Acad Sci U S A##
00705000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100014000940100
01500108010001500123010001500138010001400153810000600167012011200173030001300285
06500090029806400050030703100040031201400100031686500090032600200090033503500100
0344801001300354#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#137#27#a
rticle#40#27#^rND^sSakamoto^nH#^rND^sSado^nY#^rND^sNaito^nI#^rND^sKwon^nTH#^rND^
sInoue^nS#^rND^sEndo^nK#et al#Cellular and subcellular immunolocalization of ClC
-5 channel in mouse kidney: colocalization with H+-ATPase^len#Am J Physiol#19990
000#1999#277#F957-F965#20070500#6376.htm#0002-9513#Am J Physiol##
00529000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930120
07500111030002700186710000200213065000900215064000500224031000400229014001200233
865000900245002000900254#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#
138#28#article#40#28#^rND^sDevuyst^nO#^rND^sGuggino^nWB#Chloride channels in the
 kidney: lessons learned from knockout animals^len#Am J Physiol Renal Physiol#2#
20020000#2002#283#F1176-F1191#20070500#6376.htm##
00714000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
02100109010001500130010001700145010001800162810000600180012010800186030001300294
06500090030706400050031603100040032101400100032586500090033500200090034403500100
0353801001300363#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#139#29#a
rticle#40#29#^rND^sVandorpe^nD#^rND^sKizer^nN#^rND^sCiampollilo^nF#^rND^sMoyer^n
B#^rND^sKarlson^nK#^rND^sGuggino^nWB#et al#CFTR mediates electrogenic chloride s
ecretion in mouse inner medullary collecting duct (mIMCD-K2) cells^len#Am J Phys
iol#19950000#1995#269#C683-C689#20070500#6376.htm#0002-9513#Am J Physiol##
00525000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930120
04300111030002000154065000900174064000500183031000300188014000800191865000900199
002000900208035001000217801002000227#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
376.htm#S#c#140#30#article#40#30#^rND^sDevidas^nS#^rND^sGuggino^nWB#CFTR: domain
s, structure, and function^len#J Bioenerg Biomembr#19970000#1997#29#443-451#2007
0500#6376.htm#0145-479X#J Bioenerg Biomembr##
00596000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01900109010001700128012007200145030001200217065000900229064000500238031000300243
014000800246865000900254002000900263035001000272801001200282#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6376.htm#S#c#141#31#article#40#31#^rND^sJentsch^nTJ#^rND^
sStein^nV#^rND^sWeinreich^nF#^rND^sZdebik^nAA#Molecular structure and physiologi
cal function of chloride channels^len#Physiol Rev#20020000#2002#82#503-568#20070
500#6376.htm#0031-9333#Physiol Rev##
00503000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120050000950300
02000145065000900165064000500174031000200179014000800181865000900189002000900198
035001000207801002000217#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#
142#32#article#40#32#^rND^sal-Awqati^nQ#Chloride channels of intracellular organ
elles^len#Curr Opin Cell Biol#19950000#1995#7#504-508#20070500#6376.htm#0955-067
4#Curr Opin Cell Biol##
00742000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100013000940100
01600107010001600123010001500139010001800154012016400172030001200336065000900348
06400050035703100040036201400100036686500090037600200090038503500100039480100120
0404#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#143#33#article#40#33
#^rND^sGentzsch^nM#^rND^sCui^nL#^rND^sMengos^nA#^rND^sChang^nXB#^rND^sChen^nJH#^
rND^sRiordan^nJR#The PDZ-binding chloride channel ClC-3B localizes to the Golgi 
and associates with cystic fibrosis transmembrane conductance regulator-interact
ing PDZ proteins^len#J Biol Chem#20030000#2003#278#6440-6449#20070500#6376.htm#0
021-9258#J Biol Chem##
00522000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950120
04800114030001200162065000900174064000500183031000400188014001200192865000900204
002000900213035001000222801001200232#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
376.htm#S#c#144#34#article#40#34#^rND^sSchapiro^nFB#^rND^sGrinstein^nS#Determina
nts of the pH of the Golgi complex^len#J Biol Chem#20000000#2000#275#21025-21032
#20070500#6376.htm#0021-9258#J Biol Chem##
00703000000000349000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100014000920100
01700106010001700123010001400140010001700154810000600171012009300177030001000270
06500090028006400050028903100040029406100090029801400080030786500090031500200090
0324035001000333801001000343#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#
S#c#145#35#article#40#35#^rND^sOhkuma^nS#^rND^sSato^nT#^rND^sOkamoto^nM#^rND^sMa
tsuya^nH#^rND^sArai^nK#^rND^sKataoka^nT#et al#Prodigiosins uncouple lysosomal va
cuolar-type ATPase through promotion of H+/Cl- symport^len#Biochem J#19980000#19
98#334#(Part 3)#731-741#20070500#6376.htm#0264-6021#Biochem J##
00488000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120041000940300
01700135065000900152064000500161031000300166014000800169865000900177002000900186
035001000195801001700205#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#
146#36#article#40#36#^rND^sFoskett^nJK#ClC and CFTR chloride channel gating^len#
Annu Rev Physiol#19980000#1998#60#689-717#20070500#6376.htm#0066-4278#Annu Rev P
hysiol##
00648000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100015000900100
01900105010001500124012010000139030002500239065000900264064000500273031000300278
014001200281865000900293002000900302035001000311801002500321#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6376.htm#S#c#147#37#article#40#37#^rND^sWang^nY#^rND^sRom
an^nR#^rND^sLidofsky^nSD#^rND^sFitz^nJG#Autocrine signaling through ATP release 
represents a novel mechanism for cell volume regulation^len#Proc Natl Acad Sci U
 S A#19960000#1996#93#12020-12025#20070500#6376.htm#0027-8424#Proc Natl Acad Sci
 U S A##
00782000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100016000970100
01700113010001700130010001700147010002000164810000600184012017400190030001200364
06500090037606400050038503100040039001400100039486500090040400200090041303500100
0422801001200432#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#148#38#a
rticle#40#38#^rND^sBraunstein^nGM#^rND^sRoman^nRM#^rND^sClancy^nJP#^rND^sKudlow^
nBA#^rND^sTaylor^nAL#^rND^sShylonsky^nVG#et al#Cystic fibrosis transmembrane con
ductance regulator facilitates ATP release by stimulating a separate ATP release
 channel for autocrine control of cell volume regulation^len#J Biol Chem#2001000
0#2001#276#6621-6630#20070500#6376.htm#0021-9258#J Biol Chem##
00653000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01600106010001500122010001900137010001600156012009500172030002600267710000200293
065000900295064000500304031000400309014000800313865000900321002000900330#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#149#39#article#40#39#^rND^sYao^n
XB#^rND^sKaram^nSM#^rND^sRamilo^nM#^rND^sRong^nQF#^rND^sThibodeau^nA#^rND^sForte
^nJG#Stimulation of gastric acid secretion by cAMP in a novel a-toxin-permeabili
zed gland model^len#Am J Physiol Cell Physiol#2#19960000#1996#271#C61-C73#200705
00#6376.htm##
00485000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120061000950300
02700156710000200183065000900185064000500194031000400199014001000203865000900213
002000900222#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6376.htm#S#c#150#40#artic
le#40#40#^rND^sLeipziger^nJ#Control of epithelial transport via luminal P2 recep
tors^len#Am J Physiol Renal Physiol#2#20030000#2003#284#F419-F432#20070500#6376.
htm##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#o#1#1#article#1#20
080213#155316#6455.htm#120##
03619000000000685000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001201110
01700100023002810100028003040100024003320100030003560100026003860100024004120100
02200436010002500458010002700483010002500510070007500535070009800610070016800708
08318000087608500080267608500380268408500230272208500360274508500310278108500340
28121170006028460720003028520580005028550580007028600580006028671120009028731110
01502882114000902897113001802906002000902924#v40n5#v:\scielo\serial\bjmbr\v40n5\
markup\6455.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#09#BJMBR070#FAPESP#
Braz J Med Biol Res#40#5#20070500#^f663^l670#0100-879X#In vitro evaluation of th
e cytotoxic and trypanocidal activities of Ampelozizyphus amazonicus (Rhamnaceae
)^len#^rND^1A01^nL.V.^sRosas#^rND^1A01^nM.S.C.^sCordeiro#^rND^1A01^nF.R.^sCampos
#^rND^1A01^nS.K.R.^sNascimento#^rND^1A02^nA.H.^sJanuário#^rND^1A02^nS.C.^sFrança
#^rND^1A03^nA.^sNomizo#^rND^1A03^nM.P.A.^sToldo#^rND^1A03^nS.^sAlbuquerque#^rND^
1A02^nP.S.^sPereira#Universidade do Amazonas^iA01^1Departamento de Química^cMana
us^sAM^pBrasil#Universidade de Ribeirão Preto^iA02^1Unidade de Biotecnologia Veg
etal^cRibeirão Preto^sSP^pBrasil#Universidade de Ribeirão Preto^iA03^1Faculdade 
de Ciências Farmacêuticas^2Departamento de Análises Clínicas, Toxicológicas e Br
omatológicas^cRibeirão Preto^sSP^pBrasil#^len^aAmpelozizyphus amazonicus Ducke i
s a tree commonly found in the Amazon region and an extract of its stem bark is 
popularly used as an antimalarial and anti-inflammatory agent and as an antidote
 to snake venom. Ursolic acid; five lupane type triterpenes: betulin, betulinic 
acid, lupenone, 3ß-hydroxylup-20(29)-ene-27,28-dioic acid, and 2a,3ß-dihydroxylu
p-20(29)-ene-27,28-dioic acid, and three phytosteroids: stigmasterol, sitosterol
 and campesterol, have been isolated from stem extracts of A. amazonicus Ducke. 
Their structures were characterized by spectral data including COSY and HMQC. In
 an in vitro biological screening of the isolated compounds, 3ß-hydroxylup-20(29
)-ene-27,28-dioic acid was cytotoxic against the SKBR-3 human adenocarcinoma cel
l line (1 to 10 mg/mL), while 2a,3ß-dihydroxylup-20(29)-ene-27,28-dioic acid exh
ibited cytotoxicity against both SKBR-3 human adenocarcinoma and C-8161 human me
lanoma tumor cell lines (>0.1 mg/mL). In the present study, different extracts a
nd some fractions of this plant were also investigated for trypanocidal activity
 due to the presence of pentacyclic triterpenes. The triterpene classes are pote
nt against Trypanosoma cruzi. The bioassays were carried out using blood collect
ed from Swiss albino mice by cardiac puncture during the parasitemic peak (7th d
ay) after infection with the Y strain of T. cruzi. The results obtained showed t
hat A. amazonicus is a potential source of bioactive compounds since its extract
s and fractions isolated from it exhibited in vitro parasite lysis against trypo
mastigote forms of T. cruzi at concentrations >100 µg/mL. Fractions containing m
ainly betulin, lupenone, 3ß-hydroxylup-20(29)-ene-27,28-dioic acid, and 2a,3ß-di
hydroxylup-20(29)-ene-27,28-dioic acid showed more activity than crude extracts.
#^dnd^i1#^tm^len^kAmpelozizyphus amazonicus^i1#^tm^len^kRhamnaceae^i1#^tm^len^kP
entacyclic triterpenes^i1#^tm^len^kCytotoxic activity^i1#^tm^len^kTrypanocidal a
ctivity^i1#other#28#UFAM#UNAERP#CAPES#20060411#April 11, 2006#20070221#February 
21, 2007#6455.htm##
03695000000000685000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001201180
01700100023002880100028003110100024003390100030003630100026003930100024004190100
02200443010002500465010002700490010002500517070007500542070009800617070016800715
08318620088308500080274508500450275308500230279808500360282108500310285708500340
28881170006029220720003029280580005029310580007029360580006029431120009029491110
01502958114000902973113001802982002000903000#v40n5#v:\scielo\serial\bjmbr\v40n5\
markup\6455.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#09#BJMBR070#FAPESP#
Braz J Med Biol Res#40#5#20070500#^f663^l670#0100-879X#In vitro evaluation of th
e cytotoxic and trypanocidal activities of <i>Ampelozizyphus amazonicus</i> (Rha
mnaceae)^len#^rND^1A01^nL.V.^sRosas#^rND^1A01^nM.S.C.^sCordeiro#^rND^1A01^nF.R.^
sCampos#^rND^1A01^nS.K.R.^sNascimento#^rND^1A02^nA.H.^sJanuário#^rND^1A02^nS.C.^
sFrança#^rND^1A03^nA.^sNomizo#^rND^1A03^nM.P.A.^sToldo#^rND^1A03^nS.^sAlbuquerqu
e#^rND^1A02^nP.S.^sPereira#Universidade do Amazonas^iA01^1Departamento de Químic
a^cManaus^sAM^pBrasil#Universidade de Ribeirão Preto^iA02^1Unidade de Biotecnolo
gia Vegetal^cRibeirão Preto^sSP^pBrasil#Universidade de Ribeirão Preto^iA03^1Fac
uldade de Ciências Farmacêuticas^2Departamento de Análises Clínicas, Toxicológic
as e Bromatológicas^cRibeirão Preto^sSP^pBrasil#^len^a<i>Ampelozizyphus amazonic
us</i> Ducke is a tree commonly found in the Amazon region and an extract of its
 stem bark is popularly used as an antimalarial and anti-inflammatory agent and 
as an antidote to snake venom. Ursolic acid; five lupane type triterpenes: betul
in, betulinic acid, lupenone, 3ß-hydroxylup-20(29)-ene-27,28-dioic acid, and 2a,
3ß-dihydroxylup-20(29)-ene-27,28-dioic acid, and three phytosteroids: stigmaster
ol, sitosterol and campesterol, have been isolated from stem extracts of <i>A. a
mazonicus</i> Ducke. Their structures were characterized by spectral data includ
ing COSY and HMQC. In an <i>in vitro</i> biological screening of the isolated co
mpounds, 3ß-hydroxylup-20(29)-ene-27,28-dioic acid was cytotoxic against the SKB
R-3 human adenocarcinoma cell line (1 to 10 mg/mL), while 2a,3ß-dihydroxylup-20(
29)-ene-27,28-dioic acid exhibited cytotoxicity against both SKBR-3 human adenoc
arcinoma and C-8161 human melanoma tumor cell lines (&gt;0.1 mg/mL). In the pres
ent study, different extracts and some fractions of this plant were also investi
gated for trypanocidal activity due to the presence of pentacyclic triterpenes. 
The triterpene classes are potent against <i>Trypanosoma cruzi</i>. The bioassay
s were carried out using blood collected from Swiss albino mice by cardiac punct
ure during the parasitemic peak (7th day) after infection with the Y strain of <
i>T. cruzi</i>. The results obtained showed that <i>A. amazonicus</i> is a poten
tial source of bioactive compounds since its extracts and fractions isolated fro
m it exhibited <i>in vitro</i> parasite lysis against trypomastigote forms of <i
>T. cruzi</i> at concentrations &gt;100 µg/mL. Fractions containing mainly betul
in, lupenone, 3ß-hydroxylup-20(29)-ene-27,28-dioic acid, and 2a,3ß-dihydroxylup-
20(29)-ene-27,28-dioic acid showed more activity than crude extracts.#^dnd^i1#^t
m^len^k<i>Ampelozizyphus amazonicus</i>^i1#^tm^len^kRhamnaceae^i1#^tm^len^kPenta
cyclic triterpenes^i1#^tm^len^kCytotoxic activity^i1#^tm^len^kTrypanocidal activ
ity^i1#other#28#UFAM#UNAERP#CAPES#20060411#April 11, 2006#20070221#February 21, 
2007#6455.htm##
03755000000000709000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640012000690710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01760120111001860100023002970100029003200100024003490100031003730100026004040100
02400430010002100454010002600475010002600501010002500527070007700552070010000629
07001700072908318000089908500080269908500380270708500230274508500360276808500310
28040850034028351170006028690720003028750580005028780580007028830580006028901120
00902896111001502905114000902920113001802929002000902947008008902956#v40n5#v:\sc
ielo\serial\bjmbr\v40n5\markup\6455.htm#S#l#4#1#article#1#^mMay^a2007#oa#en#bjmb
r#1#3.1#ilus#tab#09#BJMBR070#FAPESP#Braz. j. med. biol. res#40#5#20070500#^f663^
l670#0100-879X#In vitro evaluation of the cytotoxic and trypanocidal activities 
of Ampelozizyphus amazonicus (Rhamnaceae)^len#^rND^1A01^nL. V^sRosas#^rND^1A01^n
M. S. C^sCordeiro#^rND^1A01^nF. R^sCampos#^rND^1A01^nS. K. R^sNascimento#^rND^1A
02^nA. H^sJanuário#^rND^1A02^nS. C^sFrança#^rND^1A03^nA^sNomizo#^rND^1A03^nM. P.
 A^sToldo#^rND^1A03^nS^sAlbuquerque#^rND^1A02^nP. S^sPereira#^iA01^1Universidade
 do Amazonas^2Departamento de Química^cManaus^sAM^pBrasil#^iA02^1Universidade de
 Ribeirão Preto^2Unidade de Biotecnologia Vegetal^cRibeirão Preto^sSP^pBrasil#^i
A03^1Universidade de Ribeirão Preto^2Faculdade de Ciências Farmacêuticas^3Depart
amento de Análises Clínicas, Toxicológicas e Bromatológicas^cRibeirão Preto^sSP^
pBrasil#^len^aAmpelozizyphus amazonicus Ducke is a tree commonly found in the Am
azon region and an extract of its stem bark is popularly used as an antimalarial
 and anti-inflammatory agent and as an antidote to snake venom. Ursolic acid; fi
ve lupane type triterpenes: betulin, betulinic acid, lupenone, 3ß-hydroxylup-20(
29)-ene-27,28-dioic acid, and 2a,3ß-dihydroxylup-20(29)-ene-27,28-dioic acid, an
d three phytosteroids: stigmasterol, sitosterol and campesterol, have been isola
ted from stem extracts of A. amazonicus Ducke. Their structures were characteriz
ed by spectral data including COSY and HMQC. In an in vitro biological screening
 of the isolated compounds, 3ß-hydroxylup-20(29)-ene-27,28-dioic acid was cytoto
xic against the SKBR-3 human adenocarcinoma cell line (1 to 10 mg/mL), while 2a,
3ß-dihydroxylup-20(29)-ene-27,28-dioic acid exhibited cytotoxicity against both 
SKBR-3 human adenocarcinoma and C-8161 human melanoma tumor cell lines (>0.1 mg/
mL). In the present study, different extracts and some fractions of this plant w
ere also investigated for trypanocidal activity due to the presence of pentacycl
ic triterpenes. The triterpene classes are potent against Trypanosoma cruzi. The
 bioassays were carried out using blood collected from Swiss albino mice by card
iac puncture during the parasitemic peak (7th day) after infection with the Y st
rain of T. cruzi. The results obtained showed that A. amazonicus is a potential 
source of bioactive compounds since its extracts and fractions isolated from it 
exhibited in vitro parasite lysis against trypomastigote forms of T. cruzi at co
ncentrations >100 µg/mL. Fractions containing mainly betulin, lupenone, 3ß-hydro
xylup-20(29)-ene-27,28-dioic acid, and 2a,3ß-dihydroxylup-20(29)-ene-27,28-dioic
 acid showed more activity than crude extracts.#^dnd^i1#^tm^len^kAmpelozizyphus 
amazonicus^i1#^tm^len^kRhamnaceae^i1#^tm^len^kPentacyclic triterpenes^i1#^tm^len
^kCytotoxic activity^i1#^tm^len^kTrypanocidal activity^i1#other#28#UFAM#UNAERP#C
APES#20060411#April 11, 2006#20070221#February 21, 2007#6455.htm#Internet^ihttp:
//www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500009##
00370000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014500070002000900215#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#5#1#article#88#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, May 2007, Volume
 40(5) 663-670</B> </font></P>      ^cY#6455.htm##
00459000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023400070002000900304#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#6#2#article#88#<P><B><font face="Arial, 
Helvetica, sans-serif"><I><font size="5">In vitro</font></I><font size="5"> eval
uation of the cytotoxic and trypanocidal activities of <I>Ampelozizyphus amazoni
cus</I> (Rhamnaceae)</font></font></B>       ^cY#6455.htm##
00780000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704055500070002000900625#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#7#3#article#88#<P><font face="Arial, Hel
vetica, sans-serif">L.V. Rosas<SUP>1</SUP>, M.S.C. Cordeiro<SUP>1</SUP>,    F.R.
 Campos<SUP>1</SUP>, S.K.R. Nascimento<SUP>1</SUP>, A.H. Janu&aacute;rio<SUP>2</
SUP>,    S.C. Fran&ccedil;a<SUP>2</SUP>, A. Nomizo<SUP>3</SUP>, M.P.A. Toldo<SUP
>3</SUP>,    S. Albuquerque<SUP>3</SUP> and <b><a href="#Correspondence"><img sr
c="/img/revistas/bjmbr/v40n5/recor.gif" border="0"></a></b>    <a href="mailto:p
pereira@unaerp.br"><img src="/img/revistas/bjmbr/v40n5/email-ca.gif" border="0">
</a>    P.S. Pereira<SUP>2</SUP> </font>      ^cY#6455.htm##
00367000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014200070002000900212#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#8#4#article#88#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento de Qu&iacute;mica, Universidade do 
Amazonas, Manaus, AM, Brasil     ^cY#6455.htm##
00364000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704013900070002000900209#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#9#5#article#88#<br>        <SUP>2</SUP>U
nidade de Biotecnologia Vegetal, Universidade de Ribeir&atilde;o Preto, Ribeir&a
tilde;o Preto, SP, Brasil     ^cY#6455.htm##
00479000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704025300071002000900324#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#10#6#article#88#<br>        <SUP>3</SUP>
Departamento de An&aacute;lises Cl&iacute;nicas, Toxicol&oacute;gicas e Bromatol
&oacute;gicas, Faculdade de Ci&ecirc;ncias Farmac&ecirc;uticas, Universidade de 
S&atilde;o Paulo, Ribeir&atilde;o Preto, SP, Brasil</font>       ^cY#6455.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019000071002000900261#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#11#7#article#88#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><img src="/img/revistas/bjmbr/v40n5/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6455.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#12#8#article#88#<BR>   <A HREF="#Introdu
ction"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6455.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#13#9#article#88#<BR>   <A HREF="#Materia
l"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#6455.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018800072002000900260#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#14#10#article#88#<BR>   <A HREF="#Result
s"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results and Discussion </strong></A>   
 ^cY#6455.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#15#11#article#88#<BR>   <A HREF="#Refere
nces"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6455.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023400072002000900306#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#16#12#article#88#<br>   </strong></A>   
<A HREF="#Correspondence"><img src="/img/revistas/bjmbr/v40n5/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#6455.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#17#13#article#88#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6455.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031900072002000900391#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#18#14#article#88#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">  </font>      ^cY#6455.htm##
02312000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704208500072002000902157#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#19#15#article#88#<P><font face="Arial, H
elvetica, sans-serif"><I>Ampelozizyphus amazonicus</I> Ducke is a tree commonly 
found in the Amazon region and an extract of its stem bark is popularly used as 
an antimalarial and anti-inflammatory agent and as an antidote to snake venom. U
rsolic acid; five lupane type triterpenes: betulin, betulinic acid, lupenone, 3&
szlig;-hydroxylup-20(29)-ene-27,28-dioic acid, and 2<font face="Symbol">a</font>
,3&szlig;-dihydroxylup-20(29)-ene-27,28-dioic acid, and three phytosteroids: sti
gmasterol, sitosterol and campesterol, have been isolated from stem extracts of 
<I>A. amazonicus</I> Ducke. Their structures were characterized by spectral data
 including COSY and HMQC. In an <I>in vitro</I> biological screening of the isol
ated compounds, 3&szlig;-hydroxylup-20(29)-ene-27,28-dioic acid was cytotoxic ag
ainst the SKBR-3 human adenocarcinoma cell line (1 to 10 mg/mL), while 2<font fa
ce="Symbol">a</font>,3&szlig;-dihydroxylup-20(29)-ene-27,28-dioic acid exhibited
 cytotoxicity against both SKBR-3 human adenocarcinoma and C-8161 human melanoma
 tumor cell lines (&gt;0.1 mg/mL). In the present study, different extracts and 
some fractions of this plant were also investigated for trypanocidal activity du
e to the presence of pentacyclic triterpenes. The triterpene classes are potent 
against <I>Trypanosoma cruzi</I>. The bioassays were carried out using blood col
lected from Swiss albino mice by cardiac puncture during the parasitemic peak (7
th day) after infection with the Y strain of <I>T. cruzi</I>. The results obtain
ed showed that <I>A. amazonicus</I> is a potential source of bioactive compounds
 since its extracts and fractions isolated from it exhibited <I>in vitro</I> par
asite lysis against trypomastigote forms of <I>T. cruzi</I> at concentrations &g
t;100 &#181;g/mL. Fractions containing mainly betulin, lupenone, 3&szlig;-hydrox
ylup-20(29)-ene-27,28-dioic acid, and 2<font face="Symbol">a</font>,3&szlig;-dih
ydroxylup-20(29)-ene-27,28-dioic acid showed more activity than crude extracts. 
</font>   <font face="Arial, Helvetica, sans-serif">      ^cY#6455.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018800072002000900260#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#20#16#article#88#<P><B>Key words: </B> <
I>Ampelozizyphus amazonicus</I>, Rhamnaceae, Pentacyclic triterpenes, Cytotoxic 
activity, Trypanocidal activity  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     
 ^cY#6455.htm##
00664000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043700072002000900509#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#21#17#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Introduction</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-se
rif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gi
f" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>  <font fac
e="Arial, Helvetica, sans-serif"></font>  <font face="Arial, Helvetica, sans-ser
if">      ^cY#6455.htm##
01006000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704077900072002000900851#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#22#18#article#88#<P><I>Ampelozizyphus am
azonicus</I> Ducke (Rhamnaceae) is a native tree of the Amazon forest that is po
pularly known in Brazil as <I>saracura-mir&aacute;</I> or <I>cerveja de &iacute;
ndio</I>. Infusions of <I>A. amazonicus</I> roots are commonly used in tradition
al medicine as anti-inflammatory preparations, as an antidote to snake venoms an
d for the treatment and prevention of malaria (1,2). Earlier chemical investigat
ions have reported the presence of saponins in <I>A. amazonicus</I> (1,3). Addit
ionally, Rhamnaceae species have shown an inhibitory effect on alcohol-induced m
uscle relaxation and cytotoxic, genotoxic, neurotoxic, anti-inflammatory, antipy
retic, and hepatoprotective activities have been associated with its extracts an
d pure compounds (4-8).         ^cY#6455.htm##
01442000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704121500072002000901287#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#23#19#article#88#<P>The transmission of 
Chagas' disease has become a major health problem in South and Central America, 
with the transfusion of infected blood being the most significant transmission m
echanism (9). The lack of effective medicines against acute and chronic diseases
 justifies the search for more efficient and less toxic drugs than those current
ly used. At present, the only trypanocidal compound used to prevent infection in
 blood banks is gentian violet, but due to its toxic effects and the alarming co
lor acquired by the skin and urine of transfusion recipients, its use is limited
 (10). Since most of the synthetic compounds used thus far to treat parasitic di
seases produce toxic side effects, the nitroheterocycles nifurtimox and benzimid
azole used to be the only drugs prescribed in the early stages of trypanosomiasi
s in America (11,12), but more recently nifurtimox has been banned from the mark
et. For this reason, a continuous search for bioactive trypanocidal compounds, i
n combination with studies on their mechanism of action to validate the rational
 development of lead compounds, has motivated the screening of natural products 
active against <I>Trypanosoma cruzi</I> and related organisms.      ^cY#6455.htm
##
00669000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044200072002000900514#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#24#20#article#88#<P>In the present study
, we report the isolation and structural elucidation of constituents of extracts
 from <I>A. amazonicus</I> stems collected in Manaus, AM, Brazil. The EtOAc extr
act and its fractions inhibited the growth of two tumor cell lines and showed po
tential <I>in vitro</I> lysis of <I>A. amazonicus </I>extracts and fractions aga
inst trypomastigote forms of <I>T. cruzi</I>.  </font>  <HR ALIGN=LEFT WIDTH=100
% SIZE=2>      ^cY#6455.htm##
00573000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034600072002000900418#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#25#21#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Material and Methods</B></FONT></FONT></font> <font face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^
cY#6455.htm##
00871000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704064400072002000900716#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#26#22#article#88#<P><font face="Arial, H
elvetica, sans-serif"><I>Ampelozizyphus amazonicus</I> stems were collected in t
he Ducke Reserve (Manaus, AM, Brazil). A voucher specimen was identified by Mad 
de Souza INPA, AM, Brazil) and deposited in the herbarium of the Instituto Nacio
nal de Pesquisa da Amaz&ocirc;nia, INPA, under code number 189,858. The bioassay
 procedures adopted were approved by the Ethics Committee of Faculdade de Ci&eci
rc;ncias Farmac&ecirc;uticas, Universidade de S&atilde;o Paulo, which follows th
e rules recommended by International Guiding Principles for Biochemical Research
 Involving Animals (CIOMS), Geneva, 1985. </font>        ^cY#6455.htm##
01419000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704119200072002000901264#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#27#23#article#88#<P><font face="Arial, H
elvetica, sans-serif">General <SUP>1</SUP>H and <SUP>13</SUP>C NMR spectra were 
recorded in pyridine-<I>d</I><SUB>5</SUB> at 300 and 75 MHz (Brucker DPX-300, De
partamento de Qu&iacute;mica, FFCLRP, USP, Ribeir&atilde;o Preto, SP, Brazil), r
espectively, using tetramethylsilane as internal standard. <SUP>13</SUP>C NMR ch
emical resonances were qualified for multiplicity by the DEPT sequence. Thin lay
er chromatography (TLC) precoated plates with silica gel PF<SUB>254</SUB> (Aldri
ch<SUP>&#174;</SUP>, Milwaukee, WI, USA) using the following solvent systems: he
xane:EtOAc (7:3), CHCl<SUB>3</SUB>:MeOH (4:1) and n-butanol:acetic acid:water, 4
:1:5, upper phase. TLC color reagent: vanillin-sulfuric acid followed by heating
. CC: silica gel (230-400 mesh; Merck, Darmstadt, Hessen, Germany). Preparative 
thin layer chromatography (PTLC) precoated plates with silica gel G (1.0 mm) usi
ng solvent system CHCl<SUB>3</SUB>:MeOH (95:5). HPLC was performed under isocrat
ic conditions (MeOH:H<SUB>2</SUB>O, 4:1, v/v) using a diode array detector (Shim
adzu, Kyoto, Japan) and a Supelcosil&#153; LC-18 column (10 x 250 mm, 5 &#181;m)
 and a flow rate of 3.0 mL/min. </font>      ^cY#6455.htm##
00321000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009400072002000900166#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#28#24#article#88#<P><font face="Arial, H
elvetica, sans-serif"><B>Extraction and isolation</B> </font>      ^cY#6455.htm#
#
01146000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704091900072002000900991#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#29#25#article#88#<P><font face="Arial, H
elvetica, sans-serif">Air-dried and powdered plant material (900 g) was macerate
d and successively extracted (1:2 kg/L) with organic solvents (hexane, EtOAc, Et
OH, and MeOH) and water at room temperature for each 7 days. Next, the material 
was filtered, the solvent evaporated, water was added and the sample was lyophil
ized. Crude extracts were concentrated to yield hexane (E<SUB>1</SUB>, 1.74 g), 
EtOAc (E<SUB>2</SUB>, 17.33 g), EtOH (E<SUB>3</SUB>, 42.09 g), MeOH (E<SUB>4</SU
B>, 11.02 g), and aqueous (E<SUB>5</SUB>, 1.83 g) extracts. A second extract was
 obtained by maceration of 2500 g air-dried and powdered <I>A. amazonicus </I>st
ems in 5 L methanol. This MeOH extract (E<SUB>6</SUB>, 50 g) was concentrated un
der vacuum and submitted to partition with <I>n</I>-butanol (E<SUB>7</SUB>, 45.2
3 g). The insoluble fraction was separated and dried (E<SUB>10</SUB>, 3.84 g). <
/font>      ^cY#6455.htm##
01027000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704080000072002000900872#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#30#26#article#88#<P><font face="Arial, H
elvetica, sans-serif">Extract E<SUB>2</SUB> and fraction E<SUB>7</SUB> were subm
itted to successive steps of column chromatography (silica gel) eluted with a st
ep gradient of hexane, EtOAc and/or chloroform and methanol. Fractions E<SUB>2</
SUB>P (10.63 g), E<SUB>2</SUB>P<SUB>3</SUB> (0.97 g), E<SUB>2</SUB>P<SUB>9</SUB>
 (0.17 g), and E<SUB>7(5/6)</SUB> (5.78 g) were obtained as above. PTLC and HPLC
 were used for purification. Fractions were collected and monitored by TLC. Comp
ounds 2 (38.6 mg), 5 (95.1 mg) and 6 (23.9 mg) were obtained from the E<SUB>2 </
SUB>extract and compounds 1 (18.1 mg), 3 (4.5 mg) and 4 (36.5 mg) from the E<SUB
>7</SUB> fraction. The E<SUB>3</SUB> extract (15.0 g) was submitted to partition
 with<I> n</I>-butanol (EEBAa, 4.15 g). </font>      ^cY#6455.htm##
00554000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032700072002000900399#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#31#27#article#88#<P><font face="Arial, H
elvetica, sans-serif">The stem bark aqueous extract was prepared with 1000 g air
-dried stem bark in 2 L water under mechanical shaking and the extracts with no 
froth (E<SUB>8</SUB>) and with froth (E<SUB>9</SUB>) were separated and lyophili
zed, yielding 12.27 and 16.65 g, respectively. </font>      ^cY#6455.htm##
00320000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009300072002000900165#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#32#28#article#88#<P><font face="Arial, H
elvetica, sans-serif"><B>Tumor cell line culture</B> </font>      ^cY#6455.htm##
00837000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704061000072002000900682#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#33#29#article#88#<P><font face="Arial, H
elvetica, sans-serif">The SKBR-3 human breast adenocarcinoma and C-8161 human me
lanoma tumor cell lines were obtained from the American Type Culture Collection 
(ATCC, Rockville, MD, USA). The tumor cell lines were cultured and maintained in
 RPMI 1640 medium supplemented with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate
, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate, 10% fetal bovine serum, 
100 units/mL penicillin, and 100 &#181;g/mL streptomycin. All cell lines were ma
intained at 37&#186;C in an atmosphere of 5% CO<SUB>2</SUB> and 95% air and 95% 
humidity. </font>      ^cY#6455.htm##
00330000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704010300072002000900175#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#34#30#article#88#<P><font face="Arial, H
elvetica, sans-serif"><B>Cytotoxic activity of tumor cells</B> </font>      ^cY#
6455.htm##
01471000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704124400072002000901316#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#35#31#article#88#<P><font face="Arial, H
elvetica, sans-serif">The cytotoxic activity of tumor cells was evaluated by the
 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method (13)
. Briefly, tumor cells cultured in appropriate flasks and maintained in continuo
us exponential growth were detached with 0.05% trypsin, 0.02% EDTA in calcium-fr
ee phosphate-buffered saline and washed three times with RPMI medium at 1000 rpm
/15 min at 10&#186;C. Cells were placed on 96-well plates at a density of 1 x 10
<SUP>5</SUP> cells per well. After 24 h of culture, the medium was removed and f
resh medium, with or without different concentrations of the indicated extracts/
compounds/or the control drug methotrexate (10-0.01 mg/mL), was added to the wel
ls and incubated for 24 h. At the end of treatment, 10 &#181;L MTT (10 mg/mL) wa
s added to the wells, and cells were incubated for a further 4 h. Finally, 50 &#
181;L 20% sodium dodecyl sulfate solution was added to each well. Formazan cryst
als were dissolved at 37&#186;C overnight. The absorbance of each well was read 
on a microplate reader at 540 nm. The cytotoxic rate was calculated as follows: 
% cytotoxicity of compounds = 1 - absorbance drug treated/absorbance control x l
00. </font>      ^cY#6455.htm##
00315000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008800072002000900160#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#36#32#article#88#<P><font face="Arial, H
elvetica, sans-serif"><B>Trypanocidal assay</B> </font>      ^cY#6455.htm##
01541000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704131400072002000901386#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#37#33#article#88#<P><font face="Arial, H
elvetica, sans-serif">Crude extracts and their subfractions were tested <I>in vi
tro</I> against trypomastigote blood forms of <I>T. cruzi</I> (Y strain). The bi
oassays were carried out using blood collected from Swiss albino mice by cardiac
 puncture during the parasitemic peak (7th day) after infection with the Y strai
n of <I>T. cruzi</I>. The blood was diluted in non-infected murine blood to give
 a concentration of ca. 2 x 10<SUP>6</SUP> trypomastigote forms/mL. Stock soluti
ons of the extracts and fractions to be tested were prepared by dissolving dimet
hyl sulfoxide to a final concentration of 25 mg/mL. The bioassays were performed
 in triplicate on 96-well microtiter plates containing 200 &#181;L of mixture/we
ll. For each sample, aliquots of the stock solutions were added to the diluted b
lood in such quantities as to give final concentrations of 100, 250 and 500 &#18
1;g/mL sample per mL of mixture in the wells. The plates were incubated at 4&#18
6;C for 24 h and the number of parasites was determined (14). Blood of infected 
mice and infected blood with dimethyl sulfoxide added in amounts equivalent to t
he samples were used as control, and infected blood plus gentian violet (250 &#1
81;g/mL) was used as positive control. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2
>      ^cY#6455.htm##
00505000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027800072002000900350#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#38#34#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT SIZE=4><FONT COLOR=#00007F><B>
Results and Discussion </B></FONT><A HREF="#Home"><B><img src="/img/revistas/bjm
br/v40n5/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font
></P>      ^cY#6455.htm##
00504000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027700072002000900349#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#39#35#article#88#<P><font face="Arial, H
elvetica, sans-serif">Pentacyclic lupane- and ursane-like triterpene skeletons w
ere detected in <I>A. amazonicus </I>stem crude extracts and fractions. Some of 
them were previously reported in root extracts of the same species (1). </font> 
</P>      ^cY#6455.htm##
01039000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704081200072002000900884#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#40#36#article#88#<P><font face="Arial, H
elvetica, sans-serif">Bioassay-guided fractionation of the EtOAc (E<SUB>2</SUB>)
 and MeOH (E<SUB>6</SUB>) extracts using a combination of column chromatography,
 PTLC and HPLC led to the isolation of ursolic acid (1), betulinic acid (2), lup
enone (3), betulin (4), 3&szlig;-hydroxylup-20(29)-ene-27,28-dioic acid (5), and
 2<font face="Symbol">a</font>,3&szlig;-dihydroxylup-20(29)-ene-27,28-dioic acid
 (6) (<a href="#Fig1">Figure 1</a>), as well as the well-known phytosteroids sti
gmasterol, sitosterol and campesterol. Compounds 2 and 4 have been isolated from
 <I>A. amazonicus</I> root bark extract (1) whereas the others are reported here
 for the first time for this species. Compounds 5 and 6 are correlated, at least
 in part, to the cytotoxic activity of the extract. </font>      ^cY#6455.htm##
00873000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704064600072002000900718#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#41#37#article#88#<P><font face="Arial, H
elvetica, sans-serif">The structures of the isolated compounds were determined u
sing spectroscopic methods (MS, <SUP>1</SUP>H and <SUP>13</SUP>C NMR, DEPT, COSY
, and HMQC) in comparison with previously published data (1,15-19). Both 1-D and
 2-D NMR experiments (<SUP>1</SUP>H, <SUP>13</SUP>C, DEPT, <SUP>1</SUP>H-<SUP>1<
/SUP>H COSY, and HMQC) were performed in order to fully assign <SUP>1</SUP>H and
 <SUP>13</SUP>C chemical shifts to compounds 1-6. The <SUP>13</SUP>C NMR spectra
 of compounds 1-6 revealed 30 carbon signals whose multiplicities were sorted by
 DEPT spectrum (<a href="#Tab1">Table 1</a>). </font>      ^cY#6455.htm##
00570000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034300072002000900415#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#42#38#article#88#<P><font face="Arial, H
elvetica, sans-serif">The <font face="Symbol">D</font><SUP>20,29</SUP>-functiona
lity of a lupane skeleton was inferred for compounds 2-6 from the resonance of t
he sp<SUP>2</SUP> carbons at C-29 (secondary carbon signal deduced by DEPT pulse
 sequence) at 110 ppm and C-20 (quaternary carbon) at 151 ppm. </font>      ^cY#
6455.htm##
01164000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704093700072002000901009#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#43#39#article#88#<P><font face="Arial, H
elvetica, sans-serif">A detailed analysis of the <SUP>1</SUP>H NMR of 2-6 confir
med the characteristic features of a lupane parent structure, with some modifica
tions. The spectra of 5 and 6 were characterized by signals of four tertiary met
hyls (<font face="Symbol">d</font> 0.8-1.2, Me-23-Me-26) and one vinylic methyl 
(<font face="Symbol">d</font> 1.9, Me-30), two protons of an isopropenyl moiety 
at <font face="Symbol">d</font> 4.7 and 5.0 (1 H each, s, H<SUB>a</SUB>-29 and H
<SUB>b</SUB>-29), and one carbinolic proton for 5 and two carbinolic protons for
 6. The <SUP>1</SUP>H NMR spectrum of 5 showed a signal at <font face="Symbol">d
</font> 3.2 (dd with <I>J</I> = 10.5 and 5.3 Hz) due to coupling with two methyl
ene protons. The values of the chemical shift and <I>J</I> couplings (diaxial an
d axial/equatorial interactions) suggested the presence of &szlig;-OH substituti
ons at C-3 (15). </font>      ^cY#6455.htm##
00814000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704058700072002000900659#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#44#40#article#88#<P><font face="Arial, H
elvetica, sans-serif">The <SUP>1</SUP>H NMR spectrum of 6 showed a signal for a 
carbinyl proton at <font face="Symbol">d</font> 3.2 (d with <I>J</I> = 9.0 Hz) d
ue to coupling with one proton, a diaxial interaction. A signal at <font face="S
ymbol">d</font> 4.0 (1 H, ddd) was also present in the same region of the <SUP>1
</SUP>H NMR spectrum of 6. The COSY spectrum showed the correlation between H-2 
and H-3. The chemical shifts and <I>J</I> couplings were typical for a 2<font fa
ce="Symbol">a</font>,3&szlig;-dihydroxy substitution pattern (16). </font>      
^cY#6455.htm##
00689000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704046200072002000900534#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#45#41#article#88#<P><font face="Arial, H
elvetica, sans-serif">The <SUP>13</SUP>C NMR spectrum of compound 5 revealed 30 
carbon signals. The signals of 5 were sorted by DEPT spectrum as 5 methyls, 10 m
ethylenes, 5 methines, 5 quaternaries, 1 alcoholic methine, 2 carboxylic acids, 
and 2 olefinic carbons (1 = CH<SUB>2</SUB> and one quaternary). The signals of 6
 were similar to those of 5, except for the substitution of one proton of methyl
ene carbon with 1 OH. </font>      ^cY#6455.htm##
00695000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704046800072002000900540#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#46#42#article#88#<P><font face="Arial, H
elvetica, sans-serif">The substitution at C-14 was revealed by a shift of the ca
rbon signal at carboxylic group at <font face="Symbol">d</font> 42.8 of betulini
c acid to <font face="Symbol">d</font> 60.0 and by the deshielded of signals of 
C-7, C-9, C-12, C-13, C-16 and C-26, and by the shielded of signals of C-8 and C
-15 due to <font face="Symbol">d</font> and <font face="Symbol">g</font> steric 
effects of this substitute. </font>      ^cY#6455.htm##
00632000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040500072002000900477#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#47#43#article#88#<P><font face="Arial, H
elvetica, sans-serif">Other triterpenoids isolated from this plant were identifi
ed as ursolic acid (1), betulinic acid (2), lupenone (3), and betulin (4) by the
ir spectral data as well as by comparison with spectral data from the literature
 (16,17). Besides these triterpenes, three phytosteroids were identified by GC/M
S: sitosterol, stigmasterol and campesterol. </font>      ^cY#6455.htm##
00626000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039900072002000900471#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#48#44#article#88#<P><font face="Arial, H
elvetica, sans-serif">The cytotoxic activities of 5 and 6 were evaluated on the 
SKBR-3 and C-8161 human tumor cell lines. Both compounds exhibited cytotoxic act
ivity against SKBR-3 breast adenocarcinoma tumor cells. Compound 6, even at mode
rate concentrations, also showed cytotoxic activity against C-8161 melanoma tumo
r cells (<a href="#Tab2">Table 2</a>). </font>      ^cY#6455.htm##
00634000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040700072002000900479#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#49#45#article#88#<P><font face="Arial, H
elvetica, sans-serif">Previous study reported that <I>A. amazonicus</I> stem ext
racts are sources of pentacyclic triterpenes that exhibit selective cytotoxicity
 against several melanoma-derived cell lines (20). It has been recently reported
 that betulinic acid is cytotoxic against non-melanoma (neuroectodermal and mali
gnant brain tumor) human tumor varieties (21). </font>      ^cY#6455.htm##
01967000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704174000072002000901812#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#50#46#article#88#<P><font face="Arial, H
elvetica, sans-serif">The present results support previous data showing that com
pounds found in <I>A. amazonicus</I> extracts exhibit tumor cytotoxicity. We als
o suggest that the compounds 5 and 6 isolated from <I>A. amazonicus</I> stem ext
racts and described here play a role in the tumor cytotoxicity exhibited by such
 extracts. In particular, the present results show that compound 5 has selective
 cytotoxicity against breast adenocarcinoma tumor cells and that compound 6 disp
lays cytotoxic activity against both tumor cell lines assayed at the tested conc
entration. Compounds 5 and 6 did not show significant cytotoxic activity on peri
pheral blood mononuclear cells (data not shown). This observation agrees with da
ta showing that lupane-type triterpenes such as betulinic acid present specific 
cytotoxicity against tumor cells and a favorable therapeutic index even at doses
 up to 500 mg/kg body weight. Betulinic acid is a very promising new chemotherap
eutic agent for the treatment of cancer (20-23). The mechanisms of triterpene cy
totoxic activity on tumor cells have not been fully elucidated. Betulinic acid s
eems to function by inducing apoptosis of cells irrespective of their p53 status
 (21). Further experiments are necessary to check the apoptosis-inducing ability
 of compounds 5 and 6. The activity of extracts and pure compounds seems to be m
uch lower than established by the criteria of the American National Cancer Insti
tute. However, activity should not be judged by direct comparison of numerical v
alues because the cell lines and the bioassay experimental conditions, and proba
bly the criteria for the judgment of activity used by different laboratories mig
ht not be the same. </font>      ^cY#6455.htm##
01236000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704100900072002000901081#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#51#47#article#88#<P><font face="Arial, H
elvetica, sans-serif">The trypanocidal activity of crude extracts and fractions 
of <I>A. amazonicus</I> is shown in <a href="#Tab3">Table 3</a>. The results dem
onstrated that all samples tested were effective against the Y strain of <I>T. c
ruzi</I>; however, the E<SUB>9</SUB> and EEBAa extracts and fractions E<SUB>2</S
UB>P, E<SUB>2</SUB>P<SUB>3</SUB>, E<SUB>2</SUB>P<SUB>9</SUB>, and E<SUB>7(5/6)</
SUB> were more efficient and exhibited more than 50% parasite lysis at a concent
ration of 500 &#181;g/mL. Though the other extracts and fractions were less effe
ctive they presented active compounds. Fraction E<SUB>2</SUB>P showed activity m
ainly due to compounds 2, 5 and 6. After chromatographic purification, two fract
ions, E<SUB>2</SUB>P<SUB>3</SUB> and E<SUB>2</SUB>P<SUB>9</SUB>, were obtained, 
containing compounds 5 and 6, respectively. Fraction E<SUB>7(5/6)</SUB>, obtaine
d by <I>n</I>-butanol partition of E<SUB>7</SUB>, contains lupenone (3) and betu
lin (4). </font>      ^cY#6455.htm##
01277000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704105000072002000901122#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#52#48#article#88#<P><font face="Arial, H
elvetica, sans-serif">The lupane- and ursane-like skeletons of pentacyclic trite
rpenes were identified in the extracts and fractions, as well as in the roots of
 <I>A. amazonicus</I> (1). Ursolic and oleanolic acids and their derivatives sho
wed trypanocidal activity, with ursolic acid being the most active (24). The pre
sence of a free hydroxyl group at C-3 and/or the carboxyl group at C-17 is requi
red for trypanocidal activity (24). The results obtained demonstrate that <I>A. 
amazonicus </I>extracts contain potential compounds for use as chemoprophylactic
 agents against <I>T. cruzi</I>. In addition, triterpenes, compounds such as phe
nols, saponins, peptide alkaloids, and others have been identified in Rhamnaceae
 species (5,25-28).</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="10
0%"  border="0">    <tr align="left" valign="top">      <td width="11%"><a href=
"/img/revistas/bjmbr/v40n5/html/6455i01.htm"><img src="/img/revistas/bjmbr/v40n5
/6455i01peq.jpg" border="2"></a></td>      <td width="89%">    ^cY#6455.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036700072002000900439#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#53#49#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Structures of pentacyclic tri
terpenes. Ursolic acid (1), betulinic acid (2), lupenone (3), betulin (4), 3&szl
ig;-hydroxylup-20(29)-ene-27,28-dioic acid (5), and 2<font face="Symbol">a</font
>,3&szlig;-dihydroxylup-20(29)-ene-27,28-dioic acid (6). </font>      </td>    <
/tr>  </table>      ^cY#6455.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038200072002000900454#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#54#50#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (82 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="11%"><a href="/img/revistas/bjmbr/v4
0n5/html/6455t01.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2">
</a></td>      <td width="89%">    ^cY#6455.htm##
00490000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704026300072002000900335#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#55#51#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab1"></a>Table 1. <SUP>13</SUP>C NMR chemical sh
ifts of pentacyclic triterpenes 1-6 (pyridine-<I>d</I><SUB>5</SUB>) with tetrame
thylsilane as internal standard. </font>      </td>    </tr>  </table>      ^cY#
6455.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038300072002000900455#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#56#52#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (181 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="11%"><a href="/img/revistas/bjmbr/v
40n5/html/6455t02.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"
></a></td>      <td width="89%">    ^cY#6455.htm##
00520000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029300072002000900365#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#57#53#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab2"></a>Table 2. Characterization of the <I>in 
vitro</I> cytotoxicity-related anti-tumor effects of the crude extract of <I>Amp
elozizyphus amazonicus</I> stem bark and of compounds 5 and 6. </font>      </td
>    </tr>  </table>      ^cY#6455.htm##
00876000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704064900072002000900721#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#58#54#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (123 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="11%"><a href="/img/revistas/bjmbr/v
40n5/html/6455t03.htm"><img src="/img/revistas/bjmbr/v40n5/table.jpg" border="2"
></a></td>      <td width="89%"><font face="Arial, Helvetica, sans-serif"><a nam
e="Tab3"></a>Table 3. Percent parasite lysis induced by extracts and fractions o
f<I> Ampelozizyphus amazonicus</I> against the trypomastigote form of <I>Trypano
soma cruzi</I> Y strain. </font></td>    </tr>  </table>      ^cY#6455.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011800072002000900190#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#59#55#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (192 K JPG file)]</font
></P>      ^cY#6455.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004900072002000900121#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#60#56#article#88#<P>   <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6455.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#61#57#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>References</B></FONT></FONT></font> <font face="Arial, Helvetica, sans-serif"
><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/back.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      ^cY#6455.
htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023200074002000900306#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#62#58#article#88#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Brandao MG, Lacaille-Dubois MA, Teixera M
A, Wagner H. Triterpene saponins from the roots of <I>Ampelozizyphus amazonicus<
/I>. <I>Phytochemistry</I> 1992; 31: 352-354. </font>      ^cY#6455.htm##
00530000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028900074002000900363#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#63#59#article#88#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Krettli AU, Andrade-Neto VF, Brandao MG, 
Ferrari WM. The search for new antimalarial drugs from plants used to treat feve
r and malaria or plants randomly selected: a review. <I>Mem Inst Oswaldo Cruz</I
> 2001; 96: 1033-1042. </font>      ^cY#6455.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024000074002000900314#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#64#60#article#88#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Brandao MG, Lacaille-Dubois MA, Teixeira 
MA, Wagner H. A dammarane-type saponin from the roots of <I>Ampelozizyphus amazo
nicus</I>. <I>Phytochemistry</I> 1993; 34: 1123-1127. </font>      ^cY#6455.htm#
#
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024600074002000900320#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#65#61#article#88#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Popoca J, Aguilar A, Alonso D, Villarreal
 ML. Cytotoxic activity of selected plants used as antitumorals in Mexican tradi
tional medicine. <I>J Ethnopharmacol</I> 1998; 59: 173-177. </font>      ^cY#645
5.htm##
00557000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704031600074002000900390#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#66#62#article#88#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Suksamrarn S, Panseeta P, Kunchanawatta S
, Distaporn T, Ruktasing S, Suksamrarn A. Ceanothane- and lupane-type triterpene
s with antiplasmodial and antimycobacterial activities from <I>Ziziphus cambodia
na</I>. <I>Chem Pharm Bull </I>2006; 54: 535-537. </font>      ^cY#6455.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027700074002000900351#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#67#63#article#88#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Velazco MR, Montero R, Rojas E, Gonsebatt
 ME, Sordo M, Pineyro A, et al. Genotoxic effects of <I>Karwinskia humboldtiana<
/I> toxin T-514 in peripheral blood lymphocytes. <I>Anticancer Drugs</I> 1996; 7
: 710-715. </font>      ^cY#6455.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022300074002000900297#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#68#64#article#88#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Lin CC, Chang CH, Yang JJ, Namba T, Hatto
ri M. Hepatoprotective effects of emodin from <I>Ventilago leiocarpa</I>. <I>J E
thnopharmacol</I> 1996; 52: 107-111. </font>      ^cY#6455.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022100074002000900295#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#69#65#article#88#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Chang CH, Lin CC, Yang JJ, Namba T, Hatto
ri M. Anti-inflammatory effects of emodin from <I>Ventilago leiocarpa</I>. <I>Am
 J Chin Med</I> 1996; 24: 139-142. </font>      ^cY#6455.htm##
00538000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029700074002000900371#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#70#66#article#88#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Docampo R, Moreno SN, Gadelha FR, de Souz
a W, Cruz FS. Prevention of Chagas' disease resulting from blood transfusion by 
treatment of blood: toxicity and mode of action of gentian violet. <I>Biomed Env
iron Sci</I> 1988; 1: 406-413. </font>      ^cY#6455.htm##
00433000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019100075002000900266#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#71#67#article#88#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Sepulveda-Boza S, Cassels BK. Plant met
abolites active against <I>Trypanosoma cruzi</I>. <I>Planta Med</I> 1996; 62: 98
-105. </font>      ^cY#6455.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028000075002000900355#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#72#68#article#88#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Rassi A, Amato Neto V, de Siqueira AF, 
Ferriolli FF, Amato VS, Rassi GG, et al. Treatment of chronic Chagas' disease wi
th an association of nifurtimox and corticoid. <I>Rev Soc Bras Med Trop</I> 2002
; 35: 547-550. </font>      ^cY#6455.htm##
00554000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031200075002000900387#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#73#69#article#88#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Lauria-Pires L, Braga MS, Vexenat AC, N
itz N, Simoes-Barbosa A, Tinoco DL, et al. Progressive chronic Chagas heart dise
ase ten years after treatment with anti-<I>Trypanosoma cruzi</I> nitroderivative
s. <I>Am J Trop Med Hyg</I> 2000; 63: 111-118. </font>      ^cY#6455.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023200075002000900307#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#74#70#article#88#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Mosmann T. Rapid colorimetric assay for
 cellular growth and survival: application to proliferation and cytotoxicity ass
ays. <I>J Immunol Methods</I> 1983; 65: 55-63. </font>      ^cY#6455.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024200075002000900317#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#75#71#article#88#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Brener Z. Therapeutic activity and crit
erion of cure on mice experimentally infected with <I>Trypanosoma cruzi</I>. <I>
Rev Inst Med Trop S&atilde;o Paulo</I> 1962; 4: 389-396. </font>      ^cY#6455.h
tm##
00444000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020200075002000900277#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#76#72#article#88#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Bilia AR, Morelli I, Mendez J. New lupa
ne derivatives from the leaves of <I>Licania pyrifolia</I>. <I>J Nat Prod</I> 19
96; 59: 297-300. </font>      ^cY#6455.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022900075002000900304#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#77#73#article#88#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Mahato SB, Kundu AP. <SUP>13</SUP>C NMR
 spectra of pentacyclic triterpenoids - A compilation and some salient features.
 <I>Phytochemistry</I> 1994; 37: 1517-1575. </font>      ^cY#6455.htm##
00529000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028700075002000900362#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#78#74#article#88#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Dantanarayana AP, Kumar NS, Muthukuda P
M, Mohamed I, Wazeer M. A lupane derivative and the <SUP>13</SUP>C NMR chemical 
shifts of some lupanols from <I>Pleurostylia opposita</I>. <I>Phytochemistry</I>
 1982; 21: 2065-2068. </font>      ^cY#6455.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022000075002000900295#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#79#75#article#88#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Kiem PV, Dat NT, Minh CV, Lee JJ, Kim Y
H. Lupane-triterpenes from the leaves of <I>Brassaiopsis glomerulata</I>. <I>Arc
h Pharm Res</I> 2003; 26: 594-596. </font>      ^cY#6455.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023200075002000900307#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#80#76#article#88#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Plaza A, Cinco M, Tubaro A, Pizza C, Pi
acente S. New triterpene glycosides from the stems of <I>Anomospermum grandifoli
um</I>. <I>J Nat Prod</I> 2003; 66: 1606-1610. </font>      ^cY#6455.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027000075002000900345#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#81#77#article#88#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Cichewicz RH, Kouzi SA. Chemistry, biol
ogical activity, and chemotherapeutic potential of betulinic acid for the preven
tion and treatment of cancer and HIV infection. <I>Med Res Rev</I> 2004; 24: 90-
114. </font>      ^cY#6455.htm##
00516000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027400075002000900349#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#82#78#article#88#21#<P><font
 face="Arial, Helvetica, sans-serif">21. Zuco V, Supino R, Righetti SC, Cleris L
, Marchesi E, Gambacorti-Passerini C, et al. Selective cytotoxicity of betulinic
 acid on tumor cell lines, but not on normal cells. <I>Cancer Lett</I> 2002; 175
: 17-25. </font>      ^cY#6455.htm##
00502000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026000075002000900335#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#83#79#article#88#22#<P><font
 face="Arial, Helvetica, sans-serif">22. Mukherjee R, Kumar V, Srivastava SK, Ag
arwal SK, Burman AC. Betulinic acid derivatives as anticancer agents: structure 
activity relationship. <I>Anticancer Agents Med Chem</I> 2006; 6: 271-279. </fon
t>      ^cY#6455.htm##
00449000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020700075002000900282#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#84#80#article#88#23#<P><font
 face="Arial, Helvetica, sans-serif">23. Yogeeswari P, Sriram D. Betulinic acid 
and its derivatives: a review on their biological properties. <I>Curr Med Chem</
I> 2005; 12: 657-666. </font>      ^cY#6455.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024800075002000900323#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#85#81#article#88#24#<P><font
 face="Arial, Helvetica, sans-serif">24. Cunha WR, Martins C, da Silva FD, Crott
i AE, Lopes NP, Albuquerque S. <I>In vitro</I> trypanocidal activity of triterpe
nes from miconia species. <I>Planta Med</I> 2003; 69: 470-472. </font>      ^cY#
6455.htm##
00747000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704050500075002000900580#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#86#82#article#88#25#<P><font
 face="Arial, Helvetica, sans-serif">25. Yoshikawa M, Murakami T, Ueda T, Matsud
a H, Yamahara J, Murakami N. Bioactive saponins and glycosides. IV. Four methyl-
migrated 16,17-seco-dammarane triterpene glycosides from Chinese natural medicin
e, hoveniae semen seu fructus, the seeds and fruit of <I>Hovenia dulcis</I> THUN
B.: absolute stereostructures and inhibitory activity on histamine release of ho
venidulciosides A1, A2, B1, and B2. <I>Chem Pharm Bull</I> 1996; 44: 1736-1743. 
</font>      ^cY#6455.htm##
00498000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025600075002000900331#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#87#83#article#88#26#<P><font
 face="Arial, Helvetica, sans-serif">26. Auvin C, Lezenven F, Blond A, Augeven-B
our I, Pousset JL, Bodo B, et al. Mucronine J a 14-membered cyclopeptide alkaloi
d from <I>Zizyphus mucronata</I>. <I>J Nat Prod</I> 1996; 59: 676-678. </font>  
    ^cY#6455.htm##
00430000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018800075002000900263#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#88#84#article#88#27#<P><font
 face="Arial, Helvetica, sans-serif">27. Suttisri R, Lee IS, Kinghorn AD. Plant-
derived triterpenoid sweetness inhibitors. <I>J Ethnopharmacol</I> 1995; 47: 9-2
6. </font>      ^cY#6455.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029900075002000900374#v40
n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#p#89#85#article#88#28#<P><font
 face="Arial, Helvetica, sans-serif">28. Li G, Min BS, Zheng C, Lee J, Oh SR, Ah
n KS, et al. Neuroprotective and free radical scavenging activities of phenolic 
compounds from <I>Hovenia dulcis</I>. <I>Arch Pharm Res</I> 2005; 28: 804-809.</
font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6455.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034800072002000900420#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#90#86#article#88#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><FONT SIZE=4><B><img src="/img/revistas/bjmbr/v40n5/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></FONT></A></font></P>      
 ^cY#6455.htm##
00686000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704045900072002000900531#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#91#87#article#88#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v40n5/rec
or.gif" border="0"></a>    Address for correspondence:</b> </font><font face="Ar
ial, Helvetica, sans-serif">P.S.    Pereira, Unidade de Biotecnologia, UNAERP, A
v. Cost&aacute;bile Romano, 2201,    14096-900 Ribeir&atilde;o Preto, SP, Brasil
. Fax: +55-16-3603-7030. E-mail:    <a href="mailto:ppereira@unaerp.br">ppereira
@unaerp.br</a></font> </p>      ^cY#6455.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031900072002000900391#v40n5#v:\scielo
\serial\bjmbr\v40n5\markup\6455.htm#S#p#92#88#article#88#<P><font face="Arial, H
elvetica, sans-serif">Research supported by the Universidade Federal do Amazonas
 (UFAM) and Universidade de Ribeir&atilde;o Preto (UNAERP). L.V. Rosas was the r
ecipient of a CAPES scholarship. Publication supported by FAPESP. Received April
 11, 2006. Accepted February 21, 2007. </font>      ^cY#6455.htm##
00604000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100026000910100
01800117010001600135012006800151030001500219065000900234064000500243031000300248
014000800251865000900259002000900268035001000277801001500287#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6455.htm#S#c#93#1#article#28#1#^rND^sBrandao^nMG#^rND^sLa
caille-Dubois^nMA#^rND^sTeixera^nMA#^rND^sWagner^nH#Triterpene saponins from the
 roots of Ampelozizyphus amazonicus^len#Phytochemistry#19920000#1992#31#352-354#
20070500#6455.htm#0031-9422#Phytochemistry##
00675000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100023000910100
01800114010001800132012012400150030002200274065000900296064000500305031000300310
014001000313865000900323002000900332035001000341801002200351#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6455.htm#S#c#94#2#article#28#2#^rND^sKrettli^nAU#^rND^sAn
drade-Neto^nVF#^rND^sBrandao^nMG#^rND^sFerrari^nWM#The search for new antimalari
al drugs from plants used to treat fever and malaria or plants randomly selected
: a review^len#Mem Inst Oswaldo Cruz#20010000#2001#96#1033-1042#20070500#6455.ht
m#0074-0276#Mem Inst Oswaldo Cruz##
00612000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100026000910100
01900117010001600136012007300152030001500225065000900240064000500249031000300254
014001000257865000900267002000900276035001000285801001500295#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6455.htm#S#c#95#3#article#28#3#^rND^sBrandao^nMG#^rND^sLa
caille-Dubois^nMA#^rND^sTeixeira^nMA#^rND^sWagner^nH#A dammarane-type saponin fr
om the roots of Ampelozizyphus amazonicus^len#Phytochemistry#19930000#1993#34#11
23-1127#20070500#6455.htm#0031-9422#Phytochemistry##
00627000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100017000890100
01600106010002100122012009500143030001700238065000900255064000500264031000300269
014000800272865000900280002000900289035001000298801001700308#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6455.htm#S#c#96#4#article#28#4#^rND^sPopoca^nJ#^rND^sAgui
lar^nA#^rND^sAlonso^nD#^rND^sVillarreal^nML#Cytotoxic activity of selected plant
s used as antitumorals in Mexican traditional medicine^len#J Ethnopharmacol#1998
0000#1998#59#173-177#20070500#6455.htm#0378-8741#J Ethnopharmacol##
00689000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100018000930100
02300111010001900134010001900153010002000172012012200192030001600314710000200330
065000900332064000500341031000300346014000800349865000900357002000900366#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#97#5#article#28#5#^rND^sSuksamra
rn^nS#^rND^sPanseeta^nP#^rND^sKunchanawatta^nS#^rND^sDistaporn^nT#^rND^sRuktasin
g^nS#^rND^sSuksamrarn^nA#Ceanothane- and lupane-type triterpenes with antiplasmo
dial and antimycobacterial activities from Ziziphus cambodiana^len#Chem Pharm Bu
ll#2#20060000#2006#54#535-537#20070500#6455.htm##
00698000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910100
01500108010002000123010001500143010001700158810000600175012009300181030001700274
06500090029106400050030003100020030501400080030786500090031500200090032403500100
0333801001700343#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#98#6#art
icle#28#6#^rND^sVelazco^nMR#^rND^sMontero^nR#^rND^sRojas^nE#^rND^sGonsebatt^nME#
^rND^sSordo^nM#^rND^sPineyro^nA#et al#Genotoxic effects of Karwinskia humboldtia
na toxin T-514 in peripheral blood lymphocytes^len#Anticancer Drugs#19960000#199
6#7#710-715#20070500#6455.htm#0959-4973#Anticancer Drugs##
00615000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100016000870100
01500103010001500118010001700133012006400150030001700214065000900231064000500240
031000300245014000800248865000900256002000900265035001000274801001700284#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#99#7#article#28#7#^rND^sLin^nCC#
^rND^sChang^nCH#^rND^sYang^nJJ#^rND^sNamba^nT#^rND^sHattori^nM#Hepatoprotective 
effects of emodin from Ventilago leiocarpa^len#J Ethnopharmacol#19960000#1996#52
#107-111#20070500#6455.htm#0378-8741#J Ethnopharmacol##
00611000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100014000900100
01500104010001500119010001700134012006500151030001400216065000900230064000500239
031000300244014000800247865000900255002000900264035001000273801001400283#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#100#8#article#28#8#^rND^sChang^n
CH#^rND^sLin^nCC#^rND^sYang^nJJ#^rND^sNamba^nT#^rND^sHattori^nM#Anti-inflammator
y effects of emodin from Ventilago leiocarpa^len#Am J Chin Med#19960000#1996#24#
139-142#20070500#6455.htm#0090-2942#Am J Chin Med##
00699000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100017000910100
01800108010001800126010001500144012013600159030001900295065000900314064000500323
031000200328014000800330865000900338002000900347035001000356801001900366#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#101#9#article#28#9#^rND^sDocampo
^nR#^rND^sMoreno^nSN#^rND^sGadelha^nFR#^rND^sde^nSouza W#^rND^sCruz^nFS#Preventi
on of Chagas' disease resulting from blood transfusion by treatment of blood: to
xicity and mode of action of gentian violet^len#Biomed Environ Sci#19880000#1988
#1#406-413#20070500#6455.htm#0895-3988#Biomed Environ Sci##
00525000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760100018001000120
05500118030001100173065000900184064000500193031000300198014000700201865000900208
002000900217035001000226801001100236#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
455.htm#S#c#102#10#article#28#10#^rND^sSepulveda-Boza^nS#^rND^sCassels^nBK#Plant
 metabolites active against Trypanosoma cruzi^len#Planta Med#19960000#1996#62#98
-105#20070500#6455.htm#0032-0943#Planta Med##
00715000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100020000910100
02200111010002000133010001600153010001600169810000600185012008900191030002200280
06500090030206400050031103100030031601400080031986500090032700200090033603500100
0345801002200355#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#103#11#a
rticle#28#11#^rND^sRassi^nA#^rND^sAmato^nNeto V#^rND^sde^nSiqueira AF#^rND^sFerr
iolli^nFF#^rND^sAmato^nVS#^rND^sRassi^nGG#et al#Treatment of chronic Chagas' dis
ease with an association of nifurtimox and corticoid^len#Rev Soc Bras Med Trop#2
0020000#2002#35#547-550#20070500#6455.htm#0037-8682#Rev Soc Bras Med Trop##
00736000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100016000980100
01800114010001400132010002400146010001700170810000600187012011600193030001800309
06500090032706400050033603100030034101400080034486500090035200200090036103500100
0370801001800380#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#104#12#a
rticle#28#12#^rND^sLauria-Pires^nL#^rND^sBraga^nMS#^rND^sVexenat^nAC#^rND^sNitz^
nN#^rND^sSimoes-Barbosa^nA#^rND^sTinoco^nDL#et al#Progressive chronic Chagas hea
rt disease ten years after treatment with anti-Trypanosoma cruzi nitroderivative
s^len#Am J Trop Med Hyg#20000000#2000#63#111-118#20070500#6455.htm#0002-9637#Am 
J Trop Med Hyg##
00562000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120116000930300
01800209065000900227064000500236031000300241014000600244865000900250002000900259
035001000268801001800278#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#
105#13#article#28#13#^rND^sMosmann^nT#Rapid colorimetric assay for cellular grow
th and survival: application to proliferation and cytotoxicity assays^len#J Immu
nol Methods#19830000#1983#65#55-63#20070500#6455.htm#0022-1759#J Immunol Methods
##
00568000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120102000920300
02800194065000900222064000500231031000200236014000800238865000900246002000900255
035001000264801002800274#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#
106#14#article#28#14#^rND^sBrener^nZ#Therapeutic activity and criterion of cure 
on mice experimentally infected with Trypanosoma cruzi^len#Rev Inst Med Trop São
 Paulo#19620000#1962#4#389-396#20070500#6455.htm#0036-4665#Rev Inst Med Trop São
 Paulo##
00554000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01600109012006400125030001100189065000900200064000500209031000300214014000800217
865000900225002000900234035001000243801001100253#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6455.htm#S#c#107#15#article#28#15#^rND^sBilia^nAR#^rND^sMorelli^nI#^r
ND^sMendez^nJ#New lupane derivatives from the leaves of Licania pyrifolia^len#J 
Nat Prod#19960000#1996#59#297-300#20070500#6455.htm#0163-3864#J Nat Prod##
00563000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930120
09100109030001500200065000900215064000500224031000300229014001000232865000900242
002000900251035001000260801001500270#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
455.htm#S#c#108#16#article#28#16#^rND^sMahato^nSB#^rND^sKundu^nAP#13C NMR spectr
a of pentacyclic triterpenoids - A compilation and some salient features^len#Phy
tochemistry#19940000#1994#37#1517-1575#20070500#6455.htm#0031-9422#Phytochemistr
y##
00668000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760100016001000100
02000116010001700136010001600153012010000169030001500269065000900284064000500293
031000300298014001000301865000900311002000900320035001000329801001500339#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#109#17#article#28#17#^rND^sDanta
narayana^nAP#^rND^sKumar^nNS#^rND^sMuthukuda^nPM#^rND^sMohamed^nI#^rND^sWazeer^n
M#A lupane derivative and the 13C NMR chemical shifts of some lupanols from Pleu
rostylia opposita^len#Phytochemistry#19820000#1982#21#2065-2068#20070500#6455.ht
m#0031-9422#Phytochemistry##
00612000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100014000910100
01500105010001400120010001400134012006700148030001500215065000900230064000500239
031000300244014000800247865000900255002000900264035001000273801001500283#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#110#18#article#28#18#^rND^sKiem^
nPV#^rND^sDat^nNT#^rND^sMinh^nCV#^rND^sLee^nJJ#^rND^sKim^nYH#Lupane-triterpenes 
from the leaves of Brassaiopsis glomerulata^len#Arch Pharm Res#20030000#2003#26#
594-596#20070500#6455.htm#0253-6269#Arch Pharm Res##
00620000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
01600106010001500122010001800137012007400155030001100229065000900240064000500249
031000300254014001000257865000900267002000900276035001000285801001100295#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#111#19#article#28#19#^rND^sPlaza
^nA#^rND^sCinco^nM#^rND^sTubaro^nA#^rND^sPizza^nC#^rND^sPiacente^nS#New triterpe
ne glycosides from the stems of Anomospermum grandifolium^len#J Nat Prod#2003000
0#2003#66#1606-1610#20070500#6455.htm#0163-3864#J Nat Prod##
00612000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100016000960120
14600112030001200258065000900270064000500279031000300284014000700287865000900294
002000900303035001000312801001200322#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
455.htm#S#c#112#20#article#28#20#^rND^sCichewicz^nRH#^rND^sKouzi^nSA#Chemistry, 
biological activity, and chemotherapeutic potential of betulinic acid for the pr
evention and treatment of cancer and HIV infection^len#Med Res Rev#20040000#2004
#24#90-114#20070500#6455.htm#0198-6325#Med Res Rev##
00699000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01900106010001600125010001800141010003000159810000600189012009000195030001200285
06500090029706400050030603100040031101400060031586500090032100200090033003500100
0339801001200349#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#113#21#a
rticle#28#21#^rND^sZuco^nV#^rND^sSupino^nR#^rND^sRighetti^nSC#^rND^sCleris^nL#^r
ND^sMarchesi^nE#^rND^sGambacorti-Passerini^nC#et al#Selective cytotoxicity of be
tulinic acid on tumor cell lines, but not on normal cells^len#Cancer Lett#200200
00#2002#175#17-25#20070500#6455.htm#0096-3917#Cancer Lett##
00624000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
02100110010001800131010001700149012008500166030002700251710000200278065000900280
064000500289031000200294014000800296865000900304002000900313#v40n5#v:\scielo\ser
ial\bjmbr\v40n5\markup\6455.htm#S#c#114#22#article#28#22#^rND^sMukherjee^nR#^rND
^sKumar^nV#^rND^sSrivastava^nSK#^rND^sAgarwal^nSK#^rND^sBurman^nAC#Betulinic aci
d derivatives as anticancer agents: structure activity relationship^len#Anticanc
er Agents Med Chem#2#20060000#2006#6#271-279#20070500#6455.htm##
00551000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100016000960120
08000112030001400192065000900206064000500215031000300220014000800223865000900231
002000900240035001000249801001400259#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6
455.htm#S#c#115#23#article#28#23#^rND^sYogeeswari^nP#^rND^sSriram^nD#Betulinic a
cid and its derivatives: a review on their biological properties^len#Curr Med Ch
em#20050000#2005#12#657-666#20070500#6455.htm#0929-8673#Curr Med Chem##
00654000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01900109010001700128010001600145010002100161012007100182030001100253065000900264
06400050027303100030027801400080028186500090028900200090029803500100030780100110
0317#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#116#24#article#28#24
#^rND^sCunha^nWR#^rND^sMartins^nC#^rND^sda^nSilva FD#^rND^sCrotti^nAE#^rND^sLope
s^nNP#^rND^sAlbuquerque^nS#In vitro trypanocidal activity of triterpenes from mi
conia species^len#Planta Med#20030000#2003#69#470-472#20070500#6455.htm#0032-094
3#Planta Med##
00880000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01400113010001700127010001800144010001800162012032300180030001600503710000200519
065000900521064000500530031000300535014001000538865000900548002000900557#v40n5#v
:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#117#25#article#28#25#^rND^sYoshi
kawa^nM#^rND^sMurakami^nT#^rND^sUeda^nT#^rND^sMatsuda^nH#^rND^sYamahara^nJ#^rND^
sMurakami^nN#Bioactive saponins and glycosides. IV. Four methyl-migrated 16,17-s
eco-dammarane triterpene glycosides from Chinese natural medicine, hoveniae seme
n seu fructus, the seeds and fruit of Hovenia dulcis THUNB.: absolute stereostru
ctures and inhibitory activity on histamine release of hovenidulciosides A1, A2,
 B1, and B2^len#Chem Pharm Bull#2#19960000#1996#44#1736-1743#20070500#6455.htm##
00673000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01500109010002200124010001800146010001400164810000600178012007600184030001100260
06500090027106400050028003100030028501400080028886500090029600200090030503500100
0314801001100324#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#118#26#a
rticle#28#26#^rND^sAuvin^nC#^rND^sLezenven^nF#^rND^sBlond^nA#^rND^sAugeven-Bour^
nI#^rND^sPousset^nJL#^rND^sBodo^nB#et al#Mucronine J a 14-membered cyclopeptide 
alkaloid from Zizyphus mucronata^len#J Nat Prod#19960000#1996#59#676-678#2007050
0#6455.htm#0163-3864#J Nat Prod##
00553000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100014000940100
01900108012005200127030001700179065000900196064000500205031000300210014000500213
865000900218002000900227035001000236801001700246#v40n5#v:\scielo\serial\bjmbr\v4
0n5\markup\6455.htm#S#c#119#27#article#28#27#^rND^sSuttisri^nR#^rND^sLee^nIS#^rN
D^sKinghorn^nAD#Plant-derived triterpenoid sweetness inhibitors^len#J Ethnopharm
acol#19950000#1995#47#9-26#20070500#6455.htm#0378-8741#J Ethnopharmacol##
00685000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100014000880100
01500102010001300117010001300130010001400143810000600157012010100163030001500264
06500090027906400050028803100030029301400080029686500090030400200090031303500100
0322801001500332#v40n5#v:\scielo\serial\bjmbr\v40n5\markup\6455.htm#S#c#120#28#a
rticle#28#28#^rND^sLi^nG#^rND^sMin^nBS#^rND^sZheng^nC#^rND^sLee^nJ#^rND^sOh^nSR#
^rND^sAhn^nKS#et al#Neuroprotective and free radical scavenging activities of ph
enolic compounds from Hovenia dulcis^len#Arch Pharm Res#20050000#2005#28#804-809
#20070500#6455.htm#0253-6269#Arch Pharm Res##
